{
  "nbformat": 4,
  "nbformat_minor": 0,
  "metadata": {
    "colab": {
      "provenance": [],
      "toc_visible": true,
      "authorship_tag": "ABX9TyMQjLq6THGIlZK0eyZpVv2C",
      "include_colab_link": true
    },
    "kernelspec": {
      "name": "python3",
      "display_name": "Python 3"
    },
    "language_info": {
      "name": "python"
    }
  },
  "cells": [
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "view-in-github",
        "colab_type": "text"
      },
      "source": [
        "<a href=\"https://colab.research.google.com/github/EskawatiKD/Thesis/blob/main/GenerateDataPenyakit.ipynb\" target=\"_parent\"><img src=\"https://colab.research.google.com/assets/colab-badge.svg\" alt=\"Open In Colab\"/></a>"
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "Generate Data Dari PubMed"
      ],
      "metadata": {
        "id": "c1LUiKaIxgfk"
      }
    },
    {
      "cell_type": "code",
      "execution_count": 1,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "leP9n26CxFBC",
        "outputId": "0ea946de-4dca-46c5-e330-205b627581c3"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Requirement already satisfied: requests in /usr/local/lib/python3.10/dist-packages (2.31.0)\n",
            "Requirement already satisfied: charset-normalizer<4,>=2 in /usr/local/lib/python3.10/dist-packages (from requests) (3.3.2)\n",
            "Requirement already satisfied: idna<4,>=2.5 in /usr/local/lib/python3.10/dist-packages (from requests) (3.6)\n",
            "Requirement already satisfied: urllib3<3,>=1.21.1 in /usr/local/lib/python3.10/dist-packages (from requests) (2.0.7)\n",
            "Requirement already satisfied: certifi>=2017.4.17 in /usr/local/lib/python3.10/dist-packages (from requests) (2023.11.17)\n"
          ]
        }
      ],
      "source": [
        "pip install requests\n"
      ]
    },
    {
      "cell_type": "markdown",
      "source": [],
      "metadata": {
        "id": "cXx3sPC4xdwL"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "import requests\n",
        "from xml.etree import ElementTree as ET\n",
        "from requests.exceptions import HTTPError, ConnectionError, Timeout, RequestException\n",
        "\n",
        "def search_pubmed(api_key, query, retmax=50):\n",
        "    base_url = \"https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi\"\n",
        "\n",
        "    params = {\n",
        "        'db': 'pubmed',\n",
        "        'term': query,\n",
        "        'api_key': api_key,\n",
        "        'retmax':retmax\n",
        "    }\n",
        "\n",
        "    try:\n",
        "        response = requests.get(base_url, params=params)\n",
        "        response.raise_for_status()  # Check for errors in the response\n",
        "\n",
        "        print(\"Search URL:\", response.url)  # Debugging: Print the URL\n",
        "        print(\"Search Response Content:\", response.text)  # Debugging: Print the response content\n",
        "\n",
        "        if response.text.strip():  # Check if response content is non-empty\n",
        "            return response.text  # Return XML content\n",
        "        else:\n",
        "            print(\"Empty response content\")\n",
        "    except HTTPError as errh:\n",
        "        print(\"HTTP Error:\", errh)\n",
        "    except ConnectionError as errc:\n",
        "        print(\"Error Connecting:\", errc)\n",
        "    except Timeout as errt:\n",
        "        print(\"Timeout Error:\", errt)\n",
        "    except RequestException as err:\n",
        "        print(\"Error:\", err)\n",
        "\n",
        "    return None\n",
        "\n",
        "def get_article_details(api_key, pmid):\n",
        "    base_url = \"https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi\"\n",
        "\n",
        "    params = {\n",
        "        'db': 'pubmed',\n",
        "        'id': pmid,\n",
        "        'retmode': 'xml',  # Set retmode to XML\n",
        "        'api_key': api_key\n",
        "    }\n",
        "\n",
        "    try:\n",
        "        response = requests.get(base_url, params=params)\n",
        "        response.raise_for_status()  # Check for errors in the response\n",
        "\n",
        "        print(\"Details URL:\", response.url)  # Debugging: Print the URL\n",
        "        print(\"Details Response Content:\", response.text)  # Debugging: Print the response content\n",
        "\n",
        "        if response.text.strip():  # Check if response content is non-empty\n",
        "            return response.text  # Return XML content\n",
        "        else:\n",
        "            print(\"Empty response content\")\n",
        "    except HTTPError as errh:\n",
        "        print(\"HTTP Error:\", errh)\n",
        "    except ConnectionError as errc:\n",
        "        print(\"Error Connecting:\", errc)\n",
        "    except Timeout as errt:\n",
        "        print(\"Timeout Error:\", errt)\n",
        "    except RequestException as err:\n",
        "        print(\"Error:\", err)\n",
        "\n",
        "    return None\n",
        "\n",
        "def main():\n",
        "    api_key = '9edd38677707c08b2a96ed1a6e8c61c47408'  # Ganti dengan kunci API PubMed Anda\n",
        "    query = 'lung cancer AND comorbidities'  # Sesuaikan dengan query pencarian Anda\n",
        "\n",
        "    search_result = search_pubmed(api_key, query)\n",
        "\n",
        "    if search_result:\n",
        "        # Skip this part for now, as we need to handle XML response in get_article_details\n",
        "        pass\n",
        "\n",
        "if __name__ == \"__main__\":\n",
        "    main()\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "-vVydGIwxaIc",
        "outputId": "588d0d89-d32e-40c2-95b1-f91efa2259ab"
      },
      "execution_count": 31,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Search URL: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi?db=pubmed&term=lung+cancer+AND+comorbidities&api_key=9edd38677707c08b2a96ed1a6e8c61c47408&retmax=50\n",
            "Search Response Content: <?xml version=\"1.0\" encoding=\"UTF-8\" ?>\n",
            "<!DOCTYPE eSearchResult PUBLIC \"-//NLM//DTD esearch 20060628//EN\" \"https://eutils.ncbi.nlm.nih.gov/eutils/dtd/20060628/esearch.dtd\">\n",
            "<eSearchResult><Count>6209</Count><RetMax>50</RetMax><RetStart>0</RetStart><IdList>\n",
            "<Id>38112578</Id>\n",
            "<Id>38103121</Id>\n",
            "<Id>38103006</Id>\n",
            "<Id>38102837</Id>\n",
            "<Id>38100106</Id>\n",
            "<Id>38097480</Id>\n",
            "<Id>38092558</Id>\n",
            "<Id>38090511</Id>\n",
            "<Id>38090326</Id>\n",
            "<Id>38090298</Id>\n",
            "<Id>38085543</Id>\n",
            "<Id>38075997</Id>\n",
            "<Id>38075485</Id>\n",
            "<Id>38071660</Id>\n",
            "<Id>38067372</Id>\n",
            "<Id>38067306</Id>\n",
            "<Id>38066848</Id>\n",
            "<Id>38066463</Id>\n",
            "<Id>38063366</Id>\n",
            "<Id>38063017</Id>\n",
            "<Id>38056855</Id>\n",
            "<Id>38056852</Id>\n",
            "<Id>38037323</Id>\n",
            "<Id>38029831</Id>\n",
            "<Id>38029007</Id>\n",
            "<Id>38027239</Id>\n",
            "<Id>38025819</Id>\n",
            "<Id>38023992</Id>\n",
            "<Id>38023743</Id>\n",
            "<Id>38021960</Id>\n",
            "<Id>38016200</Id>\n",
            "<Id>38016003</Id>\n",
            "<Id>38012569</Id>\n",
            "<Id>38011678</Id>\n",
            "<Id>38007507</Id>\n",
            "<Id>38003929</Id>\n",
            "<Id>37999149</Id>\n",
            "<Id>37999105</Id>\n",
            "<Id>37997884</Id>\n",
            "<Id>37996867</Id>\n",
            "<Id>37995046</Id>\n",
            "<Id>37990203</Id>\n",
            "<Id>37985822</Id>\n",
            "<Id>37983029</Id>\n",
            "<Id>37981476</Id>\n",
            "<Id>37979368</Id>\n",
            "<Id>37977487</Id>\n",
            "<Id>37974211</Id>\n",
            "<Id>37973983</Id>\n",
            "<Id>37970369</Id>\n",
            "</IdList><TranslationSet><Translation>     <From>lung cancer</From>     <To>\"lung neoplasms\"[MeSH Terms] OR (\"lung\"[All Fields] AND \"neoplasms\"[All Fields]) OR \"lung neoplasms\"[All Fields] OR (\"lung\"[All Fields] AND \"cancer\"[All Fields]) OR \"lung cancer\"[All Fields]</To>    </Translation><Translation>     <From>comorbidities</From>     <To>\"comorbid\"[All Fields] OR \"comorbidity\"[MeSH Terms] OR \"comorbidity\"[All Fields] OR \"comorbidities\"[All Fields] OR \"comorbids\"[All Fields]</To>    </Translation></TranslationSet><QueryTranslation>(\"lung neoplasms\"[MeSH Terms] OR (\"lung\"[All Fields] AND \"neoplasms\"[All Fields]) OR \"lung neoplasms\"[All Fields] OR (\"lung\"[All Fields] AND \"cancer\"[All Fields]) OR \"lung cancer\"[All Fields]) AND (\"comorbid\"[All Fields] OR \"comorbidity\"[MeSH Terms] OR \"comorbidity\"[All Fields] OR \"comorbidities\"[All Fields] OR \"comorbids\"[All Fields])</QueryTranslation></eSearchResult>\n",
            "\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "import xml.etree.ElementTree as ET\n",
        "\n",
        "# Contoh respons XML (ganti dengan respons XML yang sebenarnya)\n",
        "xml_response = '''\n",
        "<eSearchResult>\n",
        "  <Count>6209</Count>\n",
        "  <RetMax>20</RetMax>\n",
        "  <RetStart>0</RetStart>\n",
        "  <IdList>\n",
        "    <Id>38112578</Id>\n",
        "    <Id>38103121</Id>\n",
        "    <Id>38103006</Id>\n",
        "    <Id>38102837</Id>\n",
        "    <Id>38100106</Id>\n",
        "    <Id>38097480</Id>\n",
        "    <Id>38092558</Id>\n",
        "    <Id>38090511</Id>\n",
        "    <Id>38090326</Id>\n",
        "    <Id>38090298</Id>\n",
        "    <Id>38085543</Id>\n",
        "    <Id>38075997</Id>\n",
        "    <Id>38075485</Id>\n",
        "    <Id>38071660</Id>\n",
        "    <Id>38067372</Id>\n",
        "    <Id>38067306</Id>\n",
        "    <Id>38066848</Id>\n",
        "    <Id>38066463</Id>\n",
        "    <Id>38063366</Id>\n",
        "    <Id>38063017</Id>\n",
        "    <Id>38056855</Id>\n",
        "    <Id>38056852</Id>\n",
        "    <Id>38037323</Id>\n",
        "    <Id>38029831</Id>\n",
        "    <Id>38029007</Id>\n",
        "    <Id>38027239</Id>\n",
        "    <Id>38025819</Id>\n",
        "    <Id>38023992</Id>\n",
        "    <Id>38023743</Id>\n",
        "    <Id>38021960</Id>\n",
        "    <Id>38016200</Id>\n",
        "    <Id>38016003</Id>\n",
        "    <Id>38012569</Id>\n",
        "    <Id>38011678</Id>\n",
        "    <Id>38007507</Id>\n",
        "    <Id>38003929</Id>\n",
        "    <Id>37999149</Id>\n",
        "    <Id>37999105</Id>\n",
        "    <Id>37997884</Id>\n",
        "    <Id>37996867</Id>\n",
        "    <Id>37995046</Id>\n",
        "    <Id>37990203</Id>\n",
        "    <Id>37985822</Id>\n",
        "    <Id>37983029</Id>\n",
        "    <Id>37981476</Id>\n",
        "    <Id>37979368</Id>\n",
        "    <Id>37977487</Id>\n",
        "    <Id>37974211</Id>\n",
        "    <Id>37973983</Id>\n",
        "    <Id>37970369</Id>\n",
        "  </IdList>\n",
        "  <TranslationSet>\n",
        "     <Translation>     <From>lung cancer</From>     <To>\"lung neoplasms\"[MeSH Terms] OR (\"lung\"[All Fields] AND \"neoplasms\"[All Fields]) OR \"lung neoplasms\"[All Fields] OR (\"lung\"[All Fields] AND \"cancer\"[All Fields]) OR \"lung cancer\"[All Fields]</To>    </Translation>\n",
        "     <Translation>     <From>comorbidities</From>     <To>\"comorbid\"[All Fields] OR \"comorbidity\"[MeSH Terms] OR \"comorbidity\"[All Fields] OR \"comorbidities\"[All Fields] OR \"comorbids\"[All Fields]</To>    </Translation>\n",
        "  </TranslationSet>\n",
        "  <QueryTranslation>(\"lung neoplasms\"[MeSH Terms] OR (\"lung\"[All Fields] AND \"neoplasms\"[All Fields]) OR \"lung neoplasms\"[All Fields] OR (\"lung\"[All Fields] AND \"cancer\"[All Fields]) OR \"lung cancer\"[All Fields]) AND (\"comorbid\"[All Fields] OR \"comorbidity\"[MeSH Terms] OR \"comorbidity\"[All Fields] OR \"comorbidities\"[All Fields] OR \"comorbids\"[All Fields])</QueryTranslation>\n",
        "</eSearchResult>\n",
        "'''\n",
        "\n",
        "# Parsing XML\n",
        "root = ET.fromstring(xml_response)\n",
        "\n",
        "# Mendapatkan daftar ID\n",
        "id_list = [elem.text for elem in root.findall('.//IdList/Id')]\n",
        "print(\"List of IDs:\", id_list)\n",
        "\n",
        "# Mendapatkan QueryTranslation\n",
        "query_translation = root.find('.//QueryTranslation').text\n",
        "print(\"Query Translation:\", query_translation)\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "3AsHcDvwBHIy",
        "outputId": "e71ec6de-8920-41d6-860e-6e1e2d595d0f"
      },
      "execution_count": 32,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "List of IDs: ['38112578', '38103121', '38103006', '38102837', '38100106', '38097480', '38092558', '38090511', '38090326', '38090298', '38085543', '38075997', '38075485', '38071660', '38067372', '38067306', '38066848', '38066463', '38063366', '38063017', '38056855', '38056852', '38037323', '38029831', '38029007', '38027239', '38025819', '38023992', '38023743', '38021960', '38016200', '38016003', '38012569', '38011678', '38007507', '38003929', '37999149', '37999105', '37997884', '37996867', '37995046', '37990203', '37985822', '37983029', '37981476', '37979368', '37977487', '37974211', '37973983', '37970369']\n",
            "Query Translation: (\"lung neoplasms\"[MeSH Terms] OR (\"lung\"[All Fields] AND \"neoplasms\"[All Fields]) OR \"lung neoplasms\"[All Fields] OR (\"lung\"[All Fields] AND \"cancer\"[All Fields]) OR \"lung cancer\"[All Fields]) AND (\"comorbid\"[All Fields] OR \"comorbidity\"[MeSH Terms] OR \"comorbidity\"[All Fields] OR \"comorbidities\"[All Fields] OR \"comorbids\"[All Fields])\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "import os\n",
        "import xml.etree.ElementTree as ET\n",
        "import requests\n",
        "\n",
        "def get_article_details(api_key, pmid, save_path):\n",
        "    base_url = \"https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi\"\n",
        "\n",
        "    params = {\n",
        "        'db': 'pubmed',\n",
        "        'id': pmid,\n",
        "        'retmode': 'xml',\n",
        "        'api_key': api_key\n",
        "    }\n",
        "\n",
        "    try:\n",
        "        response = requests.get(base_url, params=params)\n",
        "        response.raise_for_status()  # Check for errors in the response\n",
        "\n",
        "        print(\"Details URL:\", response.url)  # Debugging: Print the URL\n",
        "        print(\"Details Response Content:\", response.text)  # Debugging: Print the response content\n",
        "\n",
        "        if response.text.strip():  # Check if response content is non-empty\n",
        "            # Save XML to file\n",
        "            save_xml_to_file(response.text, os.path.join(save_path, f'{pmid}.xml'))\n",
        "        else:\n",
        "            print(\"Empty response content\")\n",
        "    except requests.exceptions.HTTPError as errh:\n",
        "        print(\"HTTP Error:\", errh)\n",
        "    except requests.exceptions.ConnectionError as errc:\n",
        "        print(\"Error Connecting:\", errc)\n",
        "    except requests.exceptions.Timeout as errt:\n",
        "        print(\"Timeout Error:\", errt)\n",
        "    except requests.exceptions.RequestException as err:\n",
        "        print(\"Error:\", err)\n",
        "\n",
        "    return None\n",
        "\n",
        "def save_xml_to_file(xml_content, file_path):\n",
        "    try:\n",
        "        os.makedirs(os.path.dirname(file_path), exist_ok=True)  # Create directory if not exists\n",
        "        with open(file_path, 'w', encoding='utf-8') as file:\n",
        "            file.write(xml_content)\n",
        "        print(f\"XML saved to: {file_path}\")\n",
        "    except Exception as e:\n",
        "        print(f\"Error saving XML: {e}\")\n",
        "\n",
        "def main():\n",
        "    api_key = '9edd38677707c08b2a96ed1a6e8c61c47408'  # Ganti dengan kunci API PubMed Anda\n",
        "    query = 'lung cancer AND comorbidities'  # Sesuaikan dengan query pencarian Anda\n",
        "    save_path = 'path/to/save/xml/'  # Sesuaikan dengan path penyimpanan XML\n",
        "\n",
        "    # Get list of IDs\n",
        "    id_list =['38112578', '38103121', '38103006', '38102837', '38100106', '38097480', '38092558', '38090511', '38090326', '38090298', '38085543', '38075997', '38075485', '38071660', '38067372', '38067306', '38066848', '38066463', '38063366', '38063017', '38056855', '38056852', '38037323', '38029831', '38029007', '38027239', '38025819', '38023992', '38023743', '38021960', '38016200', '38016003', '38012569', '38011678', '38007507', '38003929', '37999149', '37999105', '37997884', '37996867', '37995046', '37990203', '37985822', '37983029', '37981476', '37979368', '37977487', '37974211', '37973983', '37970369']\n",
        "\n",
        "    for pmid in id_list:\n",
        "        get_article_details(api_key, pmid, save_path)\n",
        "\n",
        "if __name__ == \"__main__\":\n",
        "    main()\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "RSYjj2P5Cyya",
        "outputId": "ea65edb3-dd07-426d-8964-70506eb7a81a"
      },
      "execution_count": 41,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Details URL: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=38112578&retmode=xml&api_key=9edd38677707c08b2a96ed1a6e8c61c47408\n",
            "Details Response Content: <?xml version=\"1.0\" ?>\n",
            "<!DOCTYPE PubmedArticleSet PUBLIC \"-//NLM//DTD PubMedArticle, 1st January 2023//EN\" \"https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd\">\n",
            "<PubmedArticleSet>\n",
            "<PubmedArticle><MedlineCitation Status=\"Publisher\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38112578</PMID><DateRevised><Year>2023</Year><Month>12</Month><Day>19</Day></DateRevised><Article PubModel=\"Print-Electronic\"><Journal><ISSN IssnType=\"Electronic\">1872-6623</ISSN><JournalIssue CitedMedium=\"Internet\"><PubDate><Year>2023</Year><Month>Dec</Month><Day>15</Day></PubDate></JournalIssue><Title>Pain</Title><ISOAbbreviation>Pain</ISOAbbreviation></Journal><ArticleTitle>A systematic review of the prevalence of postamputation and chronic neuropathic pain associated with combat injury in military personnel.</ArticleTitle><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.1097/j.pain.0000000000003094</ELocationID><Abstract><AbstractText>Combat trauma can lead to widespread tissue damage and limb loss. This may result in chronic neuropathic and post amputation pain, including phantom limb pain (PLP) and residual limb pain (RLP). The military population is distinct with respect to demographic, injury, and social characteristics compared with other amputation and trauma cohorts. We undertook a systematic review of studies of military personnel, with a history of combat injury, that reported a prevalence of any type of postamputation pain or chronic neuropathic pain, identified from Embase and MEDLINE databases.Using the inverse variance method with a random-effects model, we undertook a meta-analysis to determine an overall prevalence and performed exploratory analyses to identify the effect of the type of pain, conflict, and time since injury on prevalence. Pain definitions and types of pain measurement tools used in studies were recorded. Thirty-one studies (14,738 participants) were included. The pooled prevalence of PLP, RLP, and chronic neuropathic pain were 57% (95% CI: 46-68), 61% (95% CI: 50-71), and 26% (95% CI: 10-54), respectively. Between-study heterogeneity was high (I2: 94%-98%). Characterisation of duration, frequency, and impact of pain was limited. Factors reported by included studies as being associated with PLP included the presence of RLP and psychological comorbidity. The prevalence of postamputation pain and chronic neuropathic pain after combat trauma is high. We highlight inconsistency of case definitions and terminology for pain and the need for consensus in future research of traumatic injury.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the International Association for the Study of Pain.</CopyrightInformation></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Kumar</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Surgery and Cancer, Pain Research Group, Imperial College, London, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Academic Department of Military Anaesthesia, Royal Centre for Defence Medicine, Birmingham, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Soliman</LastName><ForeName>Nadia</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Surgery and Cancer, Pain Research Group, Imperial College, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Gan</LastName><ForeName>Zoe</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Surgery and Cancer, Pain Research Group, Imperial College, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Cullinan</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>National Heart and Lung Institute, Imperial College, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Vollert</LastName><ForeName>Jan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Surgery and Cancer, Pain Research Group, Imperial College, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Rice</LastName><ForeName>Andrew S C</ForeName><Initials>ASC</Initials><AffiliationInfo><Affiliation>Department of Surgery and Cancer, Pain Research Group, Imperial College, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Kemp</LastName><ForeName>Harriet</ForeName><Initials>H</Initials><Identifier Source=\"ORCID\">0000-0001-5657-3009</Identifier><AffiliationInfo><Affiliation>Department of Surgery and Cancer, Pain Research Group, Imperial College, London, United Kingdom.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2023</Year><Month>12</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Pain</MedlineTA><NlmUniqueID>7508686</NlmUniqueID><ISSNLinking>0304-3959</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"medline\"><Year>2023</Year><Month>12</Month><Day>19</Day><Hour>19</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2023</Year><Month>12</Month><Day>19</Day><Hour>19</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"received\"><Year>2023</Year><Month>5</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus=\"accepted\"><Year>2023</Year><Month>8</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2023</Year><Month>12</Month><Day>19</Day><Hour>11</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38112578</ArticleId><ArticleId IdType=\"doi\">10.1097/j.pain.0000000000003094</ArticleId><ArticleId IdType=\"pii\">00006396-990000000-00472</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aldington D, Small C, Edwards D, Ralph J, Woods P, Jagdish S, Moore RA. A survey of post-amputation pains in serving military personnel. J R Army Med Corps 2014;160:38&#x2013;41.</Citation></Reference><Reference><Citation>Allami M, Faraji E, Mohammadzadeh F, Soroush MR. Chronic musculoskeletal pain, phantom sensation, phantom and stump pain in veterans with unilateral below-knee amputation. Scand J Pain 2019;19:779&#x2013;87.</Citation></Reference><Reference><Citation>Baker S, O'Neill B, Haddon W Jr, Long W. The injury severity score: a method for describing patients with multiple injuries and evaluating emergency care. J Trauma 1974;14:187&#x2013;96.</Citation></Reference><Reference><Citation>Bannister K, Sachau J, Baron R, Dickenson AH. Neuropathic pain: mechanism-based therapeutics. Annu Rev Pharmacol Toxicol 2020; 60:257&#x2013;74.</Citation></Reference><Reference><Citation>Bedigrew KM, Stinner DJ, Kragh JF, Potter BK, Shawen SB, Hsu JR. Effectiveness of foot fasciotomies in foot and ankle trauma. J R Army Med Corps 2017;163:324&#x2013;8.</Citation></Reference><Reference><Citation>Bennett AN, Dyball DM, Boos CJ, Fear NT, Schofield S, Bull AMJ, Cullinan P. Study protocol for a prospective, longitudinal cohort study investigating the medical and psychosocial outcomes of UK combat casualties from the Afghanistan war: the ADVANCE study. BMJ Open 2020;10:e037850.</Citation></Reference><Reference><Citation>Bennett M. The LANSS pain scale: the leeds assessment of neuropathic symptoms and signs. PAIN 2001;92:147&#x2013;57.</Citation></Reference><Reference><Citation>Birch R, Eardley W, Ramasamy A, Brown K, Shenoy R, Anand P, Clasper J, Dunn R, Etherington J, Misra P, Stewart M. Nerve injuries sustained during warfare PART II: OUTCOMES. J Bone Joint Surg Br 2012;94:529&#x2013;64.</Citation></Reference><Reference><Citation>Buch NS, Nikolajsen L, Karlsson P. Possible inflammatory pain biomarkers in postamputation pain. Scand J Pain 2019;19:623&#x2013;27.</Citation></Reference><Reference><Citation>Buchheit T, Van De Ven T, Hsia HLJ, McDuffie M, Macleod DB, White W, Chamessian A, Keefe FJ, Buckenmaier CT, Shaw AD. Pain phenotypes and associated clinical risk factors following traumatic amputation: results from veterans integrated pain evaluation research (VIPER). Pain Med (United States) 2016;17:149&#x2013;61.</Citation></Reference><Reference><Citation>Clarke C, Lindsay DR, Pyati S, Buchheit T. Residual limb pain is not a diagnosis a proposed algorithm to classify postamputation pain. Clin J Pain 2013;29:551&#x2013;62.</Citation></Reference><Reference><Citation>Cohen SP, Brown C, Kurihara C, Plunkett A, Nguyen C, Strassels SA. Diagnoses and factors associated with medical evacuation and return to duty among nonmilitary personnel participating in military operations in Iraq and Afghanistan. CMAJ Can Med Assoc J 2011;183:E289&#x2013;E295.</Citation></Reference><Reference><Citation>Defence Statistics: Ministry of Defence. UK armed forces biannual diversity statistics. Whitehall: Analysis (Tri-Service), 2022.</Citation></Reference><Reference><Citation>Desmond DM, MacLachlan M. Prevalence and characteristics of phantom limb pain and residual limb pain in the long term after upper limb amputation. Int J Rehabil Res 2010;33:279&#x2013;82.</Citation></Reference><Reference><Citation>Duffy JR, Warburg FE, Koelle SFT, Werner MU, Nielsen PR. Pain-related psychological distress, self-rated health and significance of neuropathic pain in Danish soldiers injured in Afghanistan. Acta Anaesthesiol Scand 2015;59:1367&#x2013;76.</Citation></Reference><Reference><Citation>Ebrahimzadeh M, Hariri S. Long-term outcomes of unilateral transtibial amputations. Mil Med 2009;174:593&#x2013;97.</Citation></Reference><Reference><Citation>Ebrahimzadeh MH, Fattahi AS. Long-term clinical outcomes of Iranian veterans with unilateral transfemoral amputation. Disabil Rehabil 2009;31:1873&#x2013;7.</Citation></Reference><Reference><Citation>Ebrahimzadeh MH, Fattahi AS, Nejad AB. Long-term follow-up of Iranian veteran upper extremity amputees from the Iran-Iraq war (1980-1988). J Trauma 2006;61:886&#x2013;8.</Citation></Reference><Reference><Citation>Ebrahimzadeh MH, Kachooei AR, Soroush MR, Hasankhani EG, Razi S, Birjandinejad A. Long-term clinical outcomes of war-related hip disarticulation and transpelvic amputation. J Bone Joint Surg 2013;95:e114.</Citation></Reference><Reference><Citation>Ebrahimzadeh MH, Moradi A, Bozorgnia S, Hallaj-Moghaddam M. Evaluation of disabilities and activities of daily living of war-related bilateral lower extremity amputees. Prosthet Orthot Int 2016;40:51&#x2013;57.</Citation></Reference><Reference><Citation>Ebrahimzadeh MH, Rajabi MT. Long-term outcomes of patients undergoing war-related amputations of the foot and ankle. J Foot Ankle Surg 2007;46:429&#x2013;433.</Citation></Reference><Reference><Citation>Eckhoff MD, Craft MR, Nicholson TC, Nesti LJ, Dunn JC. Lower extremity combat sustained peripheral nerve injury in US military personnel. Plast Reconstr Surg Glob Open 2021;9:e3447.</Citation></Reference><Reference><Citation>Edwards DS, Mayhew ER, Rice ASC. &#x201c;Doomed to go in company with miserable pain&#x201d;: surgical recognition and treatment of amputation-related pain on the Western Front during World War 1. Lancet 2014;384:1715&#x2013;1719.</Citation></Reference><Reference><Citation>Ehde DM, Czerniecki JM, Smith DG, Campbell KM, Edwards WT, Jensen MP, Robinson LR. Chronic phantom sensations, phantom pain, residual limb pain, and other regional pain after lower limb amputation. Arch Phys Med Rehabil 2000;81:1039&#x2013;44.</Citation></Reference><Reference><Citation>Esfandiari E, Yavari A, Karimi A, Masoumi M, Soroush M, Saeedi H. Long-term symptoms and function after war-related lower limb amputation: a national cross-sectional study. Acta Orthop Traumatol Turc 2018;52:348&#x2013;51.</Citation></Reference><Reference><Citation>Faraji E, Allami M, Feizollahi N, Karimi A, Yavari A, Soroush M, Moudi M. Health concerns of veterans with high-level lower extremity amputations. Mil Med Res 2018;5:36.</Citation></Reference><Reference><Citation>Finnerup NB, Attal N, Haroutounian S, Mcnicol E, Baron R, Dworkin RH, Gilron I, Haanp&#xe4;&#xe4; M, Hansson P, Jensen TS, Kamerman PR, Lund K, Moore A, Raja SN, Rice ASC, Rowbotham M, Sena E, Siddall P, Smith BH, Wallace M. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet 2015;14:162&#x2013;73.</Citation></Reference><Reference><Citation>Finnerup NB, Haroutounian S, Kamerman P, Baron R, Bennett DL, Bouhassira D, Cruccu G, Freeman R, Hansson P, Nurmikko T, Raja SN, Rice AS, Serra J, Smith BH, Treede RD, Jensen TS. Neuropathic pain: updated grading system for research and clinical practice. PAIN 2016;157:1599&#x2013;606.</Citation></Reference><Reference><Citation>Flor H, Nikolajsen L, Jensen TS. Phantom limb pain: a case of maladaptive CNS plasticity? Nat Rev Neurosci 2006;7:873&#x2013;81.</Citation></Reference><Reference><Citation>Foote C, Kinnon J, Robbins C, Pessagno R, Portner M. Long-term health and quality of life experiences of Vietnam veterans with combat-related limb loss. Qual Life Res 2015;24:2853&#x2013;61.</Citation></Reference><Reference><Citation>Freynhagen R, Baron R, Gockel U, T&#xf6;lle TR. painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin 2006;22:1911&#x2013;20.</Citation></Reference><Reference><Citation>Griffin SC, Tsao JW. A mechanism-based classification of phantom limb pain. PAIN 2014;155:2236&#x2013;42.</Citation></Reference><Reference><Citation>Gunawardena NS, de Alwis Seneviratne R, Athauda T. Functional outcomes of unilateral lower limb amputee soldiers in two districts of Sri Lanka. Mil Med 2006;171:283&#x2013;7.</Citation></Reference><Reference><Citation>Hoy D, Brooks P, Woolf A, Blyth F, March L, Bain C, Baker P, Smith E, Buchbinder R. Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement. J Clin Epidemiol 2012;65:934&#x2013;39.</Citation></Reference><Reference><Citation>Jensen TS, Baron R, Haanp&#xe4;&#xe4; M, Kalso E, Loeser JD, Rice ASC, Treede R. A new definition of neuropathic pain. PAIN 2011;152:2204&#x2013;5.</Citation></Reference><Reference><Citation>Kehoe A, Smith JE, Edwards A, Yates D, Lecky F. The changing face of major trauma in the UK. Emerg Med J 2015;32:911&#x2013;5.</Citation></Reference><Reference><Citation>Keil G. So-called initial description of phantom pain by Ambroise Par&#xe9;. &#x201c;Chose digne d&#x2019;admiration et quasi incredible&#x201d;: the &#x201c;douleur &#xe8;s parties mortes et amput&#xe9;es&#x201d; Fortschr Med 1990;108:62&#x2013;6.</Citation></Reference><Reference><Citation>Ketz AK. The experience of phantom limb pain in patients with combat-related traumatic amputations. Arch Phys Med Rehabil 2008;89:1127&#x2013;32.</Citation></Reference><Reference><Citation>Kinch K, Clasper JC. A brief history of war amputation. J R Army Med Corps 2011;157:374&#x2013;80.</Citation></Reference><Reference><Citation>Krueger CA, Rivera JC, Tennent DJ, Sheean AJ, Stinner DJ, Wenke JC. Late amputation may not reduce complications or improve mental health in combat-related, lower extremity limb salvage patients. Injury 2015;46:1527&#x2013;32.</Citation></Reference><Reference><Citation>Limakatso K, Bedwell GJ, Madden VJ, Parker R. The prevalence and risk factors for phantom limb pain in people with amputations: a systematic review and meta-analysis. PLoS One 2020;15:e0240431.</Citation></Reference><Reference><Citation>Lipsey M, Wilson DB. Practical Meta-Analysis. Thousand Oaks: SAGE Publications, 2000.</Citation></Reference><Reference><Citation>List EB, Krijgh DD, Martin E, Coert JH. Prevalence of residual limb pain and symptomatic neuromas after lower extremity amputation: a systematic review and meta-analysis. PAIN 2021;162:1906&#x2013;1913.</Citation></Reference><Reference><Citation>Mayo A, Kluger Y. Terrorist bombing. World J Emerg Surg 2006;1:33.</Citation></Reference><Reference><Citation>Mercer S, Chavan S, Tong J, Connor D, de Mello W. The early detection and management of neuropathic pain following combat injury. J R Army Med Corps 2009;155:94&#x2013;8.</Citation></Reference><Reference><Citation>Ministry of Defence. Types of injuries sustained by UK service personnel on Op HERRICK in 2016. Available at: https://assets.publishing.service.gov.uk/media/5a80e0eaed915d74e6230f79/20160223_Afghanistan_Types_of_Injuries_Official_Statistic_Final_OS.pdf Published 25 February 2016.</Citation></Reference><Reference><Citation>Moher D, Liberati A, Tetzlaff J, Altman D, Group TP. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e10000097.</Citation></Reference><Reference><Citation>Nikolajsen L, Jensen TS. Phantom limb pain. Br J Anaesth 2001;87:107&#x2013;16.</Citation></Reference><Reference><Citation>Olenick M, Flowers M, Diaz VJ. Us veterans and their unique issues: enhancing health care professional awareness. Adv Med Educ Pract 2015;6:635&#x2013;9.</Citation></Reference><Reference><Citation>Penn-Barwell JG, Roberts SAG, Midwinter MJ, Bishop JRB. Improved survival in UK combat casualties from Iraq and Afghanistan: 2003-2012. J Trauma Acute Care Surg 2015;78:1014&#x2013;20.</Citation></Reference><Reference><Citation>Rafferty M, Bennett Britton TM, Drew BT, Phillip RD. Cross-sectional study of alteration of phantom limb pain with visceral stimulation in military personnel with amputation. J Rehabil Res Dev 2015;52:441&#x2013;8.</Citation></Reference><Reference><Citation>Rahimi A, Mousavi B, Soroush M, Masumi M, Montazeri A. Pain and health-related quality of life in war veterans with bilateral lower limb amputations. Trauma Mon 2012;17:282&#x2013;6.</Citation></Reference><Reference><Citation>Raja SN, Carr DB, Cohen M, Finnerup NB, Flor H, Gibson S, Keefe FJ, Mogil JS, Ringkamp M, Sluka KA, Song XJ, Stevens B, Sullivan MD, Tutelman PR, Ushida T, Vader K. The revised International Association for the Study of Pain definition of pain: concepts, challenges, and compromises. PAIN 2020;161:1976&#x2013;82.</Citation></Reference><Reference><Citation>Rathore FA, Ayaz SB, Mansoor SN, Qureshi AR, Fahim M. Demographics of lower limb amputations in the Pakistan military: a single center, three-year prospective survey. Cureus 2016;8:e566.</Citation></Reference><Reference><Citation>Rauh M, Aralis H, Melcer T, Macera C, Sessoms P, Bartlett J, Galarneau M. Effect of traumatic brain injury among U.S. servicemembers with amputation. J of Rehab Res and Dev 2013;50:161&#x2013;72.</Citation></Reference><Reference><Citation>Rayegani SM, Aryanmehr A, Soroosh MR, Baghbani M. Phantom pain, phantom sensation, and spine pain in bilateral lower limb amputees: results of a national survey of Iraq-Iran war victims' health status. Iran J Child Neurol 2010;10:42&#x2013;7.</Citation></Reference><Reference><Citation>Reiber G, Mcfarland L, Hubbard S, Maynard C, Blough D, Gambel J, Smith D. Servicemembers and veterans with major traumatic limb loss from vietnam war and OIF/OEF conflicts: survey methods, participants, and summary findings. J of Rehab Res and Dev 2010;47:275&#x2013;97.</Citation></Reference><Reference><Citation>Rivera J, Glebus G, Cho M. Disability following combat-sustained nerve injury of the upper limb. Bone Joint J 2014;96:254&#x2013;8.</Citation></Reference><Reference><Citation>Rothberg J, Tahmoush A, Oldakowski R. The epidemiology of causalgia among soldiers injured in Vietnam. Mil Med 1983;148:347&#x2013;50.</Citation></Reference><Reference><Citation>Schone HR, Baker CI, Katz J, Nikolajsen L, Limakatso K, Flor H, Makin TR. Making sense of phantom limb pain. J Neurol Neurosurg Psychiatry 2022;93:833&#x2013;43.</Citation></Reference><Reference><Citation>Schug SA, Lavand'Homme P, Barke A, Korwisi B, Rief W, Treede RD. The IASP classification of chronic pain for ICD-11: chronic postsurgical or posttraumatic pain. PAIN 2019;160:45&#x2013;52.</Citation></Reference><Reference><Citation>Sherman RA. Utilization of prostheses among US veterans with traumatic amputation: a pilot survey. J Rehabil Res Dev 1999;36:100&#x2013;8.</Citation></Reference><Reference><Citation>Sherman R, Sherman C. Prevalence and characteristics of chronic phantom limb pain among American veterans. Am J Phys Med 1983;62:227&#x2013;38.</Citation></Reference><Reference><Citation>Sherman RA, Sherman CJ, Parker L. Chronic phantom and stump pain among American veterans: results of a survey. PAIN 1984;18:83&#x2013;95.</Citation></Reference><Reference><Citation>Smith S, Devine M, Taddeo J, McAlister VC. Injury profile suffered by targets of antipersonnel improvised explosive devices: prospective cohort study. BMJ Open 2017;7:e014697.</Citation></Reference><Reference><Citation>S&#xf8;reide K. Epidemiology of major trauma. Br J Surg 2009;96:697&#x2013;8.</Citation></Reference><Reference><Citation>Stankevicius A, Wallwork SB, Summers SJ, Hordacre B, Stanton TR. Prevalence and incidence of phantom limb pain, phantom limb sensations and telescoping in amputees: a systematic rapid review. Eur J Pain 2021;25:23&#x2013;38.</Citation></Reference><Reference><Citation>Strand V, Wright GC, Bergman MJ, Tambiah J, Taylor PC. Patient expectations and perceptions of goal-setting strategies for disease management in rheumatoid arthritis. J Rheumatol 2015;42:2046&#x2013;54.</Citation></Reference><Reference><Citation>Taghipour H, Moharamzad Y, Mafi AR, Amini A, Naghizadeh MM, Soroush MR, Namavari A. Quality of life among veterans with war-related unilateral lower extremity amputation: a long-term survey in a prosthesis center in Iran. J Orthop Trauma 2009;23:525&#x2013;30.</Citation></Reference><Reference><Citation>Tintle SM, Baechler MF, Nanos GP, Forsberg JA, Potter BK. Reoperations following combat-related upper-extremity amputations. J Bone Joint Surg 2012;94:e119.</Citation></Reference><Reference><Citation>Toblin RL, Quartana PJ, Riviere LA, Walper KC, Hoge CW. Chronic pain and opioid use in us soldiers after combat deployment. JAMA Intern Med 2014;174:1400&#x2013;1.</Citation></Reference><Reference><Citation>Truusa T-T, Castro C. Definition of a veteran: the military viewed as a culture. In: Castro C, Dursan S, editors. Military reintegration, approach, management, and assessment of military veterans transitioning to civilian life. Cambridge: Academic Press, 2019. p. 5&#x2013;19.</Citation></Reference><Reference><Citation>Tuttle AH, Tohyama S, Ramsay T, Kimmelman J, Schweinhardt P, Bennett GJ, Mogil JS. Increasing placebo responses over time in U.S. clinical trials of neuropathic pain. PAIN 2015;156:2616&#x2013;26.</Citation></Reference><Reference><Citation>Vaso A, Adahan HM, Gjika A, Zahaj S, Zhurda T, Vyshka G, Devor M. Peripheral nervous system origin of phantom limb pain. PAIN 2014;155:1384&#x2013;91.</Citation></Reference><Reference><Citation>Wang L, Cohen JC, Devasenapathy N, Hong BY, Kheyson S, Lu D, Oparin Y, Kennedy SA, Romerosa B, Arora N, Kwon HY, Jackson K, Prasad M, Jayasekera D, Li A, Guarna G, Natalwalla S, Couban RJ, Reid S, Khan JS, McGillion M, Busse JW. Prevalence and intensity of persistent post-surgical pain following breast cancer surgery: a systematic review and meta-analysis of observational studies. Br J Anaesth 2020;125:346&#x2013;57.</Citation></Reference><Reference><Citation>Wartan SW, Hamann W, Wedley JR, Mccoll I. Phantom pain and sensation among British veteran amputees. Br J Anaesth 1997;78:652&#x2013;9.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>\n",
            "XML saved to: path/to/save/xml/38112578.xml\n",
            "Details URL: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=38103121&retmode=xml&api_key=9edd38677707c08b2a96ed1a6e8c61c47408\n",
            "Details Response Content: <?xml version=\"1.0\" ?>\n",
            "<!DOCTYPE PubmedArticleSet PUBLIC \"-//NLM//DTD PubMedArticle, 1st January 2023//EN\" \"https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd\">\n",
            "<PubmedArticleSet>\n",
            "<PubmedArticle><MedlineCitation Status=\"Publisher\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38103121</PMID><DateRevised><Year>2023</Year><Month>12</Month><Day>16</Day></DateRevised><Article PubModel=\"Print-Electronic\"><Journal><ISSN IssnType=\"Electronic\">1699-3055</ISSN><JournalIssue CitedMedium=\"Internet\"><PubDate><Year>2023</Year><Month>Dec</Month><Day>16</Day></PubDate></JournalIssue><Title>Clinical &amp; translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico</Title><ISOAbbreviation>Clin Transl Oncol</ISOAbbreviation></Journal><ArticleTitle>Cardiovascular comorbidities and their prognostic value in small cell lung cancer patients with chemoradiotherapy.</ArticleTitle><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.1007/s12094-023-03359-3</ELocationID><Abstract><AbstractText Label=\"BACKGROUND\" NlmCategory=\"BACKGROUND\">Small cell lung cancer (SCLC) is an extremely malignant subtype of lung cancer because of its high potential for metastases. Cardiac invasion of SCLC is a serious concern that may lead to systemic embolism or tract obstruction. It has aroused much concern that cardiovascular comorbidities may significantly affect the survival of SCLC patients and their treatment decisions.</AbstractText><AbstractText Label=\"METHODS\" NlmCategory=\"METHODS\">We consecutively recruited 772 small cell lung cancer (SCLC) patients between January 2011 and December 2018 from 4 cancer specialty hospitals in China. Only newly diagnosed primary cancer inpatients were included. Univariable and multivariable adjusted Cox proportional hazard models were conducted to evaluate the risk factors associated with mortality. Hazard ratios (HRs) for mortality and corresponding 95% confidence intervals (95% CIs) were calculated.</AbstractText><AbstractText Label=\"RESULTS\" NlmCategory=\"RESULTS\">The prevalence of cardiovascular diseases (CVDs) was 34.6% in all SCLC patients. Log-rank analysis presented statistically significant differences in median survival time (MST) between patients with CVD and without CVD in all SCLC patients (9.0&#xa0;months vs. 15.0&#xa0;months, P&#x2009;=&#x2009;0.005) and patients with chemotherapy only (12.0&#xa0;months vs. 18.0&#xa0;months, P&#x2009;=&#x2009;0.048). Pericardial effusion (HR 1.671, 95% CI 1.082-2.580, P&#x2009;=&#x2009;0.021) and heart failure (HR 1.752, 95% CI 1.290-2.379, P&#x2009;&lt;&#x2009;0.001) were independent risk factors associated with mortality in all SCLC patients. VTE is related to poorer prognosis in patients with chemotherapy only (HR 5.558, 95% CI 1.335-23.135, P&#x2009;=&#x2009;0.018) and chemoradiotherapy (HR 3.057, 95% CI 1.270-7.539, P&#x2009;=&#x2009;0.013).</AbstractText><AbstractText Label=\"CONCLUSIONS\" NlmCategory=\"CONCLUSIONS\">Comprehensive management of CVD comorbidities is of vital importance for the long-term prognosis of SCLC patients.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s), under exclusive licence to Federaci&#xf3;n de Sociedades Espa&#xf1;olas de Oncolog&#xed;a (FESEO).</CopyrightInformation></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\" EqualContrib=\"Y\"><LastName>Liang</LastName><ForeName>Hanyang</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, FuWai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.167 North Lishi Road, Xicheng District, Beijing, 100037, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\" EqualContrib=\"Y\"><LastName>Wang</LastName><ForeName>Tianjie</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, FuWai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.167 North Lishi Road, Xicheng District, Beijing, 100037, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Liu</LastName><ForeName>Dong</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, FuWai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.167 North Lishi Road, Xicheng District, Beijing, 100037, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Wang</LastName><ForeName>Hao</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, FuWai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.167 North Lishi Road, Xicheng District, Beijing, 100037, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Ba</LastName><ForeName>Zhengqing</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, FuWai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.167 North Lishi Road, Xicheng District, Beijing, 100037, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Xiao</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, FuWai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.167 North Lishi Road, Xicheng District, Beijing, 100037, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Liu</LastName><ForeName>Yilu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, FuWai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.167 North Lishi Road, Xicheng District, Beijing, 100037, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Yuan</LastName><ForeName>Jiansong</ForeName><Initials>J</Initials><Identifier Source=\"ORCID\">0000-0002-5389-295X</Identifier><AffiliationInfo><Affiliation>State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, FuWai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.167 North Lishi Road, Xicheng District, Beijing, 100037, China. jsyuantg@163.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Pulmonary Vascular Medicine, National Center for Cardiovascular Diseases, FuWai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.167 North Lishi Road, Xicheng District, Beijing, 100037, China. jsyuantg@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Yang</LastName><ForeName>Weixian</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, FuWai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.167 North Lishi Road, Xicheng District, Beijing, 100037, China. wxyang2009@sina.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Pulmonary Vascular Medicine, National Center for Cardiovascular Diseases, FuWai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.167 North Lishi Road, Xicheng District, Beijing, 100037, China. wxyang2009@sina.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2023</Year><Month>12</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Clin Transl Oncol</MedlineTA><NlmUniqueID>101247119</NlmUniqueID><ISSNLinking>1699-048X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner=\"NOTNLM\"><Keyword MajorTopicYN=\"N\">Cardio-oncology</Keyword><Keyword MajorTopicYN=\"N\">Cardiovascular disease</Keyword><Keyword MajorTopicYN=\"N\">Comorbidity</Keyword><Keyword MajorTopicYN=\"N\">Small cell lung cancer</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"received\"><Year>2023</Year><Month>10</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus=\"accepted\"><Year>2023</Year><Month>11</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus=\"medline\"><Year>2023</Year><Month>12</Month><Day>16</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2023</Year><Month>12</Month><Day>16</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2023</Year><Month>12</Month><Day>16</Day><Hour>11</Hour><Minute>7</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38103121</ArticleId><ArticleId IdType=\"doi\">10.1007/s12094-023-03359-3</ArticleId><ArticleId IdType=\"pii\">10.1007/s12094-023-03359-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rudin CM, Brambilla E, Faivre-Finn C, Sage J. Small-cell lung cancer[J]. Nat Rev Dis Primers. 2021;7(1):3. https://doi.org/10.1038/s41572-020-00235-0 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/s41572-020-00235-0</ArticleId><ArticleId IdType=\"pubmed\">33446664</ArticleId><ArticleId IdType=\"pmc\">8177722</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang L, Shi Y. Prognostic value of pretreatment smoking status for small cell lung cancer: A meta-analysis[J]. Thorac Cancer. 2020;11(11):3252&#x2013;9. https://doi.org/10.1111/1759-7714.13661 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1111/1759-7714.13661</ArticleId><ArticleId IdType=\"pubmed\">32959954</ArticleId><ArticleId IdType=\"pmc\">7605986</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee W, Hwang SH, Choi H, Kim H. The association between smoking or passive smoking and cardiovascular diseases using a Bayesian hierarchical model: based on the 2008&#x2013;2013 Korea Community Health Survey[J]. Epidemiol Health. 2017;39: e2017026. https://doi.org/10.4178/epih.e2017026 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.4178/epih.e2017026</ArticleId><ArticleId IdType=\"pubmed\">28728350</ArticleId><ArticleId IdType=\"pmc\">5723911</ArticleId></ArticleIdList></Reference><Reference><Citation>Mets OM, Vliegenthart R, Gondrie MJ, Viergever MA, Oudkerk M, de Koning HJ, et al. Lung cancer screening CT-based prediction of cardiovascular events[J]. JACC Cardiovasc Imaging. 2013;6(8):899&#x2013;907. https://doi.org/10.1016/j.jcmg.2013.02.008 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jcmg.2013.02.008</ArticleId><ArticleId IdType=\"pubmed\">23769488</ArticleId></ArticleIdList></Reference><Reference><Citation>Chao H, Shan H, Homayounieh F, Singh R, Khera RD, Guo H, et al. Deep learning predicts cardiovascular disease risks from lung cancer screening low dose computed tomography[J]. Nat Commun. 2021;12(1):2963. https://doi.org/10.1038/s41467-021-23235-4 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/s41467-021-23235-4</ArticleId><ArticleId IdType=\"pubmed\">34017001</ArticleId><ArticleId IdType=\"pmc\">8137697</ArticleId></ArticleIdList></Reference><Reference><Citation>Pham N, Bonnen MD, Ghebre YT. Silent Neoplastic Cardiac Invasion in Small Cell Lung Cancer: A Case Report and Review of the Literature[J]. Am J Case Rep. 2018;19:619&#x2013;22. https://doi.org/10.12659/ajcr.908374 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.12659/ajcr.908374</ArticleId><ArticleId IdType=\"pubmed\">29844305</ArticleId><ArticleId IdType=\"pmc\">6004049</ArticleId></ArticleIdList></Reference><Reference><Citation>Torre-Bouscoulet L, Mu&#xf1;oz-Monta&#xf1;o WR, Mart&#xed;nez-Brise&#xf1;o D, Lozano-Ruiz FJ, Fern&#xe1;ndez-Plata R, Beck-Maga&#xf1;a JA, et al. Abnormal pulmonary function tests predict the development of radiation-induced pneumonitis in advanced non-small cell lung Cancer[J]. Respir Res. 2018;19(1):72. https://doi.org/10.1186/s12931-018-0775-2 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1186/s12931-018-0775-2</ArticleId><ArticleId IdType=\"pubmed\">29690880</ArticleId><ArticleId IdType=\"pmc\">5937833</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y, Qin F, Ji Q, Xia W, He B. Primary site as a novel prognostic factor for cardiovascular mortality post-radiotherapy in limited-stage small cell lung cancer: A large population-based study[J]. Front Cardiovasc Med. 2022;9: 922811. https://doi.org/10.3389/fcvm.2022.922811 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3389/fcvm.2022.922811</ArticleId><ArticleId IdType=\"pubmed\">36035954</ArticleId><ArticleId IdType=\"pmc\">9411942</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu D, Ma Z, Yang J, Zhao M, Ao H, Zheng X, et al. Prevalence and prognosis significance of cardiovascular disease in cancer patients: a population-based study[J]. Aging (Albany NY). 2019;11(18):7948&#x2013;60. https://doi.org/10.18632/aging.102301 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.18632/aging.102301</ArticleId><ArticleId IdType=\"pubmed\">31562288</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang HY, Liu D, Wang H, Ba ZQ, Xiao Y, Liu YL, et al. Pre-existing cardiometabolic comorbidities and survival of middle-aged and elderly non-small cell lung cancer patients[J]. J Geriatr Cardiol. 2023;20(10):737&#x2013;47. https://doi.org/10.26599/1671-5411.2023.10.002 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.26599/1671-5411.2023.10.002</ArticleId><ArticleId IdType=\"pubmed\">37970226</ArticleId><ArticleId IdType=\"pmc\">10630173</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrero Rivera D, Nieto-Guerrero G&#xf3;mez JM, Fern&#xe1;ndez C, de Bobadilla J, Delgado D, Rivin Del Campo E, Praena-Fern&#xe1;ndez JM, et al. Cardiovascular disease and survival in non-small cell lung cancer: a multicenter prospective assessment[J]. Clin Transl Oncol. 2019;21(9):1220&#x2013;30.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s12094-019-02047-5</ArticleId><ArticleId IdType=\"pubmed\">30680608</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun JY, Zhang ZY, Qu Q, Wang N, Zhang YM, Miao LF, et al. Cardiovascular disease-specific mortality in 270,618 patients with non-small cell lung cancer[J]. Int J Cardiol. 2021;330:186&#x2013;93. https://doi.org/10.1016/j.ijcard.2021.02.025 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.ijcard.2021.02.025</ArticleId><ArticleId IdType=\"pubmed\">33581175</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu XQ, Li JY, Du WJ. Causes of death following small cell lung cancer diagnosis: a population-based analysis[J]. BMC Pulm Med. 2022;22(1):262. https://doi.org/10.1186/s12890-022-02053-4 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1186/s12890-022-02053-4</ArticleId><ArticleId IdType=\"pubmed\">35787685</ArticleId><ArticleId IdType=\"pmc\">9254402</ArticleId></ArticleIdList></Reference><Reference><Citation>Aarts MJ, Aerts JG, van den Borne BE, Biesma B, Lemmens VE, Kloover JS. Comorbidity in Patients With Small-Cell Lung Cancer: Trends and Prognostic Impact[J]. Clin Lung Cancer. 2015;16(4):282&#x2013;91. https://doi.org/10.1016/j.cllc.2014.12.003 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.cllc.2014.12.003</ArticleId><ArticleId IdType=\"pubmed\">25572007</ArticleId></ArticleIdList></Reference><Reference><Citation>Pijls-Johannesma M, De Ruysscher D, Vansteenkiste J, Kester A, Rutten I, Lambin P. Timing of chest radiotherapy in patients with limited stage small cell lung cancer: a systematic review and meta-analysis of randomised controlled trials[J]. Cancer Treat Rev. 2007;33(5):461&#x2013;73. https://doi.org/10.1016/j.ctrv.2007.03.002 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.ctrv.2007.03.002</ArticleId><ArticleId IdType=\"pubmed\">17513057</ArticleId></ArticleIdList></Reference><Reference><Citation>Bi N, Deng L, Hu X, Shayan G, Zhao L, Zhang L, et al. 30 Gy vs. 45 Gy Consolidative Thoracic Radiation (cTRT) for Extensive Stage Small Cell Lung Cancer (ES-SCLC): A Multicenter, Randomized, Phase 3 Trial[J]. Int J Radiat Oncol Biol Phys. 2023. https://doi.org/10.1016/j.ijrobp.2023.06.350 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.ijrobp.2023.06.350</ArticleId><ArticleId IdType=\"pubmed\">36623605</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Pechoux C, Pourel N, Barlesi F, Lerouge D, Antoni D, Lamezec B, et al. Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART): an open-label, randomised, phase 3 trial[J]. Lancet Oncol. 2022;23(1):104&#x2013;14. https://doi.org/10.1016/s1470-2045(21)00606-9 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/s1470-2045(21)00606-9</ArticleId><ArticleId IdType=\"pubmed\">34919827</ArticleId></ArticleIdList></Reference><Reference><Citation>Banfill K, Giuliani M, Aznar M, Franks K, McWilliam A, Schmitt M, et al. Cardiac Toxicity of Thoracic Radiotherapy: Existing Evidence and Future Directions[J]. J Thorac Oncol. 2021;16(2):216&#x2013;27. https://doi.org/10.1016/j.jtho.2020.11.002 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jtho.2020.11.002</ArticleId><ArticleId IdType=\"pubmed\">33278607</ArticleId><ArticleId IdType=\"pmc\">7870458</ArticleId></ArticleIdList></Reference><Reference><Citation>Shojaee S, Singh I, Solsky I, Nana-Sinkam P. Malignant Pleural Effusion at Presentation in Patients with Small-Cell Lung Cancer[J]. Respiration. 2019;98(3):198&#x2013;202. https://doi.org/10.1159/000499372 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1159/000499372</ArticleId><ArticleId IdType=\"pubmed\">31121583</ArticleId></ArticleIdList></Reference><Reference><Citation>Niho S, Kubota K, Yoh K, Goto K, Ohmatsu H, Nihei K, et al. Clinical outcome of small cell lung cancer with pericardial effusion but without distant metastasis[J]. J Thorac Oncol. 2011;6(4):796&#x2013;800. https://doi.org/10.1097/JTO.0b013e318208ec77 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1097/JTO.0b013e318208ec77</ArticleId><ArticleId IdType=\"pubmed\">21258253</ArticleId></ArticleIdList></Reference><Reference><Citation>Kashima A, Fukuda Y, Shimamura M, Ijichi M, Sagara H. Successful treatment of extensive-stage small cell lung cancer with concurrent pleural and pericardial effusions: Case report[J]. Front Oncol. 2022;12:1040452. https://doi.org/10.3389/fonc.2022.1040452 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3389/fonc.2022.1040452</ArticleId><ArticleId IdType=\"pubmed\">36620539</ArticleId><ArticleId IdType=\"pmc\">9816567</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang LK, Kuo YW, Wu SG, Chung KP, Shih JY. Recurrence of pericardial effusion after different procedure modalities in patients with non-small-cell lung cancer[J]. ESMO Open. 2022;7(1): 100354. https://doi.org/10.1016/j.esmoop.2021.100354 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.esmoop.2021.100354</ArticleId><ArticleId IdType=\"pubmed\">34953402</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy D, Liu CC, Cormier JN, Xia R, Du XL. Cardiac toxicity in association with chemotherapy and radiation therapy in a large cohort of older patients with non-small-cell lung cancer[J]. Ann Oncol. 2010;21(9):1825&#x2013;33. https://doi.org/10.1093/annonc/mdq042 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/annonc/mdq042</ArticleId><ArticleId IdType=\"pubmed\">20211871</ArticleId><ArticleId IdType=\"pmc\">2980940</ArticleId></ArticleIdList></Reference><Reference><Citation>Verma V, Fakhreddine MH, Haque W, Butler EB, Teh BS, Simone CB 2nd. Cardiac mortality in limited-stage small cell lung cancer[J]. Radiother Oncol. 2018;128(3):492&#x2013;7. https://doi.org/10.1016/j.radonc.2018.06.011 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.radonc.2018.06.011</ArticleId><ArticleId IdType=\"pubmed\">29934110</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyon AR, Yousaf N, Battisti NML, Moslehi J, Larkin J. Immune checkpoint inhibitors and cardiovascular toxicity[J]. Lancet Oncol. 2018;19(9):e447&#x2013;58. https://doi.org/10.1016/s1470-2045(18)30457-1 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/s1470-2045(18)30457-1</ArticleId><ArticleId IdType=\"pubmed\">30191849</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu JR, Florido R, Lipson EJ, Naidoo J, Ardehali R, Tocchetti CG, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors[J]. Cardiovasc Res. 2019;115(5):854&#x2013;68. https://doi.org/10.1093/cvr/cvz026 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/cvr/cvz026</ArticleId><ArticleId IdType=\"pubmed\">30715219</ArticleId><ArticleId IdType=\"pmc\">6452314</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardinale D, Salvatici M, Sandri MT. Role of biomarkers in cardioncology[J]. Clin Chem Lab Med. 2011;49(12):1937&#x2013;48. https://doi.org/10.1515/cclm.2011.692 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1515/cclm.2011.692</ArticleId><ArticleId IdType=\"pubmed\">21892906</ArticleId></ArticleIdList></Reference><Reference><Citation>Okura Y, Takayama T, Ozaki K, Tanaka H, Seki H, Takenouchi T, et al. Burden of cardiovascular disease in Japanese cancer patients and survivors: a single cancer-center study in Niigata City[J]. Int J Clin Oncol. 2019;24(2):196&#x2013;210. https://doi.org/10.1007/s10147-018-1341-0 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s10147-018-1341-0</ArticleId><ArticleId IdType=\"pubmed\">30218412</ArticleId></ArticleIdList></Reference><Reference><Citation>Kourelis TV, Wysokinska EM, Wang Y, Yang P, Mansfield AS, Tafur AJ. Early venous thromboembolic events are associated with worse prognosis in patients with lung cancer[J]. Lung Cancer. 2014;86(3):358&#x2013;62. https://doi.org/10.1016/j.lungcan.2014.10.003 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.lungcan.2014.10.003</ArticleId><ArticleId IdType=\"pubmed\">25453848</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki T, Fujino S, Inaba S, Yamamura R, Katoh H, Noji Y, et al. Venous Thromboembolism in Patents With Lung Cancer[J]. Clin Appl Thromb Hemost. 2020;26:1076029620977910. https://doi.org/10.1177/1076029620977910 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1177/1076029620977910</ArticleId><ArticleId IdType=\"pubmed\">33350315</ArticleId><ArticleId IdType=\"pmc\">7758641</ArticleId></ArticleIdList></Reference><Reference><Citation>Grover SP, Hisada YM, Kasthuri RS, Reeves BN, Mackman N. Cancer Therapy-Associated Thrombosis[J]. Arterioscler Thromb Vasc Biol. 2021;41(4):1291&#x2013;305. https://doi.org/10.1161/atvbaha.120.314378 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1161/atvbaha.120.314378</ArticleId><ArticleId IdType=\"pubmed\">33567864</ArticleId><ArticleId IdType=\"pmc\">7990713</ArticleId></ArticleIdList></Reference><Reference><Citation>Young K, Paz-Ares L, Thatcher N, Spigel DR, Shahidi J, Soldatenkova V, et al. Venous thromboembolism with EGFR monoclonal antibody necitumumab in stage IV non-small cell lung cancer: A retrospective cohort analysis[J]. Thromb Res. 2018;167:50&#x2013;6. https://doi.org/10.1016/j.thromres.2018.05.004 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.thromres.2018.05.004</ArticleId><ArticleId IdType=\"pubmed\">29787943</ArticleId></ArticleIdList></Reference><Reference><Citation>Hurwitz HI, Saltz LB, Van Cutsem E, Cassidy J, Wiedemann J, Sirz&#xe9;n F, et al. Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies[J]. J Clin Oncol. 2011;29(13):1757&#x2013;64. https://doi.org/10.1200/jco.2010.32.3220 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1200/jco.2010.32.3220</ArticleId><ArticleId IdType=\"pubmed\">21422411</ArticleId></ArticleIdList></Reference><Reference><Citation>Trigo J, Subbiah V, Besse B, Moreno V, L&#xf3;pez R, Sala MA, et al. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial[J]. Lancet Oncol. 2020;21(5):645&#x2013;54. https://doi.org/10.1016/s1470-2045(20)30068-1 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/s1470-2045(20)30068-1</ArticleId><ArticleId IdType=\"pubmed\">32224306</ArticleId></ArticleIdList></Reference><Reference><Citation>Aix SP, Ciuleanu TE, Navarro A, Cousin S, Bonanno L, Smit EF, et al. Combination lurbinectedin and doxorubicin versus physician&#x2019;s choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial[J]. Lancet Respir Med. 2023;11(1):74&#x2013;86. https://doi.org/10.1016/s2213-2600(22)00309-5 .</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/s2213-2600(22)00309-5</ArticleId><ArticleId IdType=\"pubmed\">36252599</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>\n",
            "XML saved to: path/to/save/xml/38103121.xml\n",
            "Details URL: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=38103006&retmode=xml&api_key=9edd38677707c08b2a96ed1a6e8c61c47408\n",
            "Details Response Content: <?xml version=\"1.0\" ?>\n",
            "<!DOCTYPE PubmedArticleSet PUBLIC \"-//NLM//DTD PubMedArticle, 1st January 2023//EN\" \"https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd\">\n",
            "<PubmedArticleSet>\n",
            "<PubmedArticle><MedlineCitation Status=\"MEDLINE\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38103006</PMID><DateCompleted><Year>2023</Year><Month>12</Month><Day>18</Day></DateCompleted><DateRevised><Year>2023</Year><Month>12</Month><Day>18</Day></DateRevised><Article PubModel=\"Electronic-eCollection\"><Journal><ISSN IssnType=\"Electronic\">2544-4646</ISSN><JournalIssue CitedMedium=\"Internet\"><Volume>72</Volume><Issue>4</Issue><PubDate><Year>2023</Year><Month>Dec</Month><Day>01</Day></PubDate></JournalIssue><Title>Polish journal of microbiology</Title><ISOAbbreviation>Pol J Microbiol</ISOAbbreviation></Journal><ArticleTitle>The Effects of Antibiotics on the Development and Treatment of Non-Small Cell Lung Cancer.</ArticleTitle><Pagination><StartPage>365</StartPage><EndPage>375</EndPage><MedlinePgn>365-375</MedlinePgn></Pagination><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.33073/pjm-2023-047</ELocationID><Abstract><AbstractText>There have been studies on antibiotic use concerning lung cancer and its potential impact on carcinogenesis and microbiome. However, subsequent research has failed to support these associations consistently. In terms of the potential carcinogenic of antibiotics on lung cancer, the available evidence has not been sufficient to draw any definitive conclusions. Maintaining immune homeostasis and preventing pathogen invasion is critically dependent on the microbiome. The subtle balance of the body microbiota, including the lungs, is susceptible to disruption by antibiotic use. There is an association between disruptions of the lung microbiome and respiratory diseases, including lung cancer, and decreased efficacy of treatments. Patients with lung cancer are often indicated for antibiotic treatment due to respiratory infections or other comorbidities. Pulmonary infections in the area of undetected lung tumors are not uncommon. They can be an early sign of malignancy, which may explain the association between antibiotic use and lung cancer diagnosis. Antibiotic use can also affect the effectiveness of immune checkpoint inhibitor therapy. Studies suggest that antibiotic use can impair the efficacy of immune checkpoint inhibitor therapy in lung cancer patients, particularly around the time when treatment is initiated. These findings require further study, understanding underlying mechanisms, and identifying microbiota signatures associated with treatment response.</AbstractText><CopyrightInformation>&#xa9; 2023 Petra &#x160;vecov&#xe1; et al., published by Sciendo.</CopyrightInformation></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>&#x160;vecov&#xe1;</LastName><ForeName>Petra</ForeName><Initials>P</Initials><Identifier Source=\"ORCID\">0000-0002-4140-9318</Identifier><AffiliationInfo><Affiliation>1Department of Respiratory Diseases and Tuberculosis, University Hospital Olomouc and Faculty of Medicine, Palack&#xfd; University Olomouc, Olomouc, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Jakubec</LastName><ForeName>Petr</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>1Department of Respiratory Diseases and Tuberculosis, University Hospital Olomouc and Faculty of Medicine, Palack&#xfd; University Olomouc, Olomouc, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>&#x160;karda</LastName><ForeName>Jozef</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>2Department of Clinical and Molecular Pathology and Genetics, University Hospital Ostrava, Ostrava, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Glogarov&#xe1;</LastName><ForeName>Veronika</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>3Department of Foreign Languages, Faculty of Medicine, Palack&#xfd; University Olomouc, Olomouc, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Mitt&#xe1;k</LastName><ForeName>Marcel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>4Department of Surgical Studies, University Hospital Ostrava and Faculty of Medicine University of Ostrava, Ostrava, Czech Republic.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2023</Year><Month>12</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Poland</Country><MedlineTA>Pol J Microbiol</MedlineTA><NlmUniqueID>101229003</NlmUniqueID><ISSNLinking>1733-1331</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI=\"D000900\">Anti-Bacterial Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI=\"D000082082\">Immune Checkpoint Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI=\"D006801\" MajorTopicYN=\"N\">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D002289\" MajorTopicYN=\"Y\">Carcinoma, Non-Small-Cell Lung</DescriptorName><QualifierName UI=\"Q000188\" MajorTopicYN=\"N\">drug therapy</QualifierName><QualifierName UI=\"Q000473\" MajorTopicYN=\"N\">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D008175\" MajorTopicYN=\"Y\">Lung Neoplasms</DescriptorName><QualifierName UI=\"Q000188\" MajorTopicYN=\"N\">drug therapy</QualifierName><QualifierName UI=\"Q000473\" MajorTopicYN=\"N\">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D000900\" MajorTopicYN=\"N\">Anti-Bacterial Agents</DescriptorName><QualifierName UI=\"Q000009\" MajorTopicYN=\"N\">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D000082082\" MajorTopicYN=\"N\">Immune Checkpoint Inhibitors</DescriptorName><QualifierName UI=\"Q000627\" MajorTopicYN=\"N\">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D008168\" MajorTopicYN=\"N\">Lung</DescriptorName><QualifierName UI=\"Q000473\" MajorTopicYN=\"N\">pathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner=\"NOTNLM\"><Keyword MajorTopicYN=\"N\">antibiotics</Keyword><Keyword MajorTopicYN=\"N\">immunotherapy</Keyword><Keyword MajorTopicYN=\"N\">lung</Keyword><Keyword MajorTopicYN=\"N\">microbiome</Keyword><Keyword MajorTopicYN=\"N\">non-small-cell lung cancer</Keyword></KeywordList><CoiStatement>Conflict of interest. The authors do not report any financial or personal connections with other persons or organizations, which might negatively affect the contents of this publication and/or claim authorship rights to this publication.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"received\"><Year>2023</Year><Month>8</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus=\"accepted\"><Year>2023</Year><Month>10</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus=\"medline\"><Year>2023</Year><Month>12</Month><Day>18</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2023</Year><Month>12</Month><Day>16</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2023</Year><Month>12</Month><Day>16</Day><Hour>9</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38103006</ArticleId><ArticleId IdType=\"pmc\">PMC10725157</ArticleId><ArticleId IdType=\"doi\">10.33073/pjm-2023-047</ArticleId><ArticleId IdType=\"pii\">pjm-2023-047</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alkan G, Senturk Oztas N, Turna ZH, Ozguroglu M. 1168P Effect of antibiotic treatment on immune checkpoint inhibitor efficacy in patients with advanced non-small cell lung cancer Ann Oncol 2022;33 doi: 10.1016/j.annonc.2022.07.1291. . . ; :S1082. https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.annonc.2022.07.1291</ArticleId><ArticleId IdType=\"pubmed\">37597304</ArticleId></ArticleIdList></Reference><Reference><Citation>American Cancer Society  . What causes lung cancer? [Internet] Atlanta (USA): American Cancer Society, Inc; 2019.  [cited 2023 May 5].  . . : .; [ ]. Available from  https://www.cancer.org/cancer/lung-cancer/causes-risks-prevention/what-causes.html.</Citation></Reference><Reference><Citation>Brawley OW, Glynn TJ, Khuri FR, Wender RC, Seffrin JR. The first Surgeon General&#x2019;s report on smoking and health: the 50th anniversary CA Cancer J Clin 2014 NaN64(1):5. doi: 10.3322/caac.21210. . . ; ( ): &#x2013;. . https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3322/caac.21210</ArticleId><ArticleId IdType=\"pubmed\">24249254</ArticleId></ArticleIdList></Reference><Reference><Citation>Bullman S, Pedamallu CS, Sicinska E, Clancy TE, Zhang X, Cai D, Neuberg D, Huang K, Guevara F, Nelson T, et al. Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer Science 2017 NaN358(6369):1443. doi: 10.1126/science.aal5240. . . . ; ( ): &#x2013;. . https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1126/science.aal5240</ArticleId><ArticleId IdType=\"pmc\">PMC5823247</ArticleId><ArticleId IdType=\"pubmed\">29170280</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC  . What are the risk factors for lung cancer? [Internet] Atlanta (USA): Centers for Disease Control and Prevention; 2023.  [cited 2023 May 5].  . . : ; [ ]. Available from  https://www.cdc.gov/cancer/lung/basic_info/risk_factors.htm.</Citation></Reference><Reference><Citation>Chalabi M, Cardona A, Nagarkar DR, Dhawahir Scala A, Gandara DR, Rittmeyer A, Albert ML, Powles T, Kok M, Herrera FG, im CORE working group of early career investigators Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials Ann Oncol 2020 NaN31(4):525. doi: 10.1016/j.annonc.2020.01.006. . . . ; ( ): &#x2013;. . https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.annonc.2020.01.006</ArticleId><ArticleId IdType=\"pubmed\">32115349</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang ET, Smedby KE, Hjalgrim H, Sch&#xf6;llkopf C, Porwit-Mac-Donald A, Sundstr&#xf6;m C, Tani E, d&#x2019;Amore F, Melbye M, Adami HO, et al. Medication use and risk of non-Hodgkin&#x2019;s lymphoma Am J Epidemiol 2005 NaN162(10):965. doi: 10.1093/aje/kwi311. . . . ; ( ): &#x2013;. . https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/aje/kwi311</ArticleId><ArticleId IdType=\"pubmed\">16192343</ArticleId></ArticleIdList></Reference><Reference><Citation>Derosa L, Hellmann MD, Spaziano M, Halpenny D, Fidelle M, Rizvi H, Long N, Plodkowski AJ, Arbour KC, Chaft JE, et al. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and nonsmall-cell lung cancer Ann Oncol 2018 NaN29(6):1437. doi: 10.1093/annonc/mdy103. . . . ; ( ): &#x2013;. . https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/annonc/mdy103</ArticleId><ArticleId IdType=\"pmc\">PMC6354674</ArticleId><ArticleId IdType=\"pubmed\">29617710</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickson RP, Huffnagle GB. The lung microbiome: New principles for respiratory bacteriology in health and disease PLoS Pathog 2015 NaN11(7):2023047. doi: 10.1371/journal.ppat.1004923. . . ; ( ) :e1004923. https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1371/journal.ppat.1004923</ArticleId><ArticleId IdType=\"pmc\">PMC4497592</ArticleId><ArticleId IdType=\"pubmed\">26158874</ArticleId></ArticleIdList></Reference><Reference><Citation>Didham RC, Reith DM, McConnell DW, Harrison KS. Antibiotic exposure and breast cancer in New Zealand Breast Cancer Res Treat 2005 NaN92(2):163. doi: 10.1007/s10549-005-2115-8. . . ; ( ): &#x2013;. . https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s10549-005-2115-8</ArticleId><ArticleId IdType=\"pubmed\">15986126</ArticleId></ArticleIdList></Reference><Reference><Citation>ECIS  . European Cancer Information System. Brussels (Belgium): European Union; 2023.  [cited 2023 May 5].  . . : ; [ ]. Available from  https://ecis.jrc.ec.europa.eu.</Citation></Reference><Reference><Citation>Elkrief A, Derosa L, Kroemer G, Zitvogel L, Routy B. The negative impact of antibiotics on outcomes in cancer patients treated with immunotherapy: A new independent prognostic factor? Ann Oncol 2019 NaN30(10):1572. doi: 10.1093/annonc/mdz206. . ; ( ): &#x2013;. . https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/annonc/mdz206</ArticleId><ArticleId IdType=\"pubmed\">31268133</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang YH, Yang YH, Hsieh MJ, Hung MS, Lin YC. Concurrent proton-pump inhibitors increase risk of death for lung cancer patients receiving 1st-line gefitinib treatment &#x2013; a nationwide populationbased study Cancer Manag Res 2019 NaN11:8539. doi: 10.2147/CMAR.S222278. . . ; : &#x2013;. . https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.2147/CMAR.S222278</ArticleId><ArticleId IdType=\"pmc\">PMC6756852</ArticleId><ArticleId IdType=\"pubmed\">31572008</ArticleId></ArticleIdList></Reference><Reference><Citation>Galli G, Poggi M, Fuc&#xe0; G, Imbimbo M, Proto C, Signorelli D, Vitali M, Zilembo N, Ganzinelli M, de Braud F, et al. Effects of antibiotic use during immunotherapy in metastatic non-small cell lung cancer Ann Oncol 2018 NaN29 doi: 10.1093/annonc/mdy292.088. . . . ; :viii531. https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/annonc/mdy292.088</ArticleId></ArticleIdList></Reference><Reference><Citation>Geum MJ, Kim C, Kang JE, Choi JH, Kim JS, Son ES, Lim SM, Rhie SJ. Broad-spectrum antibiotic regimen affects survival in patients receiving nivolumab for non-small cell lung cancer Pharmaceuticals 2021 NaN14(5):445. doi: 10.3390/ph14050445. . . ; ( ): . https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3390/ph14050445</ArticleId><ArticleId IdType=\"pmc\">PMC8151442</ArticleId><ArticleId IdType=\"pubmed\">34066877</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonugunta AS, Von Itzstein MS, Hsiehchen D, Le T, Rashdan S, Yang H, Selby C, Alvarez C, Gerber DE. Antibiotic prescriptions in lung cancer and melanoma populations: Differences with potential clinical implications in the immunotherapy era Clin Lung Cancer 2023 NaN24(1):11. doi: 10.1016/j.cllc.2022.09.005. . . ; ( ): &#x2013;. . https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.cllc.2022.09.005</ArticleId><ArticleId IdType=\"pubmed\">36253271</ArticleId></ArticleIdList></Reference><Reference><Citation>Gopalakrishnan V, Helmink BA, Spencer CN, Reuben A, Wargo JA. The influence of the gut microbiome on cancer, immunity, and cancer immunotherapy Cancer Cell 2018 NaN33(4):570. doi: 10.1016/j.ccell.2018.03.015. . . ; ( ): &#x2013;. . https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.ccell.2018.03.015</ArticleId><ArticleId IdType=\"pmc\">PMC6529202</ArticleId><ArticleId IdType=\"pubmed\">29634945</ArticleId></ArticleIdList></Reference><Reference><Citation>Jernberg C, L&#xf6;fmark S, Edlund C, Jansson JK. Long-term ecological impacts of antibiotic administration on the human intestinal microbiota ISME J 2007 NaN1(1):56. doi: 10.1038/ismej.2007.3. . . ; ( ): &#x2013;. . https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/ismej.2007.3</ArticleId><ArticleId IdType=\"pubmed\">18043614</ArticleId></ArticleIdList></Reference><Reference><Citation>Kilkkinen A, Rissanen H, Klaukka T, Pukkala E, Heli&#xf6;vaara M, Huovinen P, M&#xe4;nnist&#xf6; S, Aromaa A, Knekt P. Antibiotic use predicts an increased risk of cancer Int J Cancer 2008 NaN123(9):2152. doi: 10.1002/ijc.23622. . . ; ( ): &#x2013;. . https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1002/ijc.23622</ArticleId><ArticleId IdType=\"pubmed\">18704945</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamb R, Ozsvari B, Lisanti CL, Tanowitz HB, Howell A, Martinez--Outschoorn UE, Sotgia F, Lisanti MP. Antibiotics that target mitochondria effectively eradicate cancer stem cells, across multiple tumor types: Treating cancer like an infectious disease Oncotarget 2015 NaN6(7):4569. doi: 10.18632/oncotarget.3174. . . ; ( ): &#x2013;. . https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.18632/oncotarget.3174</ArticleId><ArticleId IdType=\"pmc\">PMC4467100</ArticleId><ArticleId IdType=\"pubmed\">25625193</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Noci V, Guglielmetti S, Arioli S, Camisaschi C, Bianchi F, Sommariva M, Storti C, Triulzi T, Castelli C, Balsari A, et al. Modulation of pulmonary microbiota by antibiotic or probiotic aerosol therapy: A strategy to promote immunosurveillance against lung metastases Cell Rep 2018 NaN24(13):3528. doi: 10.1016/j.celrep.2018.08.090. . . . ; ( ): &#x2013;. . https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.celrep.2018.08.090</ArticleId><ArticleId IdType=\"pubmed\">30257213</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SH, Sung JY, Yong D, Chun J, Kim SY, Song JH, Chung KS, Kim EY, Jung JY, Kang YA, et al. Characterization of microbiome in bronchoalveolar lavage fluid of patients with lung cancer comparing with benign mass like lesions Lung Cancer 2016 NaN102:89. doi: 10.1016/j.lungcan.2016.10.016. . . . ; : &#x2013;. . https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.lungcan.2016.10.016</ArticleId><ArticleId IdType=\"pubmed\">27987594</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu HX, Tao LL, Zhang J, Zhu YG, Zheng Y, Liu D, Zhou M, Ke H, Shi MM, Qu JM. Difference of lower airway microbiome in bilateral protected specimen brush between lung cancer patients with unilateral lobar masses and control subjects Int J Cancer 2018 NaN142(4):769. doi: 10.1002/ijc.31098. . . ; ( ): &#x2013;. . https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1002/ijc.31098</ArticleId><ArticleId IdType=\"pubmed\">29023689</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xf6;fling L, Bahmanyar S, Kieler H, Lambe M, Wagenius G. Anti-biotic use prior to a lung cancer diagnosis: A population-based study Cancer Causes Control 2021 NaN32(6):597. doi: 10.1007/s10552-021-01413-5. . . ; ( ): &#x2013;. . https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s10552-021-01413-5</ArticleId><ArticleId IdType=\"pmc\">PMC8089077</ArticleId><ArticleId IdType=\"pubmed\">33754218</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xf6;fmark S, Jernberg C, Jansson JK, Edlund C. Clindamycin-induced enrichment and long-term persistence of resistant Bacteroides spp. and resistance genes J Antimicrob Chemother 2006 NaN58(6):1160. doi: 10.1093/jac/dkl420. . . ; ( ): &#x2013;. . https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/jac/dkl420</ArticleId><ArticleId IdType=\"pubmed\">17046967</ArticleId></ArticleIdList></Reference><Reference><Citation>Lozupone CA, Stombaugh JI, Gordon JI, Jansson JK, Knight R. Diversity, stability and resilience of the human gut microbiota Nature 2012 NaN489(7415):220. doi: 10.1038/nature11550. . . ; ( ): &#x2013;. . https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/nature11550</ArticleId><ArticleId IdType=\"pmc\">PMC3577372</ArticleId><ArticleId IdType=\"pubmed\">22972295</ArticleId></ArticleIdList></Reference><Reference><Citation>Lurienne L, Cervesi J, Duhalde L, de Gunzburg J, Andremont A, Zalcman G, Buffet R, Bandinelli PA. NSCLC immunotherapy efficacy and antibiotic use: A systematic review and meta-analysis J Thorac Oncol 2020 NaN15(7):1147. doi: 10.1016/j.jtho.2020.03.002. . . ; ( ): &#x2013;. . https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jtho.2020.03.002</ArticleId><ArticleId IdType=\"pubmed\">32173463</ArticleId></ArticleIdList></Reference><Reference><Citation>Majeed U, Zhou K, Heng F, Seegobin K, Zhao Y, Manochakian R, Lou Y. P13.01 Use of antibiotics is associated with an increase in immunotherapy related adverse effects in patients with non-small cell lung cancer J Thorac Oncol 2021 NaN16(10):2023047. doi: 10.1016/j.jtho.2021.08.330. . . ; ( ) :S1010. https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jtho.2021.08.330</ArticleId></ArticleIdList></Reference><Reference><Citation>Matson V, Fessler J, Bao R, Chongsuwat T, Zha Y, Alegre ML, Luke JJ, Gajewski TF. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients Science 2018 NaN359(6371):104. doi: 10.1126/science.aao3290. . . ; ( ): &#x2013;. . https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1126/science.aao3290</ArticleId><ArticleId IdType=\"pmc\">PMC6707353</ArticleId><ArticleId IdType=\"pubmed\">29302014</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayo Clinic  . Antibiotics: Are you misusing them? [Internet] Rochester (USA): Mayo Foundation for Medical Education and Research; 2023.  [cited 2023 May 5].  . . : ; [ ]. Available from  https://www.mayoclinic.org/healthy-lifestyle/consumer-health/in-depth/antibiotics/art-20045720.</Citation></Reference><Reference><Citation>Nyein AF, Bari S, Hogue S, Zhao Y, Maller B, Sha S, Gomez MF, Rollison DE, Robinson LA. Effect of prior antibiotic or chemotherapy treatment on immunotherapy response in non-small cell lung cancer BMC Cancer 2022 NaN22(1):101. doi: 10.1186/s12885-022-09210-2. . . ; ( ): . https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1186/s12885-022-09210-2</ArticleId><ArticleId IdType=\"pmc\">PMC8787935</ArticleId><ArticleId IdType=\"pubmed\">35073876</ArticleId></ArticleIdList></Reference><Reference><Citation>Ochi N, Ichihara E, Takigawa N, Harada D, Inoue K, Shibayama T, Hosokawa S, Kishino D, Harita S, Oda N, et al. The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression Eur J Cancer 2021 NaN149:73. doi: 10.1016/j.ejca.2021.02.040. . . . ; : &#x2013;. . https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.ejca.2021.02.040</ArticleId><ArticleId IdType=\"pubmed\">33838391</ArticleId></ArticleIdList></Reference><Reference><Citation>Palleja A, Mikkelsen KH, Forslund SK, Kashani A, Allin KH, Nielsen T, Hansen TH, Liang S, Feng Q, Zhang C, et al. Recovery of gut microbiota of healthy adults following antibiotic exposure Nat Microbiol 2018 NaN3(11):1255. doi: 10.1038/s41564-018-0257-9. . . ; ( ): &#x2013;. . https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/s41564-018-0257-9</ArticleId><ArticleId IdType=\"pubmed\">30349083</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrelli F, Ghidini M, Ghidini A, Perego G, Cabiddu M, Khakoo S, Oggionni E, Abeni C, Hahne JC, Tomasello G, et al. Use of antibiotics and risk of cancer: A systematic review and meta-analysis of observational studies Cancers 2019 NaN11(8):1174. doi: 10.3390/cancers11081174. . . . ; ( ): . https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3390/cancers11081174</ArticleId><ArticleId IdType=\"pmc\">PMC6721461</ArticleId><ArticleId IdType=\"pubmed\">31416208</ArticleId></ArticleIdList></Reference><Reference><Citation>Pierrard J, Seront E. Impact of the gut microbiome on immune checkpoint inhibitor efficacy &#x2013; a systematic review Curr Oncol 2019 NaN26(6):395. doi: 10.3747/co.26.5177. . . ; ( ): &#x2013;. . https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3747/co.26.5177</ArticleId><ArticleId IdType=\"pmc\">PMC6927774</ArticleId><ArticleId IdType=\"pubmed\">31896938</ArticleId></ArticleIdList></Reference><Reference><Citation>Ram&#xed;rez-Labrada AG, Isla D, Artal A, Arias M, Rezusta A, Pardo J, G&#xe1;lvez EM. The influence of lung microbiota on lung carcinogenesis, immunity, and immunotherapy Trends Cancer 2020 NaN6(2):86. doi: 10.1016/j.trecan.2019.12.007. . . ; ( ): &#x2013;. . https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.trecan.2019.12.007</ArticleId><ArticleId IdType=\"pubmed\">32061309</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritter JM, Flower R, Henderson G, Loke YK, MacEwan D, Rang HP. Rang and Dale&#x2019;s pharmacology. 9th ed Edinburgh (UK): Elsevier; p. 673. , . : . p. .</Citation></Reference><Reference><Citation>Rizzo A, Cusmai A, Giovannelli F, Acquafredda S, Rinaldi L, Misino A, Montagna ES, Ungaro V, Lorusso M, Palmiotti G. Impact of proton pump inhibitors and histamine-2-receptor antagonists on non-small cell lung cancer immunotherapy: A systematic review and meta-analysis Cancers 2022 NaN14(6):1404. doi: 10.3390/cancers14061404. . . ; ( ): . https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3390/cancers14061404</ArticleId><ArticleId IdType=\"pmc\">PMC8945985</ArticleId><ArticleId IdType=\"pubmed\">35326555</ArticleId></ArticleIdList></Reference><Reference><Citation>Routy B, Gopalakrishnan V, Daill&#xe8;re R, Zitvogel L, Wargo JA, Kroemer G. The gut microbiota influences anticancer immunosurveillance and general health Nat Rev Clin Oncol 2018b NaN15(6):382. doi: 10.1038/S41571-018-0006-2. . . ; ( ): &#x2013;. . https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/S41571-018-0006-2</ArticleId><ArticleId IdType=\"pubmed\">29636538</ArticleId></ArticleIdList></Reference><Reference><Citation>Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daill&#xe8;re R, Fluckiger A, Messaoudene M, Rauber C, Roberti MP, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors Science 2018a NaN359(6371):91. doi: 10.1126/science.aan3706. . . . ; ( ): &#x2013;. . https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1126/science.aan3706</ArticleId><ArticleId IdType=\"pubmed\">29097494</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz-Pati&#xf1;o A, Barr&#xf3;n F, Cardona AF, Corrales L, Mas L, Mart&#xed;n C, Zatarain-Barr&#xf3;n ZL, Recondo G, Ricaurte L, Rojas L, et al. CLICaP. Antibiotics impair immune checkpoint inhibitor effectiveness in Hispanic patients with non-small cell lung cancer (AB-CLICaP) Thorac Cancer 2020 NaN11(9):2552. doi: 10.1111/1759-7714.13573. .; . . ; ( ): &#x2013;. . https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1111/1759-7714.13573</ArticleId><ArticleId IdType=\"pmc\">PMC7471049</ArticleId><ArticleId IdType=\"pubmed\">32705787</ArticleId></ArticleIdList></Reference><Reference><Citation>Santacroce L, Charitos IA, Ballini A, Inchingolo F, Luperto P, De Nitto E, Topi S. The Human respiratory system and its microbiome at a glimpse Biology 2020 NaN9(10):318. doi: 10.3390/biology9100318. . . ; ( ): . https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3390/biology9100318</ArticleId><ArticleId IdType=\"pmc\">PMC7599718</ArticleId><ArticleId IdType=\"pubmed\">33019595</ArticleId></ArticleIdList></Reference><Reference><Citation>Schabath MB, Cote ML. Cancer progress and priorities: Lung cancer Cancer Epidemiol Biomarkers Prev 2019 NaN28(10):1563. doi: 10.1158/1055-9965.EPI-19-0221. . . ; ( ): &#x2013;. . https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1158/1055-9965.EPI-19-0221</ArticleId><ArticleId IdType=\"pmc\">PMC6777859</ArticleId><ArticleId IdType=\"pubmed\">31575553</ArticleId></ArticleIdList></Reference><Reference><Citation>Schett A, Rothschild SI, Curioni-Fontecedro A, Kr&#xe4;henb&#xfc;hl S, Fr&#xfc;h M, Schmid S, Driessen C, Joerger M. Predictive impact of antibiotics in patients with advanced non small-cell lung cancer receiving immune checkpoint inhibitors: Antibiotics immune checkpoint inhibitors in advanced NSCLC Cancer Chemother Pharmacol 2020 NaN85(1):121. doi: 10.1007/s00280-019-03993-1. . . ; ( ): &#x2013;. . https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s00280-019-03993-1</ArticleId><ArticleId IdType=\"pubmed\">31745593</ArticleId></ArticleIdList></Reference><Reference><Citation>Seki H, Shiohara M, Matsumura T, Miyagawa N, Tanaka M, Komiyama A, Kurata S. Prevention of antibiotic-associated diarrhea in children by Clostridium butyricum MIYAIRI Pediatr Int 2003 NaN45(1):86. doi: 10.1046/j.1442-200X.2003.01671.x. . . ; ( ): &#x2013;. . https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1046/j.1442-200X.2003.01671.x</ArticleId><ArticleId IdType=\"pubmed\">12654076</ArticleId></ArticleIdList></Reference><Reference><Citation>Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM, Benyamin FW, Lei YM, Jabri B, Alegre ML, et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy Science 2015 NaN350(6264):1084. doi: 10.1126/science.aac4255. . . . ; ( ): &#x2013;. . https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1126/science.aac4255</ArticleId><ArticleId IdType=\"pmc\">PMC4873287</ArticleId><ArticleId IdType=\"pubmed\">26541606</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan A, Edlund C, Nord CE. Effect of antimicrobial agents on the ecological balance of human microflora Lancet Infect Dis 2001 NaN1(2):101. doi: 10.1016/S1473-3099(01)00066-4. . . ; ( ): &#x2013;. . https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/S1473-3099(01)00066-4</ArticleId><ArticleId IdType=\"pubmed\">11871461</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas S. Antimicrobial resistance: Global challenges and future interventions. Singapore: Springer Singapore; 2020. . : ; . https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/978-981-15-3658-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomita Y, Ikeda T, Sakata S, Saruwatari K, Sato R, Iyama S, Jodai T, Akaike K, Ishizuka S, Saeki S, et al. Association of probiotic Clostridium butyricum therapy with survival and response to immune checkpoint blockade in patients with lung cancer Cancer Immunol Res 2020 NaN8(10):1236. doi: 10.1158/2326-6066.CIR-20-0051. . . . ; ( ): &#x2013;. . https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1158/2326-6066.CIR-20-0051</ArticleId><ArticleId IdType=\"pubmed\">32665261</ArticleId></ArticleIdList></Reference><Reference><Citation>Velicer CM, Heckbert SR, Lampe JW, Potter JD, Robertson CA, Taplin SH. Antibiotic use in relation to the risk of breast cancer JAMA 2004 NaN291(7):827. doi: 10.1001/jama.291.7.827. . . ; ( ): &#x2013;. . https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1001/jama.291.7.827</ArticleId><ArticleId IdType=\"pubmed\">14970061</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinberger SE, Cockrill BA, Mandel J. Principles of pulmonary medicine. 7th ed Philadelphia (USA): Elsevier; 2019. 20 &#x2013; Lung cancer: Etiologic and pathologic aspects; p. 263. , . : ; . p. . https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/B978-0-323-52371-4.00023-4</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO  . Antibiotic resistance [Internet] Geneva (Switzerland): World Health Organization; 2023.  [cited 2023 April 30].  . . : ; [ ]. Available from  https://www.who.int/news-room/fact-sheets/detail/antibiotic-resistance.</Citation></Reference><Reference><Citation>Wu X, Li F, Wang X, Li C, Meng Q, Wang C, Huang J, Chen S, Zhu Z. Antibiotic bedaquiline effectively targets growth, survival and tumor angiogenesis of lung cancer through suppressing energy metabolism Biochem Biophys Res Commun 2018 NaN495(1):267. doi: 10.1016/j.bbrc.2017.10.136. . . ; ( ): &#x2013;. . https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.bbrc.2017.10.136</ArticleId><ArticleId IdType=\"pubmed\">29107691</ArticleId></ArticleIdList></Reference><Reference><Citation>You WC, Brown LM, Zhang L, Li JY, Jin ML, Chang YS, Ma JL, Pan KF, Liu WD, Hu Y, et al. Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions J Natl Cancer Inst 2006 NaN98(14):974. doi: 10.1093/jnci/djj264. . . . ; ( ): &#x2013;. . https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/jnci/djj264</ArticleId><ArticleId IdType=\"pubmed\">16849680</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H, Garc&#xed;a Rodr&#xed;guez LA, Hern&#xe1;ndez-D&#xed;az S. Antibiotic use and the risk of lung cancer Cancer Epidemiol Biomarkers Prev 2008 NaN17(6):1308. doi: 10.1158/1055-9965.EPI-07-2817. . . ; ( ): &#x2013;. . https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1158/1055-9965.EPI-07-2817</ArticleId><ArticleId IdType=\"pubmed\">18544646</ArticleId></ArticleIdList></Reference><Reference><Citation>Zitvogel L, Ayyoub M, Routy B, Kroemer G. Microbiome and anticancer immunosurveillance Cell 2016 NaN165(2):276. doi: 10.1016/j.cell.2016.03.001. . . ; ( ): &#x2013;. . https://doi.org/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.cell.2016.03.001</ArticleId><ArticleId IdType=\"pubmed\">27058662</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>\n",
            "XML saved to: path/to/save/xml/38103006.xml\n",
            "Details URL: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=38102837&retmode=xml&api_key=9edd38677707c08b2a96ed1a6e8c61c47408\n",
            "Details Response Content: <?xml version=\"1.0\" ?>\n",
            "<!DOCTYPE PubmedArticleSet PUBLIC \"-//NLM//DTD PubMedArticle, 1st January 2023//EN\" \"https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd\">\n",
            "<PubmedArticleSet>\n",
            "<PubmedArticle><MedlineCitation Status=\"Publisher\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38102837</PMID><DateRevised><Year>2023</Year><Month>12</Month><Day>16</Day></DateRevised><Article PubModel=\"Print-Electronic\"><Journal><ISSN IssnType=\"Electronic\">1600-0757</ISSN><JournalIssue CitedMedium=\"Internet\"><PubDate><Year>2023</Year><Month>Dec</Month><Day>15</Day></PubDate></JournalIssue><Title>Periodontology 2000</Title><ISOAbbreviation>Periodontol 2000</ISOAbbreviation></Journal><ArticleTitle>Periodontitis and risk of cancer: Mechanistic evidence.</ArticleTitle><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.1111/prd.12540</ELocationID><Abstract><AbstractText>This review aims to critically analyze the pathways of interaction and the pathogenic mechanisms linking periodontitis and oral bacteria with the initiation/progression of cancer at different body compartments. A higher risk of head and neck cancer has been consistently associated with periodontitis. This relationship has been explained by the local promotion of dysbiosis, chronic inflammation, immune evasion, and direct (epi)genetic damage to epithelial cells by periodontal pathobionts and their toxins. Epidemiological reports have also studied a possible link between periodontitis and the incidence of other malignancies at distant sites, such as lung, breast, prostate, and digestive tract cancers. Mechanistically, different pathways have been involved, including the induction of a chronic systemic inflammatory state and the spreading of oral pathobionts with carcinogenic potential. Indeed, periodontitis may promote low-grade systemic inflammation and phenotypic changes in the mononuclear cells, leading to the release of free radicals and cytokines, as well as extracellular matrix degradation, which are all mechanisms involved in carcinogenic and metastatic processes. Moreover, the transient hematogenous spill out or micro-aspiration/swallowing of periodontal bacteria and their virulence factors (i.e., lipopolysaccharides, fimbriae), may lead to non-indigenous bacterial colonization of multiple microenvironments. These events may in turn replenish the tumor-associated microbiome and thus influence the molecular hallmarks of cancer. Particularly, specific strains of oral pathobionts (e.g., Porphyromonas gingivalis and Fusobacterium nucleatum) may translocate through the hematogenous and enteral routes, being implicated in esophageal, gastric, pancreatic, and colorectal tumorigenesis through the modulation of the gastrointestinal antitumor immune system (i.e., tumor-infiltrating T cells) and the increased expression of pro-inflammatory/oncogenic genes. Ultimately, the potential influence of common risk factors, relevant comorbidities, and upstream drivers, such as gerovulnerability to multiple diseases, in explaining the relationship cannot be disregarded. The evidence analyzed here emphasizes the possible relevance of periodontitis in cancer initiation/progression and stimulates future research endeavors.</AbstractText><CopyrightInformation>&#xa9; 2023 The Authors. Periodontology 2000 published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Baima</LastName><ForeName>Giacomo</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Surgical Sciences, C.I.R. Dental School, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Minoli</LastName><ForeName>Margherita</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Periodontology, Universit&#xe0; Vita-Salute San Raffaele, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Michaud</LastName><ForeName>Dominique S</ForeName><Initials>DS</Initials><AffiliationInfo><Affiliation>Department of Public Health and Community Medicine, Tufts University School of Medicine, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Aimetti</LastName><ForeName>Mario</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Surgical Sciences, C.I.R. Dental School, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Sanz</LastName><ForeName>Mariano</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Faculty of Odontology, University Complutense, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Periodontology, Faculty of Dentistry, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Loos</LastName><ForeName>Bruno G</ForeName><Initials>BG</Initials><AffiliationInfo><Affiliation>Department of Periodontology, ACTA - Academic Centre for Dentistry Amsterdam, University of Amsterdam and Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Romandini</LastName><ForeName>Mario</ForeName><Initials>M</Initials><Identifier Source=\"ORCID\">0000-0001-5646-083X</Identifier><AffiliationInfo><Affiliation>Department of Periodontology, Faculty of Dentistry, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType><PublicationType UI=\"D016454\">Review</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2023</Year><Month>12</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Periodontol 2000</MedlineTA><NlmUniqueID>9313276</NlmUniqueID><ISSNLinking>0906-6713</ISSNLinking></MedlineJournalInfo><KeywordList Owner=\"NOTNLM\"><Keyword MajorTopicYN=\"N\">epidemiology</Keyword><Keyword MajorTopicYN=\"N\">neoplasms</Keyword><Keyword MajorTopicYN=\"N\">periodontal disease</Keyword><Keyword MajorTopicYN=\"N\">periodontal medicine</Keyword><Keyword MajorTopicYN=\"N\">risk factors</Keyword><Keyword MajorTopicYN=\"N\">systemic health/disease</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"revised\"><Year>2023</Year><Month>10</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus=\"received\"><Year>2023</Year><Month>9</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus=\"accepted\"><Year>2023</Year><Month>11</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus=\"medline\"><Year>2023</Year><Month>12</Month><Day>16</Day><Hour>11</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2023</Year><Month>12</Month><Day>16</Day><Hour>11</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2023</Year><Month>12</Month><Day>16</Day><Hour>1</Hour><Minute>57</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38102837</ArticleId><ArticleId IdType=\"doi\">10.1111/prd.12540</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Sung H, Ferlay J, Siegel RL, et&#xa0;al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249.</Citation></Reference><Reference><Citation>Tomasetti C, Vogelstein B. Cancer etiology.Variation in cancer risk among tissues can be explained by the number of stem cell divisions. Science. 2015;347(6217):78-81.</Citation></Reference><Reference><Citation>Plummer M, de Martel C, Vignat J, Ferlay J, Bray F, Franceschi S. Global burden of cancers attributable to infections in 2012: a synthetic analysis. Lancet Glob Health. 2016;4(9):e609-e616.</Citation></Reference><Reference><Citation>Johnston CD, Bullman S. The tumour-associated microbiome. Nat Rev Gastroenterol Hepatol. 2022;19(6):347-348.</Citation></Reference><Reference><Citation>Hanahan D. Hallmarks of Cancer: new dimensions. Cancer Discov. 2022;12(1):31-46.</Citation></Reference><Reference><Citation>Papapanou PN, Sanz M, Buduneli N, et&#xa0;al. Periodontitis: consensus report of workgroup 2 of the 2017 world workshop on the classification of periodontal and peri-implant diseases and conditions. J Periodontol. 2018;89(S1):S173-S182.</Citation></Reference><Reference><Citation>Morales A, Strauss FJ, H&#xe4;mmerle CHF, et&#xa0;al. Performance of the 2017 AAP/EFP case definition compared with the CDC/AAP definition in population-based studies. J Periodontol. 2022;93(7):1003-1013.</Citation></Reference><Reference><Citation>Michaud DS, Liu Y, Meyer M, Giovannucci E, Joshipura K. Periodontal disease, tooth loss, and cancer risk in male health professionals: a prospective cohort study. Lancet Oncol. 2008;9(6):550-558.</Citation></Reference><Reference><Citation>Romandini M, Baima G, Antonoglou G, Bueno J, Figuero E, Sanz M. Periodontitis, edentulism, and risk of mortality: a systematic review with meta-analyses. J Dent Res. 2021;100(1):37-49.</Citation></Reference><Reference><Citation>Antonoglou GN, Romandini M, Meurman JH, Surakka M, Janket SJ, Sanz M. Periodontitis and edentulism as risk indicators for mortality: results from a prospective cohort study with 20&#x2009;years of follow-up. J Periodontal Res. 2023;58(1):12-21.</Citation></Reference><Reference><Citation>Teles FRF, Alawi F, Castilho RM, Wang Y. Association or causation? Exploring the Oral microbiome and Cancer links. J Dent Res. 2020;99(13):1411-1424.</Citation></Reference><Reference><Citation>Gillies RJ, Verduzco D, Gatenby RA. Evolutionary dynamics of carcinogenesis and why targeted therapy does not work. Nat Rev Cancer. 2012;12(7):487-493.</Citation></Reference><Reference><Citation>Wu S, Zhu W, Thompson P, Hannun YA. Evaluating intrinsic and non-intrinsic cancer risk factors. Nat Commun. 2018;9(1):3490.</Citation></Reference><Reference><Citation>Nowell PC. The clonal evolution of tumor cell populations. Science. 1976;194(4260):23-28.</Citation></Reference><Reference><Citation>Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674.</Citation></Reference><Reference><Citation>Anderson NM, Simon MC. The tumor microenvironment. Curr Biol. 2020;30(16):R921-R925.</Citation></Reference><Reference><Citation>Fane M, Weeraratna AT. How the ageing microenvironment influences tumour progression. Nat Rev Cancer. 2020;20(2):89-106.</Citation></Reference><Reference><Citation>Proctor DM, Shelef KM, Gonzalez A, et&#xa0;al. Microbial biogeography and ecology of the mouth and implications for periodontal diseases. Periodontol 2000. 2000;82(1):26-41.</Citation></Reference><Reference><Citation>Baima G, Shin HS, Arrica M, Lafor&#xed; A, Cordaro M, Romandini M. The co-occurrence of the two main oral diseases: periodontitis and dental caries. Clin Oral Investig. 2023;27(11):6483-6492.</Citation></Reference><Reference><Citation>Hajishengallis G, Chavakis T. Local and systemic mechanisms linking periodontal disease and inflammatory comorbidities. Nat Rev Immunol. 2021;21(7):426-440.</Citation></Reference><Reference><Citation>Sanz M, Ceriello A, Buysschaert M, et&#xa0;al. Scientific evidence on the links between periodontal diseases and diabetes: consensus report and guidelines of the joint workshop on periodontal diseases and diabetes by the international diabetes federation and the European Federation of Periodontology. Diabetes Res Clin Pract. 2018;137:231-241.</Citation></Reference><Reference><Citation>Figuero E, S&#xe1;nchez-Beltr&#xe1;n M, Cuesta-Frechoso S, et&#xa0;al. Detection of periodontal bacteria in atheromatous plaque by nested polymerase chain reaction. J Periodontol. 2011;82(10):1469-1477.</Citation></Reference><Reference><Citation>Sanz M, Marco Del Castillo A, Jepsen S, et&#xa0;al. Periodontitis and cardiovascular diseases: Consensus report. J Clin Periodontol. 2020;47(3):268-288.</Citation></Reference><Reference><Citation>Michaud DS, Izard J, Wilhelm-Benartzi CS, et&#xa0;al. Plasma antibodies to oral bacteria and risk of pancreatic cancer in a large European prospective cohort study. Gut. 2013;62(12):1764-1770.</Citation></Reference><Reference><Citation>Nwizu N, Wactawski-Wende J, Genco RJ. Periodontal disease and cancer: epidemiologic studies and possible mechanisms. Periodontology 2000. 2020;83(1):213-233.</Citation></Reference><Reference><Citation>Romandini M, Lafori A, Romandini P, Baima G, Cordaro M. Periodontitis and platelet count: a new potential link with cardiovascular and other systemic inflammatory diseases. J Clin Periodontol. 2018;45(11):1299-1310.</Citation></Reference><Reference><Citation>Michaud DS, Kelsey KT, Papathanasiou E, Genco CA, Giovannucci E. Periodontal disease and risk of all cancers among male never smokers: an updated analysis of the health professionals follow-up study. Ann Oncol. 2016;27(5):941-947.</Citation></Reference><Reference><Citation>Hashim D, Sartori S, Brennan P, et&#xa0;al. The role of oral hygiene in head and neck cancer: results from international head and neck Cancer epidemiology (INHANCE) consortium. Ann Oncol. 2016;27(8):1619-1625.</Citation></Reference><Reference><Citation>Shin YJ, Choung HW, Lee JH, Rhyu IC, Kim HD. Association of Periodontitis with Oral Cancer: a case-control study. J Dent Res. 2019;98(5):526-533.</Citation></Reference><Reference><Citation>Zhao H, Chu M, Huang Z, et&#xa0;al. Variations in oral microbiota associated with oral cancer. Sci Rep. 2017;7(1):11773.</Citation></Reference><Reference><Citation>Radaic A, Ganther S, Kamarajan P, Grandis J, Yom SS, Kapila YL. Paradigm shift in the pathogenesis and treatment of oral cancer and other cancers focused on the oralome and antimicrobial-based therapeutics. Periodontol 2000. 2021;87(1):76-93.</Citation></Reference><Reference><Citation>Karpi&#x144;ski TM. Role of Oral microbiota in Cancer development. Microorganisms. 2019;7(1):20.</Citation></Reference><Reference><Citation>Lin KY, Chung CH, Ciou JS, et&#xa0;al. Molecular damage and responses of oral keratinocyte to hydrogen peroxide. BMC Oral Health. 2019;19(1):10.</Citation></Reference><Reference><Citation>Gabusi A, Gissi DB, Grillini S, et&#xa0;al. Shared epigenetic alterations between oral cancer and periodontitis: a preliminary study. Oral Dis. 2023;29(5):2052-2060.</Citation></Reference><Reference><Citation>Geng F, Zhang Y, Lu Z, Zhang S, Pan Y. Fusobacterium nucleatum caused DNA damage and promoted cell proliferation by the Ku70/p53 pathway in Oral Cancer cells. DNA Cell Biol. 2020;39(1):144-151.</Citation></Reference><Reference><Citation>Yost S, Stashenko P, Choi Y, et&#xa0;al. Increased virulence of the oral microbiome in oral squamous cell carcinoma revealed by metatranscriptome analyses. Int J Oral Sci. 2018;10(4):32.</Citation></Reference><Reference><Citation>Groeger S, Herrmann JM, Chakraborty T, Domann E, Ruf S, Meyle J. Porphyromonas gingivalis W83 membrane components induce distinct profiles of metabolic genes in Oral squamous carcinoma cells. Int J Mol Sci. 2022;23(7):3442.</Citation></Reference><Reference><Citation>Rakoff-Nahoum S, Medzhitov R. Toll-like receptors and cancer. Nat Rev Cancer. 2009;9(1):57-63.</Citation></Reference><Reference><Citation>Schwabe RF, Jobin C. The microbiome and cancer. Nat Rev Cancer. 2013;13(11):800-812.</Citation></Reference><Reference><Citation>Groeger S, Jarzina F, Domann E, Meyle J. Porphyromonas gingivalis activates NF&#x3ba;B and MAPK pathways in human oral epithelial cells. BMC Immunol. 2017;18(1):1.</Citation></Reference><Reference><Citation>Groeger S, Zhou Y, Ruf S, Meyle J. Pathogenic mechanisms of fusobacterium nucleatum on Oral epithelial cells. Front Oral Health. 2022;3:831607. doi:10.3389/froh.2022.831607</Citation></Reference><Reference><Citation>Pang X, Tang YJ, Ren XH, Chen QM, Tang YL, Liang XH. Microbiota, epithelium, inflammation, and TGF-&#x3b2; signaling: an intricate interaction in oncogenesis. Front Microbiol. 2018;9:1353.</Citation></Reference><Reference><Citation>Takeuchi H, Sasaki N, Yamaga S, Kuboniwa M, Matsusaki M, Amano A. Porphyromonas gingivalis induces penetration of lipopolysaccharide and peptidoglycan through the gingival epithelium via degradation of junctional adhesion molecule 1. PLoS Pathog. 2019;15(11):e1008124.</Citation></Reference><Reference><Citation>Groeger S, Howaldt HP, Raifer H, Gattenloehner S, Chakraborty T, Meyle J. Oral squamous carcinoma cells express B7-H1 and B7-DC receptors in&#xa0;vivo. Pathol Oncol Res. 2017;23(1):99-110.</Citation></Reference><Reference><Citation>Groeger S, Domann E, Gonzales JR, Chakraborty T, Meyle J. B7-H1 and B7-DC receptors of oral squamous carcinoma cells are upregulated by Porphyromonas gingivalis. Immunobiology. 2011;216(12):1302-1310.</Citation></Reference><Reference><Citation>Groeger S, Doman E, Chakraborty T, Meyle J. Effects of Porphyromonas gingivalis infection on human gingival epithelial barrier function in&#xa0;vitro. Eur J Oral Sci. 2010;118(6):582-589.</Citation></Reference><Reference><Citation>Groeger S, Jarzina F, Mamat U, Meyle J. Induction of B7-H1 receptor by bacterial cells fractions of Porphyromonas gingivalis on human oral epithelial cells: B7-H1 induction by Porphyromonas gingivalis fractions. Immunobiology. 2017;222(2):137-147.</Citation></Reference><Reference><Citation>Hormia M, Willberg J, Ruokonen H, Syrj&#xe4;nen S. Marginal periodontium as a potential reservoir of human papillomavirus in oral mucosa. J Periodontol. 2005;76:358-363.</Citation></Reference><Reference><Citation>Han YW, Houcken W, Loos BG, Schenkein HA, Tezal M. Periodontal disease, atherosclerosis, adverse pregnancy outcomes, and head-and-neck cancer. Adv Dent Res. 2014;26(1):47-55.</Citation></Reference><Reference><Citation>Tezal M, Scannapieco FA, Wactawski-Wende J, et&#xa0;al. Local inflammation and human papillomavirus status of head and neck cancers. Arch Otolaryngol Head Neck Surg. 2012;138(7):669-675.</Citation></Reference><Reference><Citation>Fitzsimonds ZR, Rodriguez-Hernandez CJ, Bagaitkar J, Lamont RJ. From beyond the pale to the pale riders: The emerging association of bacteria with oral cancer. J Dent Res. 2020;99(6):604-612.</Citation></Reference><Reference><Citation>The Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. Nature. 2012;486(7402):207-214.</Citation></Reference><Reference><Citation>Michaud DS, Lu J, Peacock-Villada AY, et&#xa0;al. Periodontal disease assessed using clinical dental measurements and Cancer risk in the ARIC study. J Natl Cancer Inst. 2018;110(8):843-854.</Citation></Reference><Reference><Citation>Wang J, Yang X, Zou X, Zhang Y, Wang J, Wang Y. Relationship between periodontal disease and lung cancer: a systematic review and meta-analysis. J Periodontal Res. 2020;55(5):581-593.</Citation></Reference><Reference><Citation>Pu CY, Seshadri M, Manuballa S, Yendamuri S. The Oral microbiome and lung diseases. Curr Oral Health Rep. 2020;7(1):79-86.</Citation></Reference><Reference><Citation>Baima G, Marruganti C, Sanz M, Aimetti M, Romandini M. Periodontitis and COVID-19: biological mechanisms and meta-analyses of epidemiological evidence. J Dent Res. 2022;101(12):1430-1440.</Citation></Reference><Reference><Citation>Liu Y, Yuan X, Chen K, et&#xa0;al. Clinical significance and prognostic value of Porphyromonas gingivalis infection in lung cancer. Transl Oncol. 2021;14(1):100972.</Citation></Reference><Reference><Citation>Fang J, Long L, Maeda H. Enhancement of tumor-targeted delivery of bacteria with nitroglycerin involving augmentation of the EPR effect. Methods Mol Biol. 2016;1409:9-23.</Citation></Reference><Reference><Citation>Maeda H, Tsukigawa K, Fang J. A retrospective 30&#x2009;years after discovery of the enhanced permeability and retention effect of solid tumors: next-generation chemotherapeutics and photodynamic therapy-problems, solutions, and prospects. Microcirculation. 2016;23(3):173-182.</Citation></Reference><Reference><Citation>Nwizu NN, Marshall JR, Moysich K, et&#xa0;al. Periodontal disease and incident Cancer risk among postmenopausal women: results from the Women's Health Initiative observational cohort. Cancer Epidemiol Biomarkers Prev. 2017;26(8):1255-1265.</Citation></Reference><Reference><Citation>Shi T, Min M, Sun C, Zhang Y, Liang M, Sun Y. Periodontal disease and susceptibility to breast cancer: a meta-analysis of observational studies. J Clin Periodontol. 2018;45(9):1025-1033.</Citation></Reference><Reference><Citation>Nejman D, Livyatan I, Fuks G, et&#xa0;al. The human tumor microbiome is composed of tumor type-specific intracellular bacteria. Science. 2020;368(6494):973-980.</Citation></Reference><Reference><Citation>Parhi L, Alon-Maimon T, Sol A, et&#xa0;al. Breast cancer colonization by fusobacterium nucleatum accelerates tumor growth and metastatic progression. Nat Commun. 2020;11(1):3259.</Citation></Reference><Reference><Citation>Kim D-H, Jeong SN, Lee JH. Chronic periodontal disease increases risk for prostate Cancer in elderly individuals in South Korea: a retrospective Nationwide population-based cohort study. J Cancer. 2020;11(16):4716-4723.</Citation></Reference><Reference><Citation>Estemalik J, Demko C, Bissada NF, et&#xa0;al. Simultaneous detection of Oral pathogens in subgingival plaque and prostatic fluid of men with periodontal and prostatic diseases. J Periodontol. 2017;88(9):823-829.</Citation></Reference><Reference><Citation>Groeger S, Wu F, Wagenlehner F, et&#xa0;al. PD-L1 up-regulation in prostate Cancer cells by Porphyromonas gingivalis. Front Cell Infect Microbiol. 2022;12:935806.</Citation></Reference><Reference><Citation>Baima G, Ribaldone DG, Romano F, Aimetti M, Romandini M. The gum-gut Axis: periodontitis and the risk of gastrointestinal cancers. Cancers (Basel). 2023;15(18):4594.</Citation></Reference><Reference><Citation>Lo CH, Kwon S, Wang L, et&#xa0;al. Periodontal disease, tooth loss, and risk of oesophageal and gastric adenocarcinoma: a prospective study. Gut. 2021;70(3):620-621.</Citation></Reference><Reference><Citation>Kim EH, Nam S, Park CH, et&#xa0;al. Periodontal disease and cancer risk: a nationwide population-based cohort study. Front Oncol. 2022;12:901098.</Citation></Reference><Reference><Citation>Gao S, Li S, Ma Z, et&#xa0;al. Presence of Porphyromonas gingivalis in esophagus and its association with the clinicopathological characteristics and survival in patients with esophageal cancer. Infect Agent Cancer. 2016;11:3.</Citation></Reference><Reference><Citation>Boehm ET, Thon C, Kupcinskas J, et&#xa0;al. Fusobacterium nucleatum is associated with worse prognosis in Lauren's diffuse type gastric cancer patients. Sci Rep. 2020;10(1):16240.</Citation></Reference><Reference><Citation>Zari&#x107; S, Boji&#x107; B, Jankovi&#x107; LJ, et&#xa0;al. Periodontal therapy improves gastric helicobacter pylori eradication. J Dent Res. 2009;88(10):946-950.</Citation></Reference><Reference><Citation>Sung CE, Lin FG, Huang RY, et&#xa0;al. Periodontitis, helicobacter pylori infection, and gastrointestinal tract cancer mortality. J Clin Periodontol. 2022;49(3):210-220.</Citation></Reference><Reference><Citation>Michaud DS, Joshipura K, Giovannucci E, Fuchs CS. A prospective study of periodontal disease and pancreatic cancer in US male health professionals. J Natl Cancer Inst. 2007;99(2):171-175.</Citation></Reference><Reference><Citation>Maisonneuve P, Amar S, Lowenfels AB. Periodontal disease, edentulism, and pancreatic cancer: a meta-analysis. Ann Oncol. 2017;28(5):985-995.</Citation></Reference><Reference><Citation>Klein AP. Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors. Nat Rev Gastroenterol Hepatol. 2021;18(7):493-502.</Citation></Reference><Reference><Citation>Archibugi L, Signoretti M, Capurso G. The microbiome and pancreatic Cancer: an evidence-based association? J Clin Gastroenterol. 2018;52(Supplement 1):S82-S85.</Citation></Reference><Reference><Citation>Gaiser RA, Halimi A, Alkharaan H, et&#xa0;al. Enrichment of oral microbiota in early cystic precursors to invasive pancreatic cancer. Gut. 2019;68(12):2186-2194.</Citation></Reference><Reference><Citation>Nieminen MT, Listyarifah D, Hagstr&#xf6;m J, et&#xa0;al. Treponema denticola chymotrypsin-like proteinase may contribute to orodigestive carcinogenesis through immunomodulation. Br J Cancer. 2018;118(3):428-434.</Citation></Reference><Reference><Citation>Fan X, Alekseyenko AV, Wu J, et&#xa0;al. Human oral microbiome and prospective risk for pancreatic cancer: a population-based nested case-control study. Gut. 2018;67(1):120-127.</Citation></Reference><Reference><Citation>Tan Q, Ma X, Yang B, et&#xa0;al. Periodontitis pathogen Porphyromonas gingivalis promotes pancreatic tumorigenesis via neutrophil elastase from tumor-associated neutrophils. Gut Microbes. 2022;14(1):2073785.</Citation></Reference><Reference><Citation>Gnanasekaran J, Binder Gallimidi A, Saba E, et&#xa0;al. Intracellular Porphyromonas gingivalis promotes the tumorigenic behavior of pancreatic carcinoma cells. Cancers (Basel). 2020;12(8):2331.</Citation></Reference><Reference><Citation>Fu MM, Chien WC, Chung CH, Lee WC, Tu HP, Fu E. Is periodontitis a risk factor of benign or malignant colorectal tumor? A population-based cohort study. J Periodontal Res. 2022;57(2):284-293.</Citation></Reference><Reference><Citation>Li W, Xu J, Zhang R, et&#xa0;al. Is periodontal disease a risk indicator for colorectal cancer? A systematic review and meta-analysis. J Clinic Periodontol. 2021;48(3):336-347.</Citation></Reference><Reference><Citation>Schmidt TS, Hayward MR, Coelho LP, et&#xa0;al. Extensive transmission of microbes along the gastrointestinal tract. Elife. 2019;8:e42693.</Citation></Reference><Reference><Citation>Alon-Maimon T, Mandelboim O, Bachrach G. Fusobacterium nucleatum and cancer. Periodontol 2000. 2022;89(1):166-180.</Citation></Reference><Reference><Citation>Mesa F, Mesa-L&#xf3;pez MJ, Egea-Valenzuela J, et&#xa0;al. A new comorbidity in periodontitis: fusobacterium nucleatum and colorectal Cancer. Medicina (Kaunas). 2022;58(4):546.</Citation></Reference><Reference><Citation>Proen&#xe7;a MA, Biselli JM, Succi M, et&#xa0;al. Relationship between fusobacterium nucleatum, inflammatory mediators and microRNAs in colorectal carcinogenesis. World J Gastroenterol. 2018;24(47):5351-5365.</Citation></Reference><Reference><Citation>Gur C, Ibrahim Y, Isaacson B, et&#xa0;al. Binding of the Fap2 protein of fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack. Immunity. 2015;42(2):344-355.</Citation></Reference><Reference><Citation>Rubinstein MR, Wang X, Liu W, Hao Y, Cai G, Han YW. Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/&#x3b2;-catenin signaling via its FadA adhesin. Cell Host Microbe. 2013;14(2):195-206.</Citation></Reference><Reference><Citation>Abed J, Emg&#xe5;rd JEM, Zamir G, et&#xa0;al. Fap2 mediates fusobacterium nucleatum colorectal adenocarcinoma enrichment by binding to tumor-expressed Gal-GalNAc. Cell Host Microbe. 2016;20(2):215-225.</Citation></Reference><Reference><Citation>Adel-Khattab D, Groeger S, Domann E, Chakraborty T, Lochnit G, Meyle J. Porphyromonas gingivalis induced up-regulation of PD-L1 in colon carcinoma cells. Mol Oral Microbiol. 2021;36(3):172-181.</Citation></Reference><Reference><Citation>Baima G, Ribaldone DG, Muwalla M, et&#xa0;al. Can periodontitis affect the health and disease of the digestive system? A comprehensive review of epidemiological evidence and biological mechanisms. Curr Oral Health Rep. 2021;8(4):96-106.</Citation></Reference><Reference><Citation>Amicarella F, Muraro MG, Hirt C, et&#xa0;al. Dual role of tumour-infiltrating T helper 17 cells in human colorectal cancer. Gut. 2017;66(4):692-704.</Citation></Reference><Reference><Citation>Bertrand KA, Shingala J, Evens A, Birmann BM, Giovannucci E, Michaud DS. Periodontal disease and risk of non-Hodgkin lymphoma in the health professionals follow-up study: periodontal disease and risk of non-Hodgkin lymphoma. Int J Cancer. 2017;140(5):1020-1026.</Citation></Reference><Reference><Citation>Fine N, Chadwick JW, Sun C, et&#xa0;al. Periodontal inflammation primes the systemic innate immune response. J Dent Res. 2021;100(3):318-325.</Citation></Reference><Reference><Citation>Kalafati L, Kourtzelis I, Schulte-Schrepping J, et&#xa0;al. Innate immune training of granulopoiesis promotes anti-tumor activity. Cell. 2020;183(3):771-785.e12.</Citation></Reference><Reference><Citation>Carvalho-Filho PC, Moura-Costa LF, Pimentel ACM, et&#xa0;al. Apoptosis transcriptional profile induced by Porphyromonas gingivalis HmuY. Mediators Inflamm. 2019;2019:6758159.</Citation></Reference><Reference><Citation>Dongre A, Weinberg RA. New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol. 2019;20(2):69-84.</Citation></Reference><Reference><Citation>Sztukowska MN, Ojo A, Ahmed S, et&#xa0;al. Porphyromonas gingivalis initiates a mesenchymal-like transition through ZEB1 in gingival epithelial cells. Cell Microbiol. 2016;18(6):844-858.</Citation></Reference><Reference><Citation>Ohshima J, Wang Q, Fitzsimonds ZR, et&#xa0;al. Streptococcus gordonii programs epithelial cells to resist ZEB2 induction by Porphyromonas gingivalis. Proc Natl Acad Sci U S A. 2019;116(17):8544-8553.</Citation></Reference><Reference><Citation>Cheng R, Billet S, Liu C, et&#xa0;al. Periodontal inflammation recruits distant metastatic breast cancer cells by increasing myeloid-derived suppressor cells. Oncogene. 2020;39(7):1543-1556.</Citation></Reference><Reference><Citation>Marruganti C, Baima G, Grandini S, et&#xa0;al. Leisure-time and occupational physical activity demonstrate divergent associations with periodontitis: a population-based study. J Clin Periodontol. 2023;50:559-570.</Citation></Reference><Reference><Citation>Marruganti C, Baima G, Aimetti M, Grandini S, Sanz M, Romandini M. Periodontitis and low cognitive performance: a population-based study. J Clin Periodontol. 2023;50(4):418-429.</Citation></Reference><Reference><Citation>Romandini M, Shin HS, Romandini P, Lafor&#xed; A, Cordaro M. Hormone-related events and periodontitis in women. J Clin Periodontol. 2020;47(4):429-441.</Citation></Reference><Reference><Citation>Marruganti C, Shin HS, Sim SJ, Grandini S, Lafor&#xed; A, Romandini M. Air pollution as a risk indicator for periodontitis. Biomedicine. 2023;11(2):443.</Citation></Reference><Reference><Citation>Marruganti C, Romandini M, Gaeta C, et&#xa0;al. Healthy lifestyles are associated with a better response to periodontal therapy: a prospective cohort study. J Clin Periodontol. 2023;50:1089-1100.</Citation></Reference><Reference><Citation>Marruganti C, Gaeta C, Romandini M, et&#xa0;al. Multiplicative effect of stress and poor sleep quality on periodontitis: a university-based cross-sectional study. J Periodonto. 2023. doi:10.1002/JPER.23-0209</Citation></Reference><Reference><Citation>Ayilavarapu S, Doctor A, Lee CT, et&#xa0;al. Altered human alveolar bone gene expression in type 2 diabetes-a cross-sectional study. J Periodontal Res. 2022;57(1):142-151.</Citation></Reference><Reference><Citation>Romano F, Perotto S, Mohamed SEO, et&#xa0;al. Bidirectional association between metabolic control in Type-2 diabetes mellitus and periodontitis inflammatory burden: a cross-sectional study in an Italian population. J Clin Med. 2021;10(8):1787.</Citation></Reference><Reference><Citation>D'Aiuto F, Parkar M, Andreou G, et&#xa0;al. Periodontitis and systemic inflammation: control of the local infection is associated with a reduction in serum inflammatory markers. J Dent Res. 2004;83(2):156-160.</Citation></Reference><Reference><Citation>Larvin H, Wilmott S, Kang J, Aggarwal VR, Pavitt S, Wu J. Additive effect of periodontal disease and obesity on COVID-19 outcomes. J Dent Res. 2021;100(11):1228-1235.</Citation></Reference><Reference><Citation>Baima G, Romandini M, Citterio F, Romano F, Aimetti M. Periodontitis and accelerated biological aging: a Geroscience approach. J Dent Res. 2022;101(2):125-132.</Citation></Reference><Reference><Citation>Roato I, Baima G, Orrico C, et&#xa0;al. Senescent markers expressed by periodontal ligament-derived stem cells (PDLSCs) harvested from patients with periodontitis can Be rejuvenated by RG108. Biomedicine. 2023;11(9):2535.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>\n",
            "XML saved to: path/to/save/xml/38102837.xml\n",
            "Details URL: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=38100106&retmode=xml&api_key=9edd38677707c08b2a96ed1a6e8c61c47408\n",
            "Details Response Content: <?xml version=\"1.0\" ?>\n",
            "<!DOCTYPE PubmedArticleSet PUBLIC \"-//NLM//DTD PubMedArticle, 1st January 2023//EN\" \"https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd\">\n",
            "<PubmedArticleSet>\n",
            "<PubmedArticle><MedlineCitation Status=\"MEDLINE\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38100106</PMID><DateCompleted><Year>2023</Year><Month>12</Month><Day>16</Day></DateCompleted><DateRevised><Year>2023</Year><Month>12</Month><Day>18</Day></DateRevised><Article PubModel=\"Electronic\"><Journal><ISSN IssnType=\"Electronic\">2574-3805</ISSN><JournalIssue CitedMedium=\"Internet\"><Volume>6</Volume><Issue>12</Issue><PubDate><Year>2023</Year><Month>Dec</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA network open</Title><ISOAbbreviation>JAMA Netw Open</ISOAbbreviation></Journal><ArticleTitle>Biomarker Testing in Patients With Unresectable Advanced or Recurrent Non-Small Cell Lung Cancer.</ArticleTitle><Pagination><StartPage>e2347700</StartPage><MedlinePgn>e2347700</MedlinePgn></Pagination><ELocationID EIdType=\"pii\" ValidYN=\"Y\">e2347700</ELocationID><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.1001/jamanetworkopen.2023.47700</ELocationID><Abstract><AbstractText Label=\"IMPORTANCE\" NlmCategory=\"UNASSIGNED\">Biomarker testing for driver mutations is essential for selecting appropriate non-small cell lung cancer (NSCLC) treatment but is insufficient.</AbstractText><AbstractText Label=\"OBJECTIVE\" NlmCategory=\"UNASSIGNED\">To investigate the status of biomarker testing and drug therapy for NSCLC in Japan for identifying problems in treatment.</AbstractText><AbstractText Label=\"DESIGN, SETTING, AND PARTICIPANTS\" NlmCategory=\"UNASSIGNED\">The REVEAL cohort study included retrospective data collection and prospective follow-up from 29 institutions across Japan. Of 1500 patients diagnosed with advanced or recurrent NSCLC between January 1 and March 18, 2021, 1479 were eligible. Cases recognized at the wrong clinical stage (n&#x2009;=&#x2009;12), diagnosed outside the study period (n&#x2009;=&#x2009;6), not treated according to eligibility criteria before recurrence (n&#x2009;=&#x2009;2), and with deficient consent acquisition procedure (n&#x2009;=&#x2009;1) were excluded.</AbstractText><AbstractText Label=\"MAIN OUTCOMES AND MEASURES\" NlmCategory=\"UNASSIGNED\">The primary end point was the biomarker testing status. Treatment-related factors were examined.</AbstractText><AbstractText Label=\"RESULTS\" NlmCategory=\"UNASSIGNED\">Among the 1479 patients included in the analysis, the median age was 72 (range, 30-95) years; 1013 (68.5%) were men; 1161 (78.5%) had an Eastern Cooperative Oncology Group performance status 0 or 1; 1097 (74.2%) were current or past smokers; and 947 (64.0%) had adenocarcinoma. Biomarker status was confirmed in 1273 patients (86.1%). Multigene testing was performed in 705 cases (47.7%); single-gene testing, in 847 (57.3%); and both, in 279 (18.9%). Biomarker testing was performed for EGFR in 1245 cases (84.2%); ALK, in 1165 (78.8%); ROS1, in 1077 (72.8%); BRAF, in 803 (54.3%); and MET, in 805 (54.4%). Positivity rates among 898 adenocarcinoma cases included 305 (34.0%) for EGFR, 29 (3.2%) for ALK, 19 (2.1%) for ROS1, 11 (1.2%) for BRAF, and 14 (1.6%) for MET. Positivity rates among 375 nonadenocarcinoma cases were 14 (3.7%) for EGFR, 6 (1.6%) for ALK, 1 (0.3%) for ROS1, 3 (0.8%) for BRAF, and 8 (2.1%) for MET. Poor physical status, squamous cell carcinoma, and other comorbidities were associated with hampered multigene testing. Targeted therapy was received as first-line treatment by 263 of 278 cases (94.6%) positive for EGFR, 25 of 32 (78.1%) positive for ALK, 15 of 24 (62.5%) positive for ROS1, 9 of 12 (75.0%) positive for BRAF, and 12 of 19 (63.2%) positive for MET. Median overall survival of patients with positive findings for driver gene alteration and who received targeted therapy was 24.3 (95% CI, not reported) months; with positive findings for driver gene alteration and who did not receive targeted therapy, 15.2 (95% CI, 7.7 to not reported) months; and with negative findings for driver gene alteration, 11.0 (95% CI, 10.0-12.5) months. Multigene testing for nonadenocarcinomas and adenocarcinomas accounted for 705 (47.7%) of all NSCLC cases.</AbstractText><AbstractText Label=\"CONCLUSIONS AND RELEVANCE\" NlmCategory=\"UNASSIGNED\">These findings suggest that multigene testing has not been sufficiently implemented in Japan and should be considered prospectively, even in nonadenocarcinomas, to avoid missing rare driver gene alterations.</AbstractText></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Sakamoto</LastName><ForeName>Tomohiro</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Respiratory Medicine and Rheumatology, Department of Multidisciplinary Internal Medicine, Faculty of Medicine, Tottori University, Yonago, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Matsubara</LastName><ForeName>Taichi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Thoracic Surgery, Kitakyushu Municipal Medical Center, Kitakyushu, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Takahama</LastName><ForeName>Takayuki</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Yokoyama</LastName><ForeName>Toshihide</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Kurashiki Central Hospital, Kurashiki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Nakamura</LastName><ForeName>Atsushi</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Tokito</LastName><ForeName>Takaaki</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, Kurume, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Okamoto</LastName><ForeName>Tatsuro</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Akamatsu</LastName><ForeName>Hiroaki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine III, Wakayama Medical University, Wakayama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Oki</LastName><ForeName>Masahide</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Sato</LastName><ForeName>Yuki</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Kobe City Medical Center General Hospital, Kobe, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Tobino</LastName><ForeName>Kazunori</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Iizuka Hospital, Iizuka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Ikeda</LastName><ForeName>Satoshi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Mori</LastName><ForeName>Masahide</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Thoracic Oncology, National Hospital Organization Osaka Toneyama Medical Center, Toyonaka City, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Mimura</LastName><ForeName>Chihiro</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Maeno</LastName><ForeName>Ken</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Miura</LastName><ForeName>Satoru</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Niigata Cancer Center Hospital, Niigata, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Harada</LastName><ForeName>Toshiyuki</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Center for Respiratory Diseases, Japan Community Health Care Organization Hokkaido Hospital, Sapporo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Nishimura</LastName><ForeName>Kunihiro</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Xcoo Inc, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Hiraoka</LastName><ForeName>Manabu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Japan Medical Affairs, Japan Oncology Business Unit, Takeda Pharmaceutical Company Limited, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Kenmotsu</LastName><ForeName>Hirotsugu</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Division of Thoracic Oncology, Shizuoka Cancer Center, Nagaizumi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Fujimoto</LastName><ForeName>Junya</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Shimokawa</LastName><ForeName>Mototsugu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Ube, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Yamamoto</LastName><ForeName>Nobuyuki</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine III, Wakayama Medical University, Wakayama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Nakagawa</LastName><ForeName>Kazuhiko</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2023</Year><Month>12</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Netw Open</MedlineTA><NlmUniqueID>101729235</NlmUniqueID><ISSNLinking>2574-3805</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI=\"D011505\">Protein-Tyrosine Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI=\"D048493\">Proto-Oncogene Proteins B-raf</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI=\"D011518\">Proto-Oncogene Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI=\"D015415\">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI=\"D066246\">ErbB Receptors</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI=\"D020794\">Receptor Protein-Tyrosine Kinases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI=\"D008297\" MajorTopicYN=\"N\">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D006801\" MajorTopicYN=\"N\">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D000368\" MajorTopicYN=\"N\">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D005260\" MajorTopicYN=\"N\">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D002289\" MajorTopicYN=\"Y\">Carcinoma, Non-Small-Cell Lung</DescriptorName><QualifierName UI=\"Q000188\" MajorTopicYN=\"N\">drug therapy</QualifierName><QualifierName UI=\"Q000235\" MajorTopicYN=\"N\">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D015331\" MajorTopicYN=\"N\">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D011446\" MajorTopicYN=\"N\">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D011505\" MajorTopicYN=\"N\">Protein-Tyrosine Kinases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D048493\" MajorTopicYN=\"N\">Proto-Oncogene Proteins B-raf</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D012189\" MajorTopicYN=\"N\">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D008175\" MajorTopicYN=\"Y\">Lung Neoplasms</DescriptorName><QualifierName UI=\"Q000235\" MajorTopicYN=\"N\">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D011518\" MajorTopicYN=\"N\">Proto-Oncogene Proteins</DescriptorName><QualifierName UI=\"Q000235\" MajorTopicYN=\"N\">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D000230\" MajorTopicYN=\"Y\">Adenocarcinoma</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D015415\" MajorTopicYN=\"N\">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D066246\" MajorTopicYN=\"N\">ErbB Receptors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D020794\" MajorTopicYN=\"N\">Receptor Protein-Tyrosine Kinases</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Sakamoto reported receiving grant funding from Takeda Pharmaceutical Company Limited during the conduct of the study and personal fees from Chugai Pharmaceutical Co Ltd, Eli Lilly and Company, Novartis AG, Merck &amp; Co Inc, MSD, Ono Pharmaceutical Co Ltd, Taiho Pharmaceutical Co Ltd, Hisamitsu Pharmaceutical Co Inc, Janssen Global Services LLC, Amgen Inc, Daiichi Sankyo Company Limited, AstraZeneca, Kyowa Kirin Co Ltd, Takeda Pharmaceutical Company Limited, and Illumina Inc outside the submitted work. Dr Takahama reported receiving grant funding from Takeda Pharmaceutical Company Limited during the conduct of the study and personal fees from AstraZeneca, Chugai Pharmaceutical Co Ltd, Roche Diagnostics, and MSD and grant funding from Pfizer Inc outside the submitted work. Dr Yokoyama reported grant funding from MSD, Chugai Pharmaceutical Co Ltd, Bristol Myers Squibb Company, Boehringer Ingelheim, Takeda Pharmaceutical Company Limited, Delta-Fly Pharma Inc, Janssen Global Services LLC, AbbVie Inc, Daiichi Sankyo Company Limited, and Parexel International Corporation and personal fees from AstraZeneca, Chugai Pharmaceutical Co Ltd, Eli Lilly and Company, Pfizer Inc, Bristol Myers Squibb Company, Ono Pharmaceutical Co Ltd, Takeda Pharmaceutical Company Limited, Nippon Kayaku Co Ltd, MSD, Novartis AG, and Merck &amp; Co Inc outside the submitted work. Dr Nakamura reported receiving personal fees from AstraZeneca, Chugai Pharmaceutical Co Ltd, Eli Lilly and Company, Novartis AG, Thermo Fisher Scientific, Taiho Pharmaceutical Co Ltd, Pfizer Inc, Nippon Kayaku Co Ltd, and Merck &amp; Co Inc. Dr Tokito reported receiving personal fees from AstraZeneca, Ono Pharmaceutical Co Ltd, MSD Oncology, Chugai Pharmaceutical Co Ltd, Bristol Myers Squibb Company, Nippon Kayaku Co Ltd, and Boehringer Ingelheim outside the submitted work. Dr Okamoto reported receiving research funding from MSD, Chugai Pharmaceutical Co Ltd, Eli Lilly and Company, Pfizer Inc, Boehringer Ingelheim, Novartis AG, Ono Pharmaceutical Co Ltd, and Taiho Pharmaceutical Co Ltd and personal fees from AstraZeneca, MSD, Chugai Pharmaceutical Co Ltd, Eli Lilly and Company, and Taiho Pharmaceutical Co Ltd. Dr Akamatsu reported receiving personal fees from Amgen Inc, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb Company, Chugai Pharmaceutical Co Ltd, Eli Lilly and Company, MSD, Nippon Kayaku Co Ltd, Novartis AG, Ono Pharmaceutical Co Ltd, Pfizer Inc, Takeda Pharmaceutical Company Limited, Taiho Pharmaceutical Co Ltd, Janssen Global Services LLC, and Sandoz Group AG and grant funding from Amgen Inc, MSD, and Chugai Pharmaceutical Co Ltd outside the submitted work. Dr Oki reported receiving grant funding from AbbVie Inc, Chugai Pharmaceutical Co Ltd, GSK plc, MSD, Parexel International Corporation, Sanofi, AstraZeneca, FUJIFILM Toyama Chemical Co Ltd, Janssen Global Services LLC, Ono Pharmaceutical Co Ltd, and Pfizer Inc and personal fees from Amco Inc, Canon Medical Systems Corporation, FUJIFILM Toyama Chemical Co Ltd, Merit Medical Systems, Olympus Corporation, AstraZeneca, Chugai Pharmaceutical Co Ltd, Kaneka Medix Corp, Novartis AG, and Sanofi outside the submitted work. Dr Sato reported receiving personal fees from AstraZeneca, MSD, Novartis AG, Chugai Pharmaceutical Co Ltd, Ono Pharmaceutical Co Ltd, Pfizer Inc, Taiho Pharmaceutical Co Ltd, Nippon Kayaku Co Ltd, Bristol Myers Squibb Company, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Kyowa Kirin Co Ltd, and Boehringer Ingelheim outside the submitted work. Dr Ikeda reported receiving personal fees from AstraZeneca, Chugai Pharmaceutical Co Ltd, Bristol Myers Squibb Company, Ono Pharmaceutical Co Ltd, Taiho Pharmaceutical Co Ltd, Boehringer Ingelheim, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, and Pfizer Inc and grant funding from AstraZeneca and Chugai Pharmaceutical Co Ltd outside the submitted work. Dr Mori reported receiving personal fees from AstraZeneca, Boehringer Ingelheim, Ono Pharmaceutical Co Ltd, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Nippon Kayaku Co Ltd, Taiho Pharmaceutical Co Ltd, Merck &amp; Co Inc, Chugai Pharmaceutical Co Ltd, Daiichi Sankyo Company Limited, Delta-Fly Pharma Inc, MSD, and Pfizer Inc outside the submitted work. Dr Mimura reported receiving grant funding from Takeda Pharmaceutical Company Limited during the conduct of the study. Dr Maeno reported receiving personal fees from AstraZeneca, Chugai Pharmaceutical Co Ltd, Boehringer Ingelheim, Eli Lilly and Company, and Takeda Pharmaceutical Company Limited and grant funding from Boehringer Ingelheim and Eli Lilly and Company outside the submitted work. Dr Miura reported receiving personal fees from Chugai Pharmaceutical Co Ltd, Taiho Pharmaceutical Co Ltd, Pfizer Inc, Eli Lilly and Company, Boehringer Ingelheim, Ono Pharmaceutical Co Ltd, AstraZeneca, Novartis AG, MSD, Bristol Myers Squibb Company, Amgen Inc, Merck &amp; Co Inc, and Takeda Pharmaceutical Company Limited outside the submitted work. Dr Nishimura reported being the chief executive officer and founder of Xcoo Inc and receiving research funding from Medical Data Card Inc and Systems Engineering Consultants Co Ltd outside the submitted work. Dr Kenmotsu reported receiving grant funding from Novartis AG, Eli Lilly and Company, AstraZeneca, and Loxo Oncology and personal fees from Amgen Inc, AstraZeneca, Bayer AG, Boehringer Ingelheim, Chugai Pharmaceutical Co Ltd, Daiichi Sankyo Company Limited, Eli Lilly and Company, Merck &amp; Co Inc, Novartis AG, Pfizer Inc, and Takeda Pharmaceutical Company Limited during the conduct of the study and grant funding from Ono Pharmaceutical Co Ltd and personal fees from Bristol Myers Squibb Company, Kyowa Kirin Co Ltd, MSD, Ono Pharmaceutical Co Ltd, and Taiho Pharmaceutical Co Ltd outside the submitted work. Dr Fujimoto reported receiving grant funding from Sakura Finetek Japan Co Ltd outside the submitted work. Dr Yamamoto reported receiving grant funding from Boehringer Ingelheim, Taiho Pharmaceutical Co Ltd, Chugai Pharmaceutical Co Ltd, Shionogi Inc, Eli Lilly and Company, Daiichi Sankyo Company Limited, Tumura, Nippon Kayaku Co Ltd, Asahi Kasei Pharma Corporation, AstraZeneca, Janssen Global Services LLC, Sanofi, Amgen Inc, Novartis AG, Astellas Pharma Inc, MSD, Esai Co Ltd, Bristol Myers Squibb Company, AbbVie Inc, and Tosoh Corporation and personal fees from MSD, AstraZeneca, Amgen Inc, Ono Pharmaceutical Co Ltd, Otsuka Holdings Co Ltd, Guardant Health Inc, Tumura, Kyowa Kirin Co Ltd, Kyorin Pharmaceutical Co Ltd, GSK plc, Sanofi, Daiichi Sankyo Company Limited, Taiho Pharmaceutical Co Ltd, Takeda Pharmaceutical Company Limited Chugai Pharmaceutical Co Ltd, Eli Lilly and Company, Nippon Kayaku Co Ltd, Boehringer Ingelheim, Novartis AG, Pfizer Inc, Bristol Myers Squibb Company, Miyarisan Pharmaceutical Co Ltd, Merck &amp; Co Inc, and Janssen Global Services LLC outside the submitted work. Dr Nakagawa reported grant funding from Parexel International Corporation, PRA Health Sciences, EPS Corporation, Kissei Pharmaceutical Co Ltd, EPS International Co Ltd, Daiichi Sankyo Company Limited, Taiho Pharmaceutical Co Ltd, MSD, Ono Pharmaceutical Co Ltd, PPD-SNBL, SymBio Pharmaceuticals Limited, IQVIA Inc, Syneos Health, Nippon Kayaku Co Ltd, EP-CRSU Co Ltd, Mebix Inc, Bristol Myers Squibb Company, Janssen Global Services LLC, CMIC Holdings Co Ltd, Shionogi Inc, Astellas Pharma Inc, Kobayashi Pharmaceutical Co Ltd, Eisai Co Ltd, AstraZeneca, Mochida Pharmaceutical Co Ltd, LabCorp-Covance, Japan Clinical Research Operations, Takeda Pharmaceutical Company Limited, GSK plc, Sanofi, Chugai Pharmaceutical Co Ltd, Boehringer Ingelheim, Sysmex Corporation, Medical Research Support, Eli Lilly and Company, Amgen Inc, Novartis AG, Otsuka Holdings Co Ltd, SRL Inc, Pfizer Japan Inc, Bayer Yakuhin Ltd, Pfizer Inc, and Ascent Development Services and personal fees from Ono Pharmaceutical Co Ltd, Amgen Inc, Nippon Kayaku Co Ltd, AstraZeneca, Chugai Pharmaceutical Co Ltd, Eli Lilly and Company, MSD, Pfizer Inc, Boehringer Ingelheim, Taiho Pharmaceutical Co Ltd, Bayer Yakuhin Ltd, CMIC ShiftZero, Life Technologies Japan Ltd, NEO Communication, Daiichi Sankyo Company Limited, Incyte, Merck &amp; Co Inc, Kyowa Kirin Co Ltd, Takeda Pharmaceutical Company Limited, 3H Clinical Trial Inc, Care Net, Medical Review Co Ltd, Medical Mobile Communications Co Ltd, Yodosha Co Ltd, Nikkei Business Publications Inc, Japan Clinical Research Operations, CMIC Holdings Co Ltd, Novartis AG, Taiyo Pharma Co Ltd, Bristol Myers Squibb Company, and Janssen Global Services LLC outside the submitted work; and having a patent for Daiichi Sankyo Company Limited issued. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"medline\"><Year>2023</Year><Month>12</Month><Day>17</Day><Hour>17</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2023</Year><Month>12</Month><Day>15</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2023</Year><Month>12</Month><Day>15</Day><Hour>11</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38100106</ArticleId><ArticleId IdType=\"pmc\">PMC10724778</ArticleId><ArticleId IdType=\"doi\">10.1001/jamanetworkopen.2023.47700</ArticleId><ArticleId IdType=\"pii\">2812963</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Soria JC, Ohe Y, Vansteenkiste J, et al. ; FLAURA Investigators . Osimertinib in untreated EGFR-mutated advanced non&#x2013;small-cell lung cancer. N Engl J Med. 2018;378(2):113-125. doi:10.1056/NEJMoa1713137</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1056/NEJMoa1713137</ArticleId><ArticleId IdType=\"pubmed\">29151359</ArticleId></ArticleIdList></Reference><Reference><Citation>Hida T, Nokihara H, Kondo M, et al. . Alectinib versus crizotinib in patients with ALK-positive non&#x2013;small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet. 2017;390(10089):29-39. doi:10.1016/S0140-6736(17)30565-2</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/S0140-6736(17)30565-2</ArticleId><ArticleId IdType=\"pubmed\">28501140</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw AT, Ou SH, Bang YJ, et al. . Crizotinib in ROS1-rearranged non&#x2013;small-cell lung cancer. N Engl J Med. 2014;371(21):1963-1971. doi:10.1056/NEJMoa1406766</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1056/NEJMoa1406766</ArticleId><ArticleId IdType=\"pmc\">PMC4264527</ArticleId><ArticleId IdType=\"pubmed\">25264305</ArticleId></ArticleIdList></Reference><Reference><Citation>Planchard D, Smit EF, Groen HJM, et al. . Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non&#x2013;small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncol. 2017;18(10):1307-1316. doi:10.1016/S1470-2045(17)30679-4</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/S1470-2045(17)30679-4</ArticleId><ArticleId IdType=\"pubmed\">28919011</ArticleId></ArticleIdList></Reference><Reference><Citation>Paik PK, Felip E, Veillon R, et al. . Tepotinib in non&#x2013;small-cell lung cancer with MET exon 14 skipping mutations. N Engl J Med. 2020;383(10):931-943. doi:10.1056/NEJMoa2004407</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1056/NEJMoa2004407</ArticleId><ArticleId IdType=\"pmc\">PMC8422679</ArticleId><ArticleId IdType=\"pubmed\">32469185</ArticleId></ArticleIdList></Reference><Reference><Citation>Drilon A, Oxnard GR, Tan DSW, et al. . Efficacy of selpercatinib in RET fusion-positive non&#x2013;small-cell lung cancer. N Engl J Med. 2020;383(9):813-824. doi:10.1056/NEJMoa2005653</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1056/NEJMoa2005653</ArticleId><ArticleId IdType=\"pmc\">PMC7506467</ArticleId><ArticleId IdType=\"pubmed\">32846060</ArticleId></ArticleIdList></Reference><Reference><Citation>Skoulidis F, Li BT, Dy GK, et al. . Sotorasib for lung cancers with KRAS p.G12C mutation. N Engl J Med. 2021;384(25):2371-2381. doi:10.1056/NEJMoa2103695</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1056/NEJMoa2103695</ArticleId><ArticleId IdType=\"pmc\">PMC9116274</ArticleId><ArticleId IdType=\"pubmed\">34096690</ArticleId></ArticleIdList></Reference><Reference><Citation>Lassen U. Entrectinib for ROS1 fusion-positive NSCLC and NTRK fusion-positive solid tumours. Lancet Oncol. 2020;21(2):193-194. doi:10.1016/S1470-2045(19)30789-2</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/S1470-2045(19)30789-2</ArticleId><ArticleId IdType=\"pubmed\">31838008</ArticleId></ArticleIdList></Reference><Reference><Citation>Japan Lung Cancer Society . Lung cancer treatment guidelines&#x2014;including malignant pleural mesothelioma and thymic tumors. 2022. Accessed July 1, 2023. https://www.haigan.gr.jp/guideline/2022/.</Citation></Reference><Reference><Citation>Sakata S, Otsubo K, Yoshida H, et al. . Real-world data on NGS using the Oncomine DxTT for detecting genetic alterations in non&#x2013;small-cell lung cancer: WJOG13019L. Cancer Sci. 2022;113(1):221-228. doi:10.1111/cas.15176</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1111/cas.15176</ArticleId><ArticleId IdType=\"pmc\">PMC8748216</ArticleId><ArticleId IdType=\"pubmed\">34704312</ArticleId></ArticleIdList></Reference><Reference><Citation>World Medical Association . World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191-2194. doi:10.1001/jama.2013.281053</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1001/jama.2013.281053</ArticleId><ArticleId IdType=\"pubmed\">24141714</ArticleId></ArticleIdList></Reference><Reference><Citation>A project to investigate the actual status of biomarker testing in unresectable advanced or recurrent non-small cell lung cancer (REVEAL)(WJOG15421L). UMIN Identifier: UMIN000046079. April 1, 2022. Accessed July 1, 2023. https://rctportal.niph.go.jp/en/detail?trial_id=UMIN000046079</Citation></Reference><Reference><Citation>Hess LM, Krein PM, Haldane D, Han Y, Sireci AN. Biomarker testing for patients with advanced/metastatic non-squamous NSCLC in the United States of America, 2015 to 2021. JTO Clin Res Rep. 2022;3(6):100336. doi:10.1016/j.jtocrr.2022.100336</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jtocrr.2022.100336</ArticleId><ArticleId IdType=\"pmc\">PMC9168140</ArticleId><ArticleId IdType=\"pubmed\">35677681</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo YH, Chiu CH, Scott Kuo CH, et al. . Lung cancer in Republic of China. J Thorac Oncol. 2021;16(4):519-527. doi:10.1016/j.jtho.2020.10.155</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jtho.2020.10.155</ArticleId><ArticleId IdType=\"pubmed\">33781442</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajadurai P, How SH, Liam CK, Sachithanandan A, Soon SY, Tho LM. Lung cancer in Malaysia. J Thorac Oncol. 2020;15(3):317-323. doi:10.1016/j.jtho.2019.10.021</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jtho.2019.10.021</ArticleId><ArticleId IdType=\"pubmed\">32093853</ArticleId></ArticleIdList></Reference><Reference><Citation>Reungwetwattana T, Oranratnachai S, Puataweepong P, Tangsujaritvijit V, Cherntanomwong P. Lung cancer in Thailand. J Thorac Oncol. 2020;15(11):1714-1721. doi:10.1016/j.jtho.2020.04.024</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jtho.2020.04.024</ArticleId><ArticleId IdType=\"pubmed\">33148410</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitsudomi T, Tan D, Yang JC, et al. . Expert consensus recommendations on biomarker testing in metastatic and nonmetastatic NSCLC in Asia. J Thorac Oncol. 2023;18(4):436-446. doi:10.1016/j.jtho.2022.10.021</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jtho.2022.10.021</ArticleId><ArticleId IdType=\"pubmed\">36379356</ArticleId></ArticleIdList></Reference><Reference><Citation>Teishikata T, Shiraishi K, Shinno Y, et al. . An alert to possible false positives with a commercial assay for MET exon 14 skipping. J Thorac Oncol. 2021;16(12):2133-2138. doi:10.1016/j.jtho.2021.07.028</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jtho.2021.07.028</ArticleId><ArticleId IdType=\"pubmed\">34419686</ArticleId></ArticleIdList></Reference><Reference><Citation>Viola P, Maurya M, Croud J, et al. . A validation study for the use of ROS1 immunohistochemical staining in screening for ROS1 translocations in lung cancer. J Thorac Oncol. 2016;11(7):1029-1039. doi:10.1016/j.jtho.2016.03.019</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jtho.2016.03.019</ArticleId><ArticleId IdType=\"pubmed\">27179848</ArticleId></ArticleIdList></Reference><Reference><Citation>Tong JH, Yeung SF, Chan AWH, et al. . MET amplification and exon 14 splice site mutation define unique molecular subgroups of non&#x2013;small cell lung carcinoma with poor prognosis. Clin Cancer Res. 2016;22(12):3048-3056. doi:10.1158/1078-0432.CCR-15-2061</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1158/1078-0432.CCR-15-2061</ArticleId><ArticleId IdType=\"pubmed\">26847053</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakashima K, Ozawa Y, Daga H, et al. . Osimertinib for patients with poor performance status and EGFR T790M mutation-positive advanced non-small cell lung cancer: a phase II clinical trial. Invest New Drugs. 2020;38(6):1854-1861. doi:10.1007/s10637-020-00943-0</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s10637-020-00943-0</ArticleId><ArticleId IdType=\"pubmed\">32424780</ArticleId></ArticleIdList></Reference><Reference><Citation>Igawa S, Fukui T, Kasajima M, et al. . First-line osimertinib for poor performance status patients with EGFR mutation-positive non&#x2013;small cell lung cancer: a prospective observational study. Invest New Drugs. 2022;40(2):430-437. doi:10.1007/s10637-021-01195-2</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s10637-021-01195-2</ArticleId><ArticleId IdType=\"pubmed\">34807331</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwama E, Goto Y, Murakami H, et al. . Alectinib for patients with ALK rearrangement-positive non&#x2013;small cell lung cancer and a poor performance status (Lung Oncology Group in Kyushu 1401). J Thorac Oncol. 2017;12(7):1161-1166. doi:10.1016/j.jtho.2017.02.012</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jtho.2017.02.012</ArticleId><ArticleId IdType=\"pubmed\">28238961</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimizu J, Masago K, Saito H, et al. . Biomarker testing for personalized, first-line therapy in advanced nonsquamous non&#x2013;small cell lung cancer patients in the real world setting in Japan: a retrospective, multicenter, observational study (the BRAVE study). Ther Adv Med Oncol. 2020;12:1758835920904522. doi:10.1177/1758835920904522</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1177/1758835920904522</ArticleId><ArticleId IdType=\"pmc\">PMC7036489</ArticleId><ArticleId IdType=\"pubmed\">32127924</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeda M, Sakai K, Terashima M, et al. . Clinical application of amplicon-based next-generation sequencing to therapeutic decision making in lung cancer. Ann Oncol. 2015;26(12):2477-2482. doi:10.1093/annonc/mdv475</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/annonc/mdv475</ArticleId><ArticleId IdType=\"pubmed\">26420428</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>\n",
            "XML saved to: path/to/save/xml/38100106.xml\n",
            "Details URL: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=38097480&retmode=xml&api_key=9edd38677707c08b2a96ed1a6e8c61c47408\n",
            "Details Response Content: <?xml version=\"1.0\" ?>\n",
            "<!DOCTYPE PubmedArticleSet PUBLIC \"-//NLM//DTD PubMedArticle, 1st January 2023//EN\" \"https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd\">\n",
            "<PubmedArticleSet>\n",
            "<PubmedArticle><MedlineCitation Status=\"Publisher\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38097480</PMID><DateRevised><Year>2023</Year><Month>12</Month><Day>14</Day></DateRevised><Article PubModel=\"Print-Electronic\"><Journal><ISSN IssnType=\"Electronic\">1995-9133</ISSN><JournalIssue CitedMedium=\"Internet\"><PubDate><Year>2023</Year><Month>Dec</Month><Day>01</Day></PubDate></JournalIssue><Title>Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi</Title><ISOAbbreviation>J Microbiol Immunol Infect</ISOAbbreviation></Journal><ArticleTitle>The role of treatment regimen and duration in treating patients with Mycobacterium avium complex lung disease: A real-world experience and case-control study.</ArticleTitle><ELocationID EIdType=\"pii\" ValidYN=\"Y\">S1684-1182(23)00212-8</ELocationID><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.1016/j.jmii.2023.11.006</ELocationID><Abstract><AbstractText Label=\"PURPOSE\" NlmCategory=\"OBJECTIVE\">The treatment advantage of guideline-based therapy (GBT) in Mycobacterium avium complex lung disease (MAC-LD) is well-known. However, GBT is not always feasible. The aim of the study was to analyze the relationship of treatment regimens and duration with outcomes.</AbstractText><AbstractText Label=\"MATERIALS AND METHODS\" NlmCategory=\"METHODS\">This study screened patients with MAC-LD from Jan 2011 to Dec 2020 and enrolled those who received treatment. The treatment regimens were categorized to triple therapy (three active drugs) and non-triple therapy. The favorable outcomes included microbiological cure or clinical cure if no microbiologic persistence.</AbstractText><AbstractText Label=\"RESULTS\" NlmCategory=\"RESULTS\">A total of 106 patients with MAC-LD were enrolled. Among them, 88 subjects (83&#xa0;%) received triple therapy, 58 (54.7&#xa0;%) had MAC treatment &gt;12 months, and 66 (62.3&#xa0;%) had favorable outcomes. Patients receiving triple therapy (90.9&#xa0;% vs. 67.5&#xa0;%, p&#xa0;=&#xa0;0.008) and treatment &gt;12 months (62.1&#xa0;% vs. 42.5&#xa0;%, p&#xa0;=&#xa0;0.07) had higher proportion of favorable outcomes than unfavorable outcomes. Multivariable logistic regression analysis showed that age &gt;65, comorbidities of COPD and prior tuberculosis, low hemoglobin, and high MAC burden were independent risk factors of unfavorable outcome. In contrast, triple therapy (OR: 0.018, 95&#xa0;% CI: 0.04-0.78, p&#xa0;=&#xa0;0.022) and treatment duration &gt;12 months (OR: 0.20, 95&#xa0;% CI: 0.055-0.69, p&#xa0;=&#xa0;0.012) were protective factors against unfavorable outcome.</AbstractText><AbstractText Label=\"CONCLUSIONS\" NlmCategory=\"CONCLUSIONS\">Triple therapy including GBT, and treatment more than 12 months achieved more favorable outcome. Maintenance of triple therapy, but not reducing the number of active drugs, might be an acceptable alternative of GBT.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023. Published by Elsevier B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Wang</LastName><ForeName>Ping-Huai</ForeName><Initials>PH</Initials><AffiliationInfo><Affiliation>Division of Thoracic Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan; School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Shu</LastName><ForeName>Chin-Chung</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan; College of Medicine, National Taiwan University, Taipei, Taiwan. Electronic address: ccshu@ntu.edu.tw.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Chen</LastName><ForeName>Chung-Yu</ForeName><Initials>CY</Initials><AffiliationInfo><Affiliation>College of Medicine, National Taiwan University, Taipei, Taiwan; Department of Internal Medicine, National Taiwan University Hospital Yunlin Branch, Yunlin County, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Wei</LastName><ForeName>Yu-Feng</ForeName><Initials>YF</Initials><AffiliationInfo><Affiliation>School of Medicine for International Students, College of Medicine, I-Shou University, Kaohsiung, Taiwan; Department of Internal Medicine, E-Da Cancer Hospital, I-Shou University, Kaohsiung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Cheng</LastName><ForeName>Shih-Lung</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Division of Thoracic Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan; Department of Chemical Engineering and Materials Science, Yuan-Ze University, Taiwan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2023</Year><Month>12</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Microbiol Immunol Infect</MedlineTA><NlmUniqueID>100956211</NlmUniqueID><ISSNLinking>1684-1182</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner=\"NOTNLM\"><Keyword MajorTopicYN=\"N\">Mycobacterium avium complex</Keyword><Keyword MajorTopicYN=\"N\">Non-tuberculous mycobacterium</Keyword><Keyword MajorTopicYN=\"N\">Outcome</Keyword><Keyword MajorTopicYN=\"N\">Treatment</Keyword></KeywordList><CoiStatement>Conflicts of interest All of the authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"received\"><Year>2023</Year><Month>8</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus=\"revised\"><Year>2023</Year><Month>11</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus=\"accepted\"><Year>2023</Year><Month>11</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus=\"medline\"><Year>2023</Year><Month>12</Month><Day>15</Day><Hour>0</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2023</Year><Month>12</Month><Day>15</Day><Hour>0</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2023</Year><Month>12</Month><Day>14</Day><Hour>22</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38097480</ArticleId><ArticleId IdType=\"doi\">10.1016/j.jmii.2023.11.006</ArticleId><ArticleId IdType=\"pii\">S1684-1182(23)00212-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>\n",
            "XML saved to: path/to/save/xml/38097480.xml\n",
            "Details URL: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=38092558&retmode=xml&api_key=9edd38677707c08b2a96ed1a6e8c61c47408\n",
            "Details Response Content: <?xml version=\"1.0\" ?>\n",
            "<!DOCTYPE PubmedArticleSet PUBLIC \"-//NLM//DTD PubMedArticle, 1st January 2023//EN\" \"https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd\">\n",
            "<PubmedArticleSet>\n",
            "<PubmedArticle><MedlineCitation Status=\"Publisher\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38092558</PMID><DateRevised><Year>2023</Year><Month>12</Month><Day>13</Day></DateRevised><Article PubModel=\"Print-Electronic\"><Journal><ISSN IssnType=\"Electronic\">2005-6648</ISSN><JournalIssue CitedMedium=\"Internet\"><PubDate><Year>2023</Year><Month>Dec</Month><Day>14</Day></PubDate></JournalIssue><Title>The Korean journal of internal medicine</Title><ISOAbbreviation>Korean J Intern Med</ISOAbbreviation></Journal><ArticleTitle>Sex differences in chronic obstructive pulmonary disease characteristics: the Korea National Health and Nutrition Examination Survey 2007-2018.</ArticleTitle><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.3904/kjim.2023.036</ELocationID><Abstract><AbstractText Label=\"BACKGROUND/AIMS\" NlmCategory=\"UNASSIGNED\">Chronic obstructive pulmonary disease (COPD) is less prevalent in females than males, but it affects mortality in females. There may be sex differences in the clinical characteristics of COPD.</AbstractText><AbstractText Label=\"METHODS\" NlmCategory=\"UNASSIGNED\">We analyzed the Korea National Health and Nutrition Examination Survey dataset from 2007 to 2018. We compared the clinical characteristics and comorbidities in subjects with COPD according to sex. We adjusted the multivariate logistic regression of lung cancer prevalence according to COPD and sex by age and smoking amount.</AbstractText><AbstractText Label=\"RESULTS\" NlmCategory=\"UNASSIGNED\">Females with COPD tended to be older than males with COPD (64.1 &#xb1; 0.4 yr vs. 62.3 &#xb1; 0.2 yr, respectively, p &lt; 0.001). Approximately 89% of males with COPD had a smoking history, while 86% of females with COPD were non-smokers (p &lt; 0.001). Household income was lower (p &lt; 0.001) and asthma and overall malignancy were more prevalent in females with COPD than males with COPD (25.5 vs. 11.6%, respectively, p &lt; 0.001; (6.3 vs. 5.4%, respectively, p &lt; 0.001). However, lung cancer was more common in males with COPD than females with COPD (0.9 vs. 0.1%, respectively, p &lt; 0.001). Lung cancer prevalence increased in males with moderate COPD compared to subjects without COPD (OR, 4.409; 95% CI, 1.741-9.419).</AbstractText><AbstractText Label=\"CONCLUSIONS\" NlmCategory=\"UNASSIGNED\">Females with COPD had a lower smoking rate, household income, and lung cancer prevalence than males with COPD. More active COPD screening is needed for women of low socioeconomic status, even if they do not smoke.</AbstractText></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Baek</LastName><ForeName>Moon Seong</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Shin</LastName><ForeName>Haegwang</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Gu</LastName><ForeName>Kang-Mo</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Jung</LastName><ForeName>Hae In</ForeName><Initials>HI</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Kim</LastName><ForeName>Won Young</ForeName><Initials>WY</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Jung</LastName><ForeName>Jae-Woo</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Shin</LastName><ForeName>Jong-Wook</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Jung</LastName><ForeName>Sun-Young</ForeName><Initials>SY</Initials><AffiliationInfo><Affiliation>College of Pharmacy, Chung-Ang University, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Kim</LastName><ForeName>Jae-Yeol</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2023</Year><Month>12</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>Korea (South)</Country><MedlineTA>Korean J Intern Med</MedlineTA><NlmUniqueID>8712418</NlmUniqueID><ISSNLinking>1226-3303</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner=\"NOTNLM\"><Keyword MajorTopicYN=\"N\">Lung neoplasm</Keyword><Keyword MajorTopicYN=\"N\">Pulmonary disease, chronic obstructive</Keyword><Keyword MajorTopicYN=\"N\">Sex</Keyword><Keyword MajorTopicYN=\"N\">Smoking</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"received\"><Year>2023</Year><Month>1</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus=\"accepted\"><Year>2023</Year><Month>10</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus=\"medline\"><Year>2023</Year><Month>12</Month><Day>14</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2023</Year><Month>12</Month><Day>14</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2023</Year><Month>12</Month><Day>13</Day><Hour>21</Hour><Minute>30</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38092558</ArticleId><ArticleId IdType=\"doi\">10.3904/kjim.2023.036</ArticleId><ArticleId IdType=\"pii\">kjim.2023.036</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>\n",
            "XML saved to: path/to/save/xml/38092558.xml\n",
            "Details URL: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=38090511&retmode=xml&api_key=9edd38677707c08b2a96ed1a6e8c61c47408\n",
            "Details Response Content: <?xml version=\"1.0\" ?>\n",
            "<!DOCTYPE PubmedArticleSet PUBLIC \"-//NLM//DTD PubMedArticle, 1st January 2023//EN\" \"https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd\">\n",
            "<PubmedArticleSet>\n",
            "<PubmedArticle><MedlineCitation Status=\"PubMed-not-MEDLINE\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38090511</PMID><DateRevised><Year>2023</Year><Month>12</Month><Day>13</Day></DateRevised><Article PubModel=\"Print-Electronic\"><Journal><ISSN IssnType=\"Print\">2218-6751</ISSN><JournalIssue CitedMedium=\"Print\"><Volume>12</Volume><Issue>11</Issue><PubDate><Year>2023</Year><Month>Nov</Month><Day>30</Day></PubDate></JournalIssue><Title>Translational lung cancer research</Title><ISOAbbreviation>Transl Lung Cancer Res</ISOAbbreviation></Journal><ArticleTitle>Seven preoperative factors have strong predictive value for postoperative pneumonia in patients undergoing thoracoscopic lung cancer surgery.</ArticleTitle><Pagination><StartPage>2193</StartPage><EndPage>2208</EndPage><MedlinePgn>2193-2208</MedlinePgn></Pagination><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.21037/tlcr-23-512</ELocationID><Abstract><AbstractText Label=\"BACKGROUND\" NlmCategory=\"UNASSIGNED\">Postoperative pneumonia (POP) is a hospital acquired pneumonia that occurs &gt;48 hours after tracheal intubation. The diagnosis of POP should be based on clinical and radiological findings within 30 days after surgery. It is a common complication after thoracoscopic surgery for lung cancer patients. However, the specific impact of preoperative comorbidities on the incidence of POP remains unclear. This study aimed to analyze the preoperative data of patients with lung cancer to help surgeons predict the risk of incidence of POP after thoracoscopic lung resection.</AbstractText><AbstractText Label=\"METHODS\" NlmCategory=\"UNASSIGNED\">This study is a prospective study that included patients with lung cancer who were scheduled for thoracoscopic surgery in 1 year. All cases came from two medical centers. Preoperative demographic information, tumor information, preoperative comorbidities, quality of life scores, and incidence of POP were collected. Variables were screened by univariate analysis and multivariate regression. Finally, a prediction model was constructed. A total of 53 preoperative factors were included as candidate predictors. The binary outcome variable was defined as the presence or absence of POP. The incidence of POP was the primary outcome variable. The predictive performance of the model was verified internally through 1,000 iterations of bootstrap resampling.</AbstractText><AbstractText Label=\"RESULTS\" NlmCategory=\"UNASSIGNED\">A total of 1,229 patients with lung cancer who underwent thoracoscopic surgery were enrolled. In addition, 196 cases (15.95%) had POP; 1,025 (83.40%) patients had comorbid conditions. The total number of comorbidity diagnosed in all samples was 2,929. The prediction model suggested that patients with advanced age, high body mass index (BMI), smoking, poor physical condition, respiratory diseases, diabetes, and neurological diseases were more likely to develop POP. The area under the curve (AUC) and Brier scores were 0.851 and 0.091, respectively. The expected and observed results were in strong agreement, according to the likelihood of POP calibration curve.</AbstractText><AbstractText Label=\"CONCLUSIONS\" NlmCategory=\"UNASSIGNED\">The constructed model is capable of evaluating the probability of POP occurrence in patients with lung cancer. Seven preoperative factors in patients with lung cancer were found to be associated with increased probability of having pneumonia after thoracoscopic lung resection. This model can help predict the incidence of POP after surgery.</AbstractText><CopyrightInformation>2023 Translational Lung Cancer Research. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Bian</LastName><ForeName>Hongliang</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Lung Cancer Surgery, Tianjin Medical University General Hospital, Tianjin, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Thoracic Surgery, Affiliated Hospital of Chifeng University &amp; Institute of Thoracic Trauma and Tumor of Chifeng University, Chifeng, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Liu</LastName><ForeName>Minghui</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Lung Cancer Surgery, Tianjin Medical University General Hospital, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Liu</LastName><ForeName>Jinghao</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Lung Cancer Surgery, Tianjin Medical University General Hospital, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Dong</LastName><ForeName>Ming</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Lung Cancer Surgery, Tianjin Medical University General Hospital, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Hong</LastName><ForeName>Goohyeon</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Dankook University Hospital, Dankook University College of Medicine, Cheonan, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Agrafiotis</LastName><ForeName>Apostolos C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Department of Thoracic Surgery, Saint-Pierre University Hospital, Universit&#xe9; Libre de Bruxelles (ULB), Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Patel</LastName><ForeName>Akshay J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Institute of Immunology and Immunotherapy (III), College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Thoracic Surgery, University Hospitals Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Ding</LastName><ForeName>Lei</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Thoracic Surgery, Affiliated Hospital of Chifeng University &amp; Institute of Thoracic Trauma and Tumor of Chifeng University, Chifeng, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Wu</LastName><ForeName>Jingbo</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Thoracic Surgery, Affiliated Hospital of Chifeng University &amp; Institute of Thoracic Trauma and Tumor of Chifeng University, Chifeng, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Chen</LastName><ForeName>Jun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Lung Cancer Surgery, Tianjin Medical University General Hospital, Tianjin, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Tianjin Key Laboratory of Lung Cancer Metastasis and Tumor Microenvironment, Tianjin Lung Cancer Institute, Tianjin Medical University General Hospital, Tianjin, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2023</Year><Month>10</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Transl Lung Cancer Res</MedlineTA><NlmUniqueID>101646875</NlmUniqueID><ISSNLinking>2218-6751</ISSNLinking></MedlineJournalInfo><KeywordList Owner=\"NOTNLM\"><Keyword MajorTopicYN=\"N\">Lung cancer</Keyword><Keyword MajorTopicYN=\"N\">comorbidities</Keyword><Keyword MajorTopicYN=\"N\">pneumonia</Keyword><Keyword MajorTopicYN=\"N\">thoracoscopic surgery</Keyword></KeywordList><CoiStatement>Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-23-512/coif). The authors have no conflicts of interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"received\"><Year>2023</Year><Month>8</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus=\"accepted\"><Year>2023</Year><Month>9</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus=\"medline\"><Year>2023</Year><Month>12</Month><Day>13</Day><Hour>18</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2023</Year><Month>12</Month><Day>13</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2023</Year><Month>12</Month><Day>13</Day><Hour>13</Hour><Minute>10</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38090511</ArticleId><ArticleId IdType=\"pmc\">PMC10713263</ArticleId><ArticleId IdType=\"doi\">10.21037/tlcr-23-512</ArticleId><ArticleId IdType=\"pii\">tlcr-12-11-2193</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Molt&#xf3; A, Dougados M. Comorbidity indices. Clin Exp Rheumatol 2014;32:S-131-4.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">25365102</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubio FJ, Alvares D, Redondo-Sanchez D, et al. Bayesian variable selection and survival modeling: assessing the Most important comorbidities that impact lung and colorectal cancer survival in Spain. BMC Med Res Methodol 2022;22:95. 10.1186/s12874-022-01582-0</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1186/s12874-022-01582-0</ArticleId><ArticleId IdType=\"pmc\">PMC8978388</ArticleId><ArticleId IdType=\"pubmed\">35369875</ArticleId></ArticleIdList></Reference><Reference><Citation>Fowler H, Belot A, Ellis L, et al. Comorbidity prevalence among cancer patients: a population-based cohort study of four cancers. BMC Cancer 2020;20:2. 10.1186/s12885-019-6472-9</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1186/s12885-019-6472-9</ArticleId><ArticleId IdType=\"pmc\">PMC6986047</ArticleId><ArticleId IdType=\"pubmed\">31987032</ArticleId></ArticleIdList></Reference><Reference><Citation>Anwar SL, Cahyono R, Prabowo D, et al. Metabolic comorbidities and the association with risks of recurrent metastatic disease in breast cancer survivors. BMC Cancer 2021;21:590. 10.1186/s12885-021-08343-0</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1186/s12885-021-08343-0</ArticleId><ArticleId IdType=\"pmc\">PMC8141199</ArticleId><ArticleId IdType=\"pubmed\">34022845</ArticleId></ArticleIdList></Reference><Reference><Citation>Handforth C, Clegg A, Young C, et al. The prevalence and outcomes of frailty in older cancer patients: a systematic review. Ann Oncol 2015;26:1091-101. 10.1093/annonc/mdu540</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/annonc/mdu540</ArticleId><ArticleId IdType=\"pubmed\">25403592</ArticleId></ArticleIdList></Reference><Reference><Citation>Russotto V, Sabat&#xe9; S, Canet J, et al. Development of a prediction model for postoperative pneumonia: A multicentre prospective observational study. Eur J Anaesthesiol 2019;36:93-104. 10.1097/EJA.0000000000000921</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1097/EJA.0000000000000921</ArticleId><ArticleId IdType=\"pubmed\">30431500</ArticleId></ArticleIdList></Reference><Reference><Citation>Islam KM, Jiang X, Anggondowati T, et al. Comorbidity and Survival in Lung Cancer Patients. Cancer Epidemiol Biomarkers Prev 2015;24:1079-85. 10.1158/1055-9965.EPI-15-0036</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1158/1055-9965.EPI-15-0036</ArticleId><ArticleId IdType=\"pubmed\">26065838</ArticleId></ArticleIdList></Reference><Reference><Citation>Charlson ME, Carrozzino D, Guidi J, et al. Charlson Comorbidity Index: A Critical Review of Clinimetric Properties. Psychother Psychosom 2022;91:8-35. 10.1159/000521288</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1159/000521288</ArticleId><ArticleId IdType=\"pubmed\">34991091</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta HB, Sura SD, Adhikari D, et al. Adapting the Elixhauser comorbidity index for cancer patients. Cancer 2018;124:2018-25. 10.1002/cncr.31269</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1002/cncr.31269</ArticleId><ArticleId IdType=\"pmc\">PMC5910176</ArticleId><ArticleId IdType=\"pubmed\">29390174</ArticleId></ArticleIdList></Reference><Reference><Citation>British Thoracic Society. Society of Cardiothoracic Surgeons of Great Britain and Ireland Working Party . BTS guidelines: guidelines on the selection of patients with lung cancer for surgery. Thorax 2001;56:89-108. 10.1136/thorax.56.2.89</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1136/thorax.56.2.89</ArticleId><ArticleId IdType=\"pmc\">PMC1745996</ArticleId><ArticleId IdType=\"pubmed\">11209097</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunelli A, Kim AW, Berger KI, et al. Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013;143:e166S-90S.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">23649437</ArticleId></ArticleIdList></Reference><Reference><Citation>Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-76. 10.1093/jnci/85.5.365</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/jnci/85.5.365</ArticleId><ArticleId IdType=\"pubmed\">8433390</ArticleId></ArticleIdList></Reference><Reference><Citation>Prommik P, Tootsi K, Saluse T, et al. Simple Excel and ICD-10 based dataset calculator for the Charlson and Elixhauser comorbidity indices. BMC Med Res Methodol 2022;22:4. 10.1186/s12874-021-01492-7</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1186/s12874-021-01492-7</ArticleId><ArticleId IdType=\"pmc\">PMC8742382</ArticleId><ArticleId IdType=\"pubmed\">34996364</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun JW, Rogers JR, Her Q, et al. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care 2017;55:1046-51. 10.1097/MLR.0000000000000824</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1097/MLR.0000000000000824</ArticleId><ArticleId IdType=\"pubmed\">29087983</ArticleId></ArticleIdList></Reference><Reference><Citation>Abbott TEF, Fowler AJ, Pelosi P, et al. A systematic review and consensus definitions for standardised end-points in perioperative medicine: pulmonary complications. Br J Anaesth 2018;120:1066-79. 10.1016/j.bja.2018.02.007</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.bja.2018.02.007</ArticleId><ArticleId IdType=\"pubmed\">29661384</ArticleId></ArticleIdList></Reference><Reference><Citation>Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008;36:309-32. 10.1016/j.ajic.2008.03.002</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.ajic.2008.03.002</ArticleId><ArticleId IdType=\"pubmed\">18538699</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdel Jalil R, Abou Chaar MK, Al-Qudah O, et al. Early surgical and oncological outcomes during adoption of a single port VATS lung resection in a tertiary cancer center: a retrospective analysis. J Cardiothorac Surg 2022;17:26. 10.1186/s13019-022-01777-y</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1186/s13019-022-01777-y</ArticleId><ArticleId IdType=\"pmc\">PMC8890027</ArticleId><ArticleId IdType=\"pubmed\">35236401</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen TF, Xie CY, Rao BY, et al. Surgical treatment to multiple primary lung cancer patients: a systematic review and meta-analysis. BMC Surg 2019;19:185. 10.1186/s12893-019-0643-0</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1186/s12893-019-0643-0</ArticleId><ArticleId IdType=\"pmc\">PMC6892192</ArticleId><ArticleId IdType=\"pubmed\">31795997</ArticleId></ArticleIdList></Reference><Reference><Citation>Ely S, Jiang SF, Dominguez DA, et al. Effect of thoracic surgery regionalization on long-term survival after lung cancer resection. J Thorac Cardiovasc Surg 2022;163:769-77. 10.1016/j.jtcvs.2021.03.050</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jtcvs.2021.03.050</ArticleId><ArticleId IdType=\"pubmed\">33934900</ArticleId></ArticleIdList></Reference><Reference><Citation>Powell HA, Tata LJ, Baldwin DR, et al. Early mortality after surgical resection for lung cancer: an analysis of the English National Lung cancer audit. Thorax 2013;68:826-34. 10.1136/thoraxjnl-2012-203123</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1136/thoraxjnl-2012-203123</ArticleId><ArticleId IdType=\"pubmed\">23687050</ArticleId></ArticleIdList></Reference><Reference><Citation>Batchelor TJP, Rasburn NJ, Abdelnour-Berchtold E, et al. Guidelines for enhanced recovery after lung surgery: recommendations of the Enhanced Recovery After Surgery (ERAS&#xae;) Society and the European Society of Thoracic Surgeons (ESTS). Eur J Cardiothorac Surg 2019;55:91-115. 10.1093/ejcts/ezy301</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/ejcts/ezy301</ArticleId><ArticleId IdType=\"pubmed\">30304509</ArticleId></ArticleIdList></Reference><Reference><Citation>Dutkowska AE, Antczak A. Comorbidities in lung cancer. Pneumonol Alergol Pol 2016;84:186-92. 10.5603/PiAP.2016.0022</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.5603/PiAP.2016.0022</ArticleId><ArticleId IdType=\"pubmed\">27238182</ArticleId></ArticleIdList></Reference><Reference><Citation>Grose D, Milroy R. Chronic obstructive pulmonary disease: a complex comorbidity of lung cancer. J Comorb 2011;1:45-50. 10.15256/joc.2011.1.5</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.15256/joc.2011.1.5</ArticleId><ArticleId IdType=\"pmc\">PMC5556420</ArticleId><ArticleId IdType=\"pubmed\">29090135</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta H, Ramanan B, Gupta PK, et al. Impact of COPD on postoperative outcomes: results from a national database. Chest 2013;143:1599-606. 10.1378/chest.12-1499</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1378/chest.12-1499</ArticleId><ArticleId IdType=\"pubmed\">23287892</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuyama W, Suetsugu T, Kawabata T, et al. Successful lobectomy in 3 lung cancer cases with severe COPD after treatment with tiotropium bromide. Nihon Kokyuki Gakkai Zasshi 2007;45:194-7.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">17352180</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Yu M, Ma Y, et al. Effect of Pulmonary Rehabilitation on Postoperative Clinical Status in Patients with Lung Cancer and Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis. Evid Based Complement Alternat Med 2022;2022:4133237. 10.1155/2022/4133237</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1155/2022/4133237</ArticleId><ArticleId IdType=\"pmc\">PMC9122671</ArticleId><ArticleId IdType=\"pubmed\">35600945</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu W, Zhu J, Li L, et al. The Prognostic Role of Chronic Obstructive Pulmonary Disease for Lung Cancer After Pulmonary Resection. J Surg Res 2022;275:137-48. 10.1016/j.jss.2022.01.014</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jss.2022.01.014</ArticleId><ArticleId IdType=\"pubmed\">35278725</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin CS, Chang CC, Yeh CC, et al. Postoperative Adverse Outcomes in Patients With Asthma: A Nationwide Population-based Cohort Study. Medicine (Baltimore) 2016;95:e2548. 10.1097/MD.0000000000002548</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1097/MD.0000000000002548</ArticleId><ArticleId IdType=\"pmc\">PMC4998277</ArticleId><ArticleId IdType=\"pubmed\">26817903</ArticleId></ArticleIdList></Reference><Reference><Citation>Iyoda A, Azuma Y, Sakamoto S, et al. Surgical treatment for patients with idiopathic pulmonary fibrosis and lung cancer: postoperative acute exacerbation of idiopathic pulmonary fibrosis and outcomes. Surg Today 2022;52:736-44. 10.1007/s00595-021-02343-0</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s00595-021-02343-0</ArticleId><ArticleId IdType=\"pubmed\">34347162</ArticleId></ArticleIdList></Reference><Reference><Citation>Carr ZJ, Yan L, Chavez-Duarte J, et al. Perioperative Management of Patients with Idiopathic Pulmonary Fibrosis Undergoing Noncardiac Surgery: A Narrative Review. Int J Gen Med 2022;15:2087-100. 10.2147/IJGM.S266217</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.2147/IJGM.S266217</ArticleId><ArticleId IdType=\"pmc\">PMC8882471</ArticleId><ArticleId IdType=\"pubmed\">35237071</ArticleId></ArticleIdList></Reference><Reference><Citation>Hata A, Sekine Y, Kota O, et al. Impact of combined pulmonary fibrosis and emphysema on surgical complications and long-term survival in patients undergoing surgery for non-small-cell lung cancer. Int J Chron Obstruct Pulmon Dis 2016;11:1261-8. 10.2147/COPD.S94119</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.2147/COPD.S94119</ArticleId><ArticleId IdType=\"pmc\">PMC4907478</ArticleId><ArticleId IdType=\"pubmed\">27354784</ArticleId></ArticleIdList></Reference><Reference><Citation>Iachina M, Jakobsen E, M&#xf8;ller H, et al. The effect of different comorbidities on survival of non-small cells lung cancer patients. Lung 2015;193:291-7. 10.1007/s00408-014-9675-5</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s00408-014-9675-5</ArticleId><ArticleId IdType=\"pubmed\">25516286</ArticleId></ArticleIdList></Reference><Reference><Citation>Dominguez-Ventura A, Allen MS, Cassivi SD, et al. Lung cancer in octogenarians: factors affecting morbidity and mortality after pulmonary resection. Ann Thorac Surg 2006;82:1175-9. 10.1016/j.athoracsur.2006.04.052</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.athoracsur.2006.04.052</ArticleId><ArticleId IdType=\"pubmed\">16996903</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S, Wong ML, Hamilton N, et al. Impact of age and comorbidity on non-small-cell lung cancer treatment in older veterans. J Clin Oncol 2012;30:1447-55. 10.1200/JCO.2011.39.5269</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1200/JCO.2011.39.5269</ArticleId><ArticleId IdType=\"pmc\">PMC3383118</ArticleId><ArticleId IdType=\"pubmed\">22454424</ArticleId></ArticleIdList></Reference><Reference><Citation>Pei G, Zhou S, Han Y, et al. Risk factors for postoperative complications after lung resection for non-small cell lung cancer in elderly patients at a single institution in China. J Thorac Dis 2014;6:1230-8. 10.3978/j.issn.2072-1439.2014.07.23</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3978/j.issn.2072-1439.2014.07.23</ArticleId><ArticleId IdType=\"pmc\">PMC4178082</ArticleId><ArticleId IdType=\"pubmed\">25276365</ArticleId></ArticleIdList></Reference><Reference><Citation>Benker M, Citak N, Neuer T, et al. Impact of preoperative comorbidities on postoperative complication rate and outcome in surgically resected non-small cell lung cancer patients. Gen Thorac Cardiovasc Surg 2022;70:248-56. 10.1007/s11748-021-01710-5</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s11748-021-01710-5</ArticleId><ArticleId IdType=\"pmc\">PMC8881261</ArticleId><ArticleId IdType=\"pubmed\">34554366</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S, Wang Z, Huang J, et al. Systematic review of prognostic roles of body mass index for patients undergoing lung cancer surgery: does the 'obesity paradox' really exist? Eur J Cardiothorac Surg 2017;51:817-28. 10.1093/ejcts/ezw386</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/ejcts/ezw386</ArticleId><ArticleId IdType=\"pubmed\">28040677</ArticleId></ArticleIdList></Reference><Reference><Citation>Nitsche LJ, Mukherjee S, Cheruvu K, et al. Exploring the Impact of the Obesity Paradox on Lung Cancer and Other Malignancies. Cancers (Basel) 2022;14:1440. 10.3390/cancers14061440</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3390/cancers14061440</ArticleId><ArticleId IdType=\"pmc\">PMC8946288</ArticleId><ArticleId IdType=\"pubmed\">35326592</ArticleId></ArticleIdList></Reference><Reference><Citation>Launer H, Nguyen DV, Cooke DT. National perioperative outcomes of pulmonary lobectomy for cancer in the obese patient: a propensity score matched analysis. J Thorac Cardiovasc Surg 2013;145:1312-8. 10.1016/j.jtcvs.2012.10.012</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jtcvs.2012.10.012</ArticleId><ArticleId IdType=\"pubmed\">23142119</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaw RK. Spectrum of postoperative complications in pulmonary hypertension and obesity hypoventilation syndrome. Curr Opin Anaesthesiol 2017;30:140-5. 10.1097/ACO.0000000000000420</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1097/ACO.0000000000000420</ArticleId><ArticleId IdType=\"pubmed\">27906717</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukui M, Suzuki K, Matsunaga T, et al. Importance of Smoking Cessation on Surgical Outcome in Primary Lung Cancer. Ann Thorac Surg 2019;107:1005-9. 10.1016/j.athoracsur.2018.12.002</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.athoracsur.2018.12.002</ArticleId><ArticleId IdType=\"pubmed\">30610851</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang IA, Brown JL, George J, et al. COPD-X Australian and New Zealand guidelines for the diagnosis and management of chronic obstructive pulmonary disease: 2017 update. Med J Aust 2017;207:436-42. 10.5694/mja17.00686</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.5694/mja17.00686</ArticleId><ArticleId IdType=\"pubmed\">29129177</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferguson MK, Parma CM, Celauro AD, et al. Quality of life and mood in older patients after major lung resection. Ann Thorac Surg 2009;87:1007-12; discussion 1012-3. 10.1016/j.athoracsur.2008.12.084</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.athoracsur.2008.12.084</ArticleId><ArticleId IdType=\"pubmed\">19324120</ArticleId></ArticleIdList></Reference><Reference><Citation>Paull DE, Thomas ML, Meade GE, et al. Determinants of quality of life in patients following pulmonary resection for lung cancer. Am J Surg 2006;192:565-71. 10.1016/j.amjsurg.2006.08.019</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.amjsurg.2006.08.019</ArticleId><ArticleId IdType=\"pubmed\">17071185</ArticleId></ArticleIdList></Reference><Reference><Citation>Gagn&#xe9; S, McIsaac DI. Modifiable risk factors for patients undergoing lung cancer surgery and their optimization: a review. J Thorac Dis 2018;10:S3761-72. 10.21037/jtd.2018.10.04</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.21037/jtd.2018.10.04</ArticleId><ArticleId IdType=\"pmc\">PMC6258652</ArticleId><ArticleId IdType=\"pubmed\">30505563</ArticleId></ArticleIdList></Reference><Reference><Citation>Stokes SM, Wakeam E, Antonoff MB, et al. Optimizing health before elective thoracic surgery: systematic review of modifiable risk factors and opportunities for health services research. J Thorac Dis 2019;11:S537-54. 10.21037/jtd.2019.01.06</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.21037/jtd.2019.01.06</ArticleId><ArticleId IdType=\"pmc\">PMC6465421</ArticleId><ArticleId IdType=\"pubmed\">31032072</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>\n",
            "XML saved to: path/to/save/xml/38090511.xml\n",
            "Details URL: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=38090326&retmode=xml&api_key=9edd38677707c08b2a96ed1a6e8c61c47408\n",
            "Details Response Content: <?xml version=\"1.0\" ?>\n",
            "<!DOCTYPE PubmedArticleSet PUBLIC \"-//NLM//DTD PubMedArticle, 1st January 2023//EN\" \"https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd\">\n",
            "<PubmedArticleSet>\n",
            "<PubmedArticle><MedlineCitation Status=\"PubMed-not-MEDLINE\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38090326</PMID><DateRevised><Year>2023</Year><Month>12</Month><Day>13</Day></DateRevised><Article PubModel=\"Print-Electronic\"><Journal><ISSN IssnType=\"Print\">2072-1439</ISSN><JournalIssue CitedMedium=\"Print\"><Volume>15</Volume><Issue>11</Issue><PubDate><Year>2023</Year><Month>Nov</Month><Day>30</Day></PubDate></JournalIssue><Title>Journal of thoracic disease</Title><ISOAbbreviation>J Thorac Dis</ISOAbbreviation></Journal><ArticleTitle>A nationwide analysis of disparities in guideline-concordant care in American Indians and Alaska Natives with stage I non-small cell lung cancer.</ArticleTitle><Pagination><StartPage>5891</StartPage><EndPage>5900</EndPage><MedlinePgn>5891-5900</MedlinePgn></Pagination><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.21037/jtd-23-801</ELocationID><Abstract><AbstractText Label=\"BACKGROUND\" NlmCategory=\"UNASSIGNED\">Several studies have shown racial disparities in lung cancer care in the United States in the Black and Hispanic populations but not many have included American Indian/Alaska Native (AI/AN) patients. We retrospectively evaluated the factors associated with receipt of guideline-concordant care in AI/AN and non-Hispanic White (NHW) patients with stage I non-small cell lung cancer (NSCLC) and describe the relationship between guideline-concordant care and survival outcomes in these populations.</AbstractText><AbstractText Label=\"METHODS\" NlmCategory=\"UNASSIGNED\">Using the National Cancer Database, we identified NHW and AI/AN patients diagnosed with stage I NSCLC between 2004 and 2017. We evaluated the utilization of anatomic resection among both NHW and AI/AN and described the variables associated with anatomic resection. We also evaluated 5-year overall survival (OS) by treatment and race. We used the chi-square test, multivariable analysis, and the Kaplan-Meier method for statistical analysis.</AbstractText><AbstractText Label=\"RESULTS\" NlmCategory=\"UNASSIGNED\">We identified 196,349 patients. Of these, 195,736 (99.69%) were NHW and 613 (0.31%) were AI/AN. Relative to NHW, AI/AN were more frequently diagnosed at a younger age (40% <i>vs.</i> 28% diagnosed at 18-64 years of age; P&lt;0.001) and more commonly resided in rural areas (14% <i>vs.</i> 5%; P&lt;0.001). In our multivariable analysis adjusting for all patient factors [age at diagnosis, sex, race, residence location, Charlson Comorbidity Index (CCI), tumor stage, lymph node status, and treatment facility], AI/AN patients were less likely to undergo anatomic resection than NHW patients [odds ratio (OR), 0.74; 95% confidence interval (CI): 0.62-0.89]. In our unadjusted survival analysis, AI/AN patients had lower 5-year OS than NHW (58% <i>vs.</i> 56%; P=0.04). When adjusted for surgery this difference was no longer significant.</AbstractText><AbstractText Label=\"CONCLUSIONS\" NlmCategory=\"UNASSIGNED\">AI/AN patients with stage I NSCLC undergo anatomic resection less frequently than do NHW, with lower 5-year OS than NHW. However, this survival difference is mitigated when AI/AN undergo anatomic resection.</AbstractText><CopyrightInformation>2023 Journal of Thoracic Disease. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Schoephoerster</LastName><ForeName>Jamee</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>University of Minnesota Medical School, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Praska</LastName><ForeName>Corinne</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>University of Minnesota Medical School, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>White</LastName><ForeName>McKenzie</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Surgery, University of Minnesota, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Salami</LastName><ForeName>Aitua</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Thoracic Surgery, Department of Surgery, University of Minnesota, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Marmor</LastName><ForeName>Schelomo</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Surgery, University of Minnesota, Minneapolis, MN, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Clinical Quality &amp; Outcomes Discovery &amp; Evaluation (C-QODE), University of Minnesota, Minneapolis, MN, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Andrade</LastName><ForeName>Rafael</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Division of Thoracic Surgery, Department of Surgery, University of Minnesota, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Bhargava</LastName><ForeName>Amit</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Thoracic Surgery, Department of Surgery, University of Minnesota, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Diaz-Gutierrez</LastName><ForeName>Ilitch</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Division of Thoracic Surgery, Department of Surgery, University of Minnesota, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Hui</LastName><ForeName>Jane</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Surgery, University of Minnesota, Minneapolis, MN, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Tuttle</LastName><ForeName>Todd</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Surgery, University of Minnesota, Minneapolis, MN, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Owen</LastName><ForeName>Mary</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>University of Minnesota Medical School, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Rao</LastName><ForeName>Madhuri</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Thoracic Surgery, Department of Surgery, University of Minnesota, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2023</Year><Month>10</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>J Thorac Dis</MedlineTA><NlmUniqueID>101533916</NlmUniqueID><ISSNLinking>2072-1439</ISSNLinking></MedlineJournalInfo><KeywordList Owner=\"NOTNLM\"><Keyword MajorTopicYN=\"N\">American Indian/Alaska Native (AI/AN)</Keyword><Keyword MajorTopicYN=\"N\">Guideline-concordant care</Keyword><Keyword MajorTopicYN=\"N\">health disparities</Keyword><Keyword MajorTopicYN=\"N\">lung cancer</Keyword><Keyword MajorTopicYN=\"N\">surgical resection</Keyword></KeywordList><CoiStatement>Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://jtd.amegroups.com/article/view/10.21037/jtd-23-801/coif). A.B. serves as an unpaid editorial board member of Journal of Thoracic Disease from October 2021 to September 2023. The other authors have no conflicts of interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"received\"><Year>2023</Year><Month>5</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus=\"accepted\"><Year>2023</Year><Month>9</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus=\"medline\"><Year>2023</Year><Month>12</Month><Day>13</Day><Hour>18</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2023</Year><Month>12</Month><Day>13</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2023</Year><Month>12</Month><Day>13</Day><Hour>13</Hour><Minute>7</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38090326</ArticleId><ArticleId IdType=\"pmc\">PMC10713313</ArticleId><ArticleId IdType=\"doi\">10.21037/jtd-23-801</ArticleId><ArticleId IdType=\"pii\">jtd-15-11-5891</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>DeShazer C. Racial differences in the treatment of early-stage lung cancer. N Engl J Med 2000;342:518-9.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">10691494</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmad FB, Anderson RN. The Leading Causes of Death in the US for 2020. JAMA 2021;325:1829-30. 10.1001/jama.2021.5469</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1001/jama.2021.5469</ArticleId><ArticleId IdType=\"pmc\">PMC8145781</ArticleId><ArticleId IdType=\"pubmed\">33787821</ArticleId></ArticleIdList></Reference><Reference><Citation>ICT. (2021, August 13). 2020 census: Native population increased by 86.5 percent. ICT. Retrieved September 21, 2022. Available online: https://indiancountrytoday.com/news/2020-census-native-population-increased-by-86-5-percent#:~:text=The%20demographic%20data%20will%20be,2020%2C%20a%2086.5%20percent%20increase</Citation></Reference><Reference><Citation>Smith CB, Bonomi M, Packer S, et al. Disparities in lung cancer stage, treatment and survival among American Indians and Alaskan Natives. Lung Cancer 2011;72:160-4. 10.1016/j.lungcan.2010.08.015</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.lungcan.2010.08.015</ArticleId><ArticleId IdType=\"pubmed\">20889227</ArticleId></ArticleIdList></Reference><Reference><Citation>Simpson DR, Mart&#xed;nez ME, Gupta S, et al. Racial disparity in consultation, treatment, and the impact on survival in metastatic colorectal cancer. J Natl Cancer Inst 2013;105:1814-20. 10.1093/jnci/djt318</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/jnci/djt318</ArticleId><ArticleId IdType=\"pmc\">PMC4383284</ArticleId><ArticleId IdType=\"pubmed\">24231453</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun M, Karakiewicz PI, Sammon JD, et al. Disparities in selective referral for cancer surgeries: implications for the current healthcare delivery system. BMJ Open 2014;4:e003921. 10.1136/bmjopen-2013-003921</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1136/bmjopen-2013-003921</ArticleId><ArticleId IdType=\"pmc\">PMC3963094</ArticleId><ArticleId IdType=\"pubmed\">24657917</ArticleId></ArticleIdList></Reference><Reference><Citation>van Ryn M. Research on the provider contribution to race/ethnicity disparities in medical care. Med Care 2002;40:I140-51. 10.1097/00005650-200201001-00015</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1097/00005650-200201001-00015</ArticleId><ArticleId IdType=\"pubmed\">11789627</ArticleId></ArticleIdList></Reference><Reference><Citation>Cobb N, Espey D, King J. Health behaviors and risk factors among American Indians and Alaska Natives, 2000-2010. Am J Public Health 2014;104 Suppl 3:S481-9. 10.2105/AJPH.2014.301879</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.2105/AJPH.2014.301879</ArticleId><ArticleId IdType=\"pmc\">PMC4035866</ArticleId><ArticleId IdType=\"pubmed\">24754662</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuckerman S, Haley J, Roubideaux Y, et al. Health service access, use, and insurance coverage among American Indians/Alaska Natives and Whites: what role does the Indian Health Service play? Am J Public Health 2004;94:53-9. 10.2105/ajph.94.1.53</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.2105/ajph.94.1.53</ArticleId><ArticleId IdType=\"pmc\">PMC1449826</ArticleId><ArticleId IdType=\"pubmed\">14713698</ArticleId></ArticleIdList></Reference><Reference><Citation>Lefkowitz DC, Underwood C. Personal Health Practices: Findings from the Survey of American Indians and Alaska Natives. Rockville, MD: Public Health Service; 1991. Agency for Health Care Policy and Research Publication. 91&#x2013;0034. Research Findings 10.</Citation></Reference><Reference><Citation>Lepisto E, Vandergrift JL, Kalemkerian GP, et al. PCN121 Oncology Medication Utilization Based on Federal Drug Administration (Fda) Labeling, National Comprehensive Cancer Network (NCCN) Clinical Practice Guideline (GL) Recommendations, and Evidence for Patients with Advanced Non Small Cell Lung Cancer (NSCLC): An Analysis from the NCCN Oncology Outcomes Database. Value Health 2011;14:A176-7.</Citation></Reference><Reference><Citation>National Cancer Database. ACS. Available online: https://www.facs.org/quality-programs/cancer-programs/national-cancer-database/</Citation></Reference><Reference><Citation>Ettinger DS, Wood DE, Aisner DL, et al. NCCN Guidelines&#xae; Insights: Non-Small Cell Lung Cancer, Version 2.2023. J Natl Compr Canc Netw 2023;21:340-50. 10.6004/jnccn.2023.0020</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.6004/jnccn.2023.0020</ArticleId><ArticleId IdType=\"pubmed\">37015337</ArticleId></ArticleIdList></Reference><Reference><Citation>Javid SH, Varghese TK, Morris AM, et al. Guideline-concordant cancer care and survival among American Indian/Alaskan Native patients. Cancer 2014;120:2183-90. 10.1002/cncr.28683</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1002/cncr.28683</ArticleId><ArticleId IdType=\"pmc\">PMC4219619</ArticleId><ArticleId IdType=\"pubmed\">24711210</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalwadi SM, Lewis GD, Bernicker EH, et al. Disparities in the Treatment and Outcome of Stage I Non-Small-Cell Lung Cancer in the 21st Century. Clin Lung Cancer 2019;20:194-200. 10.1016/j.cllc.2018.11.004</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.cllc.2018.11.004</ArticleId><ArticleId IdType=\"pubmed\">30655194</ArticleId></ArticleIdList></Reference><Reference><Citation>Melkonian SC, Jim MA, Haverkamp D, et al. Disparities in Cancer Incidence and Trends among American Indians and Alaska Natives in the United States, 2010-2015. Cancer Epidemiol Biomarkers Prev 2019;28:1604-11. 10.1158/1055-9965.EPI-19-0288</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1158/1055-9965.EPI-19-0288</ArticleId><ArticleId IdType=\"pmc\">PMC6777852</ArticleId><ArticleId IdType=\"pubmed\">31575554</ArticleId></ArticleIdList></Reference><Reference><Citation>Lung Cancer Incidence in the American Indian and Alaska Native Population, United States Purchased/Referred Care Delivery Areas&#x2014;2012&#x2013;2016. Available online: https://www.cdc.gov/cancer/uscs/about/data-briefs/no14-lung-cancer-incidence-AIAN-PRCDA-2012-2016.htm (2022).</Citation></Reference><Reference><Citation>Bliss A, Cobb N, Solomon T, et al. Lung cancer incidence among American Indians and Alaska Natives in the United States, 1999-2004. Cancer 2008;113:1168-78. 10.1002/cncr.23738</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1002/cncr.23738</ArticleId><ArticleId IdType=\"pmc\">PMC6800122</ArticleId><ArticleId IdType=\"pubmed\">18720387</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin SC, Gathua N, Thompson C, et al. Disparities in smoking prevalence and associations with mental health and substance use disorders in underserved communities across the United States. Cancer 2022;128:1826-31. 10.1002/cncr.34132</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1002/cncr.34132</ArticleId><ArticleId IdType=\"pubmed\">35253202</ArticleId></ArticleIdList></Reference><Reference><Citation>Cornelius ME, Loretan CG, Wang TW, et al. Tobacco Product Use Among Adults - United States, 2020. MMWR Morb Mortal Wkly Rep 2022;71:397-405. 10.15585/mmwr.mm7111a1</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.15585/mmwr.mm7111a1</ArticleId><ArticleId IdType=\"pmc\">PMC8942309</ArticleId><ArticleId IdType=\"pubmed\">35298455</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura H, Ando K, Shinmyo T, et al. Female gender is an independent prognostic factor in non-small-cell lung cancer: a meta-analysis. Ann Thorac Cardiovasc Surg 2011;17:469-80. 10.5761/atcs.oa.10.01637</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.5761/atcs.oa.10.01637</ArticleId><ArticleId IdType=\"pubmed\">21881356</ArticleId></ArticleIdList></Reference><Reference><Citation>Amini A, Shinde A, Li R, et al. Disparate outcomes in non-small cell lung cancer by race and immigrant status. Int J Radiat Oncol Biol Phys 2019;105:E444-5.</Citation></Reference><Reference><Citation>Balekian AA, Wisnivesky JP, Gould MK. Surgical Disparities Among Patients With Stage I Lung Cancer in the National Lung Screening Trial. Chest 2019;155:44-52. 10.1016/j.chest.2018.07.011</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.chest.2018.07.011</ArticleId><ArticleId IdType=\"pubmed\">30056040</ArticleId></ArticleIdList></Reference><Reference><Citation>Chau B, Ituarte PH, Shinde A, et al. Disparate outcomes in nonsmall cell lung cancer by immigration status. Cancer Med 2021;10:2660-7. 10.1002/cam4.3848</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1002/cam4.3848</ArticleId><ArticleId IdType=\"pmc\">PMC8026917</ArticleId><ArticleId IdType=\"pubmed\">33734614</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolf A, Alpert N, Tran BV, et al. Persistence of racial disparities in early-stage lung cancer treatment. J Thorac Cardiovasc Surg 2019;157:1670-1679.e4. 10.1016/j.jtcvs.2018.11.108</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jtcvs.2018.11.108</ArticleId><ArticleId IdType=\"pmc\">PMC6433143</ArticleId><ArticleId IdType=\"pubmed\">30685165</ArticleId></ArticleIdList></Reference><Reference><Citation>Heiden BT, Eaton DB, Jr, Chang SH, et al. Racial Disparities in the Surgical Treatment of Clinical Stage I Non-Small Cell Lung Cancer Among Veterans. Chest 2022;162:920-9. 10.1016/j.chest.2022.03.045</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.chest.2022.03.045</ArticleId><ArticleId IdType=\"pmc\">PMC9562435</ArticleId><ArticleId IdType=\"pubmed\">35405111</ArticleId></ArticleIdList></Reference><Reference><Citation>Guadagnolo BA, Petereit DG, Coleman CN. Cancer Care Access and Outcomes for American Indian Populations in the United States: Challenges and Models for Progress. Semin Radiat Oncol 2017;27:143-9. 10.1016/j.semradonc.2016.11.006</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.semradonc.2016.11.006</ArticleId><ArticleId IdType=\"pmc\">PMC5363281</ArticleId><ArticleId IdType=\"pubmed\">28325240</ArticleId></ArticleIdList></Reference><Reference><Citation>Markin A, Habermann EB, Zhu Y, et al. Cancer surgery among American Indians. JAMA Surg 2013;148:277-84; discussion 284. 10.1001/jamasurg.2013.1423</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1001/jamasurg.2013.1423</ArticleId><ArticleId IdType=\"pubmed\">23552658</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonner SN, Dualeh SHA, Kunnath N, et al. Hospital-Level Segregation Among Medicare Beneficiaries Undergoing Lung Cancer Resection. Ann Thorac Surg 2023;115:820-6. 10.1016/j.athoracsur.2022.12.032</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.athoracsur.2022.12.032</ArticleId><ArticleId IdType=\"pubmed\">36608754</ArticleId></ArticleIdList></Reference><Reference><Citation>Parsons HM, Habermann EB, Stain SC, et al. What happens to racial and ethnic minorities after cancer surgery at American College of Surgeons National Surgical Quality Improvement Program hospitals? J Am Coll Surg 2012;214:539-47; discussion 547-9. 10.1016/j.jamcollsurg.2011.12.024</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jamcollsurg.2011.12.024</ArticleId><ArticleId IdType=\"pubmed\">22321524</ArticleId></ArticleIdList></Reference><Reference><Citation>Marr L, Neale D, Wolfe V, et al. Confronting myths: the Native American experience in an academic inpatient palliative care consultation program. J Palliat Med 2012;15:71-6. 10.1089/jpm.2011.0197</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1089/jpm.2011.0197</ArticleId><ArticleId IdType=\"pubmed\">22242715</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawchuk CN, Van Dyke E, Omidpanah A, et al. Barriers to Cancer Care among American Indians and Alaska Natives. J Health Care Poor Underserved 2016;27:84-96. 10.1353/hpu.2016.0003</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1353/hpu.2016.0003</ArticleId><ArticleId IdType=\"pubmed\">27763460</ArticleId></ArticleIdList></Reference><Reference><Citation>Jim MA, Arias E, Seneca DS, et al. Racial misclassification of American Indians and Alaska Natives by Indian Health Service Contract Health Service Delivery Area. Am J Public Health 2014;104 Suppl 3:S295-302. 10.2105/AJPH.2014.301933</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.2105/AJPH.2014.301933</ArticleId><ArticleId IdType=\"pmc\">PMC4035863</ArticleId><ArticleId IdType=\"pubmed\">24754617</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>\n",
            "XML saved to: path/to/save/xml/38090326.xml\n",
            "Details URL: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=38090298&retmode=xml&api_key=9edd38677707c08b2a96ed1a6e8c61c47408\n",
            "Details Response Content: <?xml version=\"1.0\" ?>\n",
            "<!DOCTYPE PubmedArticleSet PUBLIC \"-//NLM//DTD PubMedArticle, 1st January 2023//EN\" \"https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd\">\n",
            "<PubmedArticleSet>\n",
            "<PubmedArticle><MedlineCitation Status=\"PubMed-not-MEDLINE\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38090298</PMID><DateRevised><Year>2023</Year><Month>12</Month><Day>13</Day></DateRevised><Article PubModel=\"Print-Electronic\"><Journal><ISSN IssnType=\"Print\">2072-1439</ISSN><JournalIssue CitedMedium=\"Print\"><Volume>15</Volume><Issue>11</Issue><PubDate><Year>2023</Year><Month>Nov</Month><Day>30</Day></PubDate></JournalIssue><Title>Journal of thoracic disease</Title><ISOAbbreviation>J Thorac Dis</ISOAbbreviation></Journal><ArticleTitle>What is the benefit of preserving the superior segment in anatomical thoracoscopic resections of the lower lobe?</ArticleTitle><Pagination><StartPage>6009</StartPage><EndPage>6018</EndPage><MedlinePgn>6009-6018</MedlinePgn></Pagination><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.21037/jtd-23-791</ELocationID><Abstract><AbstractText Label=\"BACKGROUND\" NlmCategory=\"UNASSIGNED\">The beneficial effect of preserved superior segment (S6) after common basal segmentectomy remains unknown. We aimed to evaluate the effect of preserved superior segment on lung volume and function.</AbstractText><AbstractText Label=\"METHODS\" NlmCategory=\"UNASSIGNED\">Among 671 segmentectomies and 2,249 lobectomies for clinical stage IA lung cancer between 2004 and 2020, 48 patients who received thoracoscopic common basal segmentectomy were included and compared with 96 patients who received thoracoscopic lower lobectomy after propensity score matching. The variables analyzed were age, sex, comorbidity, smoking history, preoperative forced expiratory volume in one second (FEV1), clinical T stage, histology, and tumor location. Lung volume was assessed using a three-dimensional (3D) computed tomography (CT)-based volumetric method.</AbstractText><AbstractText Label=\"RESULTS\" NlmCategory=\"UNASSIGNED\">There were no significant differences between common basal segmentectomy (segmentectomy group) and lower lobectomy (lobectomy group) (4,183.8&#xb1;1,114.9 versus 3,850.7&#xb1;1,132.1 mL; P=0.10) in terms of preoperative CT-measured total lung volume. At the immediate postoperative median follow-up period (6.4 months), the reduced percentage of CT-measured total lung volume in the segmentectomy group was significantly larger than that in the lobectomy group (-16.2% versus -6.5%; P=0.004). The percentage of CT-measured contralateral lung volume expansion in the segmentectomy group was significantly smaller than that in the lobectomy group (-0.7% versus +8.9%; P=0.006). At the last median follow-up period (43.1 months), the reduced percentage of CT-measured total lung volume in the segmentectomy group remained larger than that in the lobectomy group (-13.0% versus -3.0%; P=0.01). The reduced percentage of postoperative FEV1 in the segmentectomy group did not differ from that in the lobectomy group (-9.9% versus -11.5%, P=0.63).</AbstractText><AbstractText Label=\"CONCLUSIONS\" NlmCategory=\"UNASSIGNED\">Preserving the superior segment might not provide beneficial effect on the preservation of postoperative lung volume and function after common basal segmentectomy compared with lower lobectomy.</AbstractText><CopyrightInformation>2023 Journal of Thoracic Disease. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Yoon</LastName><ForeName>Seung Keun</ForeName><Initials>SK</Initials><AffiliationInfo><Affiliation>Department of Thoracic and Cardiovascular Surgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Yun</LastName><ForeName>Jae Kwang</ForeName><Initials>JK</Initials><AffiliationInfo><Affiliation>Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Choi</LastName><ForeName>Sehoon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Kim</LastName><ForeName>Hyeong Ryul</ForeName><Initials>HR</Initials><AffiliationInfo><Affiliation>Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Kim</LastName><ForeName>Yong-Hee</ForeName><Initials>YH</Initials><AffiliationInfo><Affiliation>Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Kim</LastName><ForeName>Dong Kwan</ForeName><Initials>DK</Initials><AffiliationInfo><Affiliation>Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Park</LastName><ForeName>Seung-Il</ForeName><Initials>SI</Initials><AffiliationInfo><Affiliation>Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Lee</LastName><ForeName>Geun Dong</ForeName><Initials>GD</Initials><AffiliationInfo><Affiliation>Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2023</Year><Month>11</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>J Thorac Dis</MedlineTA><NlmUniqueID>101533916</NlmUniqueID><ISSNLinking>2072-1439</ISSNLinking></MedlineJournalInfo><KeywordList Owner=\"NOTNLM\"><Keyword MajorTopicYN=\"N\">Superior segment</Keyword><Keyword MajorTopicYN=\"N\">common basal segmentectomy</Keyword><Keyword MajorTopicYN=\"N\">lobectomy</Keyword></KeywordList><CoiStatement>Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://jtd.amegroups.com/article/view/10.21037/jtd-23-791/coif). The authors have no conflicts of interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"received\"><Year>2023</Year><Month>5</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus=\"accepted\"><Year>2023</Year><Month>9</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus=\"medline\"><Year>2023</Year><Month>12</Month><Day>13</Day><Hour>18</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2023</Year><Month>12</Month><Day>13</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2023</Year><Month>12</Month><Day>13</Day><Hour>13</Hour><Minute>7</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38090298</ArticleId><ArticleId IdType=\"pmc\">PMC10713294</ArticleId><ArticleId IdType=\"doi\">10.21037/jtd-23-791</ArticleId><ArticleId IdType=\"pii\">jtd-15-11-6009</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Muraoka Y, Yoshida Y, Nakagawa K, et al. Maximum standardized uptake value of the primary tumor does not improve candidate selection for sublobar resection. J Thorac Cardiovasc Surg 2022;163:1656-1665.e3. 10.1016/j.jtcvs.2021.06.053</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jtcvs.2021.06.053</ArticleId><ArticleId IdType=\"pubmed\">34275620</ArticleId></ArticleIdList></Reference><Reference><Citation>Tane S, Nishio W, Nishioka Y, et al. Evaluation of the Residual Lung Function After Thoracoscopic Segmentectomy Compared With Lobectomy. Ann Thorac Surg 2019;108:1543-50. 10.1016/j.athoracsur.2019.05.052</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.athoracsur.2019.05.052</ArticleId><ArticleId IdType=\"pubmed\">31302085</ArticleId></ArticleIdList></Reference><Reference><Citation>Okada M, Koike T, Higashiyama M, et al. Radical sublobar resection for small-sized non-small cell lung cancer: a multicenter study. J Thorac Cardiovasc Surg 2006;132:769-75. 10.1016/j.jtcvs.2006.02.063</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jtcvs.2006.02.063</ArticleId><ArticleId IdType=\"pubmed\">17000286</ArticleId></ArticleIdList></Reference><Reference><Citation>Kushibe K, Takahama M, Tojo T, et al. Assessment of pulmonary function after lobectomy for lung cancer--upper lobectomy might have the same effect as lung volume reduction surgery. Eur J Cardiothorac Surg 2006;29:886-90. 10.1016/j.ejcts.2006.02.047</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.ejcts.2006.02.047</ArticleId><ArticleId IdType=\"pubmed\">16675249</ArticleId></ArticleIdList></Reference><Reference><Citation>Ueda K, Tanaka T, Hayashi M, et al. Compensation of pulmonary function after upper lobectomy versus lower lobectomy. J Thorac Cardiovasc Surg 2011;142:762-7. 10.1016/j.jtcvs.2011.04.037</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jtcvs.2011.04.037</ArticleId><ArticleId IdType=\"pubmed\">21679975</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshimoto K, Nomori H, Mori T, et al. Postoperative change in pulmonary function of the ipsilateral preserved lung after segmentectomy versus lobectomy. Eur J Cardiothorac Surg 2010;37:36-9. 10.1016/j.ejcts.2009.07.002</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.ejcts.2009.07.002</ArticleId><ArticleId IdType=\"pubmed\">19716312</ArticleId></ArticleIdList></Reference><Reference><Citation>Ueda K, Tanaka T, Hayashi M, et al. Computed tomography-defined functional lung volume after segmentectomy versus lobectomy. Eur J Cardiothorac Surg 2010;37:1433-7. 10.1016/j.ejcts.2010.01.002</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.ejcts.2010.01.002</ArticleId><ArticleId IdType=\"pubmed\">20153214</ArticleId></ArticleIdList></Reference><Reference><Citation>Saji H, Okada M, Tsuboi M, et al. Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial. Lancet 2022;399:1607-17. 10.1016/S0140-6736(21)02333-3</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/S0140-6736(21)02333-3</ArticleId><ArticleId IdType=\"pubmed\">35461558</ArticleId></ArticleIdList></Reference><Reference><Citation>Hwang Y, Kang CH, Kim HS, et al. Comparison of thoracoscopic segmentectomy and thoracoscopic lobectomy on the patients with non-small cell lung cancer: a propensity score matching study. Eur J Cardiothorac Surg 2015;48:273-8. 10.1093/ejcts/ezu422</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/ejcts/ezu422</ArticleId><ArticleId IdType=\"pubmed\">25406426</ArticleId></ArticleIdList></Reference><Reference><Citation>Bae SY, Lee H, Na KJ, et al. Computed tomography volumetric analysis for predicting postoperative lung function for segmentectomy. Interact Cardiovasc Thorac Surg 2022;35:ivac195. 10.1093/icvts/ivac195</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/icvts/ivac195</ArticleId><ArticleId IdType=\"pmc\">PMC9338704</ArticleId><ArticleId IdType=\"pubmed\">35876799</ArticleId></ArticleIdList></Reference><Reference><Citation>Bongiolatti S, Salvicchi A, Mugnaini G, et al. Does thoracoscopic basal pyramid segmentectomy really offer functional advantages in comparison with thoracoscopic lower lobectomy? Interdiscip Cardiovasc Thorac Surg 2023;36:ivad018. 10.1093/icvts/ivad018</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/icvts/ivad018</ArticleId><ArticleId IdType=\"pmc\">PMC9901411</ArticleId><ArticleId IdType=\"pubmed\">36847673</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunelli A, Kim AW, Berger KI, et al. Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013;143:e166S-90S.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">23649437</ArticleId></ArticleIdList></Reference><Reference><Citation>Aokage K, Saji H, Suzuki K, et al. A non-randomized confirmatory trial of segmentectomy for clinical T1N0 lung cancer with dominant ground glass opacity based on thin-section computed tomography (JCOG1211). Gen Thorac Cardiovasc Surg 2017;65:267-72. 10.1007/s11748-016-0741-1</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s11748-016-0741-1</ArticleId><ArticleId IdType=\"pubmed\">28255781</ArticleId></ArticleIdList></Reference><Reference><Citation>Sengul AT, Sahin B, Celenk C, et al. Postoperative lung volume change depending on the resected lobe. Thorac Cardiovasc Surg 2013;61:131-7. 10.1055/s-0032-1322625</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1055/s-0032-1322625</ArticleId><ArticleId IdType=\"pubmed\">23475808</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali MK, Mountain CF, Ewer MS, et al. Predicting loss of pulmonary function after pulmonary resection for bronchogenic carcinoma. Chest 1980;77:337-42. 10.1378/chest.77.3.337</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1378/chest.77.3.337</ArticleId><ArticleId IdType=\"pubmed\">7357934</ArticleId></ArticleIdList></Reference><Reference><Citation>Mechanisms and limits of induced postnatal lung growth. Am J Respir Crit Care Med 2004;170:319-43. 10.1164/rccm.200209-1062ST</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1164/rccm.200209-1062ST</ArticleId><ArticleId IdType=\"pubmed\">15280177</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler JP, Loring SH, Patz S, et al. Evidence for adult lung growth in humans. N Engl J Med 2012;367:244-7. 10.1056/NEJMoa1203983</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1056/NEJMoa1203983</ArticleId><ArticleId IdType=\"pmc\">PMC3422892</ArticleId><ArticleId IdType=\"pubmed\">22808959</ArticleId></ArticleIdList></Reference><Reference><Citation>Dane DM, Yilmaz C, Gyawali D, et al. Perfusion-related stimuli for compensatory lung growth following pneumonectomy. J Appl Physiol (1985) 2016;121:312-23. 10.1152/japplphysiol.00297.2016</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1152/japplphysiol.00297.2016</ArticleId><ArticleId IdType=\"pmc\">PMC4967253</ArticleId><ArticleId IdType=\"pubmed\">27150830</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsia CC. Comparative analysis of the mechanical signals in lung development and compensatory growth. Cell Tissue Res 2017;367:687-705. 10.1007/s00441-016-2558-8</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s00441-016-2558-8</ArticleId><ArticleId IdType=\"pmc\">PMC5321790</ArticleId><ArticleId IdType=\"pubmed\">28084523</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xe9;dat B, Abdelnour-Berchtold E, Krueger T, et al. Clinical outcome and risk factors for complications after pulmonary segmentectomy by video-assisted thoracoscopic surgery: results of an initial experience. J Thorac Dis 2018;10:5023-9. 10.21037/jtd.2018.07.42</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.21037/jtd.2018.07.42</ArticleId><ArticleId IdType=\"pmc\">PMC6129883</ArticleId><ArticleId IdType=\"pubmed\">30233876</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki K, Saji H, Aokage K, et al. Comparison of pulmonary segmentectomy and lobectomy: Safety results of a randomized trial. J Thorac Cardiovasc Surg 2019;158:895-907. 10.1016/j.jtcvs.2019.03.090</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jtcvs.2019.03.090</ArticleId><ArticleId IdType=\"pubmed\">31078312</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>\n",
            "XML saved to: path/to/save/xml/38090298.xml\n",
            "Details URL: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=38085543&retmode=xml&api_key=9edd38677707c08b2a96ed1a6e8c61c47408\n",
            "Details Response Content: <?xml version=\"1.0\" ?>\n",
            "<!DOCTYPE PubmedArticleSet PUBLIC \"-//NLM//DTD PubMedArticle, 1st January 2023//EN\" \"https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd\">\n",
            "<PubmedArticleSet>\n",
            "<PubmedArticle><MedlineCitation Status=\"MEDLINE\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38085543</PMID><DateCompleted><Year>2023</Year><Month>12</Month><Day>16</Day></DateCompleted><DateRevised><Year>2023</Year><Month>12</Month><Day>16</Day></DateRevised><Article PubModel=\"Electronic\"><Journal><ISSN IssnType=\"Electronic\">2574-3805</ISSN><JournalIssue CitedMedium=\"Internet\"><Volume>6</Volume><Issue>12</Issue><PubDate><Year>2023</Year><Month>Dec</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA network open</Title><ISOAbbreviation>JAMA Netw Open</ISOAbbreviation></Journal><ArticleTitle>Opportunistic Screening With Low-Dose Computed Tomography and Lung Cancer Mortality in China.</ArticleTitle><Pagination><StartPage>e2347176</StartPage><MedlinePgn>e2347176</MedlinePgn></Pagination><ELocationID EIdType=\"pii\" ValidYN=\"Y\">e2347176</ELocationID><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.1001/jamanetworkopen.2023.47176</ELocationID><Abstract><AbstractText Label=\"IMPORTANCE\" NlmCategory=\"UNASSIGNED\">Despite the recommendations of lung cancer screening guidelines and the evidence supporting the effectiveness of population-based lung screening, a common barrier to effective lung cancer screening is that the participation rates of low-dose computed tomography (LDCT) screening among individuals with the highest risk are not large. There are limited data from clinical practice regarding whether opportunistic LDCT screening is associated with reduced lung-cancer mortality.</AbstractText><AbstractText Label=\"OBJECTIVE\" NlmCategory=\"UNASSIGNED\">To evaluate whether opportunistic LDCT screening is associated with improved prognosis among adults with lung cancer in mainland China.</AbstractText><AbstractText Label=\"DESIGN, SETTING, AND PARTICIPANTS\" NlmCategory=\"UNASSIGNED\">This cohort study included patients diagnosed with lung cancer at Weihai Municipal Hospital Healthcare Group, Weihai City, China, from 2016 to 2021. Data were analyzed from January 2022 to February 2023.</AbstractText><AbstractText Label=\"EXPOSURES\" NlmCategory=\"UNASSIGNED\">Data collected included demographic indicators, tumor characteristics, comorbidities, blood indexes, and treatment information. Patients were classified into screened and nonscreened groups on the basis of whether or not their lung cancer diagnosis occurred through opportunistic screening.</AbstractText><AbstractText Label=\"MAIN OUTCOMES AND MEASURES\" NlmCategory=\"UNASSIGNED\">Follow-up outcome indicators included lung cancer-specific mortality and all-cause mortality. Propensity score matching (PSM) was adopted to account for potential imbalanced factors between groups. The associations between LDCT screening and outcomes were analyzed using Cox regression models based on the matched data. Propensity score regression adjustment and inverse probability treatment weighting were used for sensitivity analysis.</AbstractText><AbstractText Label=\"RESULTS\" NlmCategory=\"UNASSIGNED\">A total of 5234 patients (mean [SD] baseline age, 61.8 [9.8] years; 2518 [48.1%] female) with complete opportunistic screening information were included in the analytical sample, with 2251 patients (42.91%) receiving their lung cancer diagnosis through opportunistic screening. After 1:1 PSM, 2788 patients (1394 in each group) were finally included. The baseline characteristics of the matched patients were balanced between groups. Opportunistic screening with LDCT was associated with a 49% lower risk of lung cancer death (HR, 0.51; 95% CI, 0.42-0.62) and 46% lower risk of all-cause death (HR, 0.54; 95% CI, 0.45-0.64).</AbstractText><AbstractText Label=\"CONCLUSIONS AND RELEVANCE\" NlmCategory=\"UNASSIGNED\">In this cohort study of patients with lung cancer, opportunistic lung cancer screening with LDCT was associated with lower lung cancer mortality and all-cause mortality. These findings suggest that opportunistic screening is an important supplement to population screening to improve prognosis of adults with lung cancer.</AbstractText></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Wang</LastName><ForeName>Lijie</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Healthcare Big Data Research Institute, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Endocrinology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Qi</LastName><ForeName>Yue</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Oncology, Weihai Municipal Hospital, Cheeloo College of Medicine, Shandong University, Weihai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Liu</LastName><ForeName>Ailing</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pulmonary and Critical Care Medicine, Weihai Municipal Hospital, Cheeloo College of Medicine, Shandong University, Weihai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Guo</LastName><ForeName>Xiaolei</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department for Chronic and Non-Communicable Disease Control and Prevention, Shandong Center for Disease Control and Prevention, Jinan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Sun</LastName><ForeName>Shanshan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Oncology, Weihai Municipal Hospital, Cheeloo College of Medicine, Shandong University, Weihai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Zhang</LastName><ForeName>Lanfang</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Chemotherapy, Weihai Municipal Hospital, Cheeloo College of Medicine, Shandong University, Weihai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Ji</LastName><ForeName>Huaijun</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Thoracic Surgery, Weihai Municipal Hospital, Cheeloo College of Medicine, Shandong University, Weihai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Liu</LastName><ForeName>Guiyuan</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Radiology, Weihai Municipal Hospital, Cheeloo College of Medicine, Shandong University, Weihai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Zhao</LastName><ForeName>Huan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Oncology, Weihai Municipal Hospital, Cheeloo College of Medicine, Shandong University, Weihai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Jiang</LastName><ForeName>Yinan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Radiotherapy, Weihai Municipal Hospital, Cheeloo College of Medicine, Shandong University, Weihai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Li</LastName><ForeName>Jingyi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Radiotherapy, Weihai Municipal Hospital, Cheeloo College of Medicine, Shandong University, Weihai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Song</LastName><ForeName>Chengcun</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Chemotherapy, Weihai Municipal Hospital, Cheeloo College of Medicine, Shandong University, Weihai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Yu</LastName><ForeName>Xin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Oncology, Weihai Municipal Hospital, Cheeloo College of Medicine, Shandong University, Weihai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Yang</LastName><ForeName>Liu</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Chemotherapy, Weihai Municipal Hospital, Cheeloo College of Medicine, Shandong University, Weihai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Yu</LastName><ForeName>Jinchao</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Radiology, Weihai Municipal Hospital, Cheeloo College of Medicine, Shandong University, Weihai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Feng</LastName><ForeName>Hu</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Oncology, Weihai Municipal Hospital, Cheeloo College of Medicine, Shandong University, Weihai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Yang</LastName><ForeName>Fujun</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Oncology, Weihai Municipal Hospital, Cheeloo College of Medicine, Shandong University, Weihai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Xue</LastName><ForeName>Fuzhong</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Healthcare Big Data Research Institute, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2023</Year><Month>12</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Netw Open</MedlineTA><NlmUniqueID>101729235</NlmUniqueID><ISSNLinking>2574-3805</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI=\"D000328\" MajorTopicYN=\"N\">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D006801\" MajorTopicYN=\"N\">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D005260\" MajorTopicYN=\"N\">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D008875\" MajorTopicYN=\"N\">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D008297\" MajorTopicYN=\"N\">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D008175\" MajorTopicYN=\"Y\">Lung Neoplasms</DescriptorName><QualifierName UI=\"Q000000981\" MajorTopicYN=\"N\">diagnostic imaging</QualifierName><QualifierName UI=\"Q000453\" MajorTopicYN=\"N\">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D015331\" MajorTopicYN=\"N\">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D055088\" MajorTopicYN=\"N\">Early Detection of Cancer</DescriptorName><QualifierName UI=\"Q000379\" MajorTopicYN=\"N\">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D014057\" MajorTopicYN=\"N\">Tomography, X-Ray Computed</DescriptorName><QualifierName UI=\"Q000379\" MajorTopicYN=\"N\">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D008168\" MajorTopicYN=\"N\">Lung</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> None reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"medline\"><Year>2023</Year><Month>12</Month><Day>17</Day><Hour>9</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2023</Year><Month>12</Month><Day>12</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2023</Year><Month>12</Month><Day>12</Day><Hour>11</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38085543</ArticleId><ArticleId IdType=\"pmc\">PMC10716726</ArticleId><ArticleId IdType=\"doi\">10.1001/jamanetworkopen.2023.47176</ArticleId><ArticleId IdType=\"pii\">2812774</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sung H, Ferlay J, Siegel RL, et al. . Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249. doi:10.3322/caac.21660</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3322/caac.21660</ArticleId><ArticleId IdType=\"pubmed\">33538338</ArticleId></ArticleIdList></Reference><Reference><Citation>Surveillance, Epidemiology, and End Results Program . Cancer stat facts: cancer of the lung and bronchus. Accessed August 10, 2021. https://seer.cancer.gov/statfacts/html/lungb.html</Citation></Reference><Reference><Citation>Schabath MB, Cote ML. Cancer Progress and Priorities: Lung Cancer. Cancer Epidemiol Biomarkers Prev. 2019;28(10):1563-1579. doi:10.1158/1055-9965.EPI-19-0221</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1158/1055-9965.EPI-19-0221</ArticleId><ArticleId IdType=\"pmc\">PMC6777859</ArticleId><ArticleId IdType=\"pubmed\">31575553</ArticleId></ArticleIdList></Reference><Reference><Citation>Thai AA, Solomon BJ, Sequist LV, Gainor JF, Heist RS. Lung cancer. Lancet. 2021;398(10299):535-554. doi:10.1016/S0140-6736(21)00312-3</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/S0140-6736(21)00312-3</ArticleId><ArticleId IdType=\"pubmed\">34273294</ArticleId></ArticleIdList></Reference><Reference><Citation>Aberle DR, Adams AM, Berg CD, et al. ; National Lung Screening Trial Research Team . Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5):395-409. doi:10.1056/NEJMoa1102873</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1056/NEJMoa1102873</ArticleId><ArticleId IdType=\"pmc\">PMC4356534</ArticleId><ArticleId IdType=\"pubmed\">21714641</ArticleId></ArticleIdList></Reference><Reference><Citation>Henschke CI, Yip R, Shaham D, et al. ; I-ELCAP Investigators . The regimen of computed tomography screening for lung cancer: lessons learned over 25 years from the International Early Lung Cancer Action Program. J Thorac Imaging. 2021;36(1):6-23. doi:10.1097/RTI.0000000000000538</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1097/RTI.0000000000000538</ArticleId><ArticleId IdType=\"pmc\">PMC7771636</ArticleId><ArticleId IdType=\"pubmed\">32520848</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood DE, Kazerooni EA, Aberle D, et al. . NCCN Guidelines Insights: lung cancer screening, version 1.2022. J Natl Compr Canc Netw. 2022;20(7):754-764. doi:10.6004/jnccn.2022.0036</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.6004/jnccn.2022.0036</ArticleId><ArticleId IdType=\"pubmed\">35830884</ArticleId></ArticleIdList></Reference><Reference><Citation>Krist AH, Davidson KW, Mangione CM, et al. ; US Preventive Services Task Force . Screening for lung cancer: US Preventive Services Task Force recommendation statement. JAMA. 2021;325(10):962-970. doi:10.1001/jama.2021.1117</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1001/jama.2021.1117</ArticleId><ArticleId IdType=\"pubmed\">33687470</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzone PJ, Silvestri GA, Souter LH, et al. . Screening for lung cancer: CHEST guideline and expert panel report. Chest. 2021;160(5):e427-e494. doi:10.1016/j.chest.2021.06.063</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.chest.2021.06.063</ArticleId><ArticleId IdType=\"pmc\">PMC8727886</ArticleId><ArticleId IdType=\"pubmed\">34270968</ArticleId></ArticleIdList></Reference><Reference><Citation>de Koning HJ, van der Aalst CM, de Jong PA, et al. . Reduced lung-cancer mortality with volume CT screening in a randomized trial. N Engl J Med. 2020;382(6):503-513. doi:10.1056/NEJMoa1911793</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1056/NEJMoa1911793</ArticleId><ArticleId IdType=\"pubmed\">31995683</ArticleId></ArticleIdList></Reference><Reference><Citation>Field JK, Vulkan D, Davies MPA, et al. . Lung cancer mortality reduction by LDCT screening: UKLS randomised trial results and international meta-analysis. Lancet Reg Health Eur. 2021;10:100179. doi:10.1016/j.lanepe.2021.100179</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.lanepe.2021.100179</ArticleId><ArticleId IdType=\"pmc\">PMC8589726</ArticleId><ArticleId IdType=\"pubmed\">34806061</ArticleId></ArticleIdList></Reference><Reference><Citation>Pastorino U, Silva M, Sestini S, et al. . Prolonged lung cancer screening reduced 10-year mortality in the MILD trial: new confirmation of lung cancer screening efficacy. Ann Oncol. 2019;30(7):1162-1169. doi:10.1093/annonc/mdz117</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/annonc/mdz117</ArticleId><ArticleId IdType=\"pmc\">PMC6637372</ArticleId><ArticleId IdType=\"pubmed\">30937431</ArticleId></ArticleIdList></Reference><Reference><Citation>Lung Cancer Canada . Screening. Accessed May 22, 2022. https://www.lungcancercanada.ca/en-CA/Lung-Cancer/Screening.aspx</Citation></Reference><Reference><Citation>He J, Li N, Chen WQ, et al. ; Consulting Group of China Guideline for the Screening and Early Diagnosis and Treatment of Lung Cancer; Expert Group of China Guideline for the Screening and Early Diagnosis and Treatment of Lung Cancer; Working Group of China Guideline for the Screening and Early Diagnosis and Treatment of Lung Cancer . China guideline for the screening and early detection of lung cancer(2021, Beijing). Article in Chinese. Zhonghua Zhong Liu Za Zhi. 2021;43(3):243-268. doi:10.3760/cma.j.cn112152-20210119-00060.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3760/cma.j.cn112152-20210119-00060</ArticleId><ArticleId IdType=\"pubmed\">33752304</ArticleId></ArticleIdList></Reference><Reference><Citation>Li N, Tan F, Chen W, et al. ; National Lung Cancer Screening programme group . One-off low-dose CT for lung cancer screening in China: a multicentre, population-based, prospective cohort study. Lancet Respir Med. 2022;10(4):378-391. doi:10.1016/S2213-2600(21)00560-9</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/S2213-2600(21)00560-9</ArticleId><ArticleId IdType=\"pubmed\">35276087</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo LW, Chen Q, Shen YC, et al. . Evaluation of a low-dose computed tomography lung cancer screening program in Henan, China. JAMA Netw Open. 2020;3(11):e2019039. doi:10.1001/jamanetworkopen.2020.19039</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1001/jamanetworkopen.2020.19039</ArticleId><ArticleId IdType=\"pmc\">PMC7610188</ArticleId><ArticleId IdType=\"pubmed\">33141158</ArticleId></ArticleIdList></Reference><Reference><Citation>Huo J, Shen C, Volk RJ, Shih YT. Use of CT and chest radiography for lung cancer screening before and after publication of screening guidelines: intended and unintended uptake. JAMA Intern Med. 2017;177(3):439-441. doi:10.1001/jamainternmed.2016.9016</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1001/jamainternmed.2016.9016</ArticleId><ArticleId IdType=\"pmc\">PMC5893328</ArticleId><ArticleId IdType=\"pubmed\">28135349</ArticleId></ArticleIdList></Reference><Reference><Citation>Huo J, Hong YR, Bian J, Guo Y, Wilkie DJ, Mainous AG III. Low rates of patient-reported physician-patient discussion about lung cancer screening among current smokers: data from Health Information National Trends Survey. Cancer Epidemiol Biomarkers Prev. 2019;28(5):963-973. doi:10.1158/1055-9965.EPI-18-0629</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1158/1055-9965.EPI-18-0629</ArticleId><ArticleId IdType=\"pubmed\">31023697</ArticleId></ArticleIdList></Reference><Reference><Citation>International Cancer Control Partnership . Healthy China Initiative (2019-2030) cancer prevention and control actions. Accessed October 11, 2022. https://www.iccp-portal.org/plans/healthy-china-initiative-2019-2030-cancer-prevention-and-control-actions\n",
            "</Citation></Reference><Reference><Citation>Kim BJ, Heo C, Kim BK, Kim JY, Kim JG. Effectiveness of gastric cancer screening programs in South Korea: organized vs opportunistic models. World J Gastroenterol. 2013;19(5):736-741. doi:10.3748/wjg.v19.i5.736</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3748/wjg.v19.i5.736</ArticleId><ArticleId IdType=\"pmc\">PMC3574600</ArticleId><ArticleId IdType=\"pubmed\">23430471</ArticleId></ArticleIdList></Reference><Reference><Citation>Tranberg M, Larsen MB, Mikkelsen EM, Svanholm H, Andersen B. Impact of opportunistic testing in a systematic cervical cancer screening program: a nationwide registry study. BMC Public Health. 2015;15:681. doi:10.1186/s12889-015-2039-0</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1186/s12889-015-2039-0</ArticleId><ArticleId IdType=\"pmc\">PMC4508820</ArticleId><ArticleId IdType=\"pubmed\">26194007</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu M, He Z, Guo C, et al. . Effectiveness of intensive endoscopic screening for esophageal cancer in China: a community-based study. Am J Epidemiol. 2019;188(4):776-784. doi:10.1093/aje/kwy291</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/aje/kwy291</ArticleId><ArticleId IdType=\"pubmed\">30608546</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng R, Zhang S, Zeng H, et al. . Cancer incidence and mortality in China, 2016. J Natl Cancer Cent. 2022;2:1-9. doi:10.1016/j.jncc.2022.02.002</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jncc.2022.02.002</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70(1):41-55. doi:10.1093/biomet/70.1.41</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/biomet/70.1.41</ArticleId></ArticleIdList></Reference><Reference><Citation>VanderWeele TJ. Principles of confounder selection. Eur J Epidemiol. 2019;34(3):211-219. doi:10.1007/s10654-019-00494-6</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s10654-019-00494-6</ArticleId><ArticleId IdType=\"pmc\">PMC6447501</ArticleId><ArticleId IdType=\"pubmed\">30840181</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin PC. An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies. Multivariate Behav Res. 2011;46(3):399-424. doi:10.1080/00273171.2011.568786</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1080/00273171.2011.568786</ArticleId><ArticleId IdType=\"pmc\">PMC3144483</ArticleId><ArticleId IdType=\"pubmed\">21818162</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark TG, Bradburn MJ, Love SB, Altman DG. Survival analysis part I: basic concepts and first analyses. Br J Cancer. 2003;89(2):232-238. doi:10.1038/sj.bjc.6601118</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/sj.bjc.6601118</ArticleId><ArticleId IdType=\"pmc\">PMC2394262</ArticleId><ArticleId IdType=\"pubmed\">12865907</ArticleId></ArticleIdList></Reference><Reference><Citation>Reitsma MB, Kendrick PJ, Ababneh E, et al. ; GBD 2019 Tobacco Collaborators . Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and attributable disease burden in 204 countries and territories, 1990-2019: a systematic analysis from the Global Burden of Disease Study 2019. Lancet. 2021;397(10292):2337-2360. doi:10.1016/S0140-6736(21)01169-7</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/S0140-6736(21)01169-7</ArticleId><ArticleId IdType=\"pmc\">PMC8223261</ArticleId><ArticleId IdType=\"pubmed\">34051883</ArticleId></ArticleIdList></Reference><Reference><Citation>Siegel DA, Fedewa SA, Henley SJ, Pollack LA, Jemal A. Proportion of never smokers among men and women with lung cancer in 7 US states. JAMA Oncol. 2021;7(2):302-304. doi:10.1001/jamaoncol.2020.6362</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1001/jamaoncol.2020.6362</ArticleId><ArticleId IdType=\"pmc\">PMC7716251</ArticleId><ArticleId IdType=\"pubmed\">33270100</ArticleId></ArticleIdList></Reference><Reference><Citation>Islami F, Goding Sauer A, Miller KD, et al. . Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States. CA Cancer J Clin. 2018;68(1):31-54. doi:10.3322/caac.21440</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3322/caac.21440</ArticleId><ArticleId IdType=\"pubmed\">29160902</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang JB, Fan YG, Jiang Y, et al. . Attributable causes of lung cancer incidence and mortality in China. Thorac Cancer. 2011;2(4):156-163. doi:10.1111/j.1759-7714.2011.00067.x</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1111/j.1759-7714.2011.00067.x</ArticleId><ArticleId IdType=\"pubmed\">27755858</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong SJ, Goodman M, Kaphingst KA. Relationships of family history-related factors and causal beliefs to cancer risk perception and mammography screening adherence among medically underserved women. J Health Commun. 2020;25(7):531-542. doi:10.1080/10810730.2020.1788677</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1080/10810730.2020.1788677</ArticleId><ArticleId IdType=\"pmc\">PMC7749030</ArticleId><ArticleId IdType=\"pubmed\">32673182</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonnalagadda S, Bergamo C, Lin JJ, et al. . Beliefs and attitudes about lung cancer screening among smokers. Lung Cancer. 2012;77(3):526-531. doi:10.1016/j.lungcan.2012.05.095</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.lungcan.2012.05.095</ArticleId><ArticleId IdType=\"pmc\">PMC5055380</ArticleId><ArticleId IdType=\"pubmed\">22681870</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu FZ, Kuo PL, Huang YL, et al. . Differences in lung cancer characteristics and mortality rate between screened and non-screened cohorts. Sci Rep. 2019;9(1):19386. doi:10.1038/s41598-019-56025-6</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/s41598-019-56025-6</ArticleId><ArticleId IdType=\"pmc\">PMC6920422</ArticleId><ArticleId IdType=\"pubmed\">31852960</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang YL, Yuan JQ, Wang KF, et al. . The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget. 2016;7(48):78985-78993. doi:10.18632/oncotarget.12587</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.18632/oncotarget.12587</ArticleId><ArticleId IdType=\"pmc\">PMC5346692</ArticleId><ArticleId IdType=\"pubmed\">27738317</ArticleId></ArticleIdList></Reference><Reference><Citation>Midha A, Dearden S, McCormack R. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). Am J Cancer Res. 2015;5(9):2892-2911.</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC4633915</ArticleId><ArticleId IdType=\"pubmed\">26609494</ArticleId></ArticleIdList></Reference><Reference><Citation>Patz EF Jr, Pinsky P, Gatsonis C, et al. ; NLST Overdiagnosis Manuscript Writing Team . Overdiagnosis in low-dose computed tomography screening for lung cancer. JAMA Intern Med. 2014;174(2):269-274. doi:10.1001/jamainternmed.2013.12738</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1001/jamainternmed.2013.12738</ArticleId><ArticleId IdType=\"pmc\">PMC4040004</ArticleId><ArticleId IdType=\"pubmed\">24322569</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>\n",
            "XML saved to: path/to/save/xml/38085543.xml\n",
            "Details URL: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=38075997&retmode=xml&api_key=9edd38677707c08b2a96ed1a6e8c61c47408\n",
            "Details Response Content: <?xml version=\"1.0\" ?>\n",
            "<!DOCTYPE PubmedArticleSet PUBLIC \"-//NLM//DTD PubMedArticle, 1st January 2023//EN\" \"https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd\">\n",
            "<PubmedArticleSet>\n",
            "<PubmedArticle><MedlineCitation Status=\"PubMed-not-MEDLINE\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38075997</PMID><DateRevised><Year>2023</Year><Month>12</Month><Day>11</Day></DateRevised><Article PubModel=\"Electronic-eCollection\"><Journal><ISSN IssnType=\"Print\">1301-5680</ISSN><JournalIssue CitedMedium=\"Print\"><Volume>31</Volume><Issue>4</Issue><PubDate><Year>2023</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Turk gogus kalp damar cerrahisi dergisi</Title><ISOAbbreviation>Turk Gogus Kalp Damar Cerrahisi Derg</ISOAbbreviation></Journal><ArticleTitle>Extended resections in the treatment of locally advanced lung cancer.</ArticleTitle><Pagination><StartPage>538</StartPage><EndPage>546</EndPage><MedlinePgn>538-546</MedlinePgn></Pagination><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.5606/tgkdc.dergisi.2023.24788</ELocationID><Abstract><AbstractText Label=\"BACKGROUND\" NlmCategory=\"UNASSIGNED\">This study aims to evaluate surgical outcomes and prognosis in patients who underwent extended lung resection for locally advanced lung cancer.</AbstractText><AbstractText Label=\"METHODS\" NlmCategory=\"UNASSIGNED\">Between January 2015 and December 2019, a total of 61 patients (60 males, 1 female; mean age: 61.7&#xb1;12.2 years; range, 32 to 90 years) with locally advanced non-small-cell lung cancer who underwent extended lung resection were retrospectively analyzed. Data including age, sex, comorbid diseases, symptoms, smoking status, pulmonary function test results, tumor location, methods used for preoperative tissue diagnosis, histopathological cell type, type of surgical resection, pathological stage, nodal involvement, postoperative complications, types of adjuvant therapy, and mortality rate were recorded. Survival and the factors affecting survival were examined.</AbstractText><AbstractText Label=\"RESULTS\" NlmCategory=\"UNASSIGNED\">Seven (11.4%) patients had Stage IIIB, 40 (65.5%) patients had Stage IIIA, and 14 (22.9%) patients had Stage IB disease. Intrapericardial pneumonectomy accounted for 30 (49.1%) of all extended lung resections. Chemotherapy was administered to 31 (50.8%) patients and chemoradiotherapy to 24 (39.3%) patients in the postoperative period. In the survival analysis, 70-month survival rate was calculated as 63.9% and the median survival was 48 months. There was a statistically significant association between survival with adjuvant chemotherapy and chemoradiotherapy (p=0.003). The mortality rate at 70 months of follow-up was 36.1%.</AbstractText><AbstractText Label=\"CONCLUSION\" NlmCategory=\"UNASSIGNED\">Extended lung resection contributes significantly to the improvement of survival rates in carefully selected locally advanced cases. Particularly with adjuvant chemotherapy, local recurrences can be prevented, and survival rates can be improved.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023, Turkish Society of Cardiovascular Surgery.</CopyrightInformation></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Topalo&#x11f;lu</LastName><ForeName>&#xd6;mer</ForeName><Initials>&#xd6;</Initials><Identifier Source=\"ORCID\">0000-0001-5652-6018</Identifier><AffiliationInfo><Affiliation>Department of Thoracic Surgery, Karadeniz Technical University Faculty of Medicine, Trabzon, T&#xfc;rkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>T&#xfc;rky&#x131;lmaz</LastName><ForeName>Atila</ForeName><Initials>A</Initials><Identifier Source=\"ORCID\">0000-0002-4827-7469</Identifier><AffiliationInfo><Affiliation>Department of Thoracic Surgery, Karadeniz Technical University Faculty of Medicine, Trabzon, T&#xfc;rkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Karapolat</LastName><ForeName>Sami</ForeName><Initials>S</Initials><Identifier Source=\"ORCID\">0000-0001-8309-5348</Identifier><AffiliationInfo><Affiliation>Department of Thoracic Surgery, Karadeniz Technical University Faculty of Medicine, Trabzon, T&#xfc;rkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Buran</LastName><ForeName>Alaaddin</ForeName><Initials>A</Initials><Identifier Source=\"ORCID\">0000-0003-0523-0887</Identifier><AffiliationInfo><Affiliation>Department of Thoracic Surgery, Karadeniz Technical University Faculty of Medicine, Trabzon, T&#xfc;rkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Tekinba&#x15f;</LastName><ForeName>Celal</ForeName><Initials>C</Initials><Identifier Source=\"ORCID\">0000-0001-9361-9483</Identifier><AffiliationInfo><Affiliation>Department of Thoracic Surgery, Karadeniz Technical University Faculty of Medicine, Trabzon, T&#xfc;rkiye.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2023</Year><Month>10</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Turkey</Country><MedlineTA>Turk Gogus Kalp Damar Cerrahisi Derg</MedlineTA><NlmUniqueID>100887967</NlmUniqueID><ISSNLinking>1301-5680</ISSNLinking></MedlineJournalInfo><KeywordList Owner=\"NOTNLM\"><Keyword MajorTopicYN=\"N\">Chemotherapy</Keyword><Keyword MajorTopicYN=\"N\">extended resection</Keyword><Keyword MajorTopicYN=\"N\">locally advanced disease</Keyword><Keyword MajorTopicYN=\"N\">lung cancer.</Keyword></KeywordList><CoiStatement>Conflict of Interest: The authors declared no conflicts of interest with respect to the authorship and/or publication of this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"received\"><Year>2023</Year><Month>2</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus=\"accepted\"><Year>2023</Year><Month>4</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus=\"medline\"><Year>2023</Year><Month>12</Month><Day>11</Day><Hour>12</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2023</Year><Month>12</Month><Day>11</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2023</Year><Month>12</Month><Day>11</Day><Hour>6</Hour><Minute>5</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38075997</ArticleId><ArticleId IdType=\"pmc\">PMC10704529</ArticleId><ArticleId IdType=\"doi\">10.5606/tgkdc.dergisi.2023.24788</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Crin&#xf2; L, Weder W, van Meerbeeck J, Felip E, ESMO Guidelines Working Group Early stage and locally advanced (nonmetastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. v103-15Ann Oncol. 2010;21 Suppl 5 doi: 10.1093/annonc/mdq207.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/annonc/mdq207</ArticleId><ArticleId IdType=\"pubmed\">20555058</ArticleId></ArticleIdList></Reference><Reference><Citation>Yaran P, Yaz&#x131;c&#x131; &#xdc;, Ta&#x15f;tepe A&#x130;. Akci&#x11f;er kanserinde geni&#x15f;letilmi&#x15f; rezeksiyonlar. J Clin Anal Med. 2010:32&#x2013;40.</Citation></Reference><Reference><Citation>Choi HS, Jeong BK, Jeong H, Lee YH, Ha IB, Song JH, et al. Application of the new 8th TNM staging system for non-small cell lung cancer: Treated with curative concurrent chemoradiotherapy. Radiat Oncol. 2017;12:122&#x2013;122. doi: 10.1186/s13014-017-0848-2.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1186/s13014-017-0848-2</ArticleId><ArticleId IdType=\"pmc\">PMC5521086</ArticleId><ArticleId IdType=\"pubmed\">28732516</ArticleId></ArticleIdList></Reference><Reference><Citation>Downey RJ, Martini N, Rusch VW, Bains MS, Korst RJ, Ginsberg RJ. Extent of chest wall invasion and survival in patients with lung cancer. Ann Thorac Surg. 1999;68:188&#x2013;193. doi: 10.1016/s0003-4975(99)00456-7.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/s0003-4975(99)00456-7</ArticleId><ArticleId IdType=\"pubmed\">10421139</ArticleId></ArticleIdList></Reference><Reference><Citation>LoCicero III J. 8th ed. Philadelphia: Lippincott Williams &amp; Wilkins; 2018. Results of surgical treatment of non-small cell lung cancer; pp. 1222&#x2013;1252.</Citation></Reference><Reference><Citation>Watanabe Y, Hayashi Y, Shimizu J, Oda M, Iwa T. Mediastinal nodal involvement and the prognosis of non-small cell lung cancer. Chest. 1991;100:422&#x2013;428. doi: 10.1378/chest.100.2.422.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1378/chest.100.2.422</ArticleId><ArticleId IdType=\"pubmed\">1650679</ArticleId></ArticleIdList></Reference><Reference><Citation>Asamura H, Goya T, Koshiishi Y, Sohara Y, Eguchi K, Mori M, et al. A Japanese Lung Cancer Registry study: Prognosis of 13,010 resected lung cancers. J Thorac Oncol. 2008;3:46&#x2013;52. doi: 10.1097/JTO.0b013e31815e8577.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1097/JTO.0b013e31815e8577</ArticleId><ArticleId IdType=\"pubmed\">18166840</ArticleId></ArticleIdList></Reference><Reference><Citation>Martini N, Kris MG, Flehinger BJ, Gralla RJ, Bains MS, Burt ME, et al. Preoperative chemotherapy for stage IIIa (N2) lung cancer: The Sloan-Kettering experience with 136 patients. Ann Thorac Surg. 1993;55:1365&#x2013;1374. doi: 10.1016/0003-4975(93)91072-u.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/0003-4975(93)91072-u</ArticleId><ArticleId IdType=\"pubmed\">8390230</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, et al. The IASLC Lung Cancer Staging Project: Proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol. 2007;2:706&#x2013;714. doi: 10.1097/JTO.0b013e31812f3c1a.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1097/JTO.0b013e31812f3c1a</ArticleId><ArticleId IdType=\"pubmed\">17762336</ArticleId></ArticleIdList></Reference><Reference><Citation>Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, et al. Non-small cell lung cancer, version 3. 2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20:497&#x2013;530. doi: 10.6004/jnccn.2022.0025.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.6004/jnccn.2022.0025</ArticleId><ArticleId IdType=\"pubmed\">35545176</ArticleId></ArticleIdList></Reference><Reference><Citation>Naruke T, Goya T, Tsuchiya R, Suemasu K. Prognosis and survival in resected lung carcinoma based on the new international staging system. J Thorac Cardiovasc Surg. 1988;96:440&#x2013;447.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">2842549</ArticleId></ArticleIdList></Reference><Reference><Citation>McCaughan BC, Martini N, Bains MS, McCormack PM. Chest wall invasion in carcinoma of the lung. Therapeutic and prognostic implications. J Thorac Cardiovasc Surg. 1985;89:836&#x2013;841.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">2987619</ArticleId></ArticleIdList></Reference><Reference><Citation>Piehler JM, Pairolero PC, Weiland LH, Offord KP, Payne WS, Bernatz PE. Bronchogenic carcinoma with chest wall invasion: factors affecting survival following en bloc resection. Ann Thorac Surg. 1982;34:684&#x2013;691. doi: 10.1016/s0003-4975(10)60909-5.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/s0003-4975(10)60909-5</ArticleId><ArticleId IdType=\"pubmed\">7149846</ArticleId></ArticleIdList></Reference><Reference><Citation>Facciolo F, Cardillo G, Lopergolo M, Pallone G, Sera F, Martelli M. Chest wall invasion in non-small cell lung carcinoma: a rationale for en bloc resection. J Thorac Cardiovasc Surg. 2001;121:649&#x2013;656. doi: 10.1067/mtc.2001.112826.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1067/mtc.2001.112826</ArticleId><ArticleId IdType=\"pubmed\">11279404</ArticleId></ArticleIdList></Reference><Reference><Citation>Dartevelle PG. Herbert Sloan ecture. Extended operations for the treatment of lung cancer. Ann Thorac Surg. 1997;63:12&#x2013;19. doi: 10.1016/s0003-4975(96)01084-3.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/s0003-4975(96)01084-3</ArticleId><ArticleId IdType=\"pubmed\">8993235</ArticleId></ArticleIdList></Reference><Reference><Citation>Roviaro G, Vergani C, Maciocco M, Varoli F, Francese M, Despini L. Tracheal sleeve pneumonectomy: Longterm outcome. Lung Cancer. 2006;52:105&#x2013;110. doi: 10.1016/j.lungcan.2005.12.001.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.lungcan.2005.12.001</ArticleId><ArticleId IdType=\"pubmed\">16481067</ArticleId></ArticleIdList></Reference><Reference><Citation>Ta&#x15f;tepe &#x130;, Gezer S, &#xd6;z G, Ege T, G&#xfc;lhan E, Yaz&#x131;c&#x131; &#xdc;, et al. Tracheal sleeve pneumonectomy: An analysis of 13 cases. Turk Gogus Kalp Dama. 2011;19:221&#x2013;226. doi: 10.5606/tgkdc.dergisi.2011.017.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.5606/tgkdc.dergisi.2011.017</ArticleId></ArticleIdList></Reference><Reference><Citation>Yildizeli B, Dartevelle PG, Fadel E, Mussot S, Chapelier A. Results of primary surgery with T4 non-small cell lung cancer during a 25-year period in a single center: The benefit is worth the risk. Ann Thorac Surg. 2008;86:1065&#x2013;1075. doi: 10.1016/j.athoracsur.2008.07.004.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.athoracsur.2008.07.004</ArticleId><ArticleId IdType=\"pubmed\">18805134</ArticleId></ArticleIdList></Reference><Reference><Citation>Dartevelle PG, Chapelier AR, Pastorino U, Corbi P, Lenot B, Cerrina J, et al. Long-term follow-up after prosthetic replacement of the superior vena cava combined with resection of mediastinal-pulmonary malignant tumors. J Thorac Cardiovasc Surg. 1991;102:259&#x2013;265. doi: 10.1016/S0022-5223(19)36558-4.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/S0022-5223(19)36558-4</ArticleId><ArticleId IdType=\"pubmed\">1865699</ArticleId></ArticleIdList></Reference><Reference><Citation>Gandhi S, Walsh GL, Komaki R, Gokaslan ZL, Nesbitt JC, Putnam JB Jr, et al. A multidisciplinary surgical approach to superior sulcus tumors with vertebral invasion. Ann Thorac Surg. 1999;68:1778&#x2013;1784. doi: 10.1016/s0003-4975(99)01068-1.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/s0003-4975(99)01068-1</ArticleId><ArticleId IdType=\"pubmed\">10585058</ArticleId></ArticleIdList></Reference><Reference><Citation>Rusch VW, Parekh KR, Leon L, Venkatraman E, Bains MS, Downey RJ, et al. Factors determining outcome after surgical resection of T3 and T4 lung cancers of the superior sulcus. J Thorac Cardiovasc Surg. 2000;119:1147&#x2013;1153. doi: 10.1067/mtc.2000.106089.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1067/mtc.2000.106089</ArticleId><ArticleId IdType=\"pubmed\">10838531</ArticleId></ArticleIdList></Reference><Reference><Citation>Yokoi K, Tsuchiya R, Mori T, Nagai K, Furukawa T, Fujimura S, et al. Results of surgical treatment of lung cancer involving the diaphragm. J Thorac Cardiovasc Surg. 2000;120:799&#x2013;805. doi: 10.1067/mtc.2000.109706.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1067/mtc.2000.109706</ArticleId><ArticleId IdType=\"pubmed\">11003765</ArticleId></ArticleIdList></Reference><Reference><Citation>Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ, et al. Lung adjuvant cisplatin evaluation: A pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008;26:3552&#x2013;3559. doi: 10.1200/JCO.2007.13.9030.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1200/JCO.2007.13.9030</ArticleId><ArticleId IdType=\"pubmed\">18506026</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart LA, Burdett S, Tierney JF, Pignon J. Surgery and adjuvant chemotherapy (CT) compared to surgery alone in non-small cell lung cancer (NSCLC): A meta-analysis using individual patient data (IPD) from randomized clinical trials (RCT) J Clin Oncol. 2007;25(18 Suppl):7552&#x2013;7552. doi: 10.1200/jco.2007.25.18_suppl.7552.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1200/jco.2007.25.18_suppl.7552</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>\n",
            "XML saved to: path/to/save/xml/38075997.xml\n",
            "Details URL: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=38075485&retmode=xml&api_key=9edd38677707c08b2a96ed1a6e8c61c47408\n",
            "Details Response Content: <?xml version=\"1.0\" ?>\n",
            "<!DOCTYPE PubmedArticleSet PUBLIC \"-//NLM//DTD PubMedArticle, 1st January 2023//EN\" \"https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd\">\n",
            "<PubmedArticleSet>\n",
            "<PubmedArticle><MedlineCitation Status=\"PubMed-not-MEDLINE\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38075485</PMID><DateRevised><Year>2023</Year><Month>12</Month><Day>11</Day></DateRevised><Article PubModel=\"Electronic-eCollection\"><Journal><ISSN IssnType=\"Electronic\">2331-5180</ISSN><JournalIssue CitedMedium=\"Internet\"><Volume>10</Volume><Issue>2</Issue><PubDate><Year>2023</Year><Season>Fall</Season></PubDate></JournalIssue><Title>International journal of particle therapy</Title><ISOAbbreviation>Int J Part Ther</ISOAbbreviation></Journal><ArticleTitle>Proton Therapy in the Treatment of Men with Breast Cancer.</ArticleTitle><Pagination><StartPage>94</StartPage><EndPage>104</EndPage><MedlinePgn>94-104</MedlinePgn></Pagination><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.14338/IJPT-23-00007.1</ELocationID><Abstract><AbstractText Label=\"PURPOSE\" NlmCategory=\"UNASSIGNED\">Male breast cancer treatment involves multimodality therapy, including radiation therapy; nevertheless, few men have received proton therapy (PT) for it. Further, heart disease is an established leading cause of death in men, and radiation therapy heart dose correlates with cardiac toxicity, highlighting the need for cardiac-sparing radiation techniques. Thus, we provide a descriptive analysis of PT in a male breast cancer cohort.</AbstractText><AbstractText Label=\"PATIENTS AND METHODS\" NlmCategory=\"UNASSIGNED\">Men who received PT for localized breast cancer between 2012 and 2022 were identified from a prospective database. Toxicities were prospectively recorded by using the Common Terminology Criteria for Adverse Events (CTCAE), version 4.0.</AbstractText><AbstractText Label=\"RESULTS\" NlmCategory=\"UNASSIGNED\">Five male patients were identified. All had estrogen receptor (ER)-positive, Her2neu-negative disease and received adjuvant endocrine therapy. One had genetic testing positive for <i>BRCA2</i>, one had a variant of unknown significance (VUS) in the <i>APC</i> gene, and one had a VUS in <i>MSH2</i>. Median age was 73 years (range, 41-80). Baseline comorbidities included obesity (n&#x2009;=&#x2009;1), diabetes (n&#x2009;=&#x2009;1), hypertension (n&#x2009;=&#x2009;4), history of deep vein thrombosis (n&#x2009;=&#x2009;1), personal history of myocardial infarction (n&#x2009;=&#x2009;3; 1 with a pacemaker), and a history of lung cancer (n&#x2009;=&#x2009;1). All received PT to the left chest wall and comprehensive regional lymphatics. One received passive-scattering PT, and 4 received pencil beam scanning. One patient received a boost to the mastectomy incision via electrons. Median heart dose was 1 GyRBE (range, 0-1.0), median 0.1-cm<sup>3</sup> dose to the left anterior descending artery was 7.5 GyRBE (range, 0-14.2), and median follow-up was 2 years (range, 0.75-6.5); no patient experienced a new cardiac event, and all remain free from breast cancer recurrence and progression.</AbstractText><AbstractText Label=\"CONCLUSION\" NlmCategory=\"UNASSIGNED\">In a small case series for a rare diagnosis, PT to the chest wall and regional lymphatics, including internal mammary nodes, resulted in low cardiac exposure, high local regional disease control rates, and minimal toxicity. Proton therapy should be considered for treating men with breast cancer to achieve cardiac sparing.</AbstractText><CopyrightInformation>&#xa9;Copyright 2023 The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Bradley</LastName><ForeName>Julie A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, University of Florida College of Medicine, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Gracie</LastName><ForeName>Jayden</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, Vanderbilt University Medical Center, Nashville, TN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Mailhot Vega</LastName><ForeName>Raymond B</ForeName><Initials>RB</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, University of Florida College of Medicine, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Brooks</LastName><ForeName>Eric D</ForeName><Initials>ED</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, University of Florida College of Medicine, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Burchianti</LastName><ForeName>Tenna</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>University of Florida Health Proton Therapy Institute, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Oladeru</LastName><ForeName>Oluwadamilola T</ForeName><Initials>OT</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Liang</LastName><ForeName>Xiaoying</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Mendenhall</LastName><ForeName>Nancy P</ForeName><Initials>NP</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, University of Florida College of Medicine, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D002363\">Case Reports</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2023</Year><Month>10</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Int J Part Ther</MedlineTA><NlmUniqueID>101674108</NlmUniqueID><ISSNLinking>2331-5180</ISSNLinking></MedlineJournalInfo><KeywordList Owner=\"NOTNLM\"><Keyword MajorTopicYN=\"N\">cardiac toxicity</Keyword><Keyword MajorTopicYN=\"N\">male breast cancer</Keyword><Keyword MajorTopicYN=\"N\">proton therapy</Keyword><Keyword MajorTopicYN=\"N\">radiation therapy</Keyword></KeywordList><CoiStatement>Conflicts of Interest: Nancy P. Mendenhall, MD, serves as Editor-in-Chief of the International Journal of Particle Therapy. The authors have no additional conflicts of interest to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"received\"><Year>2023</Year><Month>5</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus=\"accepted\"><Year>2023</Year><Month>7</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus=\"medline\"><Year>2023</Year><Month>12</Month><Day>11</Day><Hour>6</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2023</Year><Month>12</Month><Day>11</Day><Hour>6</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2023</Year><Month>12</Month><Day>11</Day><Hour>5</Hour><Minute>57</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38075485</ArticleId><ArticleId IdType=\"pmc\">PMC10698632</ArticleId><ArticleId IdType=\"doi\">10.14338/IJPT-23-00007.1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Anderson WF, Althuis MD, Brinton LA, Devesa SS. Is male breast cancer similar or different than female breast cancer? Breast Cancer Res Treat 2004. 83 77&#x2013;86</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">14997057</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu P, He D, Zhu S, Chang H, Wang Q, Shao Q, Li G. The role of postoperative radiation therapy in stage I-III male breast cancer: a population-based study from the Surveillance, Epidemiology, and End Results database Breast 2022. 65 41&#x2013;8</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC9272391</ArticleId><ArticleId IdType=\"pubmed\">35810531</ArticleId></ArticleIdList></Reference><Reference><Citation>Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021 CA Cancer J Clin 2021. 71 7&#x2013;33</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">33433946</ArticleId></ArticleIdList></Reference><Reference><Citation>Speirs V, Shaaban AM. The rising incidence of male breast cancer Breast Cancer Res Treat 2009. 115 429&#x2013;30</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">18478326</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdelwahab Yousef AJ. Male breast cancer: epidemiology and risk factors Semin Oncol 2017. 44 267&#x2013;72</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">29526255</ArticleId></ArticleIdList></Reference><Reference><Citation>Yalaza M, Inan A, Bozer M. Male breast cancer J Breast Health 2016. 12 1&#x2013;8</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC5351429</ArticleId><ArticleId IdType=\"pubmed\">28331724</ArticleId></ArticleIdList></Reference><Reference><Citation>Yadav S, Karam D, Bin Riaz I, Xie H, Durani U, Duma N, Giridhar KV, Hieken TJ, Boughey JC, Mutter RW, Hawse JR, Jimenez RE, Couch FJ, Leon-Ferre RA, Ruddy KJ. Male breast cancer in the United States: treatment patterns and prognostic factors in the 21st century Cancer 2020. 126 26&#x2013;36</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC7668385</ArticleId><ArticleId IdType=\"pubmed\">31588557</ArticleId></ArticleIdList></Reference><Reference><Citation>Gucalp A, Traina TA, Eisner JR, Parker JS, Selitsky SR, Park BH, Elias AD, Baskin-Bey ES, Cardoso F. Male breast cancer: a disease distinct from female breast cancer Breast Cancer Res Treat 2019. 173 37&#x2013;48</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC7513797</ArticleId><ArticleId IdType=\"pubmed\">30267249</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor CW, Wang Z, Macaulay E, Jagsi R, Duane F, Darby SC. Exposure of the heart in breast cancer radiation therapy: a systematic review of heart doses published during 2003 to 2013 Int J Radiat Oncol Biol Phys 2015. 93 845&#x2013;53</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">26530753</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention (CDC) Men and heart disease.  October 14, 2022. Accessed March 1, 2023.  https://www.cdc.gov/heartdisease/men.htm.</Citation></Reference><Reference><Citation>Curtin SC. Trends in cancer and heart disease death rates among adults aged 45-64: United States, 1999-2017 Natl Vital Stat Rep 2019. 68 1&#x2013;9</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">32501204</ArticleId></ArticleIdList></Reference><Reference><Citation>NRG Oncology. Breast Contouring RADCOM Consortium v3.  February 23, 2016.  https://imsva91-ctp.trendmicro.com:443/wis/clicktime/v1/query?url=https%3a%2f%2fwww.nrgoncology.org%2fPortals%2f0%2fScientific%2520Program%2fCIRO%2fAtlases%2fRADCOMP%2fRADCOMP%2520Breast%2520Atlas%2520v.3%2520%2d%2520bigreduced.pdf%3fver%3d2020%2d08%2d01%2d140849%2d360&amp;umid=68A0644F-05E5-5806-86B8-129E0C502999&amp;auth=5ab06289d9c3b14f9a77f69d29e7a25870e86301-bb68c94ce9b005d551cc0ab6f2f36b7fe0c70d47. Accessed April 1, 2023.</Citation></Reference><Reference><Citation>Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, editors. AJCC cancer staging manual ( 7th ed). New York, NY: Springer; 2010.</Citation></Reference><Reference><Citation>Amin MB, Edge S, Greene F, Byrd DR, Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR, et al. (Eds.). AJCC Cancer Staging Manual ( 8th edition). Springer International Publishing: American Joint Commission on Cancer; 2017.</Citation></Reference><Reference><Citation>Giap BQ, Giap F, Einck JP, LePage R, Blasongame DM, Waldinger A, Dong L, Mascia A, Chang A, Rossi CJ, Giap H. A Case Study: Proton Therapy for Male Breast Cancer with Previous Irradiation Int J Part Ther 2016. 2 579&#x2013;83</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC6871644</ArticleId><ArticleId IdType=\"pubmed\">31772969</ArticleId></ArticleIdList></Reference><Reference><Citation>Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, Bronnum D, Correa C, Cutter D, Gagliardi G, Gigante B, Jensen MB, Nisbet A, Peto R, Rahimi K, Taylor C, Hall P. Risk of ischemic heart disease in women after radiotherapy for breast cancer N Engl J Med 2013. 368 987&#x2013;98</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">23484825</ArticleId></ArticleIdList></Reference><Reference><Citation>van den Bogaard VA, Ta BD, van der Schaaf A, Bouma AB, Middag AM, Bantema-Joppe EJ, van Dijk LV, van Dijk-Peters FB, Marteijn LA, de Bock GH, Burgerhof JG, Gietema JA, Langendijk JA, Maduro JH, Crijns AP. Validation and Modification of a Prediction Model for Acute Cardiac Events in Patients With Breast Cancer Treated With Radiotherapy Based on Three-Dimensional Dose Distributions to Cardiac Substructures J Clin Oncol 2017. 35 1171&#x2013;8</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC5455600</ArticleId><ArticleId IdType=\"pubmed\">28095159</ArticleId></ArticleIdList></Reference><Reference><Citation>Zureick AH, Grzywacz VP, Almahariq MF, Silverman BR, Vayntraub A, Chen PY, Gustafson GS, Jawad MS, Dilworth JT. Dose to the Left Anterior Descending Artery Correlates With Cardiac Events After Irradiation for Breast Cancer Int J Radiat Oncol Biol Phys 2022. 114 130&#x2013;9</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">35483540</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin LL, Vennarini S, Dimofte A, Ravanelli D, Shillington K, Batra S, Tochner Z, Both S, Freedman G. Proton beam versus photon beam dose to the heart and left anterior descending artery for left-sided breast cancer Acta Oncol 2015. 54 1032&#x2013;9</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">25789715</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee HL, Lim LH, Master Z, Wong SMM. The role of breath hold intensity modulated proton therapy for a case of left-sided breast cancer with IMN involvement. How protons compare with other conformal techniques? Tech Innov Patient Support Radiat Oncol 2020. 15 1&#x2013;5</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC7256639</ArticleId><ArticleId IdType=\"pubmed\">32490219</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu N, Ho MW, Li Z, Morris CG, Mendenhall NP. Can proton therapy improve the therapeutic ratio in breast cancer patients at risk for nodal disease? Am J Clin Oncol 2014. 37 568&#x2013;74</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">23466577</ArticleId></ArticleIdList></Reference><Reference><Citation>Depauw N, Batin E, Daartz J, Rosenfeld A, Adams J, Kooy H, MacDonald S, Lu HM. A novel approach to postmastectomy radiation therapy using scanned proton beams Int J Radiat Oncol Biol Phys 2015. 91 427&#x2013;34</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">25636765</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardoso F, Bartlett JMS, Slaets L, van Deurzen CHM, van Leeuwen-Stok E, Porter P, Linderholm B, Hedenfalk I, Schroder C, Martens J, Bayani J, van Asperen C, Murray M, Hudis C, Middleton L, Vermeij J, Punie K, Fraser J, Nowaczyk M, Rubio IT, Aebi S, Kelly C, Ruddy KJ, Winer E, Nilsson C, Lago LD, Korde L, Benstead K, Bogler O, Goulioti T, Peric A, Litiere S, Aalders KC, Poncet C, Tryfonidis K, Giordano SH. Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program Ann Oncol 2018. 29 405&#x2013;17</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC5834077</ArticleId><ArticleId IdType=\"pubmed\">29092024</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu N, Johnson KJ, Ma CX. Male breast cancer: an updated Surveillance, Epidemiology, and End Results data analysis Clin Breast Cancer 2018. 18 e997&#x2013;1002</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">30007834</ArticleId></ArticleIdList></Reference><Reference><Citation>Leone J, Freedman RA, Lin NU, Tolaney SM, Vallejo CT, Leone BA, Winer EP, Leone JP. Tumor subtypes and survival in male breast cancer Breast Cancer Res Treat 2021. 188 695&#x2013;702</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">33770314</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>\n",
            "XML saved to: path/to/save/xml/38075485.xml\n",
            "Details URL: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=38071660&retmode=xml&api_key=9edd38677707c08b2a96ed1a6e8c61c47408\n",
            "Details Response Content: <?xml version=\"1.0\" ?>\n",
            "<!DOCTYPE PubmedArticleSet PUBLIC \"-//NLM//DTD PubMedArticle, 1st January 2023//EN\" \"https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd\">\n",
            "<PubmedArticleSet>\n",
            "<PubmedArticle><MedlineCitation Status=\"Publisher\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38071660</PMID><DateRevised><Year>2023</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel=\"Print-Electronic\"><Journal><ISSN IssnType=\"Electronic\">1469-994X</ISSN><JournalIssue CitedMedium=\"Internet\"><PubDate><Year>2023</Year><Month>Dec</Month><Day>10</Day></PubDate></JournalIssue><Title>Nicotine &amp; tobacco research : official journal of the Society for Research on Nicotine and Tobacco</Title><ISOAbbreviation>Nicotine Tob Res</ISOAbbreviation></Journal><ArticleTitle>Barriers and facilitators to engaging in smoking cessation support among lung screening participants.</ArticleTitle><ELocationID EIdType=\"pii\" ValidYN=\"Y\">ntad245</ELocationID><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.1093/ntr/ntad245</ELocationID><Abstract><AbstractText Label=\"INTRODUCTION\" NlmCategory=\"BACKGROUND\">Embedded smoking cessation support within lung cancer screening is recommended in the UK; however, little is known about why individuals decline smoking cessation support in this setting. This study identified psychosocial factors that influence smoking cessation and quit motivation among those who declined support for quitting smoking alongside lung cancer screening.</AbstractText><AbstractText Label=\"METHODS\" NlmCategory=\"METHODS\">Qualitative interviews conducted between August 2019 - April 2021 with thirty adults with a smoking history, recruited from the Yorkshire Lung Screening Trial. Participants had declined smoking cessation support. Verbatim interview transcripts were thematically analysed.</AbstractText><AbstractText Label=\"RESULTS\" NlmCategory=\"RESULTS\">Fifty percent of participants were male and the majority were from the most deprived groups. Participants reported low motivation and a variety of barriers to stopping smoking. Participants described modifiable behavioural factors that influenced their quit motivation including self-efficacy, perceived effectiveness of stop-smoking services including smoking cessation aids, risk-minimising beliefs, lack of social support, absence of positive influences on smoking and beliefs about smoking/smoking cessation. Broader contextual factors included social isolation and stigma, COVID-19 and comorbid mental and physical health conditions that deterred smoking cessation.</AbstractText><AbstractText Label=\"CONCLUSIONS\" NlmCategory=\"CONCLUSIONS\">To encourage engagement in smoking cessation support during lung cancer screening, interventions should seek to encourage positive beliefs about the effectiveness of smoking cessation aids and increase confidence in quitting as part of supportive, person-centred care. Interventions should also acknowledge the wider social determinants of health among the lung screening-eligible population.</AbstractText><AbstractText Label=\"IMPLICATIONS\" NlmCategory=\"CONCLUSIONS\">This study provides an in-depth understanding of the beliefs surrounding smoking and smoking cessation and further potential psychosocial factors that influence those attending lung cancer screening. Many of the barriers to smoking cessation found in the present study are similar to those outside of a lung screening setting however this work offers an understanding of potential facilitators that should be considered in future lung screening programmes.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2023. Published by Oxford University Press on behalf of the Society for Research on Nicotine and Tobacco.</CopyrightInformation></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Smith</LastName><ForeName>Pamela</ForeName><Initials>P</Initials><Identifier Source=\"ORCID\">0000-0002-0336-215X</Identifier><AffiliationInfo><Affiliation>Cardiff University, Division of Population Medicine, Heath Park, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Quinn-Scoggins</LastName><ForeName>Harriet</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Cardiff University, Division of Population Medicine, Heath Park, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Murray</LastName><ForeName>Rachael L</ForeName><Initials>RL</Initials><AffiliationInfo><Affiliation>University of Nottingham, Division of Epidemiology and Public Health Clinical Sciences, Nottingham City Hospital.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>McCutchan</LastName><ForeName>Grace</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Cardiff University, Division of Population Medicine, Heath Park, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Nelson</LastName><ForeName>Annmarie</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cardiff University, Marie Curie Research Centre, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Moore</LastName><ForeName>Graham</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Cardiff University, School of Social Sciences, 1-3 Museum Place, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Callister</LastName><ForeName>Mat</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Leeds Teaching Hospitals NHS Trust, Leeds, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Tong</LastName><ForeName>Hoang</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Cardiff University, Division of Population Medicine, Heath Park, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Brain</LastName><ForeName>Kate</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Cardiff University, Division of Population Medicine, Heath Park, Cardiff, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2023</Year><Month>12</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nicotine Tob Res</MedlineTA><NlmUniqueID>9815751</NlmUniqueID><ISSNLinking>1462-2203</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"received\"><Year>2023</Year><Month>5</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus=\"medline\"><Year>2023</Year><Month>12</Month><Day>10</Day><Hour>18</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2023</Year><Month>12</Month><Day>10</Day><Hour>18</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2023</Year><Month>12</Month><Day>10</Day><Hour>15</Hour><Minute>12</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38071660</ArticleId><ArticleId IdType=\"doi\">10.1093/ntr/ntad245</ArticleId><ArticleId IdType=\"pii\">7468512</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>\n",
            "XML saved to: path/to/save/xml/38071660.xml\n",
            "Details URL: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=38067372&retmode=xml&api_key=9edd38677707c08b2a96ed1a6e8c61c47408\n",
            "Details Response Content: <?xml version=\"1.0\" ?>\n",
            "<!DOCTYPE PubmedArticleSet PUBLIC \"-//NLM//DTD PubMedArticle, 1st January 2023//EN\" \"https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd\">\n",
            "<PubmedArticleSet>\n",
            "<PubmedArticle><MedlineCitation Status=\"PubMed-not-MEDLINE\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38067372</PMID><DateRevised><Year>2023</Year><Month>12</Month><Day>09</Day></DateRevised><Article PubModel=\"Electronic\"><Journal><ISSN IssnType=\"Print\">2072-6694</ISSN><JournalIssue CitedMedium=\"Print\"><Volume>15</Volume><Issue>23</Issue><PubDate><Year>2023</Year><Month>Nov</Month><Day>30</Day></PubDate></JournalIssue><Title>Cancers</Title><ISOAbbreviation>Cancers (Basel)</ISOAbbreviation></Journal><ArticleTitle>Sarcopenia and Mediastinal Adipose Tissue as a Prognostic Marker for Short- and Long-Term Outcomes after Primary Surgical Treatment for Lung Cancer.</ArticleTitle><ELocationID EIdType=\"pii\" ValidYN=\"Y\">5666</ELocationID><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.3390/cancers15235666</ELocationID><Abstract><AbstractText>Surgical resection remains the gold standard of treatment for early-stage lung cancer. Several risk models exist to predict postoperative morbidity and mortality. Psoas muscle sarcopenia has already successfully been used for morbidity prediction in lung transplantation and is not yet included in the available risk scores for pulmonary resections. We hypothesized that the skeletal muscle index and mediastinal adipose tissue might also have an impact on postoperative outcomes after primary surgery for primary lung cancer. The institutional database was queried for patients with primary lung cancer who were treated with primary lobectomy or segmentectomy between February 2009 and November 2018. In total, 311 patients were included for analysis. Patients receiving neo-/adjuvant chemotherapy or with a positive nodal status were excluded to rule out any morbidity or mortality due to (neo-)adjuvant treatment. Sarcopenia was defined as a skeletal muscle index of &lt;34.4 cm<sup>2</sup>/m<sup>2</sup> for women and &lt;45.4 cm<sup>2</sup>/m<sup>2</sup> for men. Mediastinal adipose tissue was defined with a radiodensity of -150 to -30 Hounsfield units. Sarcopenia was diagnosed in 78 (25.1%) of the 311 patients. Male patients were significantly more likely to suffer from sarcopenia (31.5% vs. 18.1%, <i>p</i> = 0.009). Comorbidities, lung function, tumour histology, pathologic tumour staging, mediastinal adipose tissue and age did not differ between groups with or without sarcopenia. Sarcopenic patients had a significantly longer length of stay, with 13.0 days vs. 9.5 (<i>p</i> = 0.003), and a higher rate of any postoperative complications (59.0% vs. 44.6%, <i>p</i> = 0.036). There was no difference in recurrence rate. Five-year overall survival was significantly better in the patient cohort without sarcopenia (75.6% vs. 64.5%, <i>p</i> = 0.044). Mediastinal adipose tissue showed no significant impact on length of stay, postoperative complications, recurrence rate, morbidity or survival. Sarcopenia, quantified with the skeletal muscle index, is shown to be a risk factor for postoperative morbidity and reduced survival in primary lung cancer. Efforts should be taken to pre-emptively screen for sarcopenia and start countermeasures (e.g., physical prehabilitation, protein-rich nutrition, etc.) during the preoperative workup phase.</AbstractText></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Ponholzer</LastName><ForeName>Florian</ForeName><Initials>F</Initials><Identifier Source=\"ORCID\">0000-0003-3486-7166</Identifier><AffiliationInfo><Affiliation>Department of Visceral, Transplant and Thoracic Surgery, Center of Operative Medicine, Medical University of Innsbruck, 6020 Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Groemer</LastName><ForeName>Georg</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Visceral, Transplant and Thoracic Surgery, Center of Operative Medicine, Medical University of Innsbruck, 6020 Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Ng</LastName><ForeName>Caecilia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Visceral, Transplant and Thoracic Surgery, Center of Operative Medicine, Medical University of Innsbruck, 6020 Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Maier</LastName><ForeName>Herbert</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Visceral, Transplant and Thoracic Surgery, Center of Operative Medicine, Medical University of Innsbruck, 6020 Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Lucciarini</LastName><ForeName>Paolo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Visceral, Transplant and Thoracic Surgery, Center of Operative Medicine, Medical University of Innsbruck, 6020 Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Kocher</LastName><ForeName>Florian</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine V: Hematology and Oncology, Medical University Innsbruck, 6020 Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>&#xd6;fner</LastName><ForeName>Dietmar</ForeName><Initials>D</Initials><Identifier Source=\"ORCID\">0000-0001-8909-8566</Identifier><AffiliationInfo><Affiliation>Department of Visceral, Transplant and Thoracic Surgery, Center of Operative Medicine, Medical University of Innsbruck, 6020 Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Gassner</LastName><ForeName>Eva</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Radiology, Medical University Innsbruck, 6020 Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Schneeberger</LastName><ForeName>Stefan</ForeName><Initials>S</Initials><Identifier Source=\"ORCID\">0000-0002-2619-8639</Identifier><AffiliationInfo><Affiliation>Department of Visceral, Transplant and Thoracic Surgery, Center of Operative Medicine, Medical University of Innsbruck, 6020 Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Augustin</LastName><ForeName>Florian</ForeName><Initials>F</Initials><Identifier Source=\"ORCID\">0000-0002-6785-4241</Identifier><AffiliationInfo><Affiliation>Department of Visceral, Transplant and Thoracic Surgery, Center of Operative Medicine, Medical University of Innsbruck, 6020 Innsbruck, Austria.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2023</Year><Month>11</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Cancers (Basel)</MedlineTA><NlmUniqueID>101526829</NlmUniqueID><ISSNLinking>2072-6694</ISSNLinking></MedlineJournalInfo><KeywordList Owner=\"NOTNLM\"><Keyword MajorTopicYN=\"N\">VATS</Keyword><Keyword MajorTopicYN=\"N\">lung cancer</Keyword><Keyword MajorTopicYN=\"N\">mediastinal adipose tissue</Keyword><Keyword MajorTopicYN=\"N\">morbidity</Keyword><Keyword MajorTopicYN=\"N\">sarcopenia</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"received\"><Year>2023</Year><Month>10</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus=\"revised\"><Year>2023</Year><Month>11</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus=\"accepted\"><Year>2023</Year><Month>11</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus=\"medline\"><Year>2023</Year><Month>12</Month><Day>9</Day><Hour>10</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2023</Year><Month>12</Month><Day>9</Day><Hour>10</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2023</Year><Month>12</Month><Day>9</Day><Hour>1</Hour><Minute>4</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38067372</ArticleId><ArticleId IdType=\"pmc\">PMC10705152</ArticleId><ArticleId IdType=\"doi\">10.3390/cancers15235666</ArticleId><ArticleId IdType=\"pii\">cancers15235666</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chen H., Laba J.M., Boldt R.G., Goodman C.D., Palma D.A., Senan S., VLouie A. Stereotactic Ablative Radiation Therapy Versus Surgery in Early Lung Cancer: A Meta-analysis of Propensity Score Studies. Int. J. Radiat. Oncol. Biol. Phys. 2018;101:186&#x2013;194. doi: 10.1016/j.ijrobp.2018.01.064.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.ijrobp.2018.01.064</ArticleId><ArticleId IdType=\"pubmed\">29619964</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang J.Y., Mehran R.J., Feng L., Verma V., Liao Z., Welsh J.W., Lin S.H., O&#x2019;Reilly M.S., Jeter M.D., Balter P.A., et al. Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): Long-term results of a single-arm, prospective trial with prespecified comparison to surgery. Lancet Oncol. 2021;22:1448&#x2013;1457. doi: 10.1016/S1470-2045(21)00401-0.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/S1470-2045(21)00401-0</ArticleId><ArticleId IdType=\"pmc\">PMC8521627</ArticleId><ArticleId IdType=\"pubmed\">34529930</ArticleId></ArticleIdList></Reference><Reference><Citation>Ponholzer F., Chorazy K., Ng C., Kocher F., Maier H., Lucciarini P., &#xd6;fner D., Augustin F. External validation of risk prediction scores in patients undergoing anatomic video-assisted thoracoscopic resection. Surg. Endosc. 2022;37:2789&#x2013;2799. doi: 10.1007/s00464-022-09786-7.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s00464-022-09786-7</ArticleId><ArticleId IdType=\"pmc\">PMC10081977</ArticleId><ArticleId IdType=\"pubmed\">36477642</ArticleId></ArticleIdList></Reference><Reference><Citation>Derstine B.A., Holcombe S.A., Ross B.E., Wang N.C., Su G.L., Wang S.C. Skeletal muscle cutoff values for sarcopenia diagnosis using T10 to L5 measurements in a healthy US population. Sci. Rep. 2018;8:11369. doi: 10.1038/s41598-018-29825-5.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/s41598-018-29825-5</ArticleId><ArticleId IdType=\"pmc\">PMC6063941</ArticleId><ArticleId IdType=\"pubmed\">30054580</ArticleId></ArticleIdList></Reference><Reference><Citation>Jitwongwai S., Lertudomphonwanit C., Junhasavasdikul T., Fuangfa P., Tanpowpong P., Gesprasert G., Treepongkaruna S. Low psoas muscle index as an unfavorable factor in children with end-stage liver disease undergoing liver transplantation. Pediatr. Transplant. 2021;25:e13996. doi: 10.1111/petr.13996.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1111/petr.13996</ArticleId><ArticleId IdType=\"pubmed\">33734542</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwasaki Y., Shiotsuka J., Kawarai Lefor A., Sanui M. The Psoas Muscle Index Is Associated with Prognosis in Elderly Patients Undergoing Cardiovascular Surgery. Anesth. Pain. Med. 2021;11:e118608. doi: 10.5812/aapm.118608.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.5812/aapm.118608</ArticleId><ArticleId IdType=\"pmc\">PMC8782061</ArticleId><ArticleId IdType=\"pubmed\">35075413</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu M., Li T., Kong M., Geng N., Song W., Guo G., Duan Z., Han Y., Chen Y. Psoas Muscle Index Can Be Used to Predict Long-Term Mortality in Young Male Patients With Acute-on-Chronic Liver Failure. Front. Nutr. 2022;9:811826. doi: 10.3389/fnut.2022.811826.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3389/fnut.2022.811826</ArticleId><ArticleId IdType=\"pmc\">PMC8894235</ArticleId><ArticleId IdType=\"pubmed\">35252298</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozeki N., Kawaguchi K., Fukui T., Nakamura S., Hakiri S., Mori S., Goto M., Iwano S., Yokoi K., Chen-Yoshikawa T.F. Psoas muscle mass in patients undergoing lung cancer surgery: A prognostic difference between squamous cell carcinoma and adenocarcinoma. Int. J. Clin. Oncol. 2020;25:876&#x2013;884. doi: 10.1007/s10147-020-01624-x.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s10147-020-01624-x</ArticleId><ArticleId IdType=\"pubmed\">31955305</ArticleId></ArticleIdList></Reference><Reference><Citation>Verhoek O.G., Jungblut L., Lauk O., Bl&#xfc;thgen C., Opitz I., Frauenfelder T., Martini K. Sarcopenia, Precardial Adipose Tissue and High Tumor Volume as Outcome Predictors in Surgically Treated Pleural Mesothelioma. Diagnostics. 2022;12:99. doi: 10.3390/diagnostics12010099.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3390/diagnostics12010099</ArticleId><ArticleId IdType=\"pmc\">PMC8774409</ArticleId><ArticleId IdType=\"pubmed\">35054268</ArticleId></ArticleIdList></Reference><Reference><Citation>Cano Meg&#xed;as M., Guisado Vasco P., Bouarich H., Aguilera I.L., La Arriba-de Fuente G de Rodr&#xed;guez-Puyol D. Tejido graso epic&#xe1;rdico, calcificaci&#xf3;n arterial coronaria y mortalidad en pacientes con enfermedad renal cr&#xf3;nica avanzada y hemodi&#xe1;lisis. Nefrologia (Engl. Ed.) 2021;41:174&#x2013;181. doi: 10.1016/j.nefroe.2020.09.008.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.nefroe.2020.09.008</ArticleId><ArticleId IdType=\"pubmed\">33384175</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen O., Sharma A., Ahmad I., Bourji N., Nestoiter K., Hua P., Hua B., Ivanov A., Yossef J., Klem I., et al. Correlation between pericardial, mediastinal, and intrathoracic fat volumes with the presence and severity of coronary artery disease, metabolic syndrome, and cardiac risk factors. Eur. Heart J. Cardiovasc. Imaging. 2015;16:37&#x2013;46. doi: 10.1093/ehjci/jeu145.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/ehjci/jeu145</ArticleId><ArticleId IdType=\"pubmed\">25227267</ArticleId></ArticleIdList></Reference><Reference><Citation>Cikim A.S., Topal E., Harputluoglu M., Keskin L., Zengin Z., Cikim K., Ozdemir R., Aladag M., Yologlu S. Epicardial adipose tissue, hepatic steatosis and obesity. J. Endocrinol. Investig. 2007;30:459&#x2013;464. doi: 10.1007/BF03346328.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/BF03346328</ArticleId><ArticleId IdType=\"pubmed\">17646719</ArticleId></ArticleIdList></Reference><Reference><Citation>Rozenberg D., Orsso C.E., Chohan K., Orchanian-Cheff A., Nourouzpour S., Nicholson J.M., Elangeswaran B., Vagaon A., Fidler L., Singer L.G., et al. Clinical outcomes associated with computed tomography-based body composition measures in lung transplantation: A systematic review. Transpl. Int. 2020;33:1610&#x2013;1625. doi: 10.1111/tri.13749.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1111/tri.13749</ArticleId><ArticleId IdType=\"pubmed\">32970877</ArticleId></ArticleIdList></Reference><Reference><Citation>Rollins K.E., Awwad A., Macdonald I.A., Lobo D.N. A comparison of two different software packages for analysis of body composition using computed tomography images. Nutrition. 2019;57:92&#x2013;96. doi: 10.1016/j.nut.2018.06.003.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.nut.2018.06.003</ArticleId><ArticleId IdType=\"pmc\">PMC6269124</ArticleId><ArticleId IdType=\"pubmed\">30153585</ArticleId></ArticleIdList></Reference><Reference><Citation>Volbers B., Staykov D., Wagner I., D&#xf6;rfler A., Saake M., Schwab S., Bardutzky J. Semi-automatic volumetric assessment of perihemorrhagic edema with computed tomography. Eur. J. Neurol. 2011;18:1323&#x2013;1328. doi: 10.1111/j.1468-1331.2011.03395.x.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1111/j.1468-1331.2011.03395.x</ArticleId><ArticleId IdType=\"pubmed\">21457176</ArticleId></ArticleIdList></Reference><Reference><Citation>Derstine B.A., Holcombe S.A., Goulson R.L., Ross B.E., Wang N.C., Sullivan J.A., Su G.L., Wang S.C. Quantifying Sarcopenia Reference Values Using Lumbar and Thoracic Muscle Areas in a Healthy Population. J. Nutr. Health Aging. 2017;21:180&#x2013;185. doi: 10.1007/s12603-017-0983-3.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s12603-017-0983-3</ArticleId><ArticleId IdType=\"pubmed\">29300439</ArticleId></ArticleIdList></Reference><Reference><Citation>Marchiori E., Hochhegger B., Zanetti G. Anterior mediastinal mass. J. Bras. Pneumol. 2018;44:3. doi: 10.1590/s1806-37562017000000381.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1590/s1806-37562017000000381</ArticleId><ArticleId IdType=\"pmc\">PMC6104533</ArticleId><ArticleId IdType=\"pubmed\">29538534</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruz-Jentoft A.J., Bahat G., Bauer J., Boirie Y., Bruy&#xe8;re O., Cederholm T., Cooper C., Landi F., Rolland Y., Sayer A.A., et al. Sarcopenia: Revised European consensus on definition and diagnosis. Age Ageing. 2019;48:16&#x2013;31. doi: 10.1093/ageing/afy169.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/ageing/afy169</ArticleId><ArticleId IdType=\"pmc\">PMC6322506</ArticleId><ArticleId IdType=\"pubmed\">30312372</ArticleId></ArticleIdList></Reference><Reference><Citation>Dindo D., Demartines N., Clavien P.-A. Classification of surgical complications: A new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann. Surg. 2004;240:205&#x2013;213. doi: 10.1097/01.sla.0000133083.54934.ae.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1097/01.sla.0000133083.54934.ae</ArticleId><ArticleId IdType=\"pmc\">PMC1360123</ArticleId><ArticleId IdType=\"pubmed\">15273542</ArticleId></ArticleIdList></Reference><Reference><Citation>Charlson M., Szatrowski T.P., Peterson J., Gold J. Validation of a combined comorbidity index. J. Clin. Epidemiol. 1994;47:1245&#x2013;1251. doi: 10.1016/0895-4356(94)90129-5.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/0895-4356(94)90129-5</ArticleId><ArticleId IdType=\"pubmed\">7722560</ArticleId></ArticleIdList></Reference><Reference><Citation>R Foundation for Statistical Computing  . R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing; Vienna, Austria: 2023.  [(accessed on 30 August 2023)].  Available online:  https://www.R-project.org/</Citation></Reference><Reference><Citation>Kassambara A., Kosinski M., Biecek P., Scheipl F. Drawing Survival Curves Using &#x2018;ggplot2&#x2019; 2023. [cited 2023 Oct 2]  [(accessed on 30 August 2023)].  Available online:  https://cran.r-project.org/web/packages/survminer/survminer.pdf.</Citation></Reference><Reference><Citation>Wilcox R.R.  Introduction to Robust Estimation and Hypothesis Testing. 3rd ed. Elsevier Science &amp; Technology Books; San Diego, CA, USA: 2013.  [(accessed on 30 August 2023)].  Statistical Modeling and Decision Science. Available online:  http://www.sciencedirect.com/science/book/9780123869838.</Citation></Reference><Reference><Citation>Pagano R.R. Understanding Statistics in the Behavioral Sciences. 9th ed. Wadsworth/Cengage Learning; Belmont, CA, USA: 2010.</Citation></Reference><Reference><Citation>Rasch D., Guiard V. The robustness of parametric statistical methods. Psychol. Sci. 2004;46:175&#x2013;208.</Citation></Reference><Reference><Citation>Box G.E., Tidwell P.W. Transformation of the Independent Variables. Technometrics. 1962;4:531&#x2013;550. doi: 10.1080/00401706.1962.10490038.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1080/00401706.1962.10490038</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunelli A., Cicconi S., Decaluwe H., Szanto Z., Falcoz P.E. Parsimonious Eurolung risk models to predict cardiopulmonary morbidity and mortality following anatomic lung resections: An updated analysis from the European Society of Thoracic Surgeons database. Eur. J. Cardiothorac. Surg. 2020;57:455&#x2013;461. doi: 10.1093/ejcts/ezz272.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/ejcts/ezz272</ArticleId><ArticleId IdType=\"pubmed\">31605105</ArticleId></ArticleIdList></Reference><Reference><Citation>Ponholzer F., Ng C., Maier H., Lucciarini P., &#xd6;fner D., Augustin F. Risk factors, complications and costs of prolonged air leak after video-assisted thoracoscopic surgery for primary lung cancer. J. Thorac. Dis. 2023;15:866&#x2013;877. doi: 10.21037/jtd-21-2011.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.21037/jtd-21-2011</ArticleId><ArticleId IdType=\"pmc\">PMC9992586</ArticleId><ArticleId IdType=\"pubmed\">36910082</ArticleId></ArticleIdList></Reference><Reference><Citation>Goligher E.C., Dres M., Fan E., Rubenfeld G.D., Scales D.C., Herridge M.S., Vorona S., Sklar M.C., Rittayamai N., Lanys A., et al. Mechanical Ventilation-induced Diaphragm Atrophy Strongly Impacts Clinical Outcomes. Am. J. Respir. Crit. Care Med. 2018;197:204&#x2013;213. doi: 10.1164/rccm.201703-0536OC.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1164/rccm.201703-0536OC</ArticleId><ArticleId IdType=\"pubmed\">28930478</ArticleId></ArticleIdList></Reference><Reference><Citation>Varela G., Jim&#xe9;nez M.F., Novoa N., Aranda J.L. Estimating hospital costs attributable to prolonged air leak in pulmonary lobectomy. Eur. J. Cardiothorac. Surg. 2005;27:329&#x2013;333. doi: 10.1016/j.ejcts.2004.11.005.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.ejcts.2004.11.005</ArticleId><ArticleId IdType=\"pubmed\">15691691</ArticleId></ArticleIdList></Reference><Reference><Citation>Topan M.-M., Sporea I., D&#x103;nil&#x103; M., Popescu A., Ghiuchici A.-M., Lupu&#x15f;oru R., &#x15e;irli R. Impact of Sarcopenia on Survival and Clinical Outcomes in Patients With Liver Cirrhosis. Front. Nutr. 2021;8:766451. doi: 10.3389/fnut.2021.766451.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3389/fnut.2021.766451</ArticleId><ArticleId IdType=\"pmc\">PMC8566695</ArticleId><ArticleId IdType=\"pubmed\">34746216</ArticleId></ArticleIdList></Reference><Reference><Citation>Anjanappa M., Corden M., Green A., Roberts D., Hoskin P., McWilliam A., Choudhury A. Sarcopenia in cancer: Risking more than muscle loss. Tech. Innov. Patient Support. Radiat. Oncol. 2020;16:50&#x2013;57. doi: 10.1016/j.tipsro.2020.10.001.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.tipsro.2020.10.001</ArticleId><ArticleId IdType=\"pmc\">PMC7769854</ArticleId><ArticleId IdType=\"pubmed\">33385074</ArticleId></ArticleIdList></Reference><Reference><Citation>Joglekar S., Nau P.N., Mezhir J.J. The impact of sarcopenia on survival and complications in surgical oncology: A review of the current literature. J. Surg. Oncol. 2015;112:503&#x2013;509. doi: 10.1002/jso.24025.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1002/jso.24025</ArticleId><ArticleId IdType=\"pmc\">PMC5112759</ArticleId><ArticleId IdType=\"pubmed\">26310812</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsukioka T., Izumi N., Mizuguchi S., Kyukwang C., Komatsu H., Toda M., Hara K., Miyamoto H., Nishiyama N. Positive correlation between sarcopenia and elevation of neutrophil/lymphocyte ratio in pathological stage IIIA (N2-positive) non-small cell lung cancer patients. Gen. Thorac. Cardiovasc. Surg. 2018;66:716&#x2013;722. doi: 10.1007/s11748-018-0985-z.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s11748-018-0985-z</ArticleId><ArticleId IdType=\"pubmed\">30105630</ArticleId></ArticleIdList></Reference><Reference><Citation>Templeton A.J., McNamara M.G., &#x160;eruga B., Vera-Badillo F.E., Aneja P., Oca&#xf1;a A., Leibowitz-Amit R., Sonpavde G., Knox J.J., Tran B., et al.  Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: A systematic review and meta-analysis.  [(accessed on 10 September 2023)];J. Natl. Cancer Inst. 2014 106:dju124. doi: 10.1093/jnci/dju124. Available online:  https://pubmed.ncbi.nlm.nih.gov/24875653/</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/jnci/dju124</ArticleId><ArticleId IdType=\"pubmed\">24875653</ArticleId></ArticleIdList></Reference><Reference><Citation>Lo J.H., Kin P.U., Yiu T., Ong M.T., Lee W.Y. Sarcopenia: Current treatments and new regenerative therapeutic approaches. J. Orthop. Translat. 2020;23:38&#x2013;52. doi: 10.1016/j.jot.2020.04.002.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jot.2020.04.002</ArticleId><ArticleId IdType=\"pmc\">PMC7256062</ArticleId><ArticleId IdType=\"pubmed\">32489859</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho M.-R., Lee S., Song S.-K. A Review of Sarcopenia Pathophysiology, Diagnosis, Treatment and Future Direction. J. Korean Med. Sci. 2022;37:e146. doi: 10.3346/jkms.2022.37.e146.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3346/jkms.2022.37.e146</ArticleId><ArticleId IdType=\"pmc\">PMC9091430</ArticleId><ArticleId IdType=\"pubmed\">35535373</ArticleId></ArticleIdList></Reference><Reference><Citation>Morano M.T., Ara&#xfa;jo A.S., Nascimento F.B., da Silva G.F., Mesquita R., Pinto J.S., de Moraes Filho M.O., Pereira E.D. Preoperative pulmonary rehabilitation versus chest physical therapy in patients undergoing lung cancer resection: A pilot randomized controlled trial. Arch. Phys. Med. Rehabil. 2013;94:53&#x2013;58. doi: 10.1016/j.apmr.2012.08.206.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.apmr.2012.08.206</ArticleId><ArticleId IdType=\"pubmed\">22926460</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai Y., Huang J., Yang M., Su J., Liu J., Che G. Seven-day intensive preoperative rehabilitation for elderly patients with lung cancer: A randomized controlled trial. J. Surg. Res. 2017;209:30&#x2013;36. doi: 10.1016/j.jss.2016.09.033.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jss.2016.09.033</ArticleId><ArticleId IdType=\"pubmed\">28032568</ArticleId></ArticleIdList></Reference><Reference><Citation>Ponholzer F., Kroepfl V., Ng C., Maier H., Kocher F., Lucciarini P., &#xd6;fner D., Augustin F. Delay to surgical treatment in lung cancer patients and its impact on survival in a video-assisted thoracoscopic lobectomy cohort. Sci. Rep. 2021;11:4914. doi: 10.1038/s41598-021-84162-4.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/s41598-021-84162-4</ArticleId><ArticleId IdType=\"pmc\">PMC7921130</ArticleId><ArticleId IdType=\"pubmed\">33649361</ArticleId></ArticleIdList></Reference><Reference><Citation>Bing&#xfc;l E.S., &#x15e;ent&#xfc;rk N.M., Kaynar A.M. Prehabilitation: A narrative review focused on exercise therapy for the prevention of postoperative pulmonary complications following lung resection. Front. Med. 2023;10:1196981. doi: 10.3389/fmed.2023.1196981.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3389/fmed.2023.1196981</ArticleId><ArticleId IdType=\"pmc\">PMC10577193</ArticleId><ArticleId IdType=\"pubmed\">37849492</ArticleId></ArticleIdList></Reference><Reference><Citation>Zoico E., Rubele S., Caro A de Nori N., Mazzali G., Fantin F., Rossi A., Zamboni M. Brown and Beige Adipose Tissue and Aging. Front. Endocrinol. 2019;10:368. doi: 10.3389/fendo.2019.00368.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3389/fendo.2019.00368</ArticleId><ArticleId IdType=\"pmc\">PMC6595248</ArticleId><ArticleId IdType=\"pubmed\">31281288</ArticleId></ArticleIdList></Reference><Reference><Citation>Ou M.-Y., Zhang H., Tan P.-C., Zhou S.-B., Li Q.-F. Adipose tissue aging: Mechanisms and therapeutic implications. Cell Death Dis. 2022;13:300. doi: 10.1038/s41419-022-04752-6.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/s41419-022-04752-6</ArticleId><ArticleId IdType=\"pmc\">PMC8980023</ArticleId><ArticleId IdType=\"pubmed\">35379822</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanders K.J.C., Ash S.Y., Washko G.R., Mottaghy F.M., Schols A.M.W.J. Imaging approaches to understand disease complexity: Chronic obstructive pulmonary disease as a clinical model. J. Appl. Physiol. 2018;124:512&#x2013;520. doi: 10.1152/japplphysiol.00143.2017.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1152/japplphysiol.00143.2017</ArticleId><ArticleId IdType=\"pmc\">PMC6050198</ArticleId><ArticleId IdType=\"pubmed\">28751367</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>\n",
            "XML saved to: path/to/save/xml/38067372.xml\n",
            "Details URL: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=38067306&retmode=xml&api_key=9edd38677707c08b2a96ed1a6e8c61c47408\n",
            "Details Response Content: <?xml version=\"1.0\" ?>\n",
            "<!DOCTYPE PubmedArticleSet PUBLIC \"-//NLM//DTD PubMedArticle, 1st January 2023//EN\" \"https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd\">\n",
            "<PubmedArticleSet>\n",
            "<PubmedArticle><MedlineCitation Status=\"PubMed-not-MEDLINE\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38067306</PMID><DateRevised><Year>2023</Year><Month>12</Month><Day>09</Day></DateRevised><Article PubModel=\"Electronic\"><Journal><ISSN IssnType=\"Print\">2072-6694</ISSN><JournalIssue CitedMedium=\"Print\"><Volume>15</Volume><Issue>23</Issue><PubDate><Year>2023</Year><Month>Nov</Month><Day>27</Day></PubDate></JournalIssue><Title>Cancers</Title><ISOAbbreviation>Cancers (Basel)</ISOAbbreviation></Journal><ArticleTitle>Timing of Initiation of Palliative Chemotherapy in Asymptomatic Patients with Metastatic Pancreatic Cancer: An International Expert Survey and Case-Vignette Study.</ArticleTitle><ELocationID EIdType=\"pii\" ValidYN=\"Y\">5603</ELocationID><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.3390/cancers15235603</ELocationID><Abstract><AbstractText><b>Background</b>: The use of imaging, in general, and during follow-up after resection of pancreatic cancer, is increasing. Consequently, the number of asymptomatic patients diagnosed with metastatic pancreatic cancer (mPDAC) is increasing. In these patients, palliative systemic therapy is the only tumor-directed treatment option; hence, it is often immediately initiated. However, delaying therapy in asymptomatic palliative patients may preserve quality of life and avoid therapy-related toxicity, but the impact on survival is unknown. This study aimed to gain insight into the current perspectives and clinical decision=making of experts regarding the timing of treatment initiation of patients with asymptomatic mPDAC. <b>Methods</b>: An online survey (13 questions, 9 case-vignettes) was sent to all first and last authors of published clinical trials on mPDAC over the past 10 years and medical oncologists of the Dutch Pancreatic Cancer Group. Inter-rater variability was determined using the Kappa Light test. Differences in the preferred timing of treatment initiation among countries, continents, and years of experience were analyzed using Fisher's exact test. <b>Results</b>: Overall, 78 of 291 (27%) medical oncologists from 15 countries responded (62% from Europe, 23% from North America, and 15% from Asia-Pacific). The majority of respondents (63%) preferred the immediate initiation of chemotherapy following diagnosis. In 3/9 case-vignettes, delayed treatment was favored in specific clinical contexts (i.e., patient with only one small lung metastasis, significant comorbidities, and higher age). A significant degree of inter-rater variability was present within 7/9 case-vignettes. The recommended timing of treatment initiation differed between continents for 2/9 case-vignettes (22%), in 7/9 (77.9%) comparing the Netherlands with other countries, and based on years of experience for 5/9 (56%). <b>Conclusions</b>: Although the response rate was limited, in asymptomatic patients with mPDAC, immediate treatment is most often preferred. Delaying treatment until symptoms occur is considered in patients with limited metastatic disease, more comorbidities, and higher age.</AbstractText></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Augustinus</LastName><ForeName>Simone</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Surgery, Location University of Amsterdam, Amsterdam University Medical Center, 1105 Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cancer Center Amsterdam, 1105 Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>van Laarhoven</LastName><ForeName>Hanneke W M</ForeName><Initials>HWM</Initials><Identifier Source=\"ORCID\">0000-0003-1274-5643</Identifier><AffiliationInfo><Affiliation>Cancer Center Amsterdam, 1105 Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Oncology, Location University of Amsterdam, Amsterdam University Medical Center, 1105 Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Cirkel</LastName><ForeName>Geert A</ForeName><Initials>GA</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, 3584 Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>de Groot</LastName><ForeName>Jan Willem B</ForeName><Initials>JWB</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Isala Oncology Center, 8025 Zwolle, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Groot Koerkamp</LastName><ForeName>Bas</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Surgery, Erasmus MC Cancer Institute, 3015 Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Macarulla</LastName><ForeName>Teresa</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Vall d'Hebron Unveristy Hospital, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Melisi</LastName><ForeName>Davide</ForeName><Initials>D</Initials><Identifier Source=\"ORCID\">0000-0002-4031-7585</Identifier><AffiliationInfo><Affiliation>Digestive Molecular Clinical Oncology Unit, Univeristy of Verona, 37134 Verona, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>O'Reilly</LastName><ForeName>Eileen M</ForeName><Initials>EM</Initials><Identifier Source=\"ORCID\">0000-0002-8076-9199</Identifier><AffiliationInfo><Affiliation>Department of Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>van Santvoort</LastName><ForeName>Hjalmar C</ForeName><Initials>HC</Initials><AffiliationInfo><Affiliation>Department of Surgery, Regional Academic Cancer Center Utrecht, UMC Utrecht Cancer Center, St. Antonius Hospital Nieuwegein, Utrecht University, 3584 Utrech, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Mackay</LastName><ForeName>Tara M</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>Department of Surgery, Location University of Amsterdam, Amsterdam University Medical Center, 1105 Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cancer Center Amsterdam, 1105 Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Besselink</LastName><ForeName>Marc G</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Department of Surgery, Location University of Amsterdam, Amsterdam University Medical Center, 1105 Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cancer Center Amsterdam, 1105 Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Wilmink</LastName><ForeName>Johanna W</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>Cancer Center Amsterdam, 1105 Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Oncology, Location University of Amsterdam, Amsterdam University Medical Center, 1105 Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><CollectiveName>Dutch Pancreatic Cancer Group</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2023</Year><Month>11</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Cancers (Basel)</MedlineTA><NlmUniqueID>101526829</NlmUniqueID><ISSNLinking>2072-6694</ISSNLinking></MedlineJournalInfo><KeywordList Owner=\"NOTNLM\"><Keyword MajorTopicYN=\"N\">asymptomatic</Keyword><Keyword MajorTopicYN=\"N\">case-vignette</Keyword><Keyword MajorTopicYN=\"N\">expert survey</Keyword><Keyword MajorTopicYN=\"N\">pancreatic cancer</Keyword><Keyword MajorTopicYN=\"N\">timing of chemotherapy</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"received\"><Year>2023</Year><Month>9</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus=\"revised\"><Year>2023</Year><Month>11</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus=\"accepted\"><Year>2023</Year><Month>11</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus=\"medline\"><Year>2023</Year><Month>12</Month><Day>9</Day><Hour>10</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2023</Year><Month>12</Month><Day>9</Day><Hour>10</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2023</Year><Month>12</Month><Day>9</Day><Hour>1</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38067306</ArticleId><ArticleId IdType=\"pmc\">PMC10705283</ArticleId><ArticleId IdType=\"doi\">10.3390/cancers15235603</ArticleId><ArticleId IdType=\"pii\">cancers15235603</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rahib L., Smith B.D., Aizenberg R., Rosenzweig A.B., Fleshman J.M., Matrisian L.M. Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74:2913&#x2013;2921. doi: 10.1158/0008-5472.CAN-14-0155.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1158/0008-5472.CAN-14-0155</ArticleId><ArticleId IdType=\"pubmed\">24840647</ArticleId></ArticleIdList></Reference><Reference><Citation>Park W., Chawla A., O&#x2019;Reilly E.M. Pancreatic Cancer: A Review. JAMA. 2021;326:851&#x2013;862. doi: 10.1001/jama.2021.13027.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1001/jama.2021.13027</ArticleId><ArticleId IdType=\"pmc\">PMC9363152</ArticleId><ArticleId IdType=\"pubmed\">34547082</ArticleId></ArticleIdList></Reference><Reference><Citation>Conroy T., Desseigne F., Ychou M., Bouch&#xe9; O., Guimbaud R., B&#xe9;couarn Y., Adenis A., Raoul J.-L., Gourgou-Bourgade S., de la Fouchardi&#xe8;re C., et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 2011;364:1817&#x2013;1825. doi: 10.1056/NEJMoa1011923.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1056/NEJMoa1011923</ArticleId><ArticleId IdType=\"pubmed\">21561347</ArticleId></ArticleIdList></Reference><Reference><Citation>Von Hoff D.D., Ervin T., Arena F.P., Chiorean E.G., Infante J., Moore M., Seay T., Tjulandin S.A., Ma W.W., Saleh M.N., et al. Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine. N. Engl. J. Med. 2013;369:1691&#x2013;1703. doi: 10.1056/NEJMoa1304369.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1056/NEJMoa1304369</ArticleId><ArticleId IdType=\"pmc\">PMC4631139</ArticleId><ArticleId IdType=\"pubmed\">24131140</ArticleId></ArticleIdList></Reference><Reference><Citation>Gourgou-Bourgade S., Bascoul-Mollevi C., Desseigne F., Ychou M., Bouch&#xe9; O., Guimbaud R., B&#xe9;couarn Y., Adenis A., Raoul J.-L., Boige V., et al. Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: Results from the PRODIGE 4/ACCORD 11 randomized trial. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2013;31:23&#x2013;29. doi: 10.1200/JCO.2012.44.4869.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1200/JCO.2012.44.4869</ArticleId><ArticleId IdType=\"pubmed\">23213101</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiritescu G., Dumon K., Verslype C., Prenen H., Houbiers G., Peeters M., Janssens J., Van Daele D., Laurent S., Arts J., et al. Gemcitabine with nab-paclitaxel in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC): A quality of life randomized cross-over study (QOLINPAC) Ann. Oncol. 2018;29((Suppl. 5)):v101. doi: 10.1093/annonc/mdy149.002.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/annonc/mdy149.002</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Gioia D., Stieber P., Schmidt G.P., Nagel D., Heinemann V., Baur-Melnyk A. Early detection of metastatic disease in asymptomatic breast cancer patients with whole-body imaging and defined tumor marker increase. Br. J. Cancer. 2015;112:809&#x2013;818. doi: 10.1038/bjc.2015.8.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/bjc.2015.8</ArticleId><ArticleId IdType=\"pmc\">PMC4453962</ArticleId><ArticleId IdType=\"pubmed\">25647014</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan H.-P., Liu W.-S., Liou W.-S., Hu C., Chiu Y.-L., Peng N.-J. Comparison of FDG-PET/CT for Cancer Detection in Populations with Different Risks of Underlying Malignancy. In Vivo. 2020;34:469&#x2013;478. doi: 10.21873/invivo.11797.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.21873/invivo.11797</ArticleId><ArticleId IdType=\"pmc\">PMC6984113</ArticleId><ArticleId IdType=\"pubmed\">31882515</ArticleId></ArticleIdList></Reference><Reference><Citation>Tzeng C.-W.D., Fleming J.B., Lee J.E., Wang X., Pisters P.W.T., Vauthey J.-N., Varadhachary G., Wolff R.A., Katz M.H.G. Yield of clinical and radiographic surveillance in patients with resected pancreatic adenocarcinoma following multimodal therapy. HPB Off. J. Int. Hepato Pancreato Biliary Assoc. 2012;14:365&#x2013;372. doi: 10.1111/j.1477-2574.2012.00445.x.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1111/j.1477-2574.2012.00445.x</ArticleId><ArticleId IdType=\"pmc\">PMC3384860</ArticleId><ArticleId IdType=\"pubmed\">22568412</ArticleId></ArticleIdList></Reference><Reference><Citation>Daamen L.A., Groot V.P., Besselink M.G., Bosscha K., Busch O.R., Cirkel G.A., van Dam R.M., Festen S., Groot Koerkamp B., Haj Mohammad N., et al. Detection, Treatment, and Survival of Pancreatic Cancer Recurrence in the Netherlands: A Nationwide Analysis. Ann. Surg. 2020;275:769&#x2013;775. doi: 10.1097/SLA.0000000000004093.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1097/SLA.0000000000004093</ArticleId><ArticleId IdType=\"pubmed\">32773631</ArticleId></ArticleIdList></Reference><Reference><Citation>Tjaden C., Michalski C.W., Strobel O., Giese N., Hennche A.-K., B&#xfc;chler M.W., Hackert T. Clinical Impact of Structured Follow-up After Pancreatic Surgery. Pancreas. 2016;45:895&#x2013;899. doi: 10.1097/MPA.0000000000000564.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1097/MPA.0000000000000564</ArticleId><ArticleId IdType=\"pubmed\">26646267</ArticleId></ArticleIdList></Reference><Reference><Citation>Tempero M.A., Malafa M.P., Al-Hawary M., Asbun H., Bain A., Behrman S.W., Benson A.B., Binder E., Cardin D.B., Cha C., et al. Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Cancer Netw. 2017;15:1028&#x2013;1061. doi: 10.6004/jnccn.2017.0131.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.6004/jnccn.2017.0131</ArticleId><ArticleId IdType=\"pubmed\">28784865</ArticleId></ArticleIdList></Reference><Reference><Citation>Cascinu S., Falconi M., Valentini V., Jelic S. Pancreatic cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2010;21((Suppl. 5)):v55&#x2013;v58. doi: 10.1093/annonc/mdq165.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/annonc/mdq165</ArticleId><ArticleId IdType=\"pubmed\">20555103</ArticleId></ArticleIdList></Reference><Reference><Citation>Claassen Y.H., van der Valk M.J., Breugom A.J., Frouws M.A., Bastiaannet E., Liefers G.-J., van de Velde C.J., Kapiteijn E. Survival differences with immediate versus delayed chemotherapy for asymptomatic incurable metastatic colorectal cancer. Cochrane Database Syst. Rev. 2018;11:CD012326. doi: 10.1002/14651858.CD012326.pub2.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1002/14651858.CD012326.pub2</ArticleId><ArticleId IdType=\"pmc\">PMC6517244</ArticleId><ArticleId IdType=\"pubmed\">30480771</ArticleId></ArticleIdList></Reference><Reference><Citation>Augustinus S., Thurairajah G., Besselink M.G., van Laarhoven H.W.M., van Oijen M.G.H., Mackay T.M., Wilmink J.W. Delayed Versus Immediate Start of Chemotherapy in Asymptomatic Patients with Advanced Cancer: A Meta-Analysis. Oncologist. 2023;28:961&#x2013;968. doi: 10.1093/oncolo/oyad235.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/oncolo/oyad235</ArticleId><ArticleId IdType=\"pmc\">PMC10628561</ArticleId><ArticleId IdType=\"pubmed\">37589234</ArticleId></ArticleIdList></Reference><Reference><Citation>Jooste V., Dejardin O., Bouvier V., Arveux P., Maynadie M., Launoy G., Bouvier A.-M. Pancreatic cancer: Wait times from presentation to treatment and survival in a population-based study. Int. J. Cancer. 2016;139:1073&#x2013;1080. doi: 10.1002/ijc.30166.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1002/ijc.30166</ArticleId><ArticleId IdType=\"pubmed\">27130333</ArticleId></ArticleIdList></Reference><Reference><Citation>Kruger S., Schirle K., Haas M., Crispin A., Schirra J., Mayerle J., D&#x2019;Haese J.G., Kunz W.G., Ricke J., Ormanns S., et al. Prolonged time to treatment initiation in advanced pancreatic cancer patients has no major effect on treatment outcome: A retrospective cohort study controlled for lead time bias and waiting time paradox. J. Cancer Res. Clin. Oncol. 2020;146:391&#x2013;399. doi: 10.1007/s00432-019-03061-4.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s00432-019-03061-4</ArticleId><ArticleId IdType=\"pubmed\">31642961</ArticleId></ArticleIdList></Reference><Reference><Citation>Pitt S.C., Schwartz T.A., Chu D. AAPOR Reporting Guidelines for Survey Studies. JAMA Surg. 2021;156:785&#x2013;786. doi: 10.1001/jamasurg.2021.0543.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1001/jamasurg.2021.0543</ArticleId><ArticleId IdType=\"pubmed\">33825811</ArticleId></ArticleIdList></Reference><Reference><Citation>Landis J.R., Koch G.G. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159&#x2013;174. doi: 10.2307/2529310.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.2307/2529310</ArticleId><ArticleId IdType=\"pubmed\">843571</ArticleId></ArticleIdList></Reference><Reference><Citation>Groot V.P., Gemenetzis G., Blair A.B., Ding D., Javed A.A., Burkhart R.A., Yu J., Borel Rinkes I.H., Molenaar I.Q., Cameron J.L., et al. Implications of the Pattern of Disease Recurrence on Survival Following Pancreatectomy for Pancreatic Ductal Adenocarcinoma. Ann. Surg. Oncol. 2018;25:2475&#x2013;2483. doi: 10.1245/s10434-018-6558-7.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1245/s10434-018-6558-7</ArticleId><ArticleId IdType=\"pmc\">PMC6220676</ArticleId><ArticleId IdType=\"pubmed\">29948425</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu F., Poruk K.E., Weiss M.J. Surgery for oligometastasis of pancreatic cancer. Chin. J. Cancer Res. 2015;27:358&#x2013;367. doi: 10.3978/j.issn.1000-9604.2015.05.02.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3978/j.issn.1000-9604.2015.05.02</ArticleId><ArticleId IdType=\"pmc\">PMC4560742</ArticleId><ArticleId IdType=\"pubmed\">26361405</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung H.A., Han B.R., Kim H.Y., Kim H.J., Zang D.Y., Jung J.Y. Treatment and Outcomes of Metastatic Pancreatic Cancer in Elderly Patients. Chemotherapy. 2021;66:107&#x2013;112. doi: 10.1159/000517245.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1159/000517245</ArticleId><ArticleId IdType=\"pmc\">PMC8619775</ArticleId><ArticleId IdType=\"pubmed\">34350854</ArticleId></ArticleIdList></Reference><Reference><Citation>Li D., Capanu M., Yu K.H., Lowery M.A., Kelsen D.P., O&#x2019;Reilly E.M. Treatment, Outcomes, and Clinical Trial Participation in Elderly Patients with Metastatic Pancreas Adenocarcinoma. Clin. Colorectal Cancer. 2015;14:269&#x2013;276.e1. doi: 10.1016/j.clcc.2015.05.005.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.clcc.2015.05.005</ArticleId><ArticleId IdType=\"pmc\">PMC4981476</ArticleId><ArticleId IdType=\"pubmed\">26072442</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X., Huang D.-B., Zhang Q., Guo C.-X., Fu Q.-H., Zhang X.-C., Tang T.-Y., Su W., Chen Y.-W., Chen W., et al. The efficacy and toxicity of chemotherapy in the elderly with advanced pancreatic cancer. Pancreatology. 2020;20:95&#x2013;100. doi: 10.1016/j.pan.2019.11.012.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.pan.2019.11.012</ArticleId><ArticleId IdType=\"pubmed\">31786057</ArticleId></ArticleIdList></Reference><Reference><Citation>Zijlstra M., van der Geest L.G.M., van Laarhoven H.W.M., Lemmens V.E.P.P., van de Poll-Franse L.V., Raijmakers N.J.H. Patient characteristics and treatment considerations in pancreatic cancer: A population based study in the Netherlands. Acta Oncol. 2018;57:1185&#x2013;1191. doi: 10.1080/0284186X.2018.1470330.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1080/0284186X.2018.1470330</ArticleId><ArticleId IdType=\"pubmed\">29741436</ArticleId></ArticleIdList></Reference><Reference><Citation>Saade-Lemus P., Biller L., Bullock A. Safety and efficacy of combination chemotherapy regimens in older adults with pancreatic ductal adenocarcinoma: A systematic review. J. Gastrointest. Oncol. 2021;12:2591&#x2013;2599. doi: 10.21037/jgo-21-87.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.21037/jgo-21-87</ArticleId><ArticleId IdType=\"pmc\">PMC8748029</ArticleId><ArticleId IdType=\"pubmed\">35070390</ArticleId></ArticleIdList></Reference><Reference><Citation>Augustinus S., Broekman T., Creemers G.-J., Daamen L.A., van Dieren S., de Groot J.-W.B., Cirkel G.A., Homs M.Y.V., van Laarhoven H.W.M., van Leeuwen L., et al. Timing of start of systemic treatment in patients with asymptomatic metastasized pancreatic cancer (TIMEPAN): A protocol of a multicenter prospective patient preference non-randomized trial. Acta Oncol. 2023;62:1973&#x2013;1978. doi: 10.1080/0284186X.2023.2273898.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1080/0284186X.2023.2273898</ArticleId><ArticleId IdType=\"pubmed\">37897803</ArticleId></ArticleIdList></Reference><Reference><Citation>de Leede N., Bastiaannet E., van der Geest L., Egan K., van de Velde C., Balducci L., Bonsing B., Extermann M. An international comparison of treatment and short-term overall survival for older patients with pancreatic cancer. J. Geriatr. Oncol. 2019;10:584&#x2013;590. doi: 10.1016/j.jgo.2019.02.006.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jgo.2019.02.006</ArticleId><ArticleId IdType=\"pubmed\">30799177</ArticleId></ArticleIdList></Reference><Reference><Citation>Sibeoni J., Picard C., Orri M., Labey M., Bousquet G., Verneuil L., Revah-Levy A. Patients&#x2019; quality of life during active cancer treatment: A qualitative study. BMC Cancer. 2018;18:951. doi: 10.1186/s12885-018-4868-6.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1186/s12885-018-4868-6</ArticleId><ArticleId IdType=\"pmc\">PMC6172766</ArticleId><ArticleId IdType=\"pubmed\">30286733</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>\n",
            "XML saved to: path/to/save/xml/38067306.xml\n",
            "Details URL: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=38066848&retmode=xml&api_key=9edd38677707c08b2a96ed1a6e8c61c47408\n",
            "Details Response Content: <?xml version=\"1.0\" ?>\n",
            "<!DOCTYPE PubmedArticleSet PUBLIC \"-//NLM//DTD PubMedArticle, 1st January 2023//EN\" \"https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd\">\n",
            "<PubmedArticleSet>\n",
            "<PubmedArticle><MedlineCitation Status=\"MEDLINE\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38066848</PMID><DateCompleted><Year>2023</Year><Month>12</Month><Day>16</Day></DateCompleted><DateRevised><Year>2023</Year><Month>12</Month><Day>19</Day></DateRevised><Article PubModel=\"Print\"><Journal><ISSN IssnType=\"Electronic\">1520-4383</ISSN><JournalIssue CitedMedium=\"Internet\"><Volume>2023</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Dec</Month><Day>08</Day></PubDate></JournalIssue><Title>Hematology. American Society of Hematology. Education Program</Title><ISOAbbreviation>Hematology Am Soc Hematol Educ Program</ISOAbbreviation></Journal><ArticleTitle>Clinical manifestations of telomere biology disorders in adults.</ArticleTitle><Pagination><StartPage>563</StartPage><EndPage>572</EndPage><MedlinePgn>563-572</MedlinePgn></Pagination><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.1182/hematology.2023000490</ELocationID><Abstract><AbstractText>Telomere biology disorders (TBDs) are a spectrum of inherited bone marrow failure syndromes caused by impaired telomere function due to pathogenic germline variants in genes involved in telomere maintenance. TBDs can affect many organ systems and are often thought of as diseases of childhood. However, TBDs may present in mid- or even late adulthood with features similar to but not always the same as the childhood-onset TBDs. Adult-onset TBDs are often cryptic with isolated pulmonary, liver, or hematologic disease, or cancer, and may lack the classic disease-defining triad of abnormal skin pigmentation, nail dysplasia, and oral leukoplakia. Diagnostics include detection of very short leukocyte telomeres and germline genetic testing. Notably, adult-onset TBDs may show telomeres in the 1st to 10th percentile for age, and some cases may not have an identifiable genetic cause. TBD genetic etiology includes all modes of inheritance, with autosomal dominant the most frequent in adult-onset disease. Variable symptom onset due to incomplete penetrance, variable expressivity, and genetic anticipation add to the diagnostic challenges. Adult-onset TBDs are likely underrecognized, but their correct identification is of utmost importance, since affected patients are faced with numerous clinical complications, including but not limited to an increased risk of malignancies requiring close surveillance for early detection. Currently lung, liver, or hematopoietic cell transplants are the only curative therapeutic approaches but can be complicated by comorbidities, despite improved medical care. This review highlights the challenges of identifying adult-onset TBDs and addresses currently recommended clinical screening measures and therapy options.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 by The American Society of Hematology.</CopyrightInformation></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Niewisch</LastName><ForeName>Marena R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Department of Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Beier</LastName><ForeName>Fabian</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Medical Faculty, RWTH Aachen University, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Integrated Oncology Aachen Bonn Cologne D&#xfc;sseldorf (CIO ABCD), Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Savage</LastName><ForeName>Sharon A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Clinical Genetics Branch, Division of Cancer and Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016454\">Review</PublicationType><PublicationType UI=\"D016428\">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Hematology Am Soc Hematol Educ Program</MedlineTA><NlmUniqueID>100890099</NlmUniqueID><ISSNLinking>1520-4383</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI=\"D000328\" MajorTopicYN=\"N\">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D006801\" MajorTopicYN=\"N\">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D018095\" MajorTopicYN=\"N\">Germ-Line Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D006402\" MajorTopicYN=\"Y\">Hematologic Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D009369\" MajorTopicYN=\"Y\">Neoplasms</DescriptorName><QualifierName UI=\"Q000175\" MajorTopicYN=\"N\">diagnosis</QualifierName><QualifierName UI=\"Q000235\" MajorTopicYN=\"N\">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D016615\" MajorTopicYN=\"N\">Telomere</DescriptorName><QualifierName UI=\"Q000235\" MajorTopicYN=\"N\">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D001695\" MajorTopicYN=\"N\">Biology</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Marena R. Niewisch: no competing financial interests to declare. Fabian Beier: no competing financial interests to declare. Sharon A. Savage: no competing financial interests to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"medline\"><Year>2023</Year><Month>12</Month><Day>17</Day><Hour>9</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2023</Year><Month>12</Month><Day>9</Day><Hour>10</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2023</Year><Month>12</Month><Day>9</Day><Hour>1</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38066848</ArticleId><ArticleId IdType=\"doi\">10.1182/hematology.2023000490</ArticleId><ArticleId IdType=\"pii\">506396</ArticleId><ArticleId IdType=\"pmc\">PMC10726987</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brenner KA, Nandakumar J.. Consequences of telomere replication failure: the other end-replication problem. Trends Biochem Sci. 2022;47(6): 506-517. doi:10.1016/j.tibs.2022.03.013.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.tibs.2022.03.013</ArticleId><ArticleId IdType=\"pmc\">PMC9106919</ArticleId><ArticleId IdType=\"pubmed\">35440402</ArticleId></ArticleIdList></Reference><Reference><Citation>Revy P, Kannengiesser C, Bertuch AA. Genetics of human telomere biology disorders. Nat Rev Genet. 2023;24(2):86-108. doi:10.1038/s41576-022-00527-z.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/s41576-022-00527-z</ArticleId><ArticleId IdType=\"pubmed\">36151328</ArticleId></ArticleIdList></Reference><Reference><Citation>Tometten M, Kirschner M, Meyer R, et al.. Identification of adult patients with classical dyskeratosis congenita or cryptic telomere biology disorder by telomere length screening using age-modified criteria. HemaSphere. 2023;7(5):e874. doi:10.1097/hs9.0000000000000874.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1097/hs9.0000000000000874</ArticleId><ArticleId IdType=\"pmc\">PMC10121438</ArticleId><ArticleId IdType=\"pubmed\">37096215</ArticleId></ArticleIdList></Reference><Reference><Citation>Norris K, Walne AJ, Ponsford MJ, et al.. High-throughput STELA provides a rapid test for the diagnosis of telomere biology disorders. Hum Genet. 2021;140(6):945-955. doi:10.1007/s00439-021-02257-4.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s00439-021-02257-4</ArticleId><ArticleId IdType=\"pmc\">PMC8099822</ArticleId><ArticleId IdType=\"pubmed\">33709208</ArticleId></ArticleIdList></Reference><Reference><Citation>Tummala H, Walne A, Dokal I.. The biology and management of dyskeratosis congenita and related disorders of telomeres. Expert Rev Hematol. 2022;15(8):685-696. doi:10.1080/17474086.2022.2108784.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1080/17474086.2022.2108784</ArticleId><ArticleId IdType=\"pubmed\">35929966</ArticleId></ArticleIdList></Reference><Reference><Citation>Maryoung L, Yue Y, Young A, et al.. Somatic mutations in telomerase promoter counterbalance germline loss-of-function mutations. J Clin Invest. 2017;127(3):982-986. doi:10.1172/JCI91161.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1172/JCI91161</ArticleId><ArticleId IdType=\"pmc\">PMC5330735</ArticleId><ArticleId IdType=\"pubmed\">28192371</ArticleId></ArticleIdList></Reference><Reference><Citation>Niewisch MR, Giri N, McReynolds LJ, et al.. Disease progression and clinical outcomes in telomere biology disorders. Blood. 2022;139(12):1807-1819. doi:10.1182/blood.2021013523.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1182/blood.2021013523</ArticleId><ArticleId IdType=\"pmc\">PMC8952184</ArticleId><ArticleId IdType=\"pubmed\">34852175</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward SC, Savage SA, Giri N, et al.. Beyond the triad: inheritance, mucocutaneous phenotype, and mortality in a cohort of patients with dyskeratosis congenita. J Am Acad Dermatol. 2018;78(4):804-806. doi:10.1016/j.jaad.2017.10.017.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jaad.2017.10.017</ArticleId><ArticleId IdType=\"pmc\">PMC5857208</ArticleId><ArticleId IdType=\"pubmed\">29042228</ArticleId></ArticleIdList></Reference><Reference><Citation>Newton CA, Oldham JM, Applegate C, et al; Pulmonary Fibrosis Foundation Genetic Testing Work Group. The role of genetic testing in pulmonary fibrosis: a perspective from the Pulmonary Fibrosis Foundation Genetic Testing Work Group. Chest. 2022;162(2):394-405. doi:10.1016/j.chest.2022.03.023.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.chest.2022.03.023</ArticleId><ArticleId IdType=\"pmc\">PMC9424324</ArticleId><ArticleId IdType=\"pubmed\">35337808</ArticleId></ArticleIdList></Reference><Reference><Citation>Alder JK, Armanios M.. Telomere-mediated lung disease. Physiol Rev. 2022;102(4):1703-1720. doi:10.1152/physrev.00046.2021.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1152/physrev.00046.2021</ArticleId><ArticleId IdType=\"pmc\">PMC9306791</ArticleId><ArticleId IdType=\"pubmed\">35532056</ArticleId></ArticleIdList></Reference><Reference><Citation>Newton CA, Batra K, Torrealba J, et al.. Telomere-related lung fibrosis is diagnostically heterogeneous but uniformly progressive. Eur Respir J. 2016;48(6):1710-1720. doi:10.1183/13993003.00308-2016.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1183/13993003.00308-2016</ArticleId><ArticleId IdType=\"pmc\">PMC5433348</ArticleId><ArticleId IdType=\"pubmed\">27540018</ArticleId></ArticleIdList></Reference><Reference><Citation>Giri N, Ravichandran S, Wang Yet al.. Prognostic significance of pulmonary function tests in dyskeratosis congenita, a telomere biology disorder. ERJ Open Res. 2019;5(4):00209-2019. doi:10.1183/23120541.00209-2019.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1183/23120541.00209-2019</ArticleId><ArticleId IdType=\"pmc\">PMC6856494</ArticleId><ArticleId IdType=\"pubmed\">31754622</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorgy AI, Jonassaint NL, Stanley SE, et al.. Hepatopulmonary syndrome is a frequent cause of dyspnea in the short telomere disorders. Chest. 2015;148(4):1019-1026. doi:10.1378/chest.15-0825.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1378/chest.15-0825</ArticleId><ArticleId IdType=\"pmc\">PMC4594621</ArticleId><ArticleId IdType=\"pubmed\">26158642</ArticleId></ArticleIdList></Reference><Reference><Citation>Khincha PP, Bertuch AA, Agarwal Set al.. Pulmonary arteriovenous malformations: an uncharacterised phenotype of dyskeratosis congenita and related telomere biology disorders. Eur Respir J. 2017;49(1):1601640. doi:10.1183/13993003.01640-2016.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1183/13993003.01640-2016</ArticleId><ArticleId IdType=\"pmc\">PMC5841586</ArticleId><ArticleId IdType=\"pubmed\">27824607</ArticleId></ArticleIdList></Reference><Reference><Citation>Alter BP, Giri N, Savage SA, Rosenberg PS. Cancer in the National Cancer Institute Inherited Bone Marrow Failure Syndrome Cohort after fifteen years of follow-up. Haematologica. 2018;103(1):30-39. doi:10.3324/haematol.2017.178111.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3324/haematol.2017.178111</ArticleId><ArticleId IdType=\"pmc\">PMC5777188</ArticleId><ArticleId IdType=\"pubmed\">29051281</ArticleId></ArticleIdList></Reference><Reference><Citation>McReynolds LJ, Rafati M, Wang Yet al.. Genetic testing in severe aplastic anemia is required for optimal hematopoietic cell transplant outcomes. Blood. 2022;140(8):909-921. doi:10.1182/blood.2022016508.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1182/blood.2022016508</ArticleId><ArticleId IdType=\"pmc\">PMC9412004</ArticleId><ArticleId IdType=\"pubmed\">35776903</ArticleId></ArticleIdList></Reference><Reference><Citation>Schratz KE, Haley L, Danoff SK, et al.. Cancer spectrum and outcomes in the Mendelian short telomere syndromes. Blood. 2020;135(22):1946-1956. doi:10.1182/blood.2019003264.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1182/blood.2019003264</ArticleId><ArticleId IdType=\"pmc\">PMC7256360</ArticleId><ArticleId IdType=\"pubmed\">32076714</ArticleId></ArticleIdList></Reference><Reference><Citation>Vittal A, Niewisch MR, Bhala Set al.. \n",
            "Progression of liver disease and portal hypertension in dyskeratosis congenita and related telomere biology disorders. Hepatology. 2023:10.1097/HEP.0000000000000461. doi:10.1097/HEP.0000000000000461.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1097/HEP.0000000000000461</ArticleId><ArticleId IdType=\"doi\">10.1097/HEP.0000000000000461</ArticleId><ArticleId IdType=\"pubmed\">37184208</ArticleId></ArticleIdList></Reference><Reference><Citation>Kapuria D, Ben-Yakov G, Ortolano Ret al.. The spectrum of hepatic involvement in patients with telomere disease. Hepatology. 2019;69(6):2579-2585. doi:10.1002/hep.30578.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1002/hep.30578</ArticleId><ArticleId IdType=\"pmc\">PMC7440774</ArticleId><ArticleId IdType=\"pubmed\">30791107</ArticleId></ArticleIdList></Reference><Reference><Citation>Tometten M, Kirschner M, Isfort S, Berres M-L, Br&#xfc;mmendorf T-H, Beier F.. Transient elastography in adult patients with cryptic dyskeratosis congenita reveals subclinical liver fibrosis: a retrospective analysis of the Aachen telomere biology disease registry. Orphanet J Rare Dis. 2021;16(1): 395. doi:10.1186/s13023-021-02024-8.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1186/s13023-021-02024-8</ArticleId><ArticleId IdType=\"pmc\">PMC8474920</ArticleId><ArticleId IdType=\"pubmed\">34565437</ArticleId></ArticleIdList></Reference><Reference><Citation>Aviv A, Anderson JJ, Shay JW. Mutations, cancer and the telomere length paradox. Trends Cancer. 2017;3(4):253-258. doi:10.1016/j.trecan.2017.02.005.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.trecan.2017.02.005</ArticleId><ArticleId IdType=\"pmc\">PMC5903276</ArticleId><ArticleId IdType=\"pubmed\">28718437</ArticleId></ArticleIdList></Reference><Reference><Citation>McNally EJ, Luncsford PJ, Armanios M.. Long telomeres and cancer risk: the price of cellular immortality. J Clin Invest. 2019;129(9):3474-3481. doi:10.1172/JCI120851.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1172/JCI120851</ArticleId><ArticleId IdType=\"pmc\">PMC6715353</ArticleId><ArticleId IdType=\"pubmed\">31380804</ArticleId></ArticleIdList></Reference><Reference><Citation>Schratz KE, Flasch DA, Atik CC, et al.. T cell immune deficiency rather than chromosome instability predisposes patients with short telomere syndromes to squamous cancers. Cancer Cell. 2023;41(4):807-817.e6817e6. doi:10.1016/j.ccell.2023.03.005.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.ccell.2023.03.005</ArticleId><ArticleId IdType=\"pmc\">PMC10188244</ArticleId><ArticleId IdType=\"pubmed\">37037617</ArticleId></ArticleIdList></Reference><Reference><Citation>Feurstein S, Adegunsoye A, Mojsilovic Det al.. Telomere biology disorder prevalence and phenotypes in adults with familial hematologic and/or pulmonary presentations. Blood Adv. 2020;4(19):4873-4886. doi:10.1182/bloodadvances.2020001721.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1182/bloodadvances.2020001721</ArticleId><ArticleId IdType=\"pmc\">PMC7556157</ArticleId><ArticleId IdType=\"pubmed\">33035329</ArticleId></ArticleIdList></Reference><Reference><Citation>Himes RW, Chiou EH, Queliza Ket al.. Gastrointestinal hemorrhage: a manifestation of the telomere biology disorders. J Pediatr. 2021;230:55-61.e461e4. doi:10.1016/j.jpeds.2020.09.038.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jpeds.2020.09.038</ArticleId><ArticleId IdType=\"pubmed\">32971146</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner CL, Hanumanthu VS, Talbot CC, et al.. Short telomere syndromes cause a primary T cell immunodeficiency. J Clin Invest. 2018;128(12): 5222-5234. doi:10.1172/JCI120216.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1172/JCI120216</ArticleId><ArticleId IdType=\"pmc\">PMC6264634</ArticleId><ArticleId IdType=\"pubmed\">30179220</ArticleId></ArticleIdList></Reference><Reference><Citation>Alter BP, Rosenberg PS, Giri N, Baerlocher GM, Lansdorp PM, Savage SA. Telomere length is associated with disease severity and declines with age in dyskeratosis congenita. Haematologica. 2012;97(3):353-359. doi:10.3324/haematol.2011.055269.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3324/haematol.2011.055269</ArticleId><ArticleId IdType=\"pmc\">PMC3291588</ArticleId><ArticleId IdType=\"pubmed\">22058220</ArticleId></ArticleIdList></Reference><Reference><Citation>Alder JK, Hanumanthu VS, Strong MA, et al.. Diagnostic utility of telomere length testing in a hospital-based setting. Proc Natl Acad Sci U S A. 2018;115(10):e2358-e2365. doi:10.1073/pnas.1720427115.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1073/pnas.1720427115</ArticleId><ArticleId IdType=\"pmc\">PMC5877993</ArticleId><ArticleId IdType=\"pubmed\">29463756</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhala S, Savage SA. What is the future of telomere length testing in telomere biology disorders? Expert Rev Hematol. 2023;16(7):475-478. doi:10.1080/17474086.2023.2215423.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1080/17474086.2023.2215423</ArticleId><ArticleId IdType=\"pmc\">PMC10330493</ArticleId><ArticleId IdType=\"pubmed\">37191632</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira MSV, Kirschner M, Halfmeyer Iet al.. Comparison of flow-FISH and MM&#x2013;qPCR telomere length assessment techniques for the screening of telomeropathies. Ann NY Acad Sci. 2020;1466(1):93-103. doi:10.1111/nyas.14248.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1111/nyas.14248</ArticleId><ArticleId IdType=\"pubmed\">31647584</ArticleId></ArticleIdList></Reference><Reference><Citation>Kermasson L, Churikov D, Awad Aet al.. Inherited human Apollo deficiency causes severe bone marrow failure and developmental defects. Blood. 2022;139(16):2427-2440. doi:10.1182/blood.2021010791.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1182/blood.2021010791</ArticleId><ArticleId IdType=\"pubmed\">35007328</ArticleId></ArticleIdList></Reference><Reference><Citation>Br&#xfc;mmendorf TH, Balabanov S.. Telomere length dynamics in normal hematopoiesis and in disease states characterized by increased stem cell turnover. Leukemia. 2006;20(10):1706-1716. doi:10.1038/sj.leu.2404339.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/sj.leu.2404339</ArticleId><ArticleId IdType=\"pubmed\">16888616</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma R, Sahoo SS, Honda Met al.. Gain-of-function mutations in RPA1 cause a syndrome with short telomeres and somatic genetic rescue. Blood. 2022;139(7):1039-1051. doi:10.1182/blood.2021011980.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1182/blood.2021011980</ArticleId><ArticleId IdType=\"pmc\">PMC8854676</ArticleId><ArticleId IdType=\"pubmed\">34767620</ArticleId></ArticleIdList></Reference><Reference><Citation>Dressen A, Abbas AR, Cabanski Cet al.. Analysis of protein-altering variants in telomerase genes and their association with MUC5B common variant status in patients with idiopathic pulmonary fibrosis: a candidate gene sequencing study. Lancet Respir Med. 2018;6(8):603-614. doi:10.1016/s2213-2600(18)30135-8.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/s2213-2600(18)30135-8</ArticleId><ArticleId IdType=\"pmc\">PMC6487850</ArticleId><ArticleId IdType=\"pubmed\">29891356</ArticleId></ArticleIdList></Reference><Reference><Citation>Reilly CR, Myllym&#xe4;ki M, Redd Ret al.. The clinical and functional effects of TERT variants in myelodysplastic syndrome. Blood. 2021;138(10):898-911. doi:10.1182/blood.2021011075.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1182/blood.2021011075</ArticleId><ArticleId IdType=\"pmc\">PMC8432045</ArticleId><ArticleId IdType=\"pubmed\">34019641</ArticleId></ArticleIdList></Reference><Reference><Citation>Alder JK, Stanley SE, Wagner CL, Hamilton M, Hanumanthu VS, Armanios M.. Exome sequencing identifies mutant TINF2 in a family with pulmonary fibrosis. Chest. 2015;147(5):1361-1368. doi:10.1378/chest.14-1947.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1378/chest.14-1947</ArticleId><ArticleId IdType=\"pmc\">PMC4420184</ArticleId><ArticleId IdType=\"pubmed\">25539146</ArticleId></ArticleIdList></Reference><Reference><Citation>Agarwal S, Savage S, Stevens K, Raj H, Carson H, eds. Telomere Biology Disorders: Diagnosis and Management Guidelines. Coeur d'Alene, ID: Team Telomere Inc.; 2022.</Citation></Reference><Reference><Citation>Swaminathan AC, Neely ML, Frankel CW, et al.. Lung transplant outcomes in patients with pulmonary fibrosis with telomere-related gene variants. Chest. 2019;156(3):477-485. doi:10.1016/j.chest.2019.03.030.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.chest.2019.03.030</ArticleId><ArticleId IdType=\"pubmed\">30978332</ArticleId></ArticleIdList></Reference><Reference><Citation>Alebrahim M, Akateh C, Arnold CA, et al.. Liver transplant for management of hepatic complications of dyskeratosis congenita: a case report. Exp Clin Transpl. 2022;20(7):702-705. doi:10.6002/ect.2020.0073.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.6002/ect.2020.0073</ArticleId><ArticleId IdType=\"pmc\">PMC8155112</ArticleId><ArticleId IdType=\"pubmed\">33272154</ArticleId></ArticleIdList></Reference><Reference><Citation>Fioredda F, Iacobelli S, Korthof ET, et al.. Outcome of haematopoietic stem cell transplantation in dyskeratosis congenita. Br J Haematol. 2018;183(1):110-118. doi:10.1111/bjh.15495.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1111/bjh.15495</ArticleId><ArticleId IdType=\"pubmed\">29984823</ArticleId></ArticleIdList></Reference><Reference><Citation>Agarwal S. Evaluation and management of hematopoietic failure in dyskeratosis congenita. Hematol/Oncol Clin North Am. 2018;32(4):669-685. doi:10.1016/j.hoc.2018.04.003.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.hoc.2018.04.003</ArticleId><ArticleId IdType=\"pmc\">PMC7307713</ArticleId><ArticleId IdType=\"pubmed\">30047419</ArticleId></ArticleIdList></Reference><Reference><Citation>Lebeer M, Wuyts WA, Cassiman Det al.. Multiple solid organ transplantation in telomeropathy: case series and literature review. Transplantation. 2018;102(10):1747-1755. doi:10.1097/tp.0000000000002198.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1097/tp.0000000000002198</ArticleId><ArticleId IdType=\"pubmed\">29596117</ArticleId></ArticleIdList></Reference><Reference><Citation>Justet A, Klay D, Porcher Ret al.. Safety and efficacy of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis and carrying a telomere-related gene mutation. Eur Respir J. 2021;57(2):2003198. doi:10.1183/13993003.03198-2020.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1183/13993003.03198-2020</ArticleId><ArticleId IdType=\"pubmed\">33214205</ArticleId></ArticleIdList></Reference><Reference><Citation>Vieri M, Kirschner M, Tometten Met al.. Comparable effects of the androgen derivatives danazol, oxymetholone and nandrolone on telomerase activity in human primary hematopoietic cells from patients with dyskeratosis congenita. Int J Mol Sci. 2020;21(19). doi:10.3390/ijms21197196.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3390/ijms21197196</ArticleId><ArticleId IdType=\"pmc\">PMC7584039</ArticleId><ArticleId IdType=\"pubmed\">33003434</ArticleId></ArticleIdList></Reference><Reference><Citation>Khincha PP, Bertuch AA, Gadalla SM, Giri N, Alter BP, Savage SA. Similar telomere attrition rates in androgen-treated and untreated patients with dyskeratosis congenita. Blood Adv. 2018;2(11):1243-1249. doi:10.1182/bloodadvances.2018016964.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1182/bloodadvances.2018016964</ArticleId><ArticleId IdType=\"pmc\">PMC5998921</ArticleId><ArticleId IdType=\"pubmed\">29853525</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirschner M, Vieri M, Kricheldorf Ket al.. Androgen derivatives improve blood counts and elongate telomere length in adult cryptic dyskeratosis congenita. Br J Haematol. 2021;193(3):669-673. doi:10.1111/bjh.16997.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1111/bjh.16997</ArticleId><ArticleId IdType=\"pubmed\">32744739</ArticleId></ArticleIdList></Reference><Reference><Citation>Cl&#xe9; DV, Catto LFB, Gutierrez-Rodrigues Fet al.. Effects of nandrolone decanoate on telomere length and clinical outcome in patients with telomeropathies: a prospective trial. Haematologica. 2023;108(5):1300-1312. doi:10.3324/haematol.2022.281808.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3324/haematol.2022.281808</ArticleId><ArticleId IdType=\"pmc\">PMC10153533</ArticleId><ArticleId IdType=\"pubmed\">36579443</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsley DM, Dumitriu B, Young NS. Danazol treatment for telomere diseases. N Engl J Med. 2016;375(11):1095-1096. doi:10.1056/nejmc1607752.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1056/nejmc1607752</ArticleId><ArticleId IdType=\"pubmed\">27626528</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanley SE, Rao AD, Gable DL, McGrath-Morrow S, Armanios M.. Radiation sensitivity and radiation necrosis in the short telomere syndromes. Int J Radiat Oncol Biol Phys. 2015;93(5):1115-1117. doi:10.1016/j.ijrobp.2015.08.048.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.ijrobp.2015.08.048</ArticleId><ArticleId IdType=\"pmc\">PMC4708077</ArticleId><ArticleId IdType=\"pubmed\">26581148</ArticleId></ArticleIdList></Reference><Reference><Citation>Tummala H, Walne A, Buccafusca Ret al.. Germline thymidylate synthase deficiency impacts nucleotide metabolism and causes dyskeratosis congenita. Am J Hum Genet. 2022;109(8):1472-1483. doi:10.1016/j.ajhg.2022.06.014.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.ajhg.2022.06.014</ArticleId><ArticleId IdType=\"pmc\">PMC9388389</ArticleId><ArticleId IdType=\"pubmed\">35931051</ArticleId></ArticleIdList></Reference><Reference><Citation>Mannherz W, Agarwal S.. Thymidine nucleotide metabolism controls human telomere length. Nat Genet. 2023;55(4):568-580. doi:10.1038/s41588-023-01339-5.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/s41588-023-01339-5</ArticleId><ArticleId IdType=\"pubmed\">36959362</ArticleId></ArticleIdList></Reference><Reference><Citation>Choo S, Lorbeer FK, Regalado SG, et al.. Editing TINF2 as a potential therapeutic approach to restore telomere length in dyskeratosis congenita. Blood. 2022;140(6):608-618. doi:10.1182/blood.2021013750.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1182/blood.2021013750</ArticleId><ArticleId IdType=\"pmc\">PMC9373014</ArticleId><ArticleId IdType=\"pubmed\">35421215</ArticleId></ArticleIdList></Reference><Reference><Citation>Nachmani D, Bothmer AH, Grisendi Set al.. Germline NPM1 mutations lead to altered rRNA 2&#x2019;-O-methylation and cause dyskeratosis congenita. Nat Genet. 2019;51(10):1518-1529. doi:10.1038/s41588-019-0502-z.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/s41588-019-0502-z</ArticleId><ArticleId IdType=\"pmc\">PMC6858547</ArticleId><ArticleId IdType=\"pubmed\">31570891</ArticleId></ArticleIdList></Reference><Reference><Citation>Toufektchan E, Lejour V, Durand Ret al.. Germline mutation of MDM4, a major p53 regulator, in a familial syndrome of defective telomere maintenance. Sci Adv. 2020;6(15):eaay3511. doi:10.1126/sciadv.aay3511.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1126/sciadv.aay3511</ArticleId><ArticleId IdType=\"pmc\">PMC7148086</ArticleId><ArticleId IdType=\"pubmed\">32300648</ArticleId></ArticleIdList></Reference><Reference><Citation>Niewisch MR, Savage SA. An update on the biology and management of dyskeratosis congenita and related telomere biology disorders. Expert Rev Hematol. 2019;12(12):1037-1052. doi:10.1080/17474086.2019.1662720.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1080/17474086.2019.1662720</ArticleId><ArticleId IdType=\"pmc\">PMC9400112</ArticleId><ArticleId IdType=\"pubmed\">31478401</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh MF, Chang VY, Kohlmann WK, et al.. Recommendations for childhood cancer screening and surveillance in DNA repair disorders. Clin Cancer Res. 2017;23(11):e23-e31. doi:10.1158/1078-0432.CCR-17-0465.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1158/1078-0432.CCR-17-0465</ArticleId><ArticleId IdType=\"pmc\">PMC5697784</ArticleId><ArticleId IdType=\"pubmed\">28572264</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>\n",
            "XML saved to: path/to/save/xml/38066848.xml\n",
            "Details URL: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=38066463&retmode=xml&api_key=9edd38677707c08b2a96ed1a6e8c61c47408\n",
            "Details Response Content: <?xml version=\"1.0\" ?>\n",
            "<!DOCTYPE PubmedArticleSet PUBLIC \"-//NLM//DTD PubMedArticle, 1st January 2023//EN\" \"https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd\">\n",
            "<PubmedArticleSet>\n",
            "<PubmedArticle><MedlineCitation Status=\"MEDLINE\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38066463</PMID><DateCompleted><Year>2023</Year><Month>12</Month><Day>16</Day></DateCompleted><DateRevised><Year>2023</Year><Month>12</Month><Day>16</Day></DateRevised><Article PubModel=\"Electronic\"><Journal><ISSN IssnType=\"Electronic\">1471-2482</ISSN><JournalIssue CitedMedium=\"Internet\"><Volume>23</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Dec</Month><Day>08</Day></PubDate></JournalIssue><Title>BMC surgery</Title><ISOAbbreviation>BMC Surg</ISOAbbreviation></Journal><ArticleTitle>\"Low-age, low-frequency\" lung cancer screening strategies maybe adaptable to the situation in China.</ArticleTitle><Pagination><StartPage>367</StartPage><MedlinePgn>367</MedlinePgn></Pagination><ELocationID EIdType=\"pii\" ValidYN=\"Y\">367</ELocationID><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.1186/s12893-023-02279-x</ELocationID><Abstract><AbstractText Label=\"BACKGROUND\" NlmCategory=\"BACKGROUND\">The object was to compare changes in patients undergoing lung surgery before and after COVID-19 outbreak, and to explore the impact of COVID-19 on lung surgery and its coping strategies.</AbstractText><AbstractText Label=\"METHOD\" NlmCategory=\"METHODS\">A retrospective review of patients undergoing thoracic surgery at a single institution was conducted. Group A included patients treated between January 23, 2019, and January 23, 2020, while Group B included patients treated between June 1, 2020, and June 1, 2021, at our center. We compared the reasons of seeking medical treatment, the general characteristics of patients, imaging features, pathological features, surgical methods and postoperative recovery.</AbstractText><AbstractText Label=\"RESULT\" NlmCategory=\"RESULTS\">Compared to Group A, the number of patients with pulmonary nodules screened by routine check-up increased in Group B (57.6% vs 46.9%, p&#x2009;&lt;&#x2009;0.05). Female patient increased (55.2%vs 44.7%). Patient without smoking history or with family history of lung cancer increased (70.7% vs 60.7%) (10.1%vs 7.8%). Early stage lung cancer increased. Lobectomy decreased (53.4% vs 64.1%). Segmental resection increased (33.3% vs 12.7%). Patients without postoperative comorbidities increased (96.1%vs 85.7%). In the case of patients with Ground Glass Opacity(GGO), their age was comparatively lower (52&#x2009;&#xb1;&#x2009;9.9 vs. 55&#x2009;&#xb1;&#x2009;10.7), the female patients increased, patient without smoking history, tumor history, family history of tumor increased, small GGO increased. Lobectomy decreased (35.2% vs 49.7%). Segmental resection increased (49.6% vs 21.2%). Patients without postoperative comorbidities increased (96.5% vs 87.4%).</AbstractText><AbstractText Label=\"CONCLUSION\" NlmCategory=\"CONCLUSIONS\">Since COVID-19 outbreak, more young, non-smoking, female lung cancers, more Ground Glass Opacity, none high risk patients have been detected through screening, suggesting that our current screening criteria for lung cancer may need to be revised. Higher requirements, including the selection of the timing of nodular surgery, surgical methods were put forward for thoracic surgeons' skills.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\" EqualContrib=\"Y\"><LastName>Hu</LastName><ForeName>Peixuan</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Thoracic Surgery, Tongji Hospital, Tongji Medical College, HuaZhong University of Science and Technology, Wuhan, Hubei, 430030, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Second Clinical School, Tongji Medical College, HuaZhong University of Science and Technology, Wuhan, Hubei, 430030, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\" EqualContrib=\"Y\"><LastName>Song</LastName><ForeName>Xiaozhen</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Thoracic Surgery, Tongji Hospital, Tongji Medical College, HuaZhong University of Science and Technology, Wuhan, Hubei, 430030, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Second Clinical School, Tongji Medical College, HuaZhong University of Science and Technology, Wuhan, Hubei, 430030, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Fan</LastName><ForeName>Xiaowu</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Thoracic Surgery, Tongji Hospital, Tongji Medical College, HuaZhong University of Science and Technology, Wuhan, Hubei, 430030, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Zhu</LastName><ForeName>Yunpeng</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Thoracic Surgery, Tongji Hospital, Tongji Medical College, HuaZhong University of Science and Technology, Wuhan, Hubei, 430030, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Fu</LastName><ForeName>Xiangning</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Thoracic Surgery, Tongji Hospital, Tongji Medical College, HuaZhong University of Science and Technology, Wuhan, Hubei, 430030, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Fu</LastName><ForeName>Shengling</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Thoracic Surgery, Tongji Hospital, Tongji Medical College, HuaZhong University of Science and Technology, Wuhan, Hubei, 430030, People's Republic of China. 2008tj0517@hust.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2023</Year><Month>12</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Surg</MedlineTA><NlmUniqueID>100968567</NlmUniqueID><ISSNLinking>1471-2482</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI=\"D006801\" MajorTopicYN=\"N\">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D005260\" MajorTopicYN=\"N\">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D008175\" MajorTopicYN=\"Y\">Lung Neoplasms</DescriptorName><QualifierName UI=\"Q000175\" MajorTopicYN=\"N\">diagnosis</QualifierName><QualifierName UI=\"Q000453\" MajorTopicYN=\"N\">epidemiology</QualifierName><QualifierName UI=\"Q000601\" MajorTopicYN=\"N\">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D055088\" MajorTopicYN=\"N\">Early Detection of Cancer</DescriptorName><QualifierName UI=\"Q000379\" MajorTopicYN=\"N\">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D014057\" MajorTopicYN=\"N\">Tomography, X-Ray Computed</DescriptorName><QualifierName UI=\"Q000379\" MajorTopicYN=\"N\">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D012189\" MajorTopicYN=\"N\">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D002681\" MajorTopicYN=\"N\" Type=\"Geographic\">China</DescriptorName><QualifierName UI=\"Q000453\" MajorTopicYN=\"N\">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D000086382\" MajorTopicYN=\"Y\">COVID-19</DescriptorName><QualifierName UI=\"Q000453\" MajorTopicYN=\"N\">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner=\"NOTNLM\"><Keyword MajorTopicYN=\"N\">Ground Glass Opacity</Keyword><Keyword MajorTopicYN=\"N\">Lung cancer</Keyword><Keyword MajorTopicYN=\"N\">Screening</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"received\"><Year>2023</Year><Month>7</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus=\"accepted\"><Year>2023</Year><Month>11</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus=\"medline\"><Year>2023</Year><Month>12</Month><Day>17</Day><Hour>13</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2023</Year><Month>12</Month><Day>9</Day><Hour>10</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2023</Year><Month>12</Month><Day>9</Day><Hour>0</Hour><Minute>2</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38066463</ArticleId><ArticleId IdType=\"pmc\">PMC10704619</ArticleId><ArticleId IdType=\"doi\">10.1186/s12893-023-02279-x</ArticleId><ArticleId IdType=\"pii\">10.1186/s12893-023-02279-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87&#x2013;108. doi: 10.3322/caac.21262.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3322/caac.21262</ArticleId><ArticleId IdType=\"pubmed\">25651787</ArticleId></ArticleIdList></Reference><Reference><Citation>Xing PY, Zhu YX, Wang L, et al. What are the clinical symptoms and physical signs for non-small cell lung cancer before diagnosis is made? A nation-wide multicenter 10-year retrospective study in China. Cancer Med. 2019;8(8):4055&#x2013;4069. doi: 10.1002/cam4.2256.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1002/cam4.2256</ArticleId><ArticleId IdType=\"pmc\">PMC6639195</ArticleId><ArticleId IdType=\"pubmed\">31150167</ArticleId></ArticleIdList></Reference><Reference><Citation>Ettinger DS, Wood DE, Aisner DL, et al. NCCN guidelines insights: non-small cell lung Cancer, version 2.2021. J Natl Compr Cancer Netw. 2021;19(3):254&#x2013;266. doi: 10.6004/jnccn.2021.0013.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.6004/jnccn.2021.0013</ArticleId><ArticleId IdType=\"pubmed\">33668021</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WE, Nicholson AG, Groome P, Mitchell A, Bolejack V, International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee, Advisory Boards, and Participating Institutions; International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee Advisory Boards and Participating Institutions The IASLC lung Cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung Cancer. J Thorac Oncol. 2016;11(1):39&#x2013;51. doi: 10.1016/j.jtho.2015.09.009.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jtho.2015.09.009</ArticleId><ArticleId IdType=\"pubmed\">26762738</ArticleId></ArticleIdList></Reference><Reference><Citation>Ai T, Yang Z, Hou H, et al. Correlation of chest CT and RT-PCR testing for coronavirus disease 2019 (COVID-19) in China: a report of 1014 cases. Radiology. 2020;296(2):E32&#x2013;E40. doi: 10.1148/radiol.2020200642.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1148/radiol.2020200642</ArticleId><ArticleId IdType=\"pmc\">PMC7233399</ArticleId><ArticleId IdType=\"pubmed\">32101510</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood DE, Kazerooni EA, Baum SL, et al. Lung Cancer screening, version 3.2018, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2018;16(4):412&#x2013;441. doi: 10.6004/jnccn.2018.0020.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.6004/jnccn.2018.0020</ArticleId><ArticleId IdType=\"pmc\">PMC6476336</ArticleId><ArticleId IdType=\"pubmed\">29632061</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao JW, Rizzo S, Ma LH, et al. Pulmonary ground-glass opacity: computed tomography features, histopathology and molecular pathology. Transl Lung Cancer Res. 2017;6(1):68&#x2013;75. doi: 10.21037/tlcr.2017.01.02.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.21037/tlcr.2017.01.02</ArticleId><ArticleId IdType=\"pmc\">PMC5344841</ArticleId><ArticleId IdType=\"pubmed\">28331826</ArticleId></ArticleIdList></Reference><Reference><Citation>Handa Y, Tsutani Y, Okada M. Transition of treatment for ground glass opacity-dominant non-small cell lung Cancer. Front Oncol. 2021;11:655651. doi: 10.3389/fonc.2021.655651.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3389/fonc.2021.655651</ArticleId><ArticleId IdType=\"pmc\">PMC8082027</ArticleId><ArticleId IdType=\"pubmed\">33937064</ArticleId></ArticleIdList></Reference><Reference><Citation>Pastorino U, Rossi M, Rosato V, et al. Annual or biennial CT screening versus observation in heavy smokers: 5-year results of the MILD trial. Eur J Cancer Prev. 2012;21(3):308&#x2013;315. doi: 10.1097/CEJ.0b013e328351e1b6.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1097/CEJ.0b013e328351e1b6</ArticleId><ArticleId IdType=\"pubmed\">22465911</ArticleId></ArticleIdList></Reference><Reference><Citation>Saghir Z, Dirksen A, Ashraf H, et al. CT screening for lung cancer brings forward early disease. The randomised Danish lung Cancer screening trial: status after five annual screening rounds with low-dose CT. Thorax. 2012;67(4):296&#x2013;301. doi: 10.1136/thoraxjnl-2011-200736.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1136/thoraxjnl-2011-200736</ArticleId><ArticleId IdType=\"pubmed\">22286927</ArticleId></ArticleIdList></Reference><Reference><Citation>Infante M, Cavuto S, Lutman FR, et al. Long-term follow-up results of the DANTE trial, a randomized study of lung Cancer screening with spiral computed tomography. Am J Respir Crit Care Med. 2015;191(10):1166&#x2013;1175. doi: 10.1164/rccm.201408-1475OC.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1164/rccm.201408-1475OC</ArticleId><ArticleId IdType=\"pubmed\">25760561</ArticleId></ArticleIdList></Reference><Reference><Citation>Ijsseldijk MA, Shoni M, Siegert C, et al. Oncological outcomes of lobar resection, Segmentectomy, and wedge resection for T1a non-small-cell lung carcinoma: a systematic review and Meta-analysis. Semin Thorac Cardiovasc Surg. 2020;32(3):582&#x2013;590. doi: 10.1053/j.semtcvs.2019.08.004.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1053/j.semtcvs.2019.08.004</ArticleId><ArticleId IdType=\"pubmed\">31401180</ArticleId></ArticleIdList></Reference><Reference><Citation>Qu R, Tu D, Hu S, et al. Electromagnetic navigation bronchoscopy-guided microwave ablation combined with Uniportal video-assisted thoracoscopic surgery for multiple ground glass opacities. Ann Thorac Surg. 2022;113(4):1307&#x2013;1315. doi: 10.1016/j.athoracsur.2021.04.061.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.athoracsur.2021.04.061</ArticleId><ArticleId IdType=\"pubmed\">33964257</ArticleId></ArticleIdList></Reference><Reference><Citation>Benker M, Citak N, Neuer T, Opitz I, Inci I. Impact of preoperative comorbidities on postoperative complication rate and outcome in surgically resected non-small cell lung cancer patients. Gen Thorac Cardiovasc Surg. 2022;70(3):248&#x2013;256. doi: 10.1007/s11748-021-01710-5.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s11748-021-01710-5</ArticleId><ArticleId IdType=\"pmc\">PMC8881261</ArticleId><ArticleId IdType=\"pubmed\">34554366</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>\n",
            "XML saved to: path/to/save/xml/38066463.xml\n",
            "Details URL: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=38063366&retmode=xml&api_key=9edd38677707c08b2a96ed1a6e8c61c47408\n",
            "Details Response Content: <?xml version=\"1.0\" ?>\n",
            "<!DOCTYPE PubmedArticleSet PUBLIC \"-//NLM//DTD PubMedArticle, 1st January 2023//EN\" \"https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd\">\n",
            "<PubmedArticleSet>\n",
            "<PubmedArticle><MedlineCitation Status=\"Publisher\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38063366</PMID><DateRevised><Year>2023</Year><Month>12</Month><Day>08</Day></DateRevised><Article PubModel=\"Print-Electronic\"><Journal><ISSN IssnType=\"Electronic\">2045-7634</ISSN><JournalIssue CitedMedium=\"Internet\"><PubDate><Year>2023</Year><Month>Dec</Month><Day>08</Day></PubDate></JournalIssue><Title>Cancer medicine</Title><ISOAbbreviation>Cancer Med</ISOAbbreviation></Journal><ArticleTitle>COVID-19 in cancer patients: The impact of vaccination on outcomes early in the pandemic.</ArticleTitle><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.1002/cam4.6781</ELocationID><Abstract><AbstractText Label=\"BACKGROUND\" NlmCategory=\"BACKGROUND\">With the rapid evolution of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, the development of effective and safe vaccines was of utmost importance to protect vulnerable individuals, including cancer patients. Studies comparing the clinical outcomes of cancer patients with or without vaccination against coronavirus disease 2019 (COVID-19) have not demonstrated clear benefit. We aimed to determine the protective effects of COVID-19 vaccination by comparing vaccinated and unvaccinated cancer patients after the initial phase of vaccine roll-out and to identify risk factors associated with hospitalization, severe COVID-19, and 30-day COVID-19 attributable mortality.</AbstractText><AbstractText Label=\"METHODS\" NlmCategory=\"METHODS\">We performed a retrospective cohort study of cancer patients with COVID-19 diagnosed by polymerase chain reaction on nasal swabs between January 1, 2021 and July 30, 2021. Outcomes of interest included hospitalization, severe COVID-19, and 30-day COVID-19 attributable mortality. Univariate and multivariate analyses were performed to identify factors associated with clinical outcomes, using vaccination status as a variable of interest in all models.</AbstractText><AbstractText Label=\"RESULTS\" NlmCategory=\"RESULTS\">Key risk factors, such as age&#x2009;&#x2265;&#x2009;60&#x2009;years; comorbidities including diabetes mellitus, heart failure, and lung diseases; and specific cancer types (leukemia and lymphoma) were independently associated with hospital admission for COVID-19, severe COVID-19, and 30-day COVID-19 attributable mortality in cancer patients regardless of their vaccination status. Vaccinated patients were protected against severe COVID-19 but with no impact on hospitalization or mortality due to COVID-19.</AbstractText><AbstractText Label=\"CONCLUSION\" NlmCategory=\"CONCLUSIONS\">Our study highlights a significant benefit of COVID-19 vaccination for cancer patients-specifically its protection against severe COVID-19.</AbstractText><CopyrightInformation>&#xa9; 2023 The Authors. Cancer Medicine published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Khawaja</LastName><ForeName>Fareed</ForeName><Initials>F</Initials><Identifier Source=\"ORCID\">0000-0003-4424-283X</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Angelidakis</LastName><ForeName>Georgios</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Feldman</LastName><ForeName>Adina</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Ravi</LastName><ForeName>Vinod</ForeName><Initials>V</Initials><Identifier Source=\"ORCID\">0000-0001-6080-9336</Identifier><AffiliationInfo><Affiliation>Data-Driven Determinants for COVID-19 Oncology Discovery Effort (D3CODE) Team, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Sarcoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Woodman</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Data-Driven Determinants for COVID-19 Oncology Discovery Effort (D3CODE) Team, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genomic Medicine, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Bhatti</LastName><ForeName>Micah</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Ariza-Heredia</LastName><ForeName>Ella</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Elhajj</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Spallone</LastName><ForeName>Amy</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Jiang</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Chemaly</LastName><ForeName>Roy F</ForeName><Initials>RF</Initials><Identifier Source=\"ORCID\">0000-0002-0277-3088</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2023</Year><Month>12</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cancer Med</MedlineTA><NlmUniqueID>101595310</NlmUniqueID><ISSNLinking>2045-7634</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner=\"NOTNLM\"><Keyword MajorTopicYN=\"N\">COVID-19</Keyword><Keyword MajorTopicYN=\"N\">SARS-CoV-2</Keyword><Keyword MajorTopicYN=\"N\">cancer</Keyword><Keyword MajorTopicYN=\"N\">immunocompromised</Keyword><Keyword MajorTopicYN=\"N\">vaccination</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"revised\"><Year>2023</Year><Month>11</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus=\"received\"><Year>2023</Year><Month>9</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus=\"accepted\"><Year>2023</Year><Month>11</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus=\"medline\"><Year>2023</Year><Month>12</Month><Day>8</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2023</Year><Month>12</Month><Day>8</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2023</Year><Month>12</Month><Day>8</Day><Hour>8</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38063366</ArticleId><ArticleId IdType=\"doi\">10.1002/cam4.6781</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Frederiksen LSF, Zhang Y, Foged C, Thakur A. The long road toward COVID-19 herd immunity: vaccine platform technologies and mass immunization strategies. Front Immunol. 2020;11:1817.</Citation></Reference><Reference><Citation>Ledford H. US authorization of first COVID vaccine marks new phase in safety monitoring. Nature. 2020;588(7838):377-378.</Citation></Reference><Reference><Citation>Polack FP, Thomas SJ, Kitchin N, et&#xa0;al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603-2615.</Citation></Reference><Reference><Citation>Baden LR, El Sahly HM, Essink B, et&#xa0;al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403-416.</Citation></Reference><Reference><Citation>Romano E, Pascolo S, Ott P. Implications of mRNA-based SARS-CoV-2 vaccination for cancer patients. J Immunother Cancer. 2021;9(6):e002932.</Citation></Reference><Reference><Citation>Belsky JA, Tullius BP, Lamb MG, Sayegh R, Stanek JR, Auletta JJ. COVID-19 in immunocompromised patients: a systematic review of cancer, hematopoietic cell and solid organ transplant patients. J Infect. 2021;82(3):329-338.</Citation></Reference><Reference><Citation>R&#xfc;thrich MM, Giessen-Jung C, Borgmann S, et&#xa0;al. COVID-19 in cancer patients: clinical characteristics and outcome-an analysis of the LEOSS registry. Ann Hematol. 2021;100(2):383-393.</Citation></Reference><Reference><Citation>Kong X, Qi Y, Huang J, et&#xa0;al. Epidemiological and clinical characteristics of cancer patients with COVID-19: a systematic review and meta-analysis of global data. Cancer Lett. 2021;508:30-46.</Citation></Reference><Reference><Citation>Chavez-MacGregor M, Lei X, Zhao H, Scheet P, Giordano SH. Evaluation of COVID-19 mortality and adverse outcomes in US patients with or without cancer. JAMA Oncol. 2022;8(1):69-78.</Citation></Reference><Reference><Citation>Wu JT, La J, Branch-Elliman W, et&#xa0;al. Association of COVID-19 vaccination with SARS-CoV-2 infection in patients with cancer: a US Nationwide veterans affairs study. JAMA Oncol. 2022;8(2):281-286.</Citation></Reference><Reference><Citation>Lee LYW, Starkey T, Ionescu MC, et&#xa0;al. Vaccine effectiveness against COVID-19 breakthrough infections in patients with cancer (UKCCEP): a population-based test-negative case-control study. Lancet Oncol. 2022;23(6):748-757.</Citation></Reference><Reference><Citation>Wang W, Kaelber DC, Xu R, Berger NA. Breakthrough SARS-CoV-2 infections, hospitalizations, and mortality in vaccinated patients with cancer in the US between December 2020 and November 2021. JAMA Oncol. 2022;8(7):1027-1034.</Citation></Reference><Reference><Citation>Sharafeldin N, Bates B, Song Q, et&#xa0;al. Outcomes of COVID-19 in patients with cancer: report from the national COVID cohort collaborative (N3C). J Clin Oncol. 2021;39(20):2232-2246.</Citation></Reference><Reference><Citation>Wang L, Wang W, Xu R, Berger NA. SARS-CoV-2 primary and breakthrough infections in patients with cancer: implications for patient care. Best Pract Res Clin Haematol. 2022;35(3):101384.</Citation></Reference><Reference><Citation>Blanchette PS, Chung H, Pritchard KI, et&#xa0;al. Influenza vaccine effectiveness among patients with cancer: a population-based study using health administrative and laboratory testing data from Ontario. Canada J Clin Oncol. 2019;37(30):2795-2804.</Citation></Reference><Reference><Citation>Schmidt AL, Labaki C, Hsu CY, et&#xa0;al. COVID-19 vaccination and breakthrough infections in patients with cancer. Ann Oncol. 2022;33(3):340-346.</Citation></Reference><Reference><Citation>Fendler A, de Vries EGE, GeurtsvanKessel CH, et&#xa0;al. COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety. Nat Rev Clin Oncol. 2022;19(6):385-401.</Citation></Reference><Reference><Citation>Grinshpun A, Rottenberg Y, Ben-Dov IZ, Djian E, Wolf DG, Kadouri L. Serologic response to COVID-19 infection and/or vaccine in cancer patients on active treatment. ESMO Open. 2021;6(6):100283.</Citation></Reference><Reference><Citation>Maneikis K, &#x160;ablauskas K, Ringelevi&#x10d;i&#x16b;t&#x117; U, et&#xa0;al. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study. Lancet Haematol. 2021;8(8):e583-e592.</Citation></Reference><Reference><Citation>Khoury J, Najjar-Debbiny R, Hanna A, et&#xa0;al. COVID-19 vaccine-long term immune decline and breakthrough infections. Vaccine. 2021;39(48):6984-6989.</Citation></Reference><Reference><Citation>Sun J, Zheng Q, Madhira V, et&#xa0;al. Association between immune dysfunction and COVID-19 breakthrough infection after SARS-CoV-2 vaccination in the US. JAMA Intern Med. 2022;182(2):153-162.</Citation></Reference><Reference><Citation>Lee CM, Lee E, Park WB, et&#xa0;al. Breakthrough COVID-19 infection during the Delta variant dominant period: individualized care based on vaccination status is needed. J Korean Med Sci. 2022;37(32):e252.</Citation></Reference><Reference><Citation>Wang L, Kaelber DC, Xu R, Berger NA. COVID-19 breakthrough infections, hospitalizations and mortality in fully vaccinated patients with hematologic malignancies: a clarion call for maintaining mitigation and ramping-up research. Blood Rev. 2022;54:100931.</Citation></Reference><Reference><Citation>Song Q, Bates B, Shao YR, et&#xa0;al. Risk and outcome of breakthrough COVID-19 infections in vaccinated patients with cancer: real-world evidence from the national COVID cohort collaborative. J Clin Oncol. 2022;40(13):1414-1427.</Citation></Reference><Reference><Citation>Becerril-Gaitan A, Vaca-Cartagena BF, Ferrigno AS, et&#xa0;al. Immunogenicity and risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection after coronavirus disease 2019 (COVID-19) vaccination in patients with cancer: a systematic review and meta-analysis. Eur J Cancer. 2022;160:243-260.</Citation></Reference><Reference><Citation>Ehmsen S, Asmussen A, Jeppesen SS, et&#xa0;al. Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer. Cancer Cell. 2021;39(8):1034-1036.</Citation></Reference><Reference><Citation>Di Fusco M, Moran MM, Cane A, et&#xa0;al. Evaluation of COVID-19 vaccine breakthrough infections among immunocompromised patients fully vaccinated with BNT162b2. J Med Econ. 2021;24(1):1248-1260.</Citation></Reference><Reference><Citation>Yetmar ZA, Bhaimia E, Bierle DM, Ganesh R, Razonable RR. Breakthrough COVID-19 after SARS-CoV-2 vaccination in solid organ transplant recipients: an analysis of symptomatic cases and monoclonal antibody therapy. Transpl Infect Dis. 2022;24(2):e13779.</Citation></Reference><Reference><Citation>Clinical Spectrum of SARS-CoV-2 Infection. https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/</Citation></Reference><Reference><Citation>Kothari AN, DiBrito SR, Lee JJ, et&#xa0;al. Surgical outcomes in cancer patients undergoing elective surgery after recovering from mild-to-moderate SARS-CoV-2 infection. Ann Surg Oncol. 2021;28(13):8046-8053.</Citation></Reference><Reference><Citation>Antonelli M, Penfold RS, Merino J, et&#xa0;al. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID symptom study app: a prospective, community-based, nested, case-control study. Lancet Infect Dis. 2022;22(1):43-55.</Citation></Reference><Reference><Citation>Vo AD, La J, Wu JT, et&#xa0;al. Factors associated with severe COVID-19 among vaccinated adults treated in US veterans affairs hospitals. JAMA Netw Open. 2022;5(10):e2240037.</Citation></Reference><Reference><Citation>Brosh-Nissimov T, Orenbuch-Harroch E, Chowers M, et&#xa0;al. BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel. Clin Microbiol Infect. 2021;27(11):1652-1657.</Citation></Reference><Reference><Citation>Bergwerk M, Gonen T, Lustig Y, et&#xa0;al. Covid-19 breakthrough infections in vaccinated health care workers. N Engl J Med. 2021;385(16):1474-1484.</Citation></Reference><Reference><Citation>Juthani PV, Gupta A, Borges KA, et&#xa0;al. Hospitalisation among vaccine breakthrough COVID-19 infections. Lancet Infect Dis. 2021;21(11):1485-1486.</Citation></Reference><Reference><Citation>Hippisley-Cox J, Coupland CA, Mehta N, et&#xa0;al. Risk prediction of covid-19 related death and hospital admission in adults after COVID-19 vaccination: national prospective cohort study. BMJ. 2021;374:n2244.</Citation></Reference><Reference><Citation>Kustin T, Harel N, Finkel U, et&#xa0;al. Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals. Nat Med. 2021;27(8):1379-1384.</Citation></Reference><Reference><Citation>Rajan S, Akhtar N, Sharma S, Chakrabarti D, Kumar V. COVID-19 vaccination for cancer patients: evidence, priority, and practice. Vaccine. 2021;39(36):5075-5077.</Citation></Reference><Reference><Citation>Lasagna A, Agustoni F, Percivalle E, et&#xa0;al. A snapshot of the immunogenicity, efficacy and safety of a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors: a longitudinal cohort study. ESMO Open. 2021;6(5):100272.</Citation></Reference><Reference><Citation>Ollila TA, Masel RH, Reagan JL, et&#xa0;al. Seroconversion and outcomes after initial and booster COVID-19 vaccination in adults with hematologic malignancies. Cancer. 2022;128(18):3319-3329.</Citation></Reference><Reference><Citation>Fendler A, Shepherd STC, Au L, et&#xa0;al. Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study. Nat Cancer. 2021;2:1321-1337.</Citation></Reference><Reference><Citation>Christensen PA, Olsen RJ, Long SW, et&#xa0;al. Delta variants of SARS-CoV-2 cause significantly increased vaccine breakthrough COVID-19 cases in Houston. Texas Am J Pathol. 2022;192(2):320-331.</Citation></Reference><Reference><Citation>Olsen RJ, Christensen PA, Long SW, et&#xa0;al. Trajectory of growth of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants in Houston, Texas, January through May 2021, based on 12,476 genome sequences. Am J Pathol. 2021;191(10):1754-1773.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>\n",
            "XML saved to: path/to/save/xml/38063366.xml\n",
            "Details URL: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=38063017&retmode=xml&api_key=9edd38677707c08b2a96ed1a6e8c61c47408\n",
            "Details Response Content: <?xml version=\"1.0\" ?>\n",
            "<!DOCTYPE PubmedArticleSet PUBLIC \"-//NLM//DTD PubMedArticle, 1st January 2023//EN\" \"https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd\">\n",
            "<PubmedArticleSet>\n",
            "<PubmedArticle><MedlineCitation Status=\"Publisher\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38063017</PMID><DateRevised><Year>2023</Year><Month>12</Month><Day>08</Day></DateRevised><Article PubModel=\"Print-Electronic\"><Journal><ISSN IssnType=\"Electronic\">1524-4628</ISSN><JournalIssue CitedMedium=\"Internet\"><PubDate><Year>2023</Year><Month>Dec</Month><Day>08</Day></PubDate></JournalIssue><Title>Stroke</Title><ISOAbbreviation>Stroke</ISOAbbreviation></Journal><ArticleTitle>Ischemic Stroke Temporally Associated With New-Onset Atrial Fibrillation: A Population-Based Registry-Linkage Study.</ArticleTitle><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.1161/STROKEAHA.123.044448</ELocationID><Abstract><AbstractText Label=\"BACKGROUND\" NlmCategory=\"UNASSIGNED\">Limited data exist on the temporal relationship between new-onset atrial fibrillation (AF) and ischemic stroke and its impact on patients' clinical characteristics and mortality.</AbstractText><AbstractText Label=\"METHODS\" NlmCategory=\"UNASSIGNED\">A population-based registry-linkage database includes all patients with new-onset AF in Finland from 2007 to 2018. Ischemic stroke temporally associated with AF (ISTAF) was defined as an ischemic stroke occurring within &#xb1;30 days from the first AF diagnosis. Clinical factors associated with ISTAF were studied with logistic regression and 90-day survival with Cox proportional hazards analysis.</AbstractText><AbstractText Label=\"RESULTS\" NlmCategory=\"UNASSIGNED\">Among 229&#x2005;565 patients with new-onset AF (mean age, 72.7 years; 50% female), 204&#x2005;774 (89.2%) experienced no ischemic stroke, 12&#x2005;209 (5.3%) had past ischemic stroke &gt;30 days before AF, and 12&#x2005;582 (5.8%) had ISTAF. The annual proportion of ISTAF among patients with AF decreased from 6.0% to 4.8% from 2007 to 2018. Factors associated positively with ISTAF were higher age, lower education level, and alcohol use disorder, whereas vascular disease, heart failure, chronic kidney disease cancer, and psychiatric disorders were less probable with ISTAF. Compared with patients without ischemic stroke and those with past ischemic stroke, ISTAF was associated with &#x2248;3-fold and 1.5-fold risks of death (adjusted hazard ratios, 2.90 [95% CI, 2.76-3.04] and 1.47 [95% CI, 1.39-1.57], respectively). The 90-day survival probability of patients with ISTAF increased from 0.79 (95% CI, 0.76-0.81) in 2007 to 0.89 (95% CI, 0.87-0.91) in 2018.</AbstractText><AbstractText Label=\"CONCLUSIONS\" NlmCategory=\"UNASSIGNED\">ISTAF depicts the prominent temporal clustering of ischemic strokes surrounding AF diagnosis. Despite having fewer comorbidities, patients with ISTAF had worse, albeit improving, survival than patients with a history of or no ischemic stroke.</AbstractText><AbstractText Label=\"REGISTRATION\" NlmCategory=\"UNASSIGNED\">URL: https://www.clinicaltrials.gov; Unique identifier: NCT04645537. URL: https://www.encepp.eu; Unique identifier: EUPAS29845.</AbstractText></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Putaala</LastName><ForeName>Jukka</ForeName><Initials>J</Initials><Identifier Source=\"ORCID\">0000-0002-6630-6104</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Helsinki University Hospital and University of Helsinki, Finland. (J.P., P.T., J.K.).</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Teppo</LastName><ForeName>Konsta</ForeName><Initials>K</Initials><Identifier Source=\"ORCID\">0000-0002-4460-0994</Identifier><AffiliationInfo><Affiliation>Heart Center, Turku University Hospital and University of Turku, Finland (K.T., J.J., P.M., T.K., K.E.J.A.).</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Halminen</LastName><ForeName>Olli</ForeName><Initials>O</Initials><Identifier Source=\"ORCID\">0000-0001-9266-8435</Identifier><AffiliationInfo><Affiliation>Department of Industrial Engineering and Management, Aalto University, Espoo, Finland (O.H., M. Linna).</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Haukka</LastName><ForeName>Jari</ForeName><Initials>J</Initials><Identifier Source=\"ORCID\">0000-0003-1450-6208</Identifier><AffiliationInfo><Affiliation>Department of Public Health, University of Helsinki, Finland (J. Haukka).</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Tiili</LastName><ForeName>Paula</ForeName><Initials>P</Initials><Identifier Source=\"ORCID\">0000-0002-7916-7262</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Helsinki University Hospital and University of Helsinki, Finland. (J.P., P.T., J.K.).</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Jaakkola</LastName><ForeName>Jussi</ForeName><Initials>J</Initials><Identifier Source=\"ORCID\">0000-0002-3398-4283</Identifier><AffiliationInfo><Affiliation>Heart Center, Turku University Hospital and University of Turku, Finland (K.T., J.J., P.M., T.K., K.E.J.A.).</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Karlsson</LastName><ForeName>Elin</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>University of Helsinki, Finland (E.K., M. Lehto).</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Linna</LastName><ForeName>Miika</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Industrial Engineering and Management, Aalto University, Espoo, Finland (O.H., M. Linna).</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Mustonen</LastName><ForeName>Pirjo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Heart Center, Turku University Hospital and University of Turku, Finland (K.T., J.J., P.M., T.K., K.E.J.A.).</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Kinnunen</LastName><ForeName>Janne</ForeName><Initials>J</Initials><Identifier Source=\"ORCID\">0000-0002-0592-3184</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Helsinki University Hospital and University of Helsinki, Finland. (J.P., P.T., J.K.).</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Kiviniemi</LastName><ForeName>Tuomas</ForeName><Initials>T</Initials><Identifier Source=\"ORCID\">0000-0002-0908-3741</Identifier><AffiliationInfo><Affiliation>Heart Center, Turku University Hospital and University of Turku, Finland (K.T., J.J., P.M., T.K., K.E.J.A.).</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Aro</LastName><ForeName>Aapo</ForeName><Initials>A</Initials><Identifier Source=\"ORCID\">0000-0001-7030-6740</Identifier><AffiliationInfo><Affiliation>Heart and Lung Center, Helsinki University Hospital and University of Helsinki, Finland. (A.A.).</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Hartikainen</LastName><ForeName>Juha</ForeName><Initials>J</Initials><Identifier Source=\"ORCID\">0000-0003-0847-107X</Identifier><AffiliationInfo><Affiliation>Heart Center, Kuopio University Hospital and University of Eastern Finland, Finland (J. Hartikainen).</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Airaksinen</LastName><ForeName>Juhani K E</ForeName><Initials>JKE</Initials><AffiliationInfo><Affiliation>Heart Center, Turku University Hospital and University of Turku, Finland (K.T., J.J., P.M., T.K., K.E.J.A.).</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Lehto</LastName><ForeName>Mika</ForeName><Initials>M</Initials><Identifier Source=\"ORCID\">0000-0002-8691-5142</Identifier><AffiliationInfo><Affiliation>University of Helsinki, Finland (E.K., M. Lehto).</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, Jorvi Hospital and Helsinki University Hospital, Espoo, Finland (M. Lehto).</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><CollectiveName>FinACAF Study Group</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN=\"Y\"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT04645537</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2023</Year><Month>12</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Stroke</MedlineTA><NlmUniqueID>0235266</NlmUniqueID><ISSNLinking>0039-2499</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner=\"NOTNLM\"><Keyword MajorTopicYN=\"N\">atrial fibrillation</Keyword><Keyword MajorTopicYN=\"N\">humans</Keyword><Keyword MajorTopicYN=\"N\">intracranial embolism</Keyword><Keyword MajorTopicYN=\"N\">ischemic stroke</Keyword><Keyword MajorTopicYN=\"N\">retrospective studies</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"medline\"><Year>2023</Year><Month>12</Month><Day>8</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2023</Year><Month>12</Month><Day>8</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2023</Year><Month>12</Month><Day>8</Day><Hour>5</Hour><Minute>26</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38063017</ArticleId><ArticleId IdType=\"doi\">10.1161/STROKEAHA.123.044448</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>\n",
            "XML saved to: path/to/save/xml/38063017.xml\n",
            "Details URL: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=38056855&retmode=xml&api_key=9edd38677707c08b2a96ed1a6e8c61c47408\n",
            "Details Response Content: <?xml version=\"1.0\" ?>\n",
            "<!DOCTYPE PubmedArticleSet PUBLIC \"-//NLM//DTD PubMedArticle, 1st January 2023//EN\" \"https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd\">\n",
            "<PubmedArticleSet>\n",
            "<PubmedArticle><MedlineCitation Status=\"MEDLINE\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38056855</PMID><DateCompleted><Year>2023</Year><Month>12</Month><Day>11</Day></DateCompleted><DateRevised><Year>2023</Year><Month>12</Month><Day>11</Day></DateRevised><Article PubModel=\"Print\"><Journal><ISSN IssnType=\"Print\">0021-5252</ISSN><JournalIssue CitedMedium=\"Print\"><Volume>76</Volume><Issue>10</Issue><PubDate><Year>2023</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Kyobu geka. The Japanese journal of thoracic surgery</Title><ISOAbbreviation>Kyobu Geka</ISOAbbreviation></Journal><ArticleTitle>[Perioperative Rehabolotation Usefulness in Preventing Complications].</ArticleTitle><Pagination><StartPage>878</StartPage><EndPage>882</EndPage><MedlinePgn>878-882</MedlinePgn></Pagination><Abstract><AbstractText>The number of elderly patients in thoracic surgery is increasing. The percentage of patients over the age of 80 in surgical cases of malignant diseases such as lung cancer and mediastinal tumors is increasing every year. It is also true that the indications for surgery have been expanding as surgery itself has become less invasive, such as thoracoscopic and robotic surgery. However, it is not uncommon for patients over 80 years of age to have some organ dysfunction and many comorbidities. Therefore, when performing surgery for lung cancer and other diseases, it is important to assess the patient's ability to tolerate surgery, including respiratory and cardiac functions, and to perform risk management. To prevent postoperative complications and improve the accuracy of perioperative management, respiratory rehabilitation should be conducted before and after surgery, and not only smoking cessation instruction but also inhalation training using incentive spirometry( IS), breathing exercises, and the use of inhalers such as long-acting &#x3b2;2 agonist (LABA)/long-acting muscaring antagonist (LAMA) for patients with chronic obstructive pulmonary disease( COPD) are useful.</AbstractText></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Usuda</LastName><ForeName>Jitsuo</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Thoracic Surgery, Nippon Medical School, Tokyo, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>jpn</Language><PublicationTypeList><PublicationType UI=\"D004740\">English Abstract</PublicationType><PublicationType UI=\"D016428\">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>Kyobu Geka</MedlineTA><NlmUniqueID>0413533</NlmUniqueID><ISSNLinking>0021-5252</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI=\"D018727\">Muscarinic Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI=\"D058666\">Adrenergic beta-2 Receptor Agonists</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI=\"D006801\" MajorTopicYN=\"N\">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D000369\" MajorTopicYN=\"N\">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D000368\" MajorTopicYN=\"N\">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D018727\" MajorTopicYN=\"N\">Muscarinic Antagonists</DescriptorName><QualifierName UI=\"Q000627\" MajorTopicYN=\"N\">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D058666\" MajorTopicYN=\"N\">Adrenergic beta-2 Receptor Agonists</DescriptorName><QualifierName UI=\"Q000627\" MajorTopicYN=\"N\">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D000280\" MajorTopicYN=\"N\">Administration, Inhalation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D012138\" MajorTopicYN=\"N\">Respiratory Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D029424\" MajorTopicYN=\"Y\">Pulmonary Disease, Chronic Obstructive</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D008175\" MajorTopicYN=\"Y\">Lung Neoplasms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D004359\" MajorTopicYN=\"N\">Drug Therapy, Combination</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"medline\"><Year>2023</Year><Month>12</Month><Day>11</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2023</Year><Month>12</Month><Day>7</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2023</Year><Month>12</Month><Day>6</Day><Hour>20</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38056855</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>\n",
            "XML saved to: path/to/save/xml/38056855.xml\n",
            "Details URL: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=38056852&retmode=xml&api_key=9edd38677707c08b2a96ed1a6e8c61c47408\n",
            "Details Response Content: <?xml version=\"1.0\" ?>\n",
            "<!DOCTYPE PubmedArticleSet PUBLIC \"-//NLM//DTD PubMedArticle, 1st January 2023//EN\" \"https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd\">\n",
            "<PubmedArticleSet>\n",
            "<PubmedArticle><MedlineCitation Status=\"MEDLINE\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38056852</PMID><DateCompleted><Year>2023</Year><Month>12</Month><Day>11</Day></DateCompleted><DateRevised><Year>2023</Year><Month>12</Month><Day>11</Day></DateRevised><Article PubModel=\"Print\"><Journal><ISSN IssnType=\"Print\">0021-5252</ISSN><JournalIssue CitedMedium=\"Print\"><Volume>76</Volume><Issue>10</Issue><PubDate><Year>2023</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Kyobu geka. The Japanese journal of thoracic surgery</Title><ISOAbbreviation>Kyobu Geka</ISOAbbreviation></Journal><ArticleTitle>[Risk Factors, Prevention, Diagnosis, and Treatment of Bronchopleural Fistula After Lung Resection].</ArticleTitle><Pagination><StartPage>865</StartPage><EndPage>869</EndPage><MedlinePgn>865-869</MedlinePgn></Pagination><Abstract><AbstractText>Postoperative bronchopleural fistula (BPF) is a rare but severe and sometimes life-threatening complication that needs immediate and proper treatment. Thoracic surgeons should strictly manage the comorbidities such as diabetes mellitus for BPF prevention. Also, coverage of the bronchial stump with pericardial fat tissue will prevent BPF, or at least prevent the turning severe of BPF. However, when BPF occurs, we must promptly determine whether to perform conservative treatment or invasive treatment such as fenestration.</AbstractText></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Suzuki</LastName><ForeName>Makoto</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Thoracic Surgery and Breast Surgery, Kumamoto University, Kumamoto, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>jpn</Language><PublicationTypeList><PublicationType UI=\"D004740\">English Abstract</PublicationType><PublicationType UI=\"D016428\">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>Kyobu Geka</MedlineTA><NlmUniqueID>0413533</NlmUniqueID><ISSNLinking>0021-5252</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI=\"D006801\" MajorTopicYN=\"N\">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D011013\" MajorTopicYN=\"N\">Pneumonectomy</DescriptorName><QualifierName UI=\"Q000009\" MajorTopicYN=\"N\">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D001983\" MajorTopicYN=\"Y\">Bronchial Fistula</DescriptorName><QualifierName UI=\"Q000209\" MajorTopicYN=\"N\">etiology</QualifierName><QualifierName UI=\"Q000517\" MajorTopicYN=\"N\">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D010995\" MajorTopicYN=\"Y\">Pleural Diseases</DescriptorName><QualifierName UI=\"Q000175\" MajorTopicYN=\"N\">diagnosis</QualifierName><QualifierName UI=\"Q000209\" MajorTopicYN=\"N\">etiology</QualifierName><QualifierName UI=\"Q000517\" MajorTopicYN=\"N\">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D012307\" MajorTopicYN=\"N\">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D011183\" MajorTopicYN=\"N\">Postoperative Complications</DescriptorName><QualifierName UI=\"Q000517\" MajorTopicYN=\"N\">prevention &amp; control</QualifierName><QualifierName UI=\"Q000209\" MajorTopicYN=\"N\">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D008168\" MajorTopicYN=\"N\">Lung</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D008175\" MajorTopicYN=\"Y\">Lung Neoplasms</DescriptorName><QualifierName UI=\"Q000601\" MajorTopicYN=\"N\">surgery</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"medline\"><Year>2023</Year><Month>12</Month><Day>11</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2023</Year><Month>12</Month><Day>7</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2023</Year><Month>12</Month><Day>6</Day><Hour>20</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38056852</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>\n",
            "XML saved to: path/to/save/xml/38056852.xml\n",
            "Details URL: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=38037323&retmode=xml&api_key=9edd38677707c08b2a96ed1a6e8c61c47408\n",
            "Details Response Content: <?xml version=\"1.0\" ?>\n",
            "<!DOCTYPE PubmedArticleSet PUBLIC \"-//NLM//DTD PubMedArticle, 1st January 2023//EN\" \"https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd\">\n",
            "<PubmedArticleSet>\n",
            "<PubmedArticle><MedlineCitation Status=\"Publisher\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38037323</PMID><DateRevised><Year>2023</Year><Month>12</Month><Day>01</Day></DateRevised><Article PubModel=\"Print-Electronic\"><Journal><ISSN IssnType=\"Electronic\">2092-7193</ISSN><JournalIssue CitedMedium=\"Internet\"><PubDate><Year>2023</Year><Month>Nov</Month><Day>21</Day></PubDate></JournalIssue><Title>Epidemiology and health</Title><ISOAbbreviation>Epidemiol Health</ISOAbbreviation></Journal><ArticleTitle>Risk factors for early-onset lung cancer in Korea: analysis of a nationally representative population-based cohort.</ArticleTitle><Pagination><StartPage>e2023101</StartPage><MedlinePgn>e2023101</MedlinePgn></Pagination><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.4178/epih.e2023101</ELocationID><Abstract><AbstractText Label=\"OBJECTIVES\" NlmCategory=\"UNASSIGNED\">We examined the associations of socioeconomic factors, health behaviors, and comorbidities with early-onset lung cancer.</AbstractText><AbstractText Label=\"METHODS\" NlmCategory=\"UNASSIGNED\">The study included 6,794,287 individuals aged 20-39 years who participated in a Korean national health check-up program from 2009 to 2012. During the follow-up period, 4,684 participants developed lung cancer. Multivariable Cox regression analysis was used to estimate the independent associations of potential risk factors with incident lung cancer.</AbstractText><AbstractText Label=\"RESULTS\" NlmCategory=\"UNASSIGNED\">Older age (multivariable hazard ratio [mHR], 1.13; 95% confidence interval [CI], 1.12 to 1.14) and female sex (mHR, 1.62; 95% CI, 1.49 to 1.75) were associated with increased lung cancer risk. Current smoking was also associated with elevated risk (&lt;10 pack-years: mHR, 1.12; 95% CI, 1.01 to 1.24; &#x2265;10 pack-years: mHR, 1.30; 95% CI, 1.18 to 1.45), but past smoking was not. Although mild alcohol consumption (&lt;10 g/day) was associated with lower lung cancer risk (mHR, 0.92; 95% CI, 0.86 to 0.99), heavier alcohol consumption (&#x2265;10 g/day) was not. Higher income (highest vs. lowest quartile: mHR, 0.86; 95% CI, 0.78 to 0.94), physical activity for at least 1500 metabolic equivalent of task-minutes/week (vs. non-exercisers: mHR, 0.83; 95% CI, 0.69 to 0.99) and obesity (vs. normal weight: mHR, 0.89; 95% CI, 0.83 to 0.96) were associated with lower lung cancer risk, whereas metabolic syndrome was associated with increased risk (mHR, 1.13; 95% CI, 1.03 to 1.24).</AbstractText><AbstractText Label=\"CONCLUSION\" NlmCategory=\"UNASSIGNED\">In young adults, age, female sex, smoking, and metabolic syndrome were risk factors for early-onset lung cancer, while high income, physical activity, and obesity displayed protective effects.</AbstractText></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Kang</LastName><ForeName>Jihun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Family Medicine, Kosin University Gospel Hospital, Kosin University College of Medicine, Busan, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Kim</LastName><ForeName>Taeyun</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Pulmonology, Department of Internal Medicine, The Armed Forces Goyang Hospital, , Goyang-si, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Han</LastName><ForeName>Kyung-Do</ForeName><Initials>KD</Initials><AffiliationInfo><Affiliation>Department of Statistics and Actuarial Science, Soongsil University, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Jung</LastName><ForeName>Jin-Hyung</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Medical Statistics, College of Medicine, Catholic University of Korea, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Jeong</LastName><ForeName>Su-Min</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Samsung medical center, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Yeo</LastName><ForeName>Yo Hwan</ForeName><Initials>YH</Initials><AffiliationInfo><Affiliation>Department of Family Medicine, Hallym University Sacred Heart Hospital, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Jung</LastName><ForeName>Kyuwon</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>The Korea Central Cancer Registry, Division of Cancer Registration and Surveillance, National Cancer Center, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Lee</LastName><ForeName>Hyun</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Cho</LastName><ForeName>Jong Ho</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Sungkyunkwan University, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Shin</LastName><ForeName>Dong Wook</ForeName><Initials>DW</Initials><AffiliationInfo><Affiliation>Sungkyunkwan University, Seoul, Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2023</Year><Month>11</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Korea (South)</Country><MedlineTA>Epidemiol Health</MedlineTA><NlmUniqueID>101519472</NlmUniqueID><ISSNLinking>2092-7193</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner=\"NOTNLM\"><Keyword MajorTopicYN=\"N\">Early-onset Risk factors</Keyword><Keyword MajorTopicYN=\"N\">Health behavior</Keyword><Keyword MajorTopicYN=\"N\">Korea</Keyword><Keyword MajorTopicYN=\"N\">Lung cancer</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"received\"><Year>2023</Year><Month>5</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus=\"accepted\"><Year>2023</Year><Month>11</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus=\"medline\"><Year>2023</Year><Month>12</Month><Day>1</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2023</Year><Month>12</Month><Day>1</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2023</Year><Month>12</Month><Day>1</Day><Hour>1</Hour><Minute>29</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38037323</ArticleId><ArticleId IdType=\"doi\">10.4178/epih.e2023101</ArticleId><ArticleId IdType=\"pii\">epih.e2023101</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>\n",
            "XML saved to: path/to/save/xml/38037323.xml\n",
            "Details URL: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=38029831&retmode=xml&api_key=9edd38677707c08b2a96ed1a6e8c61c47408\n",
            "Details Response Content: <?xml version=\"1.0\" ?>\n",
            "<!DOCTYPE PubmedArticleSet PUBLIC \"-//NLM//DTD PubMedArticle, 1st January 2023//EN\" \"https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd\">\n",
            "<PubmedArticleSet>\n",
            "<PubmedArticle><MedlineCitation Status=\"Publisher\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38029831</PMID><DateRevised><Year>2023</Year><Month>12</Month><Day>14</Day></DateRevised><Article PubModel=\"Print-Electronic\"><Journal><ISSN IssnType=\"Electronic\">1878-3511</ISSN><JournalIssue CitedMedium=\"Internet\"><Volume>139</Volume><PubDate><Year>2023</Year><Month>Nov</Month><Day>27</Day></PubDate></JournalIssue><Title>International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases</Title><ISOAbbreviation>Int J Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Previous immune checkpoint inhibitor therapy is associated with decreased COVID-19-related hospitalizations and complications in patients with cancer: Results of a propensity-matched analysis of the OnCovid registry.</ArticleTitle><Pagination><StartPage>13</StartPage><EndPage>20</EndPage><MedlinePgn>13-20</MedlinePgn></Pagination><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.1016/j.ijid.2023.11.021</ELocationID><ELocationID EIdType=\"pii\" ValidYN=\"Y\">S1201-9712(23)00782-8</ELocationID><Abstract><AbstractText Label=\"OBJECTIVES\" NlmCategory=\"OBJECTIVE\">To date, studies have not provided definitive answers regarding whether previous immune checkpoint inhibitor (ICI) treatment alters outcomes for cancer patients with COVID-19.</AbstractText><AbstractText Label=\"METHODS\" NlmCategory=\"METHODS\">The OnCovid registry (NCT04393974) was searched from February 27, 2020, to January 31, 2022, for patients who received systemic anti-cancer therapy in the 4 weeks before laboratory-confirmed COVID-19 diagnosis. Propensity-score matching using country, vaccination status, primary tumor type, sex, age, comorbidity burden, tumor stage, and remission status investigated differences in predefined clinical outcomes comparing those who had or had not received ICIs.</AbstractText><AbstractText Label=\"RESULTS\" NlmCategory=\"RESULTS\">Of 3523 patients screened, 137 ICI-only and 1378 non-ICI met inclusion criteria. Before matching, ICI patients were older, male, enrolled at centers in Italy, and had histories of smoking, thoracic cancers, advanced cancer stages, and active malignancies (P &#x2264;0.02). After matching, there were 120 ICI and 322 non-ICI patients. ICI patients had no differences (odds ratio: 95% CI) in presenting COVID-19 symptoms (0.69: 0.37-1.28), receipt of COVID-specific therapy (0.88: 0.54-1.41), 14-day (0.95: 0.56-1.61), or 28-day (0.79: 0.48-1.29) mortalities. However, ICI patients required less COVID-19-related hospitalization (0.37: 0.21-0.67) and oxygen therapy (0.51: 0.31-0.83) and developed fewer complications (0.57: 0.36-0.92).</AbstractText><AbstractText Label=\"CONCLUSION\" NlmCategory=\"CONCLUSIONS\">In this propensity-score matched analysis, previous ICI therapy did not worsen and potentially improved COVID-19 outcomes in patients with cancer.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Mostaghim</LastName><ForeName>Anahita</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Critical Care Medicine Department, National Institutes of Health Clinical Center, Bethesda, USA; Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Minkove</LastName><ForeName>Samuel</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Critical Care Medicine Department, National Institutes of Health Clinical Center, Bethesda, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Aguilar-Company</LastName><ForeName>Juan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Medical Oncology, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain; Infectious Diseases, Vall d'Hebron University Hospital, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Ruiz-Camps</LastName><ForeName>Isabel</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Medical Oncology, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain; Infectious Diseases, Vall d'Hebron University Hospital, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Eremiev-Eremiev</LastName><ForeName>Simeon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Medical Oncology, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain; Infectious Diseases, Vall d'Hebron University Hospital, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Dettorre</LastName><ForeName>Gino M</ForeName><Initials>GM</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Washington University School of Medicine, St. Louis, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Fox</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Hematology, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Tondini</LastName><ForeName>Carlo</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Oncology Unit, ASST Papa Giovanni XXIII, Bergamo, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Brunet</LastName><ForeName>Joan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Catalan Institute of Oncology, University Hospital Josep Trueta, Girona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Carmona-Garc&#xed;a</LastName><ForeName>MCarmen</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Catalan Institute of Oncology, University Hospital Josep Trueta, Girona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Lambertini</LastName><ForeName>Matteo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Medical Oncology Department, U.O. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, Italy; Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genova, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Bower</LastName><ForeName>Mark</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Oncology and National Centre for HIV Malignancy, Chelsea and Westminster Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Newsom-Davis</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Oncology and National Centre for HIV Malignancy, Chelsea and Westminster Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Sharkey</LastName><ForeName>Rachel</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Oncology and National Centre for HIV Malignancy, Chelsea and Westminster Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Pria</LastName><ForeName>Alessia Dalla</ForeName><Initials>AD</Initials><AffiliationInfo><Affiliation>Department of Oncology and National Centre for HIV Malignancy, Chelsea and Westminster Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Rossi</LastName><ForeName>Maura</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Oncology Unit, Azienda Ospedaliera \"SS Antonio e Biagio e Cesare Arrigo\", Alessandria, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Plaja</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Medical Oncology Department, B-ARGO Group, IGTP, Catalan Institute of Oncology-Badalona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Salazar</LastName><ForeName>Ramon</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, ICO L'Hospitalet, Oncobell Program (IDIBELL), CIBERONC, Hospitalet de Llobregat, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Sureda</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Haematology Department, ICO Hospitalet, Hospitalet de Llobregat, IDIBELL, Universitat de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Prat</LastName><ForeName>Aleix</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Hospital Clinic, Barcelona, Spain; Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Michalarea</LastName><ForeName>Vasiliki</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Medical Oncology, Guy's and St Thomas' NHS Foundation Trust (GSTT), London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Van Hemelrijck</LastName><ForeName>Mieke</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Medical Oncology, Guy's and St Thomas' NHS Foundation Trust (GSTT), London, UK; Translational Oncology and Urology Research (TOUR), School of Cancer and Pharmaceutical Sciences, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Sita-Lumsden</LastName><ForeName>Ailsa</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Medical Oncology, Guy's and St Thomas' NHS Foundation Trust (GSTT), London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Bertuzzi</LastName><ForeName>Alexia</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Medical Oncology and Hematology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Rimassa</LastName><ForeName>Lorenza</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Medical Oncology and Hematology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Milan, Italy; Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Rossi</LastName><ForeName>Sabrina</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Medical Oncology and Hematology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Rizzo</LastName><ForeName>Gianpiero</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Medical Oncology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Pedrazzoli</LastName><ForeName>Paolo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Medical Oncology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; Department of Internal Medicine and Medical Therapy, University of Pavia, Pavia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Lee</LastName><ForeName>Alvin Jx</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Cancer Division, University College London Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Murphy</LastName><ForeName>Cian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Cancer Division, University College London Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Belessiotis</LastName><ForeName>Katherine</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Cancer Division, University College London Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Diamantis</LastName><ForeName>Nikolaos</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Medical Oncology, Barts Health NHS Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Mukherjee</LastName><ForeName>Uma</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Medical Oncology, Barts Health NHS Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Pommeret</LastName><ForeName>Fanny</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Saclay, Villejuif, France.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Stoclin</LastName><ForeName>Annabelle</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Saclay, Villejuif, France.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Martinez-Vila</LastName><ForeName>Clara</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3; Althaia Manresa, Manresa, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Bruna</LastName><ForeName>Riccardo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Division of Haematology, Department of Translational Medicine, University of Piemonte Orientale and Ospedale Maggiore della Carit&#xe0; Hospital, Novara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Gaidano</LastName><ForeName>Gianluca</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Division of Haematology, Department of Translational Medicine, University of Piemonte Orientale and Ospedale Maggiore della Carit&#xe0; Hospital, Novara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>D'Avanzo</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Division of Oncology, Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Gennari</LastName><ForeName>Alessandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Oncology, Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Athale</LastName><ForeName>Janhavi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Critical Care Medicine, Mayo Clinic Arizona, Phoenix, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Eichacker</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Critical Care Medicine Department, National Institutes of Health Clinical Center, Bethesda, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Pinato</LastName><ForeName>David J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Division of Oncology, Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy; Department of Surgery and Cancer, Imperial College of London, Hammersmith Hospital Campus, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Torabi-Parizi</LastName><ForeName>Parizad</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Critical Care Medicine Department, Clinical Center and National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Cortellini</LastName><ForeName>Alessio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Surgery and Cancer, Imperial College of London, Hammersmith Hospital Campus, London, UK; Medical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo 200, 00128, Roma, Italy. Electronic address: a.cortellini@imperial.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><CollectiveName>OnCovid study group</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2023</Year><Month>11</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>Int J Infect Dis</MedlineTA><NlmUniqueID>9610933</NlmUniqueID><ISSNLinking>1201-9712</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner=\"NOTNLM\"><Keyword MajorTopicYN=\"N\">COVID-19</Keyword><Keyword MajorTopicYN=\"N\">Checkpoint inhibitor</Keyword><Keyword MajorTopicYN=\"N\">Immunotherapy</Keyword><Keyword MajorTopicYN=\"N\">Malignancy</Keyword><Keyword MajorTopicYN=\"N\">SARS-CoV-2</Keyword></KeywordList><CoiStatement>Declarations of competing interest Alessio Cortellini received consulting fees from MSD, BMS, AstraZeneca, Roche; and speakers&#x2019; fees from AstraZeneca, MSD, Novartis, and Eisai. Matteo Lambertini acted as a consultant for Roche, Novartis, Lilly, AstraZeneca, Exact Sciences, MSD, Pfizer, and Seagen and received speaker honoraria from Roche, Novartis, Lilly, Pfizer, Takeda, Ipsen and Sandoz outside the submitted work. Alessandra Gennari has declared consulting/advisory role for Roche, MSD, Eli Lilly, Pierre Fabre, Eisai, and Daichii Sankyo; speakers bureau for Eisai, Novartis, Eli Lilly, Roche, Teva, Gentili, Pfizer, Astra Zeneca, Celgene, and Daichii Sankyo; research funds: Eisai, Eli Lilly, and Roche. CMV has received travel grants and other honoraria from BMS, MSD, Novartis, and Roche. Joan Brunet has declared consulting/advisory role for MSD and Astra Zenec, and support for attending meetings and/or travel for GSK. Josep Tabernero reports personal financial interest in the form of scientific consultancy role for Array Biopharma, AstraZeneca, Bayer, Boehringer Ingelheim, Chugai, Daiichi Sankyo, F. Hoffmann-La Roche Ltd, Genentech Inc, HalioDX SAS, Hutchison MediPharma International, Ikena Oncology, Inspirna Inc, IQVIA, Lilly, Menarini, Merck Serono, Merus, MSD, Mirati, Neophore, Novartis, Ona Therapeutics, Orion Biotechnology, Peptomyc, Pfizer, Pierre Fabre, Samsung Bioepis, Sanofi, Scandion Oncology, Scorpion Therapeutics, Seattle Genetics, Servier, Sotio Biotech, Taiho, Tessa Therapeutics and TheraMyc. Stocks: Oniria Therapeutics and also educational collaboration with Imedex/HMP, Medscape Education, MJH Life Sciences, PeerView Institute for Medical Education, and Physicians Education Resource (PER). Lorenza Rimassa reports receiving consulting fees from AstraZeneca, Basilea, Bayer, BMS, Eisai, Exelixis, Genenta, Hengrui, Incyte, Ipsen, IQVIA, Lilly, MSD, Nerviano Medical Sciences, Roche, Servier, Taiho Oncology, Zymeworks; lecture fees from AstraZeneca, Bayer, Eisai, Gilead, Incyte, Ipsen, Lilly, Merck Serono, Roche, Sanofi, Servier; travel expenses from AstraZeneca; and institutional research funding from Agios, AstraZeneca, BeiGene, Eisai, Exelixis, Fibrogen, Incyte, Ipsen, Lilly, MSD, Nerviano Medical Sciences, Roche, Zymeworks. David J Pinato received lecture fees from ViiV Healthcare, Bayer Healthcare, BMS, Roche, Eisai, Falk Foundation, travel expenses from BMS and Bayer Healthcare; consulting fees for Mina Therapeutics, Eisai, Roche, DaVolterra, and Astra Zeneca; research funding (to institution) from MSD and BMS. All remaining authors have declared no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"received\"><Year>2023</Year><Month>8</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus=\"revised\"><Year>2023</Year><Month>11</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus=\"accepted\"><Year>2023</Year><Month>11</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2023</Year><Month>11</Month><Day>30</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"medline\"><Year>2023</Year><Month>11</Month><Day>30</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2023</Year><Month>11</Month><Day>29</Day><Hour>19</Hour><Minute>25</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38029831</ArticleId><ArticleId IdType=\"doi\">10.1016/j.ijid.2023.11.021</ArticleId><ArticleId IdType=\"pii\">S1201-9712(23)00782-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>\n",
            "XML saved to: path/to/save/xml/38029831.xml\n",
            "Details URL: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=38029007&retmode=xml&api_key=9edd38677707c08b2a96ed1a6e8c61c47408\n",
            "Details Response Content: <?xml version=\"1.0\" ?>\n",
            "<!DOCTYPE PubmedArticleSet PUBLIC \"-//NLM//DTD PubMedArticle, 1st January 2023//EN\" \"https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd\">\n",
            "<PubmedArticleSet>\n",
            "<PubmedArticle><MedlineCitation Status=\"PubMed-not-MEDLINE\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38029007</PMID><DateRevised><Year>2023</Year><Month>12</Month><Day>01</Day></DateRevised><Article PubModel=\"Print\"><Journal><ISSN IssnType=\"Electronic\">2156-4647</ISSN><JournalIssue CitedMedium=\"Internet\"><Volume>9</Volume><Issue>1</Issue><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Journal of radiosurgery and SBRT</Title><ISOAbbreviation>J Radiosurg SBRT</ISOAbbreviation></Journal><ArticleTitle>Safety and efficacy of stereotactic body proton therapy for high-risk lung tumors.</ArticleTitle><Pagination><StartPage>63</StartPage><EndPage>74</EndPage><MedlinePgn>63-74</MedlinePgn></Pagination><Abstract><AbstractText Label=\"PURPOSE\" NlmCategory=\"UNASSIGNED\">Stereotactic body proton therapy (SBPT) is an emerging treatment strategy for lung tumors that aims to combine the excellent local control benefits of ultra-hypofractionation with the physical advantages of protons, which reduce the integral dose to organs at risk (OARs) compared to photons. To date, however, very little data delivering SBPT in 5 or fewer fractions to lung tumors have been reported. Given that photon stereotactic body radiation therapy can struggle to deliver ablative doses to high-risk tumors (i.e., central/ultra-central location, prior in-field radiation, tumor size &gt;5 cm, or the presence of severe pulmonary comorbidities) while adhering to OAR dose constraints, we hypothesized that SBPT would be an effective alternative for patients with high-risk tumors.</AbstractText><AbstractText Label=\"METHODS AND MATERIALS\" NlmCategory=\"UNASSIGNED\">Twenty-seven high-risk patients with 29 lung tumors treated with SBPT at the New York Proton Center between December 2019 and November 2022 were retrospectively identified. Patients were divided into three major subgroups: early-stage non-small cell lung cancer (NSCLC), locally recurrent NSCLC, and metastatic cancer from lung cancer or other histologies. Patient characteristics were reported using descriptive statistics, actuarial methods were used to quantify disease control rates, and toxicities were scored using CTCAE v 5.0.</AbstractText><AbstractText Label=\"RESULTS\" NlmCategory=\"UNASSIGNED\">The most common high-risk indications for SBPT were central/ultra-central tumor location (69.0%), severe COPD (48.1%), reirradiation (44.4%), significant pulmonary fibrosis (22.2%), and large tumor size &gt; 5 cm (18.5%). In total, 96.6% of tumors were fully covered by the prescription dose without compromising target coverage. Three-year actuarial rates of local control for early-stage NSCLC, locally recurrent NSCLC, and metastatic patients were 89%, 100%, and 43%, respectively. Three-year actuarial rates of regional control were 89%, 67%, and 86%. Three-year actuarial rates of distant metastasis-free survival were 79%, 100%, and 0%. Two patients (7.4%), both of whom had clinically significant baseline interstitial lung disease and pre-treatment continuous oxygen demand, experienced grade &#x2265;2 pulmonary toxicity (1 grade 3, 1 grade 5). There were no acute or late grade &#x2265;2 toxicities related to esophagitis, cardiac injury, airway injury, pulmonary fibrosis, bronchopulmonary hemorrhage or brachial plexopathy.</AbstractText><AbstractText Label=\"CONCLUSIONS\" NlmCategory=\"UNASSIGNED\">In the largest study of proton SBRT reported to date, SBPT has a favorable toxicity profile while being an effective approach for treating most high-risk tumors without requiring dose de-escalation or compromising tumor coverage and warrants further investigation.</AbstractText><CopyrightInformation>&#xa9; 2023 Old City Publishing, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>McMillan</LastName><ForeName>Matthew T</ForeName><Initials>MT</Initials><AffiliationInfo><Affiliation>Memorial Sloan Kettering Cancer Center, Department of Radiation Oncology, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Shepherd</LastName><ForeName>Annemarie F</ForeName><Initials>AF</Initials><AffiliationInfo><Affiliation>Memorial Sloan Kettering Cancer Center, Department of Radiation Oncology, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>New York Proton Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Kang</LastName><ForeName>Minglei</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>New York Proton Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Lin</LastName><ForeName>Liyong</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Emory University, Department of Radiation Oncology, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Shaverdian</LastName><ForeName>Narek</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Memorial Sloan Kettering Cancer Center, Department of Radiation Oncology, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Wu</LastName><ForeName>Abraham J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Memorial Sloan Kettering Cancer Center, Department of Radiation Oncology, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Gelblum</LastName><ForeName>Daphna Y</ForeName><Initials>DY</Initials><AffiliationInfo><Affiliation>Memorial Sloan Kettering Cancer Center, Department of Radiation Oncology, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Ohri</LastName><ForeName>Nitin</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>New York Proton Center, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Montefiore Medical Center, Department of Radiation Oncology, Bronx, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Lazarev</LastName><ForeName>Stanislav</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>New York Proton Center, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Icahn School of Medicine at Mount Sinai, Department of Radiation Oncology, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Xu</LastName><ForeName>Lee</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>New York Proton Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Chhabra</LastName><ForeName>Arpit M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>New York Proton Center, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Icahn School of Medicine at Mount Sinai, Department of Radiation Oncology, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Hasan</LastName><ForeName>Shaakir</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>New York Proton Center, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Montefiore Medical Center, Department of Radiation Oncology, Bronx, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Choi</LastName><ForeName>J Isabelle</ForeName><Initials>JI</Initials><AffiliationInfo><Affiliation>Memorial Sloan Kettering Cancer Center, Department of Radiation Oncology, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>New York Proton Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Gomez</LastName><ForeName>Daniel R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Memorial Sloan Kettering Cancer Center, Department of Radiation Oncology, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Rimner</LastName><ForeName>Andreas</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Memorial Sloan Kettering Cancer Center, Department of Radiation Oncology, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Lin</LastName><ForeName>Haibo</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Memorial Sloan Kettering Cancer Center, Department of Radiation Oncology, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>New York Proton Center, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Montefiore Medical Center, Department of Radiation Oncology, Bronx, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Simone</LastName><ForeName>Charles B</ForeName><Initials>CB</Initials><AffiliationInfo><Affiliation>Memorial Sloan Kettering Cancer Center, Department of Radiation Oncology, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>New York Proton Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Radiosurg SBRT</MedlineTA><NlmUniqueID>101565296</NlmUniqueID></MedlineJournalInfo><KeywordList Owner=\"NOTNLM\"><Keyword MajorTopicYN=\"N\">Proton therapy</Keyword><Keyword MajorTopicYN=\"N\">lung cancer</Keyword><Keyword MajorTopicYN=\"N\">pencil beam scanning</Keyword><Keyword MajorTopicYN=\"N\">stereotactic ablative radiotherapy</Keyword><Keyword MajorTopicYN=\"N\">stereotactic body radiation therapy</Keyword><Keyword MajorTopicYN=\"N\">thoracic malignancies</Keyword></KeywordList><CoiStatement>Authors&#x2019; disclosure of potential conflicts of interest Dr Simone has received an honorarium from Varian Medical Systems and is Chair of the Particle Therapy Work Group of NRG Oncology. Dr. Liyong Lin is the cofounder of Radiotherapy Biological Optimization Solutions and the chair of proton SBRT Work Group of NRG Oncology. Other authors have nothing to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"received\"><Year>2023</Year><Month>5</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus=\"accepted\"><Year>2023</Year><Month>7</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus=\"pmc-release\"><Year>2024</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus=\"medline\"><Year>2023</Year><Month>11</Month><Day>29</Day><Hour>18</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2023</Year><Month>11</Month><Day>29</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2023</Year><Month>11</Month><Day>29</Day><Hour>17</Hour><Minute>20</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38029007</ArticleId><ArticleId IdType=\"pmc\">PMC10681142</ArticleId><ArticleId IdType=\"pii\">RSBRT-9-063</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Videtic GMM, Donington J, Giuliani M, Heinzerling J, Karas TZ, Kelsey CR, Lally BE, Latzka K, Lo SS, Moghanaki D, Movsas B, Rimner A, Roach M, Rodrigues G, Shirvani SM, Simone CB, Timmerman R, Daly ME. Stereotactic body radiation therapy for early-stage non-small cell lung cancer: Executive Summary of an ASTRO Evidence-Based Guideline Pract Radiat Oncol 2017. Sep75295-301</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">28596092</ArticleId></ArticleIdList></Reference><Reference><Citation>Simone CB, Bogart JA, Cabrera AR, Daly ME, DeNunzio NJ, Detterbeck F, Faivre-Finn C, Gatschet N, Gore E, Jabbour SK, Kruser TJ, Schneider BJ, Slotman B, Turrisi A, Wu AJ, Zeng J, Rosenzweig KE. Radiation therapy for small cell lung cancer: An ASTRO clinical practice guideline Pract Radiat Oncol 2020. May103158-73</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">32222430</ArticleId></ArticleIdList></Reference><Reference><Citation>Amini A, Verma V, Simone CB, Chetty IJ, Chun SG, Donington J, Edelman MJ, Higgins KA, Kestin LL, Movsas B, Rodrigues GB, Rosenzweig KE, Rybkin II, Slotman BJ, Wolf A, Chang JY. American radium society appropriate use criteria for radiation therapy in oligometastatic or oligoprogressive non-small cell lung cancer Int J Radiat Oncol Biol Phys 2022. Feb 11122361-75</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">34571054</ArticleId></ArticleIdList></Reference><Reference><Citation>Onishi H, Shirato H, Nagata Y, Hiraoka M, Fujino M, Gomi K, Niibe Y, Karasawa K, Hayakawa K, Takai Y, Kimura T, Takeda A, Ouchi A, Hareyama M, Kokubo M, Hara R, Itami J, Yamada K, Araki T. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study J Thorac Oncol 2007. Jul27 Suppl 3S94-100</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">17603311</ArticleId></ArticleIdList></Reference><Reference><Citation>Ball D, Mai GT, Vinod S, Babington S, Ruben J, Kron T, Chesson B, Herschtal A, Vanevski M, Rezo A, Elder C, Skala M, Wirth A, Wheeler G, Lim A, Shaw M, Schofield P, Irving L, Solomon B. TROG 09.02 CHISEL investigators. Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial Lancet Oncol 2019. Apr204494-503</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">30770291</ArticleId></ArticleIdList></Reference><Reference><Citation>Swaminath A, Parpia S, Wierzbicki M, Kundapur V, Faria SL, Okawara G, Tsakiridis T, Ahmed N, Bujold A, Hirmiz KJ, Owen TE, Leong N, Ramchandar K, Filion EJ, Lau H, Louie AV, Quan K, Levine M, Wright J, Whelan TJ. LUSTRE: A phase III randomized trial of stereotactic body radiotherapy (SBRT) vs. Conventionally hypofractionated radiotherapy (CRT) for medically inoperable stage I non-small cell lung cancer (NSCLC) Int J Radiat Oncol Biol Phys 2022. Dec11451061-2</Citation></Reference><Reference><Citation>Gupta A, Eisenhauer EA, Booth CM. The time toxicity of cancer treatment J Clin Oncol 2022. May 2040151611-5</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">35235366</ArticleId></ArticleIdList></Reference><Reference><Citation>Timmerman R, McGarry R, Yiannoutsos C, Papiez L, Tudor K, DeLuca J, Ewing M, Abdulrahman R, DesRosiers C, Williams M, Fletcher J. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer J Clin Oncol 2006. Oct 2024304833-9</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">17050868</ArticleId></ArticleIdList></Reference><Reference><Citation>Modh A, Rimner A, Williams E, Foster A, Shah M, Shi W, Zhang Z, Gelblum DY, Rosenzweig KE, Yorke ED, Jackson A, Wu AJ. Local control and toxicity in a large cohort of central lung tumors treated with stereotactic body radiation therapy Int J Radiat Oncol Biol Phys 2014. Dec 19051168-76</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC4276458</ArticleId><ArticleId IdType=\"pubmed\">25303891</ArticleId></ArticleIdList></Reference><Reference><Citation>Roach MC, Robinson CG, DeWees TA, Ganachaud J, Przybysz D, Drzymala R, Rehman S, Kashani R, Bradley JD. Stereotactic body radiation therapy for central early-stage NSCLC: Results of a prospective phase I/II trial J Thorac Oncol 2018. Nov13111727-32</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">30056162</ArticleId></ArticleIdList></Reference><Reference><Citation>Bezjak A, Paulus R, Gaspar LE, Timmerman RD, Straube WL, Ryan WF, Garces YI, Pu AT, Singh AK, Videtic GM, McGarry RC, Iyengar P, Pantarotto JR, Urbanic JJ, Sun AY, Daly ME, Grills IS, Sperduto P, Normolle DP, Bradley JD, Choy H. Safety and efficacy of a five-fraction stereotactic body radiotherapy schedule for centrally located non-small-cell lung cancer: NRG Oncology/RTOG 0813 trial J Clin Oncol 2019. May 2037151316-25</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC6524984</ArticleId><ArticleId IdType=\"pubmed\">30943123</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C, Rimner A, Gelblum DY, Flynn J, Jackson A, Yorke E, Wu AJ. Analysis of toxic effects with antiangiogenic agents plus stereotactic body radiation in ultracentral lung tumors JAMA Oncol 2019. May 155737-9</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC6512294</ArticleId><ArticleId IdType=\"pubmed\">30946430</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C, Rimner A, Gelblum DY, Dick-Godfrey R, McKnight D, Torres D, Flynn J, Zhang Z, Sidiqi B, Jackson A, Yorke E, Wu AJ. Analysis of pneumonitis and esophageal injury after stereotactic body radiation therapy for ultra-central lung tumors Lung Cancer. 2020. Sep14745-8</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC7484437</ArticleId><ArticleId IdType=\"pubmed\">32663723</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindberg K, Grozman V, Karlsson K, Lindberg S, Lax I, Wers&#xe4;ll P, Persson GF, Josipovic M, Khalil AA, Moeller DS, Nyman J, Drugge N, Bergstr&#xf6;m P, Olofsson J, Rogg LV, Ramberg C, Kristiansen C, Jeppesen SS, Nielsen TB, L&#xf6;d&#xe9;n B, Rosenbrand HO, Engelholm S, Haraldsson A, Billiet C, Lewensohn R. The HILUS-trial-a prospective Nordic multicenter phase 2 study of ultracentral lung tumors treated with stereotactic body radiotherapy J Thorac Oncol 2021. Jul1671200-10</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">33823286</ArticleId></ArticleIdList></Reference><Reference><Citation>Viani GA, Arruda CV, De Fendi LI. Effectiveness and safety of reirradiation with stereotactic ablative radiotherapy of lung cancer after a first course of thoracic radiation: A meta-analysis Am J Clin Oncol 2020. Aug438575-81</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">32554982</ArticleId></ArticleIdList></Reference><Reference><Citation>Verma V, Shostrom VK, Kumar SS, Zhen W, Hallemeier CL, Braunstein SE, Holland J, Harkenrider MM, S Iskhanian A, Neboori HJ, Jabbour SK, Attia A, Lee P, Alite F, Walker JM, Stahl JM, Wang K, Bingham BS, Hadzitheodorou C, Decker RH, McGarry RC, Simone CB. Multi-institutional experience of stereotactic body radiotherapy for large (&#x2265;5 centimeters) non-small cell lung tumors Cancer 2017. Feb 151234688-96</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">27741355</ArticleId></ArticleIdList></Reference><Reference><Citation>Verma V, Shostrom VK, Zhen W, Zhang M, Braunstein SE, Holland J, Hallemeier CL, Harkenrider MM, Iskhanian A, Jabbour SK, Attia A, Lee P, Wang K, Decker RH, McGarry RC, Simone CB. Influence of fractionation scheme and tumor location on toxicities after stereotactic body radiation therapy for large (&#x2265;5 cm) non-small cell lung cancer: A multi-institutional analysis Int J Radiat Oncol Biol Phys 2017. Mar 15974778-85</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">28244414</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuaron JJ, Yorke ED, Foster A, Hsu M, Zhang Z, Liu F, Jackson A, Mychalczak B, Rosenzweig KE, Wu AJ, Rimner A. Stereotactic body radiation therapy for primary lung cancers &gt;3 centimeters J Thorac Oncol 2013. Nov8111396-401</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">24077457</ArticleId></ArticleIdList></Reference><Reference><Citation>Kohutek ZA, Wu AJ, Zhang Z, Foster A, Din SU, Yorke ED, Downey R, Rosenzweig KE, Weber WA, Rimner A. FDG-PET maximum standardized uptake value is prognostic for recurrence and survival after stereotactic body radiotherapy for non-small cell lung cancer Lung Cancer 2015. Aug892115-20</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC5015889</ArticleId><ArticleId IdType=\"pubmed\">26078260</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamashita H, Kobayashi-Shibata S, Terahara A, Okuma K, Haga A, Wakui R, Ohtomo K, Nakagawa K. Prescreening based on the presence of CT-scan abnormalities and biomarkers (KL-6 and SP-D) may reduce severe radiation pneumonitis after stereotactic radiotherapy. Radiat Oncol. 2010 May 9;5(1):32.</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC2876174</ArticleId><ArticleId IdType=\"pubmed\">20459699</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamaguchi S, Ohguri T, Ide S, Aoki T, Imada H, Yahara K, Narisada H, Korogi Y. Stereotactic body radiotherapy for lung tumors in patients with subclinical interstitial lung disease: the potential risk of extensive radiation pneumonitis Lung Cancer 2013. Nov822260-5</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">24054547</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim H, Pyo H, Noh JM, Lee W, Park B, Park HY, Yoo H. Preliminary result of definitive radiotherapy in patients with non-small cell lung cancer who have underlying idiopathic pulmonary fibrosis: comparison between X-ray and proton therapy. Radiat Oncol. 2019 Jan 28;14(1):19.</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC6348683</ArticleId><ArticleId IdType=\"pubmed\">30691496</ArticleId></ArticleIdList></Reference><Reference><Citation>Rwigema JCM, Verma V, Lin L, Berman AT, Levin WP, Evans TL, Aggarwal C, Rengan R, Langer C, Cohen RB, Simone CB. Prospective study of proton-beam radiation therapy for limited-stage small cell lung cancer Cancer 2017. Nov 1123214244-51</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">28678434</ArticleId></ArticleIdList></Reference><Reference><Citation>Giaddui T, Chen W, Yu J, Lin L, Simone CB, Yuan L, Gong YUT, Wu QJ, Mohan R, Zhang X, Bluett JB, Gillin M, Moore K, O&#x2019;Meara E, Presley J, Bradley JD, Liao Z, Galvin J, Xiao Y. Establishing the feasibility of the dosimetric compliance criteria of RTOG 1308: phase III randomized trial comparing overall survival after photon versus proton radiochemotherapy for inoperable stage II-IIIB NSCLC. Radiat Oncol. 2016 May 4;11(1):66.</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC4855766</ArticleId><ArticleId IdType=\"pubmed\">27142674</ArticleId></ArticleIdList></Reference><Reference><Citation>Kesarwala AH, Ko CJ, Ning H, Xanthopoulos E, Haglund KE, O&#x2019;Meara WP, Simone CB, Rengan R. Intensity-modulated proton therapy for elective nodal irradiation and involved-field radiation in the definitive treatment of locally advanced non-small-cell lung cancer: a dosimetric study Clin Lung Cancer 2015. May163237-44</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC4410064</ArticleId><ArticleId IdType=\"pubmed\">25604729</ArticleId></ArticleIdList></Reference><Reference><Citation>Baumann BC, Mitra N, Harton JG, Xiao Y, Wojcieszynski AP, Gabriel PE, Zhong H, Geng H, Doucette A, Wei J, O&#x2019;Dwyer PJ, Bekelman JE, Metz JM. Comparative effectiveness of proton vs photon therapy as part of concurrent chemoradiotherapy for locally advanced cancer JAMA Oncol 2020. Feb 162237-46</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC6990870</ArticleId><ArticleId IdType=\"pubmed\">31876914</ArticleId></ArticleIdList></Reference><Reference><Citation>Verma V, Simone CB, Mishra MV. Quality of life and patient-reported outcomes following proton radiation therapy: A systematic review J Natl Cancer Inst [Internet] 2018. Apr 11104. Available from: 10.1093/jnci/djx208</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/jnci/djx208</ArticleId><ArticleId IdType=\"pubmed\">29028221</ArticleId></ArticleIdList></Reference><Reference><Citation>Veiga C, Janssens G, Teng CL, Baudier T, Hotoiu L, McClelland JR, Royle G, Lin L, Yin L, Metz J, Solberg TD, Tochner Z, Simone CB, McDonough J, Kevin Teo BK. First clinical investigation of cone beam computed tomography and deformable registration for adaptive proton therapy for lung cancer Int J Radiat Oncol Biol Phys 2016. May 1951549-59</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">27084664</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 2009. Jan452228-47</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">19097774</ArticleId></ArticleIdList></Reference><Reference><Citation>Daly ME, Redman M, Simone CB, Monjazeb AM, Bauman JR, Hesketh P, Feliciano J, Kashani R, Steuer C, Ganti AK, Jieling M, Moon J, Hu C, Bradley JD, Kelly K. SWOG/NRG S1914: A randomized phase III trial of induction/consolidation atezolizumab + SBRT vs.SBRT alone in high risk, early-stage NSCLC (NCT#04214262) Int J Radiat Oncol Biol Phys 2022. Nov1143)e414</Citation></Reference><Reference><Citation>von Reibnitz D, Shaikh F, Wu AJ, Treharne GC, Dick-Godfrey R, Foster A, Woo KM, Shi W, Zhang Z, Din SU, Gelblum DY, Yorke ED, Rosenzweig KE, Rimner A. Stereotactic body radiation therapy (SBRT) improves local control and overall survival compared to conventionally fractionated radiation for stage I non-small cell lung cancer (NSCLC) Acta Oncol 2018. Nov57111567-73</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC6508090</ArticleId><ArticleId IdType=\"pubmed\">29873277</ArticleId></ArticleIdList></Reference><Reference><Citation>Tekatli H, Haasbeek N, Dahele M, De Haan P, Verbakel W, Bongers E, Hashemi S, Nossent E, Spoelstra F, de Langen AJ, Slotman B, Senan S. Outcomes of hypofractionated high-dose radiotherapy in poor-risk patients with &#x201c;ultracentral&#x201d; non-small cell lung cancer J Thorac Oncol 2016. Jul1171081-9</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">27013408</ArticleId></ArticleIdList></Reference><Reference><Citation>Register SP, Zhang X, Mohan R, Chang JY. Proton stereotactic body radiation therapy for clinically challenging cases of centrally and superiorly located stage I non-small-cell lung cancer Int J Radiat Oncol Biol Phys 2011. Jul 158041015-22</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC2952351</ArticleId><ArticleId IdType=\"pubmed\">20615629</ArticleId></ArticleIdList></Reference><Reference><Citation>Wink KCJ, Roelofs E, Simone CB, Dechambre D, Santiago A, van der Stoep J, Dries W, Smits J, Avery S, Ammazzalorso F, Jansen N, Jelen U, Solberg T, de Ruysscher D, Troost EGC. Photons, protons or carbon ions for stage I non-small cell lung cancer - Results of the multicentric ROCOCO in silico study Radiother Oncol 2018. Jul1281139-46</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">29545019</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazarev S, Rosenzweig K, Samstein R, Salgado LR, Hasan S, Press RH, Sharma S, Powell CA, Hirsch FR, Simone CB. Where are we with proton beam therapy for thoracic malignancies? Current status and future perspectives Lung Cancer. 2021. Feb152157-64</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">33421922</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang JY, Zhang X, Knopf A, Li H, Mori S, Dong L, Lu HM, Liu W, Badiyan SN, Both S, Meijers A, Lin L, Flampouri S, Li Z, Umegaki K, Simone CB, Zhu XR. Consensus guidelines for implementing pencil-beam scanning proton therapy for thoracic malignancies on behalf of the PTCOG thoracic and lymphoma subcommittee Int J Radiat Oncol Biol Phys 2017. Sep 199141-50</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">28816159</ArticleId></ArticleIdList></Reference><Reference><Citation>Simone CB, Rengan R. The use of proton therapy in the treatment of lung cancers Cancer J 2014. Nov206427-32</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">25415690</ArticleId></ArticleIdList></Reference><Reference><Citation>Simone CB, Plastaras JP, Jabbour SK, Lee A, Lee NY, Choi JI, Frank SJ, Chang JY, Bradley J. Proton reirradiation: Expert recommendations for reducing toxicities and offering new chances of cure in patients with challenging recurrence malignancies Semin Radiat Oncol 2020. Jul303253-61</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">32503791</ArticleId></ArticleIdList></Reference><Reference><Citation>Verma V, Rwigema JCM, Malyapa RS, Regine WF, Simone CB. Systematic assessment of clinical outcomes and toxicities of proton radiotherapy for reirradiation Radiother Oncol 2017. Oct125121-30</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">28941560</ArticleId></ArticleIdList></Reference><Reference><Citation>Badiyan SN, Rutenberg MS, Hoppe BS, Mohindra P, Larson G, Hartsell WF, Tsai H, Zeng J, Rengan R, Glass E, Katz S, Vargas C, Feigenberg SJ, Simone CB. Clinical outcomes of patients with recurrent lung cancer reirradiated with proton therapy on the proton collaborative group and university of Florida proton therapy institute prospective registry studies Pract Radiat Oncol 2019. Jul94280-8</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">30802618</ArticleId></ArticleIdList></Reference><Reference><Citation>Chao HH, Berman AT, Simone CB, Ciunci C, Gabriel P, Lin H, Both S, Langer C, Lelionis K, Rengan R, Hahn SM, Prabhu K, Fagundes M, Hartsell W, Mick R, Plastaras JP. Multi-institutional prospective study of reirradiation with proton beam radiotherapy for locoregionally recurrent non-small cell lung cancer J Thorac Oncol 2017. Feb122281-92</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">27826034</ArticleId></ArticleIdList></Reference><Reference><Citation>Puckett LL, Titi M, Kujundzic K, Dawes SL, Gore E, Katsoulakis E, Park JH, Solanki AA, Kapoor R, Kelly M, Palta J, Chetty IJ, Jabbour SK, Liao Z, Movsas B, Thomas CR, Timmerman RD, Werner-Wasik M, Kudner R, Wilson E, Simone CB. Consensus quality measures and dose constraints for lung cancer from the Veterans affairs Radiation Oncology Quality Surveillance program and American Society for Radiation Oncology (ASTRO) expert panel Pract Radiat Oncol [Internet] 2023. Apr 17; Available from: 10.1016/j.prro.2023.04.003</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.prro.2023.04.003</ArticleId><ArticleId IdType=\"pubmed\">37075838</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>\n",
            "XML saved to: path/to/save/xml/38029007.xml\n",
            "Details URL: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=38027239&retmode=xml&api_key=9edd38677707c08b2a96ed1a6e8c61c47408\n",
            "Details Response Content: <?xml version=\"1.0\" ?>\n",
            "<!DOCTYPE PubmedArticleSet PUBLIC \"-//NLM//DTD PubMedArticle, 1st January 2023//EN\" \"https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd\">\n",
            "<PubmedArticleSet>\n",
            "<PubmedArticle><MedlineCitation Status=\"PubMed-not-MEDLINE\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38027239</PMID><DateRevised><Year>2023</Year><Month>12</Month><Day>01</Day></DateRevised><Article PubModel=\"Electronic-eCollection\"><Journal><ISSN IssnType=\"Print\">1179-1322</ISSN><JournalIssue CitedMedium=\"Print\"><Volume>15</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Cancer management and research</Title><ISOAbbreviation>Cancer Manag Res</ISOAbbreviation></Journal><ArticleTitle>Post-Operative Poor Sleep Quality and Its Associated Factors Among Non-Small Cell Lung Cancer Patients: A Cross-Sectional Study.</ArticleTitle><Pagination><StartPage>1283</StartPage><EndPage>1295</EndPage><MedlinePgn>1283-1295</MedlinePgn></Pagination><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.2147/CMAR.S430436</ELocationID><Abstract><AbstractText Label=\"OBJECTIVE\" NlmCategory=\"UNASSIGNED\">The study aimed to determine the post-operative prevalence and factors associated to poor sleep quality in non-small cell lung cancer (NSCLC) patients in China.</AbstractText><AbstractText Label=\"METHODS\" NlmCategory=\"UNASSIGNED\">NSCLC patients (n=307) who underwent thoracoscopic surgery at the Department of Thoracic Surgery of Shanghai Pulmonary Hospital were enrolled in this study. The Pittsburgh Sleep Quality Index (PSQI), Generalized Anxiety Disorder-7 (GAD-7), Patient Health Questionnaire-9 (PHQ-9), Prince Henry Hospital Pain Score and the Six-Minute Walk Test (6MWT), and Forced Expiratory Volume in one second (FEV-1) were used to assess the factors that could lead to poor sleep quality. All assessments were carried out between April 1 and May 30, 2023. Descriptive analyses and stepwise factor regression were employed to determine the impact of various factors on sleep quality. The factors predictive of poor sleep quality were used to develop a predictive nomogram. The Hosmer-Lemeshow test was used to assess the predictive value of the nomogram.</AbstractText><AbstractText Label=\"RESULTS\" NlmCategory=\"UNASSIGNED\">The median PQSI score was 8 (interquartile range (IQR) 5-12), and 74.6% of patients had poor sleep quality. The median anxiety and depression scores were 6 (IQR 3-9) and 4 (IQR 2-7), respectively. The PSQI latency dimension had the highest score, while the use of sleep medications dimension had the lowest score. The multivariate analysis revealed that patients who were female (OR, 2.38; 95% CI, 1.40-4.05; P&#x2009;&lt;0.01), had post-secondary education (OR, 0.42; 95% CI, 0.19-0.92; P&#x2009;=0.03), tertiary education (OR, 0.38; 95% CI, 0.17-0.84; P&#x2009;=0.02), comorbidities (OR, 2.57; 95% CI, 1.51-4.39; P&#x2009;&lt;0.01), a pain score 1 (OR, 4.22; 95% CI, 2.37-7.50; P&#x2009;&lt;0.01), and cough (OR, 2.97; 95% CI, 1.63-5.40; P&#x2009;&lt;.001) were more like to experience poor sleep quality. The positive predictive value of the nomogram was 79.80% (p=0.390).</AbstractText><AbstractText Label=\"CONCLUSION\" NlmCategory=\"UNASSIGNED\">Sociodemographic variables, comorbidities, and pain could be used to predict the post-operative sleep quality in NSCLC patients.</AbstractText><CopyrightInformation>&#xa9; 2023 Chen et al.</CopyrightInformation></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\" EqualContrib=\"Y\"><LastName>Chen</LastName><ForeName>Xinxin</ForeName><Initials>X</Initials><Identifier Source=\"ORCID\">0000-0002-5513-3332</Identifier><AffiliationInfo><Affiliation>Tongji University School of Medicine, Shanghai, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Nursing, Shanghai Pulmonary Hospital, Tongji University, Shanghai, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\" EqualContrib=\"Y\"><LastName>Hu</LastName><ForeName>Yachen</ForeName><Initials>Y</Initials><Identifier Source=\"ORCID\">0000-0002-0245-3105</Identifier><AffiliationInfo><Affiliation>Tongji University School of Medicine, Shanghai, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\" EqualContrib=\"Y\"><LastName>Fan</LastName><ForeName>Jiaxin</ForeName><Initials>J</Initials><Identifier Source=\"ORCID\">0000-0003-0711-9138</Identifier><AffiliationInfo><Affiliation>Tongji University School of Medicine, Shanghai, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Li</LastName><ForeName>Yumei</ForeName><Initials>Y</Initials><Identifier Source=\"ORCID\">0000-0001-7275-1792</Identifier><AffiliationInfo><Affiliation>Department of Nursing, Shanghai Pulmonary Hospital, Tongji University, Shanghai, People's Republic of China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2023</Year><Month>11</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Cancer Manag Res</MedlineTA><NlmUniqueID>101512700</NlmUniqueID><ISSNLinking>1179-1322</ISSNLinking></MedlineJournalInfo><KeywordList Owner=\"NOTNLM\"><Keyword MajorTopicYN=\"N\">associated factors</Keyword><Keyword MajorTopicYN=\"N\">carcinoma</Keyword><Keyword MajorTopicYN=\"N\">non-small-cell lung</Keyword><Keyword MajorTopicYN=\"N\">sleep quality</Keyword></KeywordList><CoiStatement>The authors report no conflicts of interest in this work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"received\"><Year>2023</Year><Month>7</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus=\"accepted\"><Year>2023</Year><Month>11</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus=\"medline\"><Year>2023</Year><Month>11</Month><Day>29</Day><Hour>18</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2023</Year><Month>11</Month><Day>29</Day><Hour>18</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2023</Year><Month>11</Month><Day>29</Day><Hour>17</Hour><Minute>2</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38027239</ArticleId><ArticleId IdType=\"pmc\">PMC10657758</ArticleId><ArticleId IdType=\"doi\">10.2147/CMAR.S430436</ArticleId><ArticleId IdType=\"pii\">430436</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209&#x2013;249. doi:10.3322/caac.21660</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3322/caac.21660</ArticleId><ArticleId IdType=\"pubmed\">33538338</ArticleId></ArticleIdList></Reference><Reference><Citation>Howington JA, Blum MG, Chang AC, Balekian AA, Murthy SC. Treatment of stage I and II non-small cell lung cancer. Chest. 2013;143(5):e278S&#x2013;e313S. doi:10.1378/chest.12-2359</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1378/chest.12-2359</ArticleId><ArticleId IdType=\"pubmed\">23649443</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan TD, Black D, Bannon PG, Mccaughan BC. Systematic review and meta-analysis of randomized and nonrandomized trials on safety and efficacy of video-assisted thoracic surgery lobectomy for early-stage non-small-cell lung cancer. J Clin Oncol. 2009;27(15):2553&#x2013;2562. doi:10.1200/JCO.2008.18.2733</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1200/JCO.2008.18.2733</ArticleId><ArticleId IdType=\"pubmed\">19289625</ArticleId></ArticleIdList></Reference><Reference><Citation>Dean GE, Abu SE, Yingrengreung S, et al. Sleeping with the enemy: sleep and quality of life in patients with lung cancer. Cancer Nurs. 2015;38(1):60&#x2013;70. doi:10.1097/NCC.0000000000000128</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1097/NCC.0000000000000128</ArticleId><ArticleId IdType=\"pubmed\">25486204</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidson JR, Maclean AW, Brundage MD, Schulze K. Sleep disturbance in cancer patients. Soc Sci Med. 2002;54(9):1309&#x2013;1321. doi:10.1016/s0277-9536(01)00043-0</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/s0277-9536(01)00043-0</ArticleId><ArticleId IdType=\"pubmed\">12058848</ArticleId></ArticleIdList></Reference><Reference><Citation>Sateia MJ. International classification of sleep disorders-Third edition. Chest. 2014;146(5):1387&#x2013;1394. doi:10.1378/chest.14-0970</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1378/chest.14-0970</ArticleId><ArticleId IdType=\"pubmed\">25367475</ArticleId></ArticleIdList></Reference><Reference><Citation>Cullen T, Thomas G, Wadley AJ, Myers T. The effects of a single night of complete and partial sleep deprivation on physical and cognitive performance: a Bayesian analysis. J Sport Sci. 2019;37(23):2726&#x2013;2734. doi:10.1080/02640414.2019.1662539</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1080/02640414.2019.1662539</ArticleId><ArticleId IdType=\"pubmed\">31608829</ArticleId></ArticleIdList></Reference><Reference><Citation>Loh KP, Pandya C, Zittel J, et al. Associations of sleep disturbance with physical function and cognition in older adults with cancer. Support Care Cancer. 2017;25(10):3161&#x2013;3169. doi:10.1007/s00520-017-3724-6</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s00520-017-3724-6</ArticleId><ArticleId IdType=\"pmc\">PMC5660663</ArticleId><ArticleId IdType=\"pubmed\">28455547</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishiura M, Tamura A, Nagai H, Matsushima E. Assessment of sleep disturbance in lung cancer patients: relationship between sleep disturbance and pain, fatigue, quality of life, and psychological distress. Palliat Support Care. 2015;13(3):575&#x2013;581. doi:10.1017/S1478951513001119</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1017/S1478951513001119</ArticleId><ArticleId IdType=\"pubmed\">24524428</ArticleId></ArticleIdList></Reference><Reference><Citation>Rampes S, Ma K, Divecha YA, Alam A, Ma D. Post-operative sleep disorders and their potential impacts on surgical outcomes. J Biomed Res. 2019;34(4):271&#x2013;280. doi:10.7555/JBR.33.20190054</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.7555/JBR.33.20190054</ArticleId><ArticleId IdType=\"pmc\">PMC7386412</ArticleId><ArticleId IdType=\"pubmed\">32519977</ArticleId></ArticleIdList></Reference><Reference><Citation>Halle IH, Westgaard TK, Wahba A, Oksholm T, Rustoen T, Gjeilo KH. Trajectory of sleep disturbances in patients undergoing lung cancer surgery: a prospective study. Interact Cardiovasc Thorac Surg. 2017;25(2):285&#x2013;291. doi:10.1093/icvts/ivx076</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/icvts/ivx076</ArticleId><ArticleId IdType=\"pubmed\">28486702</ArticleId></ArticleIdList></Reference><Reference><Citation>Sodhi A, Pisani M, Glassberg MK, Bourjeily G, D&#x2019;Ambrosio C. Sex and gender in lung disease and sleep disorders: a State-of-The-Art Review. Chest. 2022;162(3):647&#x2013;658. doi:10.1016/j.chest.2022.03.006</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.chest.2022.03.006</ArticleId><ArticleId IdType=\"pmc\">PMC9808608</ArticleId><ArticleId IdType=\"pubmed\">35300976</ArticleId></ArticleIdList></Reference><Reference><Citation>Luojus MK, Lehto SM, Tolmunen T, Erkkila AT, Kauhanen J. Sleep duration and incidence of lung cancer in ageing men. BMC Public Health. 2014;14:295. doi:10.1186/1471-2458-14-295</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1186/1471-2458-14-295</ArticleId><ArticleId IdType=\"pmc\">PMC4229981</ArticleId><ArticleId IdType=\"pubmed\">24684747</ArticleId></ArticleIdList></Reference><Reference><Citation>Niekamp P. Economic conditions and sleep. Health Econ. 2019;28(3):437&#x2013;442. doi:10.1002/hec.3849</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1002/hec.3849</ArticleId><ArticleId IdType=\"pubmed\">30569593</ArticleId></ArticleIdList></Reference><Reference><Citation>August KJ. Marital status, marital transitions, and sleep quality in mid to late life. Res Aging. 2022;44(3&#x2013;4):301&#x2013;311. doi:10.1177/01640275211027281</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1177/01640275211027281</ArticleId><ArticleId IdType=\"pubmed\">34180305</ArticleId></ArticleIdList></Reference><Reference><Citation>Seid TS, Fenta AE. Postoperative poor sleep quality and its associated factors among adult patients: a multicenter cross-sectional study. Ann Med Surg. 2022;74:103273. doi:10.1016/j.amsu.2022.103273</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.amsu.2022.103273</ArticleId><ArticleId IdType=\"pmc\">PMC8819123</ArticleId><ArticleId IdType=\"pubmed\">35145662</ArticleId></ArticleIdList></Reference><Reference><Citation>Papadopoulos D, Kiagia M, Charpidou A, Gkiozos I, Syrigos K. Psychological correlates of sleep quality in lung cancer patients under chemotherapy: a single-center cross-sectional study. Psychooncology. 2019;28(9):1879&#x2013;1886. doi:10.1002/pon.5167</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1002/pon.5167</ArticleId><ArticleId IdType=\"pubmed\">31264308</ArticleId></ArticleIdList></Reference><Reference><Citation>Linares-Moya M, Rodriguez-Torres J, Heredia-Ciuro A, et al. Psychological distress prior to surgery is related to symptom burden and health status in lung cancer survivors. Support Care Cancer. 2022;30(2):1579&#x2013;1586. doi:10.1007/s00520-021-06537-7</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s00520-021-06537-7</ArticleId><ArticleId IdType=\"pmc\">PMC8727403</ArticleId><ArticleId IdType=\"pubmed\">34541609</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Zhang X. Somatization symptoms in lung cancer patients and correlative analysis between anxiety, depression and somatization symptoms. Zhongguo Fei Ai Za Zhi. 2017;20(7):473&#x2013;478. doi:10.3779/j.issn.1009-3419.2017.07.06</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3779/j.issn.1009-3419.2017.07.06</ArticleId><ArticleId IdType=\"pmc\">PMC5972940</ArticleId><ArticleId IdType=\"pubmed\">28738963</ArticleId></ArticleIdList></Reference><Reference><Citation>Bollu PC, Kaur H. Sleep medicine: insomnia and sleep. Mo Med. 2019;116(1):68&#x2013;75.</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC6390785</ArticleId><ArticleId IdType=\"pubmed\">30862990</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhaisare S, Gupta R, Saini J, Chakraborti A, Khot S. Sleep-disordered breathing in newly diagnosed patients of lung cancer. Cureus. 2022;14(5):e25230. doi:10.7759/cureus.25230</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.7759/cureus.25230</ArticleId><ArticleId IdType=\"pmc\">PMC9214459</ArticleId><ArticleId IdType=\"pubmed\">35747059</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei X, Yu H, Dai W, et al. Discrepancy in the perception of symptoms among patients and healthcare providers after lung cancer surgery. Support Care Cancer. 2022;30(2):1169&#x2013;1179. doi:10.1007/s00520-021-06506-0</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s00520-021-06506-0</ArticleId><ArticleId IdType=\"pubmed\">34448942</ArticleId></ArticleIdList></Reference><Reference><Citation>Lou VW, Chen EJ, Jian H, et al. Respiratory symptoms, sleep, and quality of life in patients with advanced lung cancer. J Pain Symptom Manage. 2017;53(2):250&#x2013;256.e1. doi:10.1016/j.jpainsymman.2016.09.006</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jpainsymman.2016.09.006</ArticleId><ArticleId IdType=\"pubmed\">27832984</ArticleId></ArticleIdList></Reference><Reference><Citation>Gangemi AJ, Satti A, Zantah M, et al. Sleep duration and efficiency associated with better functional exercise capacity in black smokers at risk for COPD. Chest. 2020;158(4):1680&#x2013;1688. doi:10.1016/j.chest.2020.03.070</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.chest.2020.03.070</ArticleId><ArticleId IdType=\"pmc\">PMC7545487</ArticleId><ArticleId IdType=\"pubmed\">32333930</ArticleId></ArticleIdList></Reference><Reference><Citation>Patterson F, Grandner MA, Malone SK, Rizzo A, Davey A, Edwards DG. Sleep as a target for optimized response to smoking cessation treatment. Nicotine Tob Res. 2019;21(2):139&#x2013;148. doi:10.1093/ntr/ntx236</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/ntr/ntx236</ArticleId><ArticleId IdType=\"pmc\">PMC6329404</ArticleId><ArticleId IdType=\"pubmed\">29069464</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Samet J, Caffo B, Punjabi NM. Cigarette smoking and nocturnal sleep architecture. Am J Epidemiol. 2006;164(6):529&#x2013;537. doi:10.1093/aje/kwj231</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/aje/kwj231</ArticleId><ArticleId IdType=\"pubmed\">16829553</ArticleId></ArticleIdList></Reference><Reference><Citation>Driver HS, Taylor SR. Exercise and sleep. Sleep Med Rev. 2000;4(4):387&#x2013;402. doi:10.1053/smrv.2000.0110</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1053/smrv.2000.0110</ArticleId><ArticleId IdType=\"pubmed\">12531177</ArticleId></ArticleIdList></Reference><Reference><Citation>Park I, Diaz J, Matsumoto S, et al. Exercise improves the quality of slow-wave sleep by increasing slow-wave stability. Sci Rep. 2021;11(1):4410. doi:10.1038/s41598-021-83817-6</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/s41598-021-83817-6</ArticleId><ArticleId IdType=\"pmc\">PMC7904822</ArticleId><ArticleId IdType=\"pubmed\">33627708</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen HM, Cheung D, Lin YY, et al. Relationships of exercise timing with sleep, fatigue and rest-activity rhythms of lung cancer patients in Taiwan: an exploratory study. Eur J Cancer Care. 2020;29(4):e13233. doi:10.1111/ecc.13233</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1111/ecc.13233</ArticleId><ArticleId IdType=\"pubmed\">32100388</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu T, Denehy L, Cao Y, et al. A 12-week multi-modal exercise program: feasibility of combined exercise and simplified 8-style Tai Chi following lung cancer surgery. Integr Cancer Ther. 2020;19:1534735420952887. doi:10.1177/1534735420952887</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1177/1534735420952887</ArticleId><ArticleId IdType=\"pmc\">PMC7457649</ArticleId><ArticleId IdType=\"pubmed\">32851871</ArticleId></ArticleIdList></Reference><Reference><Citation>Su X, Wang DX. Improve post-operative sleep: what can we do? Curr Opin Anaesthesiol. 2018;31(1):83&#x2013;88. doi:10.1097/ACO.0000000000000538</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1097/ACO.0000000000000538</ArticleId><ArticleId IdType=\"pmc\">PMC5768217</ArticleId><ArticleId IdType=\"pubmed\">29120927</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh FY. Sample size tables for logistic regression. Stat Med. 1989;8(7):795&#x2013;802. doi:10.1002/sim.4780080704</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1002/sim.4780080704</ArticleId><ArticleId IdType=\"pubmed\">2772439</ArticleId></ArticleIdList></Reference><Reference><Citation>Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiat Res. 1989;28(2):193&#x2013;213. doi:10.1016/0165-1781(89)90047-4</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/0165-1781(89)90047-4</ArticleId><ArticleId IdType=\"pubmed\">2748771</ArticleId></ArticleIdList></Reference><Reference><Citation>Levis B, Sun Y, He C, et al. Accuracy of the PHQ-2 alone and in combination with the PHQ-9 for screening to detect major depression: systematic review and meta-analysis. JAMA. 2020;323(22):2290&#x2013;2300. doi:10.1001/jama.2020.6504</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1001/jama.2020.6504</ArticleId><ArticleId IdType=\"pmc\">PMC7284301</ArticleId><ArticleId IdType=\"pubmed\">32515813</ArticleId></ArticleIdList></Reference><Reference><Citation>Manea L, Gilbody S, Mcmillan D. Optimal cut-off score for diagnosing depression with the Patient Health Questionnaire (PHQ-9): a meta-analysis. CMAJ. 2012;184(3):E191&#x2013;E196. doi:10.1503/cmaj.110829</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1503/cmaj.110829</ArticleId><ArticleId IdType=\"pmc\">PMC3281183</ArticleId><ArticleId IdType=\"pubmed\">22184363</ArticleId></ArticleIdList></Reference><Reference><Citation>Spitzer RL, Kroenke K, Williams JB, Lowe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166(10):1092&#x2013;1097. doi:10.1001/archinte.166.10.1092</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1001/archinte.166.10.1092</ArticleId><ArticleId IdType=\"pubmed\">16717171</ArticleId></ArticleIdList></Reference><Reference><Citation>Chien I, Enrique A, Palacios J, et al. A machine learning approach to understanding patterns of engagement with internet-delivered mental health interventions. JAMA Netw Open. 2020;3(7):e2010791. doi:10.1001/jamanetworkopen.2020.10791</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1001/jamanetworkopen.2020.10791</ArticleId><ArticleId IdType=\"pmc\">PMC7368176</ArticleId><ArticleId IdType=\"pubmed\">32678450</ArticleId></ArticleIdList></Reference><Reference><Citation>Zubrzycki M, Liebold A, Skrabal C, et al. Assessment and pathophysiology of pain in cardiac surgery. J Pain Res. 2018;11:1599&#x2013;1611. doi:10.2147/JPR.S162067</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.2147/JPR.S162067</ArticleId><ArticleId IdType=\"pmc\">PMC6112778</ArticleId><ArticleId IdType=\"pubmed\">30197534</ArticleId></ArticleIdList></Reference><Reference><Citation>ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166(1):111&#x2013;117. doi:10.1164/ajrccm.166.1.at1102</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1164/ajrccm.166.1.at1102</ArticleId><ArticleId IdType=\"pubmed\">12091180</ArticleId></ArticleIdList></Reference><Reference><Citation>Graham BL, Steenbruggen I, Miller MR, et al. Standardization of spirometry 2019 update. An Official American Thoracic Society and European Respiratory Society Technical Statement. Am J Respir Crit Care Med. 2019;200(8):e70&#x2013;e88. doi:10.1164/rccm.201908-1590ST</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1164/rccm.201908-1590ST</ArticleId><ArticleId IdType=\"pmc\">PMC6794117</ArticleId><ArticleId IdType=\"pubmed\">31613151</ArticleId></ArticleIdList></Reference><Reference><Citation>Butris N, Tang E, Pivetta B, et al. The prevalence and risk factors of sleep disturbances in surgical patients: a systematic review and meta-analysis. Sleep Med Rev. 2023;69:101786. doi:10.1016/j.smrv.2023.101786</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.smrv.2023.101786</ArticleId><ArticleId IdType=\"pubmed\">37121133</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang BH, Duncan MJ, Cistulli PA, Nassar N, Hamer M, Stamatakis E. Sleep and physical activity in relation to all-cause, cardiovascular disease and cancer mortality risk. Br J Sports Med. 2022;56(13):718&#x2013;724. doi:10.1136/bjsports-2021-104046</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1136/bjsports-2021-104046</ArticleId><ArticleId IdType=\"pubmed\">34187783</ArticleId></ArticleIdList></Reference><Reference><Citation>Bulbul Y, Ozlu T, Arinc S, et al. Sleep disturbances in patients with lung cancer in Turkey. Tuberk Toraks. 2018;66(4):297&#x2013;303. doi:10.5578/tt.67689</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.5578/tt.67689</ArticleId><ArticleId IdType=\"pubmed\">30683024</ArticleId></ArticleIdList></Reference><Reference><Citation>Gooneratne NS, Dean GE, Rogers AE, Nkwuo JE, Coyne JC, Kaiser LR. Sleep and quality of life in long-term lung cancer survivors. Lung Cancer. 2007;58(3):403&#x2013;410. doi:10.1016/j.lungcan.2007.07.011</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.lungcan.2007.07.011</ArticleId><ArticleId IdType=\"pmc\">PMC2206246</ArticleId><ArticleId IdType=\"pubmed\">17765353</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin RE, Loomis DM, Dean GE. Sleep and quality of life in lung cancer patients and survivors. J Am Assoc Nurse Pract. 2021;34(2):284&#x2013;291. doi:10.1097/JXX.0000000000000625</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1097/JXX.0000000000000625</ArticleId><ArticleId IdType=\"pmc\">PMC8720315</ArticleId><ArticleId IdType=\"pubmed\">34225324</ArticleId></ArticleIdList></Reference><Reference><Citation>Fekih-Romdhane F, Achouri L, Hakiri A, Jaidane O, Rahal K, Cheour M. Hopelessness is associated with poor sleep quality after breast cancer surgery among Tunisian women. Curr Probl Cancer. 2020;44(1):100504. doi:10.1016/j.currproblcancer.2019.100504</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.currproblcancer.2019.100504</ArticleId><ArticleId IdType=\"pubmed\">31548046</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu X, Ming Y, Liu J, Liu L, Cheng K, Mao P. Sleep quality and psychosocial factors in liver transplant recipients at an outpatient follow-up clinic in China. Ann Transplant. 2020;25:e920984. doi:10.12659/AOT.920984</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.12659/AOT.920984</ArticleId><ArticleId IdType=\"pmc\">PMC7047916</ArticleId><ArticleId IdType=\"pubmed\">32066650</ArticleId></ArticleIdList></Reference><Reference><Citation>van Zuylen ML, Meewisse A, Ten HW, et al. Effects of surgery and general anaesthesia on sleep-wake timing: CLOCKS observational study. Anaesthesia. 2022;77(1):73&#x2013;81. doi:10.1111/anae.15564</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1111/anae.15564</ArticleId><ArticleId IdType=\"pmc\">PMC9291940</ArticleId><ArticleId IdType=\"pubmed\">34418064</ArticleId></ArticleIdList></Reference><Reference><Citation>Kocevska D, Lysen TS, Dotinga A, et al. Sleep characteristics across the lifespan in 1.1 million people from the Netherlands, United Kingdom and United States: a systematic review and meta-analysis. Nat Hum Behav. 2021;5(1):113&#x2013;122. doi:10.1038/s41562-020-00965-x</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/s41562-020-00965-x</ArticleId><ArticleId IdType=\"pubmed\">33199855</ArticleId></ArticleIdList></Reference><Reference><Citation>Duffy JF, Cain SW, Chang AM, et al. Sex difference in the near-24-hour intrinsic period of the human circadian timing system. Proc Natl Acad Sci U S A. 2011;108(Suppl 3):15602&#x2013;15608. doi:10.1073/pnas.1010666108</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1073/pnas.1010666108</ArticleId><ArticleId IdType=\"pmc\">PMC3176605</ArticleId><ArticleId IdType=\"pubmed\">21536890</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillips KM, Jim HS, Donovan KA, Pinder-Schenck MC, Jacobsen PB. Characteristics and correlates of sleep disturbances in cancer patients. Support Care Cancer. 2012;20(2):357&#x2013;365. doi:10.1007/s00520-011-1106-z</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s00520-011-1106-z</ArticleId><ArticleId IdType=\"pubmed\">21311913</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez BD, Eisel SL, Qin B, et al. Prevalence, risk factors, and trajectories of sleep disturbance in a cohort of African-American breast cancer survivors. Support Care Cancer. 2021;29(5):2761&#x2013;2770. doi:10.1007/s00520-020-05786-2</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s00520-020-05786-2</ArticleId><ArticleId IdType=\"pmc\">PMC7981240</ArticleId><ArticleId IdType=\"pubmed\">32995999</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei Y, Li W, Zhang L, et al. Unmedicated patients with schizophrenia in economically underdeveloped areas of China. Asian J Psychiatr. 2020;47:101865. doi:10.1016/j.ajp.2019.101865</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.ajp.2019.101865</ArticleId><ArticleId IdType=\"pubmed\">31743835</ArticleId></ArticleIdList></Reference><Reference><Citation>Emre N, Yilmaz S. Sleep quality, mental health, and quality of life in women with breast cancer. Indian J Cancer. 2022. doi:10.4103/ijc.IJC_859_20</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.4103/ijc.IJC_859_20</ArticleId><ArticleId IdType=\"pubmed\">36861698</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z, Du W, Jin S, et al. Analysis of preoperative sleep quality and related influencing factors in cancer patients. Support Care Cancer. 2022;31(1):4. doi:10.1007/s00520-022-07483-8</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s00520-022-07483-8</ArticleId><ArticleId IdType=\"pubmed\">36512163</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin S, Chen Y, Yang L, Zhou J. Pain, fatigue, disturbed sleep and distress comprised a symptom cluster that related to quality of life and functional status of lung cancer surgery patients. J Clin Nurs. 2013;22(9&#x2013;10):1281&#x2013;1290. doi:10.1111/jocn.12228</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1111/jocn.12228</ArticleId><ArticleId IdType=\"pubmed\">23574291</ArticleId></ArticleIdList></Reference><Reference><Citation>Harle A, Molassiotis A, Buffin O, et al. A cross sectional study to determine the prevalence of cough and its impact in patients with lung cancer: a patient unmet need. BMC Cancer. 2020;20(1):9. doi:10.1186/s12885-019-6451-1</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1186/s12885-019-6451-1</ArticleId><ArticleId IdType=\"pmc\">PMC6943945</ArticleId><ArticleId IdType=\"pubmed\">31906892</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai W, Chang S, Pompili C, et al. Early post-operative patient-reported outcomes after thoracoscopic segmentectomy versus lobectomy for small-sized peripheral non-small-cell lung cancer. Ann Surg Oncol. 2022;29(1):547&#x2013;556. doi:10.1245/s10434-021-10946-7</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1245/s10434-021-10946-7</ArticleId><ArticleId IdType=\"pubmed\">34743281</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers LQ, Courneya KS, Oster RA, et al. Physical activity and sleep quality in breast cancer survivors: a randomized trial. Med Sci Sports Exerc. 2017;49(10):2009&#x2013;2015. doi:10.1249/MSS.0000000000001327</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1249/MSS.0000000000001327</ArticleId><ArticleId IdType=\"pmc\">PMC5600650</ArticleId><ArticleId IdType=\"pubmed\">28538261</ArticleId></ArticleIdList></Reference><Reference><Citation>Howell D, Oliver TK, Keller-Olaman S, et al. Sleep disturbance in adults with cancer: a systematic review of evidence for best practices in assessment and management for clinical practice. Ann Oncol. 2014;25(4):791&#x2013;800. doi:10.1093/annonc/mdt506</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/annonc/mdt506</ArticleId><ArticleId IdType=\"pubmed\">24287882</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>\n",
            "XML saved to: path/to/save/xml/38027239.xml\n",
            "Details URL: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=38025819&retmode=xml&api_key=9edd38677707c08b2a96ed1a6e8c61c47408\n",
            "Details Response Content: <?xml version=\"1.0\" ?>\n",
            "<!DOCTYPE PubmedArticleSet PUBLIC \"-//NLM//DTD PubMedArticle, 1st January 2023//EN\" \"https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd\">\n",
            "<PubmedArticleSet>\n",
            "<PubmedArticle><MedlineCitation Status=\"PubMed-not-MEDLINE\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38025819</PMID><DateRevised><Year>2023</Year><Month>12</Month><Day>01</Day></DateRevised><Article PubModel=\"Print-Electronic\"><Journal><ISSN IssnType=\"Print\">2218-6751</ISSN><JournalIssue CitedMedium=\"Print\"><Volume>12</Volume><Issue>10</Issue><PubDate><Year>2023</Year><Month>Oct</Month><Day>31</Day></PubDate></JournalIssue><Title>Translational lung cancer research</Title><ISOAbbreviation>Transl Lung Cancer Res</ISOAbbreviation></Journal><ArticleTitle>Exploration of a novel prognostic model based on nomogram in non-small cell lung cancer patients with distant organ metastasis: implications for immunotherapy.</ArticleTitle><Pagination><StartPage>2040</StartPage><EndPage>2054</EndPage><MedlinePgn>2040-2054</MedlinePgn></Pagination><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.21037/tlcr-23-480</ELocationID><Abstract><AbstractText Label=\"BACKGROUND\" NlmCategory=\"UNASSIGNED\">Evidence for the effects of immunotherapy in non-small cell lung cancer (NSCLC) patients with distant organ metastasis is insufficient, and the predictive efficacy of established markers in tissue and blood is elusive. Our study aimed to determine the prognostic factors and develop a survival prognosis model for these patients.</AbstractText><AbstractText Label=\"METHODS\" NlmCategory=\"UNASSIGNED\">A total of 100 advanced NSCLC patients with distant organ metastases, who received single or combination immune checkpoint inhibitors (ICIs) in Xijing Hospital between June 2018 and June 2021, were enrolled for retrospective analysis. The major clinicopathological parameters were collected, and associated survival outcomes were followed up by telephone or inpatient follow-up for nearly 3 years to assess prognoses. The survival prognosis model was established based on univariate and multivariate Cox regression analyses to determine the candidate prognostic factors.</AbstractText><AbstractText Label=\"RESULTS\" NlmCategory=\"UNASSIGNED\">From the start of immunotherapy to the last follow-up, 77 patients progressed and 42 patients died, with a median follow-up of 18 months [95% confidence interval (CI): 15-19.9]. The median progression-free survival (PFS) and overall survival (OS) were 8 months (95% CI: 5.6-10.4) and 21 months (95% CI: 8.9-33.1), respectively. Multivariate Cox proportional hazards analysis showed Eastern Cooperative Oncology Group performance status (ECOG PS), body mass index (BMI), age-adjusted Charlson comorbidity index (ACCI), lactate dehydrogenase (LDH), and absolute neutrophil count (ANC) were correlated significantly with OS. Based on these five predictive factors, a nomogram and corresponding dynamic web page were constructed with a concordance index (C-index) of 0.81 and a 95% CI of 0.778-0.842. Additionally, the calibration plot and time-receiver operating characteristic (ROC) curve validated the precision of the model at 6-, 12-, and 18-month area under the curves (AUCs) reached 0.934, 0.829, and 0.846, respectively. According to the critical point of the model, patients were further divided into a high-risk total point score (TPS) &gt;258, middle-risk (204&lt; TPS &#x2264;258), and low-risk group (TPS &#x2264;204), and significant OS differences were observed among the three subgroups (median OS: 4.8 <i>vs.</i> 13.0 <i>vs.</i> 32.9 months).</AbstractText><AbstractText Label=\"CONCLUSIONS\" NlmCategory=\"UNASSIGNED\">A feasible and practical model based on clinical characteristics has been developed to predict the prognosis of NSCLC patients with distant organ metastasis undergoing immunotherapy.</AbstractText><CopyrightInformation>2023 Translational Lung Cancer Research. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\" EqualContrib=\"Y\"><LastName>Wang</LastName><ForeName>Min</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pulmonary and Critical Care of Medicine, Xijing Hospital of Air Force Medical University, Xi'an, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\" EqualContrib=\"Y\"><LastName>Zhang</LastName><ForeName>Yong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pulmonary and Critical Care of Medicine, Xijing Hospital of Air Force Medical University, Xi'an, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\" EqualContrib=\"Y\"><LastName>Liu</LastName><ForeName>Mingchuan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Tangdu Hospital of Air Force Medical University, Xi'an, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\" EqualContrib=\"Y\"><LastName>Wang</LastName><ForeName>Yuanyong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Thoracic Surgery, Tangdu Hospital of Air Force Medical University, Xi'an, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Niu</LastName><ForeName>Xiaona</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Tangdu Hospital of Air Force Medical University, Xi'an, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Qiu</LastName><ForeName>Dan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Pulmonary and Critical Care of Medicine, Xijing Hospital of Air Force Medical University, Xi'an, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Xi</LastName><ForeName>Hangtian</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Pulmonary and Critical Care of Medicine, Xijing Hospital of Air Force Medical University, Xi'an, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Zhou</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pulmonary and Critical Care of Medicine, Xijing Hospital of Air Force Medical University, Xi'an, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Chang</LastName><ForeName>Ning</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Pulmonary and Critical Care of Medicine, Xijing Hospital of Air Force Medical University, Xi'an, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Xu</LastName><ForeName>Tianqi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Pulmonary and Critical Care of Medicine, Xijing Hospital of Air Force Medical University, Xi'an, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Xing</LastName><ForeName>Liangliang</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Pulmonary and Critical Care of Medicine, Xijing Hospital of Air Force Medical University, Xi'an, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Yamauchi</LastName><ForeName>Yoshikane</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Surgery, Teikyo University School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Terra</LastName><ForeName>Ricardo Mingarini</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Thoracic Surgery Division, Heart Institute (InCor) do Hospital das Cl&#xed;nicas da Faculdade de Medicina, Universidade de S&#xe3;o Paulo, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Tane</LastName><ForeName>Shinya</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Thoracic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Moon</LastName><ForeName>Mi Hyoung</ForeName><Initials>MH</Initials><AffiliationInfo><Affiliation>Department of Thoracic and Cardiovascular Surgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Yan</LastName><ForeName>Xiaolong</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Thoracic Surgery, Tangdu Hospital of Air Force Medical University, Xi'an, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Zhao</LastName><ForeName>Feng</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Pulmonary and Critical Care of Medicine, Xijing Hospital of Air Force Medical University, Xi'an, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Zhang</LastName><ForeName>Jian</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pulmonary and Critical Care of Medicine, Xijing Hospital of Air Force Medical University, Xi'an, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2023</Year><Month>10</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Transl Lung Cancer Res</MedlineTA><NlmUniqueID>101646875</NlmUniqueID><ISSNLinking>2218-6751</ISSNLinking></MedlineJournalInfo><KeywordList Owner=\"NOTNLM\"><Keyword MajorTopicYN=\"N\">Non-small cell lung cancer (NSCLC)</Keyword><Keyword MajorTopicYN=\"N\">distant organ metastasis</Keyword><Keyword MajorTopicYN=\"N\">immunotherapy</Keyword><Keyword MajorTopicYN=\"N\">nomogram</Keyword><Keyword MajorTopicYN=\"N\">prognostic model</Keyword></KeywordList><CoiStatement>Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-23-480/coif). The authors have no conflicts of interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"received\"><Year>2023</Year><Month>7</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus=\"accepted\"><Year>2023</Year><Month>10</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus=\"medline\"><Year>2023</Year><Month>11</Month><Day>29</Day><Hour>18</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2023</Year><Month>11</Month><Day>29</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2023</Year><Month>11</Month><Day>29</Day><Hour>16</Hour><Minute>37</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38025819</ArticleId><ArticleId IdType=\"pmc\">PMC10654434</ArticleId><ArticleId IdType=\"doi\">10.21037/tlcr-23-480</ArticleId><ArticleId IdType=\"pii\">tlcr-12-10-2040</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022. CA Cancer J Clin 2022;72:7-33. 10.3322/caac.21708</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3322/caac.21708</ArticleId><ArticleId IdType=\"pubmed\">35020204</ArticleId></ArticleIdList></Reference><Reference><Citation>Ettinger DS, Wood DE, Aisner DL, et al. Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2022;20:497-530. 10.6004/jnccn.2022.0025</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.6004/jnccn.2022.0025</ArticleId><ArticleId IdType=\"pubmed\">35545176</ArticleId></ArticleIdList></Reference><Reference><Citation>Schabath MB, Cote ML. Cancer Progress and Priorities: Lung Cancer. Cancer Epidemiol Biomarkers Prev 2019;28:1563-79. 10.1158/1055-9965.EPI-19-0221</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1158/1055-9965.EPI-19-0221</ArticleId><ArticleId IdType=\"pmc\">PMC6777859</ArticleId><ArticleId IdType=\"pubmed\">31575553</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamba N, Wen PY, Aizer AA. Epidemiology of brain metastases and leptomeningeal disease. Neuro Oncol 2021;23:1447-56. 10.1093/neuonc/noab101</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/neuonc/noab101</ArticleId><ArticleId IdType=\"pmc\">PMC8408881</ArticleId><ArticleId IdType=\"pubmed\">33908612</ArticleId></ArticleIdList></Reference><Reference><Citation>da Silva GT, Bergmann A, Thuler LCS. Incidence and Risk Factors for Bone Metastasis in Non-Small Cell Lung Cancer. Asian Pac J Cancer Prev 2019;20:45-51. 10.31557/APJCP.2019.20.1.45</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.31557/APJCP.2019.20.1.45</ArticleId><ArticleId IdType=\"pmc\">PMC6485556</ArticleId><ArticleId IdType=\"pubmed\">30678379</ArticleId></ArticleIdList></Reference><Reference><Citation>Borghaei H, Gettinger S, Vokes EE, et al. Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer. J Clin Oncol 2021;39:723-33. 10.1200/JCO.20.01605</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1200/JCO.20.01605</ArticleId><ArticleId IdType=\"pmc\">PMC8078445</ArticleId><ArticleId IdType=\"pubmed\">33449799</ArticleId></ArticleIdList></Reference><Reference><Citation>Garon EB, Hellmann MD, Rizvi NA, et al. Five-Year Overall Survival for Patients With Advanced Non-Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study. J Clin Oncol 2019;37:2518-27. 10.1200/JCO.19.00934</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1200/JCO.19.00934</ArticleId><ArticleId IdType=\"pmc\">PMC6768611</ArticleId><ArticleId IdType=\"pubmed\">31154919</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonia SJ, Borghaei H, Ramalingam SS, et al. Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis. Lancet Oncol 2019;20:1395-408. 10.1016/S1470-2045(19)30407-3</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/S1470-2045(19)30407-3</ArticleId><ArticleId IdType=\"pmc\">PMC7193685</ArticleId><ArticleId IdType=\"pubmed\">31422028</ArticleId></ArticleIdList></Reference><Reference><Citation>Reck M, Rodr&#xed;guez-Abreu D, Robinson AG, et al. Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score &#x2265;50. J Clin Oncol 2021;39:2339-49. 10.1200/JCO.21.00174</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1200/JCO.21.00174</ArticleId><ArticleId IdType=\"pmc\">PMC8280089</ArticleId><ArticleId IdType=\"pubmed\">33872070</ArticleId></ArticleIdList></Reference><Reference><Citation>Vilari&#xf1;o N, Bruna J, Bosch-Barrera J, et al. Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic. Cancer Treat Rev 2020;89:102067. 10.1016/j.ctrv.2020.102067</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.ctrv.2020.102067</ArticleId><ArticleId IdType=\"pubmed\">32682248</ArticleId></ArticleIdList></Reference><Reference><Citation>El Rassy E, Botticella A, Kattan J, et al. Non-small cell lung cancer brain metastases and the immune system: From brain metastases development to treatment. Cancer Treat Rev 2018;68:69-79. 10.1016/j.ctrv.2018.05.015</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.ctrv.2018.05.015</ArticleId><ArticleId IdType=\"pubmed\">29883857</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z, Duan J, Cai S, et al. Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel. JAMA Oncol 2019;5:696-702. 10.1001/jamaoncol.2018.7098</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1001/jamaoncol.2018.7098</ArticleId><ArticleId IdType=\"pmc\">PMC6512308</ArticleId><ArticleId IdType=\"pubmed\">30816954</ArticleId></ArticleIdList></Reference><Reference><Citation>Hulsbergen AFC, Mammi M, Nagtegaal SHJ, et al. Programmed Death Receptor Ligand One Expression May Independently Predict Survival in Patients With Non-Small Cell Lung Carcinoma Brain Metastases Receiving Immunotherapy. Int J Radiat Oncol Biol Phys 2020;108:258-67. 10.1016/j.ijrobp.2020.04.018</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.ijrobp.2020.04.018</ArticleId><ArticleId IdType=\"pubmed\">32335185</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim R, Keam B, Kim S, et al. Differences in tumor microenvironments between primary lung tumors and brain metastases in lung cancer patients: therapeutic implications for immune checkpoint inhibitors. BMC Cancer 2019;19:19. 10.1186/s12885-018-5214-8</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1186/s12885-018-5214-8</ArticleId><ArticleId IdType=\"pmc\">PMC6322302</ArticleId><ArticleId IdType=\"pubmed\">30616523</ArticleId></ArticleIdList></Reference><Reference><Citation>T&#xe9;gl&#xe1;si V, Pipek O, L&#xf3;zsa R, et al. PD-L1 Expression of Lung Cancer Cells, Unlike Infiltrating Immune Cells, Is Stable and Unaffected by Therapy During Brain Metastasis. Clin Lung Cancer 2019;20:363-369.e2. 10.1016/j.cllc.2019.05.008</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.cllc.2019.05.008</ArticleId><ArticleId IdType=\"pubmed\">31178388</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian Y, He Y, Li X, et al. Novel nomograms to predict lymph node metastasis and distant metastasis in resected patients with early-stage non-small cell lung cancer. Ann Palliat Med 2021;10:2548-66. 10.21037/apm-20-1756</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.21037/apm-20-1756</ArticleId><ArticleId IdType=\"pubmed\">33691451</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng K, Li S, Zhang J, et al. Prognostic value of thoracic tumor staging and volume parameters in non-small cell lung cancer patients with synchronous solitary bone metastasis. J Thorac Dis 2022;14:1130-8. 10.21037/jtd-22-113</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.21037/jtd-22-113</ArticleId><ArticleId IdType=\"pmc\">PMC9096287</ArticleId><ArticleId IdType=\"pubmed\">35572912</ArticleId></ArticleIdList></Reference><Reference><Citation>Cortellini A, Ricciuti B, Tiseo M, et al. Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression &#x2265;50%: a multicenter study with external validation. J Immunother Cancer 2020;8:e001403. 10.1136/jitc-2020-001403</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1136/jitc-2020-001403</ArticleId><ArticleId IdType=\"pmc\">PMC7574933</ArticleId><ArticleId IdType=\"pubmed\">33077515</ArticleId></ArticleIdList></Reference><Reference><Citation>Ready NE, Audigier-Valette C, Goldman JW, et al. First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817. J Immunother Cancer 2023;11:e006127. 10.1136/jitc-2022-006127</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1136/jitc-2022-006127</ArticleId><ArticleId IdType=\"pmc\">PMC9896179</ArticleId><ArticleId IdType=\"pubmed\">36725084</ArticleId></ArticleIdList></Reference><Reference><Citation>West H. Prognostic models for immunotherapy: emerging factors for an evolving treatment landscape. Transl Lung Cancer Res 2021;10:9-12. 10.21037/tlcr-2020-17</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.21037/tlcr-2020-17</ArticleId><ArticleId IdType=\"pmc\">PMC7867764</ArticleId><ArticleId IdType=\"pubmed\">33569288</ArticleId></ArticleIdList></Reference><Reference><Citation>Botticelli A, Salati M, Di Pietro FR, et al. A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab. J Transl Med 2019;17:99. 10.1186/s12967-019-1847-x</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1186/s12967-019-1847-x</ArticleId><ArticleId IdType=\"pmc\">PMC6437908</ArticleId><ArticleId IdType=\"pubmed\">30917841</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng H, Huang WW, Liu YJ, et al. Development and Validation of a Nomogram for Predicting Prognosis to Immune Checkpoint Inhibitors Plus Chemotherapy in Patients With Non-Small Cell Lung Cancer. Front Oncol 2021;11:685047. 10.3389/fonc.2021.685047</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3389/fonc.2021.685047</ArticleId><ArticleId IdType=\"pmc\">PMC8397581</ArticleId><ArticleId IdType=\"pubmed\">34458139</ArticleId></ArticleIdList></Reference><Reference><Citation>Blank CU, Haanen JB, Ribas A, et al. Cancer Immunology. The \"cancer immunogram\". Science 2016;352:658-60. 10.1126/science.aaf2834</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1126/science.aaf2834</ArticleId><ArticleId IdType=\"pubmed\">27151852</ArticleId></ArticleIdList></Reference><Reference><Citation>Turley SJ, Cremasco V, Astarita JL. Immunological hallmarks of stromal cells in the tumour microenvironment. Nat Rev Immunol 2015;15:669-82. 10.1038/nri3902</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/nri3902</ArticleId><ArticleId IdType=\"pubmed\">26471778</ArticleId></ArticleIdList></Reference><Reference><Citation>Murciano-Goroff YR, Warner AB, Wolchok JD. The future of cancer immunotherapy: microenvironment-targeting combinations. Cell Res 2020;30:507-19. 10.1038/s41422-020-0337-2</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/s41422-020-0337-2</ArticleId><ArticleId IdType=\"pmc\">PMC7264181</ArticleId><ArticleId IdType=\"pubmed\">32467593</ArticleId></ArticleIdList></Reference><Reference><Citation>Cali Daylan AE, Halmos B. Long-term benefit of immunotherapy in metastatic non-small cell lung cancer: the tale of the tail. Transl Lung Cancer Res 2023;12:1636-42. 10.21037/tlcr-23-245</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.21037/tlcr-23-245</ArticleId><ArticleId IdType=\"pmc\">PMC10413014</ArticleId><ArticleId IdType=\"pubmed\">37577318</ArticleId></ArticleIdList></Reference><Reference><Citation>Passiglia F, Caglevic C, Giovannetti E, et al. Primary and metastatic brain cancer genomics and emerging biomarkers for immunomodulatory cancer treatment. Semin Cancer Biol 2018;52:259-68. 10.1016/j.semcancer.2018.01.015</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.semcancer.2018.01.015</ArticleId><ArticleId IdType=\"pubmed\">29391205</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Conte A, De Carlo E, Bertoli E, et al. Bone Metastasis and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer (NSCLC): Microenvironment and Possible Clinical Implications. Int J Mol Sci 2022;23:6832. 10.3390/ijms23126832</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3390/ijms23126832</ArticleId><ArticleId IdType=\"pmc\">PMC9224636</ArticleId><ArticleId IdType=\"pubmed\">35743275</ArticleId></ArticleIdList></Reference><Reference><Citation>Asano Y, Yamamoto N, Demura S, et al. The Therapeutic Effect and Clinical Outcome of Immune Checkpoint Inhibitors on Bone Metastasis in Advanced Non-Small-Cell Lung Cancer. Front Oncol 2022;12:871675. 10.3389/fonc.2022.871675</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3389/fonc.2022.871675</ArticleId><ArticleId IdType=\"pmc\">PMC9010859</ArticleId><ArticleId IdType=\"pubmed\">35433422</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Zhang Q, Lv Y, et al. Prognostic factors of survival in patients with non-small cell lung cancer: a competing risk model using the SEER database. Transl Cancer Res 2022;11:3974-85. 10.21037/tcr-21-2114</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.21037/tcr-21-2114</ArticleId><ArticleId IdType=\"pmc\">PMC9745371</ArticleId><ArticleId IdType=\"pubmed\">36523301</ArticleId></ArticleIdList></Reference><Reference><Citation>Chai R, Fan Y, Zhao J, et al. Prognostic nomogram on clinicopathologic features and serum indicators for advanced non-small cell lung cancer patients treated with anti-PD-1 inhibitors. Ann Transl Med 2020;8:1078. 10.21037/atm-20-4297</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.21037/atm-20-4297</ArticleId><ArticleId IdType=\"pmc\">PMC7575979</ArticleId><ArticleId IdType=\"pubmed\">33145297</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheng Y, Tong L, Geyu L. An immune risk score with potential implications in prognosis and immunotherapy of metastatic melanoma. Int Immunopharmacol 2020;88:106921. 10.1016/j.intimp.2020.106921</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.intimp.2020.106921</ArticleId><ArticleId IdType=\"pubmed\">32871477</ArticleId></ArticleIdList></Reference><Reference><Citation>Felip E, Ardizzoni A, Ciuleanu T, et al. CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations. Eur J Cancer 2020;127:160-72. 10.1016/j.ejca.2019.11.019</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.ejca.2019.11.019</ArticleId><ArticleId IdType=\"pubmed\">32028209</ArticleId></ArticleIdList></Reference><Reference><Citation>Spigel DR, McCleod M, Jotte RM, et al. Safety, Efficacy, and Patient-Reported Health-Related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer, Including Patients Aged 70 Years or Older or with Poor Performance Status (CheckMate 153). J Thorac Oncol 2019;14:1628-39.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">31121324</ArticleId></ArticleIdList></Reference><Reference><Citation>Muchnik E, Loh KP, Strawderman M, et al. Immune Checkpoint Inhibitors in Real-World Treatment of Older Adults with Non-Small Cell Lung Cancer. J Am Geriatr Soc 2019;67:905-12. 10.1111/jgs.15750</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1111/jgs.15750</ArticleId><ArticleId IdType=\"pmc\">PMC7814272</ArticleId><ArticleId IdType=\"pubmed\">30698276</ArticleId></ArticleIdList></Reference><Reference><Citation>Duggal NA, Niemiro G, Harridge SDR, et al. Can physical activity ameliorate immunosenescence and thereby reduce age-related multi-morbidity? Nat Rev Immunol 2019;19:563-72. 10.1038/s41577-019-0177-9</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/s41577-019-0177-9</ArticleId><ArticleId IdType=\"pubmed\">31175337</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedlaender A, Banna GL, Buffoni L, et al. Poor-Performance Status Assessment of Patients with Non-small Cell Lung Cancer Remains Vague and Blurred in the Immunotherapy Era. Curr Oncol Rep 2019;21:107. 10.1007/s11912-019-0852-9</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s11912-019-0852-9</ArticleId><ArticleId IdType=\"pubmed\">31768759</ArticleId></ArticleIdList></Reference><Reference><Citation>Badaoui S, Shahnam A, McKinnon RA, et al. The predictive utility of patient-reported outcomes and performance status for survival in metastatic lung cancer patients treated with chemoimmunotherapy. Transl Lung Cancer Res 2022;11:432-9. 10.21037/tlcr-21-938</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.21037/tlcr-21-938</ArticleId><ArticleId IdType=\"pmc\">PMC8988084</ArticleId><ArticleId IdType=\"pubmed\">35399575</ArticleId></ArticleIdList></Reference><Reference><Citation>Facchinetti F, Mazzaschi G, Barbieri F, et al. First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status. Eur J Cancer 2020;130:155-67. 10.1016/j.ejca.2020.02.023</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.ejca.2020.02.023</ArticleId><ArticleId IdType=\"pubmed\">32220780</ArticleId></ArticleIdList></Reference><Reference><Citation>Charlson ME, Carrozzino D, Guidi J, et al. Charlson Comorbidity Index: A Critical Review of Clinimetric Properties. Psychother Psychosom 2022;91:8-35. 10.1159/000521288</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1159/000521288</ArticleId><ArticleId IdType=\"pubmed\">34991091</ArticleId></ArticleIdList></Reference><Reference><Citation>Kellokumpu I, Kairaluoma M, Mecklin JP, et al. Impact of Age and Comorbidity on Multimodal Management and Survival from Colorectal Cancer: A Population-Based Study. J Clin Med 2021;10:1751. 10.3390/jcm10081751</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3390/jcm10081751</ArticleId><ArticleId IdType=\"pmc\">PMC8073362</ArticleId><ArticleId IdType=\"pubmed\">33920665</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaseda K, Hishida T, Masai K, et al. Clinicopathological and prognostic features of operable non-small cell lung cancer patients with diabetes mellitus. J Surg Oncol 2021;123:332-41. 10.1002/jso.26243</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1002/jso.26243</ArticleId><ArticleId IdType=\"pubmed\">33002203</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao L, Leung LH, Wang J, et al. Association between Charlson comorbidity index score and outcome in patients with stage IIIB-IV non-small cell lung cancer. BMC Pulm Med 2017;17:112. 10.1186/s12890-017-0452-0</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1186/s12890-017-0452-0</ArticleId><ArticleId IdType=\"pmc\">PMC5556668</ArticleId><ArticleId IdType=\"pubmed\">28806935</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z, Aguilar EG, Luna JI, et al. Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade. Nat Med 2019;25:141-51. 10.1038/s41591-018-0221-5</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/s41591-018-0221-5</ArticleId><ArticleId IdType=\"pmc\">PMC6324991</ArticleId><ArticleId IdType=\"pubmed\">30420753</ArticleId></ArticleIdList></Reference><Reference><Citation>Kichenadasse G, Miners JO, Mangoni AA, et al. Association Between Body Mass Index and Overall Survival With Immune Checkpoint Inhibitor Therapy for Advanced Non-Small Cell Lung Cancer. JAMA Oncol 2020;6:512-8. 10.1001/jamaoncol.2019.5241</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1001/jamaoncol.2019.5241</ArticleId><ArticleId IdType=\"pmc\">PMC6990855</ArticleId><ArticleId IdType=\"pubmed\">31876896</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrucci PF, Ascierto PA, Pigozzo J, et al. Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab. Ann Oncol 2018;29:524. 10.1093/annonc/mdx059</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/annonc/mdx059</ArticleId><ArticleId IdType=\"pubmed\">28379318</ArticleId></ArticleIdList></Reference><Reference><Citation>Soyano AE, Dholaria B, Marin-Acevedo JA, et al. Peripheral blood biomarkers correlate with outcomes in advanced non-small cell lung Cancer patients treated with anti-PD-1 antibodies. J Immunother Cancer 2018;6:129. 10.1186/s40425-018-0447-2</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1186/s40425-018-0447-2</ArticleId><ArticleId IdType=\"pmc\">PMC6251165</ArticleId><ArticleId IdType=\"pubmed\">30470260</ArticleId></ArticleIdList></Reference><Reference><Citation>Sangaletti S, Ferrara R, Tripodo C, et al. Myeloid cell heterogeneity in lung cancer: implication for immunotherapy. Cancer Immunol Immunother 2021;70:2429-38. 10.1007/s00262-021-02916-5</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s00262-021-02916-5</ArticleId><ArticleId IdType=\"pmc\">PMC8017108</ArticleId><ArticleId IdType=\"pubmed\">33797567</ArticleId></ArticleIdList></Reference><Reference><Citation>Mezquita L, Preeshagul I, Auclin E, et al. Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics. Eur J Cancer 2021;151:211-20. 10.1016/j.ejca.2021.03.011</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.ejca.2021.03.011</ArticleId><ArticleId IdType=\"pubmed\">34022698</ArticleId></ArticleIdList></Reference><Reference><Citation>Bryant AK, Sankar K, Strohbehn GW, et al. Prognostic and predictive value of neutrophil-to-lymphocyte ratio with adjuvant immunotherapy in stage III non-small-cell lung cancer. Lung Cancer 2022;163:35-41. 10.1016/j.lungcan.2021.11.021</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.lungcan.2021.11.021</ArticleId><ArticleId IdType=\"pmc\">PMC8770596</ArticleId><ArticleId IdType=\"pubmed\">34896803</ArticleId></ArticleIdList></Reference><Reference><Citation>Cortellini A, Ricciuti B, Borghaei H, et al. Differential prognostic effect of systemic inflammation in patients with non-small cell lung cancer treated with immunotherapy or chemotherapy: A post hoc analysis of the phase 3 OAK trial. Cancer 2022;128:3067-79. 10.1002/cncr.34348</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1002/cncr.34348</ArticleId><ArticleId IdType=\"pubmed\">35727053</ArticleId></ArticleIdList></Reference><Reference><Citation>Koukourakis MI, Giatromanolaki A, Sivridis E, et al. Lactate dehydrogenase-5 (LDH-5) overexpression in non-small-cell lung cancer tissues is linked to tumour hypoxia, angiogenic factor production and poor prognosis. Br J Cancer 2003;89:877-85. 10.1038/sj.bjc.6601205</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/sj.bjc.6601205</ArticleId><ArticleId IdType=\"pmc\">PMC2394471</ArticleId><ArticleId IdType=\"pubmed\">12942121</ArticleId></ArticleIdList></Reference><Reference><Citation>Desai AD, Chinta S, Yeh C, et al. An analysis of lactate dehydrogenase (LDH) levels in advanced stage IV melanoma of the skin: prognostic capabilities and demographic variability. Arch Dermatol Res 2023;315:799-806. 10.1007/s00403-022-02425-0</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s00403-022-02425-0</ArticleId><ArticleId IdType=\"pubmed\">36318305</ArticleId></ArticleIdList></Reference><Reference><Citation>Tjokrowidjaja A, Lord SJ, John T, et al. Pre- and on-treatment lactate dehydrogenase as a prognostic and predictive biomarker in advanced non-small cell lung cancer. Cancer 2022;128:1574-83. 10.1002/cncr.34113</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1002/cncr.34113</ArticleId><ArticleId IdType=\"pmc\">PMC9306897</ArticleId><ArticleId IdType=\"pubmed\">35090047</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S, Lv J, Lv J, et al. Prognostic value of lactate dehydrogenase in non-small cell lung cancer patients with brain metastases: a retrospective cohort study. J Thorac Dis 2022;14:4468-81. 10.21037/jtd-22-1502</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.21037/jtd-22-1502</ArticleId><ArticleId IdType=\"pmc\">PMC9745527</ArticleId><ArticleId IdType=\"pubmed\">36524070</ArticleId></ArticleIdList></Reference><Reference><Citation>Takada K, Takamori S, Matsubara T, et al. Clinical significance of preoperative inflammatory markers in non-small cell lung cancer patients: A multicenter retrospective study. PLoS One 2020;15:e0241580. 10.1371/journal.pone.0241580</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1371/journal.pone.0241580</ArticleId><ArticleId IdType=\"pmc\">PMC7605706</ArticleId><ArticleId IdType=\"pubmed\">33137158</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>\n",
            "XML saved to: path/to/save/xml/38025819.xml\n",
            "Details URL: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=38023992&retmode=xml&api_key=9edd38677707c08b2a96ed1a6e8c61c47408\n",
            "Details Response Content: <?xml version=\"1.0\" ?>\n",
            "<!DOCTYPE PubmedArticleSet PUBLIC \"-//NLM//DTD PubMedArticle, 1st January 2023//EN\" \"https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd\">\n",
            "<PubmedArticleSet>\n",
            "<PubmedArticle><MedlineCitation Status=\"PubMed-not-MEDLINE\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38023992</PMID><DateRevised><Year>2023</Year><Month>12</Month><Day>01</Day></DateRevised><Article PubModel=\"Print-Electronic\"><Journal><ISSN IssnType=\"Electronic\">2692-3114</ISSN><JournalIssue CitedMedium=\"Internet\"><Volume>4</Volume><Issue>5</Issue><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Exploration of targeted anti-tumor therapy</Title><ISOAbbreviation>Explor Target Antitumor Ther</ISOAbbreviation></Journal><ArticleTitle>Coronavirus disease 2019 and lung cancer: where are we?</ArticleTitle><Pagination><StartPage>1082</StartPage><EndPage>1094</EndPage><MedlinePgn>1082-1094</MedlinePgn></Pagination><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.37349/etat.2023.00182</ELocationID><Abstract><AbstractText>Oncology patients are more susceptible to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection due to hospital contact and an immunological system that can be compromised by antineoplastic therapy and supportive treatments. Certain similarities have been described in the physiopathology of coronavirus disease 2019 (COVID-19) and lung cancer (LC) that may explain the higher probability of these patients of developing a more serious disease with more frequent hospitalizations and even death, especially with the addition of smoking, cardiovascular and respiratory comorbidities, old age and corticosteroids use. Pre-existing lesions and cancer therapies change the normal architecture of the lungs, so diagnostic scales such as COVID-19 Reporting and Data System (CO-RADS) are of vital importance for a correct diagnosis and patient homogenization, with a high inter-observer correlation. Moreover, anticancer treatments have required an adaptation to reduce the number of visits to the hospital [hypofractionated radiotherapy (RT), larger intervals between chemotherapy cycles, delay in follow-up tests, among others]. In a way, this has also caused a delay in the diagnosis of new cancers. On the other hand, vaccination has had a positive impact on the mortality of these patients, who maintain a similar seroprevalence to the rest of the population, with a similar impact in mortality.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2023.</CopyrightInformation></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Ocanto</LastName><ForeName>Abrahams</ForeName><Initials>A</Initials><Identifier Source=\"ORCID\">0000-0002-6494-8197</Identifier><AffiliationInfo><Affiliation>Department of Radiation Oncology, Hospital Universitario San Francisco de As&#xed;s, GenesiCare Madrid, 28002 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiation Oncology, Hospital Universitario Vithas La Milagrosa, GenesiCare Madrid, 28002 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Mielgo-Rubio</LastName><ForeName>Xabier</ForeName><Initials>X</Initials><Identifier Source=\"ORCID\">0000-0002-0985-6150</Identifier><AffiliationInfo><Affiliation>Department of Medical Oncology, Hospital Universitario Fundaci&#xf3;n Alcorc&#xf3;n, 28922 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Luna Tirado</LastName><ForeName>Javier</ForeName><Initials>J</Initials><Identifier Source=\"ORCID\">0000-0003-2904-8895</Identifier><AffiliationInfo><Affiliation>Department of Radiation Oncology, Hospital Universitario Fundaci&#xf3;n Jim&#xe9;nez D&#xed;az, 28040 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Linares Mesa</LastName><ForeName>Nuria</ForeName><Initials>N</Initials><Identifier Source=\"ORCID\">0000-0001-7414-4638</Identifier><AffiliationInfo><Affiliation>Department of Radiation Oncology, Hospital Universitario Juan Ram&#xf3;n Jim&#xe9;nez, 21005 Huelva, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>L&#xf3;pez Valc&#xe1;rcel</LastName><ForeName>Marta</ForeName><Initials>M</Initials><Identifier Source=\"ORCID\">0000-0002-4519-2136</Identifier><AffiliationInfo><Affiliation>Department of Radiation Oncology, Hospital Universitario Puerta de Hierro, 28222 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Pedraza</LastName><ForeName>Sara</ForeName><Initials>S</Initials><Identifier Source=\"ORCID\">0000-0001-9387-1937</Identifier><AffiliationInfo><Affiliation>Department of Radiation Oncology, Hospital Universitario 12 de Octubre Madrid, 28041 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Barragan</LastName><ForeName>Victoria Vera</ForeName><Initials>VV</Initials><Identifier Source=\"ORCID\">0000-0003-4841-0394</Identifier><AffiliationInfo><Affiliation>Department of Radiation Oncology, Hospital Universitario de Badajoz, 06080 Badajoz, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Nieto</LastName><ForeName>Patricia Valencia</ForeName><Initials>PV</Initials><Identifier Source=\"ORCID\">0000-0001-9916-7959</Identifier><AffiliationInfo><Affiliation>Department of Radiation Oncology, Hospital Cl&#xed;nico Universitario de Valladolid, 47003 Valladolid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Mart&#xed;n</LastName><ForeName>Juan Zafra</ForeName><Initials>JZ</Initials><Identifier Source=\"ORCID\">0000-0003-4778-4271</Identifier><AffiliationInfo><Affiliation>Group of Translational Research in Cancer Immunotherapy, Centro de Investigaciones M&#xe9;dico-Sanitarias (CIMES), Universidad de M&#xe1;laga (UMA), Instituto de Investigaci&#xf3;n Biom&#xe9;dica de M&#xe1;laga (IBIMA), 29010 M&#xe1;laga, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiation Oncology, Hospital Universitario Virgen de la Victoria, 29010 M&#xe1;laga, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Cou&#xf1;ago</LastName><ForeName>Felipe</ForeName><Initials>F</Initials><Identifier Source=\"ORCID\">0000-0001-7233-0234</Identifier><AffiliationInfo><Affiliation>Department of Radiation Oncology, Hospital Universitario San Francisco de As&#xed;s, GenesiCare Madrid, 28002 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiation Oncology, Hospital Universitario Vithas La Milagrosa, GenesiCare Madrid, 28002 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiation Oncology, Emilio Vargas, GenesisCare Madrid, 28002 Madrid, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType><PublicationType UI=\"D016454\">Review</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2023</Year><Month>10</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Explor Target Antitumor Ther</MedlineTA><NlmUniqueID>101770662</NlmUniqueID><ISSNLinking>2692-3114</ISSNLinking></MedlineJournalInfo><KeywordList Owner=\"NOTNLM\"><Keyword MajorTopicYN=\"N\">Coronavirus disease 2019</Keyword><Keyword MajorTopicYN=\"N\">lung cancer</Keyword><Keyword MajorTopicYN=\"N\">radiotherapy</Keyword></KeywordList><CoiStatement>The authors declare that they have no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"received\"><Year>2023</Year><Month>2</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus=\"accepted\"><Year>2023</Year><Month>8</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus=\"medline\"><Year>2023</Year><Month>11</Month><Day>29</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2023</Year><Month>11</Month><Day>29</Day><Hour>18</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2023</Year><Month>11</Month><Day>29</Day><Hour>16</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38023992</ArticleId><ArticleId IdType=\"pmc\">PMC10651354</ArticleId><ArticleId IdType=\"doi\">10.37349/etat.2023.00182</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Purohit D, Ahirwar AK, Sakarde A, Asia P, Gopal N. COVID-19 and lung pathologies. Horm Mol Biol Clin Investig. 2021;42:435&#x2013;43. doi: 10.1515/hmbci-2020-0096.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1515/hmbci-2020-0096</ArticleId><ArticleId IdType=\"pubmed\">34333882</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID-19 weekly epidemiological update [Internet]  [Cited 2023 Jan 14]. Available from: https://gacetamedica.com/wp-content/uploads/2022/10/20221005_Weekly_Epi_Update_112.pdf .</Citation></Reference><Reference><Citation>Luo J, Rizvi H, Preeshagul IR, Egger JV, Hoyos D, Bandlamudi C, et al. COVID-19 in patients with lung cancer. Ann Oncol. 2020;31:1386&#x2013;96. doi: 10.1016/j.annonc.2020.06.007.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.annonc.2020.06.007</ArticleId><ArticleId IdType=\"pmc\">PMC7297689</ArticleId><ArticleId IdType=\"pubmed\">32561401</ArticleId></ArticleIdList></Reference><Reference><Citation>Oldani S, Petrelli F, Dognini G, Borgonovo K, Parati MC, Ghilardi M, et al. COVID-19 and lung cancer survival: an updated systematic review and meta-analysis. Cancers (Basel) 2022;14:5706. doi: 10.3390/cancers14225706.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3390/cancers14225706</ArticleId><ArticleId IdType=\"pmc\">PMC9688481</ArticleId><ArticleId IdType=\"pubmed\">36428798</ArticleId></ArticleIdList></Reference><Reference><Citation>Rolfo C, Meshulami N, Russo A, Krammer F, Garc&#xed;a-Sastre A, Mack PC, et al. Lung cancer and severe acute respiratory syndrome coronavirus 2 infection: identifying important knowledge gaps for investigation. J Thorac Oncol. 2022;17:214&#x2013;27. doi: 10.1016/j.jtho.2021.11.001.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jtho.2021.11.001</ArticleId><ArticleId IdType=\"pmc\">PMC8579698</ArticleId><ArticleId IdType=\"pubmed\">34774792</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Niu L. Identification of the effects of COVID-19 on patients with pulmonary fibrosis and lung cancer: a bioinformatics analysis and literature review. Sci Rep. 2022;12:16040. doi: 10.1038/s41598-022-20040-x.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/s41598-022-20040-x</ArticleId><ArticleId IdType=\"pmc\">PMC9512912</ArticleId><ArticleId IdType=\"pubmed\">36163484</ArticleId></ArticleIdList></Reference><Reference><Citation>Bian DJH, Sabri S, Abdulkarim BS. Interactions between COVID-19 and lung cancer: lessons learned during the pandemic. Cancers (Basel) 2022;14:3598. doi: 10.3390/cancers14153598.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3390/cancers14153598</ArticleId><ArticleId IdType=\"pmc\">PMC9367272</ArticleId><ArticleId IdType=\"pubmed\">35892857</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmad S, Manzoor S, Siddiqui S, Mariappan N, Zafar I, Ahmad A, et al. Epigenetic underpinnings of inflammation: connecting the dots between pulmonary diseases, lung cancer and COVID-19. Semin Cancer Biol. 2022;83:384&#x2013;98. doi: 10.1016/j.semcancer.2021.01.003.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.semcancer.2021.01.003</ArticleId><ArticleId IdType=\"pmc\">PMC8046427</ArticleId><ArticleId IdType=\"pubmed\">33484868</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottschalk G, Knox K, Roy A. ACE2: at the crossroad of COVID-19 and lung cancer. Gene Rep. 2021;23:101077. doi: 10.1016/j.genrep.2021.101077.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.genrep.2021.101077</ArticleId><ArticleId IdType=\"pmc\">PMC7946539</ArticleId><ArticleId IdType=\"pubmed\">33723522</ArticleId></ArticleIdList></Reference><Reference><Citation>Aramini B, Masciale V, Samarelli AV, Tonelli R, Cerri S, Clini E, et al. Biological effects of COVID-19 on lung cancer: can we drive our decisions. Front Oncol. 2022;12:1029830. doi: 10.3389/fonc.2022.1029830.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3389/fonc.2022.1029830</ArticleId><ArticleId IdType=\"pmc\">PMC9589049</ArticleId><ArticleId IdType=\"pubmed\">36300087</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji P, Zhu J, Zhong Z, Li H, Pang J, Li B, et al. Association of elevated inflammatory markers and severe COVID-19: a meta-analysis. Medicine (Baltimore) 2020;99:e23315. doi: 10.1097/MD.0000000000023315.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1097/MD.0000000000023315</ArticleId><ArticleId IdType=\"pmc\">PMC7676531</ArticleId><ArticleId IdType=\"pubmed\">33217868</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Z, Zheng Z, Liu J. Comparison of COVID-19 and lung cancer via reactive oxygen species signaling. Front Oncol. 2021;11:708263. doi: 10.3389/fonc.2021.708263.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3389/fonc.2021.708263</ArticleId><ArticleId IdType=\"pmc\">PMC8283805</ArticleId><ArticleId IdType=\"pubmed\">34277453</ArticleId></ArticleIdList></Reference><Reference><Citation>Maheswari S, Pethannan R, Sabarimurugan S. Air pollution enhances susceptibility to novel coronavirus (COVID-19) infection &#x2013; an impact study. Environ Anal Health Toxicol. 2020;35:e2020020-0. doi: 10.5620/eaht.2020020.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.5620/eaht.2020020</ArticleId><ArticleId IdType=\"pmc\">PMC7829407</ArticleId><ArticleId IdType=\"pubmed\">33434420</ArticleId></ArticleIdList></Reference><Reference><Citation>Reyes R, L&#xf3;pez-Castro R, Auclin E, Garc&#xed;a T, Chourio MJ, Rodriguez A, et al. MA03.08 impact of COVID-19 pandemic in the diagnosis and prognosis of lung cancer. J Thorac Oncol. 2021;16:S141. doi: 10.1016/j.jtho.2021.01.219.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jtho.2021.01.219</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasymjanova G, Anwar A, Cohen V, Sultanem K, Pepe C, Sakr L, et al. The impact of COVID-19 on the diagnosis and treatment of lung cancer at a Canadian academic center: a retrospective chart review. Curr Oncol. 2021;28:4247&#x2013;55. doi: 10.3390/curroncol28060360.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3390/curroncol28060360</ArticleId><ArticleId IdType=\"pmc\">PMC8544580</ArticleId><ArticleId IdType=\"pubmed\">34898542</ArticleId></ArticleIdList></Reference><Reference><Citation>Analyse des r&#xe9;percussions de la pand&#xe9;mie de la COVID-19 sur les soins et les services en canc&#xe9;rologie au Qu&#xe9;bec [Internet]  Gouvernement du Qu&#xe9;bec; c2021 [cited 2023 Jan 14]. Available from: https://publications.msss.gouv.qc.ca/msss/fichiers/2021/21-210-132W.pdf .</Citation></Reference><Reference><Citation>Jazieh AR, Akbulut H, Curigliano G, Rogado A, Alsharm AA, Razis ED, et al. International Research Network on COVID-19 Impact on Cancer Care. Impact of the COVID-19 pandemic on cancer care: a global collaborative study. JCO Glob Oncol. 2020;6:1428&#x2013;38. doi: 10.1200/GO.20.00351.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1200/GO.20.00351</ArticleId><ArticleId IdType=\"pmc\">PMC7529504</ArticleId><ArticleId IdType=\"pubmed\">32986516</ArticleId></ArticleIdList></Reference><Reference><Citation>Park JY, Lee YJ, Kim T, Lee CY, Kim HI, Kim JH, et al. Collateral effects of the coronavirus disease 2019 pandemic on lung cancer diagnosis in Korea. BMC Cancer. 2020;20:1040. doi: 10.1186/s12885-020-07544-3.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1186/s12885-020-07544-3</ArticleId><ArticleId IdType=\"pmc\">PMC7594984</ArticleId><ArticleId IdType=\"pubmed\">33121456</ArticleId></ArticleIdList></Reference><Reference><Citation>Maringe C, Spicer J, Morris M, Purushotham A, Nolte E, Sullivan R, et al. The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study. Lancet Oncol. 2020;21:1023&#x2013;34. doi: 10.1016/S1470-2045(20)30388-0.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/S1470-2045(20)30388-0</ArticleId><ArticleId IdType=\"pmc\">PMC7417808</ArticleId><ArticleId IdType=\"pubmed\">32702310</ArticleId></ArticleIdList></Reference><Reference><Citation>Cantini L, Mentrasti G, Russo GL, Signorelli D, Pasello G, Rijavec E, et al. Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario. ESMO Open. 2022;7:100406. doi: 10.1016/j.esmoop.2022.100406. Erratum in: ESMO Open. 2022;7:100471.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.esmoop.2022.100406</ArticleId><ArticleId IdType=\"pmc\">PMC8810307</ArticleId><ArticleId IdType=\"pubmed\">35219245</ArticleId></ArticleIdList></Reference><Reference><Citation>Passaro A, Peters S, Mok TSK, Attili I, Mitsudomi T, de Marinis F. Testing for COVID-19 in lung cancer patients. Ann Oncol. 2020;31:832&#x2013;4. doi: 10.1016/j.annonc.2020.04.002.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.annonc.2020.04.002</ArticleId><ArticleId IdType=\"pmc\">PMC7144604</ArticleId><ArticleId IdType=\"pubmed\">32278879</ArticleId></ArticleIdList></Reference><Reference><Citation>Provencio M, Mazarico Gallego JM, Calles A, Anto&#xf1;anzas M, Pangua C, Mielgo Rubio X, et al. Lung cancer patients with COVID-19 in Spain: GRAVID study. Lung Cancer. 2021;157:109&#x2013;15. doi: 10.1016/j.lungcan.2021.05.014.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.lungcan.2021.05.014</ArticleId><ArticleId IdType=\"pmc\">PMC8118702</ArticleId><ArticleId IdType=\"pubmed\">34016490</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Wang Y, Cheng X, Li X, Li J. Impact of coronavirus disease 2019 on lung cancer patients: a meta-analysis. Transl Oncol. 2023;28:101605. doi: 10.1016/j.tranon.2022.101605.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.tranon.2022.101605</ArticleId><ArticleId IdType=\"pmc\">PMC9760620</ArticleId><ArticleId IdType=\"pubmed\">36568513</ArticleId></ArticleIdList></Reference><Reference><Citation>Calabr&#xf2; L, Rossi G, Covre A, Morra A, Maio M. COVID and lung cancer. Curr Oncol Rep. 2021;23:134. doi: 10.1007/s11912-021-01125-8.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s11912-021-01125-8</ArticleId><ArticleId IdType=\"pmc\">PMC8532085</ArticleId><ArticleId IdType=\"pubmed\">34677721</ArticleId></ArticleIdList></Reference><Reference><Citation>Milette S, Fiset PO, Walsh LA, Spicer JD, Quail DF. The innate immune architecture of lung tumors and its implication in disease progression. J Pathol. 2019;247:589&#x2013;605. doi: 10.1002/path.5241.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1002/path.5241</ArticleId><ArticleId IdType=\"pubmed\">30680732</ArticleId></ArticleIdList></Reference><Reference><Citation>Passaro A, Bestvina C, Velez Velez M, Garassino MC, Garon E, Peters S. Severity of COVID-19 in patients with lung cancer: evidence and challenges. J Immunother Cancer. 2021;9:e002266. doi: 10.1136/jitc-2020-002266.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1136/jitc-2020-002266</ArticleId><ArticleId IdType=\"pmc\">PMC7978268</ArticleId><ArticleId IdType=\"pubmed\">33737345</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodrigues R, Costa de Oliveira S. The impact of angiotensin-converting enzyme 2 (ACE2) expression levels in patients with comorbidities on COVID-19 severity: a comprehensive review. Microorganisms. 2021;9:1692. doi: 10.3390/microorganisms9081692.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3390/microorganisms9081692</ArticleId><ArticleId IdType=\"pmc\">PMC8398209</ArticleId><ArticleId IdType=\"pubmed\">34442770</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z, et al. Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 outbreak. Cancer Discov. 2020;10:783&#x2013;91. doi: 10.1158/2159-8290.CD-20-0422.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1158/2159-8290.CD-20-0422</ArticleId><ArticleId IdType=\"pmc\">PMC7309152</ArticleId><ArticleId IdType=\"pubmed\">32345594</ArticleId></ArticleIdList></Reference><Reference><Citation>Winkler T, Ben-David U. Elevated expression of ACE2 in tumor-adjacent normal tissues of cancer patients. Int J Cancer. 2020;147:3264&#x2013;6. doi: 10.1002/ijc.33145.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1002/ijc.33145</ArticleId><ArticleId IdType=\"pubmed\">32525565</ArticleId></ArticleIdList></Reference><Reference><Citation>Desai AD, Lavelle M, Boursiquot BC, Wan EY. Long-term complications of COVID-19. Am J Physiol Cell Physiol. 2022;322:C1&#x2013;11. doi: 10.1152/ajpcell.00375.2021.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1152/ajpcell.00375.2021</ArticleId><ArticleId IdType=\"pmc\">PMC8721906</ArticleId><ArticleId IdType=\"pubmed\">34817268</ArticleId></ArticleIdList></Reference><Reference><Citation>Bungaro M, Passiglia F, Scagliotti GV. COVID-19 and lung cancer: a comprehensive overview from outbreak to recovery. Biomedicines. 2022;10:776. doi: 10.3390/biomedicines10040776.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3390/biomedicines10040776</ArticleId><ArticleId IdType=\"pmc\">PMC9027516</ArticleId><ArticleId IdType=\"pubmed\">35453526</ArticleId></ArticleIdList></Reference><Reference><Citation>Satterfield BA, Bhatt DL, Gersh BJ. Cardiac involvement in the long-term implications of COVID-19. Nat Rev Cardiol. 2022;19:332&#x2013;41. doi: 10.1038/s41569-021-00631-3.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/s41569-021-00631-3</ArticleId><ArticleId IdType=\"pmc\">PMC8532434</ArticleId><ArticleId IdType=\"pubmed\">34686843</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27:601&#x2013;15. doi: 10.1038/s41591-021-01283-z.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType=\"pmc\">PMC8893149</ArticleId><ArticleId IdType=\"pubmed\">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Mahoney LL, Routen A, Gillies C, Ekezie W, Welford A, Zhang A, et al. The prevalence and long-term health effects of long Covid among hospitalised and non-hospitalised populations: a systematic review and meta-analysis. EClinicalMedicine. 2023;55:101762. doi: 10.1016/j.eclinm.2022.101762. Erratum in: EClinicalMedicine. 2023;59:101959.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.eclinm.2022.101762</ArticleId><ArticleId IdType=\"pmc\">PMC9714474</ArticleId><ArticleId IdType=\"pubmed\">36474804</ArticleId></ArticleIdList></Reference><Reference><Citation>Sha Z, Chang K, Mi J, Liang Z, Hu L, Long F, et al. The impact of the COVID-19 pandemic on lung cancer patients. Ann Palliat Med. 2020;9:3373&#x2013;8. doi: 10.21037/apm-20-1662.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.21037/apm-20-1662</ArticleId><ArticleId IdType=\"pubmed\">33065788</ArticleId></ArticleIdList></Reference><Reference><Citation>Rugge M, Zorzi M, Guzzinati S. SARS-CoV-2 infection in the Italian Veneto region: adverse outcomes in patients with cancer. Nat Cancer. 2020;1:784&#x2013;8. doi: 10.1038/s43018-020-0104-9.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/s43018-020-0104-9</ArticleId><ArticleId IdType=\"pubmed\">35122051</ArticleId></ArticleIdList></Reference><Reference><Citation>Garassino MC, Whisenant JG, Huang LC, Trama A, Torri V, Agustoni F, et al. TERAVOLT investigators COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. Lancet Oncol. 2020;21:914&#x2013;22. doi: 10.1016/S1470-2045(20)30314-4.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/S1470-2045(20)30314-4</ArticleId><ArticleId IdType=\"pmc\">PMC7292610</ArticleId><ArticleId IdType=\"pubmed\">32539942</ArticleId></ArticleIdList></Reference><Reference><Citation>Peravali M, Joshi I, Ahn J, Kim C. A systematic review and meta-analysis of clinical characteristics and outcomes in patients with lung cancer with coronavirus disease 2019. JTO Clin Res Rep. 2021;2:100141. doi: 10.1016/j.jtocrr.2020.100141.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jtocrr.2020.100141</ArticleId><ArticleId IdType=\"pmc\">PMC7790456</ArticleId><ArticleId IdType=\"pubmed\">33437971</ArticleId></ArticleIdList></Reference><Reference><Citation>Prokop M, van Everdingen W, van Rees Vellinga T, Quarles van Ufford H, St&#xf6;ger L, Beenen L, et al. COVID-19 Standardized Reporting Working Group of the Dutch Radiological Society CO-RADS: a categorical CT assessment scheme for patients suspected of having COVID-19&#x2014;definition and evaluation. Radiology. 2020;296:E97&#x2013;104. doi: 10.1148/radiol.2020201473.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1148/radiol.2020201473</ArticleId><ArticleId IdType=\"pmc\">PMC7233402</ArticleId><ArticleId IdType=\"pubmed\">32339082</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu G, Chen Y, Runa A, Liu J. Diagnostic performance of CO-RADS for COVID-19: a systematic review and meta-analysis. Eur Radiol. 2022;32:4414&#x2013;26. doi: 10.1007/s00330-022-08576-y.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s00330-022-08576-y</ArticleId><ArticleId IdType=\"pmc\">PMC8961267</ArticleId><ArticleId IdType=\"pubmed\">35348865</ArticleId></ArticleIdList></Reference><Reference><Citation>Penha D, Pinto EG, Matos F, Hochhegger B, Monaghan C, Taborda-Barata L, et al. CO-RADS: coronavirus classification review. J Clin Imaging Sci. 2021;11:9. doi: 10.25259/JCIS_192_2020.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.25259/JCIS_192_2020</ArticleId><ArticleId IdType=\"pmc\">PMC7981938</ArticleId><ArticleId IdType=\"pubmed\">33767901</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzone PJ, Gould MK, Arenberg DA, Chen AC, Choi HK, Detterbeck FC, et al. Management of lung nodules and lung cancer screening during the COVID-19 pandemic: CHEST expert panel report. Chest. 2020;158:406&#x2013;15. doi: 10.1016/j.chest.2020.04.020.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.chest.2020.04.020</ArticleId><ArticleId IdType=\"pmc\">PMC7177089</ArticleId><ArticleId IdType=\"pubmed\">32335067</ArticleId></ArticleIdList></Reference><Reference><Citation>Randall RE, Griffin DE. Within host RNA virus persistence: mechanisms and consequences. Curr Opin Virol. 2017;23:35&#x2013;42. doi: 10.1016/j.coviro.2017.03.001.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.coviro.2017.03.001</ArticleId><ArticleId IdType=\"pmc\">PMC5474179</ArticleId><ArticleId IdType=\"pubmed\">28319790</ArticleId></ArticleIdList></Reference><Reference><Citation>Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395:1417&#x2013;8. doi: 10.1016/S0140-6736(20)30937-5.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/S0140-6736(20)30937-5</ArticleId><ArticleId IdType=\"pmc\">PMC7172722</ArticleId><ArticleId IdType=\"pubmed\">32325026</ArticleId></ArticleIdList></Reference><Reference><Citation>Moriguchi T, Harii N, Goto J, Harada D, Sugawara H, Takamino J, et al. A first case of meningitis/encephalitis associated with SARS-Coronavirus-2. Int J Infect Dis. 2020;94:55&#x2013;8. doi: 10.1016/j.ijid.2020.03.062.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.ijid.2020.03.062</ArticleId><ArticleId IdType=\"pmc\">PMC7195378</ArticleId><ArticleId IdType=\"pubmed\">32251791</ArticleId></ArticleIdList></Reference><Reference><Citation>Saini G, Aneja R. Cancer as a prospective sequela of long COVID-19. Bioessays. 2021;43:e2000331. doi: 10.1002/bies.202000331.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1002/bies.202000331</ArticleId><ArticleId IdType=\"pmc\">PMC8206711</ArticleId><ArticleId IdType=\"pubmed\">33914346</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin L, Luo S, Qin R, Yang M, Wang X, Yang Q, et al. Long-term infection of SARS-CoV-2 changed the body&#x2019;s immune status. Clin Immunol. 2020;218:108524. doi: 10.1016/j.clim.2020.108524.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.clim.2020.108524</ArticleId><ArticleId IdType=\"pmc\">PMC7351676</ArticleId><ArticleId IdType=\"pubmed\">32659373</ArticleId></ArticleIdList></Reference><Reference><Citation>Lan L, Xu D, Ye G, Xia C, Wang S, Li Y, et al. Positive RT-PCR test results in patients recovered from COVID-19. JAMA. 2020;323:1502&#x2013;3. doi: 10.1001/jama.2020.2783.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1001/jama.2020.2783</ArticleId><ArticleId IdType=\"pmc\">PMC7047852</ArticleId><ArticleId IdType=\"pubmed\">32105304</ArticleId></ArticleIdList></Reference><Reference><Citation>Baang JH, Smith C, Mirabelli C, Valesano AL, Manthei DM, Bachman MA, et al. Prolonged severe acute respiratory syndrome coronavirus 2 replication in an immunocompromised patient. J Infect Dis. 2021;223:23&#x2013;7. doi: 10.1093/infdis/jiaa666.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/infdis/jiaa666</ArticleId><ArticleId IdType=\"pmc\">PMC7797758</ArticleId><ArticleId IdType=\"pubmed\">33089317</ArticleId></ArticleIdList></Reference><Reference><Citation>Alpalh&#xe3;o M, Ferreira JA, Filipe P. Persistent SARS-CoV-2 infection and the risk for cancer. Med Hypotheses. 2020;143:109882. doi: 10.1016/j.mehy.2020.109882.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.mehy.2020.109882</ArticleId><ArticleId IdType=\"pmc\">PMC7831646</ArticleId><ArticleId IdType=\"pubmed\">32485314</ArticleId></ArticleIdList></Reference><Reference><Citation>Tu SM. Stem cell theory of cancer: implications of a viral etiology in certain malignancies. Cancers (Basel) 2021;13:2738. doi: 10.3390/cancers13112738.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3390/cancers13112738</ArticleId><ArticleId IdType=\"pmc\">PMC8199000</ArticleId><ArticleId IdType=\"pubmed\">34205851</ArticleId></ArticleIdList></Reference><Reference><Citation>Liapis I, Baritaki S. COVID-19 vs. cancer immunosurveillance: a game of thrones within an inflamed microenviroment. Cancers (Basel) 2022;14:4330. doi: 10.3390/cancers14174330.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3390/cancers14174330</ArticleId><ArticleId IdType=\"pmc\">PMC9455004</ArticleId><ArticleId IdType=\"pubmed\">36077865</ArticleId></ArticleIdList></Reference><Reference><Citation>Habibzadeh P, Dastsooz H, Eshraghi M, &#x141;os MJ, Klionsky DJ, Ghavami S. Autophagy: the potential link between SARS-CoV-2 and cancer. Cancers (Basel) 2021;13:5721. doi: 10.3390/cancers13225721.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3390/cancers13225721</ArticleId><ArticleId IdType=\"pmc\">PMC8616402</ArticleId><ArticleId IdType=\"pubmed\">34830876</ArticleId></ArticleIdList></Reference><Reference><Citation>Jafarzadeh A, Gosain R, Mortazavi SMJ, Nemati M, Jafarzadeh S, Ghaderi A. SARS-CoV-2 infection: a possible risk factor for incidence and recurrence of cancers. Int J Hematol Oncol Stem Cell Res. 2022;16:117&#x2013;27. doi: 10.18502/ijhoscr.v16i2.9205.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.18502/ijhoscr.v16i2.9205</ArticleId><ArticleId IdType=\"pmc\">PMC9547773</ArticleId><ArticleId IdType=\"pubmed\">36304732</ArticleId></ArticleIdList></Reference><Reference><Citation>Mesri EA, Feitelson MA, Munger K. Human viral oncogenesis: a cancer hallmarks analysis. Cell Host Microbe. 2014;15:266&#x2013;82. doi: 10.1016/j.chom.2014.02.011.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.chom.2014.02.011</ArticleId><ArticleId IdType=\"pmc\">PMC3992243</ArticleId><ArticleId IdType=\"pubmed\">24629334</ArticleId></ArticleIdList></Reference><Reference><Citation>Stingi A, Cirillo L. SARS-CoV-2 infection and cancer: evidence for and against a role of SARS-CoV-2 in cancer onset. Bioessays. 2021;43:e2000289. doi: 10.1002/bies.202000289.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1002/bies.202000289</ArticleId><ArticleId IdType=\"pmc\">PMC8209829</ArticleId><ArticleId IdType=\"pubmed\">34081334</ArticleId></ArticleIdList></Reference><Reference><Citation>Slotman BJ, Cremades V, Kirby AM, Ricardi U. European radiation oncology after one year of COVID-19 pandemic. Clin Transl Radiat Oncol. 2021;28:141&#x2013;3. doi: 10.1016/j.ctro.2021.03.011.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.ctro.2021.03.011</ArticleId><ArticleId IdType=\"pmc\">PMC8049845</ArticleId><ArticleId IdType=\"pubmed\">33880421</ArticleId></ArticleIdList></Reference><Reference><Citation>Guckenberger M, Belka C, Bezjak A, Bradley J, Daly ME, DeRuysscher D, et al. Practice recommendations for lung cancer radiotherapy during the COVID-19 pandemic: an ESTRO-ASTRO consensus statement. Int J Radiat Oncol Biol Phys. 2020;107:631&#x2013;40. doi: 10.1016/j.ijrobp.2020.05.012.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.ijrobp.2020.05.012</ArticleId><ArticleId IdType=\"pmc\">PMC7836268</ArticleId><ArticleId IdType=\"pubmed\">32589990</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan L, Wang Q, Zhang D, Ding J, Huang Q, Tang YQ, et al. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. Signal Transduct Target Ther. 2020;5:33. doi: 10.1038/s41392-020-0148-4. Erratum in: Signal Transduct Target Ther. 2020;5:61.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/s41392-020-0148-4</ArticleId><ArticleId IdType=\"pmc\">PMC7100419</ArticleId><ArticleId IdType=\"pubmed\">32296069</ArticleId></ArticleIdList></Reference><Reference><Citation>Siavashpour Z, Goharpey N, Mobasheri M. Radiotherapy based management during Covid-19 pandemic &#x2013; a systematic review of presented consensus and guidelines. Crit Rev Oncol Hematol. 2021;164:103402. doi: 10.1016/j.critrevonc.2021.103402.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.critrevonc.2021.103402</ArticleId><ArticleId IdType=\"pmc\">PMC8242203</ArticleId><ArticleId IdType=\"pubmed\">34214608</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D, Bi N, Zhang T, Zhou Z, Xiao Z, Liang J, et al. Comparison of efficacy and safety between simultaneous integrated boost intensity-modulated radiotherapy and conventional intensity-modulated radiotherapy in locally advanced non-small-cell lung cancer: a retrospective study. Radiat Oncol. 2019;14:106. doi: 10.1186/s13014-019-1259-3.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1186/s13014-019-1259-3</ArticleId><ArticleId IdType=\"pmc\">PMC6567443</ArticleId><ArticleId IdType=\"pubmed\">31196118</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang P, Swanick CW, Pezzi TA, Liao Z, Welsh J, Lin SH, et al. Outcomes and toxicity following high-dose radiation therapy in 15 fractions for non-small cell lung cancer. Pract Radiat Oncol. 2017;7:433&#x2013;41. doi: 10.1016/j.prro.2017.03.005.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.prro.2017.03.005</ArticleId><ArticleId IdType=\"pubmed\">28428017</ArticleId></ArticleIdList></Reference><Reference><Citation>Cou&#xf1;ago F, Navarro-Martin A, Luna J, Rodr&#xed;guez de Dios N, Rodr&#xed;guez A, Casas F, et al. GOECP/SEOR clinical recommendations for lung cancer radiotherapy during the COVID-19 pandemic. World J Clin Oncol. 2020;11:510&#x2013;27. doi: 10.5306/wjco.v11.i8.510.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.5306/wjco.v11.i8.510</ArticleId><ArticleId IdType=\"pmc\">PMC7443829</ArticleId><ArticleId IdType=\"pubmed\">32879841</ArticleId></ArticleIdList></Reference><Reference><Citation>Turrisi AT 3rd, Kim K, Blum R, Sause WT, Livingston RB, Komaki R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med. 1999;340:265&#x2013;71. doi: 10.1056/NEJM199901283400403.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1056/NEJM199901283400403</ArticleId><ArticleId IdType=\"pubmed\">9920950</ArticleId></ArticleIdList></Reference><Reference><Citation>Faivre-Finn C, Snee M, Ashcroft L, Appel W, Barlesi F, Bhatnagar A, et al. CONVERT Study Team Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. Lancet Oncol. 2017;18:1116&#x2013;25. doi: 10.1016/S1470-2045(17)30318-2.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/S1470-2045(17)30318-2</ArticleId><ArticleId IdType=\"pmc\">PMC5555437</ArticleId><ArticleId IdType=\"pubmed\">28642008</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu AJ, Rimner A, Shepherd AF, Gelblum DY, Shaverdian N, Yorke E, et al. Thoracic radiation therapy during coronavirus disease 2019: provisional guidelines from a comprehensive cancer center within a pandemic epicenter. Adv Radiat Oncol. 2020;5:603&#x2013;7. doi: 10.1016/j.adro.2020.04.008.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.adro.2020.04.008</ArticleId><ArticleId IdType=\"pmc\">PMC7169880</ArticleId><ArticleId IdType=\"pubmed\">32318643</ArticleId></ArticleIdList></Reference><Reference><Citation>De Ruysscher D, Lueza B, Le P&#xe9;choux C, Johnson DH, O&#x2019;Brien M, Murray N, et al. RTT-SCLC Collaborative Group Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer: usefulness of the individual patient data meta-analysis. Ann Oncol. 2016;27:1818&#x2013;28. doi: 10.1093/annonc/mdw263.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/annonc/mdw263</ArticleId><ArticleId IdType=\"pmc\">PMC5035783</ArticleId><ArticleId IdType=\"pubmed\">27436850</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun JM, Ahn YC, Choi EK, Ahn MJ, Ahn JS, Lee SH, et al. Phase III trial of concurrent thoracic radiotherapy with either first- or third-cycle chemotherapy for limited-disease small-cell lung cancer. Ann Oncol. 2013;24:2088&#x2013;92. doi: 10.1093/annonc/mdt140. Erratum in: Ann Oncol. 2014;25:1672.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/annonc/mdt140</ArticleId><ArticleId IdType=\"pubmed\">23592701</ArticleId></ArticleIdList></Reference><Reference><Citation>Verma V, Simone CB 2nd, Allen PK, Gajjar SR, Shah C, Zhen W, et al. Multi-institutional experience of stereotactic ablative radiation therapy for stage I small cell lung cancer. Int J Radiat Oncol Biol Phys. 2017;97:362&#x2013;71. doi: 10.1016/j.ijrobp.2016.10.041.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.ijrobp.2016.10.041</ArticleId><ArticleId IdType=\"pubmed\">28011047</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi T, Yamanaka T, Seto T, Harada H, Nokihara H, Saka H, et al. Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18:663&#x2013;71. doi: 10.1016/S1470-2045(17)30230-9.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/S1470-2045(17)30230-9</ArticleId><ArticleId IdType=\"pubmed\">28343976</ArticleId></ArticleIdList></Reference><Reference><Citation>Chavez-MacGregor M, Lei X, Zhao H, Scheet P, Giordano SH. Evaluation of COVID-19 mortality and adverse outcomes in US patients with or without cancer. JAMA Oncol. 2022;8:69&#x2013;78. doi: 10.1001/jamaoncol.2021.5148.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1001/jamaoncol.2021.5148</ArticleId><ArticleId IdType=\"pmc\">PMC8554684</ArticleId><ArticleId IdType=\"pubmed\">34709356</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharafeldin N, Bates B, Song Q, Madhira V, Yan Y, Dong S, et al. Outcomes of COVID-19 in patients with cancer: report from the national COVID cohort collaborative (N3C) J Clin Oncol. 2021;39:2232&#x2013;46. doi: 10.1200/JCO.21.01074.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1200/JCO.21.01074</ArticleId><ArticleId IdType=\"pmc\">PMC8260918</ArticleId><ArticleId IdType=\"pubmed\">34085538</ArticleId></ArticleIdList></Reference><Reference><Citation>Jee J, Foote MB, Lumish M, Stonestrom AJ, Wills B, Narendra V, et al. Chemotherapy and COVID-19 outcomes in patients with cancer. J Clin Oncol. 2020;38:3538&#x2013;46. doi: 10.1200/JCO.20.01307.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1200/JCO.20.01307</ArticleId><ArticleId IdType=\"pmc\">PMC7571792</ArticleId><ArticleId IdType=\"pubmed\">32795225</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu H, Yang D, Chen X, Sun Z, Zou Y, Chen C, et al. The effect of anticancer treatment on cancer patients with COVID-19: a systematic review and meta-analysis. Cancer Med. 2021;10:1043&#x2013;56. doi: 10.1002/cam4.3692.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1002/cam4.3692</ArticleId><ArticleId IdType=\"pmc\">PMC7897967</ArticleId><ArticleId IdType=\"pubmed\">33381923</ArticleId></ArticleIdList></Reference><Reference><Citation>Joshi K, Muhith A, Obeid M, Milner-Watts C, Yousaf N, Popat S, et al. Safety monitoring of two and four-weekly adjuvant durvalumab for patients with stage III NSCLC: implications for the COVID-19 pandemic and beyond. Lung Cancer. 2021;156:147&#x2013;50. doi: 10.1016/j.lungcan.2021.04.021.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.lungcan.2021.04.021</ArticleId><ArticleId IdType=\"pmc\">PMC8086258</ArticleId><ArticleId IdType=\"pubmed\">33965281</ArticleId></ArticleIdList></Reference><Reference><Citation>Cantini L, Paoloni F, Pecci F, Spagnolo F, Genova C, Tanda ET, et al. Safety of extended interval dosing immune checkpoint inhibitors: a multicenter cohort study. J Natl Cancer Inst. 2023;115:796&#x2013;804. doi: 10.1093/jnci/djad061.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/jnci/djad061</ArticleId><ArticleId IdType=\"pmc\">PMC10323889</ArticleId><ArticleId IdType=\"pubmed\">37042716</ArticleId></ArticleIdList></Reference><Reference><Citation>Hijmering-Kappelle LBM, Hiltermann TJN, Bensch F. Safety and efficacy of extended interval dosing for immune checkpoint inhibitors in non-small cell lung cancer during the COVID-19 pandemic. Clin Lung Cancer. 2022;23:143&#x2013;50. doi: 10.1016/j.cllc.2021.12.005.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.cllc.2021.12.005</ArticleId><ArticleId IdType=\"pmc\">PMC8704727</ArticleId><ArticleId IdType=\"pubmed\">35034861</ArticleId></ArticleIdList></Reference><Reference><Citation>Sehgal K, Costa DB, Rangachari D. Extended-interval dosing strategy of immune checkpoint inhibitors in lung cancer: will it outlast the COVID-19 pandemic? Front Oncol. 2020;10:1193. doi: 10.3389/fonc.2020.01193.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3389/fonc.2020.01193</ArticleId><ArticleId IdType=\"pmc\">PMC7344199</ArticleId><ArticleId IdType=\"pubmed\">32714874</ArticleId></ArticleIdList></Reference><Reference><Citation>Actualizaci&#xf3;n en el posicionamiento y recomendaciones de SEOM en relaci&#xf3;n con la campa&#xf1;a de vacunaci&#xf3;n frente al COVID-19 en pacientes con c&#xe1;ncer [Internet]  [Cited 2023 Jan 14]. Available from: https://seom.org/images/Actualizacion_Posicionamiento_SEOM_Vacunas_COVID19.pdf .</Citation></Reference><Reference><Citation>Mei Q, Hu G, Yang Y, Liu B, Yin J, Li M, et al. Impact of COVID-19 vaccination on the use of PD-1 inhibitor in treating patients with cancer: a real-world study. J Immunother Cancer. 2022;10:e004157. doi: 10.1136/jitc-2021-004157.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1136/jitc-2021-004157</ArticleId><ArticleId IdType=\"pmc\">PMC8915379</ArticleId><ArticleId IdType=\"pubmed\">35264438</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirschb&#xfc;hl K, Schaller T, M&#xe4;rkl B, Claus R, Sipos E, Rentschler L, et al. High viral loads: what drives fatal cases of COVID-19 in vaccinees? &#x2013; an autopsy study. Mod Pathol. 2022;35:1013&#x2013;21. doi: 10.1038/s41379-022-01069-9.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/s41379-022-01069-9</ArticleId><ArticleId IdType=\"pmc\">PMC8974809</ArticleId><ArticleId IdType=\"pubmed\">35365771</ArticleId></ArticleIdList></Reference><Reference><Citation>Addeo A, Shah PK, Bordry N, Hudson RD, Albracht B, Di Marco M, et al. Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer. Cancer Cell. 2021;39:1091&#x2013;8.e2. doi: 10.1016/j.ccell.2021.06.009.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.ccell.2021.06.009</ArticleId><ArticleId IdType=\"pmc\">PMC8218532</ArticleId><ArticleId IdType=\"pubmed\">34214473</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowes CL, Naranbhai V, St Denis KJ, Lam EC, Bertaux B, Keane FK, et al. Heterogeneous immunogenicity of SARS-CoV-2 vaccines in cancer patients receiving radiotherapy. Radiother Oncol. 2022;166:88&#x2013;91. doi: 10.1016/j.radonc.2021.11.012.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.radonc.2021.11.012</ArticleId><ArticleId IdType=\"pmc\">PMC8613981</ArticleId><ArticleId IdType=\"pubmed\">34838892</ArticleId></ArticleIdList></Reference><Reference><Citation>Provencio M, Rodr&#xed;guez-Abreu D, Ortega AL, Serrano G, Aguado C, Franco F, et al. Seroprevalence and immunological memory against SARS-CoV-2 in lung cancer patients: the SOLID study. Transl Lung Cancer Res. 2022;11:53&#x2013;63. doi: 10.21037/tlcr-21-504.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.21037/tlcr-21-504</ArticleId><ArticleId IdType=\"pmc\">PMC8825652</ArticleId><ArticleId IdType=\"pubmed\">35242627</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>\n",
            "XML saved to: path/to/save/xml/38023992.xml\n",
            "Details URL: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=38023743&retmode=xml&api_key=9edd38677707c08b2a96ed1a6e8c61c47408\n",
            "Details Response Content: <?xml version=\"1.0\" ?>\n",
            "<!DOCTYPE PubmedArticleSet PUBLIC \"-//NLM//DTD PubMedArticle, 1st January 2023//EN\" \"https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd\">\n",
            "<PubmedArticleSet>\n",
            "<PubmedArticle><MedlineCitation Status=\"PubMed-not-MEDLINE\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38023743</PMID><DateRevised><Year>2023</Year><Month>12</Month><Day>01</Day></DateRevised><Article PubModel=\"Print\"><Journal><ISSN IssnType=\"Print\">1841-9038</ISSN><JournalIssue CitedMedium=\"Print\"><Volume>18</Volume><Issue>3</Issue><PubDate><Year>2023</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Maedica</Title><ISOAbbreviation>Maedica (Bucur)</ISOAbbreviation></Journal><ArticleTitle>EGFR Mutated Non-Small Cell Lung Cancer Complicated by Cancer Associated Ischemic Stroke.</ArticleTitle><Pagination><StartPage>515</StartPage><EndPage>518</EndPage><MedlinePgn>515-518</MedlinePgn></Pagination><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.26574/maedica.2023.18.3.515</ELocationID><Abstract><AbstractText>We describe herein two patients with epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer (NSCLC) who developed cancer-associated ischemic stroke (CAIS), infarction caused by thromboembolism in the central nervous system. Case 1 was a 63-year-old man with Exon 19 deletion type EGFR mutated lung adenocarcinoma presenting with CAIS. Case 2 was a 71-year-old woman with Exon 21 L858R type EGFR mutated lung adenocarcinoma who developed CAIS during chemotherapy after EGFR-tyrosine kinase inhibitor (TKI) resistance. Although there was no recurrence of CAIS in these patients, anticancer therapy could be hampered by the comorbidity of CAIS. This can develop anytime from before clinical manifestations of NSCLC to the next treatment after EGFR-TKI resistance. The development of CAIS should be noted in patients with EGFR mutated NSCLC, who have a promising long-term prognosis. Anticancer and anticoagulant therapies as well as rehabilitation are important for patients who develop CAIS. Establishment of measurement tests to detect CAIS before onset is desired.</AbstractText></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Taguchi</LastName><ForeName>Manato</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Respiratory Medicine, University of Tsukuba Hospital, University of Tsukuba, Amakubo, Tsukuba, Ibaraki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Kawakami</LastName><ForeName>Takeshi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Respiratory Medicine, University of Tsukuba Hospital, University of Tsukuba, Amakubo, Tsukuba, Ibaraki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Hasegawa</LastName><ForeName>Sachie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Respiratory Medicine, University of Tsukuba Hospital, University of Tsukuba, Amakubo, Tsukuba, Ibaraki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Okauchi</LastName><ForeName>Shinichiro</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Respiratory Medicine, Mito Medical Center, University of Tsukuba-Mito Kyodo General Hospital, Mito, Ibaraki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Ohara</LastName><ForeName>Gen</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Division of Respiratory Medicine, Mito Medical Center, University of Tsukuba-Mito Kyodo General Hospital, Mito, Ibaraki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Satoh</LastName><ForeName>Hiroaki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Division of Respiratory Medicine, Mito Medical Center, University of Tsukuba-Mito Kyodo General Hospital, Mito, Ibaraki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Hizawa</LastName><ForeName>Nubuyuki</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Division of Respiratory Medicine, University of Tsukuba Hospital, University of Tsukuba, Amakubo, Tsukuba, Ibaraki, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016421\">Editorial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Romania</Country><MedlineTA>Maedica (Bucur)</MedlineTA><NlmUniqueID>101526930</NlmUniqueID><ISSNLinking>1841-9038</ISSNLinking></MedlineJournalInfo></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"medline\"><Year>2023</Year><Month>11</Month><Day>29</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2023</Year><Month>11</Month><Day>29</Day><Hour>18</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2023</Year><Month>11</Month><Day>29</Day><Hour>15</Hour><Minute>54</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38023743</ArticleId><ArticleId IdType=\"pmc\">PMC10674116</ArticleId><ArticleId IdType=\"doi\">10.26574/maedica.2023.18.3.515</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Akinbo DB, Ajayi OI. Thrombotic pathogenesis and laboratory diagnosis in cancer patients, an update. Int J Gen Med. 2023;16:259&#x2013;272.</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC9879027</ArticleId><ArticleId IdType=\"pubmed\">36711430</ArticleId></ArticleIdList></Reference><Reference><Citation>Kono T, Ohtsuki T, Hosomi N, et al. Cancer-associated ischemic stroke is associated with elevated D-dimer and fibrin degradation product levels in acute ischemic stroke with advanced cancer. Geriatr Gerontol Int. 2012;12:468&#x2013;474.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">22233138</ArticleId></ArticleIdList></Reference><Reference><Citation>Grazioli S, Paciaroni M, Agnelli G, et al. Cancer-associated ischemic stroke: A retrospective multicentre cohort study. Thromb Res. 2018;165:33&#x2013;37.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">29558659</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang ZM, Lin ZH, Zhu GL. Tirofiban in the treatment of cancer-associated ischemic stroke. Eur Rev Med Pharmacol Sci. 2023;27:3590&#x2013;3596.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">37140310</ArticleId></ArticleIdList></Reference><Reference><Citation>Dowell JE. Epidermal growth factor receptor mutations in non-small cell lung cancer: a basic science discovery with immediate clinical impact. Am J Med Sci. 2006;331:139&#x2013;149.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">16538075</ArticleId></ArticleIdList></Reference><Reference><Citation>Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378:113&#x2013;125.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">29151359</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020;382:41&#x2013;50.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">31751012</ArticleId></ArticleIdList></Reference><Reference><Citation>Enewold L, Thomas A. Real-world patterns of EGFR testing and treatment with erlotinib for non-small cell lung cancer in the United States. PLoS One. 2016;11:e0156728.</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC4905679</ArticleId><ArticleId IdType=\"pubmed\">27294665</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang WT, Lin HW, Chang TC, et al. Assessment of tyrosine kinase inhibitors and survival and cardiovascular outcomes of patients with non-small cell lung cancer in Taiwan. JAMA Netw Open. 2023;6:e2313824.</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC10193184</ArticleId><ArticleId IdType=\"pubmed\">37195663</ArticleId></ArticleIdList></Reference><Reference><Citation>Masubuchi H, Maeno T, Uchida M, et al. A case of Trousseau syndrome caused by pulmonary adenocarcinoma that was controlled for one year and 10 months with thrombosis treatment using an EGFR tyrosine kinase inhibitor and chemotherapy. Respir Med Case Rep. 2015;15:101&#x2013;105.</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC4501524</ArticleId><ArticleId IdType=\"pubmed\">26236616</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z, Miao J, Wang L, et al. EGFR-mutant NSCLC presenting with stroke and massive systemic embolization as the first manifestation: case report. BMC Neurol. 2021;21:221.</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC8188717</ArticleId><ArticleId IdType=\"pubmed\">34107910</ArticleId></ArticleIdList></Reference><Reference><Citation>Naito H, Nezu T, Hosomi N, et al. Antithrombotic therapy strategy for cancer-associated ischemic stroke: a case series of 26 patients. J Stroke Cerebrovasc Dis. 2018;27:e206&#x2013;e211.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">29779882</ArticleId></ArticleIdList></Reference><Reference><Citation>Nonagase Y, Takeda M, Tanaka K, et al. Treatment of EGFR mutation-positive non-small cell lung cancer complicated by Trousseau syndrome with gefitinib followed by osimertinib: a case report. Oncotarget. 2018;9:29532&#x2013;29535.</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC6047674</ArticleId><ArticleId IdType=\"pubmed\">30034636</ArticleId></ArticleIdList></Reference><Reference><Citation>Kai Y, Ohara H, Matsuda M, et al. Endovascular therapy for cerebral infarction due to Trousseau syndrome in a patient with non-small cell lung cancer. Respir Med Case Rep. 2021;34:101531.</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC8556508</ArticleId><ArticleId IdType=\"pubmed\">34745868</ArticleId></ArticleIdList></Reference><Reference><Citation>Tai ML, Tan EC, Ang CC, Liam CK. Recurrent cerebral infarcts secondary to marantic endocarditis in a patient with adenocarcinoma of the lung. Singapore Med J. 2016;57:524&#x2013;525.</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC5027406</ArticleId><ArticleId IdType=\"pubmed\">27663211</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo PY, Chen XL, Liu YW, et al. Increased risk of cerebrovascular events in patients with cancer treated with bevacizumab: a meta-analysis. PLoS One. 2014;9:e102484.</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC4099178</ArticleId><ArticleId IdType=\"pubmed\">25025282</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon J, Jee D, Lim SH. Would intravitreal bevacizumab injection increase risk of cerebral infarction? Eur J Neurol. 2018;25:1177&#x2013;1181.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">29772097</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>\n",
            "XML saved to: path/to/save/xml/38023743.xml\n",
            "Details URL: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=38021960&retmode=xml&api_key=9edd38677707c08b2a96ed1a6e8c61c47408\n",
            "Details Response Content: <?xml version=\"1.0\" ?>\n",
            "<!DOCTYPE PubmedArticleSet PUBLIC \"-//NLM//DTD PubMedArticle, 1st January 2023//EN\" \"https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd\">\n",
            "<PubmedArticleSet>\n",
            "<PubmedArticle><MedlineCitation Status=\"PubMed-not-MEDLINE\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38021960</PMID><DateRevised><Year>2023</Year><Month>12</Month><Day>01</Day></DateRevised><Article PubModel=\"Electronic-eCollection\"><Journal><ISSN IssnType=\"Print\">2168-8184</ISSN><JournalIssue CitedMedium=\"Print\"><Volume>15</Volume><Issue>10</Issue><PubDate><Year>2023</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Cureus</Title><ISOAbbreviation>Cureus</ISOAbbreviation></Journal><ArticleTitle>Clinical and Etiological Exploration of Ventilator-Associated Pneumonia in the Intensive Care Unit of a Developing Country.</ArticleTitle><Pagination><StartPage>e47515</StartPage><MedlinePgn>e47515</MedlinePgn></Pagination><ELocationID EIdType=\"pii\" ValidYN=\"Y\">e47515</ELocationID><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.7759/cureus.47515</ELocationID><Abstract><AbstractText>Background Ventilator-associated pneumonia (VAP) is a critical concern in the intensive care unit&#xa0;(ICU), with significant implications for patient outcomes. This retrospective cross-sectional study aimed to determine the prevalence of VAP in an ICU of a developing country, identify the predominant etiological factors, assess patient outcomes, and underscore the need for tailored interventions in high-risk patient groups. Methods This retrospective cross-sectional study included 589 ICU patients who underwent ventilator-assisted breathing for over 48 hours. Among them, 151 developed VAP. The diagnosis was made on clinical, laboratory, and radiological findings, and tracheal aspirate cultures. Exclusions included pediatric patients, less than 48 hours of ventilation, and pre-existing lung infections. Patient data encompassed gender, age, comorbidities, outcomes, admission reasons, isolated microorganisms, and clinical findings. Results 151 patients out of the 589 developed VAP. The age of the patients ranged between 31 to 69 years and the mean age was 45.43 &#xb1; 8.92 years. Clinical diagnoses upon ICU admission varied, including sepsis, trauma, stroke, and metabolic disorders. Chest X-rays commonly revealed atelectasis (19.2%), consolidation (21.9%), pleural effusion (11.9%), and lobar pneumonia (45.7%). Tracheal aspirate cultures predominantly isolated multidrug-resistant gram-negative rods, with methicillin-resistant gram-positive cocci and fungal pneumonia prevalent in neutropenic sepsis cases. Notably, only 54 (35.8%) of patients survived, with significantly poorer outcomes observed in sepsis, neutropenic sepsis, and stroke cases compared to trauma and post-operative admissions. Conclusion Multidrug-resistant organisms and the spread of nosocomial infections are the predominant causes of&#xa0;VAP in the ICU. This emphasizes the urgent need for multifaceted interventions to prevent and manage VAP effectively. Developing and implementing targeted strategies, considering the unique challenges faced in resource-constrained healthcare settings can aid in decreasing the mortality associated with it.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023, Nisar et al.</CopyrightInformation></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Nisar</LastName><ForeName>Omar</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Internal Medicine, Shalamar Medical and Dental College, Lahore, PAK.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Nisar</LastName><ForeName>Samaha</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Internal Medicine, Shalamar Medical and Dental College, Lahore, PAK.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Khattak Haroon Ur Rashid</LastName><ForeName>Shahbaz</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Internal Medicine, Shifa International Hospital Islamabad, Islamabad, PAK.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Ibne Ali Jaffari</LastName><ForeName>Syed Muhammad</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Internal Medicine, Shalamar Medical and Dental College, Lahore, PAK.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Haider</LastName><ForeName>Zaki</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Internal Medicine, Rashid Latif Medical College, Lahore, PAK.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Fatima</LastName><ForeName>Fiza</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Internal Medicine, Shalamar Medical and Dental College, Lahore, PAK.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Zahra</LastName><ForeName>Shan E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Internal Medicine, Rashid Latif Medical College, Lahore, PAK.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Ijaz</LastName><ForeName>Ali Hassan</ForeName><Initials>AH</Initials><AffiliationInfo><Affiliation>Internal Medicine, Faisalabad Medical University, Faisalabad, PAK.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Kaneez</LastName><ForeName>Mehwish</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Pediatric Oncology, Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, PAK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pediatrics, Rawalpindi Medical University, Rawalpindi, PAK.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Shairwani</LastName><ForeName>Gulfam Khan</ForeName><Initials>GK</Initials><AffiliationInfo><Affiliation>Critical Care Medicine, District Headquarter Hospital, Rawalpindi, PAK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2023</Year><Month>10</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cureus</MedlineTA><NlmUniqueID>101596737</NlmUniqueID><ISSNLinking>2168-8184</ISSNLinking></MedlineJournalInfo><KeywordList Owner=\"NOTNLM\"><Keyword MajorTopicYN=\"N\">developing country</Keyword><Keyword MajorTopicYN=\"N\">etiological factors</Keyword><Keyword MajorTopicYN=\"N\">intensive care unit</Keyword><Keyword MajorTopicYN=\"N\">nosocomial infections</Keyword><Keyword MajorTopicYN=\"N\">ventilator-associated pneumonia</Keyword></KeywordList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"accepted\"><Year>2023</Year><Month>10</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus=\"medline\"><Year>2023</Year><Month>11</Month><Day>29</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2023</Year><Month>11</Month><Day>29</Day><Hour>18</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2023</Year><Month>11</Month><Day>29</Day><Hour>15</Hour><Minute>15</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38021960</ArticleId><ArticleId IdType=\"pmc\">PMC10664342</ArticleId><ArticleId IdType=\"doi\">10.7759/cureus.47515</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ventilator-associated pneumonia in paediatric intensive care unit patients: microbiological profile, risk factors, and outcome. Bhattacharya P, Kumar A, Kumar Ghosh S, Kumar S. Cureus. 2023;15:0.</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC10224744</ArticleId><ArticleId IdType=\"pubmed\">37252470</ArticleId></ArticleIdList></Reference><Reference><Citation>Ventilator-associated pneumonia among ICU patients in WHO Southeast Asian region: a systematic review. Kharel S, Bist A, Mishra SK. PLoS One. 2021;16:0.</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC7942996</ArticleId><ArticleId IdType=\"pubmed\">33690663</ArticleId></ArticleIdList></Reference><Reference><Citation>Ventilator-associated pneumonia in adults in developing countries: a systematic review. Arabi Y, Al-Shirawi N, Memish Z, Anzueto A. Int J Infect Dis. 2008;12:505&#x2013;512.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">18502674</ArticleId></ArticleIdList></Reference><Reference><Citation>A Method to Explore Variations of Ventilator-Associated Event Surveillance Definitions in Large Critical Care Databases in the United States. Wong AI, Kim H, Charpignon ML, et al. Crit Care Explor. 2022;4:0.</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC9668560</ArticleId><ArticleId IdType=\"pubmed\">36406886</ArticleId></ArticleIdList></Reference><Reference><Citation>An observational case study of hospital associated infections in a critical care unit in Astana, Kazakhstan. Viderman D, Khamzina Y, Kaligozhin Z, Khudaibergenova M, Zhumadilov A, Crape B, Azizan A. Antimicrob Resist Infect Control. 2018;7:57.</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC5918921</ArticleId><ArticleId IdType=\"pubmed\">29713464</ArticleId></ArticleIdList></Reference><Reference><Citation>Strategies to prevent ventilator-associated pneumonia, ventilator-associated events, and nonventilator hospital-acquired pneumonia in acute-care hospitals: 2022 Update. Klompas M, Branson R, Cawcutt K, et al. Infect Control Hosp Epidemiol. 2022;43:687&#x2013;713.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">35589091</ArticleId></ArticleIdList></Reference><Reference><Citation>Antimicrobial resistance in ventilator-associated pneumonia: predictive microbiology and evidence-based therapy. Alnimr A. Infect Dis Ther. 2023;12:1527&#x2013;1552.</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC10240484</ArticleId><ArticleId IdType=\"pubmed\">37273072</ArticleId></ArticleIdList></Reference><Reference><Citation>Ventilator associated pneumonia in intensive care unit patients: a systematic review. Mumtaz H, Saqib M, Khan W, Ismail SM, Sohail H, Muneeb M, Sheikh SS. Ann Med Surg (Lond) 2023;85:2932&#x2013;2939.</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC10289715</ArticleId><ArticleId IdType=\"pubmed\">37363470</ArticleId></ArticleIdList></Reference><Reference><Citation>The impact of ventilator-associated events in critically ill subjects with prolonged mechanical ventilation. Kobayashi H, Uchino S, Takinami M, Uezono S. Respir Care. 2017;62:1379&#x2013;1386.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">28720671</ArticleId></ArticleIdList></Reference><Reference><Citation>Ventilator-associated pneumonia in the ICU. Kalanuria AA, Ziai W, Mirski M. Crit Care. 2014;18:208.</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC4056625</ArticleId><ArticleId IdType=\"pubmed\">25029020</ArticleId></ArticleIdList></Reference><Reference><Citation>Clinical epidemiology and outcomes of ventilator-associated pneumonia in critically ill adult patients: protocol for a large-scale systematic review and planned meta-analysis. Guti&#xe9;rrez JM, Borromeo AR, Due&#xf1;o AL, et al. Syst Rev. 2019;8:180.</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC6642735</ArticleId><ArticleId IdType=\"pubmed\">31325967</ArticleId></ArticleIdList></Reference><Reference><Citation>Device-associated nosocomial infections in 55 intensive care units of 8 developing countries. Rosenthal VD, Maki DG, Salomao R, et al. Ann Intern Med. 2006;145:582&#x2013;591.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">17043340</ArticleId></ArticleIdList></Reference><Reference><Citation>Incidence of ventilator-associated pneumonia in Australasian intensive care units: use of a consensus-developed clinical surveillance checklist in a multisite prospective audit. Elliott D, Elliott R, Burrell A, Harrigan P, Murgo M, Rolls K, Sibbritt D. BMJ Open. 2015;5:0.</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC4636654</ArticleId><ArticleId IdType=\"pubmed\">26515685</ArticleId></ArticleIdList></Reference><Reference><Citation>Clinical and microbiological analysis of hospital-acquired pneumonia among patients with ischemic stroke: a retrospective outlook. Wattoo MA, Tabassum M, Bhutta KR, et al. Cureus. 2021;13:0.</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC8221085</ArticleId><ArticleId IdType=\"pubmed\">34178533</ArticleId></ArticleIdList></Reference><Reference><Citation>Ventilator-associated pneumonia: a persistent healthcare problem in Indian intensive care units! Mathai AS, Phillips A, Isaac R. Lung India. 2016;33:512&#x2013;516.</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC5006331</ArticleId><ArticleId IdType=\"pubmed\">27625445</ArticleId></ArticleIdList></Reference><Reference><Citation>Microbial profile of early and late onset ventilator associated pneumonia in the intensive care unit of a tertiary care hospital in Bangalore, India. Golia S, K T S, C L V. J Clin Diagn Res. 2013;7:2462&#x2013;2466.</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC3879896</ArticleId><ArticleId IdType=\"pubmed\">24392373</ArticleId></ArticleIdList></Reference><Reference><Citation>Microbial etiologies of ventilator-associated pneumonia (VAP) in intensive care unit of Beni-Suef University's Hospital. Maebed AZ, Gaber Y, Bakeer W, Dishisha T. Beni Suef Univ J Basic Appl Sci. 2021;10:41.</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC8319904</ArticleId><ArticleId IdType=\"pubmed\">34341765</ArticleId></ArticleIdList></Reference><Reference><Citation>Nosocomial infections and ventilator-associated pneumonia in cancer patients. Divatia JV, Pulinilkunnathil JG, Myatra SN. Oncologic Critical Care. 2019:1419&#x2013;1439.</Citation></Reference><Reference><Citation>Pathophysiology of Escherichia coli ventilator-associated pneumonia: implication of highly virulent extraintestinal pathogenic strains. Messika J, Magdoud F, Clermont O, et al. Intensive Care Med. 2012;38:2007&#x2013;2016.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">23052953</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>\n",
            "XML saved to: path/to/save/xml/38021960.xml\n",
            "Details URL: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=38016200&retmode=xml&api_key=9edd38677707c08b2a96ed1a6e8c61c47408\n",
            "Details Response Content: <?xml version=\"1.0\" ?>\n",
            "<!DOCTYPE PubmedArticleSet PUBLIC \"-//NLM//DTD PubMedArticle, 1st January 2023//EN\" \"https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd\">\n",
            "<PubmedArticleSet>\n",
            "<PubmedArticle><MedlineCitation Status=\"Publisher\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38016200</PMID><DateRevised><Year>2023</Year><Month>11</Month><Day>28</Day></DateRevised><Article PubModel=\"Print-Electronic\"><Journal><ISSN IssnType=\"Electronic\">1476-5616</ISSN><JournalIssue CitedMedium=\"Internet\"><Volume>226</Volume><PubDate><Year>2023</Year><Month>Nov</Month><Day>27</Day></PubDate></JournalIssue><Title>Public health</Title><ISOAbbreviation>Public Health</ISOAbbreviation></Journal><ArticleTitle>Asthma and clinical outcomes of COVID-19 in a community setting.</ArticleTitle><Pagination><StartPage>84</StartPage><EndPage>90</EndPage><MedlinePgn>84-90</MedlinePgn></Pagination><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.1016/j.puhe.2023.10.040</ELocationID><ELocationID EIdType=\"pii\" ValidYN=\"Y\">S0033-3506(23)00417-1</ELocationID><Abstract><AbstractText Label=\"OBJECTIVES\" NlmCategory=\"OBJECTIVE\">The association between asthma and COVID-19 mortality remains inconclusive. We examined the association between asthma and clinical outcomes of patients with COVID-19.</AbstractText><AbstractText Label=\"STUDY DESIGN\" NlmCategory=\"METHODS\">A case-control study based on a surveillance cohort in Harris County, Texas.</AbstractText><AbstractText Label=\"METHODS\" NlmCategory=\"METHODS\">Using the data of 21,765 patients who reported having at least one chronic health condition, we investigated the association between asthma and COVID-19 severity, characterized primarily by hospitalization and death. Unconditional logistic regression models were used to estimate the multivariable odds ratio (mOR) and its 95&#xa0;% confidence interval (CI) of COVID-19 severity associated with asthma and other chronic lung diseases, adjusting for demographic and other comorbidities. A P-value&#xa0;&lt;&#xa0;0.005 was considered statistically significant after correcting multiple testing.</AbstractText><AbstractText Label=\"RESULTS\" NlmCategory=\"RESULTS\">In total, 3034 patients (13.9&#xa0;%) had asthma, and 774 (3.56&#xa0;%) had other chronic lung diseases. The case death rate among patients with asthma and other chronic lung diseases was 0.75&#xa0;% and 19.0&#xa0;%, respectively. Compared to patients without the respective conditions, patients with asthma had lower odds of death (mOR&#xa0;=&#xa0;0.44, 95&#xa0;% CI: 0.27-0.69), while patients with other chronic lung diseases had higher odds of hospitalization (mOR&#xa0;=&#xa0;2.02, 95&#xa0;% CI: 1.68-2.42) and death (mOR&#xa0;=&#xa0;1.95, 95&#xa0;% CI: 1.52-2.49) (P-values&#xa0;&lt;&#xa0;0.005). Risk factors for COVID-19 mortality included older age, male gender, diabetes, obesity, hypertension, cardiovascular disease, active cancer, and chronic kidney disease.</AbstractText><AbstractText Label=\"CONCLUSIONS\" NlmCategory=\"CONCLUSIONS\">The public health surveillance data suggested that preexisting asthma was inversely associated with COVID-19 mortality.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 The Royal Society for Public Health. Published by Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Jiao</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Harris County Public Health, 1111 Fannin Street, Houston, TX, 77002, USA. Electronic address: li.jiao@phs.hctx.net.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Bujnowski</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Harris County Public Health, 1111 Fannin Street, Houston, TX, 77002, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Liu</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Harris County Public Health, 1111 Fannin Street, Houston, TX, 77002, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Bakota</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Harris County Public Health, 1111 Fannin Street, Houston, TX, 77002, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Liu</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Harris County Public Health, 1111 Fannin Street, Houston, TX, 77002, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Ye</LastName><ForeName>Y</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Harris County Public Health, 1111 Fannin Street, Houston, TX, 77002, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Dewangan</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Harris County Public Health, 1111 Fannin Street, Houston, TX, 77002, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Duong</LastName><ForeName>C N</ForeName><Initials>CN</Initials><AffiliationInfo><Affiliation>Harris County Public Health, 1111 Fannin Street, Houston, TX, 77002, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Kviten</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Harris County Public Health, 1111 Fannin Street, Houston, TX, 77002, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Zaheer</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Harris County Public Health, 1111 Fannin Street, Houston, TX, 77002, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Zangeneh</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Harris County Public Health, 1111 Fannin Street, Houston, TX, 77002, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Roy</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Harris County Public Health, 1111 Fannin Street, Houston, TX, 77002, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Floyd</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Harris County Public Health, 1111 Fannin Street, Houston, TX, 77002, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Monroy</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Harris County Public Health, 1111 Fannin Street, Houston, TX, 77002, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Wiltz-Beckham</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Harris County Public Health, 1111 Fannin Street, Houston, TX, 77002, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2023</Year><Month>11</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Public Health</MedlineTA><NlmUniqueID>0376507</NlmUniqueID><ISSNLinking>0033-3506</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner=\"NOTNLM\"><Keyword MajorTopicYN=\"N\">Cohort</Keyword><Keyword MajorTopicYN=\"N\">Comorbidity</Keyword><Keyword MajorTopicYN=\"N\">Epidemiology</Keyword><Keyword MajorTopicYN=\"N\">Mortality</Keyword><Keyword MajorTopicYN=\"N\">Surveillance</Keyword><Keyword MajorTopicYN=\"N\">Symptoms</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"received\"><Year>2023</Year><Month>6</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus=\"revised\"><Year>2023</Year><Month>10</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus=\"accepted\"><Year>2023</Year><Month>10</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus=\"medline\"><Year>2023</Year><Month>11</Month><Day>28</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2023</Year><Month>11</Month><Day>28</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2023</Year><Month>11</Month><Day>28</Day><Hour>18</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38016200</ArticleId><ArticleId IdType=\"doi\">10.1016/j.puhe.2023.10.040</ArticleId><ArticleId IdType=\"pii\">S0033-3506(23)00417-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>\n",
            "XML saved to: path/to/save/xml/38016200.xml\n",
            "Details URL: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=38016003&retmode=xml&api_key=9edd38677707c08b2a96ed1a6e8c61c47408\n",
            "Details Response Content: <?xml version=\"1.0\" ?>\n",
            "<!DOCTYPE PubmedArticleSet PUBLIC \"-//NLM//DTD PubMedArticle, 1st January 2023//EN\" \"https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd\">\n",
            "<PubmedArticleSet>\n",
            "<PubmedArticle><MedlineCitation Status=\"Publisher\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38016003</PMID><DateRevised><Year>2023</Year><Month>11</Month><Day>28</Day></DateRevised><Article PubModel=\"Print-Electronic\"><Journal><ISSN IssnType=\"Electronic\">1535-4970</ISSN><JournalIssue CitedMedium=\"Internet\"><PubDate><Year>2023</Year><Month>Nov</Month><Day>28</Day></PubDate></JournalIssue><Title>American journal of respiratory and critical care medicine</Title><ISOAbbreviation>Am J Respir Crit Care Med</ISOAbbreviation></Journal><ArticleTitle>Association Between T2-related Comorbidities and Effectiveness of Biologics in Severe Asthma.</ArticleTitle><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.1164/rccm.202305-0808OC</ELocationID><Abstract><AbstractText Label=\"RATIONALE\" NlmCategory=\"BACKGROUND\">Previous studies investigating comorbidity impact on biologic effectiveness have been relatively small, of short duration, and have not compared biologic classes.</AbstractText><AbstractText Label=\"OBJECTIVES\" NlmCategory=\"OBJECTIVE\">To determine the association between T2-related comorbidities and biologic effectiveness in adults with severe asthma (SA).</AbstractText><AbstractText Label=\"METHODS\" NlmCategory=\"METHODS\">This cohort study used International Severe Asthma Registry data (n=21 countries, 2017-2022) to quantify pre- to post-biologic change for four outcomes (annual asthma exacerbation rate, % predicted FEV<sub>1</sub> (ppFEV<sub>1</sub>), asthma control, and long-term oral corticosteroid daily dose [LTOCS]) in patients with/without allergic rhinitis (AR), chronic rhinosinusitis +/- nasal polyps (CRS+/-NP), NP, or eczema/atopic dermatitis (AD).</AbstractText><AbstractText Label=\"MAIN RESULTS\" NlmCategory=\"RESULTS\">Of 1765 patients, 1257, 421, and 87 initiated anti-IL-5/5R, anti-IgE, and anti-IL-4/13 therapies, respectively. In general, pre- to post-biologic improvements were noted in all four asthma outcomes assessed, irrespective of comorbidity status. However, patients with comorbid CRS+/-NP experienced 23% (95% CI 10-35%, p&lt;0.001) fewer exacerbations/year and had 59% (95% CI: 26-102%, p&lt;0.001) higher odds of better post-biologic control than those without CRS+/-NP. Similar estimates were noted for those with comorbid NP (22% less exacerbations and 56% higher odds of better post-biologic control). Patients with SA and CRS+/-NP had an additional ppFEV<sub>1</sub> improvement of 3.2% (95% CI: 1.0-5.3; p=0.004), a trend that was also noted in those with comorbid NP. The presence of AR or AD were not associated with pre- to post-biologic effect for any outcome assessed.</AbstractText><AbstractText Label=\"CONCLUSIONS\" NlmCategory=\"CONCLUSIONS\">These findings highlight the importance of systematic comorbidity evaluation. The presence of CRS+/-NP or NP may be considered a predictor of biologic effectiveness in patients with severe asthma.</AbstractText></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Wechsler</LastName><ForeName>Michael E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>NJH Cohen Family Asthma Institute, Department of Medicine, National Jewish Health,, Denver, Colorado, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Scelo</LastName><ForeName>Ghislaine</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Observational and Pragmatic Research Institute Pte Ltd, 614173, Singapore, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Optimum Patient Care Global, Cambridge, United Kingdom of Great Britain and Northern Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Larenas-Linnemann</LastName><ForeName>D&#xe9;sir&#xe9;e E S</ForeName><Initials>DES</Initials><AffiliationInfo><Affiliation>Hospital M&#xe9;dica Sur, Centro de Excelencia en Asma y Alergia, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Torres-Duque</LastName><ForeName>Carlos A</ForeName><Initials>CA</Initials><Identifier Source=\"ORCID\">0000-0003-0004-8955</Identifier><AffiliationInfo><Affiliation>Fundaci&#xf3;n Neumol&#xf3;gica Colombiana, 204431, CINEUMO, Respiratory Research Center, , Bogota, Colombia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universidad de La Sabana, 27989, Chia, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Maspero</LastName><ForeName>Jorge</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>CIDEA Foundation, 578336, Clinical Research for Allergy and Respiratory Medicine, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Tran</LastName><ForeName>Trung N</ForeName><Initials>TN</Initials><AffiliationInfo><Affiliation>AstraZeneca, BioPharmaceuticals Medical,, Gaithersburg, Maryland, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Murray</LastName><ForeName>Ruth B</ForeName><Initials>RB</Initials><AffiliationInfo><Affiliation>Optimum Patient Care Global, Cambridge, United Kingdom of Great Britain and Northern Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Martin</LastName><ForeName>Neil</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>AstraZeneca R&amp;D Cambridge, 468087, Respiratory and Immunology, BioPharmaceuticals Medical, Cambridge, Cambridgeshire, United Kingdom of Great Britain and Northern Ireland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Leicester, 4488, Leicester, Leicestershire, United Kingdom of Great Britain and Northern Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Menzies-Gow</LastName><ForeName>Andrew N</ForeName><Initials>AN</Initials><AffiliationInfo><Affiliation>AstraZeneca UK Limited, 4978, Cambridge, United Kingdom of Great Britain and Northern Ireland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Royal Brompton and Harefield Hospitals, 4964, London, United Kingdom of Great Britain and Northern Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Hew</LastName><ForeName>Mark</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Alfred Hospital, 5390, Allergy, Asthma &amp; Clinical Immunology, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Monash University Faculty of Medicine Nursing and Health Sciences, 22457, School of Public Health &amp; Preventive Medicine, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Peters</LastName><ForeName>Matthew J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Macquarie University, 7788, Department of Thoracic Medicine, Concord Hospital and Faculty of Medicine, Health and Health Sciences,, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Gibson</LastName><ForeName>Peter G</ForeName><Initials>PG</Initials><AffiliationInfo><Affiliation>University of Newcastle, 5982, Australian Severe Asthma Network, Priority Research Centre for Healthy Lungs, Callaghan, New South Wales, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The University of Newcastle Hunter Medical Research Institute, 454568, Department of Respiratory and Sleep Medicine, New Lambton, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Christoff</LastName><ForeName>George C</ForeName><Initials>GC</Initials><AffiliationInfo><Affiliation>Medical University-Sofia, 58789, Faculty of Public Health, Sofia, Bulgaria.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Popov</LastName><ForeName>Todor A</ForeName><Initials>TA</Initials><AffiliationInfo><Affiliation>University Hospital St Ivan Rilski, 266309, Sofia, Bulgaria.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>C&#xf4;t&#xe9;</LastName><ForeName>Andr&#xe9;anne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Laval University, 4440, Department of Medicine, Quebec, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Bergeron</LastName><ForeName>Celine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Vancouver General Hospital, 8167, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The University of British Columbia, 8166, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Dorscheid</LastName><ForeName>Delbert</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>The University of British Columbia, 8166, Center for Heart Lung Innovation, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>FitzGerald</LastName><ForeName>J Mark</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>The University of British Columbia, 8166, Department of Medicine, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Chapman</LastName><ForeName>Kenneth R</ForeName><Initials>KR</Initials><AffiliationInfo><Affiliation>University of Toronto, 7938, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Boulet</LastName><ForeName>Louis Philippe</ForeName><Initials>LP</Initials><AffiliationInfo><Affiliation>Universite Laval, 4440, Qu&#xe9;bec Heart and Lung Institute, Quebec City, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Bhutani</LastName><ForeName>Mohit</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>University of Alberta, 3158, Faculty of Medicine, Division of Pulmonary Medicine, Edmonton, Alberta, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Sadatsafavi</LastName><ForeName>Mohsen</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>The University of British Columbia, 8166, Respiratory Evaluation Sciences Program, Faculty of Pharmaceutical Sciences, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Jim&#xe9;nez-Maldonado</LastName><ForeName>Libardo</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3;n Neumol&#xf3;gica Colombiana, 204431, ASMAIRE Program, Bogota, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Duran-Silva</LastName><ForeName>Mauricio</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3;n Neumol&#xf3;gica Colombiana, 204431, ASMAIRE Program, Bogot&#xe1;, Colombia;, Bogota, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Rodriguez</LastName><ForeName>Bellanid</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Instituto Neumol&#xf3;gico del Oriente SA, 612649, Floridablanca, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Celis-Preciado</LastName><ForeName>Carlos Andres</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Hospital Universitario San Ignacio, 173049, Pulmonary Unit, Bogota, Colombia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pontificia Universidad Javeriana, 27964, Faculty of Medicine, Bogota, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Cano-Rosales</LastName><ForeName>Diana Jimena</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Instituto Neumol&#xf3;gico del Oriente SA, 612649, Floridablanca, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Solarte</LastName><ForeName>Ivan</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Hospital Universitario San Ignacio, 173049, Pulmonary Unit, Bogota, Colombia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pontificia Universidad Javeriana, 27964, Bogota, Faculty of Medicine, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Fernandez-Sanchez</LastName><ForeName>Maria Jose</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Hospital Universitario San Ignacio, 173049, Pulmonary Unit, Bogota, Colombia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pontificia Universidad Javeriana, 27964, Faculty of Medicine, Bogota, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Parada-Tovar</LastName><ForeName>Patricia</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3;n Neumol&#xf3;gica Colombiana, 204431, CINEUMO, Respiratory Research Center, Bogota, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>von B&#xfc;low</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Bispebjerg Hospital, 53166, Respiratory research unit, Department of Respiratory Medicine and Infectious Diseases, Kobenhavn, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Bjerrum</LastName><ForeName>Anne Sofie</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Aarhus University Hospital, 11297, Department of Respiratory Medicine and Allergy, Aarhus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Ulrik</LastName><ForeName>Charlotte S</ForeName><Initials>CS</Initials><AffiliationInfo><Affiliation>Copenhagen University Hospital, 53146, Respiratory Medicine, Hvidovre, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Assing</LastName><ForeName>Karin Dahl</ForeName><Initials>KD</Initials><AffiliationInfo><Affiliation>Aalborg University Hospital, 53141, Department of Respiratory Medicine, Aalborg, North Denmark Region, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Rasmussen</LastName><ForeName>Linda Makowska</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Copenhagen University Hospital, 53146, Allergy Clinic, Kobenhavn, Gentofte, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Hansen</LastName><ForeName>Susanne</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Bispebjerg Hospital, 53166, Respiratory Research Unit, , Kobenhavn, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Frederiksberg Hospital, 53169, Center for Clinical Research and Prevention, Frederiksberg, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Altraja</LastName><ForeName>Alan</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Tartu University Hospital, 37544, Department of Pulmonology, University of Tartu and Lung Clinic, Tartu, Tartumaa, Estonia.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Bourdin</LastName><ForeName>Arnaud</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>PhyMedExp, Univ Montpellier, CNRS, INSERM, CHU Montpellier,, Pneumonology, Montpellier, Languedoc-Roussillon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Taille</LastName><ForeName>Camille</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>AP-HP Nord-Universit&#xe9; Paris Cit&#xe9;, Department of Respiratory Diseases, Bichat Hospital, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Charriot</LastName><ForeName>Jeremy</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>PhyMedExp, Univ Montpellier, CNRS, INSERM, CHU Montpellier, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Roche</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>APHP-Centre University Paris Cit&#xe9;, Cochin Hospital and Institute (UMR1016), Department of Respiratory Medicine , Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Papaioannou</LastName><ForeName>Andriana I</ForeName><Initials>AI</Initials><AffiliationInfo><Affiliation>National and Kapodistrian University of Athens Medical School, Attikon University Hospital, 2nd Respiratory Medicine Department, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Kostikas</LastName><ForeName>Konstantinos</ForeName><Initials>K</Initials><Identifier Source=\"ORCID\">0000-0003-0774-3942</Identifier><AffiliationInfo><Affiliation>University of Ioannina, 37796, Respiratory Medicine, Ioannina, Epirus, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Papadopoulos</LastName><ForeName>Nikolaos G</ForeName><Initials>NG</Initials><AffiliationInfo><Affiliation>The University of Manchester Division of Infection Immunity and Respiratory Medicine, 574374, Manchester, England, United Kingdom of Great Britain and Northern Ireland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Athens, 68993, Allergy Department, 2nd Pediatric Clinic, Athens, Attica, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Salvi</LastName><ForeName>Sundeep</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Pulmocare Research and Education (PURE) Foundation, Clinical Research, Pune, MAHARASHTRA, India.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Long</LastName><ForeName>Deirdre</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Beaumont Hospital, 57978, Department of Medicine, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Mitchell</LastName><ForeName>Patrick D</ForeName><Initials>PD</Initials><AffiliationInfo><Affiliation>Trinity College Dublin, 8809, School of Medicine, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Costello</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Clinical Research Centre, Smurfit Building Beaumont Hospital, Department of Respiratory Medicine, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Sirena</LastName><ForeName>Concetta</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Severe Asthma Network Italy (SANI), Milano , Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Cardini</LastName><ForeName>Cristina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Severe Asthma Network Italy (SANI), Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Heffler</LastName><ForeName>Enrico</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>IRCCS Humanitas Research Hospital, 9268, Personalized Medicine, Asthma and Allergy , Rozzano, Lombardia, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Humanitas University, 437807, Department of Biomedical Sciences, Milan, Pieve Emanuele, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Puggioni</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>IRCCS Humanitas Research Hospital, 9268, Personalized Medicine, Asthma and Allergy , Rozzano, Lombardia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Canonica</LastName><ForeName>Giorgio Walter</ForeName><Initials>GW</Initials><AffiliationInfo><Affiliation>IRCCS Humanitas Research Hospital, 9268, Personalized Medicine, Asthma and Allergy, Rozzano, Lombardia, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Humanitas University, 437807, Department of Biomedical Sciences, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Guida</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>University of Turin, 9314, Department of Clinical and Biological Sciences, Severe Asthma and Rare Lung Disease Unit, San Luigi Gonzaga University Hospital, Torino, Piemonte, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Iwanaga</LastName><ForeName>Takashi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Kindai University Hospital, 326473, Osakasayama, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Al-Ahmad</LastName><ForeName>Mona</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Kuwait University, 37603, Microbiology Department, College of Medicine, Kuwait, Kuwait.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Garc&#xed;a</LastName><ForeName>Ulises</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>University of Guanajuato, 14654, Department of Allergy and Immunology, National Medical Center of Bajio, Professor of Allergy and Immunology, Guanajuato, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Kuna</LastName><ForeName>Piotr</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Medical University of Lodz, 37808, Division of Internal Medicine Asthma and Allergy, Lodz, Lodzkie, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Fonseca</LastName><ForeName>Jo&#xe3;o A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>University of Porto, 26706, CINTESIS@RISE, MEDCIDS, Faculty of Medicine, Porto, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Al-Lehebi</LastName><ForeName>Riyad</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>King Fahad Medical City, 37849, Department of Pulmonology,, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Alfaisal University, 101686, Riyadh, Riyadh Province, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Koh</LastName><ForeName>Mariko S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Singapore General Hospital, 37581, Department of Respiratory and Critical Care Medicine, Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Rhee</LastName><ForeName>Chin Kook</ForeName><Initials>CK</Initials><Identifier Source=\"ORCID\">0000-0003-4533-7937</Identifier><AffiliationInfo><Affiliation>The Catholic University of Korea, 26713, Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, Seoul, Korea (the Republic of).</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Cosio</LastName><ForeName>Borja G</ForeName><Initials>BG</Initials><Identifier Source=\"ORCID\">0000-0002-6388-8209</Identifier><AffiliationInfo><Affiliation>Son Espases University Hospital-IdISBa-Ciberes, Mallorca, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Perez de Llano</LastName><ForeName>Luis</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Hospital Universitario Lucus Augusti, 309716, Pneumology Service, Lugo, Galicia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Perng</LastName><ForeName>Diahn-Warng</ForeName><Initials>DW</Initials><AffiliationInfo><Affiliation>Taipei Veterans General Hospital, 46615, Department of Chest Medicine, Taipei, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Yang Ming Chiao Tung University, 34914, School of Medicine, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Huang</LastName><ForeName>Erick Wan-Chun</ForeName><Initials>EW</Initials><AffiliationInfo><Affiliation>Shuang Ho Hospital, Taipei Medical University, Division of Pulmonary Medicine, Department of Internal Medicine, New Taipei City, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Wang</LastName><ForeName>Hao-Chien</ForeName><Initials>HC</Initials><AffiliationInfo><Affiliation>National Taiwan University, 33561, Department of Medicine, Cancer Center, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Tsai</LastName><ForeName>Ming-Ju</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Kaohsiung Medical University Hospital, 89234, Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kaohsiung, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Kaohsiung Medical University, 38023, School of Medicine, College of Medicine, Department of Internal Medicine,, Kaohsiung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Mahboub</LastName><ForeName>Bassam</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Rashid Hospital, 62743, Dubai Health Authority (DHA), Dubai, United Arab Emirates.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Salameh</LastName><ForeName>Laila Ibraheem Jaber</ForeName><Initials>LIJ</Initials><AffiliationInfo><Affiliation>Rashid Hospital, 62743, College of Medicine, Dubai, United Arab Emirates.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Jackson</LastName><ForeName>David J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>King's College London, 4616, Guy's Severe Asthma Centre, Guy's Hospital, London, United Kingdom of Great Britain and Northern Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Busby</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Queen's University Belfast, 1596, Centre for Public Health, School of Medicine, Dentistry and Biomedical Sciences, Belfast, United Kingdom of Great Britain and Northern Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Heaney</LastName><ForeName>Liam G</ForeName><Initials>LG</Initials><AffiliationInfo><Affiliation>Queen's University Belfast, 1596, Wellcome-Wolfson Institute for Experimental Medicine, Belfast, United Kingdom of Great Britain and Northern Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Pfeffer</LastName><ForeName>Paul E</ForeName><Initials>PE</Initials><AffiliationInfo><Affiliation>Queen Mary University of London, 4617, Barts and The London School of Medicine and Dentistry, London, United Kingdom of Great Britain and Northern Ireland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Barts Health NHS Trust, 9744, Department of Respiratory Medicine, London, United Kingdom of Great Britain and Northern Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Goddard</LastName><ForeName>Amanda Grippen</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>Allergy Partners of Albuquerque, Albuquerque, New Mexico, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Wang</LastName><ForeName>Eileen</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>University of Colorado School of Medicine, 12225, Division of Allergy and Clinical Immunology, Department of Medicine, National Jewish Health, Aurora, Colorado, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Hoyte</LastName><ForeName>Flavia C L</ForeName><Initials>FCL</Initials><AffiliationInfo><Affiliation>National Jewish Health, 2930, Division of Allergy and Clinical Immunology, Department of Medicine, Denver, Colorado, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Chapman</LastName><ForeName>Nicholas M</ForeName><Initials>NM</Initials><AffiliationInfo><Affiliation>Saint Joseph Hospital, Denver CO; National Jewish Health, Denver, Colorado, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Katial</LastName><ForeName>Rohit</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>National Jewish Health, 2930, Division of Allergy and Clinical Immunology, Department of Medicine, Denver, Colorado, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Carter</LastName><ForeName>Victoria</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Optimum Patient Care Global, Cambridge, United Kingdom of Great Britain and Northern Ireland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Observational and Pragmatic Research Institute Pte Ltd, 614173, Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Bulathsinhala</LastName><ForeName>Lakmini</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Observational and Pragmatic Research Institute Pte Ltd, 614173, Singapore, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Optimum Patient Care UK, 601419, Cambridge, England, United Kingdom of Great Britain and Northern Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Eleangovan</LastName><ForeName>Neva</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Observational and Pragmatic Research Institute Pte Ltd, 614173, Singapore, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Optimum Patient Care Global, Cambridge , United Kingdom of Great Britain and Northern Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Ariti</LastName><ForeName>Con</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Observational and Pragmatic Research Institute Pte Ltd, 614173, Singapore, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Optimum Patient Care Global, Cambridge , United Kingdom of Great Britain and Northern Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Lyu</LastName><ForeName>Juntao</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Griffith University, 5723, Centre for Applied Health Economics, Nathan, Queensland, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Porsbjerg</LastName><ForeName>Celeste</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Bispebjerg Hospital, 53166, Department of Respiratory Medicine and Infections Diseases, Research Unit, Copenhagen NV, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Price</LastName><ForeName>David B</ForeName><Initials>DB</Initials><Identifier Source=\"ORCID\">0000-0002-9728-9992</Identifier><AffiliationInfo><Affiliation>Observational and Pragmatic Research Institute Pte Ltd, 614173, Singapore, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Optimum Patient Care Global, United Kingdom, Cambridge, United Kingdom of Great Britain and Northern Ireland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Aberdeen, 1019, Centre of Academic Primary Care, Division of Applied Health Sciences, Aberdeen, United Kingdom of Great Britain and Northern Ireland; dprice@opri.sg.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2023</Year><Month>11</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Respir Crit Care Med</MedlineTA><NlmUniqueID>9421642</NlmUniqueID><ISSNLinking>1073-449X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner=\"NOTNLM\"><Keyword MajorTopicYN=\"N\">allergic rhinitis; chronic rhinosinusitis; nasal polyposis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"medline\"><Year>2023</Year><Month>11</Month><Day>28</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2023</Year><Month>11</Month><Day>28</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2023</Year><Month>11</Month><Day>28</Day><Hour>14</Hour><Minute>42</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38016003</ArticleId><ArticleId IdType=\"doi\">10.1164/rccm.202305-0808OC</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>\n",
            "XML saved to: path/to/save/xml/38016003.xml\n",
            "Details URL: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=38012569&retmode=xml&api_key=9edd38677707c08b2a96ed1a6e8c61c47408\n",
            "Details Response Content: <?xml version=\"1.0\" ?>\n",
            "<!DOCTYPE PubmedArticleSet PUBLIC \"-//NLM//DTD PubMedArticle, 1st January 2023//EN\" \"https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd\">\n",
            "<PubmedArticleSet>\n",
            "<PubmedArticle><MedlineCitation Status=\"MEDLINE\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38012569</PMID><DateCompleted><Year>2023</Year><Month>11</Month><Day>29</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>30</Day></DateRevised><Article PubModel=\"Electronic\"><Journal><ISSN IssnType=\"Electronic\">1471-2318</ISSN><JournalIssue CitedMedium=\"Internet\"><Volume>23</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Nov</Month><Day>27</Day></PubDate></JournalIssue><Title>BMC geriatrics</Title><ISOAbbreviation>BMC Geriatr</ISOAbbreviation></Journal><ArticleTitle>Polypharmacy and potentially-inappropriate medications are prevalent in the elderly cancer patients receiving systemic cancer therapy and they co-relate with adverse outcomes.</ArticleTitle><Pagination><StartPage>775</StartPage><MedlinePgn>775</MedlinePgn></Pagination><ELocationID EIdType=\"pii\" ValidYN=\"Y\">775</ELocationID><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.1186/s12877-023-04471-3</ELocationID><Abstract><AbstractText Label=\"OBJECTIVES\" NlmCategory=\"OBJECTIVE\">Cancer is the disease of the ageing. Most of the elderly cancer patients have pre-existing illnesses requiring complexity of medical care. Excessive medications would lead not only futility, but also result in adverse outcomes especially if such over-prescription is not appropriate. This study was intended to determine the prevalence of polypharmacy (PP) and potentially-inappropriate medications (PIMs) among elderly cancer patients eligible for active cancer care and their associations with hospitalization and mortality.</AbstractText><AbstractText Label=\"MATERIALS AND METHODS\" NlmCategory=\"METHODS\">This was a prospective cohort study conducted among the elderly non-hematologic cancer patients (&#x2265;&#x2009;65&#xa0;years old) whom a medical oncologist had decided suitable for systemic cancer therapy. Demographic data including age, sex, primary site of cancer, cancer stage at diagnosis, Charlson Comorbidity Index (CCI), numbers and kinds of medications used both prior to and during cancer treatment were recorded. Hospitalizations not related to systemic cancer therapy administration and mortality were prospectively monitored. All of the patients had to be followed at least one year after cancer diagnosis.</AbstractText><AbstractText Label=\"RESULTS\" NlmCategory=\"RESULTS\">There were 180 eligible participants. Median age in years (IQR) was 68 (65-73). One hundred patients (55.56%) were male and 80 patients (44.44%) were female. Breast (35, 19.44%), lung (31, 17.22%) and colorectal (18, 10%) cancers were the most common diagnoses. Eighty-six patients (47.78%) had metastatic disease at cancer diagnosis. One hundred twenty-two patients (67.78%) had PP (5 or more medications a day) and thirty-six patients (20%) had hyper-PP (10 or more medications a day). One hundred twenty five of the whole cohort (69.4%) had PIMs. Patients with more serious CCI scores were associated with PP and hyper-PP. While patients with primary lung cancer was only the only factor associated with PIMs. When excluding opioids, laxatives and anti-emetics, the most frequently prescribed drugs during cancer treatment, the so-called corrected PP did not associate with worse 1-year survival. Factors correlated with 1-year mortality were more advanced age group (70&#xa0;years old or more) (OR 2.24; 95% C.I., 1.14-4.41; p&#x2009;=&#x2009;0.019), primary lung cancer (OR 2.89; 95% C.I., 1.45-5.78; p&#x2009;=&#x2009;0.003), metastatic disease at cancer diagnosis (OR 4.57; 95% C.I., 1.90-10.97; p&#x2009;=&#x2009;0.001), and unplanned hospitalizations (OR 3.09; 95% C.I.,1.60-5.99; p&#x2009;=&#x2009;0.001). While male gender (OR 2.35; 95% C.I., 1.17-4.71; p&#x2009;=&#x2009;0.016), metastatic stage at cancer diagnosis (OR 2.74; 95% C.I., 1.33-5.66; p&#x2009;=&#x2009;0.006) and corrected PP (OR 1.90; 95% C.I. 1.01-3.56; p&#x2009;=&#x2009;0.046) were the significant predictive factors of unplanned hospitalizations.</AbstractText><AbstractText Label=\"CONCLUSION\" NlmCategory=\"CONCLUSIONS\">Among elderly cancer patients suitable for systemic cancer therapy, around two thirds of patients had PP and PIMs. Higher CCI score was the only significant predictor of PP and hyper-PP; while primary lung cancer was the sole independent factor predicting PIMs. PP was associated with unplanned hospitalizations, albeit not the survival.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Bandidwattanawong</LastName><ForeName>Chanyoot</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Navamindradhiraj University, Bangkok, Thailand. chanyootmd@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Rattanaserikulchai</LastName><ForeName>Pat</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Faculty of Medicine, Navamindradhiraj University, Bangkok, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Jetsadavanit</LastName><ForeName>Nontakorn</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Faculty of Medicine, Navamindradhiraj University, Bangkok, Thailand.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2023</Year><Month>11</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Geriatr</MedlineTA><NlmUniqueID>100968548</NlmUniqueID><ISSNLinking>1471-2318</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI=\"D006801\" MajorTopicYN=\"N\">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D008297\" MajorTopicYN=\"N\">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D005260\" MajorTopicYN=\"N\">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D000368\" MajorTopicYN=\"N\">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D057970\" MajorTopicYN=\"Y\">Inappropriate Prescribing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D011446\" MajorTopicYN=\"N\">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D019338\" MajorTopicYN=\"N\">Polypharmacy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D000067561\" MajorTopicYN=\"N\">Potentially Inappropriate Medication List</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D008175\" MajorTopicYN=\"Y\">Lung Neoplasms</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner=\"NOTNLM\"><Keyword MajorTopicYN=\"N\">Adverse outcomes</Keyword><Keyword MajorTopicYN=\"N\">Elderly cancer patients</Keyword><Keyword MajorTopicYN=\"N\">Polypharmacy</Keyword><Keyword MajorTopicYN=\"N\">Potentially inappropriate medications</Keyword><Keyword MajorTopicYN=\"N\">Prevalence</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"received\"><Year>2023</Year><Month>7</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus=\"accepted\"><Year>2023</Year><Month>11</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus=\"medline\"><Year>2023</Year><Month>11</Month><Day>29</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2023</Year><Month>11</Month><Day>28</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2023</Year><Month>11</Month><Day>27</Day><Hour>23</Hour><Minute>59</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38012569</ArticleId><ArticleId IdType=\"pmc\">PMC10680314</ArticleId><ArticleId IdType=\"doi\">10.1186/s12877-023-04471-3</ArticleId><ArticleId IdType=\"pii\">10.1186/s12877-023-04471-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hajjar ER, Cafiero AC, Hanlon JT. Polypharmacy in elderly patients. Am J Geriatr Pharmacother. 2007;5(4):345&#x2013;351. doi: 10.1016/j.amjopharm.2007.12.002.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.amjopharm.2007.12.002</ArticleId><ArticleId IdType=\"pubmed\">18179993</ArticleId></ArticleIdList></Reference><Reference><Citation>Azad N, Tierney M, Victor G, Kumar P. Adverse drug events in the elderly population admitted to a tertiary care hospital. J Healthc Manag. 2002;47(5):295&#x2013;305.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">12325252</ArticleId></ArticleIdList></Reference><Reference><Citation>J&#xf6;rgensen T, Johansson S, Kennerfalk A, Wallander MA, Sv&#xe4;rdsudd K. Prescription drug use, diagnoses, and healthcare utilization among the elderly. Ann Pharmacother. 2001;35(9):1004&#x2013;1009. doi: 10.1345/aph.10351.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1345/aph.10351</ArticleId><ArticleId IdType=\"pubmed\">11573845</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho HJ, Chae J, Yoon SH, Kim DS. Factors related to polypharmacy and hyper-polypharmacy for the elderly: a nationwide cohort study using National Health Insurance data in South Korea. Clin Transl Sci. 2023;16(2):193&#x2013;205. doi: 10.1111/cts.13438.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1111/cts.13438</ArticleId><ArticleId IdType=\"pmc\">PMC9926077</ArticleId><ArticleId IdType=\"pubmed\">36401587</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma M, Loh KP, Nightingale G, Mohile SG, Holmes HM. Polypharmacy and potentially inappropriate medication use in geriatric oncology. J Geriatr Oncol. 2016;7(5):346&#x2013;353. doi: 10.1016/j.jgo.2016.07.010.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jgo.2016.07.010</ArticleId><ArticleId IdType=\"pmc\">PMC5037024</ArticleId><ArticleId IdType=\"pubmed\">27498305</ArticleId></ArticleIdList></Reference><Reference><Citation>J&#xf8;rgensen T, Herrstedt J, Friis S, Hallas J. Polypharmacy and drug use in elderly Danish cancer patients during 1996 to 2006. J Geriatr Oncol. 2012;3(1):33&#x2013;40. doi: 10.1016/j.jgo.2011.09.001.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jgo.2011.09.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Nightingale G, Hajjar E, Swartz K, Andrel-Sendecki J, Chapman A. Evaluation of a pharmacist-led medication assessment used to identify prevalence of and associations with polypharmacy and potentially inappropriate medication use among ambulatory senior adults with cancer. J Clin Oncol. 2015;33(13):1453&#x2013;1459. doi: 10.1200/JCO.2014.58.7550.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1200/JCO.2014.58.7550</ArticleId><ArticleId IdType=\"pubmed\">25800766</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeoh TT, Chan LL, Poon D, Koo WH. Polypharmacy in an Asian elderly cancer patient population [Abstract]. In: Wedding U,&#xa0;P&#xe9;rez-Manga G, editors. 8th Meeting of the International Society of Geriatric Oncology; 2007 Nov 8&#x2013;10; Madrid, Spain. Crit Rev Oncol Hematol. 2007;64(Suppl 1):S49. doi: 10.1016/S1040-8428(13)70214-2.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/S1040-8428(13)70214-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Takemoto H, Mizuno S, Katsuura C, Kado A, Furukawa M, Kitani H, et al. Examination of polypharmacy and nutritional status in cancer patients [Abstract]. In: 41st ESPEN Congress; 2019 Aug 31-Sep3; Krakow, Poland. Clin Nutr. 2019;38(Suppl 1):S95. doi: 10.1016/S0261-5614(19)32731-1.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/S0261-5614(19)32731-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohamed MR, Ramsdale E, Loh KP, Arastu A, Xu H, Obrecht S, Castillo D, Sharma M, Holmes HM, Nightingale G, Juba KM, Mohile SG. Associations of polypharmacy and inappropriate medications with adverse outcomes in older adults with cancer: a systematic review and meta-analysis. Oncologist. 2020;25(1):e94&#x2013;e108. doi: 10.1634/theoncologist.2019-0406.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1634/theoncologist.2019-0406</ArticleId><ArticleId IdType=\"pmc\">PMC6964156</ArticleId><ArticleId IdType=\"pubmed\">31570516</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramasubbu SK, Mahato SK, Agnihotri A, Pasricha RK, Nath UK, Das B Dr. Prevalence, severity, and nature of risk factors associated with drug-drug interactions in geriatric patients receiving cancer chemotherapy: a prospective study in a tertiary care teaching hospital. Cancer Treat Res Commun. 2021;26:100277.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">33348276</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohamed MR, Mohile SG, Juba KM, Awad H, Wells M, Loh KP, Flannery M, Culakova E, Tylock RG, Ramsdale EE. Association of polypharmacy and potential drug-drug interactions with adverse treatment outcomes in older adults with advanced cancer. Cancer. 2023;129(7):1096&#x2013;1104. doi: 10.1002/cncr.34642.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1002/cncr.34642</ArticleId><ArticleId IdType=\"pubmed\">36692475</ArticleId></ArticleIdList></Reference><Reference><Citation>Sganga F, Landi F, Ruggiero C, Corsonello A, Vetrano DL, Lattanzio F, Cherubini A, Bernabei R, Onder G. Polypharmacy and health outcomes among older adults discharged from hospital: results from the CRIME study. Geriatr Gerontol Int. 2015;15(2):141&#x2013;146. doi: 10.1111/ggi.12241.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1111/ggi.12241</ArticleId><ArticleId IdType=\"pubmed\">24467719</ArticleId></ArticleIdList></Reference><Reference><Citation>Jyrkk&#xe4; J, Enlund H, Korhonen MJ, Sulkava R, Hartikainen S. Polypharmacy status as an indicator of mortality in an elderly population. Drugs Aging. 2009;26(12):1039&#x2013;1048. doi: 10.2165/11319530-000000000-00000.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.2165/11319530-000000000-00000</ArticleId><ArticleId IdType=\"pubmed\">19929031</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner JP, Shakib S, Singhal N, Hogan-Doran J, Prowse R, Johns S, Bell JS. Prevalence and factors associated with polypharmacy in older people with cancer. Support Care Cancer. 2014;22(7):1727&#x2013;1734. doi: 10.1007/s00520-014-2171-x.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s00520-014-2171-x</ArticleId><ArticleId IdType=\"pubmed\">24584682</ArticleId></ArticleIdList></Reference><Reference><Citation>Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017;17(1):230. doi: 10.1186/s12877-017-0621-2.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1186/s12877-017-0621-2</ArticleId><ArticleId IdType=\"pmc\">PMC5635569</ArticleId><ArticleId IdType=\"pubmed\">29017448</ArticleId></ArticleIdList></Reference><Reference><Citation>By the 2019 American Geriatrics Society Beers Criteria&#xae; Update Expert Panel American Geriatrics Society 2019 updated AGS Beers Criteria&#xae; for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2019;67(4):674&#x2013;694. doi: 10.1111/jgs.15767.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1111/jgs.15767</ArticleId><ArticleId IdType=\"pubmed\">30693946</ArticleId></ArticleIdList></Reference><Reference><Citation>Khaledi AR, Kazemi M, Tahmasebi M. Frequency of polypharmacy in advanced cancer patients consulted with the palliative service of Imam Khomeini Hospital (Tehran), Iran, 2017. Asian Pac J Cancer Prev. 2019;20(1):131&#x2013;134. doi: 10.31557/APJCP.2019.20.1.131.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.31557/APJCP.2019.20.1.131</ArticleId><ArticleId IdType=\"pmc\">PMC6485550</ArticleId><ArticleId IdType=\"pubmed\">30678392</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramsdale E, Mohamed M, Yu V, Otto E, Juba K, Awad H, Moorthi K, Plumb S, Patil A, Vogelzang N, Dib E, Mohile S. Polypharmacy, potentially inappropriate medications, and drug-drug interactions in vulnerable older adults with advanced cancer initiating cancer treatment. Oncologist. 2022;27(7):e580&#x2013;e588. doi: 10.1093/oncolo/oyac053.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/oncolo/oyac053</ArticleId><ArticleId IdType=\"pmc\">PMC9255971</ArticleId><ArticleId IdType=\"pubmed\">35348764</ArticleId></ArticleIdList></Reference><Reference><Citation>Guthrie B, Makubate B, Hernandez-Santiago V, Dreischulte T. The rising tide of polypharmacy and drug-drug interactions: population database analysis 1995&#x2013;2010. BMC Med. 2015;7(13):74. doi: 10.1186/s12916-015-0322-7.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1186/s12916-015-0322-7</ArticleId><ArticleId IdType=\"pmc\">PMC4417329</ArticleId><ArticleId IdType=\"pubmed\">25889849</ArticleId></ArticleIdList></Reference><Reference><Citation>Sehgal V, Bajwa SJ, Sehgal R, Bajaj A, Khaira U, Kresse V. Polypharmacy and potentially inappropriate medication use as the precipitating factor in readmissions to the hospital. J Family Med Prim Care. 2013;2(2):194&#x2013;199. doi: 10.4103/2249-4863.117423.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.4103/2249-4863.117423</ArticleId><ArticleId IdType=\"pmc\">PMC3894035</ArticleId><ArticleId IdType=\"pubmed\">24479078</ArticleId></ArticleIdList></Reference><Reference><Citation>Maggiore RJ, Dale W, Gross CP, Feng T, Tew WP, Mohile SG, Owusu C, Klepin HD, Lichtman SM, Gajra A, Ramani R, Katheria V, Zavala L, Hurria A, Cancer and Aging Research Group Polypharmacy and potentially inappropriate medication use in older adults with cancer undergoing chemotherapy: effect on chemotherapy-related toxicity and hospitalization during treatment. J Am Geriatr Soc. 2014;62(8):1505&#x2013;1512. doi: 10.1111/jgs.12942.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1111/jgs.12942</ArticleId><ArticleId IdType=\"pmc\">PMC4134360</ArticleId><ArticleId IdType=\"pubmed\">25041361</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet. 2012;380(9836):37&#x2013;43. doi: 10.1016/S0140-6736(12)60240-2.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/S0140-6736(12)60240-2</ArticleId><ArticleId IdType=\"pubmed\">22579043</ArticleId></ArticleIdList></Reference><Reference><Citation>Soto-Perez-de-Celis E, Li D, Yuan Y, Lau YM, Hurria A. Functional versus chronological age: geriatric assessments to guide decision making in older patients with cancer. Lancet Oncol. 2018;19(6):e305&#x2013;e316. doi: 10.1016/S1470-2045(18)30348-6.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/S1470-2045(18)30348-6</ArticleId><ArticleId IdType=\"pubmed\">29893262</ArticleId></ArticleIdList></Reference><Reference><Citation>Rostoft S, O&#x2019;Donovan A, Soubeyran P, Alibhai SMH, Hamaker ME. Geriatric assessment and management in cancer. J Clin Oncol. 2021;39(19):2058&#x2013;2067. doi: 10.1200/JCO.21.00089.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1200/JCO.21.00089</ArticleId><ArticleId IdType=\"pubmed\">34043439</ArticleId></ArticleIdList></Reference><Reference><Citation>Karuturi MS, Holmes HM, Lei X, Johnson M, Barcenas CH, Cantor SB, et al. Potentially inappropriate medication use in older patients with breast and colorectal cancer. Cancer. 2018;124(14):3000&#x2013;3007. doi: 10.1002/cncr.31403.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1002/cncr.31403</ArticleId><ArticleId IdType=\"pmc\">PMC6033638</ArticleId><ArticleId IdType=\"pubmed\">29689595</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohile SG, Mohamed MR, Xu H, Culakova E, Loh KP, Magnuson A, et al. Evaluation of geriatric assessment and management on the toxic effects of cancer treatment (GAP70+): a cluster-randomised study. Lancet. 2021;398(10314):1894&#x2013;1904. doi: 10.1016/S0140-6736(21)01789-X.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/S0140-6736(21)01789-X</ArticleId><ArticleId IdType=\"pmc\">PMC8647163</ArticleId><ArticleId IdType=\"pubmed\">34741815</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>\n",
            "XML saved to: path/to/save/xml/38012569.xml\n",
            "Details URL: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=38011678&retmode=xml&api_key=9edd38677707c08b2a96ed1a6e8c61c47408\n",
            "Details Response Content: <?xml version=\"1.0\" ?>\n",
            "<!DOCTYPE PubmedArticleSet PUBLIC \"-//NLM//DTD PubMedArticle, 1st January 2023//EN\" \"https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd\">\n",
            "<PubmedArticleSet>\n",
            "<PubmedArticle><MedlineCitation Status=\"PubMed-not-MEDLINE\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38011678</PMID><DateRevised><Year>2023</Year><Month>12</Month><Day>09</Day></DateRevised><Article PubModel=\"Print\"><Journal><ISSN IssnType=\"Electronic\">2753-670X</ISSN><JournalIssue CitedMedium=\"Internet\"><Volume>37</Volume><Issue>6</Issue><PubDate><Year>2023</Year><Month>Dec</Month><Day>05</Day></PubDate></JournalIssue><Title>Interdisciplinary cardiovascular and thoracic surgery</Title><ISOAbbreviation>Interdiscip Cardiovasc Thorac Surg</ISOAbbreviation></Journal><ArticleTitle>Results of video-assisted thoracoscopic surgery versus thoracotomy for lung cancer in a mixed practice medium-volume hospital: a propensity-matched study.</ArticleTitle><ELocationID EIdType=\"pii\" ValidYN=\"Y\">ivad189</ELocationID><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.1093/icvts/ivad189</ELocationID><Abstract><AbstractText Label=\"OBJECTIVES\" NlmCategory=\"OBJECTIVE\">The aim of this study was to compare the short- and long-term results of video-assisted thoracoscopic surgery (VATS) and thoracotomy for non-small-cell lung cancer in a medium-volume centre, where cardiothoracic surgeons perform both cardiac and general thoracic surgery. The primary outcome of interest was 5-year overall survival and disease-specific survival. Secondary outcomes were short-term postoperative complications, length of hospital stay and lymph node yield.</AbstractText><AbstractText Label=\"METHODS\" NlmCategory=\"METHODS\">This was a retrospective cohort study including 670 lung cancer patients undergoing VATS (n&#x2009;=&#x2009;207) or open surgery (n&#x2009;=&#x2009;463) with a curative intent in Oulu University Hospital between the years 2000-2020. Propensity score matching was implemented with surgical technique as the dependent and age, sex, Charlson comorbidity index, pulmonary function, pathological stage, histological type and the year of the operation as covariates resulting in 127 pairs.</AbstractText><AbstractText Label=\"RESULTS\" NlmCategory=\"RESULTS\">In the propensity-matched cohort, 5-year overall survival was 64.3% after VATS and 63.2% after thoracotomy (P&#x2009;=&#x2009;0.969). Five-year disease-specific survival was 71.6% vs 76.2% (P&#x2009;=&#x2009;0.559). There were no differences in overall (34.6% vs 44.9%, p&#x2009;=&#x2009;0.096) or major postoperative complications (8.7% vs 14.2%, P&#x2009;=&#x2009;0.167) between the study groups. The average length of hospital stay was shorter (5.8 vs 6.6&#x2009;days, P&#x2009;=&#x2009;0.012) and the median lymph node yield was lower (4.0 vs 7.0, P&#x2009;&lt;&#x2009;0.001) in the VATS group compared to the thoracotomy group.</AbstractText><AbstractText Label=\"CONCLUSIONS\" NlmCategory=\"CONCLUSIONS\">According to this study, the long-term results of lung cancer surgery in a mixed practice are comparable between VATS and open surgery.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2023. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery.</CopyrightInformation></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Niskakangas</LastName><ForeName>Anne</ForeName><Initials>A</Initials><Identifier Source=\"ORCID\">0009-0000-4458-0105</Identifier><AffiliationInfo><Affiliation>Research Unit of Translational Medicine, Medical Research Center Oulu, University of Oulu, Oulu, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Mustonen</LastName><ForeName>Olli</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Research Unit of Translational Medicine, Medical Research Center Oulu, University of Oulu, Oulu, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Puro</LastName><ForeName>Iiris</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Research Unit of Translational Medicine, Medical Research Center Oulu, University of Oulu, Oulu, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Karjula</LastName><ForeName>Topias</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Research Unit of Translational Medicine, Medical Research Center Oulu, University of Oulu, Oulu, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Helminen</LastName><ForeName>Olli</ForeName><Initials>O</Initials><Identifier Source=\"ORCID\">0000-0001-9544-6475</Identifier><AffiliationInfo><Affiliation>Research Unit of Translational Medicine, Medical Research Center Oulu, University of Oulu, Oulu, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Gastrointestinal Surgery, Oulu University Hospital, Oulu, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Yannopoulos</LastName><ForeName>Fredrik</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Research Unit of Translational Medicine, Medical Research Center Oulu, University of Oulu, Oulu, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Oulu University Hospital, Oulu, Finland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN=\"Y\"><Grant><Agency>Finnish State Research Funding</Agency><Country/></Grant><Grant><Agency>Instrumentarium Science Foundation</Agency><Country/></Grant><Grant><Agency>Mary and Georg C. Ehrnrooth Foundation</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Interdiscip Cardiovasc Thorac Surg</MedlineTA><NlmUniqueID>9918540787006676</NlmUniqueID><ISSNLinking>2753-670X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner=\"NOTNLM\"><Keyword MajorTopicYN=\"N\">Lung cancer</Keyword><Keyword MajorTopicYN=\"N\">Mediastinal lymph node dissection</Keyword><Keyword MajorTopicYN=\"N\">Nodal upstaging</Keyword><Keyword MajorTopicYN=\"N\">Survival</Keyword><Keyword MajorTopicYN=\"N\">Thoracotomy</Keyword><Keyword MajorTopicYN=\"N\">Video-assisted thoracoscopic surgery</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"received\"><Year>2023</Year><Month>7</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus=\"revised\"><Year>2023</Year><Month>10</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus=\"medline\"><Year>2023</Year><Month>11</Month><Day>27</Day><Hour>18</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2023</Year><Month>11</Month><Day>27</Day><Hour>18</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2023</Year><Month>11</Month><Day>27</Day><Hour>16</Hour><Minute>35</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38011678</ArticleId><ArticleId IdType=\"pmc\">PMC10701201</ArticleId><ArticleId IdType=\"doi\">10.1093/icvts/ivad189</ArticleId><ArticleId IdType=\"pii\">7451843</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Postmus PE, Kerr KM, Oudkerk M, Senan S, Waller DA, Vansteenkiste J et al; ESMO Guidelines Committee. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol Ann Oncol 2017;28:iv1&#x2013;iv21.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">28881918</ArticleId></ArticleIdList></Reference><Reference><Citation>Howington JA, Blum MG, Chang AC, Balekian AA, Murthy SC.. Treatment of stage I and II non-small cell lung cancer. Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2013;143:e278S&#x2013;313S.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">23649443</ArticleId></ArticleIdList></Reference><Reference><Citation>Falcoz PE, Puyraveau M, Thomas PA, Decaluwe H, H&#xfc;rtgen M, Petersen RH. et al.; ESTS Database Committee and ESTS Minimally Invasive Interest Group. Video-assisted thoracoscopic surgery versus open lobectomy for primary non-small-cell lung cancer: a propensity-matched analysis of outcome from the European Society of Thoracic Surgeon database. Eur J Cardiothorac Surg 2016;49:602&#x2013;9.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">25913824</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao C, Manganas C, Ang SC, Peeceeyen S, Yan TD.. Video-assisted thoracic surgery versus open thoracotomy for non-small cell lung cancer: a meta-analysis of propensity score-matched patients. Interact CardioVasc Thorac Surg 2013;16:244&#x2013;9.</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC3568798</ArticleId><ArticleId IdType=\"pubmed\">23169877</ArticleId></ArticleIdList></Reference><Reference><Citation>ESTS Database Committee. European Society of Thoracic Surgeons Database Annual Report, 2023.</Citation></Reference><Reference><Citation>Gunn J, Valo J, Sipil&#xe4; J, Rautava P, Sihvo E, Kyt&#xf6; V.. Trends and results of lung cancer surgery in Finland between 2004 and 2014. Eur J Cardiothorac Surg 2018;54:127&#x2013;33.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">29325089</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang CFJ, Kumar A, Klapper JA, Hartwig MG, Tong BC, Harpole DH. et al. A national analysis of long-term survival following thoracoscopic versus open lobectomy for stage I non-small-cell lung cancer. Ann Surg 2019;269:163&#x2013;71.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">28799982</ArticleId></ArticleIdList></Reference><Reference><Citation>Licht PB, J&#xf8;rgensen OD, Ladegaard L, Jakobsen E.. A national study of nodal upstaging after thoracoscopic versus open lobectomy for clinical stage I lung cancer. Ann Thorac Surg 2013;96:943&#x2013;50.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">23684159</ArticleId></ArticleIdList></Reference><Reference><Citation>D'Amico TA, Niland J, Mamet R, Zornosa C, Dexter EU, Onaitis MW.. Efficacy of mediastinal lymph node dissection during lobectomy for lung cancer by thoracoscopy and thoracotomy. Ann Thorac Surg 2011;92:226&#x2013;32.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">21718849</ArticleId></ArticleIdList></Reference><Reference><Citation>Medbery RL, Gillespie TW, Liu Y, Nickleach DC, Lipscomb J, Sancheti MS. et al. Nodal upstaging is more common with thoracotomy than with VATS during lobectomy for early-stage lung cancer: an analysis from the national cancer data base. J Thorac Oncol 2016;11:222&#x2013;33.</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC4729646</ArticleId><ArticleId IdType=\"pubmed\">26792589</ArticleId></ArticleIdList></Reference><Reference><Citation>Boffa DJ, Kosinski AS, Paul S, Mitchell JD, Onaitis M.. Lymph node evaluation by open or video-assisted approaches in 11,500 anatomic lung cancer resections. Ann Thorac Surg 2012;94:347&#x2013;53.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">22742843</ArticleId></ArticleIdList></Reference><Reference><Citation>Paul S, Isaacs AJ, Treasure T, Altorki NK, Sedrakyan A.. Long term survival with thoracoscopic versus open lobectomy: propensity matched comparative analysis using seer-medicare database. BMJ 2014;349:g5575.</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC4183188</ArticleId><ArticleId IdType=\"pubmed\">25277994</ArticleId></ArticleIdList></Reference><Reference><Citation>Berry MF, D'Amico TA, Onaitis MW, Kelsey CR.. Thoracoscopic approach to lobectomy for lung cancer does not compromise oncologic efficacy. Ann Thorac Surg 2014;98:197&#x2013;202.</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC4118748</ArticleId><ArticleId IdType=\"pubmed\">24820392</ArticleId></ArticleIdList></Reference><Reference><Citation>\n",
            "Official Statistics of Finland (OSF). Quality Description: Causes of Death 2020. Helsinki: Statistics Finland, 2020. http://www.stat.fi/til/ksyyt/2020/ksyyt_2020_2021-12-10_laa_001_en.html.</Citation></Reference><Reference><Citation>Amin M, Edge S, Greene F, Byrd D, Brookland R, Washington M. et al. AJCC Cancer Staging Manual, 8th edn. Cham: Springer, 2017.</Citation></Reference><Reference><Citation>Armitage JN, Meulen JVD; Royal College of Surgeons Co-morbidity Consensus Group. Identifying co-morbidity in surgical patients using administrative data with the Royal College of Surgeons Charlson Score. Br J Surg 2010;97:772&#x2013;81.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">20306528</ArticleId></ArticleIdList></Reference><Reference><Citation>Dindo D, Demartines N, Clavien P-A.. Classification of surgical complications. A new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004;240:205&#x2013;13.</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC1360123</ArticleId><ArticleId IdType=\"pubmed\">15273542</ArticleId></ArticleIdList></Reference><Reference><Citation>Lardinois D, Leyn PD, Schil PV, Porta RR, Waller D, Passlick B. et al. ESTS guidelines for intraoperative lymph node staging in non-small cell lung cancer. Eur J Cardiothorac Surg 2006;30:787&#x2013;92.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">16971134</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen FF, Zhang D, Wang YL, Xiong B.. Video-assisted thoracoscopic surgery lobectomy versus open lobectomy in patients with clinical stage I non-small cell lung cancer: a meta-analysis. Eur J Surg Oncol 2013;39:957&#x2013;63.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">23845704</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitson BA, Groth SS, Duval SJ, Swanson SJ, Maddaus MA.. Surgery for early-stage non-small cell lung cancer: a systematic review of the video-assisted thoracoscopic surgery versus thoracotomy approaches to lobectomy. Ann Thorac Surg 2008;86:2008.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">19022040</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen H, Wang X, Nie Y, Zhang K, Wei Z, Yang F. et al. Minimally invasive surgery versus thoracotomy for resectable stage II and III non-small-cell lung cancers: a systematic review and meta-analysis. Eur J Cardiothorac Surg 2021;59:940&#x2013;50.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">33370437</ArticleId></ArticleIdList></Reference><Reference><Citation>Valo JK, Kyt&#xf6; V, Sipil&#xe4; J, Rautava P, Sihvo E, Gunn J.. Thoracoscopic surgery for lung cancer is associated with improved survival and shortened admission length: a nationwide propensity-matched study. Eur J Cardiothorac Surg 2020;57:100&#x2013;6.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">31243441</ArticleId></ArticleIdList></Reference><Reference><Citation>Dziedzic DA, Zbytniewski M, Gryszko GM, Cackowski MM, Langfort R, Orlowski TM.. Video-assisted versus open thoracotomy lobectomy: comparison on lymphadenectomy and survival in early stage of lung cancer. J Thorac Dis 2021;13:101&#x2013;12.</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC7867811</ArticleId><ArticleId IdType=\"pubmed\">33569190</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Ameri M, Bergman P, Franco-Cereceda A, Sartipy U, Publishing C.. Video-assisted thoracoscopic versus open thoracotomy lobectomy: a Swedish nationwide cohort study. J Thorac Dis 2018;10:3499&#x2013;506.</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC6051874</ArticleId><ArticleId IdType=\"pubmed\">30069346</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathisen DJ. Is video-assisted thoracoscopic lobectomy inferior to open lobectomy oncologically? Ann Thorac Surg 2013;96:755&#x2013;6.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">23992686</ArticleId></ArticleIdList></Reference><Reference><Citation>Merritt RE, Hoang CD, Shrager JB.. Lymph node evaluation achieved by open lobectomy compared with thoracoscopic lobectomy for N0 lung cancer. Ann Thorac Surg 2013;96:1171&#x2013;7.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">23915591</ArticleId></ArticleIdList></Reference><Reference><Citation>Denlinger CE, Fernandez F, Meyers BF, Pratt W, Zoole JB, Patterson GA. et al. Lymph node evaluation in video-assisted thoracoscopic lobectomy versus lobectomy by thoracotomy. Ann Thorac Surg 2010;89:1730&#x2013;5; discussion 1736.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">20494019</ArticleId></ArticleIdList></Reference><Reference><Citation>Ely S, Jiang SF, Dominguez DA, Patel AR, Ashiku SK, Velotta JB.. Effect of thoracic surgery regionalization on long-term survival after lung cancer resection. J Thorac Cardiovasc Surg 2022;163:769&#x2013;77.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">33934900</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyenfeldt EV, Gooiker GA, Gijn WV, Post PN, Velde CVD, Tollenaar RAEM. et al. The relationship between volume or surgeon specialty and outcome in the surgical treatment of lung cancer: a systematic review and meta-analysis. J Thorac Oncol 2012;7:1170&#x2013;8.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">22617248</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>\n",
            "XML saved to: path/to/save/xml/38011678.xml\n",
            "Details URL: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=38007507&retmode=xml&api_key=9edd38677707c08b2a96ed1a6e8c61c47408\n",
            "Details Response Content: <?xml version=\"1.0\" ?>\n",
            "<!DOCTYPE PubmedArticleSet PUBLIC \"-//NLM//DTD PubMedArticle, 1st January 2023//EN\" \"https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd\">\n",
            "<PubmedArticleSet>\n",
            "<PubmedArticle><MedlineCitation Status=\"MEDLINE\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38007507</PMID><DateCompleted><Year>2023</Year><Month>11</Month><Day>27</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>28</Day></DateRevised><Article PubModel=\"Electronic\"><Journal><ISSN IssnType=\"Electronic\">1749-8090</ISSN><JournalIssue CitedMedium=\"Internet\"><Volume>18</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Nov</Month><Day>25</Day></PubDate></JournalIssue><Title>Journal of cardiothoracic surgery</Title><ISOAbbreviation>J Cardiothorac Surg</ISOAbbreviation></Journal><ArticleTitle>Thoracic day surgery versus thoracic inpatient surgery for treatment of patients with lung cancer: a systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>341</StartPage><MedlinePgn>341</MedlinePgn></Pagination><ELocationID EIdType=\"pii\" ValidYN=\"Y\">341</ELocationID><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.1186/s13019-023-02462-4</ELocationID><Abstract><AbstractText Label=\"BACKGROUND\" NlmCategory=\"BACKGROUND\">The successful implementation of the Enhanced recovery after surgery (ERAS) concept in thoracic surgery has made it possible to complete the surgery in the day surgery unit. However, it is still unclear whether day surgery for lung cancer patients can achieve the same or even better results.</AbstractText><AbstractText Label=\"METHODS\" NlmCategory=\"METHODS\">A systematic literature search was completed in common databases for studies published before May 2022 and the data analyzed using the Review Manager 5.3 software.</AbstractText><AbstractText Label=\"RESULTS\" NlmCategory=\"RESULTS\">We ultimately included 7 retrospective articles that met our criteria for the study. The results of age, smoking status, comorbidity and pulmonary function tests in day surgery group were better than in inpatient surgery group. Minimally invasive surgical method with segmentectomy was more used in day surgery group than in normal surgery group. The 30-day mortality was also lower in Day surgery group and it displayed that early discharged patients had fewer overall complications than the inpatient surgery group.</AbstractText><AbstractText Label=\"CONCLUSIONS\" NlmCategory=\"CONCLUSIONS\">We demonstrate that younger patients, patients receiving segmental resections by VATS, and those with better pulmonary function tests or without comorbidity can be discharged early with low rates of complications and 30-day mortality, especial with ERAS program.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Shen</LastName><ForeName>Cheng</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Thoracic Surgery, West-China Hospital, Sichuan University, Chengdu, 610041, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Che</LastName><ForeName>Guowei</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Thoracic Surgery, West-China Hospital, Sichuan University, Chengdu, 610041, China. cheguowei_hx@aliyun.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D017418\">Meta-Analysis</PublicationType><PublicationType UI=\"D000078182\">Systematic Review</PublicationType><PublicationType UI=\"D016428\">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2023</Year><Month>11</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Cardiothorac Surg</MedlineTA><NlmUniqueID>101265113</NlmUniqueID><ISSNLinking>1749-8090</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI=\"D006801\" MajorTopicYN=\"N\">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D008175\" MajorTopicYN=\"Y\">Lung Neoplasms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D012189\" MajorTopicYN=\"N\">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D007297\" MajorTopicYN=\"N\">Inpatients</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D013903\" MajorTopicYN=\"Y\">Thoracic Surgery</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D000556\" MajorTopicYN=\"N\">Ambulatory Surgical Procedures</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D011013\" MajorTopicYN=\"N\">Pneumonectomy</DescriptorName><QualifierName UI=\"Q000379\" MajorTopicYN=\"N\">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D020775\" MajorTopicYN=\"N\">Thoracic Surgery, Video-Assisted</DescriptorName><QualifierName UI=\"Q000379\" MajorTopicYN=\"N\">methods</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner=\"NOTNLM\"><Keyword MajorTopicYN=\"N\">Complication</Keyword><Keyword MajorTopicYN=\"N\">Day surgery</Keyword><Keyword MajorTopicYN=\"N\">Enhanced recovery after surgery</Keyword><Keyword MajorTopicYN=\"N\">Lung cancer</Keyword><Keyword MajorTopicYN=\"N\">Video assisted thoracic surgery</Keyword></KeywordList><CoiStatement>The authors have no conflicts of interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"received\"><Year>2023</Year><Month>5</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus=\"accepted\"><Year>2023</Year><Month>11</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus=\"medline\"><Year>2023</Year><Month>11</Month><Day>27</Day><Hour>12</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2023</Year><Month>11</Month><Day>26</Day><Hour>7</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2023</Year><Month>11</Month><Day>25</Day><Hour>23</Hour><Minute>25</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38007507</ArticleId><ArticleId IdType=\"pmc\">PMC10676578</ArticleId><ArticleId IdType=\"doi\">10.1186/s13019-023-02462-4</ArticleId><ArticleId IdType=\"pii\">10.1186/s13019-023-02462-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Huang L, Kehlet H, Petersen RH. Reasons for staying in hospital after video-assisted thoracoscopic surgery lobectomy. BJS Open. 2022 doi: 10.1093/bjsopen/zrac050.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/bjsopen/zrac050</ArticleId><ArticleId IdType=\"pmc\">PMC9070644</ArticleId><ArticleId IdType=\"pubmed\">35511502</ArticleId></ArticleIdList></Reference><Reference><Citation>Drawbert HE, Hey MT, Tarrazzi F, Block M, Razi SS. Early discharge on postoperative day 1 following lobectomy for stage I non-small-cell lung cancer is safe in high-volume surgical centres: a national cancer database analysis. Eur J Cardio Thorac Surg Off J Eur Assoc Cardio Thorac Surg. 2022;61(5):1022&#x2013;1029. doi: 10.1093/ejcts/ezab490.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/ejcts/ezab490</ArticleId><ArticleId IdType=\"pubmed\">34849695</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen T, Wei H, Yue W, Su Y, Fu X. Enhanced recovery after surgery management of perioperative period in surgical lung cancer patients: protocol for a systematic review and meta-analysis of randomised controlled trials. BMJ Open. 2022;12(2):e056068. doi: 10.1136/bmjopen-2021-056068.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1136/bmjopen-2021-056068</ArticleId><ArticleId IdType=\"pmc\">PMC8852760</ArticleId><ArticleId IdType=\"pubmed\">35168979</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel DC, Leipzig M, Jeffrey Yang CF, et al. Early discharge after lobectomy for lung cancer does not equate to early readmission. Ann Thorac Surg. 2022;113(5):1634&#x2013;1640. doi: 10.1016/j.athoracsur.2021.05.053.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.athoracsur.2021.05.053</ArticleId><ArticleId IdType=\"pubmed\">34126077</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang L, Lei T, Zhou K, Ma H, Che G. Pivotal role of video-assisted thoracoscopic surgery in improving survival outcome of stage I non-small cell lung cancer in day surgery patients. Thoracic Cancer. 2021;12(21):2865&#x2013;2872. doi: 10.1111/1759-7714.14145.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1111/1759-7714.14145</ArticleId><ArticleId IdType=\"pmc\">PMC8563150</ArticleId><ArticleId IdType=\"pubmed\">34558195</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong Y, Shen C, Wang Y, et al. Safety and feasibility of video-assisted thoracoscopic day surgery and inpatient surgery in patients with non-small cell lung cancer: a single-center retrospective cohort study. Front Surg. 2021;8:779889. doi: 10.3389/fsurg.2021.779889.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3389/fsurg.2021.779889</ArticleId><ArticleId IdType=\"pmc\">PMC8635799</ArticleId><ArticleId IdType=\"pubmed\">34869571</ArticleId></ArticleIdList></Reference><Reference><Citation>Linden PA, Perry Y, Worrell S, et al. Postoperative day 1 discharge after anatomic lung resection: a society of thoracic surgeons database analysis. J Thorac Cardiovasc Surg. 2020;159(2):667&#x2013;78.e2. doi: 10.1016/j.jtcvs.2019.08.038.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jtcvs.2019.08.038</ArticleId><ArticleId IdType=\"pmc\">PMC7890415</ArticleId><ArticleId IdType=\"pubmed\">31606175</ArticleId></ArticleIdList></Reference><Reference><Citation>Towe CW, Khil A, Ho VP, et al. Early discharge after lung resection is safe: 10-year experience. J Thorac Dis. 2018;10(10):5870&#x2013;5878. doi: 10.21037/jtd.2018.09.99.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.21037/jtd.2018.09.99</ArticleId><ArticleId IdType=\"pmc\">PMC6236148</ArticleId><ArticleId IdType=\"pubmed\">30505495</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong Y, Zhu D, Che G, et al. Clinical effect of day surgery in patients with lung caner by optimize operating process. Zhongguo fei ai za zhi = Chin J Lung Cancer. 2020;23(2):77&#x2013;83. doi: 10.3779/j.issn.1009-3419.2020.02.02.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3779/j.issn.1009-3419.2020.02.02</ArticleId><ArticleId IdType=\"pmc\">PMC7049788</ArticleId><ArticleId IdType=\"pubmed\">32093451</ArticleId></ArticleIdList></Reference><Reference><Citation>Geraci TC, Chang SH, Chen S, Ferrari-Light D, Cerfolio RJ. Discharging patients by postoperative day one after robotic anatomic pulmonary resection. Ann Thorac Surg. 2021 doi: 10.1016/j.athoracsur.2021.06.088.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.athoracsur.2021.06.088</ArticleId><ArticleId IdType=\"pubmed\">34389302</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, Zhu P, Jia J, et al. Cost-effectiveness of same-day discharge surgery for primary total hip arthroplasty: a pragmatic randomized controlled study. Front Public Health. 2022;10:825727. doi: 10.3389/fpubh.2022.825727.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3389/fpubh.2022.825727</ArticleId><ArticleId IdType=\"pmc\">PMC9082643</ArticleId><ArticleId IdType=\"pubmed\">35548067</ArticleId></ArticleIdList></Reference><Reference><Citation>Paluch AJ, Matthews AH, Mullins S, Vanstone RJ, Woodacre T. Adopting the day surgery default in the provision of lumbar discectomy and decompressive surgery. J Perioper Pract. 2022 doi: 10.1177/17504589211054360.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1177/17504589211054360</ArticleId><ArticleId IdType=\"pubmed\">35322699</ArticleId></ArticleIdList></Reference><Reference><Citation>Olry de Labry Lima A, Lima A, Spacirova Z, Espin J. Description of day case costs and tariffs of cataract surgery from a sample of nine European countries. Cost Eff Resour Alloc. 2022;20(1):11. doi: 10.1186/s12962-022-00346-3.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1186/s12962-022-00346-3</ArticleId><ArticleId IdType=\"pmc\">PMC8898401</ArticleId><ArticleId IdType=\"pubmed\">35248070</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu Y, Li M, Kang R, et al. The effectiveness of telephone and internet-based supportive care for patients with esophageal cancer on enhanced recovery after surgery in China: a randomized controlled trial. Asia Pac J Oncol Nurs. 2022;9(4):217&#x2013;228. doi: 10.1016/j.apjon.2022.02.007.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.apjon.2022.02.007</ArticleId><ArticleId IdType=\"pmc\">PMC9096733</ArticleId><ArticleId IdType=\"pubmed\">35571631</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeom J, Lim HS. Effects of the enhanced recovery after surgery (ERAS) program for colorectal cancer patients undergoing laparoscopic surgery. Clin Nutr Res. 2022;11(2):75&#x2013;83. doi: 10.7762/cnr.2022.11.2.75.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.7762/cnr.2022.11.2.75</ArticleId><ArticleId IdType=\"pmc\">PMC9065394</ArticleId><ArticleId IdType=\"pubmed\">35558997</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>\n",
            "XML saved to: path/to/save/xml/38007507.xml\n",
            "Details URL: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=38003929&retmode=xml&api_key=9edd38677707c08b2a96ed1a6e8c61c47408\n",
            "Details Response Content: <?xml version=\"1.0\" ?>\n",
            "<!DOCTYPE PubmedArticleSet PUBLIC \"-//NLM//DTD PubMedArticle, 1st January 2023//EN\" \"https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd\">\n",
            "<PubmedArticleSet>\n",
            "<PubmedArticle><MedlineCitation Status=\"PubMed-not-MEDLINE\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">38003929</PMID><DateRevised><Year>2023</Year><Month>11</Month><Day>27</Day></DateRevised><Article PubModel=\"Electronic\"><Journal><ISSN IssnType=\"Print\">2075-4426</ISSN><JournalIssue CitedMedium=\"Print\"><Volume>13</Volume><Issue>11</Issue><PubDate><Year>2023</Year><Month>Nov</Month><Day>16</Day></PubDate></JournalIssue><Title>Journal of personalized medicine</Title><ISOAbbreviation>J Pers Med</ISOAbbreviation></Journal><ArticleTitle>PEAL Score to Predict the Mortality Risk of Cardiogenic Shock in the Emergency Department: An Observational Study.</ArticleTitle><ELocationID EIdType=\"pii\" ValidYN=\"Y\">1614</ELocationID><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.3390/jpm13111614</ELocationID><Abstract><AbstractText Label=\"BACKGROUND\" NlmCategory=\"BACKGROUND\">The in-hospital mortality of cardiogenic shock (CS) remains high (28% to 45%). As a result, several studies developed prediction models to assess the mortality risk and provide guidance on treatment, including CardShock and IABP-SHOCK II scores, which performed modestly in external validation studies, reflecting the heterogeneity of the CS populations. Few articles established predictive scores of CS based on Asian people with a higher burden of comorbidities than Caucasians. We aimed to describe the clinical characteristics of a contemporary Asian population with CS, identify risk factors, and develop a predictive scoring model.</AbstractText><AbstractText Label=\"METHODS\" NlmCategory=\"METHODS\">A retrospective observational study was conducted between 2014 and 2019 to collect the patients who presented with all-cause CS in the emergency department of a single medical center in Taiwan. We divided patients into subgroups of CS related to acute myocardial infarction (AMI-CS) or heart failure (HF-CS). The outcome was all-cause 30-day mortality. We built the prediction model based on the hazard ratio of significant variables, and the cutoff point of each predictor was determined using the Youden index. We also assessed the discrimination ability of the risk score using the area under a receiver operating characteristic curve.</AbstractText><AbstractText Label=\"RESULTS\" NlmCategory=\"RESULTS\">We enrolled 225 patients with CS. One hundred and seven patients (47.6%) were due to AMI-CS, and ninety-eight patients among them received reperfusion therapy. Forty-nine patients (21.8%) eventually died within 30 days. Fifty-three patients (23.55%) presented with platelet counts &lt; 155 &#xd7; 10<sup>3</sup>/&#x3bc;L, which were negatively associated with a 30-day mortality of CS in the restrictive cubic spline plot, even within the normal range of platelet counts. We identified four predictors: platelet counts &lt; 200 &#xd7; 10<sup>3</sup>/&#x3bc;L (HR 2.574, 95% CI 1.379-4.805, <i>p</i> = 0.003), left ventricular ejection fraction (LVEF) &lt; 40% (HR 2.613, 95% CI 1.020-6.692, <i>p</i> = 0.045), age &gt; 71 years (HR 2.452, 95% CI 1.327-4.531, <i>p</i> = 0.004), and lactate &gt; 2.7 mmol/L (HR 1.967, 95% CI 1.069-3.620, <i>p</i> = 0.030). The risk score ended with a maximum of 5 points and showed an AUC (95% CI) of 0.774 (0.705-0.843) for all patients, 0.781 (0.678-0.883), and 0.759 (0.662-0.855) for AMI-CS and HF-CS sub-groups, respectively, all <i>p</i> &lt; 0.001.</AbstractText><AbstractText Label=\"CONCLUSIONS\" NlmCategory=\"CONCLUSIONS\">Based on four parameters, platelet counts, LVEF, age, and lactate (PEAL), this model showed a good predictive performance for all-cause mortality at 30 days in the all patients, AMI-CS, and HF-CS subgroups. The restrictive cubic spline plot showed a significantly negative correlation between initial platelet counts and 30-day mortality risk in the AMI-CS and HF-CS subgroups.</AbstractText></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Ma</LastName><ForeName>Jen-Wen</ForeName><Initials>JW</Initials><Identifier Source=\"ORCID\">0000-0002-5156-9075</Identifier><AffiliationInfo><Affiliation>Department of Emergency Medicine, Taichung Veterans General Hospital, Taichung 407219, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung 402, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Medicine, School of Medicine, Chung Shan Medical University, Taichung 40201, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, Chung Shan Medical University, Taichung 40201, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Hu</LastName><ForeName>Sung-Yuan</ForeName><Initials>SY</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, Taichung Veterans General Hospital, Taichung 407219, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung 402, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Medicine, School of Medicine, Chung Shan Medical University, Taichung 40201, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, Chung Shan Medical University, Taichung 40201, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, National Yang Ming Chiao Tung University, Taipei 11217, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Hsieh</LastName><ForeName>Ming-Shun</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>School of Medicine, National Yang Ming Chiao Tung University, Taipei 11217, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Emergency Medicine, Taipei Veterans General Hospital, Taoyuan Branch, Taoyuan 330, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Emergency Medicine, Taipei Veterans General Hospital, Taipei 11217, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Lee</LastName><ForeName>Yi-Chen</ForeName><Initials>YC</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, Taipei Veterans General Hospital, Taipei 11217, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Huang</LastName><ForeName>Shih-Che</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>School of Medicine, Chung Shan Medical University, Taichung 40201, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Emergency Medicine, Chung Shan Medical University Hospital, Taichung 40201, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Lung Cancer Research Center, Chung Shan Medical University Hospital, Taichung 40201, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Chen</LastName><ForeName>Kuan-Ju</ForeName><Initials>KJ</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, Taichung Veterans General Hospital, Taichung 407219, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Cardiovascular Medicine, Taichung Veterans General Hospital, Taichung 407219, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Chang</LastName><ForeName>Yan-Zin</ForeName><Initials>YZ</Initials><AffiliationInfo><Affiliation>Institute of Medicine, School of Medicine, Chung Shan Medical University, Taichung 40201, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Laboratory, Drug Testing Center, Chung Shan Medical University Hospital, Taichung 40201, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Tsai</LastName><ForeName>Yi-Chun</ForeName><Initials>YC</Initials><Identifier Source=\"ORCID\">0000-0003-2734-392X</Identifier><AffiliationInfo><Affiliation>Department of Emergency Medicine, Taichung Veterans General Hospital, Taichung 407219, Taiwan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN=\"Y\"><Grant><GrantID>TCVGH-1117202C, TCVGH-1127203C, and TCVGH-T1127801</GrantID><Agency>Taichung Veterans General Hospital</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2023</Year><Month>11</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>J Pers Med</MedlineTA><NlmUniqueID>101602269</NlmUniqueID><ISSNLinking>2075-4426</ISSNLinking></MedlineJournalInfo><KeywordList Owner=\"NOTNLM\"><Keyword MajorTopicYN=\"N\">acute myocardial infarction</Keyword><Keyword MajorTopicYN=\"N\">cardiogenic shock</Keyword><Keyword MajorTopicYN=\"N\">mortality risk</Keyword><Keyword MajorTopicYN=\"N\">platelet counts</Keyword><Keyword MajorTopicYN=\"N\">score</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"received\"><Year>2023</Year><Month>10</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus=\"revised\"><Year>2023</Year><Month>11</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus=\"accepted\"><Year>2023</Year><Month>11</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus=\"medline\"><Year>2023</Year><Month>11</Month><Day>25</Day><Hour>12</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2023</Year><Month>11</Month><Day>25</Day><Hour>12</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2023</Year><Month>11</Month><Day>25</Day><Hour>1</Hour><Minute>19</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">38003929</ArticleId><ArticleId IdType=\"pmc\">PMC10672116</ArticleId><ArticleId IdType=\"doi\">10.3390/jpm13111614</ArticleId><ArticleId IdType=\"pii\">jpm13111614</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Helgestad O.K.L., Josiassen J., Hassager C., Jensen L.O., Holmvang L., S&#xf8;rensen A., Frydland M., Lassen A.T., Udesen N.L.J., Schmidt H., et al. Temporal trends in incidence and patient characteristics in CS following acute myocardial infarction from 2010 to 2017: A Danish cohort study. Eur. J. Heart Fail. 2019;21:1370&#x2013;1378. doi: 10.1002/ejhf.1566.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1002/ejhf.1566</ArticleId><ArticleId IdType=\"pubmed\">31339222</ArticleId></ArticleIdList></Reference><Reference><Citation>van Diepen S., Katz J.N., Albert N.M., Henry T.D., Jacobs A.K., Kapur N.K., Kilic A., Menon V., Ohman E.M., Sweitzer N.K., et al. Contemporary Management of CS: A Scientific Statement From the American Heart Association. Circulation. 2017;136:e232&#x2013;e268. doi: 10.1161/CIR.0000000000000525.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1161/CIR.0000000000000525</ArticleId><ArticleId IdType=\"pubmed\">28923988</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiele H., Ohman E.M., de Waha-Thiele S., Zeymer U., Desch S. Management of CS complicating myocardial infarction: An update 2019. Eur. Heart J. 2019;40:2671&#x2013;2683. doi: 10.1093/eurheartj/ehz363.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/eurheartj/ehz363</ArticleId><ArticleId IdType=\"pubmed\">31274157</ArticleId></ArticleIdList></Reference><Reference><Citation>Vahdatpour C., Collins D., Goldberg S. CS. J. Am. Heart Assoc. 2019;8:e011991. doi: 10.1161/JAHA.119.011991.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1161/JAHA.119.011991</ArticleId><ArticleId IdType=\"pmc\">PMC6507212</ArticleId><ArticleId IdType=\"pubmed\">30947630</ArticleId></ArticleIdList></Reference><Reference><Citation>Berg D.D., Bohula E.A., Morrow D.A. Epidemiology and causes of CS. Curr. Opin. Crit. Care. 2021;27:401&#x2013;408. doi: 10.1097/MCC.0000000000000845.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1097/MCC.0000000000000845</ArticleId><ArticleId IdType=\"pubmed\">34010224</ArticleId></ArticleIdList></Reference><Reference><Citation>Chioncel O., Parissis J., Mebazaa A., Thiele H., Desch S., Bauersachs J., Harjola V.P., Antohi E.L., Arrigo M., Ben Gal T., et al. Epidemiology, pathophysiology and contemporary management of CS&#x2014;A position statement from the Heart Failure Association of the European Society of Cardiology. Eur. J. Heart Fail. 2020;22:1315&#x2013;1341. doi: 10.1002/ejhf.1922.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1002/ejhf.1922</ArticleId><ArticleId IdType=\"pubmed\">32469155</ArticleId></ArticleIdList></Reference><Reference><Citation>Berg D.D., Bohula E.A., van Diepen S., Katz J.N., Alviar C.L., Baird-Zars V.M., Barnett C.F., Barsness G.W., Burke J.A., Cremer P.C., et al. Epidemiology of Shock in Contemporary Cardiac Intensive Care Units. Circ. Cardiovasc. Qual. Outcomes. 2019;12:e005618. doi: 10.1161/CIRCOUTCOMES.119.005618.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1161/CIRCOUTCOMES.119.005618</ArticleId><ArticleId IdType=\"pubmed\">30879324</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds H.R., Hochman J.S. CS: Current concepts and improving outcomes. Circulation. 2008;117:686&#x2013;697. doi: 10.1161/CIRCULATIONAHA.106.613596.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1161/CIRCULATIONAHA.106.613596</ArticleId><ArticleId IdType=\"pubmed\">18250279</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones T.L., Nakamura K., McCabe J.M. CS: Evolving definitions and future directions in management. Open Heart. 2019;6:e000960. doi: 10.1136/openhrt-2018-000960.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1136/openhrt-2018-000960</ArticleId><ArticleId IdType=\"pmc\">PMC6519403</ArticleId><ArticleId IdType=\"pubmed\">31168376</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiele H., Jobs A., Ouweneel D.M., Henriques J.P.S., Seyfarth M., Desch S., Eitel I., P&#xf6;ss J., Fuernau G., de Waha S. Percutaneous short-term active mechanical support devices in CS: A systematic review and collaborative meta-analysis of randomized trials. Eur. Heart J. 2017;38:3523&#x2013;3531. doi: 10.1093/eurheartj/ehx363.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/eurheartj/ehx363</ArticleId><ArticleId IdType=\"pubmed\">29020341</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiele H., Zeymer U., Neumann F.J., Ferenc M., Olbrich H.G., Hausleiter J., Richardt G., Hennersdorf M., Empen K., Fuernau G., et al. Intraaortic balloon support for myocardial infarction with CS. N. Engl. J. Med. 2012;367:1287&#x2013;1296. doi: 10.1056/NEJMoa1208410.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1056/NEJMoa1208410</ArticleId><ArticleId IdType=\"pubmed\">22920912</ArticleId></ArticleIdList></Reference><Reference><Citation>Sjauw K.D., Engstr&#xf6;m A.E., Vis M.M., van der Schaaf R.J., Baan J., Jr., Koch K.T., de Winter R.J., Piek J.J., Tijssen J.G., Henriques J.P. A systematic review and meta-analysis of intra-aortic balloon pump therapy in ST-elevation myocardial infarction: Should we change the guidelines? Eur. Heart J. 2009;30:459&#x2013;468. doi: 10.1093/eurheartj/ehn602.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/eurheartj/ehn602</ArticleId><ArticleId IdType=\"pubmed\">19168529</ArticleId></ArticleIdList></Reference><Reference><Citation>Prondzinsky R., Lemm H., Swyter M., Wegener N., Unverzagt S., Carter J.M., Russ M., Schlitt A., Buerke U., Christoph A., et al. Intra-aortic balloon counterpulsation in patients with acute myocardial infarction complicated by CS: The prospective, randomized IABP SHOCK Trial for attenuation of multiorgan dysfunction syndrome. Crit. Care Med. 2010;38:152&#x2013;160. doi: 10.1097/CCM.0b013e3181b78671.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1097/CCM.0b013e3181b78671</ArticleId><ArticleId IdType=\"pubmed\">19770739</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiele H., Zeymer U., Neumann F.J., Ferenc M., Olbrich H.G., Hausleiter J., de Waha A., Richardt G., Hennersdorf M., Empen K., et al. Intra-aortic balloon counterpulsation in acute myocardial infarction complicated by CS (IABP-SHOCK II): Final 12 month results of a randomised, open-label trial. Lancet. 2013;382:1638&#x2013;1645. doi: 10.1016/S0140-6736(13)61783-3.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/S0140-6736(13)61783-3</ArticleId><ArticleId IdType=\"pubmed\">24011548</ArticleId></ArticleIdList></Reference><Reference><Citation>Kapur N.K., Paruchuri V., Urbano-Morales J.A., Mackey E.E., Daly G.H., Qiao X., Pandian N., Perides G., Karas R.H. Mechanically unloading the left ventricle before coronary reperfusion reduces left ventricular wall stress and myocardial infarct size. Circulation. 2013;128:328&#x2013;336. doi: 10.1161/CIRCULATIONAHA.112.000029.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1161/CIRCULATIONAHA.112.000029</ArticleId><ArticleId IdType=\"pubmed\">23766351</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdel-Wahab M., Saad M., Kynast J., Geist V., Sherif M.A., Richardt G., Toelg R. Comparison of hospital mortality with intra-aortic balloon counterpulsation insertion before versus after primary percutaneous coronary intervention for CS complicating acute myocardial infarction. Am. J. Cardiol. 2010;105:967&#x2013;971. doi: 10.1016/j.amjcard.2009.11.021.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.amjcard.2009.11.021</ArticleId><ArticleId IdType=\"pubmed\">20346314</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwarz B., Abdel-Wahab M., Robinson D.R., Richardt G. Predictors of mortality in patients with CS treated with primary percutaneous coronary intervention and intra-aortic balloon counterpulsation. Med. Klin. Intensivmed. Notfmed. 2016;111:715&#x2013;722. doi: 10.1007/s00063-015-0118-8.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s00063-015-0118-8</ArticleId><ArticleId IdType=\"pubmed\">26596273</ArticleId></ArticleIdList></Reference><Reference><Citation>Davierwala P.M., Leontyev S., Verevkin A., Rastan A.J., Mohr M., Bakhtiary F., Misfeld M., Mohr F.W. Temporal Trends in Predictors of Early and Late Mortality After Emergency Coronary Artery Bypass Grafting for CS Complicating Acute Myocardial Infarction. Circulation. 2016;134:1224&#x2013;1237. doi: 10.1161/CIRCULATIONAHA.115.021092.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1161/CIRCULATIONAHA.115.021092</ArticleId><ArticleId IdType=\"pubmed\">27777292</ArticleId></ArticleIdList></Reference><Reference><Citation>Panuccio G., Neri G., Macr&#xec; L.M., Salerno N., De Rosa S., Torella D. Use of Impella device in cardiogenic shock and its clinical outcomes: A systematic review and meta-analysis. Int. J. Cardiol. Heart Vasc. 2022;40:101007.</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC8961185</ArticleId><ArticleId IdType=\"pubmed\">35360892</ArticleId></ArticleIdList></Reference><Reference><Citation>Harjola V.P., Lassus J., Sionis A., K&#xf8;ber L., Tarvasm&#xe4;ki T., Spinar J., Parissis J., Banaszewski M., Silva-Cardoso J., Carubelli V., et al. Clinical picture and risk prediction of short-term mortality in CS. Eur. J. Heart Fail. 2015;17:501&#x2013;509. doi: 10.1002/ejhf.260.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1002/ejhf.260</ArticleId><ArticleId IdType=\"pubmed\">25820680</ArticleId></ArticleIdList></Reference><Reference><Citation>P&#xf6;ss J., K&#xf6;ster J., Fuernau G., Eitel I., de Waha S., Ouarrak T., Lassus J., Harjola V.P., Zeymer U., Thiele H., et al. Risk Stratification for Patients in CS After Acute Myocardial Infarction. J. Am. Coll. Cardiol. 2017;69:1913&#x2013;1920. doi: 10.1016/j.jacc.2017.02.027.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jacc.2017.02.027</ArticleId><ArticleId IdType=\"pubmed\">28408020</ArticleId></ArticleIdList></Reference><Reference><Citation>Rivas-Lasarte M., Sans-Rosell&#xf3; J., Collado-Lled&#xf3; E., Gonz&#xe1;lez-Fern&#xe1;ndez V., Noriega F.J., Hern&#xe1;ndez-P&#xe9;rez F.J., Fern&#xe1;ndez-Mart&#xed;nez J., Ariza A., Lid&#xf3;n R.M., Viana-Tejedor A., et al. External validation and comparison of the CardShock and IABP-SHOCK II risk scores in real-world CS patients. Eur. Heart J. Acute Cardiovasc. Care. 2021;10:16&#x2013;24. doi: 10.1177/2048872619895230.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1177/2048872619895230</ArticleId><ArticleId IdType=\"pubmed\">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Selvarajah S., Fong A.Y., Selvaraj G., Haniff J., Uiterwaal C.S., Bots M.L. An Asian validation of the TIMI risk score for ST-segment elevation myocardial infarction. PLoS ONE. 2012;7:e40249. doi: 10.1371/journal.pone.0040249.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1371/journal.pone.0040249</ArticleId><ArticleId IdType=\"pmc\">PMC3398026</ArticleId><ArticleId IdType=\"pubmed\">22815733</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuhdi A.S., Ahmad W.A., Zaki R.A., Mariapun J., Ali R.M., Sari N.M., Ismail M.D., Kui Hian S. Acute coronary syndrome in the elderly: The Malaysian National Cardiovascular Disease Database-Acute Coronary Syndrome registry. Singapore Med. J. 2016;57:191&#x2013;197. doi: 10.11622/smedj.2015145.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.11622/smedj.2015145</ArticleId><ArticleId IdType=\"pmc\">PMC4853486</ArticleId><ArticleId IdType=\"pubmed\">26768171</ArticleId></ArticleIdList></Reference><Reference><Citation>Babaev A., Frederick P.D., Pasta D.J., Every N., Sichrovsky T., Hochman J.S., NRMI Investigators Trends in management and outcomes of patients with acute myocardial infarction complicated by CS. JAMA. 2005;294:448&#x2013;454. doi: 10.1001/jama.294.4.448.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1001/jama.294.4.448</ArticleId><ArticleId IdType=\"pubmed\">16046651</ArticleId></ArticleIdList></Reference><Reference><Citation>Menon V., Hochman J.S. Management of CS complicating acute myocardial infarction. Heart. 2002;88:531&#x2013;537. doi: 10.1136/heart.88.5.531.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1136/heart.88.5.531</ArticleId><ArticleId IdType=\"pmc\">PMC1767433</ArticleId><ArticleId IdType=\"pubmed\">12381652</ArticleId></ArticleIdList></Reference><Reference><Citation>Dziewierz A., Siudak Z., Rakowski T., Dubiel J.S., Dudek D. Predictors and in-hospital outcomes of CS on admission in patients with acute coronary syndromes admitted to hospitals without on-site invasive facilities. Acute Card. Care. 2010;12:3&#x2013;9. doi: 10.3109/17482941003637106.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3109/17482941003637106</ArticleId><ArticleId IdType=\"pubmed\">20201656</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasdai D., Califf R.M., Thompson T.D., Hochman J.S., Ohman E.M., Pfisterer M., Bates E.R., Vahanian A., Armstrong P.W., Criger D.A., et al. Predictors of CS after thrombolytic therapy for acute myocardial infarction. J. Am. Coll. Cardiol. 2000;35:136&#x2013;143. doi: 10.1016/S0735-1097(99)00508-2.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/S0735-1097(99)00508-2</ArticleId><ArticleId IdType=\"pubmed\">10636271</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarai R., Huber K., Bogaerts K., Sinnaeve P.R., Ezekowitz J., Ross A.M., Zeymer U., Armstrong P.W., Van de Werf F.J., ASSENT-4 PCI investigators Prediction of CS using plasma B-type natriuretic peptide and the N-terminal fragment of its pro-hormone [corrected] concentrations in ST elevation myocardial infarction: An analysis from the ASSENT-4 Percutaneous Coronary Intervention Trial. Crit. Care Med. 2010;38:1793&#x2013;1801. doi: 10.1097/CCM.0b013e3181eaaf2a.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1097/CCM.0b013e3181eaaf2a</ArticleId><ArticleId IdType=\"pubmed\">20562693</ArticleId></ArticleIdList></Reference><Reference><Citation>Aissaoui N., Puymirat E., Delmas C., Ortuno S., Durand E., Bataille V., Drouet E., Bonello L., Bonnefoy-Cudraz E., Lesmeles G., et al. Trends in CS complicating acute myocardial infarction. Eur. J. Heart Fail. 2020;22:664&#x2013;672. doi: 10.1002/ejhf.1750.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1002/ejhf.1750</ArticleId><ArticleId IdType=\"pubmed\">32078218</ArticleId></ArticleIdList></Reference><Reference><Citation>Thayer K.L., Zweck E., Ayouty M., Garan A.R., Hernandez-Montfort J., Mahr C., Morine K.J., Newman S., Jorde L., Haywood J.L., et al. Invasive Hemodynamic Assessment and Classification of In-Hospital Mortality Risk Among Patients With CS. Circ. Heart Fail. 2020;13:e007099. doi: 10.1161/CIRCHEARTFAILURE.120.007099.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1161/CIRCHEARTFAILURE.120.007099</ArticleId><ArticleId IdType=\"pmc\">PMC10243474</ArticleId><ArticleId IdType=\"pubmed\">32900234</ArticleId></ArticleIdList></Reference><Reference><Citation>Acharya D. Predictors of Outcomes in Myocardial Infarction and CS. Cardiol. Rev. 2018;26:255&#x2013;266. doi: 10.1097/CRD.0000000000000190.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1097/CRD.0000000000000190</ArticleId><ArticleId IdType=\"pmc\">PMC6082598</ArticleId><ArticleId IdType=\"pubmed\">29300230</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuernau G., Desch S., de Waha-Thiele S., Eitel I., Neumann F.J., Hennersdorf M., Felix S.B., Fach A., B&#xf6;hm M., P&#xf6;ss J., et al. Arterial Lactate in CS: Prognostic Value of Clearance Versus Single Values. JACC Cardiovasc. Interv. 2020;13:2208&#x2013;2216. doi: 10.1016/j.jcin.2020.06.037.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jcin.2020.06.037</ArticleId><ArticleId IdType=\"pubmed\">33032708</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindholm M.G., Hongisto M., Lassus J., Spinar J., Parissis J., Banaszewski M., Silva-Cardoso J., Carubelli V., Salvatore D., Sionis A., et al. Serum Lactate and A Relative Change in Lactate as Predictors of Mortality in Patients With CS&#x2014;Results from the Cardshock Study. Shock. 2020;53:43&#x2013;49. doi: 10.1097/SHK.0000000000001353.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1097/SHK.0000000000001353</ArticleId><ArticleId IdType=\"pubmed\">30973460</ArticleId></ArticleIdList></Reference><Reference><Citation>Aissaoui N., Riant E., Lef&#xe8;vre G., Delmas C., Bonello L., Henry P., Bonnefoy E., Schiele F., Ferri&#xe8;res J., Simon T., et al. Long-term clinical outcomes in patients with CS according to left ventricular function: The French registry of Acute ST-elevation and non-ST-elevation Myocardial Infarction (FAST-MI) programme. Arch. Cardiovasc. Dis. 2018;111:678&#x2013;685. doi: 10.1016/j.acvd.2017.11.002.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.acvd.2017.11.002</ArticleId><ArticleId IdType=\"pubmed\">29290598</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y., Zhu J., Tan H.Q., Liang Y., Liu L.S., Li Y., China CREATE Investigation Group Predictors of short term mortality in patients with acute ST-elevation myocardial infarction complicated by CS. Zhonghua Xin Xue Guan Bing Za Zhi. 2010;38:695&#x2013;701.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">21055135</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarychanski R., Houston D.S. Assessing thrombocytopenia in the intensive care unit: The past, present, and future. Hematology Am. Soc. Hematol. Educ. Program. 2017;2017:660&#x2013;666. doi: 10.1182/asheducation-2017.1.660.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1182/asheducation-2017.1.660</ArticleId><ArticleId IdType=\"pmc\">PMC6142536</ArticleId><ArticleId IdType=\"pubmed\">29222318</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanderschueren S., De Weerdt A., Malbrain M., Vankersschaever D., Frans E., Wilmer A., Bobbaers H. Thrombocytopenia and prognosis in intensive care. Crit. Care Med. 2000;28:1871&#x2013;1876. doi: 10.1097/00003246-200006000-00031.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1097/00003246-200006000-00031</ArticleId><ArticleId IdType=\"pubmed\">10890635</ArticleId></ArticleIdList></Reference><Reference><Citation>Mojadidi M.K., Galeas J.N., Goodman-Meza D., Eshtehardi P., Msaouel P., Kelesidis I., Zaman M.O., Winoker J.S., Roberts S.C., Christia P., et al. Thrombocytopaenia as a Prognostic Indicator in Heart Failure with Reduced Ejection Fraction. Heart Lung Circ. 2016;25:568&#x2013;575. doi: 10.1016/j.hlc.2015.11.010.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.hlc.2015.11.010</ArticleId><ArticleId IdType=\"pubmed\">26868831</ArticleId></ArticleIdList></Reference><Reference><Citation>Gore J.M., Spencer F.A., Gurfinkel E.P., L&#xf3;pez-Send&#xf3;n J., Steg P.G., Granger C.B., FitzGerald G., Agnelli G., GRACE Investigators Thrombocytopenia in patients with an acute coronary syndrome (from the Global Registry of Acute Coronary Events [GRACE]) Am. J. Cardiol. 2009;103:175&#x2013;180. doi: 10.1016/j.amjcard.2008.08.055.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.amjcard.2008.08.055</ArticleId><ArticleId IdType=\"pubmed\">19121432</ArticleId></ArticleIdList></Reference><Reference><Citation>Yadav M., G&#xe9;n&#xe9;reux P., Giustino G., Madhavan M.V., Brener S.J., Mintz G., Caixeta A., Xu K., Mehran R., Stone G.W. Effect of Baseline Thrombocytopenia on Ischemic Outcomes in Patients With Acute Coronary Syndromes Who Undergo Percutaneous Coronary Intervention. Can. J. Cardiol. 2016;32:226&#x2013;233. doi: 10.1016/j.cjca.2015.05.020.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.cjca.2015.05.020</ArticleId><ArticleId IdType=\"pubmed\">26341303</ArticleId></ArticleIdList></Reference><Reference><Citation>Dvir D., G&#xe9;n&#xe9;reux P., Barbash I.M., Kodali S., Ben-Dor I., Williams M., Torguson R., Kirtane A.J., Minha S., Badr S., et al. Acquired thrombocytopenia after transcatheter aortic valve replacement: Clinical correlates and association with outcomes. Eur. Heart J. 2014;35:2663&#x2013;2671. doi: 10.1093/eurheartj/ehu082.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/eurheartj/ehu082</ArticleId><ArticleId IdType=\"pubmed\">24598983</ArticleId></ArticleIdList></Reference><Reference><Citation>Roy S.K., Howard E.W., Panza J.A., Cooper H.A. Clinical implications of thrombocytopenia among patients undergoing intra-aortic balloon pump counterpulsation in the coronary care unit. Clin. Cardiol. 2010;33:30&#x2013;35. doi: 10.1002/clc.20694.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1002/clc.20694</ArticleId><ArticleId IdType=\"pmc\">PMC6652948</ArticleId><ArticleId IdType=\"pubmed\">20063298</ArticleId></ArticleIdList></Reference><Reference><Citation>Eikelboom J.W., Anand S.S., Mehta S.R., Weitz J.I., Yi C., Yusuf S. Prognostic significance of thrombocytopenia during hirudin and heparin therapy in acute coronary syndrome without ST elevation: Organization to Assess Strategies for Ischemic Syndromes (OASIS-2) study. Circulation. 2001;103:643&#x2013;650. doi: 10.1161/01.CIR.103.5.643.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1161/01.CIR.103.5.643</ArticleId><ArticleId IdType=\"pubmed\">11156874</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu R., Liu J., Yang J., Gao Z., Zhao X., Chen J., Qiao S., Gao R., Wang Q., Yang H., et al. Association of thrombocytopenia with in-hospital outcome in patients with acute ST-segment elevated myocardial infarction. Platelets. 2019;30:844&#x2013;853. doi: 10.1080/09537104.2018.1529298.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1080/09537104.2018.1529298</ArticleId><ArticleId IdType=\"pubmed\">30346854</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubinfeld G.D., Smilowitz N.R., Berger J.S., Newman J.D. Association of Thrombocytopenia, Revascularization, and In-Hospital Outcomes in Patients with Acute Myocardial Infarction. Am. J. Med. 2019;132:942&#x2013;948.e5. doi: 10.1016/j.amjmed.2019.04.003.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.amjmed.2019.04.003</ArticleId><ArticleId IdType=\"pmc\">PMC6744313</ArticleId><ArticleId IdType=\"pubmed\">31034804</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L., Shao J., Shao C., Wang H., Jia M., Hou X. The Relative Early Decrease in Platelet Count Is Associated With Mortality in Post-cardiotomy Patients Undergoing Venoarterial Extracorporeal Membrane Oxygenation. Front. Med. 2021;8:733946. doi: 10.3389/fmed.2021.733946.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3389/fmed.2021.733946</ArticleId><ArticleId IdType=\"pmc\">PMC8600067</ArticleId><ArticleId IdType=\"pubmed\">34805203</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiritano F., Serraino G.F., Ten Cate H., Fina D., Matteucci M., Mastroroberto P., Lorusso R. Platelets and extra-corporeal membrane oxygenation in adult patients: A systematic review and meta-analysis. Intensive Care Med. 2020;46:1154&#x2013;1169. doi: 10.1007/s00134-020-06031-4.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s00134-020-06031-4</ArticleId><ArticleId IdType=\"pmc\">PMC7292815</ArticleId><ArticleId IdType=\"pubmed\">32328725</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L., Yang F., Wang X., Xie H., Fan E., Ogino M., Brodie D., Wang H., Hou X. Predicting mortality in patients undergoing VA-ECMO after coronary artery bypass grafting: The REMEMBER score. Crit. Care. 2019;23:11. doi: 10.1186/s13054-019-2307-y.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1186/s13054-019-2307-y</ArticleId><ArticleId IdType=\"pmc\">PMC6330483</ArticleId><ArticleId IdType=\"pubmed\">30635022</ArticleId></ArticleIdList></Reference><Reference><Citation>Takano A.M., Iwata H., Miyosawa K., Kimura A., Mukaida H., Osawa S., Kubota K., Doi S., Funamizu T., Takasu K., et al. Reduced Number of Platelets During Intra-Aortic Balloon Pumping Counterpulsation Predicts Higher Cardiovascular Mortality After Device Removal in Association with Systemic Inflammation. Int. Heart J. 2020;61:89&#x2013;95. doi: 10.1536/ihj.19-349.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1536/ihj.19-349</ArticleId><ArticleId IdType=\"pubmed\">31956149</ArticleId></ArticleIdList></Reference><Reference><Citation>Gemmell C.H., Ramirez S.M., Yeo E.L., Sefton M.V. Platelet activation in whole blood by artificial surfaces: Identification of platelet-derived microparticles and activated platelet binding to leukocytes as material-induced activation events. J. Lab. Clin. Med. 1995;125:276&#x2013;287.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">7531214</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee H.H., Hong S.J., Ahn C.M., Yang J.H., Gwon H.C., Kim J.S., Kim B.K., Ko Y.G., Choi D., Hong M.K., et al. Clinical Implications of Thrombocytopenia at CS Presentation: Data from a Multicenter Registry. Yonsei Med. J. 2020;61:851&#x2013;859. doi: 10.3349/ymj.2020.61.10.851.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3349/ymj.2020.61.10.851</ArticleId><ArticleId IdType=\"pmc\">PMC7515787</ArticleId><ArticleId IdType=\"pubmed\">32975059</ArticleId></ArticleIdList></Reference><Reference><Citation>Huczek Z., Kochman J., Filipiak K.J., Horszczaruk G.J., Grabowski M., Piatkowski R., Wilczynska J., Zielinski A., Meier B., Opolski G. Mean platelet volume on admission predicts impaired reperfusion and long-term mortality in acute myocardial infarction treated with primary percutaneous coronary intervention. J. Am. Coll. Cardiol. 2005;46:284&#x2013;290. doi: 10.1016/j.jacc.2005.03.065.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jacc.2005.03.065</ArticleId><ArticleId IdType=\"pubmed\">16022956</ArticleId></ArticleIdList></Reference><Reference><Citation>Kandis H., Ozhan H., Ordu S., Erden I., Caglar O., Basar C., Yalcin S., Alemdar R., Aydin M. The prognostic value of mean platelet volume in decompensated heart failure. Emerg. Med. J. 2011;28:575&#x2013;578. doi: 10.1136/emj.2009.088401.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1136/emj.2009.088401</ArticleId><ArticleId IdType=\"pubmed\">20660896</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung I., Choudhury A., Lip G.Y. Platelet activation in acute, decompensated congestive heart failure. Thromb. Res. 2007;120:709&#x2013;713. doi: 10.1016/j.thromres.2007.01.003.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.thromres.2007.01.003</ArticleId><ArticleId IdType=\"pubmed\">17287016</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibbs C.R., Blann A.D., Watson R.D., Lip G.Y. Abnormalities of hemorheological, endothelial, and platelet function in patients with chronic heart failure in sinus rhythm: Effects of angiotensin-converting enzyme inhibitor and beta-blocker therapy. Circulation. 2001;103:1746&#x2013;1751. doi: 10.1161/01.CIR.103.13.1746.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1161/01.CIR.103.13.1746</ArticleId><ArticleId IdType=\"pubmed\">11282905</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Connor C.M., Gurbel P.A., Serebruany V.L. Usefulness of soluble and surface-bound P-selectin in detecting heightened platelet activity in patients with congestive heart failure. Am. J. Cardiol. 1999;83:1345&#x2013;1349. doi: 10.1016/S0002-9149(99)00098-3.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/S0002-9149(99)00098-3</ArticleId><ArticleId IdType=\"pubmed\">10235093</ArticleId></ArticleIdList></Reference><Reference><Citation>Stumpf C., Lehner C., Eskafi S., Raaz D., Yilmaz A., Ropers S., Schmeisser A., Ludwig J., Daniel W.G., Garlichs C.D. Enhanced levels of CD154 (CD40 ligand) on platelets in patients with chronic heart failure. Eur. J. Heart Fail. 2003;5:629&#x2013;637. doi: 10.1016/S1388-9842(03)00110-7.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/S1388-9842(03)00110-7</ArticleId><ArticleId IdType=\"pubmed\">14607202</ArticleId></ArticleIdList></Reference><Reference><Citation>Jafri S.M., Ozawa T., Mammen E., Levine T.B., Johnson C., Goldstein S. Platelet function, thrombin and fibrinolytic activity in patients with heart failure. Eur. Heart J. 1993;14:205&#x2013;212. doi: 10.1093/eurheartj/14.2.205.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/eurheartj/14.2.205</ArticleId><ArticleId IdType=\"pubmed\">8449196</ArticleId></ArticleIdList></Reference><Reference><Citation>Anfossi G., Trovati M. Role of catecholamines in platelet function: Pathophysiological and clinical significance. Eur. J. Clin. Invest. 1996;26:353&#x2013;370. doi: 10.1046/j.1365-2362.1996.150293.x.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1046/j.1365-2362.1996.150293.x</ArticleId><ArticleId IdType=\"pubmed\">8796362</ArticleId></ArticleIdList></Reference><Reference><Citation>Larsson P.T., Schwieler J.H., Wall&#xe9;n N.H. Platelet activation during angiotensin II infusion in healthy volunteers. Blood Coagul. Fibrinolysis. 2000;11:61&#x2013;69. doi: 10.1097/00001721-200011010-00007.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1097/00001721-200011010-00007</ArticleId><ArticleId IdType=\"pubmed\">10691100</ArticleId></ArticleIdList></Reference><Reference><Citation>Gando S., Wada T. Disseminated intravascular coagulation in cardiac arrest and resuscitation. J. Thromb. Haemost. 2019;17:1205&#x2013;1216. doi: 10.1111/jth.14480.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1111/jth.14480</ArticleId><ArticleId IdType=\"pubmed\">31102491</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalra S., Ranard L.S., Memon S., Rao P., Garan A.R., Masoumi A., O&#x2019;Neill W., Kapur N.K., Karmpaliotis D., Fried J.A., et al. Risk Prediction in CS: Current State of Knowledge, Challenges and Opportunities. J. Card. Fail. 2021;27:1099&#x2013;1110. doi: 10.1016/j.cardfail.2021.08.003.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.cardfail.2021.08.003</ArticleId><ArticleId IdType=\"pubmed\">34625129</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>\n",
            "XML saved to: path/to/save/xml/38003929.xml\n",
            "Details URL: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=37999149&retmode=xml&api_key=9edd38677707c08b2a96ed1a6e8c61c47408\n",
            "Details Response Content: <?xml version=\"1.0\" ?>\n",
            "<!DOCTYPE PubmedArticleSet PUBLIC \"-//NLM//DTD PubMedArticle, 1st January 2023//EN\" \"https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd\">\n",
            "<PubmedArticleSet>\n",
            "<PubmedArticle><MedlineCitation Status=\"MEDLINE\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">37999149</PMID><DateCompleted><Year>2023</Year><Month>11</Month><Day>27</Day></DateCompleted><DateRevised><Year>2023</Year><Month>12</Month><Day>13</Day></DateRevised><Article PubModel=\"Electronic\"><Journal><ISSN IssnType=\"Electronic\">1718-7729</ISSN><JournalIssue CitedMedium=\"Internet\"><Volume>30</Volume><Issue>11</Issue><PubDate><Year>2023</Year><Month>Nov</Month><Day>20</Day></PubDate></JournalIssue><Title>Current oncology (Toronto, Ont.)</Title><ISOAbbreviation>Curr Oncol</ISOAbbreviation></Journal><ArticleTitle>Sharing Experience with Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors in Lung Cancer: An Italian Expert Panel Discussion.</ArticleTitle><Pagination><StartPage>10033</StartPage><EndPage>10042</EndPage><MedlinePgn>10033-10042</MedlinePgn></Pagination><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.3390/curroncol30110729</ELocationID><Abstract><AbstractText Label=\"BACKGROUND\" NlmCategory=\"BACKGROUND\">ALK tyrosine kinase inhibitors (TKIs) have revolutionized the treatment and largely improved the survival outcomes of patients with NSCLC harboring <i>ALK</i> rearrangements. Different ALK TKI compounds have demonstrated antitumor activity in these patients and are available in clinical practice. However, clinical expertise across countries varies according to local regulatory approval of different drugs, identifying multiple treatment scenarios to comply with international guidelines and clinical practice.</AbstractText><AbstractText Label=\"METHODS\" NlmCategory=\"METHODS\">A virtual webinar was held on July 2023 to discuss the state of the art and future perspectives in the treatment of <i>ALK</i> rearrangement in advanced NSCLC in Italy. The faculty hosting the webinar was composed of eight medical oncologists from different regions of Italy with clinical expertise in treating patients with lung cancer. Live-shared notes were used to produce a report to serve as the basis of a review manuscript on the topic.</AbstractText><AbstractText Label=\"RESULTS\" NlmCategory=\"RESULTS\">Alectinib and brigatinib are the preferred front-line treatment options in Italy, pending approval of the front-line medicine lorlatinib, which would be considered among the choices. Due to a local regulatory limitation of second-line lorlatinib, which is not allowed after front-line brigatinib, alectinib is commonly the preferred front-line choice to follow a sequence of alectinib, followed by lorlatinib, followed by platinum plus pemetrexed chemotherapy. Age and performance status were not considered per se as clinical features influencing treatment choice. However, treatment compliance is deemed a relevant factor in decision making with regard to the number of pills to be administered. In general, given the availability of alternative choices, the spectrum of patients' comorbidities and polypharmacotherapy interactions should be taken into account in treatment selection according to the toxicity profile of each compound. In addition, several issues were debated with regard to improving treatment outcomes, including testing, brain metastases, and management of an oligoprogressive disease.</AbstractText><AbstractText Label=\"CONCLUSIONS\" NlmCategory=\"CONCLUSIONS\">The treatment scenario of ALK-positive disease is dynamically evolving. Furthermore, not all FDA- and EMA-approved compounds are approved in Italy with the same indications. This influences therapeutic opportunities and increases the need for greater clinical expertise to help and guide treatment selection.</AbstractText></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Gridelli</LastName><ForeName>Cesare</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Medical Oncology, \"S.G. Moscati\" Hospital, 83100 Avellino, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Tiseo</LastName><ForeName>Marcello</ForeName><Initials>M</Initials><Identifier Source=\"ORCID\">0000-0002-9553-8465</Identifier><AffiliationInfo><Affiliation>Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Oncology Unit, University Hospital of Parma, 43126 Parma, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Cortinovis</LastName><ForeName>Diego Luigi</ForeName><Initials>DL</Initials><Identifier Source=\"ORCID\">0000-0001-7611-7369</Identifier><AffiliationInfo><Affiliation>SC Medical Oncology, Fondazione IRCCS San Gerardo dei Tintori, 20900 Monza, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Migliorino</LastName><ForeName>Maria Rita</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Department of Oncology, San Camillo-Forlanini Hospital, 00152 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Barbieri</LastName><ForeName>Vito</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Medical Oncology Unit, AOU Renato Dulbecco, 88100 Catanzaro, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Bironzo</LastName><ForeName>Paolo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Oncology, University of Turin, 10124 Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Bearz</LastName><ForeName>Alessandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081 Aviano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Attili</LastName><ForeName>Ilaria</ForeName><Initials>I</Initials><Identifier Source=\"ORCID\">0000-0003-1333-6622</Identifier><AffiliationInfo><Affiliation>Division of Thoracic Oncology, European Institute of Oncology, IRCCS, 20141 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>de Marinis</LastName><ForeName>Filippo</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Division of Thoracic Oncology, European Institute of Oncology, IRCCS, 20141 Milan, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN=\"Y\"><Grant><GrantID>no grant number</GrantID><Agency>Associazione Italiana di Oncologia Toracica (AIOT)</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType><PublicationType UI=\"D016454\">Review</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2023</Year><Month>11</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Curr Oncol</MedlineTA><NlmUniqueID>9502503</NlmUniqueID><ISSNLinking>1198-0052</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>OSP71S83EU</RegistryNumber><NameOfSubstance UI=\"C000590786\">lorlatinib</NameOfSubstance></Chemical><Chemical><RegistryNumber>HYW8DB273J</RegistryNumber><NameOfSubstance UI=\"C000598580\">brigatinib</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI=\"D000077548\">Anaplastic Lymphoma Kinase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI=\"D011505\">Protein-Tyrosine Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI=\"D000092004\">Tyrosine Kinase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI=\"D047428\">Protein Kinase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI=\"D047029\">Lactams, Macrocyclic</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI=\"D006801\" MajorTopicYN=\"N\">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D008175\" MajorTopicYN=\"Y\">Lung Neoplasms</DescriptorName><QualifierName UI=\"Q000188\" MajorTopicYN=\"N\">drug therapy</QualifierName><QualifierName UI=\"Q000473\" MajorTopicYN=\"N\">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D000077548\" MajorTopicYN=\"N\">Anaplastic Lymphoma Kinase</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D011505\" MajorTopicYN=\"N\">Protein-Tyrosine Kinases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D000092004\" MajorTopicYN=\"N\">Tyrosine Kinase Inhibitors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D002289\" MajorTopicYN=\"Y\">Carcinoma, Non-Small-Cell Lung</DescriptorName><QualifierName UI=\"Q000188\" MajorTopicYN=\"N\">drug therapy</QualifierName><QualifierName UI=\"Q000473\" MajorTopicYN=\"N\">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D047428\" MajorTopicYN=\"N\">Protein Kinase Inhibitors</DescriptorName><QualifierName UI=\"Q000494\" MajorTopicYN=\"N\">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D047029\" MajorTopicYN=\"N\">Lactams, Macrocyclic</DescriptorName><QualifierName UI=\"Q000009\" MajorTopicYN=\"N\">adverse effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner=\"NOTNLM\"><Keyword MajorTopicYN=\"N\">ALK</Keyword><Keyword MajorTopicYN=\"N\">alectinib</Keyword><Keyword MajorTopicYN=\"N\">brigatinib</Keyword><Keyword MajorTopicYN=\"N\">lorlatinib</Keyword><Keyword MajorTopicYN=\"N\">lung cancer</Keyword></KeywordList><CoiStatement>C. Gridelli received honoraria as a speaker bureau or advisory board member or as a consultant from MSD, BMS, Roche, Astra Zeneca, Novartis, Pfizer, Menarini, Boehringer, Karyopharm, Eli Lilly, Amgen, Sanofi, GSK, and Boehringer Ingelheim. M. Tiseo received honoraria as a speaker bureau/scientific advisor from Astra-Zeneca, Pfizer, Eli-Lilly, BMS, Novartis, Roche, MSD, Boehringer Ingelheim, Takeda, Amgen, Merck, and Sanofi. M. Tiseo received research grants from Astra-Zeneca and Boehringer Ingelheim. D. Cortinovis received honoraria as a speaker bureau/scientific advisor from MSD, BMS, Astra Zeneca, Sanofi Genzyme, Seagen, Novartis, Amgen, Roche, and Takeda. M. R. Migliorino received honoraria as a speaker bureau/scientific advisor from MSD, Astra Zeneca, Sanofi Genzyme, Novartis, Roche, and Takeda. P. Bironzo received honoraria as speaker bureau or advisory board member from Bristol-Myers Squibb, Merck Sharp &amp; Dohme, Roche, Astra Zeneca, Sanofi, Regeneron, Seagen, Janssen, Takeda, and Amgen. F. de Marinis received honoraria or consulting fees from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Merck Sharp &amp; Dohme, Pfizer, Novartis, Takeda, Xcovery, and Roche. The other authors report no conflict of interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"received\"><Year>2023</Year><Month>10</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus=\"revised\"><Year>2023</Year><Month>11</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus=\"accepted\"><Year>2023</Year><Month>11</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus=\"medline\"><Year>2023</Year><Month>11</Month><Day>27</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2023</Year><Month>11</Month><Day>24</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2023</Year><Month>11</Month><Day>24</Day><Hour>9</Hour><Minute>40</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">37999149</ArticleId><ArticleId IdType=\"pmc\">PMC10670405</ArticleId><ArticleId IdType=\"doi\">10.3390/curroncol30110729</ArticleId><ArticleId IdType=\"pii\">curroncol30110729</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Shaw A.T., Yeap B.Y., Mino-Kenudson M., Digumarthy S.R., Costa D.B., Heist R.S., Solomon B., Stubbs H., Admane S., McDermott U., et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J. Clin. Oncol. 2009;27:4247&#x2013;4253. doi: 10.1200/JCO.2009.22.6993.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1200/JCO.2009.22.6993</ArticleId><ArticleId IdType=\"pmc\">PMC2744268</ArticleId><ArticleId IdType=\"pubmed\">19667264</ArticleId></ArticleIdList></Reference><Reference><Citation>Soda M., Choi Y.L., Enomoto M., Takada S., Yamashita Y., Ishikawa S., Fujiwara S., Watanabe H., Kurashina K., Hatanaka H., et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448:561&#x2013;566. doi: 10.1038/nature05945.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/nature05945</ArticleId><ArticleId IdType=\"pubmed\">17625570</ArticleId></ArticleIdList></Reference><Reference><Citation>Koivunen J.P., Mermel C., Zejnullahu K., Murphy C., Lifshits E., Holmes A.J., Choi H.G., Kim J., Chiang D., Thomas R., et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin. Cancer Res. 2008;14:4275&#x2013;4283. doi: 10.1158/1078-0432.CCR-08-0168.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1158/1078-0432.CCR-08-0168</ArticleId><ArticleId IdType=\"pmc\">PMC3025451</ArticleId><ArticleId IdType=\"pubmed\">18594010</ArticleId></ArticleIdList></Reference><Reference><Citation>Pacheco J.M., Gao D., Smith D., Purcell T., Hancock M., Bunn P., Robin T., Liu A., Karam S., Gaspar L., et al. Natural History and Factors Associated with Overall Survival in Stage IV ALK-Rearranged Non-Small Cell Lung Cancer. J. Thorac. Oncol. 2019;14:691&#x2013;700. doi: 10.1016/j.jtho.2018.12.014.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jtho.2018.12.014</ArticleId><ArticleId IdType=\"pmc\">PMC7310567</ArticleId><ArticleId IdType=\"pubmed\">30599201</ArticleId></ArticleIdList></Reference><Reference><Citation>Mok T., Camidge D.R., Gadgeel S.M., Rosell R., Dziadziuszko R., Kim D.W., P&#xe9;rol M., Ou S.I., Ahn J.S., Shaw A.T., et al. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study. Ann. Oncol. 2020;31:1056&#x2013;1064. doi: 10.1016/j.annonc.2020.04.478.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.annonc.2020.04.478</ArticleId><ArticleId IdType=\"pubmed\">32418886</ArticleId></ArticleIdList></Reference><Reference><Citation>Camidge D.R., Kim H.R., Ahn M.J., Yang J.C.H., Han J.Y., Hochmair M.J., Lee K.H., Delmonte A., Garcia Campelo M.R., Kim D.W., et al. Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial. J. Thorac. Oncol. 2021;16:2091&#x2013;2108. doi: 10.1016/j.jtho.2021.07.035.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jtho.2021.07.035</ArticleId><ArticleId IdType=\"pubmed\">34537440</ArticleId></ArticleIdList></Reference><Reference><Citation>Hendriks L.E., Kerr K.M., Menis J., Mok T.S., Nestle U., Passaro A., Peters S., Planchard D., Smit E.F., Solomon B.J., et al. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 2023;34:339&#x2013;357. doi: 10.1016/j.annonc.2022.12.009.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.annonc.2022.12.009</ArticleId><ArticleId IdType=\"pubmed\">36872130</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw A.T., Kim D.W., Nakagawa K., Seto T., Crin&#xf3; L., Ahn M.J., De Pas T., Besse B., Solomon B.J., Blackhall F., et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N. Engl. J. Med. 2013;368:2385&#x2013;2394. doi: 10.1056/NEJMoa1214886.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1056/NEJMoa1214886</ArticleId><ArticleId IdType=\"pubmed\">23724913</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon B.J., Mok T., Kim D.W., Wu Y.L., Nakagawa K., Mekhail T., Felip E., Cappuzzo F., Paolini J., Usari T., et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N. Engl. J. Med. 2014;371:2167&#x2013;2177. doi: 10.1056/NEJMoa1408440.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1056/NEJMoa1408440</ArticleId><ArticleId IdType=\"pubmed\">25470694</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon B.J., Kim D.W., Wu Y.L., Nakagawa K., Mekhail T., Felip E., Cappuzzo F., Paolini J., Usari T., Tang Y., et al. Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer. J. Clin. Oncol. 2018;36:2251&#x2013;2258. doi: 10.1200/JCO.2017.77.4794.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1200/JCO.2017.77.4794</ArticleId><ArticleId IdType=\"pubmed\">29768118</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw A.T., Kim T.M., Crin&#xf2; L., Gridelli C., Kiura K., Liu G., Novello S., Bearz A., Gautschi O., Mok T., et al. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): A randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2017;18:874&#x2013;886. doi: 10.1016/S1470-2045(17)30339-X.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/S1470-2045(17)30339-X</ArticleId><ArticleId IdType=\"pubmed\">28602779</ArticleId></ArticleIdList></Reference><Reference><Citation>Soria J.C., Tan D.S.W., Chiari R., Wu Y.L., Paz-Ares L., Wolf J., Geater S.L., Orlov S., Cortinovis D., Yu C.J., et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): A randomised, open-label, phase 3 study. Lancet. 2017;389:917&#x2013;929. doi: 10.1016/S0140-6736(17)30123-X.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/S0140-6736(17)30123-X</ArticleId><ArticleId IdType=\"pubmed\">28126333</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters S., Camidge D.R., Shaw A.T., Gadgeel S., Ahn J.S., Kim D.-W., Ou S.-H.I., P&#xe9;rol M., Dziadziuszko R., Rosell R., et al. Alectinib versus Crizotinib in Untreated ALK-Positive Non&#x2013;Small-Cell Lung Cancer. N. Engl. J. Med. 2017;377:829&#x2013;838. doi: 10.1056/NEJMoa1704795.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1056/NEJMoa1704795</ArticleId><ArticleId IdType=\"pubmed\">28586279</ArticleId></ArticleIdList></Reference><Reference><Citation>Camidge D.R., Kim H.R., Ahn M.J., Yang J.C., Han J.Y., Lee J.S., Hochmair M.J., Li J.Y., Chang G.C., Lee K.H., et al. Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer. N. Engl. J. Med. 2018;379:2027&#x2013;2039. doi: 10.1056/NEJMoa1810171.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1056/NEJMoa1810171</ArticleId><ArticleId IdType=\"pubmed\">30280657</ArticleId></ArticleIdList></Reference><Reference><Citation>Camidge D.R., Kim H.R., Ahn M.J., Yang J.C.H., Han J.Y., Hochmair M.J., Lee K.H., Delmonte A., Garc&#xed;a Campelo M.R., Kim D.W., et al. Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial. J. Clin. Oncol. 2020;38:3592&#x2013;3603. doi: 10.1200/JCO.20.00505.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1200/JCO.20.00505</ArticleId><ArticleId IdType=\"pmc\">PMC7605398</ArticleId><ArticleId IdType=\"pubmed\">32780660</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng T.L., Narasimhan N., Gupta N., Venkatakrishnan K., Kerstein D., Camidge D.R. Early-Onset Pulmonary Events Associated With Brigatinib Use in Advanced NSCLC. J. Thorac. Oncol. 2020;15:1190&#x2013;1199. doi: 10.1016/j.jtho.2020.02.011.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jtho.2020.02.011</ArticleId><ArticleId IdType=\"pubmed\">32135189</ArticleId></ArticleIdList></Reference><Reference><Citation>Horn L., Wang Z., Wu G., Poddubskaya E., Mok T., Reck M., Wakelee H., Chiappori A.A., Lee D.H., Breder V., et al. Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical Trial. JAMA Oncol. 2021;7:1617&#x2013;1625. doi: 10.1001/jamaoncol.2021.3523.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1001/jamaoncol.2021.3523</ArticleId><ArticleId IdType=\"pmc\">PMC8414368</ArticleId><ArticleId IdType=\"pubmed\">34473194</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw A.T., Bauer T.M., de Marinis F., Felip E., Goto Y., Liu G., Mazieres J., Kim D.W., Mok T., Polli A., et al. First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer. N. Engl. J. Med. 2020;383:2018&#x2013;2029. doi: 10.1056/NEJMoa2027187.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1056/NEJMoa2027187</ArticleId><ArticleId IdType=\"pubmed\">33207094</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon B.J., Bauer T.M., Mok T.S.K., Liu G., Mazieres J., de Marinis F., Goto Y., Kim D.W., Wu Y.L., Jassem J., et al. Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: Updated analysis of data from the phase 3, randomised, open-label CROWN study. Lancet Respir. Med. 2023;11:354&#x2013;366. doi: 10.1016/S2213-2600(22)00437-4.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/S2213-2600(22)00437-4</ArticleId><ArticleId IdType=\"pubmed\">36535300</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon B.J., Bauer T.M., Ignatius Ou S.H., Liu G., Hayashi H., Bearz A., Penkov K., Wu Y.L., Arrieta O., Jassem J., et al. Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients With ALK-Positive Advanced Non-Small-Cell Lung Cancer From the Phase III CROWN Study. J. Clin. Oncol. 2022;40:3593&#x2013;3602. doi: 10.1200/JCO.21.02278.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1200/JCO.21.02278</ArticleId><ArticleId IdType=\"pmc\">PMC9622589</ArticleId><ArticleId IdType=\"pubmed\">35605188</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw A.T., Friboulet L., Leshchiner I., Gainor J.F., Bergqvist S., Brooun A., Burke B.J., Deng Y.L., Liu W., Dardaei L., et al. Resensitization to crizotinib by the lorlatinib ALK resistance mutation L1198F. N. Engl. J. Med. 2016;374:54&#x2013;61. doi: 10.1056/NEJMoa1508887.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1056/NEJMoa1508887</ArticleId><ArticleId IdType=\"pmc\">PMC4773904</ArticleId><ArticleId IdType=\"pubmed\">26698910</ArticleId></ArticleIdList></Reference><Reference><Citation>Otten L.S., Piet B., Heuvel M.M.v.d., Marzolini C., Geel R.M.J.M.v., Gulikers J.L., Burger D.M., Leentjens J., Heine R.t. Practical recommendations to combine small-molecule inhibitors and direct oral anticoagulants in patients with nonsmall cell lung cancer. Eur. Respir. Rev. 2022;31:220004. doi: 10.1183/16000617.0004-2022.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1183/16000617.0004-2022</ArticleId><ArticleId IdType=\"pmc\">PMC9489148</ArticleId><ArticleId IdType=\"pubmed\">35705208</ArticleId></ArticleIdList></Reference><Reference><Citation>Addeo A., Passaro A., Malapelle U., Banna G.L., Subbiah V., Friedlaender A. Immunotherapy in non-small cell lung cancer harbouring driver mutations. Cancer Treat. Rev. 2021;96:102179. doi: 10.1016/j.ctrv.2021.102179.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.ctrv.2021.102179</ArticleId><ArticleId IdType=\"pubmed\">33798954</ArticleId></ArticleIdList></Reference><Reference><Citation>Camidge D.R., Ahn M., Reckamp K., West H., Huber R., Langer C., Bazhenova L., Leighl N., Reichmann W., Kerstein D., et al. P1.01-004 Hypertension With Brigatinib: Experience in ALTA, a Randomized Phase 2 Trial in Crizotinib-Refractory ALK+ NSCLC. J. Thorac. Oncol. 2017;12:S1893. doi: 10.1016/j.jtho.2017.09.658.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jtho.2017.09.658</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabir S.R., Yeoh S., Jackson G., Bayliss R. EML4-ALK Variants: Biological and Molecular Properties, and the Implications for Patients. Cancers. 2017;9:118. doi: 10.3390/cancers9090118.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3390/cancers9090118</ArticleId><ArticleId IdType=\"pmc\">PMC5615333</ArticleId><ArticleId IdType=\"pubmed\">28872581</ArticleId></ArticleIdList></Reference><Reference><Citation>Camidge D.R., Kono S.A., Flacco A., Tan A.C., Doebele R.C., Zhou Q., Crino L., Franklin W.A., Varella-Garcia M. Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. Clin. Cancer Res. 2010;16:5581&#x2013;5590. doi: 10.1158/1078-0432.CCR-10-0851.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1158/1078-0432.CCR-10-0851</ArticleId><ArticleId IdType=\"pmc\">PMC3395226</ArticleId><ArticleId IdType=\"pubmed\">21062932</ArticleId></ArticleIdList></Reference><Reference><Citation>Gainor J.F., Dardaei L., Yoda S., Friboulet L., Leshchiner I., Katayama R., Dagogo-Jack I., Gadgeel S., Schultz K., Singh M., et al. Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer. Cancer Discov. 2016;6:1118&#x2013;1133. doi: 10.1158/2159-8290.CD-16-0596.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1158/2159-8290.CD-16-0596</ArticleId><ArticleId IdType=\"pmc\">PMC5050111</ArticleId><ArticleId IdType=\"pubmed\">27432227</ArticleId></ArticleIdList></Reference><Reference><Citation>Dagogo-Jack I., Rooney M., Lin J.J., Nagy R.J., Yeap B.Y., Hubbeling H., Chin E., Ackil J., Farago A.F., Hata A.N., et al. Treatment with Next-Generation ALK Inhibitors Fuels Plasma ALK Mutation Diversity. Clin. Cancer Res. 2019;25:6662&#x2013;6670. doi: 10.1158/1078-0432.CCR-19-1436.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1158/1078-0432.CCR-19-1436</ArticleId><ArticleId IdType=\"pmc\">PMC6858956</ArticleId><ArticleId IdType=\"pubmed\">31358542</ArticleId></ArticleIdList></Reference><Reference><Citation>Passaro A., Attili I., Rappa A., Vacirca D., Ranghiero A., Fumagalli C., Guarize J., Spaggiari L., de Marinis F., Barberis M., et al. Genomic Characterization of Concurrent Alterations in Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Mutations. Cancers. 2021;13:2172. doi: 10.3390/cancers13092172.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3390/cancers13092172</ArticleId><ArticleId IdType=\"pmc\">PMC8124171</ArticleId><ArticleId IdType=\"pubmed\">33946519</ArticleId></ArticleIdList></Reference><Reference><Citation>Rangachari D., Yamaguchi N., VanderLaan P.A., Folch E., Mahadevan A., Floyd S.R., Uhlmann E.J., Wong E.T., Dahlberg S.E., Huberman M.S., et al. Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers. Lung Cancer. 2015;88:108&#x2013;111. doi: 10.1016/j.lungcan.2015.01.020.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.lungcan.2015.01.020</ArticleId><ArticleId IdType=\"pmc\">PMC4355240</ArticleId><ArticleId IdType=\"pubmed\">25682925</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang B., Lee H., Um S.W., Kim K., Zo J.I., Shim Y.M., Jung Kwon O., Lee K.S., Ahn M.J., Kim H. Incidence of brain metastasis in lung adenocarcinoma at initial diagnosis on the basis of stage and genetic alterations. Lung Cancer. 2019;129:28&#x2013;34. doi: 10.1016/j.lungcan.2018.12.027.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.lungcan.2018.12.027</ArticleId><ArticleId IdType=\"pubmed\">30797488</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun S., Kang J., Sun X., Men Y., Yang X., Yuan M., Bao Y., Ma Z., Liu Y., Li J., et al. Optimal Treatment Strategy of Radiotherapy and Crizotinib for Patients with Brain Metastasis from ALK-Rearranged Non-Small-Cell Lung Cancer. Int. J. Radiat. Oncol. Biol. Phys. 2022;114:e392. doi: 10.1016/j.ijrobp.2022.07.1549.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.ijrobp.2022.07.1549</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X.S., Bai Y.F., Verma V., Yu R.L., Tian W., Ao R., Deng Y., Zhu X.Q., Liu H., Pan H.X., et al. Randomized Trial of First-Line Tyrosine Kinase Inhibitor With or Without Radiotherapy for Synchronous Oligometastatic EGFR-Mutated Non-Small Cell Lung Cancer. J. Natl. Cancer Inst. 2023;115:742&#x2013;748. doi: 10.1093/jnci/djac015.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/jnci/djac015</ArticleId><ArticleId IdType=\"pmc\">PMC10248839</ArticleId><ArticleId IdType=\"pubmed\">35094066</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas N.J., Myall N.J., Sun F., Patil T., Mushtaq R., Yu C., Sinha S., Pollom E.L., Nagpal S., Camidge D.R., et al. Brain Metastases in EGFR- and ALK-Positive NSCLC: Outcomes of Central Nervous System-Penetrant Tyrosine Kinase Inhibitors Alone Versus in Combination With Radiation. J. Thorac. Oncol. 2022;17:116&#x2013;129. doi: 10.1016/j.jtho.2021.08.009.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jtho.2021.08.009</ArticleId><ArticleId IdType=\"pubmed\">34455066</ArticleId></ArticleIdList></Reference><Reference><Citation>Fong C.H., Meti N., Kruser T., Weiss J., Liu Z.A., Takami H., Narita Y., de Moraes F.Y., Dasgupta A., Ong C.K., et al. Recommended first-line management of asymptomatic brain metastases from EGFR mutant and ALK positive non-small cell lung cancer varies significantly according to specialty: An international survey of clinical practice. J. Thorac. Dis. 2023;15:4367&#x2013;4378.</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC10482634</ArticleId><ArticleId IdType=\"pubmed\">37691657</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen K.T., Sakthivel G., Milano M.T., Qiu H., Singh D.P. Oligoprogression in non-small cell lung cancer: A narrative review. J. Thorac. Dis. 2022;14:4998&#x2013;5011. doi: 10.21037/jtd-22-536.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.21037/jtd-22-536</ArticleId><ArticleId IdType=\"pmc\">PMC9840049</ArticleId><ArticleId IdType=\"pubmed\">36647502</ArticleId></ArticleIdList></Reference><Reference><Citation>Weickhardt A.J., Scheier B., Burke J.M., Gan G., Lu X., Bunn P.A., Jr., Aisner D.L., Gaspar L.E., Kavanagh B.D., Doebele R.C., et al. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J. Thorac. Oncol. 2012;7:1807&#x2013;1814. doi: 10.1097/JTO.0b013e3182745948.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1097/JTO.0b013e3182745948</ArticleId><ArticleId IdType=\"pmc\">PMC3506112</ArticleId><ArticleId IdType=\"pubmed\">23154552</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson M.L., Zvirbule Z., Laktionov K., Helland A., Cho B.C., Gutierrez V., Colinet B., Lena H., Wolf M., Gottfried M., et al. Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage-SCLC: Results From the Phase 3 MERU Study. J. Thorac. Oncol. 2021;16:1570&#x2013;1581. doi: 10.1016/j.jtho.2021.03.012.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jtho.2021.03.012</ArticleId><ArticleId IdType=\"pubmed\">33823285</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>\n",
            "XML saved to: path/to/save/xml/37999149.xml\n",
            "Details URL: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=37999105&retmode=xml&api_key=9edd38677707c08b2a96ed1a6e8c61c47408\n",
            "Details Response Content: <?xml version=\"1.0\" ?>\n",
            "<!DOCTYPE PubmedArticleSet PUBLIC \"-//NLM//DTD PubMedArticle, 1st January 2023//EN\" \"https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd\">\n",
            "<PubmedArticleSet>\n",
            "<PubmedArticle><MedlineCitation Status=\"MEDLINE\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">37999105</PMID><DateCompleted><Year>2023</Year><Month>11</Month><Day>27</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>27</Day></DateRevised><Article PubModel=\"Electronic\"><Journal><ISSN IssnType=\"Electronic\">1718-7729</ISSN><JournalIssue CitedMedium=\"Internet\"><Volume>30</Volume><Issue>11</Issue><PubDate><Year>2023</Year><Month>Oct</Month><Day>25</Day></PubDate></JournalIssue><Title>Current oncology (Toronto, Ont.)</Title><ISOAbbreviation>Curr Oncol</ISOAbbreviation></Journal><ArticleTitle>Pneumonectomy for Primary Lung Tumors and Pulmonary Metastases: A Comprehensive Study of Postoperative Morbidity, Early Mortality, and Preoperative Clinical Prognostic Factors.</ArticleTitle><Pagination><StartPage>9458</StartPage><EndPage>9474</EndPage><MedlinePgn>9458-9474</MedlinePgn></Pagination><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.3390/curroncol30110685</ELocationID><Abstract><AbstractText Label=\"BACKGROUND\" NlmCategory=\"BACKGROUND\">Pneumonectomy is a major surgical resection that still remains a high-risk operation. The current study aims to investigate perioperative risk factors for postoperative morbidity and early mortality after pneumonectomy for thoracic malignancies.</AbstractText><AbstractText Label=\"METHODS\" NlmCategory=\"METHODS\">We retrospectively analyzed all patients who underwent pneumonectomy for thoracic malignancies at our institution between 2014 and 2022. Complications were assessed up to 30 days after the operation. Mortality for any reason was recorded after 30 days and 90 days.</AbstractText><AbstractText Label=\"RESULTS\" NlmCategory=\"RESULTS\">A total of 145 out of 169 patients undergoing pneumonectomy were included in this study. The postoperative 30-day complication rate was 41.4%. The 30-day-mortality was 8.3%, and 90-day-mortality 17.2%. The presence of cardiovascular comorbidities was a risk factor for major cardiopulmonary complications (54.2% vs. 13.2%, <i>p</i> &lt; 0.01). Postoperative bronchus stump insufficiency (OR: 11.883, 95% CI: 1.288-109.591, <i>p</i> = 0.029) and American Society of Anesthesiologists (ASA) score 4 (OR: 3.023, 95% CI: 1.028-8.892, <i>p</i> = 0.044) were independent factors for early mortality.</AbstractText><AbstractText Label=\"CONCLUSION\" NlmCategory=\"CONCLUSIONS\">Pneumonectomy for thoracic malignancies remains a high-risk major lung resection with significant postoperative morbidity and mortality. Attention should be paid to the preoperative selection of patients.</AbstractText></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Grapatsas</LastName><ForeName>Konstantinos</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Thoracic Surgery, West German Cancer Center, Medical Faculty, University Hospital Essen, Ruhrlandklinik, Tueschner Weg 40, 45239 Essen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Menghesha</LastName><ForeName>Hruy</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Thoracic Surgery, West German Cancer Center, Medical Faculty, University Hospital Essen, Ruhrlandklinik, Tueschner Weg 40, 45239 Essen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>D&#xf6;rr</LastName><ForeName>Fabian</ForeName><Initials>F</Initials><Identifier Source=\"ORCID\">0000-0002-0878-0406</Identifier><AffiliationInfo><Affiliation>Department of Thoracic Surgery, West German Cancer Center, Medical Faculty, University Hospital Essen, Ruhrlandklinik, Tueschner Weg 40, 45239 Essen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Baldes</LastName><ForeName>Natalie</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Thoracic Surgery, West German Cancer Center, Medical Faculty, University Hospital Essen, Ruhrlandklinik, Tueschner Weg 40, 45239 Essen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Schuler</LastName><ForeName>Martin</ForeName><Initials>M</Initials><Identifier Source=\"ORCID\">0000-0002-2166-3394</Identifier><AffiliationInfo><Affiliation>Department of Medical Oncology, West German Cancer Center, Medical Faculty, University Hospital Essen, Hufelandstr. 55, 45147 Essen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Stuschke</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, West German Cancer Center, Medical Faculty, University Hospital Essen, Hufelandstr. 55, 45147 Essen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Darwiche</LastName><ForeName>Kaid</ForeName><Initials>K</Initials><Identifier Source=\"ORCID\">0000-0003-0681-1325</Identifier><AffiliationInfo><Affiliation>Department of Pneumology, Medical Faculty, University Hospital Essen, Hufelandstr. 55, 45147 Essen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Taube</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Pneumology, Medical Faculty, University Hospital Essen, Hufelandstr. 55, 45147 Essen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>B&#xf6;l&#xfc;kbas</LastName><ForeName>Servet</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Thoracic Surgery, West German Cancer Center, Medical Faculty, University Hospital Essen, Ruhrlandklinik, Tueschner Weg 40, 45239 Essen, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2023</Year><Month>10</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Curr Oncol</MedlineTA><NlmUniqueID>9502503</NlmUniqueID><ISSNLinking>1198-0052</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI=\"D006801\" MajorTopicYN=\"N\">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D011013\" MajorTopicYN=\"Y\">Pneumonectomy</DescriptorName><QualifierName UI=\"Q000009\" MajorTopicYN=\"N\">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D011379\" MajorTopicYN=\"N\">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D012189\" MajorTopicYN=\"N\">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D008175\" MajorTopicYN=\"Y\">Lung Neoplasms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D008168\" MajorTopicYN=\"N\">Lung</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D009017\" MajorTopicYN=\"N\">Morbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D011183\" MajorTopicYN=\"N\">Postoperative Complications</DescriptorName><QualifierName UI=\"Q000453\" MajorTopicYN=\"N\">epidemiology</QualifierName><QualifierName UI=\"Q000209\" MajorTopicYN=\"N\">etiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner=\"NOTNLM\"><Keyword MajorTopicYN=\"N\">American Society of Anesthesiologists (ASA) score</Keyword><Keyword MajorTopicYN=\"N\">bronchus stump insufficiency</Keyword><Keyword MajorTopicYN=\"N\">complications</Keyword><Keyword MajorTopicYN=\"N\">mortality</Keyword><Keyword MajorTopicYN=\"N\">non-small cell lung cancer</Keyword><Keyword MajorTopicYN=\"N\">pneumonectomy</Keyword><Keyword MajorTopicYN=\"N\">pulmonary metastasectomy</Keyword><Keyword MajorTopicYN=\"N\">pulmonary metastases</Keyword><Keyword MajorTopicYN=\"N\">thoracic malignancy</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"received\"><Year>2023</Year><Month>9</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus=\"revised\"><Year>2023</Year><Month>10</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus=\"accepted\"><Year>2023</Year><Month>10</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus=\"medline\"><Year>2023</Year><Month>11</Month><Day>27</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2023</Year><Month>11</Month><Day>24</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2023</Year><Month>11</Month><Day>24</Day><Hour>9</Hour><Minute>40</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">37999105</ArticleId><ArticleId IdType=\"pmc\">PMC10670891</ArticleId><ArticleId IdType=\"doi\">10.3390/curroncol30110685</ArticleId><ArticleId IdType=\"pii\">curroncol30110685</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rea F., Marulli G., Schiavon M., Zuin A., Hamad A.-M., Rizzardi G., Perissinotto E., Sartori F. A quarter of a century experience with sleeve lobectomy for non-small cell lung cancer. Eur. J. Cardio-Thorac. Surg. 2008;34:488&#x2013;492; discussion 492. doi: 10.1016/j.ejcts.2008.05.027.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.ejcts.2008.05.027</ArticleId><ArticleId IdType=\"pubmed\">18579399</ArticleId></ArticleIdList></Reference><Reference><Citation>Shapiro M., Swanson S.J., Wright C.D., Chin C., Sheng S., Wisnivesky J., Weiser T.S. Predictors of major morbidity and mortality after pneumonectomy utilizing the Society for Thoracic Surgeons General Thoracic Surgery Database. Ann. Thorac. Surg. 2010;90:927&#x2013;934; discussion 934&#x2013;935. doi: 10.1016/j.athoracsur.2010.05.041.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.athoracsur.2010.05.041</ArticleId><ArticleId IdType=\"pubmed\">20732520</ArticleId></ArticleIdList></Reference><Reference><Citation>Harpole D.H., Liptay M.J., DeCamp M., Jr., Mentzer S.J., Swanson S.J., Sugarbaker D.J. Prospective analysis of pneumonectomy: Risk factors for major morbidity and cardiac dysrhythmias. Ann. Thorac. Surg. 1996;61:977&#x2013;982. doi: 10.1016/0003-4975(95)01174-9.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/0003-4975(95)01174-9</ArticleId><ArticleId IdType=\"pubmed\">8619729</ArticleId></ArticleIdList></Reference><Reference><Citation>Marret E., Miled F., Bazelly B., El Metaoua S., de Montblanc J., Quesnel C., Fulgencio J.-P., Bonnet F. Risk and protective factors for major complications after pneumonectomy for lung cancer. Interact. Cardiovasc. Thorac. Surg. 2010;10:936&#x2013;939. doi: 10.1510/icvts.2009.231621.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1510/icvts.2009.231621</ArticleId><ArticleId IdType=\"pubmed\">20479075</ArticleId></ArticleIdList></Reference><Reference><Citation>Mansour Z., Kochetkova E., Santelmo N., Meyer P., Wihlm J.-M., Quoix E., Massard G. Risk factors for early mortality and morbidity after pneumonectomy: A reappraisal. Ann. Thorac. Surg. 2009;88:1737&#x2013;1743. doi: 10.1016/j.athoracsur.2009.07.016.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.athoracsur.2009.07.016</ArticleId><ArticleId IdType=\"pubmed\">19932227</ArticleId></ArticleIdList></Reference><Reference><Citation>Grapatsas K., Papaporfyriou A., Leivaditis V., Ehle B., Galanis M. Lung Metastatectomy: Can Laser-Assisted Surgery Make a Difference? Curr. Oncol. 2022;29:548. doi: 10.3390/curroncol29100548.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3390/curroncol29100548</ArticleId><ArticleId IdType=\"pmc\">PMC9600252</ArticleId><ArticleId IdType=\"pubmed\">36290825</ArticleId></ArticleIdList></Reference><Reference><Citation>Hassan M., Ehle B., Passlick B., Grapatsas K. Lung Resections for Elderly Patients with Lung Metastases: A Comparative Study of the Postoperative Complications and Overall Survival. Curr. Oncol. 2022;29:4511&#x2013;4521. doi: 10.3390/curroncol29070357.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3390/curroncol29070357</ArticleId><ArticleId IdType=\"pmc\">PMC9323760</ArticleId><ArticleId IdType=\"pubmed\">35877217</ArticleId></ArticleIdList></Reference><Reference><Citation>Grapatsas K., Hassan M., Semmelmann A., Ehle B., Passlick B., Schmid S., Le U.T. Should cardiovascular comorbidities be a contraindication for pulmonary metastasectomy? J. Thorac. Dis. 2022;14:4266&#x2013;4275. doi: 10.21037/jtd-22-409.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.21037/jtd-22-409</ArticleId><ArticleId IdType=\"pmc\">PMC9745539</ArticleId><ArticleId IdType=\"pubmed\">36524092</ArticleId></ArticleIdList></Reference><Reference><Citation>Osei-Agyemang T., Palade E., Haderthauer J., Ploenes T., Yaneva V., Passlick B. Pulmonary metastasectomy: An analysis of technical and oncological outcomes in 301 patients with a focus on laser resection. Zentralbl. Chir. 2013;138((Suppl. S1)):S45&#x2013;S51.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">24150855</ArticleId></ArticleIdList></Reference><Reference><Citation>Ambrogi V., Pompeo E., Elia S., Pistolese G.R., Mineo T.C. The impact of cardiovascular comorbidity on the outcome of surgery for stage I and II non-small-cell lung cancer. Eur. J. Cardio-Thorac. Surg. 2003;23:811&#x2013;817. doi: 10.1016/S1010-7940(03)00093-9.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/S1010-7940(03)00093-9</ArticleId><ArticleId IdType=\"pubmed\">12754038</ArticleId></ArticleIdList></Reference><Reference><Citation>Seely A.J., Ivanovic J., Threader J., Al-Hussaini A., Al-Shehab D., Ramsay T., Gilbert S., Maziak D.E., Shamji F.M., Sundaresan R.S. Systematic classification of morbidity and mortality after thoracic surgery. Ann. Thorac. Surg. 2010;90:936&#x2013;942; discussion 942. doi: 10.1016/j.athoracsur.2010.05.014.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.athoracsur.2010.05.014</ArticleId><ArticleId IdType=\"pubmed\">20732521</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirza S., Clay R.D., Koslow M.A., Scanlon P.D. COPD Guidelines: A Review of the 2018 GOLD Report. Mayo Clin. Proc. 2018;93:1488&#x2013;1502. doi: 10.1016/j.mayocp.2018.05.026.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.mayocp.2018.05.026</ArticleId><ArticleId IdType=\"pubmed\">30286833</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunswicker A., Taylor M., Grant S., Abah U., Smith M., Shackcloth M., Granato F., Shah R., Rammohan K., North West Thoracic Surgery Collaborative (NWTSC) Pneumonectomy for primary lung cancer: Contemporary outcomes, risk factors and model validation. Interact. Cardiovasc. Thorac. Surg. 2022;34:1054&#x2013;1061. doi: 10.1093/icvts/ivab340.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/icvts/ivab340</ArticleId><ArticleId IdType=\"pmc\">PMC9159428</ArticleId><ArticleId IdType=\"pubmed\">34871415</ArticleId></ArticleIdList></Reference><Reference><Citation>Kozub M., Gachewicz B., Kasprzyk M., Roszak M., Gasiorowski L., Dyszkiewicz W. Impact of smoking history on postoperative complications after lung cancer surgery&#x2014;A study based on 286 cases. Kardiochir. Torakochirurgia Pol. 2019;16:13&#x2013;18. doi: 10.5114/kitp.2019.83940.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.5114/kitp.2019.83940</ArticleId><ArticleId IdType=\"pmc\">PMC6491375</ArticleId><ArticleId IdType=\"pubmed\">31043970</ArticleId></ArticleIdList></Reference><Reference><Citation>Licker M., Spiliopoulos A., Frey J.-G., Robert J., Ho&#xef;hn L., de Perrot M., Tschopp J.-M. Risk factors for early mortality and major complications following pneumonectomy for non-small cell carcinoma of the lung. Chest J. 2002;121:1890&#x2013;1897. doi: 10.1378/chest.121.6.1890.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1378/chest.121.6.1890</ArticleId><ArticleId IdType=\"pubmed\">12065354</ArticleId></ArticleIdList></Reference><Reference><Citation>Deschamps C., Bernard A., Nichols F.C., 3rd, Allen M.S., Miller D.L., Trastek V.F., Jenkins G.D., Pairolero P.C. Empyema and bronchopleural fistula after pneumonectomy: Factors affecting incidence. Ann. Thorac. Surg. 2001;72:243&#x2013;247; discussion 248. doi: 10.1016/S0003-4975(01)02681-9.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/S0003-4975(01)02681-9</ArticleId><ArticleId IdType=\"pubmed\">11465187</ArticleId></ArticleIdList></Reference><Reference><Citation>Sirbu H., Busch T., Aleksic I., Schreiner W., Oster O., Dalichau H. Bronchopleural fistula in the surgery of non-small cell lung cancer: Incidence, risk factors, and management. Ann. Thorac. Cardiovasc. Surg. 2001;7:330&#x2013;336.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">11888471</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright C.D., Wain J.C., Mathisen D.J., Grillo H.C. Postpneumonectomy bronchopleural fistula after sutured bronchial closure: Incidence, risk factors, and management. J. Thorac. Cardiovasc. Surg. 1996;112:1367&#x2013;1371. doi: 10.1016/S0022-5223(96)70153-8.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/S0022-5223(96)70153-8</ArticleId><ArticleId IdType=\"pubmed\">8911336</ArticleId></ArticleIdList></Reference><Reference><Citation>Takenaka T., Shoji F., Tagawa T., Kinoshita F., Haratake N., Edagawa M., Yamazaki K., Takenoyama M., Takeo S., Mori M. Does short-term cessation of smoking before lung resections reduce the risk of complications? J. Thorac. Dis. 2020;12:7127&#x2013;7134. doi: 10.21037/jtd-20-2574.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.21037/jtd-20-2574</ArticleId><ArticleId IdType=\"pmc\">PMC7797847</ArticleId><ArticleId IdType=\"pubmed\">33447401</ArticleId></ArticleIdList></Reference><Reference><Citation>Shigeeda W., Deguchi H., Tomoyasu M., Kaneko Y., Yoshimura R., Iwai H., Kanno H., Kudo S., Takahashi F., Saito H. Optimal period of smoking cessation to reduce the incidence of postoperative pulmonary complications in lung cancer. Interdiscip. Cardiovasc. Thorac. Surg. 2023;36:ivad094. doi: 10.1093/icvts/ivad094.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/icvts/ivad094</ArticleId><ArticleId IdType=\"pmc\">PMC10275910</ArticleId><ArticleId IdType=\"pubmed\">37294842</ArticleId></ArticleIdList></Reference><Reference><Citation>Kudelin N., B&#xf6;l&#xfc;kbas S., Eberlein M., Schirren J. Metastasectomy with standardized lymph node dissection for metastatic renal cell carcinoma: An 11-year single-center experience. Ann. Thorac. Surg. 2013;96:265&#x2013;270; discussion 270&#x2013;271. doi: 10.1016/j.athoracsur.2013.04.047.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.athoracsur.2013.04.047</ArticleId><ArticleId IdType=\"pubmed\">23731615</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xf6;l&#xfc;kbas S., Sponholz S., Kudelin N., Eberlein M., Schirren J. Risk factors for lymph node metastases and prognosticators of survival in patients undergoing pulmonary metastasectomy for colorectal cancer. Ann. Thorac. Surg. 2014;97:1926&#x2013;1932. doi: 10.1016/j.athoracsur.2014.02.026.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.athoracsur.2014.02.026</ArticleId><ArticleId IdType=\"pubmed\">24681037</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfannschmidt J., Egerer G., Bischof M., Thomas M., Dienemann H. Surgical intervention for pulmonary metastases. Dtsch. Arztebl. Int. 2012;109:645&#x2013;651. doi: 10.3238/arztebl.2012.0645.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3238/arztebl.2012.0645</ArticleId><ArticleId IdType=\"pmc\">PMC3476611</ArticleId><ArticleId IdType=\"pubmed\">23094000</ArticleId></ArticleIdList></Reference><Reference><Citation>Bazwinsky-Wutschke I., Paulsen F., St&#xf6;vesandt D., Holzhausen H.-J., Heine H.-J., Peschke E. Anatomical changes after pneumonectomy. Ann. Anat.-Anat. Anz. 2011;193:168&#x2013;172. doi: 10.1016/j.aanat.2011.01.002.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.aanat.2011.01.002</ArticleId><ArticleId IdType=\"pubmed\">21333511</ArticleId></ArticleIdList></Reference><Reference><Citation>Margaryan R., Moscarelli M., Gasbarri T., Bianchi G., Kallushi E., Cerillo A.G., Farneti P., Solinas M. EuroSCORE Per-for-mance in Minimally Invasive Cardiac Surgery: Discrimination Ability and External Calibration. Innovations. 2017;12:282&#x2013;286. doi: 10.1097/imi.0000000000000377.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1097/imi.0000000000000377</ArticleId><ArticleId IdType=\"pubmed\">28582328</ArticleId></ArticleIdList></Reference><Reference><Citation>Amar D., Munoz D., Shi W., Zhang H., Thaler H.T. A clinical prediction rule for pulmonary complications after thoracic surgery for primary lung cancer. Anesth. Analg. 2010;110:1343&#x2013;1348. doi: 10.1213/ANE.0b013e3181bf5c99.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1213/ANE.0b013e3181bf5c99</ArticleId><ArticleId IdType=\"pubmed\">19861366</ArticleId></ArticleIdList></Reference><Reference><Citation>Yepes-Temi&#xf1;o M.J., Monedero P., P&#xe9;rez-Valdivieso J.R., Grupo Espa&#xf1;ol de Anestesia Toracica Risk prediction model for res-piratory complications after lung resection: An observational multicentre study. Eur. J. Anaesthesiol. 2016;33:326&#x2013;333. doi: 10.1097/EJA.0000000000000354.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1097/EJA.0000000000000354</ArticleId><ArticleId IdType=\"pubmed\">26535555</ArticleId></ArticleIdList></Reference><Reference><Citation>Hackett N.J., De Oliveira G.S., Jain U.K., Kim J.Y. ASA class is a reliable independent predictor of medical complications and mortality following surgery. Int. J. Surg. 2015;18:184&#x2013;190. doi: 10.1016/j.ijsu.2015.04.079.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.ijsu.2015.04.079</ArticleId><ArticleId IdType=\"pubmed\">25937154</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzella A., Mohamed S., Maisonneuve P., Borri A., Casiraghi M., Bertolaccini L., Petrella F., Lo Iacono G., Spaggiari L. ARDS after Pneumonectomy: How to Prevent It? Development of a Nomogram to Predict the Risk of ARDS after Pneumonectomy for Lung Cancer. Cancers. 2022;14:6048. doi: 10.3390/cancers14246048.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3390/cancers14246048</ArticleId><ArticleId IdType=\"pmc\">PMC9775532</ArticleId><ArticleId IdType=\"pubmed\">36551534</ArticleId></ArticleIdList></Reference><Reference><Citation>Beshay M., Carboni G., Hoksch B., Reymond M., Schmid R. The role of muscle flap in preventing bronchus stump insufficiency after pneumonectomy for malignant pleural mesothelioma in high-risk patients. Interact. Cardiovasc. Thorac. Surg. 2008;7:621&#x2013;624; discussion 624&#x2013;625. doi: 10.1510/icvts.2007.166546.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1510/icvts.2007.166546</ArticleId><ArticleId IdType=\"pubmed\">18381361</ArticleId></ArticleIdList></Reference><Reference><Citation>Terzi A., Luzzi L., Campione A., Gorla A., Calabr&#xf2; F. The split latissimus dorsi muscle flap to protect a bronchial stump at risk of bronchial insufficiency. Ann. Thorac. Surg. 2009;87:329&#x2013;330. doi: 10.1016/j.athoracsur.2008.05.065.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.athoracsur.2008.05.065</ArticleId><ArticleId IdType=\"pubmed\">19101334</ArticleId></ArticleIdList></Reference><Reference><Citation>Koryllos A., Ludwig C., Beckers F., Stoelben E. [Bronchus insufficiency: Prevention and therapy] Zentralbl. Chir. 2012;137:223&#x2013;227. doi: 10.1055/s-0031-1284012.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1055/s-0031-1284012</ArticleId><ArticleId IdType=\"pubmed\">22711321</ArticleId></ArticleIdList></Reference><Reference><Citation>Taghavi S., Marta G., Lang G., Seebacher G., Winkler G., Schmid K., Klepetko W. Bronchial stump coverage with a pedicled pericardial flap: An effective method for prevention of postpneumonectomy bronchopleural fistula. Ann. Thorac. Surg. 2005;79:284&#x2013;288. doi: 10.1016/j.athoracsur.2004.06.108.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.athoracsur.2004.06.108</ArticleId><ArticleId IdType=\"pubmed\">15620959</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai F., Wu X., Wang X., Li K., Wang Y., Shen C., Zhou J., Niu H., Deng B., Tan Q., et al. Neoadjuvant immunotherapy combined with chemotherapy significantly improved patients&#x2019; overall survival when compared with neoadjuvant chemotherapy in non-small cell lung cancer: A cohort study. Front. Oncol. 2022;12:1022123. doi: 10.3389/fonc.2022.1022123.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3389/fonc.2022.1022123</ArticleId><ArticleId IdType=\"pmc\">PMC9637677</ArticleId><ArticleId IdType=\"pubmed\">36353552</ArticleId></ArticleIdList></Reference><Reference><Citation>Misumi K., Harada H., Tsubokawa N., Tsutani Y., Matsumoto K., Miyata Y., Yamashita Y., Okada M. Clinical benefit of neoadjuvant chemoradiotherapy for the avoidance of pneumonectomy; assessment in 12 consecutive cen-trally located non-small cell lung cancers. Gen. Thorac. Cardiovasc. Surg. 2017;65:392&#x2013;399. doi: 10.1007/s11748-017-0776-y.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s11748-017-0776-y</ArticleId><ArticleId IdType=\"pubmed\">28432576</ArticleId></ArticleIdList></Reference><Reference><Citation>Weder W., Collaud S., Eberhardt W., Hillinger S., Welter S., Stahel R., Stamatis G. Pneumonectomy is a valuable treatment option after neoadjuvant therapy for stage III non-small-cell lung cancer. J. Thorac. Cardiovasc. Surg. 2010;139:1424&#x2013;1430. doi: 10.1016/j.jtcvs.2010.02.039.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jtcvs.2010.02.039</ArticleId><ArticleId IdType=\"pubmed\">20416887</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>\n",
            "XML saved to: path/to/save/xml/37999105.xml\n",
            "Details URL: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=37997884&retmode=xml&api_key=9edd38677707c08b2a96ed1a6e8c61c47408\n",
            "Details Response Content: <?xml version=\"1.0\" ?>\n",
            "<!DOCTYPE PubmedArticleSet PUBLIC \"-//NLM//DTD PubMedArticle, 1st January 2023//EN\" \"https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd\">\n",
            "<PubmedArticleSet>\n",
            "<PubmedArticle><MedlineCitation Status=\"MEDLINE\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">37997884</PMID><DateCompleted><Year>2023</Year><Month>11</Month><Day>27</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>27</Day></DateRevised><Article PubModel=\"Print\"><Journal><ISSN IssnType=\"Electronic\">1753-4666</ISSN><JournalIssue CitedMedium=\"Internet\"><Volume>17</Volume><PubDate><Year>2023</Year><Season>Jan-Dec</Season></PubDate></JournalIssue><Title>Therapeutic advances in respiratory disease</Title><ISOAbbreviation>Ther Adv Respir Dis</ISOAbbreviation></Journal><ArticleTitle>Hyperinflation and reduced diffusing capacity predict prognosis in SCLC: value of extended pre-therapeutic lung function testing.</ArticleTitle><Pagination><StartPage>17534666231199670</StartPage><MedlinePgn>17534666231199670</MedlinePgn></Pagination><ELocationID EIdType=\"pii\" ValidYN=\"Y\">17534666231199670</ELocationID><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.1177/17534666231199670</ELocationID><Abstract><AbstractText Label=\"BACKGROUND\" NlmCategory=\"UNASSIGNED\">Small cell lung cancer (SCLC) is characterized by aggressive growth and poor prognosis. Although SCLC affects nearly exclusively heavy smokers and leads to frequent respiratory symptoms, the impact of pre-therapeutic lung function testing in SCLC is sparely investigated until now. Therefore, we sought to examine whether we could find prognostic markers in pre-therapeutic lung function testing of SCLC patients.</AbstractText><AbstractText Label=\"PATIENTS AND METHODS\" NlmCategory=\"UNASSIGNED\">We retrospectively analysed a cohort of 205 patients with the diagnosis of SCLC between 2010 and 2018. Pre-therapeutic values of spirometry, body plethysmography and measurement of diffusing capacity was extracted from patients' charts. Comparisons between groups were performed using the Mann-Whitney <i>U-</i>test or by chi-square tests as appropriate. Kaplan-Meier analyses and COX-regression models were performed to correlate lung function parameters with patients' outcome.</AbstractText><AbstractText Label=\"RESULTS\" NlmCategory=\"UNASSIGNED\">Airway obstruction itself, or the diagnosis chronic obstructive pulmonary disease (COPD) based on GOLD definitions did not correlate with survival in SCLC patients. Hyperinflation measured by increased residual volume and residual volume to total lung capacity ratio (log-rank <i>p</i>&#x2009;&lt;&#x2009;0.001) and reduced diffusing capacity (log-rank <i>p</i>&#x2009;=&#x2009;0.007) were associated with reduced survival. Furthermore, patients with hyperinflation as well as impairments in gas exchange representing an emphysematic phenotype had the worst outcome (log-rank <i>p</i>&#x2009;&lt;&#x2009;0.001).</AbstractText><AbstractText Label=\"CONCLUSION\" NlmCategory=\"UNASSIGNED\">We recommend including body plethysmography and measurement of diffusing capacity in the pre-therapeutic assessment of SCLC patients. Our findings suggest that reduction of hyperinflation may lead to better outcome in SCLC patients. Thus, in addition to effective tumour therapy, adequate therapy of the comorbidity of COPD should also be provided. In particular, measures to reduce hyperinflation by means of dual bronchodilation as well as respiratory physiotherapy should be further assessed in this setting.</AbstractText></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Kahnert</LastName><ForeName>Kathrin</ForeName><Initials>K</Initials><Identifier Source=\"ORCID\">0000-0001-9633-3368</Identifier><AffiliationInfo><Affiliation>Department of Medicine V, University Hospital, LMU Munich, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Comprehensive Pneumology Center Munich (CPC-M), Member of the German Center for Lung Research (DZL), Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Lempert</LastName><ForeName>Lilli Maria</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Department of Medicine V, University Hospital, LMU Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Behr</LastName><ForeName>J&#xfc;rgen</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Medicine V, University Hospital, LMU Munich, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Comprehensive Pneumology Center Munich (CPC-M), Member of the German Center for Lung Research (DZL), Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Elsner</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Medicine V, University Hospital, LMU Munich, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Comprehensive Pneumology Center Munich (CPC-M), Member of the German Center for Lung Research (DZL), Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Bolt</LastName><ForeName>Toki</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Medicine V, University Hospital, LMU Munich, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Comprehensive Pneumology Center Munich (CPC-M), Member of the German Center for Lung Research (DZL), Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Tufman</LastName><ForeName>Amanda</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medicine V, University Hospital, LMU Munich, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Comprehensive Pneumology Center Munich (CPC-M), Member of the German Center for Lung Research (DZL), Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Kauffmann-Guerrero</LastName><ForeName>Diego</ForeName><Initials>D</Initials><Identifier Source=\"ORCID\">0000-0003-1471-3290</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine V (Pneumology/Thoracic Oncology), University Hospital, LMU Munich, Ziemssenstra&#xdf;e 1, Munich 80336, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Comprehensive Pneumology Center Munich (CPC-M), Member of the German Center for Lung Research (DZL), Munich, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Ther Adv Respir Dis</MedlineTA><NlmUniqueID>101316317</NlmUniqueID><ISSNLinking>1753-4658</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI=\"D006801\" MajorTopicYN=\"N\">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D008168\" MajorTopicYN=\"N\">Lung</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D055752\" MajorTopicYN=\"Y\">Small Cell Lung Carcinoma</DescriptorName><QualifierName UI=\"Q000175\" MajorTopicYN=\"N\">diagnosis</QualifierName><QualifierName UI=\"Q000628\" MajorTopicYN=\"N\">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D012189\" MajorTopicYN=\"N\">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D029424\" MajorTopicYN=\"Y\">Pulmonary Disease, Chronic Obstructive</DescriptorName><QualifierName UI=\"Q000628\" MajorTopicYN=\"N\">therapy</QualifierName><QualifierName UI=\"Q000188\" MajorTopicYN=\"N\">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D011379\" MajorTopicYN=\"N\">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D008175\" MajorTopicYN=\"Y\">Lung Neoplasms</DescriptorName><QualifierName UI=\"Q000175\" MajorTopicYN=\"N\">diagnosis</QualifierName><QualifierName UI=\"Q000628\" MajorTopicYN=\"N\">therapy</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner=\"NOTNLM\"><Keyword MajorTopicYN=\"N\">SCLC</Keyword><Keyword MajorTopicYN=\"N\">body plethysmography</Keyword><Keyword MajorTopicYN=\"N\">diffusion capacity</Keyword><Keyword MajorTopicYN=\"N\">hyperinflation</Keyword><Keyword MajorTopicYN=\"N\">lung function</Keyword></KeywordList><CoiStatement>The authors declare that there is no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"medline\"><Year>2023</Year><Month>11</Month><Day>27</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2023</Year><Month>11</Month><Day>24</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2023</Year><Month>11</Month><Day>24</Day><Hour>6</Hour><Minute>52</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">37997884</ArticleId><ArticleId IdType=\"pmc\">PMC10676075</ArticleId><ArticleId IdType=\"doi\">10.1177/17534666231199670</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Torre LA, Bray F, Siegel RL, et al.. Global cancer statistics, 2012. CA Cancer J Clin 2015; 65: 87&#x2013;108.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">25651787</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahnert K, Kauffmann-Guerrero D, Huber RM. SCLC-state of the art and what does the future have in store? Clin Lung Cancer 2016; 17: 325&#x2013;333.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">27397481</ArticleId></ArticleIdList></Reference><Reference><Citation>Tas F, Aydiner A, Demir C, et al.. Serum lactate dehydrogenase levels at presentation predict outcome of patients with limited-stage small-cell lung cancer. Am J Clin Oncol-Cancer Clin Trials 2001; 24: 376&#x2013;378.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">11474266</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Guo M, Fan J, et al.. Prognostic significance of serum LDH in small cell lung cancer: a systematic review with meta-analysis. Biomarkers Cancer 2016; 16: 415&#x2013;423.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">27062698</ArticleId></ArticleIdList></Reference><Reference><Citation>Proctor MJ, Morrison DS, Talwar D, et al.. A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow inflammation outcome study. Eur J Cancer 2011; 47: 2633&#x2013;2641.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">21724383</ArticleId></ArticleIdList></Reference><Reference><Citation>Minami S, Ogata Y, Ihara S, et al.. Pretreatment Glasgow prognostic score and prognostic nutritional index predict overall survival of patients with advanced small cell lung cancer. Lung Cancer-Targets Therapy 2017; 8: 249&#x2013;257.</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC5726358</ArticleId><ArticleId IdType=\"pubmed\">29263709</ArticleId></ArticleIdList></Reference><Reference><Citation>Kauffmann-Guerrero D, Kahnert K, Syunyaeva Z, et al.. Pretherapeutic inflammation predicts febrile neutropenia and reduced progression-free survival after first-line chemotherapy in SCLC. Oncol Res Treat 2018; 41: 506&#x2013;512.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">30086542</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang R, Wei Y, Hung RJ, et al.. Associated links among smoking, chronic obstructive pulmonary disease, and small cell lung cancer: a pooled analysis in the International Lung Cancer Consortium. EBioMedicine 2015; 2: 1677&#x2013;1685.</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC4740296</ArticleId><ArticleId IdType=\"pubmed\">26870794</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho O, Oh YT, Chun M, et al.. Prognostic implication of FEV1/FVC ratio for limited-stage small cell lung cancer. J Thorac Dis 2018; 10: 1797&#x2013;1805.</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC5906293</ArticleId><ArticleId IdType=\"pubmed\">29707334</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang HS, Shin AY, Yeo CD, et al.. A lower level of forced expiratory volume in one second predicts the poor prognosis of small cell lung cancer. J Thorac Dis 2018; 10: 2179&#x2013;2185.</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC5949492</ArticleId><ArticleId IdType=\"pubmed\">29850121</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SY, Choi YJ, Seo JH, et al.. Pulmonary function is implicated in the prognosis of metastatic non-small cell lung cancer but not in extended disease small cell lung cancer. J Thorac Dis 2019; 11: 4562&#x2013;4572.</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC6940228</ArticleId><ArticleId IdType=\"pubmed\">31903245</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu K, Wang J, Zhao L, et al.. The prognosis of non-small cell lung cancer combined with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Clin Respir J 2020; 14: 389&#x2013;396.</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC7187245</ArticleId><ArticleId IdType=\"pubmed\">31905419</ArticleId></ArticleIdList></Reference><Reference><Citation>Heo IR, Kim HC, Lee SJ, et al.. Impact of coexistent preserved ratio impaired spirometry on the survival of patients with lung cancer: analysis of data from the Korean Association for Lung Cancer Registry. Thorac Cancer 2021; 12: 2478&#x2013;2486.</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC8447913</ArticleId><ArticleId IdType=\"pubmed\">34337879</ArticleId></ArticleIdList></Reference><Reference><Citation>Cri&#xe9;e CP, Baur X, Berdel D, et al.. [Standardization of spirometry: 2015 update. Published by German atemwegsliga, German Respiratory Society and German Society of Occupational and Environmental Medicine]. Pneumologie 2015; 69: 147&#x2013;164.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">25750095</ArticleId></ArticleIdList></Reference><Reference><Citation>Quanjer PH, Stanojevic S, Cole TJ, et al.. Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. Eur Respir J 2012; 40: 1324&#x2013;1343.</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC3786581</ArticleId><ArticleId IdType=\"pubmed\">22743675</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanojevic S, Graham BL, Cooper BG, et al.. Official ERS technical standards: global lung function initiative reference values for the carbon monoxide transfer factor for Caucasians. Eur Respir J 2017; 50: 50.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">28893868</ArticleId></ArticleIdList></Reference><Reference><Citation>Quanjer PH, Tammeling GJ, Cotes JE, et al.. Lung volumes and forced ventilatory flows. Report working party standardization of lung function tests, European community for steel and coal. Official statement of the European respiratory society. Eur Respir J 1993; 16: 5&#x2013;40.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">8499054</ArticleId></ArticleIdList></Reference><Reference><Citation>Global Initiative for Chronic Obstructive Lung Disease. Global Strategy For Prevention, Diagnosis and Management Of COPD: 2022 Report, 2021.</Citation></Reference><Reference><Citation>Criee CP, Berdel D, J&#xf6;rres RA, et al.. Empfehlungen zur Ganzk&#xf6;rperplethysmographie (Bodyplethysmographie): Empfehlungen der Deutschen Atemwegsliga und der Deutschen Gesellschaft f&#xfc;r Pneumologie und Beatmungsmedizin: Deutsche Atemwegsliga und Deutsche Gesellschaft f&#xfc;r Pneumologie und Beatmungsmedizin, 2009.3-87185-394-1.</Citation></Reference><Reference><Citation>Das N, Topalovic M, Aerts JM, et al.. Area under the forced expiratory flow-volume loop in spirometry indicates severe hyperinflation in COPD patients. Int J Chron Obstruct Pulmon Dis 2019; 14: 409&#x2013;418.</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC6388784</ArticleId><ArticleId IdType=\"pubmed\">30863041</ArticleId></ArticleIdList></Reference><Reference><Citation>Alter P, Orszag J, Kellerer C, et al.. Prediction of air trapping or pulmonary hyperinflation by forced spirometry in COPD patients: results from COSYCONET. ERJ Open Res 2020; 6 (3):00092-2020.</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC7383055</ArticleId><ArticleId IdType=\"pubmed\">32743009</ArticleId></ArticleIdList></Reference><Reference><Citation>\n",
            "Modi P, Cascella M. Diffusing capacity of the lungs for carbon monoxide. In: Modi P. (ed.) StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing, 2023. https://www.ncbi.nlm.nih.gov/pubmed/32310609.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">32310609</ArticleId></ArticleIdList></Reference><Reference><Citation>Farago AF, Keane FK. Current standards for clinical management of small cell lung cancer. Transl Lung Cancer Res 2018; 7: 69&#x2013;79.</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC5835595</ArticleId><ArticleId IdType=\"pubmed\">29535913</ArticleId></ArticleIdList></Reference><Reference><Citation>Ju S, Lee HR, Kim JY, et al.. Impact of coexistent chronic obstructive pulmonary disease on the survival of patients with small cell lung cancer receiving chemotherapy. Thorac Cancer 2018; 9: 1271&#x2013;1278.</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC6166064</ArticleId><ArticleId IdType=\"pubmed\">30109781</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao KM, Hung CM, Shu CC, et al.. Impact of chronic obstructive pulmonary disease on the mortality of patients with small cell lung cancer. Int J Chron Obstruct Pulmon Dis 2021; 16: 3255&#x2013;3262.</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC8645948</ArticleId><ArticleId IdType=\"pubmed\">34880609</ArticleId></ArticleIdList></Reference><Reference><Citation>Mouronte-Roib&#xe1;s C, Leiro-Fern&#xe1;ndez V, Fern&#xe1;ndez-Villar A, et al.. COPD, emphysema and the onset of lung cancer. A systematic review. Cancer Lett 2016; 382: 240&#x2013;244.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">27666776</ArticleId></ArticleIdList></Reference><Reference><Citation>Divo M, Cote C, de Torres JP, et al.. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012; 186: 155&#x2013;161.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">22561964</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Z, Song X, Wu A, et al.. Pulmonary emphysema is a risk factor for radiation pneumonitis in NSCLC patients with squamous cell carcinoma after thoracic radiation therapy. Sci Rep 2017; 7: 2748.</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC5459844</ArticleId><ArticleId IdType=\"pubmed\">28584268</ArticleId></ArticleIdList></Reference><Reference><Citation>Murakami J, Ueda K, Sano F, et al.. Pulmonary emphysema and tumor microenvironment in primary lung cancer. J Surg Res 2016; 200: 690&#x2013;697.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">26428090</ArticleId></ArticleIdList></Reference><Reference><Citation>Videtic GM, Stitt LW, Dar AR, et al.. Continued cigarette smoking by patients receiving concurrent chemoradiotherapy for limited-stage small-cell lung cancer is associated with decreased survival. J Clin Oncol 2003; 21: 1544&#x2013;1549.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">12697879</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>\n",
            "XML saved to: path/to/save/xml/37997884.xml\n",
            "Details URL: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=37996867&retmode=xml&api_key=9edd38677707c08b2a96ed1a6e8c61c47408\n",
            "Details Response Content: <?xml version=\"1.0\" ?>\n",
            "<!DOCTYPE PubmedArticleSet PUBLIC \"-//NLM//DTD PubMedArticle, 1st January 2023//EN\" \"https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd\">\n",
            "<PubmedArticleSet>\n",
            "<PubmedArticle><MedlineCitation Status=\"MEDLINE\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">37996867</PMID><DateCompleted><Year>2023</Year><Month>11</Month><Day>27</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>27</Day></DateRevised><Article PubModel=\"Electronic\"><Journal><ISSN IssnType=\"Electronic\">1471-2466</ISSN><JournalIssue CitedMedium=\"Internet\"><Volume>23</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Nov</Month><Day>23</Day></PubDate></JournalIssue><Title>BMC pulmonary medicine</Title><ISOAbbreviation>BMC Pulm Med</ISOAbbreviation></Journal><ArticleTitle>Assessing the impact of socioeconomic status on incidental lung nodules at an urban safety net hospital.</ArticleTitle><Pagination><StartPage>469</StartPage><MedlinePgn>469</MedlinePgn></Pagination><ELocationID EIdType=\"pii\" ValidYN=\"Y\">469</ELocationID><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.1186/s12890-023-02726-8</ELocationID><Abstract><AbstractText Label=\"INTRODUCTION\" NlmCategory=\"BACKGROUND\">Lower socioeconomic status has been identified as an emerging risk factor for health disparities, including lung cancer outcomes. Most research investigating these outcomes includes patients from formal lung cancer screening programs. There is a paucity of studies assessing the relationship between socioeconomic status and incidental lung nodules. This study aimed to investigate the association between socioeconomic status and the size of incidental lung nodules on initial presentation at an urban safety net hospital, which did not have a formal lung cancer screening program or incidental lung nodule program.</AbstractText><AbstractText Label=\"METHODS\" NlmCategory=\"METHODS\">A retrospective chart review was conducted on patients with incidental lung nodules on CT chest imaging who were referred from primary care to a pulmonology clinic at a safety net hospital. Patients with incomplete nodule characteristics information were excluded. Data on demographics, comorbidities, smoking history, insurance type, immigration status, and geographical factors were collected. Less commonly studied determinants such as crime index, cost of living, and air quality index were also assessed. Logistic regression analysis was performed to assess relationships between nodule size and socioeconomic determinants.</AbstractText><AbstractText Label=\"RESULTS\" NlmCategory=\"RESULTS\">Out of 3,490 patients with chest CT scans, 268 patients with ILNs were included in the study. 84.7% of patients represented racial or ethnic minorities, and most patients (67.8%) had federal insurance. Patients with non-commercial insurance were more likely to have larger, inherently higher-risk nodules (&gt;&#x2009;8&#xa0;mm) compared to those with commercial insurance (OR 2.18, p 0.01). Patients from areas with higher unemployment rates were also less likely (OR 0.75, p 0.04) to have smaller nodules (&lt;&#x2009;6&#xa0;mm). Patients representing racial or ethnic minorities were also more likely to have nodules&#x2009;&gt;&#x2009;8&#xa0;mm (OR 1.6, p 0.24), and less likely to have nodules&#x2009;&lt;&#x2009;6&#xa0;mm (OR 0.6, p 0.32), however, these relationships were not statistically significant.</AbstractText><AbstractText Label=\"CONCLUSION\" NlmCategory=\"CONCLUSIONS\">This study found that lower socioeconomic status, indicated by having non-commercial insurance, was associated with larger incidental lung nodule size on initial presentation. While it is established that socioeconomic status is associated with disparities in lung cancer screening, these findings suggest that inequalities may also be present in those with incidental lung nodules. Further research is needed to understand the underlying mechanisms and develop interventions to address these disparities in incidental lung nodule evaluation and improve outcomes.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Fernandes</LastName><ForeName>Mateus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Pulmonary and Critical Care Medicine, Lenox Hill Hospital, Northwell Health, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Milla</LastName><ForeName>Cristian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Medicine, NYC Health + Hospitals/Woodhull, New York City Health and Hospitals, 760 Broadway, Brooklyn, NY, 11206, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Nephrology, SUNY Downstate/Health Sciences Center at Brooklyn, NY, Brooklyn, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Gubran</LastName><ForeName>Ahmed</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medicine, NYC Health + Hospitals/Woodhull, New York City Health and Hospitals, 760 Broadway, Brooklyn, NY, 11206, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Barrazueta</LastName><ForeName>Sandra</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medicine, NYC Health + Hospitals/Woodhull, New York City Health and Hospitals, 760 Broadway, Brooklyn, NY, 11206, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Altonen</LastName><ForeName>Brian</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Medicine, NYC Health + Hospitals/Woodhull, New York City Health and Hospitals, 760 Broadway, Brooklyn, NY, 11206, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research and Administration, New York City Health and Hospitals, NY, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>DiVittis</LastName><ForeName>Anthony</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medicine, NYC Health + Hospitals/Woodhull, New York City Health and Hospitals, 760 Broadway, Brooklyn, NY, 11206, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><CollectiveName>Woodhull Resident Research Team</CollectiveName></Author><Author ValidYN=\"Y\"><LastName>Kuperberg</LastName><ForeName>Stephen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medicine, NYC Health + Hospitals/Woodhull, New York City Health and Hospitals, 760 Broadway, Brooklyn, NY, 11206, USA. kuperbes2@nychhc.org.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pulmonary and Critical Care Medicine, New York University Grossman School of Medicine, NY, New York, USA. kuperbes2@nychhc.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2023</Year><Month>11</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Pulm Med</MedlineTA><NlmUniqueID>100968563</NlmUniqueID><ISSNLinking>1471-2466</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI=\"D006801\" MajorTopicYN=\"N\">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D008175\" MajorTopicYN=\"Y\">Lung Neoplasms</DescriptorName><QualifierName UI=\"Q000000981\" MajorTopicYN=\"N\">diagnostic imaging</QualifierName><QualifierName UI=\"Q000453\" MajorTopicYN=\"N\">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D012189\" MajorTopicYN=\"N\">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D055088\" MajorTopicYN=\"N\">Early Detection of Cancer</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D064876\" MajorTopicYN=\"N\">Safety-net Providers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D033162\" MajorTopicYN=\"N\">Incidental Findings</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D008168\" MajorTopicYN=\"N\">Lung</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D012923\" MajorTopicYN=\"N\">Social Class</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D003074\" MajorTopicYN=\"Y\">Solitary Pulmonary Nodule</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner=\"NOTNLM\"><Keyword MajorTopicYN=\"N\">Deprivation</Keyword><Keyword MajorTopicYN=\"N\">Disadvantage</Keyword><Keyword MajorTopicYN=\"N\">Disparity</Keyword><Keyword MajorTopicYN=\"N\">Inequity</Keyword><Keyword MajorTopicYN=\"N\">Lung cancer</Keyword><Keyword MajorTopicYN=\"N\">Lung nodule</Keyword><Keyword MajorTopicYN=\"N\">Socioeconomic</Keyword></KeywordList><CoiStatement>This study was approved by the New York University Institutional Review Board (i22- 00331), and it is in accordance with the Helsinki Declaration (IV adaptation). The IRB determined that written consent may be waived due to the minimal risk of this study to participants. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The authors declare no competing interests.</CoiStatement><InvestigatorList><Investigator ValidYN=\"Y\"><LastName>Rashmi</LastName><ForeName>Prama</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN=\"Y\"><LastName>Bess</LastName><ForeName>Olva</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN=\"Y\"><LastName>Asif</LastName><ForeName>Haris</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN=\"Y\"><LastName>Nwachukwu</LastName><ForeName>Ifediba</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN=\"Y\"><LastName>Aroyewun</LastName><ForeName>Opeyemi</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN=\"Y\"><LastName>Martinez</LastName><ForeName>Alberto</ForeName><Initials>A</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"received\"><Year>2023</Year><Month>8</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus=\"accepted\"><Year>2023</Year><Month>10</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus=\"medline\"><Year>2023</Year><Month>11</Month><Day>27</Day><Hour>12</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2023</Year><Month>11</Month><Day>24</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2023</Year><Month>11</Month><Day>23</Day><Hour>23</Hour><Minute>56</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">37996867</ArticleId><ArticleId IdType=\"pmc\">PMC10668357</ArticleId><ArticleId IdType=\"doi\">10.1186/s12890-023-02726-8</ArticleId><ArticleId IdType=\"pii\">10.1186/s12890-023-02726-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Non-Small Cell Lung Cancer Treatment (PDQ&#xae;)&#x2013;Health Professional Version. National Cancer Institute. Updated November 18, 2020. Accessed March 6th 2023.&#xa0;https://www.cancer.gov/types/lung/hp/non-small-cell-lung-treatment-pdq</Citation></Reference><Reference><Citation>Adams SJ, Stone E, Baldwin DR, Vliegenthart R, Lee P, Fintelmann FJ. Lung cancer screening. Lancet (London, England) 2023;401(10374):390&#x2013;408. doi: 10.1016/S0140-6736(22)01694-4.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/S0140-6736(22)01694-4</ArticleId><ArticleId IdType=\"pubmed\">36563698</ArticleId></ArticleIdList></Reference><Reference><Citation>Potter AL, Bajaj SS, Yang C-FJ. The 2021 USPSTF lung cancer screening guidelines: a new frontier. Lancet Respir Med. 2021;9(7):689&#x2013;91. doi: 10.1016/S2213-2600(21)00210-1.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/S2213-2600(21)00210-1</ArticleId><ArticleId IdType=\"pubmed\">33965004</ArticleId></ArticleIdList></Reference><Reference><Citation>Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975&#x2013;2016. National Cancer Institute; 2019. https://seer.cancer.gov/csr/1975_2016/</Citation></Reference><Reference><Citation>National Lung Screening Trial Research T. Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5):395&#x2013;409. doi: 10.1056/NEJMoa1102873.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1056/NEJMoa1102873</ArticleId><ArticleId IdType=\"pmc\">PMC4356534</ArticleId><ArticleId IdType=\"pubmed\">21714641</ArticleId></ArticleIdList></Reference><Reference><Citation>National Lung Screening Trial Research T. Church TR, Black WC, Aberle DR, Berg CD, Clingan KL, et al. Results of initial low-dose computed tomographic screening for lung cancer. N Engl J Med. 2013;368(21):1980&#x2013;91. doi: 10.1056/NEJMoa1209120.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1056/NEJMoa1209120</ArticleId><ArticleId IdType=\"pmc\">PMC3762603</ArticleId><ArticleId IdType=\"pubmed\">23697514</ArticleId></ArticleIdList></Reference><Reference><Citation>De Koning HJ, Van Der Aalst CM, De Jong PA, Scholten ET, Nackaerts K, Heuvelmans MA, et al. Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial. N Engl J Med. 2020;382(6):503&#x2013;513. doi: 10.1056/NEJMoa1911793.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1056/NEJMoa1911793</ArticleId><ArticleId IdType=\"pubmed\">31995683</ArticleId></ArticleIdList></Reference><Reference><Citation>Gould MK, Tang T, Liu ILA, Lee J, Zheng C, Danforth KN, et al. Recent Trends in the Identification of Incidental Pulmonary Nodules. American Journal of Respiratory and Critical Care Medicine. Am J Respir Crit Care Med. 2021;159(6):2477&#x2013;82.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">26214244</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Gerpen R. Creating an Incidental Pulmonary Nodule Safety-Net Program. Chest. 2021;159(6):2477&#x2013;2482. doi: 10.1016/j.chest.2020.12.053.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.chest.2020.12.053</ArticleId><ArticleId IdType=\"pubmed\">33434500</ArticleId></ArticleIdList></Reference><Reference><Citation>Osarogiagbon RU, Liao W, Faris NR, Meadows-Taylor M, Fehnel C, Lane J, et al. Lung Cancer Diagnosed Through Screening, Lung Nodule, and Neither Program: A Prospective Observational Study of the Detecting Early Lung Cancer (DELUGE) in the Mississippi Delta Cohort. J Clin Oncol. 2022;40(19):2094&#x2013;2105. doi: 10.1200/JCO.21.02496.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1200/JCO.21.02496</ArticleId><ArticleId IdType=\"pmc\">PMC9242408</ArticleId><ArticleId IdType=\"pubmed\">35258994</ArticleId></ArticleIdList></Reference><Reference><Citation>Steiling K, Kathuria H, Echieh CP, Ost DE, Rivera MP, Begnaud A, et al. Research Priorities for Interventions to Address Health Disparities in Lung Nodule Management: An Official American Thoracic Society Research Statement. Am J Respir Crit Care Med. 2023;207(6):e31&#x2013;e46. doi: 10.1164/rccm.202212-2216ST.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1164/rccm.202212-2216ST</ArticleId><ArticleId IdType=\"pmc\">PMC10037482</ArticleId><ArticleId IdType=\"pubmed\">36920066</ArticleId></ArticleIdList></Reference><Reference><Citation>LeMense GP, Waller EA, Campbell C, Bowen T. Development and outcomes of a comprehensive multidisciplinary incidental lung nodule and lung cancer screening program. BMC Pulm Med. 2020;20(1):115. doi: 10.1186/s12890-020-1129-7.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1186/s12890-020-1129-7</ArticleId><ArticleId IdType=\"pmc\">PMC7191779</ArticleId><ArticleId IdType=\"pubmed\">32349709</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown, D. Metropolitan Anchor Hospital (MAH) Case Study. American Hospital Association. June 2022. Accessed 05/24/2023. https://www.aha.org/case-studies/2022-11-22-nyc-health-hospitals-new-york</Citation></Reference><Reference><Citation>MacMahon H, Naidich DP, Goo JM, Lee KS, Leung ANC, Mayo JR, et al. Guidelines for Management of Incidental Pulmonary Nodules Detected on CT Images: From the Fleischner Society 2017. Radiology. 2017;284(1):228&#x2013;243. doi: 10.1148/radiol.2017161659.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1148/radiol.2017161659</ArticleId><ArticleId IdType=\"pubmed\">28240562</ArticleId></ArticleIdList></Reference><Reference><Citation>Advameg, Inc. City-Data.com. New York City Bigger Cities. Accessed 06/12/2023. https://www.city-data.com/city/New-York.html.</Citation></Reference><Reference><Citation>Castro S, Sosa E, Lozano V, Akhtar A, Love K, Duffels J, et al. The impact of income and education on lung cancer screening utilization, eligibility, and outcomes: a narrative review of socioeconomic disparities in lung cancer screening. J Thorac Dis. 2021;13(6):3745&#x2013;3757. doi: 10.21037/jtd-20-3281.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.21037/jtd-20-3281</ArticleId><ArticleId IdType=\"pmc\">PMC8264678</ArticleId><ArticleId IdType=\"pubmed\">34277066</ArticleId></ArticleIdList></Reference><Reference><Citation>Rivera MP, Katki HA, Tanner NT, Triplette M, Sakoda LC, Wiener RS, et al. Addressing Disparities in Lung Cancer Screening Eligibility and Healthcare Access. An Official American Thoracic Society Statement. Am J Respir Crit Care Med. 2020;202(7):e95&#x2013;e112. doi: 10.1164/rccm.202008-3053ST.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1164/rccm.202008-3053ST</ArticleId><ArticleId IdType=\"pmc\">PMC7528802</ArticleId><ArticleId IdType=\"pubmed\">33000953</ArticleId></ArticleIdList></Reference><Reference><Citation>Redondo-S&#xe1;nchez D, Petrova D, Rodr&#xed;guez-Barranco M, Fern&#xe1;ndez-Navarro P, Jim&#xe9;nez-Mole&#xf3;n JJ, S&#xe1;nchez M-J. Socio-Economic Inequalities in Lung Cancer Outcomes: An Overview of Systematic Reviews. Cancers. 2022;14(2):398. doi: 10.3390/cancers14020398.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3390/cancers14020398</ArticleId><ArticleId IdType=\"pmc\">PMC8773607</ArticleId><ArticleId IdType=\"pubmed\">35053559</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaplan GA. Social Determinants of Health, 2nd Edition. M Marmot and R Wilkinson (eds). Oxford: Oxford University Press, 2006, pp. 376, $57.50. ISBN: 9780198565895. International Journal of Epidemiology. 2006;35(4):1111&#x2013;2.</Citation></Reference><Reference><Citation>Sanderson M, Aldrich MC, Levine RS, Kilbourne B, Cai Q, Blot WJ. Neighbourhood deprivation and lung cancer risk: a nested case-control study in the USA. BMJ Open. 2018;8(9):e021059. doi: 10.1136/bmjopen-2017-021059.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1136/bmjopen-2017-021059</ArticleId><ArticleId IdType=\"pmc\">PMC6144393</ArticleId><ArticleId IdType=\"pubmed\">30206077</ArticleId></ArticleIdList></Reference><Reference><Citation>National Lung Screening Trial Research T. Aberle DR, Adams AM, Berg CD, Clapp JD, Clingan KL, et al. Baseline characteristics of participants in the randomized national lung screening trial. J Natl Cancer Inst . 2010;102(23):1771&#x2013;9. doi: 10.1093/jnci/djq434.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/jnci/djq434</ArticleId><ArticleId IdType=\"pmc\">PMC2994863</ArticleId><ArticleId IdType=\"pubmed\">21119104</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts TJ, Lennes IT, Hawari S, Sequist LV, Park ER, Willers H, et al. Integrated, Multidisciplinary Management of Pulmonary Nodules Can Streamline Care and Improve Adherence to Recommendations. Oncologist. 2020;25(5):431&#x2013;437. doi: 10.1634/theoncologist.2019-0519.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1634/theoncologist.2019-0519</ArticleId><ArticleId IdType=\"pmc\">PMC7216451</ArticleId><ArticleId IdType=\"pubmed\">31876321</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmid-Bindert G, Vogel-Claussen J, G&#xfc;tz S, Fink J, Hoffmann H, Eichhorn ME, et al. Incidental Pulmonary Nodules - What Do We Know in 2022. Respiration. 2022;101(11):1024&#x2013;1034. doi: 10.1159/000526818.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1159/000526818</ArticleId><ArticleId IdType=\"pmc\">PMC9945197</ArticleId><ArticleId IdType=\"pubmed\">36228594</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh GK, Jemal A. Socioeconomic and Racial/Ethnic Disparities in Cancer Mortality, Incidence, and Survival in the United States, 1950&#x2013;2014: Over Six Decades of Changing Patterns and Widening Inequalities. J Environ Public Health. 2017;2017:1&#x2013;19. doi: 10.1155/2017/2819372.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1155/2017/2819372</ArticleId><ArticleId IdType=\"pmc\">PMC5376950</ArticleId><ArticleId IdType=\"pubmed\">28408935</ArticleId></ArticleIdList></Reference><Reference><Citation>Pampel FC, Krueger PM, Denney JT. Socioeconomic Disparities in Health Behaviors. Ann Rev Sociol. 2010;36:349&#x2013;370. doi: 10.1146/annurev.soc.012809.102529.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1146/annurev.soc.012809.102529</ArticleId><ArticleId IdType=\"pmc\">PMC3169799</ArticleId><ArticleId IdType=\"pubmed\">21909182</ArticleId></ArticleIdList></Reference><Reference><Citation>Siahpush M, Singh GK, Jones PR, Timsina LR. Racial/ethnic and socioeconomic variations in duration of smoking: results from 2003, 2006 and 2007 Tobacco Use Supplement of the Current Population Survey. J Public Health (Oxf) 2010;32(2):210&#x2013;218. doi: 10.1093/pubmed/fdp104.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/pubmed/fdp104</ArticleId><ArticleId IdType=\"pubmed\">19892784</ArticleId></ArticleIdList></Reference><Reference><Citation>Carter-Harris L, Slaven JE, Monahan PO, Shedd-Steele R, Hanna N, Rawl SM. Understanding lung cancer screening behavior: Racial, gender, and geographic differences among Indiana long-term smokers. Prev Med Rep. 2018;10:49&#x2013;54. doi: 10.1016/j.pmedr.2018.01.018.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.pmedr.2018.01.018</ArticleId><ArticleId IdType=\"pmc\">PMC5852404</ArticleId><ArticleId IdType=\"pubmed\">29552458</ArticleId></ArticleIdList></Reference><Reference><Citation>Screening for lung cancer with low dose computed tomography (LDCT). Centers for Medicare &amp; Medicaid Services. (2022, February 10). Retrieved March 10, 2023, from https://www.cms.gov/medicare-coverage-database/view/ncacal-decision-memo.aspx?proposed=N&amp;ncaid=304</Citation></Reference><Reference><Citation>Sempokuya T, Patel KP, Azawi M, Ma J, Wong LL. Increased morbidity and mortality of hepatocellular carcinoma patients in lower cost of living areas. World J Clin Cases. 2021;9(23):6734&#x2013;6746. doi: 10.12998/wjcc.v9.i23.6734.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.12998/wjcc.v9.i23.6734</ArticleId><ArticleId IdType=\"pmc\">PMC8362534</ArticleId><ArticleId IdType=\"pubmed\">34447820</ArticleId></ArticleIdList></Reference><Reference><Citation>Air Quality Index (AQI) forecast and current observations for New York State. Air Quality Index (AQI) Forecast and Current Observations for New York State - NYS Dept. of Environmental Conservation. (n.d.). Retrieved March 13, 2023, from https://www.dec.ny.gov/chemical/34985.html</Citation></Reference><Reference><Citation>Hughes BD, Maharsi S, Obiarinze RN, Mehta HB, Nishi S, Okereke IC. Correlation between air quality and lung cancer incidence: A county by county analysis. Surgery. 2019;166(6):1099&#x2013;1104. doi: 10.1016/j.surg.2019.05.036.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.surg.2019.05.036</ArticleId><ArticleId IdType=\"pmc\">PMC7063959</ArticleId><ArticleId IdType=\"pubmed\">31296429</ArticleId></ArticleIdList></Reference><Reference><Citation>Institute of Medicine Committee on Health L. In: Nielsen-Bohlman L, Panzer AM, Kindig DA, editors. Health Literacy: A Prescription to End Confusion. Washington (DC): National Academies Press (US), 2004.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">25009856</ArticleId></ArticleIdList></Reference><Reference><Citation>Melson JE, Imperiale TF, Itzkowitz SH, Llor X, Kochman ML, Grady WM, et al. AGA White Paper: Roadmap for the Future of Colorectal Cancer Screening in the United States. Clin Gastroenterol Hepatol. 2020;18(12):2667&#x2013;78.e2. doi: 10.1016/j.cgh.2020.06.053.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.cgh.2020.06.053</ArticleId><ArticleId IdType=\"pubmed\">32634626</ArticleId></ArticleIdList></Reference><Reference><Citation>Steiling K, Loui T, Asokan S, Nims S, Moreira P, Rebello A, et al. Age, Race, and Income Are Associated With Lower Screening Rates at a Safety Net Hospital. Ann Thorac Surg. 2020;109(5):1544&#x2013;1550. doi: 10.1016/j.athoracsur.2019.11.052.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.athoracsur.2019.11.052</ArticleId><ArticleId IdType=\"pubmed\">31981498</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>\n",
            "XML saved to: path/to/save/xml/37996867.xml\n",
            "Details URL: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=37995046&retmode=xml&api_key=9edd38677707c08b2a96ed1a6e8c61c47408\n",
            "Details Response Content: <?xml version=\"1.0\" ?>\n",
            "<!DOCTYPE PubmedArticleSet PUBLIC \"-//NLM//DTD PubMedArticle, 1st January 2023//EN\" \"https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd\">\n",
            "<PubmedArticleSet>\n",
            "<PubmedArticle><MedlineCitation Status=\"Publisher\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">37995046</PMID><DateRevised><Year>2023</Year><Month>11</Month><Day>23</Day></DateRevised><Article PubModel=\"Print-Electronic\"><Journal><ISSN IssnType=\"Electronic\">1534-6307</ISSN><JournalIssue CitedMedium=\"Internet\"><PubDate><Year>2023</Year><Month>Nov</Month><Day>23</Day></PubDate></JournalIssue><Title>Current rheumatology reports</Title><ISOAbbreviation>Curr Rheumatol Rep</ISOAbbreviation></Journal><ArticleTitle>Multimorbidity in Rheumatoid Arthritis: Literature Review and Future Directions.</ArticleTitle><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.1007/s11926-023-01121-w</ELocationID><Abstract><AbstractText Label=\"PURPOSE OF REVIEW\" NlmCategory=\"OBJECTIVE\">To offer a narrative review of literature and an update on rheumatoid arthritis (RA) multimorbidity research over the past five years as well as future directions.</AbstractText><AbstractText Label=\"RECENT FINDINGS\" NlmCategory=\"RESULTS\">Patients with RA experience higher prevalence of multimorbidity (31-86% vs 18-71% in non-RA) and faster accumulation of comorbidities. Patients with multimorbidity have worse outcomes compared to non-RA multimorbid patients and RA without multimorbidity including mortality, cardiac events, and hospitalizations. Comorbid disease clusters often included: cardiopulmonary, cardiometabolic, and depression and pain-related conditions. High-frequency comorbidities included interstitial lung disease, asthma, chronic obstructive pulmonary disease, cardiovascular disease, fibromyalgia, osteoarthritis, and osteoporosis, thyroid disorders, hypertension, and cancer. Furthermore, patients with RA and multimorbidity are paradoxically at increased risk of high RA disease activity but experience a lower likelihood of biologic use and more biologic failures. RA patients experience higher prevalence of multimorbidity and worse outcomes versus non-RA and RA without multimorbidity. Findings call for further studies.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Katz</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Medicine, Rheumatology Division, University of Wisconsin School of Medicine and Public Health, 1685 Highland Ave #4132, Madison, WI, 53705, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Bartels</LastName><ForeName>Christie M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Department of Medicine, Rheumatology Division, University of Wisconsin School of Medicine and Public Health, 1685 Highland Ave #4132, Madison, WI, 53705, USA. cb4@medicine.wisc.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN=\"Y\"><Grant><GrantID>1UL1TR002373</GrantID><Agency>NIH-CTSA</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType><PublicationType UI=\"D016454\">Review</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2023</Year><Month>11</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Curr Rheumatol Rep</MedlineTA><NlmUniqueID>100888970</NlmUniqueID><ISSNLinking>1523-3774</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner=\"NOTNLM\"><Keyword MajorTopicYN=\"N\">COPD</Keyword><Keyword MajorTopicYN=\"N\">Comorbidity</Keyword><Keyword MajorTopicYN=\"N\">Depression</Keyword><Keyword MajorTopicYN=\"N\">Multimorbidity</Keyword><Keyword MajorTopicYN=\"N\">Pain</Keyword><Keyword MajorTopicYN=\"N\">Rheumatoid Arthritis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"accepted\"><Year>2023</Year><Month>10</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus=\"medline\"><Year>2023</Year><Month>11</Month><Day>23</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2023</Year><Month>11</Month><Day>23</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2023</Year><Month>11</Month><Day>23</Day><Hour>11</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">37995046</ArticleId><ArticleId IdType=\"doi\">10.1007/s11926-023-01121-w</ArticleId><ArticleId IdType=\"pii\">10.1007/s11926-023-01121-w</ArticleId></ArticleIdList><ReferenceList><Title>References&#xa0;</Title><ReferenceList><Title>Papers of particular interest, published recently, have been highlighted as: &#x2022; Of importance &#x2022;&#x2022; Of major importance</Title><Reference><Citation>Skou ST, Mair FS, Fortin M, Guthrie B, Nunes BP, Miranda JJ, et al. Multimorbidity. Nat Rev Dis Prim. 2022;8(1):48.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/s41572-022-00376-4</ArticleId><ArticleId IdType=\"pubmed\">35835758</ArticleId></ArticleIdList></Reference><Reference><Citation>Doran MF, Pond GR, Crowson CS, O&#x2019;Fallon WM, Gabriel SE. Trends in incidence and mortality in rheumatoid arthritis in Rochester, Minnesota, over a forty-year period. Arthritis Rheum. 2002;46(3):625&#x2013;31.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1002/art.509</ArticleId><ArticleId IdType=\"pubmed\">11920397</ArticleId></ArticleIdList></Reference><Reference><Citation>Naz SM, Symmons DP. Mortality in established rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2007;21(5):871&#x2013;83.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.berh.2007.05.003</ArticleId><ArticleId IdType=\"pubmed\">17870033</ArticleId></ArticleIdList></Reference><Reference><Citation>Figus FA, Piga M, Azzolin I, McConnell R, Iagnocco A. Rheumatoid arthritis: extra-articular manifestations and comorbidities. Autoimmun Rev. 2021;20(4):102776.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.autrev.2021.102776</ArticleId><ArticleId IdType=\"pubmed\">33609792</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruscitti P, Di Benedetto P, Berardicurti O, Liakouli V, Carubbi F, Cipriani P, et al. Adipocytokines in rheumatoid arthritis: the hidden link between inflammation and cardiometabolic comorbidities. J Immunol Res. 2018;2018:8410182.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1155/2018/8410182</ArticleId><ArticleId IdType=\"pubmed\">30584543</ArticleId><ArticleId IdType=\"pmc\">6280248</ArticleId></ArticleIdList></Reference><Reference><Citation>Yurkovich M, Avina-Zubieta JA, Thomas J, Gorenchtein M, Lacaille D. A systematic review identifies valid comorbidity indices derived from administrative health data. J Clin Epidemiol. 2015;68(1):3&#x2013;14.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jclinepi.2014.09.010</ArticleId><ArticleId IdType=\"pubmed\">25441702</ArticleId></ArticleIdList></Reference><Reference><Citation>England BR, Thiele GM, Anderson DR, Mikuls TR. Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications. BMJ. 2018;361:k1036.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1136/bmj.k1036</ArticleId><ArticleId IdType=\"pubmed\">29685876</ArticleId><ArticleId IdType=\"pmc\">6889899</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee EE, Shin A, Lee J, Lee JH, Ha YJ, Lee YJ, et al. All-cause and cause-specific mortality of patients with rheumatoid arthritis in Korea: a nation-wide population-based study. Joint Bone Spine. 2022;89(1):105269.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jbspin.2021.105269</ArticleId><ArticleId IdType=\"pubmed\">34534689</ArticleId></ArticleIdList></Reference><Reference><Citation>Sambamoorthi U, Tan X, Deb A. Multiple chronic conditions and healthcare costs among adults. Expert Rev Pharmacoecon Outcomes Res. 2015;15(5):823&#x2013;32.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1586/14737167.2015.1091730</ArticleId><ArticleId IdType=\"pubmed\">26400220</ArticleId><ArticleId IdType=\"pmc\">4698815</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x2022; Yoshida K, Lin TC, Wei MY, Malspeis S, Chu SH, Camargo CA Jr, et al. Roles of postdiagnosis accumulation of morbidities and lifestyle changes in excess total and cause-specific mortality risk in rheumatoid arthritis. Arthritis Care Res (Hoboken). 2021;73(2):188&#x2013;98. (Multimorbiidty was found to account for a substantial amount of the excess mortality seen in the RA patients.)</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1002/acr.24120</ArticleId><ArticleId IdType=\"pubmed\">31811708</ArticleId></ArticleIdList></Reference><Reference><Citation>Crowson CS, Gunderson TM, Dykhoff HJ, Myasoedova E, Atkinson EJ, Kronzer VL, et al. Comprehensive assessment of multimorbidity burden in a population-based cohort of patients with rheumatoid arthritis. RMD Open. 2022;8(1):e002022.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1136/rmdopen-2021-002022</ArticleId><ArticleId IdType=\"pubmed\">35042730</ArticleId><ArticleId IdType=\"pmc\">8768925</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x2022; England BR, Roul P, Yang Y, Sayles H, Yu F, Michaud K, et al. Burden and trajectory of multimorbidity in rheumatoid arthritis: a matched cohort study from 2006 to 2015. Ann Rheum Dis. 2021;80(3):286&#x2013;92. (Described how RA patients accumulate chronic conditions at a higher rate than non-RA patients)</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1136/annrheumdis-2020-218282</ArticleId><ArticleId IdType=\"pubmed\">33032999</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x2022;&#x2022; England BR, Yang Y, Roul P, Haas C, Najjar L, Sayles H, et al. Identification of multimorbidity patterns in rheumatoid arthritis through machine learning. Arthritis Care Res (Hoboken). 2023;75(2):220&#x2013;30. (One of two studies to describe phenotypic patterns of multimorbidity in RA patients, compared commercial and VHA data.)</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1002/acr.24956</ArticleId><ArticleId IdType=\"pubmed\">35588095</ArticleId></ArticleIdList></Reference><Reference><Citation>Gunderson TM, Myasoedova E, Davis JM 3rd, Crowson CS. Multimorbidity burden in rheumatoid arthritis: a population-based cohort study. J Rheumatol. 2021;48(11):1648&#x2013;54.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3899/jrheum.200971</ArticleId><ArticleId IdType=\"pubmed\">33589552</ArticleId><ArticleId IdType=\"pmc\">8364559</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang YJ, Chen JS, Luo SF, Kuo CF. Comparison of indexes to measure comorbidity burden and predict all-cause mortality in rheumatoid arthritis. J Clin Med. 2021;10(22):5460.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3390/jcm10225460</ArticleId><ArticleId IdType=\"pubmed\">34830741</ArticleId><ArticleId IdType=\"pmc\">8618526</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x2022; Kronzer VL, Dykhoff HJ, Stevens MA, Myasoedova E, Davis JM 3rd, Crowson CS. Racial differences in multimorbidity and comorbidities in rheumatoid arthritis. Arthritis Care Res (Hoboken). 2023;75(1):76&#x2013;84. (Described how RA participants had an increased risk of multimorbidity and substantial multiorbidity compared to non-RA participants and that the odds of multimorbidity vary by race in non-RA patients but are similar across racial groups in RA.)</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1002/acr.25020</ArticleId><ArticleId IdType=\"pubmed\">36094853</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x2022;&#x2022; McLoone P, Jani BD, Siebert S, Morton FR, Canning J, Macdonald S, et al. Classification of long-term condition patterns in rheumatoid arthritis and associations with adverse health events: a UK Biobank cohort study. J Multimorbidity Comorbidity. 2023;13:26335565221148616. (Found signficant phenotypic clusters in RA and reported that RA patients with these clusters had higher rates of adverse outcomes.)</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1177/26335565221148616</ArticleId></ArticleIdList></Reference><Reference><Citation>Morton FR, Jani BD, Mair FS, McLoone P, Canning J, Macdonald S, et al. Association between risk, duration and cause of hospitalisations in people with rheumatoid arthritis and multimorbidity in the UK Biobank and Scottish Early Rheumatoid Arthritis (SERA) cohorts: longitudinal observational study. Semin Arthritis Rheum. 2023;58:152130.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.semarthrit.2022.152130</ArticleId><ArticleId IdType=\"pubmed\">36459724</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x2022; Armagan B, Sari A, Erden A, Kilic L, Erdat EC, Kilickap S, et al. Starting of biological disease modifying antirheumatic drugs may be postponed in rheumatoid arthritis patients with multimorbidity: single center real life results. Medicine (Baltimore). 2018;97(13):e9930. (Identified how multimorbid RA patients experience longer time to biologic therapy compared to RA patients without multimorbidity.)</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1097/MD.0000000000009930</ArticleId><ArticleId IdType=\"pubmed\">29595700</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x2022; Biggioggero M, Mesina F, Favalli EG. The use of rheumatic disease comorbidity index for predicting clinical response and retention rate in a cohort of rheumatoid arthritis patients receiving tumor necrosis factor alpha inhibitors. Biomed Res Int. 2019;2019:6107217. (Described how multimorbidity serves as a predictor of poor outcomes in RA and higher rates of tumor necrosis factor alpha inhibitor failure.)</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1155/2019/6107217</ArticleId><ArticleId IdType=\"pubmed\">30733963</ArticleId><ArticleId IdType=\"pmc\">6348828</ArticleId></ArticleIdList></Reference><Reference><Citation>Busby AD, Wason J, Pratt AG, Young A, Isaacs JD, Nikiphorou E. Predictors of poor function in RA based on two prospective UK inception cohorts. Do comorbidities matter? Rheumatology (Oxford). 2022;61(4):1563&#x2013;9.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/rheumatology/keab598</ArticleId><ArticleId IdType=\"pubmed\">34302478</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis JM 3rd, Myasoedova E, Gunderson TM, Crowson CS. Multimorbidity and fatigue in rheumatoid arthritis: a cross-sectional study of a population-based cohort. Rheumatol Ther. 2020;7(4):979&#x2013;91.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s40744-020-00247-y</ArticleId><ArticleId IdType=\"pubmed\">33113092</ArticleId><ArticleId IdType=\"pmc\">7695756</ArticleId></ArticleIdList></Reference><Reference><Citation>Luque Ramos A, Redeker I, Hoffmann F, Callhoff J, Zink A, Albrecht K. Comorbidities in patients with rheumatoid arthritis and their association with patient-reported outcomes: results of claims data linked to questionnaire survey. J Rheumatol. 2019;46(6):564&#x2013;71.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3899/jrheum.180668</ArticleId><ArticleId IdType=\"pubmed\">30647170</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x2022; Ruscitti P, Di Muzio C, Conforti A, Di Cola I, Pavlych V, Navarini L, et al. Cardiometabolic multimorbidity may identify a more severe subset of rheumatoid arthritis, results from a &#x201c;real-life&#x201d; study. Medicine (Baltimore). 2023;102(14):e33362. (Described a cardiometabolic phenotype of multimorbidity that predicts worse outcomes in RA patients.)</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1097/MD.0000000000033362</ArticleId><ArticleId IdType=\"pubmed\">37026953</ArticleId></ArticleIdList></Reference><Reference><Citation>Tournadre A, Pereira B, Gossec L, Soubrier M, Dougados M. Impact of comorbidities on fatigue in rheumatoid arthritis patients: results from a nurse-led program for comorbidities management (COMEDRA). Joint Bone Spine. 2019;86(1):55&#x2013;60.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jbspin.2018.06.010</ArticleId><ArticleId IdType=\"pubmed\">30025953</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x2022;&#x2022; McQueenie R, Nicholl BI, Jani BD, Canning J, Macdonald S, McCowan C, et al. Patterns of multimorbidity and their effects on adverse outcomes in rheumatoid arthritis: a study of 5658 UK Biobank participants. BMJ Open. 2020;10(11):e038829. (Described the adverse outcomes in multimorbid RA patients and the synergistic effects of some comorbidites and RA on all cause mortality)</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1136/bmjopen-2020-038829</ArticleId><ArticleId IdType=\"pubmed\">33234629</ArticleId><ArticleId IdType=\"pmc\">7684828</ArticleId></ArticleIdList></Reference><Reference><Citation>Radner H. Multimorbidity in rheumatic conditions. Wien Klin Wochenschr. 2016;128(21&#x2013;22):786&#x2013;90.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s00508-016-1090-x</ArticleId><ArticleId IdType=\"pubmed\">27738754</ArticleId><ArticleId IdType=\"pmc\">5104809</ArticleId></ArticleIdList></Reference><Reference><Citation>Barber CEH, Bartels CM. Making sense of multimorbidity in rheumatoid arthritis. Arthritis Care Res. 2023;75(2):207&#x2013;9.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1002/acr.24986</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xf8;ppenthin K, Esbensen BA, &#xd8;stergaard M, Ibsen R, Kjellberg J, Jennum P. Morbidity and mortality in patients with rheumatoid arthritis compared with an age- and sex-matched control population: a nationwide register study. J Comorbidity. 2019;9:2235042x19853484.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1177/2235042X19853484</ArticleId></ArticleIdList></Reference><Reference><Citation>van den Hoek J, Boshuizen HC, Roorda LD, Tijhuis GJ, Nurmohamed MT, van den Bos GA, et al. Mortality in patients with rheumatoid arthritis: a 15-year prospective cohort study. Rheumatol Int. 2017;37(4):487&#x2013;93.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s00296-016-3638-5</ArticleId><ArticleId IdType=\"pubmed\">28032180</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacaille D, Avina-Zubieta JA, Sayre EC, Abrahamowicz M. Improvement in 5-year mortality in incident rheumatoid arthritis compared with the general population&#x2014;closing the mortality gap. Ann Rheum Dis. 2017;76(6):1057&#x2013;63.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1136/annrheumdis-2016-209562</ArticleId><ArticleId IdType=\"pubmed\">28031164</ArticleId></ArticleIdList></Reference><Reference><Citation>Listing J, Kekow J, Manger B, Burmester GR, Pattloch D, Zink A, et al. Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNF&#x3b1; inhibitors and rituximab. Ann Rheum Dis. 2015;74(2):415&#x2013;21.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1136/annrheumdis-2013-204021</ArticleId><ArticleId IdType=\"pubmed\">24291654</ArticleId></ArticleIdList></Reference><Reference><Citation>Almutairi KB, Inderjeeth CA, Preen DB, Keen HI, Nossent JC. Mortality trends among patients with rheumatoid arthritis in Western Australia. Rheumatol Ther. 2023;10(4):1021&#x2013;37.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s40744-023-00562-0</ArticleId><ArticleId IdType=\"pubmed\">37335433</ArticleId><ArticleId IdType=\"pmc\">10326173</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartels CM, Ramly E, Panyard D, Lauver DR, Johnson HM, Lewicki K, et al. BP Connect Toolkit Madison, WI: University of Wisconsin&#x2014;Madison School of Medicine and Public Health; 2020 [Available from: https://www.hipxchange.org/BPConnectHealth .</Citation></Reference><Reference><Citation>Bartels CM, Ramly E, Johnson HM, Lauver DR, Panyard DJ, Li Z, et al. Connecting rheumatology patients to primary care for high blood pressure: specialty clinic protocol improves follow-up and population blood pressures. Arthritis Care Res (Hoboken). 2019;71(4):461&#x2013;70.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1002/acr.23612</ArticleId><ArticleId IdType=\"pubmed\">29856134</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartels CM, Johnson L, Ramly E, Panyard DJ, Gilmore-Bykovskyi A, Johnson HM, et al. Impact of a rheumatology clinic protocol on tobacco cessation quit line referrals. Arthritis Care Res (Hoboken). 2022;74(9):1421&#x2013;9.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1002/acr.24589</ArticleId><ArticleId IdType=\"pubmed\">33825349</ArticleId></ArticleIdList></Reference><Reference><Citation>American College of Rheumatology. Guideline for the treatment of interstitial lung disease in people with systemic autoimmune rheumatic disease 2023 [Available from: https://assets.contentstack.io/v3/assets/bltee37abb6b278ab2c/bltaedebda97a351d47/interstitial-lung-disease-guideline-summary-treatment-2023.pdf . Accessed&#xa0;9/30/2023</Citation></Reference><Reference><Citation>Lubell J. Teamwork guides cardio-rheumatology clinics that care for unique patient population. MDedge/Rheumatology. 2023 [Available from: https://www.mdedge.com/rheumatology/article/260726/business-medicine/teamwork-guides-cardio-rheumatology-clinics-care . Accessed&#xa0;9/30/2023</Citation></Reference><Reference><Citation>Kronzer VL, Crowson CS, Sparks JA, Myasoedova E, Davis JM 3rd. Comorbidities as risk factors for rheumatoid arthritis and their accrual after diagnosis. Mayo Clin Proc. 2019;94(12):2488&#x2013;98.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.mayocp.2019.08.010</ArticleId><ArticleId IdType=\"pubmed\">31759675</ArticleId></ArticleIdList></Reference><Reference><Citation>Briot K, Roux C. Glucocorticoid-induced osteoporosis. RMD Open. 2015;1(1):e000014.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1136/rmdopen-2014-000014</ArticleId><ArticleId IdType=\"pubmed\">26509049</ArticleId><ArticleId IdType=\"pmc\">4613168</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y, Lin W, Chen Z, Wang Y, Huang Y, Tu S. Effect of tumor necrosis factor inhibitors on interstitial lung disease in rheumatoid arthritis: angel or demon? Drug Des Dev Ther. 2019;13:2111&#x2013;25.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.2147/DDDT.S204730</ArticleId></ArticleIdList></Reference><Reference><Citation>Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386(4):316&#x2013;26.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1056/NEJMoa2109927</ArticleId><ArticleId IdType=\"pubmed\">35081280</ArticleId></ArticleIdList></Reference></ReferenceList></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>\n",
            "XML saved to: path/to/save/xml/37995046.xml\n",
            "Details URL: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=37990203&retmode=xml&api_key=9edd38677707c08b2a96ed1a6e8c61c47408\n",
            "Details Response Content: <?xml version=\"1.0\" ?>\n",
            "<!DOCTYPE PubmedArticleSet PUBLIC \"-//NLM//DTD PubMedArticle, 1st January 2023//EN\" \"https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd\">\n",
            "<PubmedArticleSet>\n",
            "<PubmedArticle><MedlineCitation Status=\"MEDLINE\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">37990203</PMID><DateCompleted><Year>2023</Year><Month>11</Month><Day>27</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>27</Day></DateRevised><Article PubModel=\"Electronic\"><Journal><ISSN IssnType=\"Electronic\">1471-2466</ISSN><JournalIssue CitedMedium=\"Internet\"><Volume>23</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Nov</Month><Day>21</Day></PubDate></JournalIssue><Title>BMC pulmonary medicine</Title><ISOAbbreviation>BMC Pulm Med</ISOAbbreviation></Journal><ArticleTitle>Healthcare resource utilization in patients with pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD): a real-world data analysis.</ArticleTitle><Pagination><StartPage>455</StartPage><MedlinePgn>455</MedlinePgn></Pagination><ELocationID EIdType=\"pii\" ValidYN=\"Y\">455</ELocationID><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.1186/s12890-023-02698-9</ELocationID><Abstract><AbstractText Label=\"RATIONALE\" NlmCategory=\"BACKGROUND\">There is a lack of real-world characterization of healthcare costs and associated cost drivers in patients with pulmonary hypertension secondary to chronic obstructive pulmonary disease (PH-COPD).</AbstractText><AbstractText Label=\"OBJECTIVES\" NlmCategory=\"OBJECTIVE\">To examine (1) excess healthcare resource utilization (HCRU) and associated costs in patients with PH-COPD compared to COPD patients without PH; and (2) patient characteristics that are associated with higher healthcare costs in patients with PH-COPD.</AbstractText><AbstractText Label=\"METHODS\" NlmCategory=\"METHODS\">This study analyzed data from the IQVIA PharMetrics<sup>&#xae;</sup> Plus database (OCT2014-MAY2020). Patients with PH-COPD were identified by a claims-based algorithm based on PH diagnosis (ICD-10-CM: I27.0, I27.2, I27.20, I27.21, I27.23) after COPD diagnosis. Patients aged &#x2265;40 years and with data available &#x2265;12 months before (baseline) and &#x2265;6 months after (follow-up) the first observed PH diagnosis were included. Patients with other non-asthma chronic pulmonary diseases, PH associated with other causes, cancer, left-sided heart failure (HF), PH before the first observed COPD diagnosis, or right-sided/unspecified HF during baseline were excluded. Patients in the PH-COPD cohort were matched 1:1 to COPD patients without PH based on propensity scores derived from baseline patient characteristics. Annualized all-cause and COPD/PH-related (indicated by a primary diagnosis of COPD or PH) HCRU and costs during follow-up were compared between the matched cohorts. Baseline patient characteristics associated with higher total costs were examined in a generalized linear model in the PH-COPD cohort.</AbstractText><AbstractText Label=\"RESULTS\" NlmCategory=\"RESULTS\">A total of 2,224 patients with PH-COPD were identified and matched to COPD patients without PH. Patients with PH-COPD had higher all-cause HCRU and annual healthcare costs ($51,435 vs. $18,412, p&lt;0.001) than matched COPD patients without PH. Among patients with PH-COPD, costs were primarily driven by hospitalizations (57%), while COPD/PH-related costs accounted for 13% of all-cause costs. Having a higher comorbidity burden and a prior history of COPD exacerbation were major risk factors for higher total all-cause costs among patients with PH-COPD.</AbstractText><AbstractText Label=\"CONCLUSIONS\" NlmCategory=\"CONCLUSIONS\">Treatment strategies focusing on preventing hospitalizations and managing comorbidities may help reduce the burden of PH-COPD.</AbstractText><CopyrightInformation>&#xa9; 2023. Merck &amp; Co., Inc., Rahway, NJ, USA and its affiliates and Steven D. Nathan 2023.</CopyrightInformation></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Weiss</LastName><ForeName>Tracey</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Center for Observational and Real-World Evidence, Merck &amp; Co., Inc, 351 N Sumneytown Pike, PA, North Wales, 19454, USA. Tracey.Weiss@merck.com.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Near</LastName><ForeName>Aimee M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>IQVIA, Durham, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Zhao</LastName><ForeName>Xiaohui</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>IQVIA, Durham, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Ramey</LastName><ForeName>Dena Rosen</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Center for Observational and Real-World Evidence, Merck &amp; Co., Inc, 351 N Sumneytown Pike, PA, North Wales, 19454, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Banerji</LastName><ForeName>Tania</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>IQVIA, Durham, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Xie</LastName><ForeName>Handing</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>IQVIA, Durham, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Nathan</LastName><ForeName>Steven D</ForeName><Initials>SD</Initials><AffiliationInfo><Affiliation>Advanced Lung Disease and Lung Transplant Program, Inova Fairfax Hospital, Falls Church, VA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2023</Year><Month>11</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Pulm Med</MedlineTA><NlmUniqueID>100968563</NlmUniqueID><ISSNLinking>1471-2466</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI=\"D006801\" MajorTopicYN=\"N\">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D006976\" MajorTopicYN=\"Y\">Hypertension, Pulmonary</DescriptorName><QualifierName UI=\"Q000453\" MajorTopicYN=\"N\">epidemiology</QualifierName><QualifierName UI=\"Q000209\" MajorTopicYN=\"N\">etiology</QualifierName><QualifierName UI=\"Q000628\" MajorTopicYN=\"N\">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D012189\" MajorTopicYN=\"N\">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D029424\" MajorTopicYN=\"Y\">Pulmonary Disease, Chronic Obstructive</DescriptorName><QualifierName UI=\"Q000150\" MajorTopicYN=\"N\">complications</QualifierName><QualifierName UI=\"Q000628\" MajorTopicYN=\"N\">therapy</QualifierName><QualifierName UI=\"Q000175\" MajorTopicYN=\"N\">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D003695\" MajorTopicYN=\"N\">Delivery of Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D000078332\" MajorTopicYN=\"N\">Data Analysis</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner=\"NOTNLM\"><Keyword MajorTopicYN=\"N\">Chronic obstructive pulmonary disease (COPD)</Keyword><Keyword MajorTopicYN=\"N\">Comorbidities</Keyword><Keyword MajorTopicYN=\"N\">Healthcare cost</Keyword><Keyword MajorTopicYN=\"N\">Healthcare resource utilization</Keyword><Keyword MajorTopicYN=\"N\">Hospitalization</Keyword><Keyword MajorTopicYN=\"N\">Pulmonary hypertension secondary to COPD</Keyword></KeywordList><CoiStatement>Weiss and Ramey are employees of Merck &amp; Co., Inc. Near and Zhao are employees of IQVIA, Inc., which received consulting fees for conducting this study. Xie and Banerji were employees of IQVIA at the time of study conduct. Nathan has received consulting fees and serves on the advisory board for Merck &amp;Co., Inc., United Therapeutics Corporation, Bellerophon Therapeutics, Third Pole Therapeutics and F. Hoffmann-La Roche AG.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"received\"><Year>2023</Year><Month>4</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus=\"accepted\"><Year>2023</Year><Month>10</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus=\"medline\"><Year>2023</Year><Month>11</Month><Day>27</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2023</Year><Month>11</Month><Day>22</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2023</Year><Month>11</Month><Day>22</Day><Hour>1</Hour><Minute>18</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">37990203</ArticleId><ArticleId IdType=\"pmc\">PMC10664271</ArticleId><ArticleId IdType=\"doi\">10.1186/s12890-023-02698-9</ArticleId><ArticleId IdType=\"pii\">10.1186/s12890-023-02698-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Blanco I, Piccari L, Barber&#xe0; JA. Pulmonary vasculature in COPD: the silent component. Respirology. 2016;21(6):984&#x2013;94. doi: 10.1111/resp.12772.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1111/resp.12772</ArticleId><ArticleId IdType=\"pubmed\">27028849</ArticleId></ArticleIdList></Reference><Reference><Citation>Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2019;53(1):1801913. doi: 10.1183/13993003.01913-2018.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1183/13993003.01913-2018</ArticleId><ArticleId IdType=\"pmc\">PMC6351336</ArticleId><ArticleId IdType=\"pubmed\">30545968</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanco I, Tura-Ceide O, Peinado VI, Barber&#xe0; JA. Updated Perspectives on Pulmonary Hypertension in COPD. Int J Chron Obstruct Pulmon Dis. 2020;15:1315&#x2013;24. doi: 10.2147/COPD.S211841.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.2147/COPD.S211841</ArticleId><ArticleId IdType=\"pmc\">PMC7293405</ArticleId><ArticleId IdType=\"pubmed\">32606641</ArticleId></ArticleIdList></Reference><Reference><Citation>Olschewski H. The challenge to decide between pulmonary hypertension due to chronic lung disease and PAH with chronic lung disease. Diagnostics. 2021;11(2):311. doi: 10.3390/diagnostics11020311.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3390/diagnostics11020311</ArticleId><ArticleId IdType=\"pmc\">PMC7918977</ArticleId><ArticleId IdType=\"pubmed\">33671914</ArticleId></ArticleIdList></Reference><Reference><Citation>Hilde JM, Skj&#xf8;rten I, Hansteen V, et al. Haemodynamic responses to exercise in patients with COPD. Eur Respir J. 2013;41(5):1031. doi: 10.1183/09031936.00085612.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1183/09031936.00085612</ArticleId><ArticleId IdType=\"pubmed\">22903957</ArticleId></ArticleIdList></Reference><Reference><Citation>Gali&#xe8; N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the european respiratory society (ERS): endorsed by: Association for European Paediatric and congenital cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT) Eur Heart J. 2016;37(1):67&#x2013;119. doi: 10.1093/eurheartj/ehv317.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/eurheartj/ehv317</ArticleId><ArticleId IdType=\"pubmed\">26320113</ArticleId></ArticleIdList></Reference><Reference><Citation>Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: developed by the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the european respiratory society (ERS). Endorsed by the International Society for Heart and Lung Transplantation (ISHLT) and the european Reference Network on rare respiratory diseases (ERN-LUNG) Eur Heart J. 2022;43(38):3618&#x2013;731. doi: 10.1093/eurheartj/ehac237.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/eurheartj/ehac237</ArticleId><ArticleId IdType=\"pubmed\">36017548</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuttica MJ, Kalhan R, Shlobin OA, et al. Categorization and impact of pulmonary hypertension in patients with advanced COPD. Respir Med. 2010;104(12):1877&#x2013;82. doi: 10.1016/j.rmed.2010.05.009.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.rmed.2010.05.009</ArticleId><ArticleId IdType=\"pubmed\">20547449</ArticleId></ArticleIdList></Reference><Reference><Citation>Medrek SK, Sharafkhaneh A, Spiegelman AM, Kak A, Pandit LM. Admission for COPD Exacerbation is Associated with the clinical diagnosis of pulmonary hypertension: results from a Retrospective Longitudinal Study of a veteran Population. Copd. 2017;14(5):484&#x2013;9. doi: 10.1080/15412555.2017.1336209.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1080/15412555.2017.1336209</ArticleId><ArticleId IdType=\"pubmed\">28715281</ArticleId></ArticleIdList></Reference><Reference><Citation>Klinger JR. Group III Pulmonary Hypertension: Pulmonary Hypertension Associated with Lung Disease: Epidemiology, Pathophysiology, and treatments. Cardiol Clin. 2016;34(3):413&#x2013;33. doi: 10.1016/j.ccl.2016.04.003.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.ccl.2016.04.003</ArticleId><ArticleId IdType=\"pubmed\">27443138</ArticleId></ArticleIdList></Reference><Reference><Citation>Munshi RF, Pellegrini JR, Jr, Patel P, et al. Impact of pulmonary hypertension in patients with acute exacerbation of chronic obstructive pulmonary disease and its effect on healthcare utilization. Pulm Circ. 2021;11(4):20458940211046838. doi: 10.1177/20458940211046838.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1177/20458940211046838</ArticleId><ArticleId IdType=\"pmc\">PMC8477694</ArticleId><ArticleId IdType=\"pubmed\">34594546</ArticleId></ArticleIdList></Reference><Reference><Citation>US Bureau of Labor Services. CPI for All Urban Consumers (CPI-U). https://data.bls.gov/cgi-bin/surveymost. Published 2022. Accessed March 29, 2022.</Citation></Reference><Reference><Citation>Quan H, Li B, Couris CM, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676&#x2013;82. doi: 10.1093/aje/kwq433.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/aje/kwq433</ArticleId><ArticleId IdType=\"pubmed\">21330339</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallace AE, Kaila S, Bayer V, et al. Health Care Resource utilization and exacerbation rates in patients with COPD stratified by Disease Severity in a commercially insured Population. J Manag Care Spec Pharm. 2019;25(2):205&#x2013;17.</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC10397829</ArticleId><ArticleId IdType=\"pubmed\">30698096</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin PC. An introduction to Propensity score methods for reducing the Effects of confounding in Observational Studies. Multivar Behav Res. 2011;46(3):399&#x2013;424. doi: 10.1080/00273171.2011.568786.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1080/00273171.2011.568786</ArticleId><ArticleId IdType=\"pmc\">PMC3144483</ArticleId><ArticleId IdType=\"pubmed\">21818162</ArticleId></ArticleIdList></Reference><Reference><Citation>Heresi GA, Platt DM, Wang W, et al. Healthcare burden of pulmonary hypertension owing to lung disease and/or hypoxia. BMC Pulm Med. 2017;17(1):58. doi: 10.1186/s12890-017-0399-1.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1186/s12890-017-0399-1</ArticleId><ArticleId IdType=\"pmc\">PMC5387228</ArticleId><ArticleId IdType=\"pubmed\">28399914</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheron C, McBride SA, Antigny F, et al. Sex and gender in pulmonary arterial hypertension. Eur Respir Rev. 2021;30(162):200330.</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC9488668</ArticleId><ArticleId IdType=\"pubmed\">34750113</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xf8;rheim I-C, Johannessen A, Gulsvik A, Bakke PS, Silverman EK, DeMeo DL. Gender differences in COPD: are women more susceptible to smoking effects than men? Thorax. 2010;65(6):480. doi: 10.1136/thx.2009.122002.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1136/thx.2009.122002</ArticleId><ArticleId IdType=\"pmc\">PMC8191512</ArticleId><ArticleId IdType=\"pubmed\">20522842</ArticleId></ArticleIdList></Reference><Reference><Citation>Poms AD, Turner M, Farber HW, Meltzer LA, McGoon MD. Comorbid conditions and outcomes in patients with pulmonary arterial hypertension: a REVEAL registry analysis. Chest. 2013;144(1):169&#x2013;76. doi: 10.1378/chest.11-3241.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1378/chest.11-3241</ArticleId><ArticleId IdType=\"pubmed\">23348820</ArticleId></ArticleIdList></Reference><Reference><Citation>Anzueto A. Impact of exacerbations on COPD. Eur Respir Rev. 2010;19(116):113&#x2013;8. doi: 10.1183/09059180.00002610.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1183/09059180.00002610</ArticleId><ArticleId IdType=\"pmc\">PMC9682573</ArticleId><ArticleId IdType=\"pubmed\">20956179</ArticleId></ArticleIdList></Reference><Reference><Citation>Barber&#xe0; JA, Peinado VI, Santos S. Pulmonary hypertension in chronic obstructive pulmonary disease. Eur Respir J. 2003;21(5):892. doi: 10.1183/09031936.03.00115402.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1183/09031936.03.00115402</ArticleId><ArticleId IdType=\"pubmed\">12765440</ArticleId></ArticleIdList></Reference><Reference><Citation>Nathan SD, Barbera JA, Gaine SP, et al. Pulmonary hypertension in chronic lung disease and hypoxia. Eur Respir J. 2019;53(1):1801914. doi: 10.1183/13993003.01914-2018.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1183/13993003.01914-2018</ArticleId><ArticleId IdType=\"pmc\">PMC6351338</ArticleId><ArticleId IdType=\"pubmed\">30545980</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovacs G, Agusti A, Barber&#xe0; JA, et al. Pulmonary vascular involvement in chronic obstructive pulmonary disease. Is there a pulmonary vascular phenotype? Am J Respir Crit Care Med. 2018;198(8):1000&#x2013;11. doi: 10.1164/rccm.201801-0095PP.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1164/rccm.201801-0095PP</ArticleId><ArticleId IdType=\"pubmed\">29746142</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>\n",
            "XML saved to: path/to/save/xml/37990203.xml\n",
            "Details URL: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=37985822&retmode=xml&api_key=9edd38677707c08b2a96ed1a6e8c61c47408\n",
            "Details Response Content: <?xml version=\"1.0\" ?>\n",
            "<!DOCTYPE PubmedArticleSet PUBLIC \"-//NLM//DTD PubMedArticle, 1st January 2023//EN\" \"https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd\">\n",
            "<PubmedArticleSet>\n",
            "<PubmedArticle><MedlineCitation Status=\"MEDLINE\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">37985822</PMID><DateCompleted><Year>2023</Year><Month>12</Month><Day>16</Day></DateCompleted><DateRevised><Year>2023</Year><Month>12</Month><Day>16</Day></DateRevised><Article PubModel=\"Print-Electronic\"><Journal><ISSN IssnType=\"Electronic\">1546-1718</ISSN><JournalIssue CitedMedium=\"Internet\"><Volume>55</Volume><Issue>12</Issue><PubDate><Year>2023</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Nature genetics</Title><ISOAbbreviation>Nat Genet</ISOAbbreviation></Journal><ArticleTitle>Multi-ancestry genome-wide association study of cannabis use disorder yields insight into disease biology and public health implications.</ArticleTitle><Pagination><StartPage>2094</StartPage><EndPage>2103</EndPage><MedlinePgn>2094-2103</MedlinePgn></Pagination><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.1038/s41588-023-01563-z</ELocationID><Abstract><AbstractText>As recreational use of cannabis is being decriminalized in many places and medical use widely sanctioned, there are growing concerns about increases in cannabis use disorder (CanUD), which is associated with numerous medical comorbidities. Here we performed a genome-wide association study of CanUD in the Million Veteran Program (MVP), followed by meta-analysis in 1,054,365 individuals (n<sub>cases</sub>&#x2009;=&#x2009;64,314) from four broad ancestries designated by the reference panel used for assignment (European n&#x2009;=&#x2009;886,025, African n&#x2009;=&#x2009;123,208, admixed American n&#x2009;=&#x2009;38,289 and East Asian n&#x2009;=&#x2009;6,843). Population-specific methods were applied to calculate single nucleotide polymorphism-based heritability within each ancestry. Statistically significant single nucleotide polymorphism-based heritability for CanUD was observed in all but the smallest population (East Asian). We discovered genome-wide significant loci unique to each ancestry: 22 in European, 2 each in African and East Asian, and 1 in admixed American ancestries. A genetically informed causal relationship analysis indicated a possible effect of genetic liability for CanUD on lung cancer risk, suggesting potential unanticipated future medical and psychiatric public health consequences that require further study to disentangle from other known risk factors such as cigarette smoking.</AbstractText><CopyrightInformation>&#xa9; 2023. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.</CopyrightInformation></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Levey</LastName><ForeName>Daniel F</ForeName><Initials>DF</Initials><Identifier Source=\"ORCID\">0000-0001-8431-9569</Identifier><AffiliationInfo><Affiliation>Division of Human Genetics, Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA. daniel.levey@yale.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Veterans Affairs Connecticut Healthcare Center, West Haven, CT, USA. daniel.levey@yale.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Galimberti</LastName><ForeName>Marco</ForeName><Initials>M</Initials><Identifier Source=\"ORCID\">0000-0001-6052-156X</Identifier><AffiliationInfo><Affiliation>Division of Human Genetics, Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Veterans Affairs Connecticut Healthcare Center, West Haven, CT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Deak</LastName><ForeName>Joseph D</ForeName><Initials>JD</Initials><Identifier Source=\"ORCID\">0000-0002-0540-6080</Identifier><AffiliationInfo><Affiliation>Division of Human Genetics, Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Veterans Affairs Connecticut Healthcare Center, West Haven, CT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Wendt</LastName><ForeName>Frank R</ForeName><Initials>FR</Initials><AffiliationInfo><Affiliation>Division of Human Genetics, Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Veterans Affairs Connecticut Healthcare Center, West Haven, CT, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anthropology, University of Toronto, Mississauga, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biostatistics Division, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Bhattacharya</LastName><ForeName>Arjun</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Koller</LastName><ForeName>Dora</ForeName><Initials>D</Initials><Identifier Source=\"ORCID\">0000-0002-0415-0466</Identifier><AffiliationInfo><Affiliation>Division of Human Genetics, Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Veterans Affairs Connecticut Healthcare Center, West Haven, CT, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics, Microbiology and Statistics, Faculty of Biology, University of Barcelona, Catalonia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Harrington</LastName><ForeName>Kelly M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>VA Boston Healthcare System, Massachusetts Veterans Epidemiology Research and Information Center, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Boston University Chobanian and Avedisian School of Medicine, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Quaden</LastName><ForeName>Rachel</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>VA Boston Healthcare System, Massachusetts Veterans Epidemiology Research and Information Center, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Boston University Chobanian and Avedisian School of Medicine, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Johnson</LastName><ForeName>Emma C</ForeName><Initials>EC</Initials><Identifier Source=\"ORCID\">0000-0003-0394-777X</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University School of Medicine, Saint Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Gupta</LastName><ForeName>Priya</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Division of Human Genetics, Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Veterans Affairs Connecticut Healthcare Center, West Haven, CT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Biradar</LastName><ForeName>Mahantesh</ForeName><Initials>M</Initials><Identifier Source=\"ORCID\">0000-0002-4114-6255</Identifier><AffiliationInfo><Affiliation>NIHR Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Lam</LastName><ForeName>Max</ForeName><Initials>M</Initials><Identifier Source=\"ORCID\">0000-0002-4256-7844</Identifier><AffiliationInfo><Affiliation>Research Division, Institute of Mental Health, Singapore, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry and Molecular Medicine, Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Cooke</LastName><ForeName>Megan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Center for Addiction Medicine, Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Rajagopal</LastName><ForeName>Veera M</ForeName><Initials>VM</Initials><Identifier Source=\"ORCID\">0000-0002-5236-168X</Identifier><AffiliationInfo><Affiliation>Department of Biomedicine, Aarhus University, Aarhus, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH, Aarhus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Empke</LastName><ForeName>Stefany L L</ForeName><Initials>SLL</Initials><AffiliationInfo><Affiliation>Division of Human Genetics, Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Veterans Affairs Connecticut Healthcare Center, West Haven, CT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Zhou</LastName><ForeName>Hang</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Division of Human Genetics, Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Veterans Affairs Connecticut Healthcare Center, West Haven, CT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Nunez</LastName><ForeName>Yaira Z</ForeName><Initials>YZ</Initials><AffiliationInfo><Affiliation>Division of Human Genetics, Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Veterans Affairs Connecticut Healthcare Center, West Haven, CT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Kranzler</LastName><ForeName>Henry R</ForeName><Initials>HR</Initials><Identifier Source=\"ORCID\">0000-0002-1018-0450</Identifier><AffiliationInfo><Affiliation>Mental Illness Research, Education and Clinical Center, Crescenz VAMC and Center for Studies of Addiction, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Edenberg</LastName><ForeName>Howard J</ForeName><Initials>HJ</Initials><Identifier Source=\"ORCID\">0000-0003-0344-9690</Identifier><AffiliationInfo><Affiliation>Departments of Biochemistry and Molecular Biology and Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Agrawal</LastName><ForeName>Arpana</ForeName><Initials>A</Initials><Identifier Source=\"ORCID\">0000-0002-0313-793X</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University School of Medicine, Saint Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Smoller</LastName><ForeName>Jordan W</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>Psychiatric and Neurodevelopmental Genetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Precision Psychiatry, Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Lencz</LastName><ForeName>Todd</ForeName><Initials>T</Initials><Identifier Source=\"ORCID\">0000-0001-8586-338X</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry and Molecular Medicine, Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Hougaard</LastName><ForeName>David M</ForeName><Initials>DM</Initials><Identifier Source=\"ORCID\">0000-0001-5928-3517</Identifier><AffiliationInfo><Affiliation>The Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH, Aarhus, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Neonatal Screening, Department for Congenital Disorders, Statens Serum Institut, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>B&#xf8;rglum</LastName><ForeName>Anders D</ForeName><Initials>AD</Initials><Identifier Source=\"ORCID\">0000-0001-8627-7219</Identifier><AffiliationInfo><Affiliation>Department of Biomedicine, Aarhus University, Aarhus, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH, Aarhus, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Genomics and Personalized Medicine, Aarhus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Demontis</LastName><ForeName>Ditte</ForeName><Initials>D</Initials><Identifier Source=\"ORCID\">0000-0001-9124-2766</Identifier><AffiliationInfo><Affiliation>Department of Biomedicine, Aarhus University, Aarhus, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH, Aarhus, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Genomics and Personalized Medicine, Aarhus, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Novo Nordisk Foundation Center for Genomic Mechanisms of Disease, Broad Institute of MIT and Harvard, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><CollectiveName>Veterans Affairs Million Veteran Program</CollectiveName></Author><Author ValidYN=\"Y\"><LastName>Gaziano</LastName><ForeName>J Michael</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Million Veteran Program Coordinating Center, VA Boston Healthcare System, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Division of Aging, Brigham and Women's Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Gandal</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials><Identifier Source=\"ORCID\">0000-0001-5800-5128</Identifier><AffiliationInfo><Affiliation>Departments of Psychiatry and Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Lifespan Brain Institute, Penn Medicine and the Children's Hospital of Philadelphia, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Polimanti</LastName><ForeName>Renato</ForeName><Initials>R</Initials><Identifier Source=\"ORCID\">0000-0003-0745-6046</Identifier><AffiliationInfo><Affiliation>Division of Human Genetics, Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Veterans Affairs Connecticut Healthcare Center, West Haven, CT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Stein</LastName><ForeName>Murray B</ForeName><Initials>MB</Initials><Identifier Source=\"ORCID\">0000-0001-9564-2871</Identifier><AffiliationInfo><Affiliation>Psychiatry Service, VA San Diego Healthcare System, San Diego, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry and Herbert Wertheim School of Public Health, University of California San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Gelernter</LastName><ForeName>Joel</ForeName><Initials>J</Initials><Identifier Source=\"ORCID\">0000-0002-4067-1859</Identifier><AffiliationInfo><Affiliation>Division of Human Genetics, Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA. joel.gelernter@yale.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Veterans Affairs Connecticut Healthcare Center, West Haven, CT, USA. joel.gelernter@yale.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN=\"Y\"><Grant><GrantID>R01 MH124851</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>IK2 BX005058</GrantID><Acronym>BX</Acronym><Agency>BLRD VA</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH118233</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH121521</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>I01 CX001849</GrantID><Acronym>CX</Acronym><Agency>CSRD VA</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 DA051759</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AA026364</GrantID><Acronym>AA</Acronym><Agency>NIAAA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R33 DA047527</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH123922</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH117646</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AA028259</GrantID><Acronym>AA</Acronym><Agency>NIAAA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>I01 BX004820</GrantID><Acronym>BX</Acronym><Agency>BLRD VA</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 DC018098</GrantID><Acronym>DC</Acronym><Agency>NIDCD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 DA054869</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F32 MH122058</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI=\"D017418\">Meta-Analysis</PublicationType><PublicationType UI=\"D016428\">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2023</Year><Month>11</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Genet</MedlineTA><NlmUniqueID>9216904</NlmUniqueID><ISSNLinking>1061-4036</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI=\"D006801\" MajorTopicYN=\"N\">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D055106\" MajorTopicYN=\"Y\">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D011634\" MajorTopicYN=\"N\">Public Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D044383\" MajorTopicYN=\"N\">Black People</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D020641\" MajorTopicYN=\"N\">Polymorphism, Single Nucleotide</DescriptorName><QualifierName UI=\"Q000235\" MajorTopicYN=\"N\">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D002189\" MajorTopicYN=\"Y\">Marijuana Abuse</DescriptorName><QualifierName UI=\"Q000235\" MajorTopicYN=\"N\">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D001695\" MajorTopicYN=\"N\">Biology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D020022\" MajorTopicYN=\"N\">Genetic Predisposition to Disease</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>H.R.K. is a member of advisory boards for Dicerna Pharmaceuticals, Sophrosyne Pharmaceuticals, Clearmind Medicine and Enthion Pharmaceuticals; a consultant to Sobrera Pharmaceuticals; the recipient of research funding and medication supplies for an investigator-initiated study from Alkermes; and a member of the American Society of Clinical Psychopharmacology&#x2019;s Alcohol Clinical Trials Initiative, which was supported in the last three years by Alkermes, Dicerna, Ethypharm, Lundbeck, Mitsubishi and Otsuka. J.G. and H.R.K. are holders of US patent 10,900,082 titled: &#x2018;Genotype-guided dosing of opioid agonists&#x2019;, issued 26 January 2021. R.P. and J.G. are paid for their editorial work on the journal <i>Complex Psychiatry</i>. R.P. reports a research grant from Alkermes. The remaining authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"received\"><Year>2023</Year><Month>6</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus=\"accepted\"><Year>2023</Year><Month>10</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus=\"medline\"><Year>2023</Year><Month>12</Month><Day>17</Day><Hour>9</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2023</Year><Month>11</Month><Day>21</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2023</Year><Month>11</Month><Day>21</Day><Hour>1</Hour><Minute>28</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">37985822</ArticleId><ArticleId IdType=\"pmc\">PMC10703690</ArticleId><ArticleId IdType=\"doi\">10.1038/s41588-023-01563-z</ArticleId><ArticleId IdType=\"pii\">10.1038/s41588-023-01563-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Martins SS, et al. Racial and ethnic differences in cannabis use following legalization in US states with medical cannabis laws. JAMA Netw. Open. 2021;4:e2127002&#x2013;e2127002. doi: 10.1001/jamanetworkopen.2021.27002.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1001/jamanetworkopen.2021.27002</ArticleId><ArticleId IdType=\"pmc\">PMC8477268</ArticleId><ArticleId IdType=\"pubmed\">34570205</ArticleId></ArticleIdList></Reference><Reference><Citation>Cerd&#xe1; M, et al. Association between recreational marijuana legalization in the United States and changes in marijuana use and cannabis use disorder from 2008 to 2016. JAMA Psychiatry. 2020;77:165&#x2013;171. doi: 10.1001/jamapsychiatry.2019.3254.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1001/jamapsychiatry.2019.3254</ArticleId><ArticleId IdType=\"pmc\">PMC6865220</ArticleId><ArticleId IdType=\"pubmed\">31722000</ArticleId></ArticleIdList></Reference><Reference><Citation>Aldington S, et al. Cannabis use and risk of lung cancer: a case-control study. Eur. Respir. J. 2008;31:280&#x2013;286. doi: 10.1183/09031936.00065707.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1183/09031936.00065707</ArticleId><ArticleId IdType=\"pmc\">PMC2516340</ArticleId><ArticleId IdType=\"pubmed\">18238947</ArticleId></ArticleIdList></Reference><Reference><Citation>Volkow ND, et al. Effects of cannabis use on human behavior, including cognition, motivation, and psychosis: a review. JAMA Psychiatry. 2016;73:292&#x2013;297. doi: 10.1001/jamapsychiatry.2015.3278.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1001/jamapsychiatry.2015.3278</ArticleId><ArticleId IdType=\"pubmed\">26842658</ArticleId></ArticleIdList></Reference><Reference><Citation>Volkow, N.D. Substance use disorders in schizophrenia&#x2014;clinical implications of comorbidity. Schizophr. Bull.35 469&#x2013;472 (2009).</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC2669586</ArticleId><ArticleId IdType=\"pubmed\">19325163</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin JL, Gadegbeku B, Wu D, Viallon V, Laumon B. Cannabis, alcohol and fatal road accidents. PLoS ONE. 2017;12:e0187320. doi: 10.1371/journal.pone.0187320.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1371/journal.pone.0187320</ArticleId><ArticleId IdType=\"pmc\">PMC5678710</ArticleId><ArticleId IdType=\"pubmed\">29117206</ArticleId></ArticleIdList></Reference><Reference><Citation>Demontis D, et al. Genome-wide association study implicates CHRNA2 in cannabis use disorder. Nat. Neurosci. 2019;22:1066&#x2013;1074. doi: 10.1038/s41593-019-0416-1.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/s41593-019-0416-1</ArticleId><ArticleId IdType=\"pmc\">PMC7596896</ArticleId><ArticleId IdType=\"pubmed\">31209380</ArticleId></ArticleIdList></Reference><Reference><Citation>Bybjerg-Grauholm, J. et al. The iPSYCH2015 case-cohort sample: updated directions for unravelling genetic and environmental architectures of severe mental disorders. Preprint at medRxiv10.1101/2020.11.30.20237768 (2020).</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC5754466</ArticleId><ArticleId IdType=\"pubmed\">28924187</ArticleId></ArticleIdList></Reference><Reference><Citation>Boutin NT, et al. The evolution of a large biobank at Mass General Brigham. J. Personalized Med. 2022;12:1323. doi: 10.3390/jpm12081323.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3390/jpm12081323</ArticleId><ArticleId IdType=\"pmc\">PMC9410531</ArticleId><ArticleId IdType=\"pubmed\">36013271</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson EC, et al. A large-scale genome-wide association study meta-analysis of cannabis use disorder. Lancet Psychiatry. 2020;7:1032&#x2013;1045. doi: 10.1016/S2215-0366(20)30339-4.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/S2215-0366(20)30339-4</ArticleId><ArticleId IdType=\"pmc\">PMC7674631</ArticleId><ArticleId IdType=\"pubmed\">33096046</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaziano JM, et al. Million Veteran Program: a mega-biobank to study genetic influences on health and disease. J. Clin. Epidemiol. 2016;70:214&#x2013;223. doi: 10.1016/j.jclinepi.2015.09.016.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jclinepi.2015.09.016</ArticleId><ArticleId IdType=\"pubmed\">26441289</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo, Y. et al. Estimating heritability and its enrichment in tissue-specific gene sets in admixed populations. Hum. Mol. Genet.10.1093/hmg/ddab130 (2021).</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC8330913</ArticleId><ArticleId IdType=\"pubmed\">33987664</ArticleId></ArticleIdList></Reference><Reference><Citation>Agrawal A, et al. A genome-wide association study of DSM-IV cannabis dependence. Addict. Biol. 2011;16:514&#x2013;518. doi: 10.1111/j.1369-1600.2010.00255.x.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1111/j.1369-1600.2010.00255.x</ArticleId><ArticleId IdType=\"pmc\">PMC3117436</ArticleId><ArticleId IdType=\"pubmed\">21668797</ArticleId></ArticleIdList></Reference><Reference><Citation>Minica CC, et al. Heritability, SNP- and gene-based analyses of cannabis use initiation and age at onset. Behav. Genet. 2015;45:503&#x2013;513. doi: 10.1007/s10519-015-9723-9.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s10519-015-9723-9</ArticleId><ArticleId IdType=\"pmc\">PMC4561059</ArticleId><ArticleId IdType=\"pubmed\">25987507</ArticleId></ArticleIdList></Reference><Reference><Citation>Agrawal A, et al. DSM-5 cannabis use disorder: a phenotypic and genomic perspective. Drug Alcohol Depend. 2014;134:362&#x2013;369. doi: 10.1016/j.drugalcdep.2013.11.008.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.drugalcdep.2013.11.008</ArticleId><ArticleId IdType=\"pmc\">PMC3943464</ArticleId><ArticleId IdType=\"pubmed\">24315570</ArticleId></ArticleIdList></Reference><Reference><Citation>Verweij KJ, et al. The genetic aetiology of cannabis use initiation: a meta-analysis of genome-wide association studies and a SNP-based heritability estimation. Addict. Biol. 2013;18:846&#x2013;850. doi: 10.1111/j.1369-1600.2012.00478.x.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1111/j.1369-1600.2012.00478.x</ArticleId><ArticleId IdType=\"pmc\">PMC3548058</ArticleId><ArticleId IdType=\"pubmed\">22823124</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherva R, et al. Genome-wide association study of cannabis dependence severity, novel risk variants, and shared genetic risks. JAMA Psychiatry. 2016;73:472&#x2013;480. doi: 10.1001/jamapsychiatry.2016.0036.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1001/jamapsychiatry.2016.0036</ArticleId><ArticleId IdType=\"pmc\">PMC4974817</ArticleId><ArticleId IdType=\"pubmed\">27028160</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasman JA, et al. GWAS of lifetime cannabis use reveals new risk loci, genetic overlap with psychiatric traits, and a causal influence of schizophrenia. Nat. Neurosci. 2018;21:1161&#x2013;1170. doi: 10.1038/s41593-018-0206-1.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/s41593-018-0206-1</ArticleId><ArticleId IdType=\"pmc\">PMC6386176</ArticleId><ArticleId IdType=\"pubmed\">30150663</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown BC, Asian Genetic Epidemiology Network Type 2 Diabetes Consortium. Ye CJ, Price AL, Zaitlen N. Transethnic genetic-correlation estimates from summary statistics. Am. J. Hum. Genet. 2016;99:76&#x2013;88. doi: 10.1016/j.ajhg.2016.05.001.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.ajhg.2016.05.001</ArticleId><ArticleId IdType=\"pmc\">PMC5005434</ArticleId><ArticleId IdType=\"pubmed\">27321947</ArticleId></ArticleIdList></Reference><Reference><Citation>Saunders GRB, et al. Genetic diversity fuels gene discovery for tobacco and alcohol use. Nature. 2022;612:720&#x2013;724. doi: 10.1038/s41586-022-05477-4.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/s41586-022-05477-4</ArticleId><ArticleId IdType=\"pmc\">PMC9771818</ArticleId><ArticleId IdType=\"pubmed\">36477530</ArticleId></ArticleIdList></Reference><Reference><Citation>Connor, J.P. et al. Cannabis use and cannabis use disorder. Nat. Rev. Dis. Primers10.1038/s41572-021-00247-4 (2021).</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC8655458</ArticleId><ArticleId IdType=\"pubmed\">33627670</ArticleId></ArticleIdList></Reference><Reference><Citation>Levey DF, et al. Reproducible genetic risk loci for anxiety: results from approximately 200,000 participants in the Million Veteran Program. Am. J. Psychiatry. 2020;177:223&#x2013;232. doi: 10.1176/appi.ajp.2019.19030256.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1176/appi.ajp.2019.19030256</ArticleId><ArticleId IdType=\"pmc\">PMC7869502</ArticleId><ArticleId IdType=\"pubmed\">31906708</ArticleId></ArticleIdList></Reference><Reference><Citation>Levey DF, et al. Bi-ancestral depression GWAS in the Million Veteran Program and meta-analysis in &gt;1.2 million individuals highlight new therapeutic directions. Nat. Neurosci. 2021;24:954&#x2013;963. doi: 10.1038/s41593-021-00860-2.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/s41593-021-00860-2</ArticleId><ArticleId IdType=\"pmc\">PMC8404304</ArticleId><ArticleId IdType=\"pubmed\">34045744</ArticleId></ArticleIdList></Reference><Reference><Citation>Thorgeirsson TE, et al. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature. 2008;452:638&#x2013;642. doi: 10.1038/nature06846.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/nature06846</ArticleId><ArticleId IdType=\"pmc\">PMC4539558</ArticleId><ArticleId IdType=\"pubmed\">18385739</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Souza, D.C. et al. Consensus paper of the WFSBP task force on cannabis, cannabinoids and psychosis. World J. Biol. Psychiatry10.1080/15622975.2022.2038797 (2022).</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">35315315</ArticleId></ArticleIdList></Reference><Reference><Citation>Gelernter J, Polimanti R. Genetics of substance use disorders in the era of big data. Nat. Rev. Genet. 2021;22:712&#x2013;729. doi: 10.1038/s41576-021-00377-1.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/s41576-021-00377-1</ArticleId><ArticleId IdType=\"pmc\">PMC9210391</ArticleId><ArticleId IdType=\"pubmed\">34211176</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnston KJA, et al. Genome-wide association study of multisite chronic pain in UK Biobank. PLoS Genet. 2019;15:e1008164. doi: 10.1371/journal.pgen.1008164.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1371/journal.pgen.1008164</ArticleId><ArticleId IdType=\"pmc\">PMC6592570</ArticleId><ArticleId IdType=\"pubmed\">31194737</ArticleId></ArticleIdList></Reference><Reference><Citation>Fisher E, et al. Cannabinoids, cannabis, and cannabis-based medicine for pain management: a systematic review of randomised controlled trials. Pain. 2021;162:S45&#x2013;S66. doi: 10.1097/j.pain.0000000000001929.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1097/j.pain.0000000000001929</ArticleId><ArticleId IdType=\"pubmed\">32804836</ArticleId></ArticleIdList></Reference><Reference><Citation>Stockings E, et al. Cannabis and cannabinoids for the treatment of people with chronic noncancer pain conditions: a systematic review and meta-analysis of controlled and observational studies. Pain. 2018;159:1932&#x2013;1954. doi: 10.1097/j.pain.0000000000001293.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1097/j.pain.0000000000001293</ArticleId><ArticleId IdType=\"pubmed\">29847469</ArticleId></ArticleIdList></Reference><Reference><Citation>Jayawardana S, et al. Global consumption of prescription opioid analgesics between 2009-2019: a country-level observational study. EClinicalMedicine. 2021;42:101198. doi: 10.1016/j.eclinm.2021.101198.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.eclinm.2021.101198</ArticleId><ArticleId IdType=\"pmc\">PMC8599097</ArticleId><ArticleId IdType=\"pubmed\">34820610</ArticleId></ArticleIdList></Reference><Reference><Citation>Nugent SM, et al. The effects of cannabis among adults with chronic pain and an overview of general harms: a systematic review. Ann. Intern. Med. 2017;167:319&#x2013;331. doi: 10.7326/M17-0155.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.7326/M17-0155</ArticleId><ArticleId IdType=\"pubmed\">28806817</ArticleId></ArticleIdList></Reference><Reference><Citation>Smoking and Health: Report of the Advisory Committee to the Surgeon General of the Public Health Service (US Department of Health, Education, and Welfare, Public Health Service, 1964).</Citation></Reference><Reference><Citation>Gandal, M.J. et al. Transcriptome-wide isoform-level dysregulation in ASD, schizophrenia, and bipolar disorder. Science362 (2018).</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC6443102</ArticleId><ArticleId IdType=\"pubmed\">30545856</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker RL, et al. Genetic control of expression and splicing in developing human brain informs disease mechanisms. Cell. 2019;179:750&#x2013;771 e22. doi: 10.1016/j.cell.2019.09.021.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.cell.2019.09.021</ArticleId><ArticleId IdType=\"pmc\">PMC8963725</ArticleId><ArticleId IdType=\"pubmed\">31626773</ArticleId></ArticleIdList></Reference><Reference><Citation>Lentini JM, Alsaif HS, Faqeih E, Alkuraya FS, Fu D. DALRD3 encodes a protein mutated in epileptic encephalopathy that targets arginine tRNAs for 3-methylcytosine modification. Nat. Commun. 2020;11:2510. doi: 10.1038/s41467-020-16321-6.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/s41467-020-16321-6</ArticleId><ArticleId IdType=\"pmc\">PMC7237682</ArticleId><ArticleId IdType=\"pubmed\">32427860</ArticleId></ArticleIdList></Reference><Reference><Citation>Laugel V, et al. Mutation update for the CSB/ERCC6 and CSA/ERCC8 genes involved in Cockayne syndrome. Hum. Mutat. 2010;31:113&#x2013;126. doi: 10.1002/humu.21154.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1002/humu.21154</ArticleId><ArticleId IdType=\"pubmed\">19894250</ArticleId></ArticleIdList></Reference><Reference><Citation>Moslehi R, et al. Integrative genomic analysis implicates ERCC6 and its interaction with ERCC8 in susceptibility to breast cancer. Sci. Rep. 2020;10:21276. doi: 10.1038/s41598-020-77037-7.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/s41598-020-77037-7</ArticleId><ArticleId IdType=\"pmc\">PMC7718875</ArticleId><ArticleId IdType=\"pubmed\">33277540</ArticleId></ArticleIdList></Reference><Reference><Citation>Jing JJ, et al. Epistatic SNP interaction of ERCC6 with ERCC8 and their joint protein expression contribute to gastric cancer/atrophic gastritis risk. Oncotarget. 2017;8:43140&#x2013;43152. doi: 10.18632/oncotarget.17814.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.18632/oncotarget.17814</ArticleId><ArticleId IdType=\"pmc\">PMC5522134</ArticleId><ArticleId IdType=\"pubmed\">28562347</ArticleId></ArticleIdList></Reference><Reference><Citation>Ronchetti D, et al. A compendium of long non-coding RNAs transcriptional fingerprint in multiple myeloma. Sci. Rep. 2018;8:6557. doi: 10.1038/s41598-018-24701-8.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/s41598-018-24701-8</ArticleId><ArticleId IdType=\"pmc\">PMC5920050</ArticleId><ArticleId IdType=\"pubmed\">29700321</ArticleId></ArticleIdList></Reference><Reference><Citation>McCrory EJ, Mayes L. Understanding addiction as a developmental disorder: an argument for a developmentally informed multilevel approach. Curr. Addict. Rep. 2015;2:326&#x2013;330. doi: 10.1007/s40429-015-0079-2.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s40429-015-0079-2</ArticleId><ArticleId IdType=\"pmc\">PMC4628052</ArticleId><ArticleId IdType=\"pubmed\">26550551</ArticleId></ArticleIdList></Reference><Reference><Citation>Gunn JK, et al. Prenatal exposure to cannabis and maternal and child health outcomes: a systematic review and meta-analysis. BMJ Open. 2016;6:e009986. doi: 10.1136/bmjopen-2015-009986.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1136/bmjopen-2015-009986</ArticleId><ArticleId IdType=\"pmc\">PMC4823436</ArticleId><ArticleId IdType=\"pubmed\">27048634</ArticleId></ArticleIdList></Reference><Reference><Citation>Eyles DW. How do established developmental risk-factors for schizophrenia change the way the brain develops? Transl. Psychiatry. 2021;11:158. doi: 10.1038/s41398-021-01273-2.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/s41398-021-01273-2</ArticleId><ArticleId IdType=\"pmc\">PMC7940420</ArticleId><ArticleId IdType=\"pubmed\">33686066</ArticleId></ArticleIdList></Reference><Reference><Citation>Gulsuner S, et al. Spatial and temporal mapping of de novo mutations in schizophrenia to a fetal prefrontal cortical network. Cell. 2013;154:518&#x2013;529. doi: 10.1016/j.cell.2013.06.049.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.cell.2013.06.049</ArticleId><ArticleId IdType=\"pmc\">PMC3894107</ArticleId><ArticleId IdType=\"pubmed\">23911319</ArticleId></ArticleIdList></Reference><Reference><Citation>Susser ES, Lin SP. Schizophrenia after prenatal exposure to the Dutch Hunger Winter of 1944&#x2013;1945. Arch. Gen. Psychiatry. 1992;49:983&#x2013;988. doi: 10.1001/archpsyc.1992.01820120071010.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1001/archpsyc.1992.01820120071010</ArticleId><ArticleId IdType=\"pubmed\">1449385</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatoum, A.S. et al. The addiction risk factor: a unitary genetic vulnerability characterizes substance use disorders and their associations with common correlates. Neuropsychopharmacology10.1038/s41386-021-01209-w (2021).</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC9372072</ArticleId><ArticleId IdType=\"pubmed\">34750568</ArticleId></ArticleIdList></Reference><Reference><Citation>Levey DF, et al. Genetic associations with suicide attempt severity and genetic overlap with major depression. Transl. Psychiatry. 2019;9:22. doi: 10.1038/s41398-018-0340-2.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/s41398-018-0340-2</ArticleId><ArticleId IdType=\"pmc\">PMC6336846</ArticleId><ArticleId IdType=\"pubmed\">30655502</ArticleId></ArticleIdList></Reference><Reference><Citation>1000 Genomes Project Consortium et al. A global reference for human genetic variation. Nature. 2015;526:68&#x2013;74. doi: 10.1038/nature15393.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/nature15393</ArticleId><ArticleId IdType=\"pmc\">PMC4750478</ArticleId><ArticleId IdType=\"pubmed\">26432245</ArticleId></ArticleIdList></Reference><Reference><Citation>Loh PR, et al. Reference-based phasing using the Haplotype Reference Consortium panel. Nat. Genet. 2016;48:1443&#x2013;1448. doi: 10.1038/ng.3679.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/ng.3679</ArticleId><ArticleId IdType=\"pmc\">PMC5096458</ArticleId><ArticleId IdType=\"pubmed\">27694958</ArticleId></ArticleIdList></Reference><Reference><Citation>Howie B, Fuchsberger C, Stephens M, Marchini J, Abecasis GR. Fast and accurate genotype imputation in genome-wide association studies through pre-phasing. Nat. Genet. 2012;44:955&#x2013;959. doi: 10.1038/ng.2354.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/ng.2354</ArticleId><ArticleId IdType=\"pmc\">PMC3696580</ArticleId><ArticleId IdType=\"pubmed\">22820512</ArticleId></ArticleIdList></Reference><Reference><Citation>Iglesias AI, et al. Haplotype reference consortium panel: practical implications of imputations with large reference panels. Hum. Mutat. 2017;38:1025&#x2013;1032. doi: 10.1002/humu.23247.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1002/humu.23247</ArticleId><ArticleId IdType=\"pubmed\">28493391</ArticleId></ArticleIdList></Reference><Reference><Citation>Karlson EW, Boutin NT, Hoffnagle AG, Allen NL. Building the partners healthcare biobank at partners personalized medicine: informed consent, return of research results, recruitment lessons and operational considerations. J. Pers. Med. 2016;6:2. doi: 10.3390/jpm6010002.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.3390/jpm6010002</ArticleId><ArticleId IdType=\"pmc\">PMC4810381</ArticleId><ArticleId IdType=\"pubmed\">26784234</ArticleId></ArticleIdList></Reference><Reference><Citation>Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association scans. Bioinformatics. 2010;26:2190&#x2013;2191. doi: 10.1093/bioinformatics/btq340.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/bioinformatics/btq340</ArticleId><ArticleId IdType=\"pmc\">PMC2922887</ArticleId><ArticleId IdType=\"pubmed\">20616382</ArticleId></ArticleIdList></Reference><Reference><Citation>Magi R, et al. Trans-ethnic meta-regression of genome-wide association studies accounting for ancestry increases power for discovery and improves fine-mapping resolution. Hum. Mol. Genet. 2017;26:3639&#x2013;3650. doi: 10.1093/hmg/ddx280.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/hmg/ddx280</ArticleId><ArticleId IdType=\"pmc\">PMC5755684</ArticleId><ArticleId IdType=\"pubmed\">28911207</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasin DS, et al. Prevalence of marijuana use disorders in the United States between 2001&#x2013;2002 and 2012&#x2013;2013. JAMA Psychiatry. 2015;72:1235&#x2013;1242. doi: 10.1001/jamapsychiatry.2015.1858.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1001/jamapsychiatry.2015.1858</ArticleId><ArticleId IdType=\"pmc\">PMC5037576</ArticleId><ArticleId IdType=\"pubmed\">26502112</ArticleId></ArticleIdList></Reference><Reference><Citation>Bulik-Sullivan BK, et al. LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. Nat. Genet. 2015;47:291&#x2013;295. doi: 10.1038/ng.3211.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/ng.3211</ArticleId><ArticleId IdType=\"pmc\">PMC4495769</ArticleId><ArticleId IdType=\"pubmed\">25642630</ArticleId></ArticleIdList></Reference><Reference><Citation>Lundberg M, Campos A, Renteria M, Ngo T, Partida GC. Dissecting the genetic architecture of chronic pain using CTG-VL: complex-traits genetics virtual lab. Behav. Genet. 2019;49:517&#x2013;517.</Citation></Reference><Reference><Citation>Bulik-Sullivan B, et al. An atlas of genetic correlations across human diseases and traits. Nat. Genet. 2015;47:1236&#x2013;1241. doi: 10.1038/ng.3406.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/ng.3406</ArticleId><ArticleId IdType=\"pmc\">PMC4797329</ArticleId><ArticleId IdType=\"pubmed\">26414676</ArticleId></ArticleIdList></Reference><Reference><Citation>Hemani G, et al. The MR-Base platform supports systematic causal inference across the human phenome. Elife. 2018;7:e34408. doi: 10.7554/eLife.34408.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.7554/eLife.34408</ArticleId><ArticleId IdType=\"pmc\">PMC5976434</ArticleId><ArticleId IdType=\"pubmed\">29846171</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Z, et al. Causal associations between risk factors and common diseases inferred from GWAS summary data. Nat. Commun. 2018;9:224. doi: 10.1038/s41467-017-02317-2.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/s41467-017-02317-2</ArticleId><ArticleId IdType=\"pmc\">PMC5768719</ArticleId><ArticleId IdType=\"pubmed\">29335400</ArticleId></ArticleIdList></Reference><Reference><Citation>Gusev A, et al. Integrative approaches for large-scale transcriptome-wide association studies. Nat. Genet. 2016;48:245&#x2013;252. doi: 10.1038/ng.3506.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/ng.3506</ArticleId><ArticleId IdType=\"pmc\">PMC4767558</ArticleId><ArticleId IdType=\"pubmed\">26854917</ArticleId></ArticleIdList></Reference><Reference><Citation>Finucane HK, et al. Partitioning heritability by functional annotation using genome-wide association summary statistics. Nat. Genet. 2015;47:1228&#x2013;1235. doi: 10.1038/ng.3404.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/ng.3404</ArticleId><ArticleId IdType=\"pmc\">PMC4626285</ArticleId><ArticleId IdType=\"pubmed\">26414678</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhattacharya, A. et al. Isoform-level transcriptome-wide association uncovers extensive novel genetic risk mechanisms for neuropsychiatric disorders in the human brain. Preprint at medRxiv10.1101/2022.08.23.22279134 (2022).</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC10703692</ArticleId><ArticleId IdType=\"pubmed\">38036788</ArticleId></ArticleIdList></Reference><Reference><Citation>Mancuso N, et al. Probabilistic fine-mapping of transcriptome-wide association studies. Nat. Genet. 2019;51:675&#x2013;682. doi: 10.1038/s41588-019-0367-1.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/s41588-019-0367-1</ArticleId><ArticleId IdType=\"pmc\">PMC6619422</ArticleId><ArticleId IdType=\"pubmed\">30926970</ArticleId></ArticleIdList></Reference><Reference><Citation>Grotzinger AD, et al. Genomic structural equation modelling provides insights into the multivariate genetic architecture of complex traits. Nat. Hum. Behav. 2019;3:513&#x2013;525. doi: 10.1038/s41562-019-0566-x.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/s41562-019-0566-x</ArticleId><ArticleId IdType=\"pmc\">PMC6520146</ArticleId><ArticleId IdType=\"pubmed\">30962613</ArticleId></ArticleIdList></Reference><Reference><Citation>Turley P, et al. Multi-trait analysis of genome-wide association summary statistics using MTAG. Nat. Genet. 2018;50:229&#x2013;237. doi: 10.1038/s41588-017-0009-4.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/s41588-017-0009-4</ArticleId><ArticleId IdType=\"pmc\">PMC5805593</ArticleId><ArticleId IdType=\"pubmed\">29292387</ArticleId></ArticleIdList></Reference><Reference><Citation>Kranzler HR, et al. Genome-wide association study of alcohol consumption and use disorder in 274,424 individuals from multiple populations. Nat. Commun. 2019;10:1499. doi: 10.1038/s41467-019-09480-8.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/s41467-019-09480-8</ArticleId><ArticleId IdType=\"pmc\">PMC6445072</ArticleId><ArticleId IdType=\"pubmed\">30940813</ArticleId></ArticleIdList></Reference><Reference><Citation>Quach BC, et al. Expanding the genetic architecture of nicotine dependence and its shared genetics with multiple traits. Nat. Commun. 2020;11:5562. doi: 10.1038/s41467-020-19265-z.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1038/s41467-020-19265-z</ArticleId><ArticleId IdType=\"pmc\">PMC7642344</ArticleId><ArticleId IdType=\"pubmed\">33144568</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>\n",
            "XML saved to: path/to/save/xml/37985822.xml\n",
            "Details URL: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=37983029&retmode=xml&api_key=9edd38677707c08b2a96ed1a6e8c61c47408\n",
            "Details Response Content: <?xml version=\"1.0\" ?>\n",
            "<!DOCTYPE PubmedArticleSet PUBLIC \"-//NLM//DTD PubMedArticle, 1st January 2023//EN\" \"https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd\">\n",
            "<PubmedArticleSet>\n",
            "<PubmedArticle><MedlineCitation Status=\"MEDLINE\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">37983029</PMID><DateCompleted><Year>2023</Year><Month>11</Month><Day>27</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>27</Day></DateRevised><Article PubModel=\"Electronic\"><Journal><ISSN IssnType=\"Electronic\">2574-3805</ISSN><JournalIssue CitedMedium=\"Internet\"><Volume>6</Volume><Issue>11</Issue><PubDate><Year>2023</Year><Month>Nov</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA network open</Title><ISOAbbreviation>JAMA Netw Open</ISOAbbreviation></Journal><ArticleTitle>Social Determinants of Health and Cardiologist Involvement in the Care of Adults Hospitalized for Heart Failure.</ArticleTitle><Pagination><StartPage>e2344070</StartPage><MedlinePgn>e2344070</MedlinePgn></Pagination><ELocationID EIdType=\"pii\" ValidYN=\"Y\">e2344070</ELocationID><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.1001/jamanetworkopen.2023.44070</ELocationID><Abstract><AbstractText Label=\"IMPORTANCE\" NlmCategory=\"UNASSIGNED\">Involvement of a cardiologist in the care of adults during a hospitalization for heart failure (HF) is associated with reduced rates of in-hospital mortality and hospital readmission. However, not all patients see a cardiologist when they are hospitalized for HF.</AbstractText><AbstractText Label=\"OBJECTIVE\" NlmCategory=\"UNASSIGNED\">To determine whether social determinants of health (SDOH) are associated with cardiologist involvement in the management of adults hospitalized for HF.</AbstractText><AbstractText Label=\"DESIGN, SETTING, AND PARTICIPANTS\" NlmCategory=\"UNASSIGNED\">This retrospective cohort study used data from the Reasons for Geographic and Racial Difference in Stroke (REGARDS) cohort. Participants included adults who experienced an adjudicated hospitalization for HF between 2009 and 2017 in all 48 contiguous states in the US. Data analysis was performed from November 2022 to January 2023.</AbstractText><AbstractText Label=\"EXPOSURES\" NlmCategory=\"UNASSIGNED\">A total of 9 candidate SDOH, aligned with the Healthy People 2030 conceptual model, were examined: Black race, social isolation, social network and/or caregiver availability, educational attainment&#x2009;less than&#x2009;high school, annual household income less than $35&#x202f;000, living in rural area, living in a zip code with high poverty, living in a Health Professional Shortage Area, and living in a state with poor public health infrastructure.</AbstractText><AbstractText Label=\"MAIN OUTCOMES AND MEASURES\" NlmCategory=\"UNASSIGNED\">The primary outcome was cardiologist involvement, defined as involvement of a cardiologist as the primary responsible clinician or as a consultant. Bivariate associations between each SDOH and cardiologist involvement were examined using Poisson regression with robust SEs.</AbstractText><AbstractText Label=\"RESULTS\" NlmCategory=\"UNASSIGNED\">The study included 1000 participants (median [IQR] age, 77.8 [71.5-84.0] years; 479 women [47.9%]; 414 Black individuals [41.4%]; and 492 of 876 with low income [56.2%]) hospitalized at 549 unique US hospitals. Low annual household income (&lt;$35&#x202f;000) was the only SDOH with a statistically significant association with cardiologist involvement (relative risk, 0.88; 95% CI, 0.82-0.95). In a multivariable analysis adjusting for age, race, sex, HF characteristics, comorbidities, and hospital characteristics, low income remained inversely associated with cardiologist involvement (relative risk, 0.89; 95% CI, 0.82-0.97).</AbstractText><AbstractText Label=\"CONCLUSIONS AND RELEVANCE\" NlmCategory=\"UNASSIGNED\">This cohort study found that adults with low household income were 11% less likely than adults with higher incomes to have a cardiologist involved in their care during a hospitalization for HF. These findings suggest that socioeconomic status may bias the care provided to patients hospitalized for HF.</AbstractText></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Zhang</LastName><ForeName>David T</ForeName><Initials>DT</Initials><AffiliationInfo><Affiliation>Department of Medicine, Weill Cornell Medicine, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Onyebeke</LastName><ForeName>Chukwuma</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Medicine, Weill Cornell Medicine, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Nahid</LastName><ForeName>Musarrat</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medicine, Weill Cornell Medicine, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Balkan</LastName><ForeName>Lauren</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Medicine, Weill Cornell Medicine, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Musse</LastName><ForeName>Mahad</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medicine, Weill Cornell Medicine, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Pinheiro</LastName><ForeName>Laura C</ForeName><Initials>LC</Initials><AffiliationInfo><Affiliation>Department of Health Policy and Management, Weill Cornell Medicine, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Sterling</LastName><ForeName>Madeline R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Department of Medicine, Weill Cornell Medicine, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Durant</LastName><ForeName>Raegan W</ForeName><Initials>RW</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Alabama at Birmingham, Birmingham.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Brown</LastName><ForeName>Todd M</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Alabama at Birmingham, Birmingham.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Levitan</LastName><ForeName>Emily B</ForeName><Initials>EB</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, University of Alabama at Birmingham, Birmingham.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Safford</LastName><ForeName>Monika M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Department of Medicine, Weill Cornell Medicine, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Goyal</LastName><ForeName>Parag</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Medicine, Weill Cornell Medicine, New York, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program for the Care and Study of the Aging Heart, Weill Cornell Medicine, New York, New York.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2023</Year><Month>11</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Netw Open</MedlineTA><NlmUniqueID>101729235</NlmUniqueID><ISSNLinking>2574-3805</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI=\"D006801\" MajorTopicYN=\"N\">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D000328\" MajorTopicYN=\"N\">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D005260\" MajorTopicYN=\"N\">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D000368\" MajorTopicYN=\"N\">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D015331\" MajorTopicYN=\"N\">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D012189\" MajorTopicYN=\"N\">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D064890\" MajorTopicYN=\"N\">Social Determinants of Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D000072096\" MajorTopicYN=\"Y\">Cardiologists</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D006333\" MajorTopicYN=\"Y\">Heart Failure</DescriptorName><QualifierName UI=\"Q000453\" MajorTopicYN=\"N\">epidemiology</QualifierName><QualifierName UI=\"Q000628\" MajorTopicYN=\"N\">therapy</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Pinheiro reported receiving grants from National Heart, Lung, and Blood Institute (NHLBI) during the conduct of the study and grants from the National Cancer Institute and from Conquer Cancer Foundation outside the submitted work. Dr Sterling reported receiving grant K23HL150160 from the NHLBI outside the submitted work. Dr Durant reported receiving grants from NHLBI during the conduct of the study. Dr Brown reported receiving grants from NHLBI during the conduct of the study and grants from American Association of Cardiovascular and Pulmonary Rehabilitation outside the submitted work. Dr Levitan reported receiving grants from NHLBI during the conduct of the study and grants from Amgen, Inc, outside the submitted work. Dr Safford reported being the founder of MedExplain, a patient education company; she derives no financial benefit from this company. Dr Goyal reported receiving grants from the American Heart Association (grant 20CDA35310455), National Institute on Aging (NIA; grant K76AG064428), and Loan Repayment Program (award L30AG060521) and receiving consulting fees from Sensorum Health. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"medline\"><Year>2023</Year><Month>11</Month><Day>27</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2023</Year><Month>11</Month><Day>20</Day><Hour>13</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2023</Year><Month>11</Month><Day>20</Day><Hour>11</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">37983029</ArticleId><ArticleId IdType=\"pmc\">PMC10660170</ArticleId><ArticleId IdType=\"doi\">10.1001/jamanetworkopen.2023.44070</ArticleId><ArticleId IdType=\"pii\">2812077</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Dharmarajan K, Rich MW. Epidemiology, pathophysiology, and prognosis of heart failure in older adults. Heart Fail Clin. 2017;13(3):417-426. doi:10.1016/j.hfc.2017.02.001</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.hfc.2017.02.001</ArticleId><ArticleId IdType=\"pubmed\">28602363</ArticleId></ArticleIdList></Reference><Reference><Citation>Foody JM, Rathore SS, Wang Y, et al. . Physician specialty and mortality among elderly patients hospitalized with heart failure. Am J Med. 2005;118(10):1120-1125. doi:10.1016/j.amjmed.2005.01.075</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.amjmed.2005.01.075</ArticleId><ArticleId IdType=\"pubmed\">16194643</ArticleId></ArticleIdList></Reference><Reference><Citation>Parmar KR, Xiu PY, Chowdhury MR, Patel E, Cohen M. In-hospital treatment and outcomes of heart failure in specialist and non-specialist services: a retrospective cohort study in the elderly. Open Heart. 2015;2(1):e000095. doi:10.1136/openhrt-2014-000095</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1136/openhrt-2014-000095</ArticleId><ArticleId IdType=\"pmc\">PMC4442175</ArticleId><ArticleId IdType=\"pubmed\">26019879</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng RK, Cox M, Neely ML, et al. . Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population. Am Heart J. 2014;168(5):721-730. doi:10.1016/j.ahj.2014.07.008</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.ahj.2014.07.008</ArticleId><ArticleId IdType=\"pubmed\">25440801</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah KS, Xu H, Matsouaka RA, et al. . Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes. J Am Coll Cardiol. 2017;70(20):2476-2486. doi:10.1016/j.jacc.2017.08.074</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jacc.2017.08.074</ArticleId><ArticleId IdType=\"pubmed\">29141781</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed A, Allman RM, Kiefe CI, et al. . Association of consultation between generalists and cardiologists with quality and outcomes of heart failure care. Am Heart J. 2003;145(6):1086-1093. doi:10.1016/S0002-8703(02)94778-2</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/S0002-8703(02)94778-2</ArticleId><ArticleId IdType=\"pubmed\">12796767</ArticleId></ArticleIdList></Reference><Reference><Citation>Ezekowitz JA, van Walraven C, McAlister FA, Armstrong PW, Kaul P. Impact of specialist follow-up in outpatients with congestive heart failure. CMAJ. 2005;172(2):189-194. doi:10.1503/cmaj.1032017</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1503/cmaj.1032017</ArticleId><ArticleId IdType=\"pmc\">PMC543981</ArticleId><ArticleId IdType=\"pubmed\">15655239</ArticleId></ArticleIdList></Reference><Reference><Citation>Indridason OS, Coffman CJ, Oddone EZ. Is specialty care associated with improved survival of patients with congestive heart failure? Am Heart J. 2003;145(2):300-309. doi:10.1067/mhj.2003.54</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1067/mhj.2003.54</ArticleId><ArticleId IdType=\"pubmed\">12595848</ArticleId></ArticleIdList></Reference><Reference><Citation>Jong P, Gong Y, Liu PP, Austin PC, Lee DS, Tu JV. Care and outcomes of patients newly hospitalized for heart failure in the community treated by cardiologists compared with other specialists. Circulation. 2003;108(2):184-191. doi:10.1161/01.CIR.0000080290.39027.48</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1161/01.CIR.0000080290.39027.48</ArticleId><ArticleId IdType=\"pubmed\">12821540</ArticleId></ArticleIdList></Reference><Reference><Citation>Philbin EF, Weil HF, Erb TA, Jenkins PL. Cardiology or primary care for heart failure in the community setting: process of care and clinical outcomes. Chest. 1999;116(2):346-354. doi:10.1378/chest.116.2.346</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1378/chest.116.2.346</ArticleId><ArticleId IdType=\"pubmed\">10453861</ArticleId></ArticleIdList></Reference><Reference><Citation>Salata BM, Sterling MR, Beecy AN, et al. . Discharge processes and 30-day readmission rates of patients hospitalized for heart failure on general medicine and cardiology services. Am J Cardiol. 2018;121(9):1076-1080. doi:10.1016/j.amjcard.2018.01.027</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.amjcard.2018.01.027</ArticleId><ArticleId IdType=\"pmc\">PMC6557434</ArticleId><ArticleId IdType=\"pubmed\">29548676</ArticleId></ArticleIdList></Reference><Reference><Citation>Selim AM, Mazurek JA, Iqbal M, Wang D, Negassa A, Zolty R. Mortality and readmission rates in patients hospitalized for acute decompensated heart failure: a comparison between cardiology and general-medicine service outcomes in an underserved population. Clin Cardiol. 2015;38(3):131-138. doi:10.1002/clc.22372</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1002/clc.22372</ArticleId><ArticleId IdType=\"pmc\">PMC6711015</ArticleId><ArticleId IdType=\"pubmed\">25694226</ArticleId></ArticleIdList></Reference><Reference><Citation>Uthamalingam S, Kandala J, Selvaraj V, et al. . Outcomes of patients with acute decompensated heart failure managed by cardiologists versus noncardiologists. Am J Cardiol. 2015;115(4):466-471. doi:10.1016/j.amjcard.2014.11.034</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.amjcard.2014.11.034</ArticleId><ArticleId IdType=\"pubmed\">25637324</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellotti P, Badano LP, Acquarone N, et al. ; OSCUR Investigators . Specialty-related differences in the epidemiology, clinical profile, management and outcome of patients hospitalized for heart failure; the OSCUR study. Oucome dello Scompenso Cardiaco in relazione all&#x2019;Utilizzo delle Risore. Eur Heart J. 2001;22(7):596-604. doi:10.1053/euhj.2000.2362</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1053/euhj.2000.2362</ArticleId><ArticleId IdType=\"pubmed\">11259147</ArticleId></ArticleIdList></Reference><Reference><Citation>Reis SE, Holubkov R, Edmundowicz D, et al. . Treatment of patients admitted to the hospital with congestive heart failure: specialty-related disparities in practice patterns and outcomes. J Am Coll Cardiol. 1997;30(3):733-738. doi:10.1016/S0735-1097(97)00214-3</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/S0735-1097(97)00214-3</ArticleId><ArticleId IdType=\"pubmed\">9283533</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabit CE, Coplan MJ, Spencer KT, et al. . Cardiology consultation in the emergency department reduces re-hospitalizations for low-socioeconomic patients with acute decompensated heart failure. Am J Med. 2017;130(9):1112.e17-1112.e31. doi:10.1016/j.amjmed.2017.03.044</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.amjmed.2017.03.044</ArticleId><ArticleId IdType=\"pmc\">PMC5572103</ArticleId><ArticleId IdType=\"pubmed\">28457798</ArticleId></ArticleIdList></Reference><Reference><Citation>Auerbach AD, Hamel MB, Califf RM, et al. ; SUPPORT Investigators. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments . Patient characteristics associated with care by a cardiologist among adults hospitalized with severe congestive heart failure. J Am Coll Cardiol. 2000;36(7):2119-2125. doi:10.1016/S0735-1097(00)01005-6</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/S0735-1097(00)01005-6</ArticleId><ArticleId IdType=\"pubmed\">11127450</ArticleId></ArticleIdList></Reference><Reference><Citation>Breathett K, Liu WG, Allen LA, et al. . African Americans are less likely to receive care by a cardiologist during an intensive care unit admission for heart failure. JACC Heart Fail. 2018;6(5):413-420. doi:10.1016/j.jchf.2018.02.015</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.jchf.2018.02.015</ArticleId><ArticleId IdType=\"pmc\">PMC5940011</ArticleId><ArticleId IdType=\"pubmed\">29724363</ArticleId></ArticleIdList></Reference><Reference><Citation>Eberly LA, Richterman A, Beckett AG, et al. . Identification of racial inequities in access to specialized inpatient heart failure care at an academic medical center. Circ Heart Fail. 2019;12(11):e006214. doi:10.1161/CIRCHEARTFAILURE.119.006214</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1161/CIRCHEARTFAILURE.119.006214</ArticleId><ArticleId IdType=\"pmc\">PMC7183732</ArticleId><ArticleId IdType=\"pubmed\">31658831</ArticleId></ArticleIdList></Reference><Reference><Citation>Damiani G, Salvatori E, Silvestrini G, et al. . Influence of socioeconomic factors on hospital readmissions for heart failure and acute myocardial infarction in patients 65 years and older: evidence from a systematic review. Clin Interv Aging. 2015;10:237-245. doi:10.2147/CIA.S71165</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.2147/CIA.S71165</ArticleId><ArticleId IdType=\"pmc\">PMC4310718</ArticleId><ArticleId IdType=\"pubmed\">25653510</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee WC, Serag H, Ohsfeldt RL, et al. . Racial disparities in type of heart failure and hospitalization. J Immigr Minor Health. 2019;21(1):98-104. doi:10.1007/s10903-018-0727-4</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s10903-018-0727-4</ArticleId><ArticleId IdType=\"pubmed\">29564642</ArticleId></ArticleIdList></Reference><Reference><Citation>Su A, Al&#x2019;Aref SJ, Beecy AN, Min JK, Karas MG. Clinical and socioeconomic predictors of heart failure readmissions: a review of contemporary literature. Mayo Clin Proc. 2019;94(7):1304-1320. doi:10.1016/j.mayocp.2019.01.017</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.mayocp.2019.01.017</ArticleId><ArticleId IdType=\"pubmed\">31272573</ArticleId></ArticleIdList></Reference><Reference><Citation>Havranek EP, Mujahid MS, Barr DA, et al. ; American Heart Association Council on Quality of Care and Outcomes Research, Council on Epidemiology and Prevention, Council on Cardiovascular and Stroke Nursing, Council on Lifestyle and Cardiometabolic Health, and Stroke Council . Social determinants of risk and outcomes for cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2015;132(9):873-898. doi:10.1161/CIR.0000000000000228</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1161/CIR.0000000000000228</ArticleId><ArticleId IdType=\"pubmed\">26240271</ArticleId></ArticleIdList></Reference><Reference><Citation>Alderwick H, Gottlieb L. Meanings and misunderstandings: a social determinants of health lexicon for health care systems. Milbank Quarterly. June 2019. Accessed April 2022. https://www.milbank.org/quarterly/articles/meanings-and-misunderstandings-a-social-determinants-of-health-lexicon-for-health-care-systems/</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC6554506</ArticleId><ArticleId IdType=\"pubmed\">31069864</ArticleId></ArticleIdList></Reference><Reference><Citation>Sterling MR, Ringel JB, Pinheiro LC, et al. . Social determinants of health and 90-day mortality after hospitalization for heart failure in the REGARDS Study. J Am Heart Assoc. 2020;9(9):e014836. doi:10.1161/JAHA.119.014836</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1161/JAHA.119.014836</ArticleId><ArticleId IdType=\"pmc\">PMC7428585</ArticleId><ArticleId IdType=\"pubmed\">32316807</ArticleId></ArticleIdList></Reference><Reference><Citation>Sterling MR, Ringel JB, Pinheiro LC, et al. . Social determinants of health and 30-day readmissions among adults hospitalized for heart failure in the REGARDS Study. Circ Heart Fail. 2022;15(1):e008409. doi:10.1161/CIRCHEARTFAILURE.121.008409</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1161/CIRCHEARTFAILURE.121.008409</ArticleId><ArticleId IdType=\"pmc\">PMC8849604</ArticleId><ArticleId IdType=\"pubmed\">34865525</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinheiro LC, Reshetnyak E, Sterling MR, Levitan EB, Safford MM, Goyal P. Multiple vulnerabilities to health disparities and incident heart failure hospitalization in the REGARDS Study. Circ Cardiovasc Qual Outcomes. 2020;13(8):e006438. doi:10.1161/CIRCOUTCOMES.119.006438</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1161/CIRCOUTCOMES.119.006438</ArticleId><ArticleId IdType=\"pmc\">PMC7577176</ArticleId><ArticleId IdType=\"pubmed\">32703013</ArticleId></ArticleIdList></Reference><Reference><Citation>Safford MM, Reshetnyak E, Sterling MR, et al. . Number of social determinants of health and fatal and nonfatal incident coronary heart disease in the REGARDS Study. Circulation. 2021;143(3):244-253. doi:10.1161/CIRCULATIONAHA.120.048026</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1161/CIRCULATIONAHA.120.048026</ArticleId><ArticleId IdType=\"pmc\">PMC7856168</ArticleId><ArticleId IdType=\"pubmed\">33269599</ArticleId></ArticleIdList></Reference><Reference><Citation>King JB, Pinheiro LC, Bryan Ringel J, et al. . Multiple social vulnerabilities to health disparities and hypertension and death in the REGARDS Study. Hypertension. 2022;79(1):196-206. doi:10.1161/HYPERTENSIONAHA.120.15196</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1161/HYPERTENSIONAHA.120.15196</ArticleId><ArticleId IdType=\"pmc\">PMC8665033</ArticleId><ArticleId IdType=\"pubmed\">34784734</ArticleId></ArticleIdList></Reference><Reference><Citation>Reshetnyak E, Ntamatungiro M, Pinheiro LC, et al. . Impact of multiple social determinants of health on incident stroke. Stroke. 2020;51(8):2445-2453. doi:10.1161/STROKEAHA.120.028530</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1161/STROKEAHA.120.028530</ArticleId><ArticleId IdType=\"pmc\">PMC9264323</ArticleId><ArticleId IdType=\"pubmed\">32673521</ArticleId></ArticleIdList></Reference><Reference><Citation>Schroff P, Gamboa CM, Durant RW, Oikeh A, Richman JS, Safford MM. Vulnerabilities to health disparities and statin use in the REGARDS (Reasons for Geographic and Racial Differences in Stroke) Study. J Am Heart Assoc. 2017;6(9):e005449. doi:10.1161/JAHA.116.005449</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1161/JAHA.116.005449</ArticleId><ArticleId IdType=\"pmc\">PMC5634251</ArticleId><ArticleId IdType=\"pubmed\">28847913</ArticleId></ArticleIdList></Reference><Reference><Citation>Colantonio LD, Richman JS, Carson AP, et al. . Performance of the atherosclerotic cardiovascular disease pooled cohort risk equations by social deprivation status. J Am Heart Assoc. 2017;6(3):e005676. doi:10.1161/JAHA.117.005676</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1161/JAHA.117.005676</ArticleId><ArticleId IdType=\"pmc\">PMC5524046</ArticleId><ArticleId IdType=\"pubmed\">28314800</ArticleId></ArticleIdList></Reference><Reference><Citation>Howard VJ, Cushman M, Pulley L, et al. . The reasons for geographic and racial differences in stroke study: objectives and design. Neuroepidemiology. 2005;25(3):135-143. doi:10.1159/000086678</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1159/000086678</ArticleId><ArticleId IdType=\"pubmed\">15990444</ArticleId></ArticleIdList></Reference><Reference><Citation>American Hospital Association. American Hospital Association Annual Survey dataset. Accessed July 2022. https://www.ahadata.com/aha-annual-survey-database</Citation></Reference><Reference><Citation>Stekhoven DJ, B&#xfc;hlmann P. MissForest: non-parametric missing value imputation for mixed-type data. Bioinformatics. 2012;28(1):112-118. doi:10.1093/bioinformatics/btr597</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/bioinformatics/btr597</ArticleId><ArticleId IdType=\"pubmed\">22039212</ArticleId></ArticleIdList></Reference><Reference><Citation>Stekhoven D. MissForest: nonparametric missing value imputation using random forest. R package version 1.5. October 13, 2022. Accessed October 20, 2023. https://cran.r-project.org/web/packages/missForest/missForest.pdf</Citation></Reference><Reference><Citation>US Department of Health and Human Services, Office of Disease Prevention and Health Promotion. Healthy People 2030: social determinants of health. Accessed April 2022. https://health.gov/healthypeople/objectives-and-data/social-determinants-health</Citation></Reference><Reference><Citation>Redmond N, Richman J, Gamboa CM, et al. . Perceived stress is associated with incident coronary heart disease and all-cause mortality in low- but not high-income participants in the Reasons for Geographic And Racial Differences in Stroke study. J Am Heart Assoc. 2013;2(6):e000447. doi:10.1161/JAHA.113.000447</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1161/JAHA.113.000447</ArticleId><ArticleId IdType=\"pmc\">PMC3886761</ArticleId><ArticleId IdType=\"pubmed\">24356528</ArticleId></ArticleIdList></Reference><Reference><Citation>United Health Foundation. America&#x2019;s Health Rankings. Accessed April 2022. https://www.americashealthrankings.org/</Citation></Reference><Reference><Citation>Unlu O, Levitan EB, Reshetnyak E, et al. . Polypharmacy in older adults hospitalized for heart failure. Circ Heart Fail. 2020;13(11):e006977. doi:10.1161/CIRCHEARTFAILURE.120.006977</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1161/CIRCHEARTFAILURE.120.006977</ArticleId><ArticleId IdType=\"pmc\">PMC8819498</ArticleId><ArticleId IdType=\"pubmed\">33045844</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen R, Davidson P. Improving access to care in America: individual and contextual indicators. In: Kominski GF, ed. Changing the US Health Care System: Key Issues in Health Services Policy and Management. Jossey-Bass; 2007:1-30.</Citation></Reference><Reference><Citation>Heidenreich PA, Bozkurt B, Aguilar D, et al. . 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895-e1032. doi:10.1161/CIR.0000000000001063</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1161/CIR.0000000000001063</ArticleId><ArticleId IdType=\"pubmed\">35363499</ArticleId></ArticleIdList></Reference><Reference><Citation>Peterson PN, Rumsfeld JS, Liang L, et al. ; American Heart Association Get With the Guidelines-Heart Failure Program . A validated risk score for in-hospital mortality in patients with heart failure from the American Heart Association get with the guidelines program. Circ Cardiovasc Qual Outcomes. 2010;3(1):25-32. doi:10.1161/CIRCOUTCOMES.109.854877</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1161/CIRCOUTCOMES.109.854877</ArticleId><ArticleId IdType=\"pubmed\">20123668</ArticleId></ArticleIdList></Reference><Reference><Citation>Knol MJ, Le Cessie S, Algra A, Vandenbroucke JP, Groenwold RH. Overestimation of risk ratios by odds ratios in trials and cohort studies: alternatives to logistic regression. CMAJ. 2012;184(8):895-899. doi:10.1503/cmaj.101715</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1503/cmaj.101715</ArticleId><ArticleId IdType=\"pmc\">PMC3348192</ArticleId><ArticleId IdType=\"pubmed\">22158397</ArticleId></ArticleIdList></Reference><Reference><Citation>Churchwell K, Elkind MSV, Benjamin RM, et al. ; American Heart Association . Call to action: structural racism as a fundamental driver of health disparities&#x2014;a Presidential Advisory from the American Heart Association. Circulation. 2020;142(24):e454-e468. doi:10.1161/CIR.0000000000000936</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1161/CIR.0000000000000936</ArticleId><ArticleId IdType=\"pubmed\">33170755</ArticleId></ArticleIdList></Reference><Reference><Citation>Javed Z, Haisum Maqsood M, Yahya T, et al. . Race, racism, and cardiovascular health: applying a social determinants of health framework to racial/ethnic disparities in cardiovascular disease. Circ Cardiovasc Qual Outcomes. 2022;15(1):e007917. doi:10.1161/CIRCOUTCOMES.121.007917</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1161/CIRCOUTCOMES.121.007917</ArticleId><ArticleId IdType=\"pubmed\">35041484</ArticleId></ArticleIdList></Reference><Reference><Citation>Nayak A, Hicks AJ, Morris AA. Understanding the complexity of heart failure risk and treatment in Black patients. Circ Heart Fail. 2020;13(8):e007264. doi:10.1161/CIRCHEARTFAILURE.120.007264</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1161/CIRCHEARTFAILURE.120.007264</ArticleId><ArticleId IdType=\"pmc\">PMC7644144</ArticleId><ArticleId IdType=\"pubmed\">32787445</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradley AS, Adeleke IO, Estime SR. Healthcare disparities in trauma: why they exist and what we can do. Curr Opin Anaesthesiol. 2022;35(2):150-153. doi:10.1097/ACO.0000000000001094</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1097/ACO.0000000000001094</ArticleId><ArticleId IdType=\"pubmed\">35045002</ArticleId></ArticleIdList></Reference><Reference><Citation>Khidir H, McWilliams JM, O&#x2019;Malley AJ, Zaborski L, Landon BE, Smulowitz PB. Analysis of consistency in emergency department physician variation in propensity for admission across patient sociodemographic groups. JAMA Netw Open. 2021;4(9):e2125193. doi:10.1001/jamanetworkopen.2021.25193</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1001/jamanetworkopen.2021.25193</ArticleId><ArticleId IdType=\"pmc\">PMC8456378</ArticleId><ArticleId IdType=\"pubmed\">34546373</ArticleId></ArticleIdList></Reference><Reference><Citation>Egede LE, Walker RJ, Williams JS. Intersection of structural racism, social determinants of health, and implicit bias with emergency physician admission tendencies. JAMA Netw Open. 2021;4(9):e2126375. doi:10.1001/jamanetworkopen.2021.26375</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1001/jamanetworkopen.2021.26375</ArticleId><ArticleId IdType=\"pmc\">PMC8594614</ArticleId><ArticleId IdType=\"pubmed\">34546376</ArticleId></ArticleIdList></Reference><Reference><Citation>Hawkins NM, Jhund PS, McMurray JJ, Capewell S. Heart failure and socioeconomic status: accumulating evidence of inequality. Eur J Heart Fail. 2012;14(2):138-146. doi:10.1093/eurjhf/hfr168</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/eurjhf/hfr168</ArticleId><ArticleId IdType=\"pubmed\">22253454</ArticleId></ArticleIdList></Reference><Reference><Citation>Potter EL, Hopper I, Sen J, Salim A, Marwick TH. Impact of socioeconomic status on incident heart failure and left ventricular dysfunction: systematic review and meta-analysis. Eur Heart J Qual Care Clin Outcomes. 2019;5(2):169-179. doi:10.1093/ehjqcco/qcy047</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/ehjqcco/qcy047</ArticleId><ArticleId IdType=\"pubmed\">30295783</ArticleId></ArticleIdList></Reference><Reference><Citation>Schrage B, Lund LH, Benson L, et al. . Lower socioeconomic status predicts higher mortality and morbidity in patients with heart failure. Heart. 2021;107(3):229-236. doi:10.1136/heartjnl-2020-317216</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1136/heartjnl-2020-317216</ArticleId><ArticleId IdType=\"pubmed\">32769169</ArticleId></ArticleIdList></Reference><Reference><Citation>Squire I. Socioeconomic status and outcomes in heart failure with reduced ejection fraction. Heart. 2018;104(12):966-967. doi:10.1136/heartjnl-2017-312814</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1136/heartjnl-2017-312814</ArticleId><ArticleId IdType=\"pubmed\">29371375</ArticleId></ArticleIdList></Reference><Reference><Citation>Joynt Maddox KE, Reidhead M, Hu J, et al. . Adjusting for social risk factors impacts performance and penalties in the hospital readmissions reduction program. Health Serv Res. 2019;54(2):327-336. doi:10.1111/1475-6773.13133</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1111/1475-6773.13133</ArticleId><ArticleId IdType=\"pmc\">PMC6407348</ArticleId><ArticleId IdType=\"pubmed\">30848491</ArticleId></ArticleIdList></Reference><Reference><Citation>Trapl ES, Smith S, Joshi K, et al. . Dietary impact of produce prescriptions for patients with hypertension. Prev Chronic Dis. 2018;15:E138. doi:10.5888/pcd15.180301</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.5888/pcd15.180301</ArticleId><ArticleId IdType=\"pmc\">PMC6266424</ArticleId><ArticleId IdType=\"pubmed\">30447106</ArticleId></ArticleIdList></Reference><Reference><Citation>Behforouz HL, Drain PK, Rhatigan JJ. Rethinking the social history. N Engl J Med. 2014;371(14):1277-1279. doi:10.1056/NEJMp1404846</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1056/NEJMp1404846</ArticleId><ArticleId IdType=\"pubmed\">25271600</ArticleId></ArticleIdList></Reference><Reference><Citation>Samra R, Hankivsky O. Adopting an intersectionality framework to address power and equity in medicine. Lancet. 2021;397(10277):857-859. doi:10.1016/S0140-6736(20)32513-7</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/S0140-6736(20)32513-7</ArticleId><ArticleId IdType=\"pmc\">PMC9752210</ArticleId><ArticleId IdType=\"pubmed\">33357466</ArticleId></ArticleIdList></Reference><Reference><Citation>Powell-Wiley TM, Baumer Y, Baah FO, et al. . Social determinants of cardiovascular disease. Circ Res. 2022;130(5):782-799. doi:10.1161/CIRCRESAHA.121.319811</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1161/CIRCRESAHA.121.319811</ArticleId><ArticleId IdType=\"pmc\">PMC8893132</ArticleId><ArticleId IdType=\"pubmed\">35239404</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>\n",
            "XML saved to: path/to/save/xml/37983029.xml\n",
            "Details URL: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=37981476&retmode=xml&api_key=9edd38677707c08b2a96ed1a6e8c61c47408\n",
            "Details Response Content: <?xml version=\"1.0\" ?>\n",
            "<!DOCTYPE PubmedArticleSet PUBLIC \"-//NLM//DTD PubMedArticle, 1st January 2023//EN\" \"https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd\">\n",
            "<PubmedArticleSet>\n",
            "<PubmedArticle><MedlineCitation Status=\"Publisher\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">37981476</PMID><DateRevised><Year>2023</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel=\"Print-Electronic\"><Journal><ISSN IssnType=\"Electronic\">1938-0690</ISSN><JournalIssue CitedMedium=\"Internet\"><PubDate><Year>2023</Year><Month>Oct</Month><Day>31</Day></PubDate></JournalIssue><Title>Clinical lung cancer</Title><ISOAbbreviation>Clin Lung Cancer</ISOAbbreviation></Journal><ArticleTitle>Barriers to Timely Lung Cancer Care in Early Stage Non-Small Cell Lung Cancer and Impact on Patient Outcomes.</ArticleTitle><ELocationID EIdType=\"pii\" ValidYN=\"Y\">S1525-7304(23)00226-7</ELocationID><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.1016/j.cllc.2023.10.013</ELocationID><Abstract><AbstractText Label=\"BACKGROUND\" NlmCategory=\"BACKGROUND\">Optimal time to treatment for early-stage lung cancer is uncertain. We examined causes of delays in care for Veterans who presented with early-stage non-small cell lung cancer (NSCLC) and whether workup time was associated with increased upstaging or all-cause mortality.</AbstractText><AbstractText Label=\"METHODS\" NlmCategory=\"METHODS\">We performed a retrospective analysis of Veterans referred to our facility with radiographic stage I or II NSCLC between January 2013 to December 2017, with follow-up through October 2021. Patient demographics, tumor characteristics, time intervals of care, and reasons for delays were collected. Guideline concordance (GC) was defined as treatment within 14 weeks of abnormal image. Multivariable analyses were performed to determine association between delays in care, survival, and upstaging.</AbstractText><AbstractText Label=\"RESULTS\" NlmCategory=\"RESULTS\">Data from 203 Veterans were analyzed. Median time between abnormal imaging to treatment was 17.7 weeks (IQR 12.7-26.6). Only 33% of Veterans received GC care. Most common patient-related delays were: intercurrent hospitalization/comorbidity (23%), no-shows (16%) and inability to reach Veteran (17%). Most common system-related delay: lack of scheduling availability (25%). Delays associated with upstaging: transportation issues, request for coordination of appointments, and unforeseen appointment changes. Rates of upstaging did not differ between GC and discordant groups (P&#xa0;=&#xa0;.6). GC care was not an independent predictor of mortality. Post-hoc, treatment within 8 weeks was associated with lower rates of upstaging (P&#xa0;=&#xa0;.05).</AbstractText><AbstractText Label=\"CONCLUSION\" NlmCategory=\"CONCLUSIONS\">Although GC care did not impact survival or upstaging for early-stage NSCLC, shorter timeframes may be beneficial. Modifiable delays in care exist which may be addressed at an institutional level to improve timeliness of care.</AbstractText><CopyrightInformation>Published by Elsevier Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Pirzadeh</LastName><ForeName>Mina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, MI; Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, MI. Electronic address: mpirzad@med.umich.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Lagina</LastName><ForeName>Madeline</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, MI; Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, MI.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Wood</LastName><ForeName>Cameron</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Hematology and Oncology, Duke University, Durham, NC.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Valley</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, MI; Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, MI; Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor, MI.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Ramnath</LastName><ForeName>Nithya</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, MI; Division of Hematology and Oncology, University of Michigan, Ann Arbor, MI.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Arenberg</LastName><ForeName>Douglas</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, MI.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Deng</LastName><ForeName>Jane C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, MI; Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, MI.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2023</Year><Month>10</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Lung Cancer</MedlineTA><NlmUniqueID>100893225</NlmUniqueID><ISSNLinking>1525-7304</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner=\"NOTNLM\"><Keyword MajorTopicYN=\"N\">Evidence-based medicine</Keyword><Keyword MajorTopicYN=\"N\">Oncology</Keyword><Keyword MajorTopicYN=\"N\">Quality improvement</Keyword><Keyword MajorTopicYN=\"N\">Smoking</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"received\"><Year>2023</Year><Month>6</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus=\"revised\"><Year>2023</Year><Month>10</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus=\"accepted\"><Year>2023</Year><Month>10</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus=\"medline\"><Year>2023</Year><Month>11</Month><Day>20</Day><Hour>0</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2023</Year><Month>11</Month><Day>20</Day><Hour>0</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2023</Year><Month>11</Month><Day>19</Day><Hour>21</Hour><Minute>57</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">37981476</ArticleId><ArticleId IdType=\"doi\">10.1016/j.cllc.2023.10.013</ArticleId><ArticleId IdType=\"pii\">S1525-7304(23)00226-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>\n",
            "XML saved to: path/to/save/xml/37981476.xml\n",
            "Details URL: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=37979368&retmode=xml&api_key=9edd38677707c08b2a96ed1a6e8c61c47408\n",
            "Details Response Content: <?xml version=\"1.0\" ?>\n",
            "<!DOCTYPE PubmedArticleSet PUBLIC \"-//NLM//DTD PubMedArticle, 1st January 2023//EN\" \"https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd\">\n",
            "<PubmedArticleSet>\n",
            "<PubmedArticle><MedlineCitation Status=\"Publisher\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">37979368</PMID><DateRevised><Year>2023</Year><Month>11</Month><Day>18</Day></DateRevised><Article PubModel=\"Print-Electronic\"><Journal><ISSN IssnType=\"Electronic\">1879-4076</ISSN><JournalIssue CitedMedium=\"Internet\"><Volume>15</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Nov</Month><Day>16</Day></PubDate></JournalIssue><Title>Journal of geriatric oncology</Title><ISOAbbreviation>J Geriatr Oncol</ISOAbbreviation></Journal><ArticleTitle>Self-reported electronic symptom monitoring in older patients with multimorbidity treated for cancer: Development of a core dataset based on expert consensus, literature review, and quality of life questionnaires.</ArticleTitle><Pagination><StartPage>101643</StartPage><MedlinePgn>101643</MedlinePgn></Pagination><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.1016/j.jgo.2023.101643</ELocationID><ELocationID EIdType=\"pii\" ValidYN=\"Y\">S1879-4068(23)00240-0</ELocationID><Abstract><AbstractText Label=\"INTRODUCTION\" NlmCategory=\"BACKGROUND\">In cancer care, symptom monitoring during treatment results in improved clinical outcomes such as improved quality of life, longer survival, and fewer hospital admissions. However, as the majority of patients with cancer are older and have multimorbidity, they may benefit from monitoring of additional symptoms. The aim of this study was to identify a core set of symptoms to monitor in older patients with multimorbidity treated for cancer, including symptoms caused by treatment side effects, destabilization of comorbidities, and functional decline.</AbstractText><AbstractText Label=\"MATERIALS AND METHODS\" NlmCategory=\"METHODS\">During a scoping literature search, 17 quality of life questionnaires were used to select 53 possible symptoms to monitor. An expert panel of cancer and geriatrics specialists was asked to participate in multiple online surveys to indicate whether these symptoms were not relevant to monitor, only relevant to monitor in a specific patient group, or relevant to monitor in all patients. In a subsequent round the list was reduced and the panel indicated how frequently these symptoms should be monitored during cancer treatment and after cancer treatment completion. Finally, a digital consensus meeting was organised to decide when symptoms had to trigger a recommendation to the patient to get in touch with their medical team.</AbstractText><AbstractText Label=\"RESULTS\" NlmCategory=\"RESULTS\">In total, 30 healthcare professionals participated in the online surveys. After two rounds, a dataset of 19 symptoms related to cancer, cancer treatment, functional decline, and destabilization of comorbidities was agreed upon for monitoring. Five symptoms were selected for daily monitoring during treatment, seven for weekly, and seven for monthly. After treatment completion, the panel agreed upon less frequent reporting. Additionally, nine symptoms to be monitored only in patients with specific cancer types or treatment types were chosen, such as \"cough up blood\" in lung cancer.</AbstractText><AbstractText Label=\"DISCUSSION\" NlmCategory=\"CONCLUSIONS\">This study is the first to identify a core set of symptoms to monitor in older patients with multimorbidity treated for cancer. Future research is needed to investigate whether the monitoring of these symptoms is feasible and improves clinical outcomes in older patients with multimorbidity treated for cancer.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023. Published by Elsevier Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Nelleke Seghers</LastName><ForeName>P A L</ForeName><Initials>PAL</Initials><AffiliationInfo><Affiliation>Department of Geriatric Medicine, Diakonessenhuis, 3582, KE, Utrecht, the Netherlands. Electronic address: nseghers@diakhuis.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Hamaker</LastName><ForeName>Marije E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Department of Geriatric Medicine, Diakonessenhuis, 3582, KE, Utrecht, the Netherlands. Electronic address: mhamaker@diakhuis.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>O'Hanlon</LastName><ForeName>Shane</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Geriatric Medicine, St Vincent's University Hospital, D04 T6F4 Dublin, Ireland; Department of Geriatric Medicine, University College Dublin, D04 V1W8 Dublin, Ireland. Electronic address: Shaneohanlon@svhg.ie.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Portielje</LastName><ForeName>Johanneke E A</ForeName><Initials>JEA</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Leiden University Medical Center-LUMC, 2333, ZA, Leiden, the Netherlands. Electronic address: j.e.a.portielje@lumc.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Wildiers</LastName><ForeName>Hans</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium. Electronic address: hans.wildiers@uzleuven.be.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Soubeyran</LastName><ForeName>Pierre</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Institut Bergoni&#xe9;, Inserm U1312, SIRIC BRIO, Universit&#xe9; de Bordeaux, 33076 Bordeaux, France. Electronic address: p.soubeyran@bordeaux.unicancer.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Coolbrandt</LastName><ForeName>Annemarie</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Oncology Nursing, University Hospitals Leuven, Leuven, Belgium; Department of Public Health and Primary Care, Academic Centre for Nursing and Midwifery, KU Leuven, Leuven, Belgium. Electronic address: annemarie.coolbrandt@uzleuven.be.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Rostoft</LastName><ForeName>Siri</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Geriatric Medicine, Oslo University Hospital, 0424 Oslo, Norway; Institute of Clinical Medicine, University of Oslo, 0318 Oslo, Norway. Electronic address: siri.rostoft@medisin.uio.no.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2023</Year><Month>11</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Geriatr Oncol</MedlineTA><NlmUniqueID>101534770</NlmUniqueID><ISSNLinking>1879-4068</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner=\"NOTNLM\"><Keyword MajorTopicYN=\"N\">Comorbidity</Keyword><Keyword MajorTopicYN=\"N\">Functional decline</Keyword><Keyword MajorTopicYN=\"N\">Geriatric oncology</Keyword><Keyword MajorTopicYN=\"N\">Multimorbidity</Keyword><Keyword MajorTopicYN=\"N\">Older patients</Keyword><Keyword MajorTopicYN=\"N\">Symptom monitoring</Keyword><Keyword MajorTopicYN=\"N\">cancer care</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest Pierre Soubeyran: Board member with TEVA, Sandoz, BMS and EISAI. All other authors: No competing interests to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"received\"><Year>2022</Year><Month>12</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus=\"revised\"><Year>2023</Year><Month>5</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus=\"accepted\"><Year>2023</Year><Month>10</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus=\"medline\"><Year>2023</Year><Month>11</Month><Day>19</Day><Hour>9</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2023</Year><Month>11</Month><Day>19</Day><Hour>9</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2023</Year><Month>11</Month><Day>18</Day><Hour>18</Hour><Minute>8</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">37979368</ArticleId><ArticleId IdType=\"doi\">10.1016/j.jgo.2023.101643</ArticleId><ArticleId IdType=\"pii\">S1879-4068(23)00240-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>\n",
            "XML saved to: path/to/save/xml/37979368.xml\n",
            "Details URL: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=37977487&retmode=xml&api_key=9edd38677707c08b2a96ed1a6e8c61c47408\n",
            "Details Response Content: <?xml version=\"1.0\" ?>\n",
            "<!DOCTYPE PubmedArticleSet PUBLIC \"-//NLM//DTD PubMedArticle, 1st January 2023//EN\" \"https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd\">\n",
            "<PubmedArticleSet>\n",
            "<PubmedArticle><MedlineCitation Status=\"Publisher\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">37977487</PMID><DateRevised><Year>2023</Year><Month>12</Month><Day>06</Day></DateRevised><Article PubModel=\"Print-Electronic\"><Journal><ISSN IssnType=\"Electronic\">1556-1380</ISSN><JournalIssue CitedMedium=\"Internet\"><PubDate><Year>2023</Year><Month>Nov</Month><Day>17</Day></PubDate></JournalIssue><Title>Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer</Title><ISOAbbreviation>J Thorac Oncol</ISOAbbreviation></Journal><ArticleTitle>Outcomes in Incidentally Versus Screening Detected Stage I Lung Cancer Surgery Patients.</ArticleTitle><ELocationID EIdType=\"pii\" ValidYN=\"Y\">S1556-0864(23)02364-X</ELocationID><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.1016/j.jtho.2023.11.008</ELocationID><Abstract><AbstractText Label=\"INTRODUCTION\" NlmCategory=\"BACKGROUND\">Although the importance of lung cancer screening for early diagnosis is established, because of poor enrollment, incidental findings still play a role in diagnosis of patients who qualify. Nevertheless, analysis of this incidental cohort is lacking. We present a retrospective analysis comparing patients with thoracic surgery with incidental versus screening detected stage I lung cancer.</AbstractText><AbstractText Label=\"METHODS\" NlmCategory=\"METHODS\">Thoracic surgery cases at Mount Sinai Hospital from March, 1, 2012, to June, 30, 2022, were queried for patients eligible for lung cancer screening and a stage I diagnosis. The basis of lung nodule detection (incidental versus screening detected) was identified. We compared demographic variables, comorbidities, tumor staging, procedure details, and postoperative outcomes between the cohorts.</AbstractText><AbstractText Label=\"RESULTS\" NlmCategory=\"RESULTS\">Of the patients eligible for screening with lung cancer resection and stage I diagnosis at Mount Sinai, 153 were identified incidentally and 67 through screening. The patients in the incidental cohort were older (p&#xa0;= 0.005), more likely to have quit smoking (p&#xa0;= 0.04), and had a greater number of comorbidities (p&#xa0;= 0.0002). There was no statistically significant difference between the groups with regard to pack-year smoking history, lung cancer histological type, location or size of tumor, and surgical approach, length of surgery or stay, number of postoperative outcomes, and survival.</AbstractText><AbstractText Label=\"CONCLUSIONS\" NlmCategory=\"CONCLUSIONS\">In stage I lung cancers, no significant differences were identified between incidentally and screening detected lung nodules with regard to tumor characteristics, surgical approach, and postoperative outcomes. Imaging conducted for other reasons should be considered as a valid and important diagnostic tool, similar to traditional low-dose computed tomography, in patients who qualify for screening.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Gulati</LastName><ForeName>Shubham</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Icahn School of Medicine at Mount Sinai, New York, New York; Institute for Translational Epidemiology, Icahn School of Medicine at Mount Sinai, New York, New York; Department of Thoracic Surgery, Icahn School of Medicine at Mount Sinai, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Ivic-Pavlicic</LastName><ForeName>Tara</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Institute for Translational Epidemiology, Icahn School of Medicine at Mount Sinai, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Joasil</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Icahn School of Medicine at Mount Sinai, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Flores</LastName><ForeName>Raja</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Thoracic Surgery, Icahn School of Medicine at Mount Sinai, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Taioli</LastName><ForeName>Emanuela</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Institute for Translational Epidemiology, Icahn School of Medicine at Mount Sinai, New York, New York; Department of Thoracic Surgery, Icahn School of Medicine at Mount Sinai, New York, New York; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: Emanuela.taioli@mountsinai.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2023</Year><Month>11</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Thorac Oncol</MedlineTA><NlmUniqueID>101274235</NlmUniqueID><ISSNLinking>1556-0864</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner=\"NOTNLM\"><Keyword MajorTopicYN=\"N\">Incidental findings</Keyword><Keyword MajorTopicYN=\"N\">LDCT</Keyword><Keyword MajorTopicYN=\"N\">Lung cancer resections</Keyword><Keyword MajorTopicYN=\"N\">NSCLC</Keyword><Keyword MajorTopicYN=\"N\">Surgical complications</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"received\"><Year>2023</Year><Month>9</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus=\"revised\"><Year>2023</Year><Month>10</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus=\"accepted\"><Year>2023</Year><Month>11</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2023</Year><Month>11</Month><Day>18</Day><Hour>11</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"medline\"><Year>2023</Year><Month>11</Month><Day>18</Day><Hour>11</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2023</Year><Month>11</Month><Day>17</Day><Hour>19</Hour><Minute>39</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">37977487</ArticleId><ArticleId IdType=\"doi\">10.1016/j.jtho.2023.11.008</ArticleId><ArticleId IdType=\"pii\">S1556-0864(23)02364-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>\n",
            "XML saved to: path/to/save/xml/37977487.xml\n",
            "Details URL: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=37974211&retmode=xml&api_key=9edd38677707c08b2a96ed1a6e8c61c47408\n",
            "Details Response Content: <?xml version=\"1.0\" ?>\n",
            "<!DOCTYPE PubmedArticleSet PUBLIC \"-//NLM//DTD PubMedArticle, 1st January 2023//EN\" \"https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd\">\n",
            "<PubmedArticleSet>\n",
            "<PubmedArticle><MedlineCitation Status=\"MEDLINE\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">37974211</PMID><DateCompleted><Year>2023</Year><Month>11</Month><Day>20</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>29</Day></DateRevised><Article PubModel=\"Electronic\"><Journal><ISSN IssnType=\"Electronic\">1748-717X</ISSN><JournalIssue CitedMedium=\"Internet\"><Volume>18</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Nov</Month><Day>16</Day></PubDate></JournalIssue><Title>Radiation oncology (London, England)</Title><ISOAbbreviation>Radiat Oncol</ISOAbbreviation></Journal><ArticleTitle>Proton therapy (PT) combined with concurrent chemotherapy for locally advanced non-small cell lung cancer with negative driver genes.</ArticleTitle><Pagination><StartPage>189</StartPage><MedlinePgn>189</MedlinePgn></Pagination><ELocationID EIdType=\"pii\" ValidYN=\"Y\">189</ELocationID><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.1186/s13014-023-02372-8</ELocationID><Abstract><AbstractText Label=\"PURPOSE\" NlmCategory=\"OBJECTIVE\">To discuss the optimal treatment modality for inoperable locally advanced Non-Small Cell Lung Cancer patients with poor physical status, impaired cardio-pulmonary function, and negative driver genes, and provide clinical evidence.</AbstractText><AbstractText Label=\"MATERIALS AND METHODS\" NlmCategory=\"METHODS\">Retrospective analysis of 62 cases of locally advanced non-small cell lung cancer patients with negative driver genes treated at Tsukuba University Hospital(Japan) and Qingdao University Affiliated Hospital(China).The former received proton therapy with concurrent chemotherapy, referred to as the proton group, with 25 cases included; while the latter underwent X-ray therapy with concurrent chemoradiotherapy followed by 1 year of sequential immunomodulatory maintenance therapy, referred to as the X-ray group, with 37 cases included.The treatment response and adverse reactions were assessed using RECIST v1.1 criteria and CTCAE v3.0, and radiotherapy planning and evaluation of organs at risk were performed using the CB-CHOP method.All data were subjected to statistical analysis using GraphPad Prism v9.0, with a T-test using P&#x2009;&lt;&#x2009;0.05 considered statistically significant.</AbstractText><AbstractText Label=\"RESULTS\" NlmCategory=\"RESULTS\">(1)Target dose distribution: compared to the X-ray group, the proton group exhibited smaller CTV and field sizes, with a more pronounced bragg peak.(2)Organs at risk dose: When comparing the proton group to the X-ray group, lung doses (V5, V20, MLD) and heart doses (V40, Dmax) were lower, with statistical significance (P&#x2009;&lt;&#x2009;0.05), while spinal cord and esophagus doses showed no significant differences between the two groups (P&#x2009;&gt;&#x2009;0.05).(3)Treatment-related toxicities: The incidence of grade 3 or higher adverse events in the proton group and X-ray group was 28.6% and 4.2%, respectively, with a statistically significant difference (P&#x2009;&lt;&#x2009;0.05). In terms of the types of adverse events, the proton group primarily experienced esophagitis and pneumonia, while the X-ray group primarily experienced pneumonia, esophagitis, and myocarditis. Both groups did not experience radiation myelitis or esophagotracheal fistula.(4)Efficacy evaluation: The RR in the proton group and X-ray group was 68.1% and 70.2%, respectively (P&#x2009;&gt;&#x2009;0.05), and the DCR was 92.2% and 86.4%, respectively (P&#x2009;&gt;&#x2009;0.05), indicating no significant difference in short-term efficacy between the two treatment modalities.(5)Survival status: The PFS in the proton group and X-ray group was 31.6&#x2009;&#xb1;&#x2009;3.5 months (95% CI: 24.7&#x2009;~&#x2009;38.5) and 24.9&#x2009;&#xb1;&#x2009;1.55 months (95% CI: 21.9&#x2009;~&#x2009;27.9), respectively (P&#x2009;&gt;&#x2009;0.05), while the OS was 51.6&#x2009;&#xb1;&#x2009;4.62 months (95% CI: 42.5&#x2009;~&#x2009;60.7) and 33.1&#x2009;&#xb1;&#x2009;1.99 months (95% CI: 29.2&#x2009;~&#x2009;37.1), respectively (P&#x2009;&lt;&#x2009;0.05).According to the annual-specific analysis, the PFS rates for the first to third years in both groups were as follows: 100%, 56.1% and 32.5% for the proton group vs. 100%, 54.3% and 26.3% for the X-ray group. No statistical differences were observed at each time point (P&#x2009;&gt;&#x2009;0.05).The OS rates for the first to third years in both groups were as follows: 100%, 88.2%, 76.4% for the proton group vs. 100%, 91.4%, 46.3% for the X-ray group. There was no significant difference in the first to second years (P&#x2009;&gt;&#x2009;0.05), but the third year showed a significant difference (P&#x2009;&lt;&#x2009;0.05). Survival curve graphs also depicted a similar trend.</AbstractText><AbstractText Label=\"CONCLUSION\" NlmCategory=\"CONCLUSIONS\">There were no significant statistical differences observed between the two groups in terms of PFS and OS within the first two years. However, the proton group demonstrated a clear advantage over the X-ray group in terms of adverse reactions and OS in the third year. This suggests a more suitable treatment modality and clinical evidence for populations with frail health, compromised cardio-pulmonary function, post-COVID-19 sequelae, and underlying comorbidities.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Jin</LastName><ForeName>Yonglong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Radiotherapy, The Affiliated Hospital of Qingdao University, Qingdao, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Public Health, Qingdao University, Qingdao, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Shimizu</LastName><ForeName>Shosei</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, University of Tsukuba Hospital, Tsukuba, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiotherapy, YIZHOU Cancer Hospital, Qingdao, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Li</LastName><ForeName>Yinuo</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, University of Tsukuba Hospital, Tsukuba, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Yao</LastName><ForeName>Yuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Graduate School of Environmental Science, Hokkaido University, Sapporo, Hokkaido, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Liu</LastName><ForeName>Xiguang</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Radiotherapy, The Affiliated Hospital of Qingdao University, Qingdao, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Si</LastName><ForeName>Hongzong</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>School of Public Health, Qingdao University, Qingdao, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Sakurai</LastName><ForeName>Hideyuki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, University of Tsukuba Hospital, Tsukuba, Japan. hsakurai@pmrc.tsukuba.ac.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Xiao</LastName><ForeName>Wenjing</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Radiotherapy, The Affiliated Hospital of Qingdao University, Qingdao, China. yjin5799@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN=\"Y\"><Grant><GrantID>YXH2022ZX02204</GrantID><Agency>Qilu Scientific Research Special Project of Shandong Medical Association</Agency><Country/></Grant><Grant><GrantID>QDFY+X202101034</GrantID><Agency>Clinical Medicine + X Scientific Research Project</Agency><Country/></Grant><Grant><GrantID>2019-0405</GrantID><Agency>Shandong Traditional Chinese Medicine Science and Technology Development Plan project</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2023</Year><Month>11</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Radiat Oncol</MedlineTA><NlmUniqueID>101265111</NlmUniqueID><ISSNLinking>1748-717X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI=\"D011522\">Protons</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI=\"D006801\" MajorTopicYN=\"N\">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D002289\" MajorTopicYN=\"Y\">Carcinoma, Non-Small-Cell Lung</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D008175\" MajorTopicYN=\"Y\">Lung Neoplasms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D061766\" MajorTopicYN=\"Y\">Proton Therapy</DescriptorName><QualifierName UI=\"Q000009\" MajorTopicYN=\"N\">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D011522\" MajorTopicYN=\"N\">Protons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D012189\" MajorTopicYN=\"N\">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D059248\" MajorTopicYN=\"N\">Chemoradiotherapy</DescriptorName><QualifierName UI=\"Q000009\" MajorTopicYN=\"N\">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D000971\" MajorTopicYN=\"N\">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName UI=\"Q000627\" MajorTopicYN=\"N\">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D004941\" MajorTopicYN=\"Y\">Esophagitis</DescriptorName><QualifierName UI=\"Q000209\" MajorTopicYN=\"N\">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D011014\" MajorTopicYN=\"Y\">Pneumonia</DescriptorName><QualifierName UI=\"Q000150\" MajorTopicYN=\"N\">complications</QualifierName><QualifierName UI=\"Q000188\" MajorTopicYN=\"N\">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D003131\" MajorTopicYN=\"N\">Combined Modality Therapy</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner=\"NOTNLM\"><Keyword MajorTopicYN=\"N\">Cardio-pulmonary function</Keyword><Keyword MajorTopicYN=\"N\">DVH</Keyword><Keyword MajorTopicYN=\"N\">Negative driver genes</Keyword><Keyword MajorTopicYN=\"N\">Non-small cell Lung cancer(NSCLC)</Keyword><Keyword MajorTopicYN=\"N\">Proton therapy</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"received\"><Year>2023</Year><Month>10</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus=\"accepted\"><Year>2023</Year><Month>10</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus=\"medline\"><Year>2023</Year><Month>11</Month><Day>20</Day><Hour>6</Hour><Minute>55</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2023</Year><Month>11</Month><Day>17</Day><Hour>15</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2023</Year><Month>11</Month><Day>17</Day><Hour>1</Hour><Minute>55</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">37974211</ArticleId><ArticleId IdType=\"pmc\">PMC10652584</ArticleId><ArticleId IdType=\"doi\">10.1186/s13014-023-02372-8</ArticleId><ArticleId IdType=\"pii\">10.1186/s13014-023-02372-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Narjust Duma, Rafael Santana-Davila, Julian R Molina. Non-Small Cell Lung Cancer: Epidemiology, Screening, diagnosis, and Treatment[J]. Mayo Clin Proc 2019,94(8):1623&#x2013;40.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">31378236</ArticleId></ArticleIdList></Reference><Reference><Citation>Tetsuya MDTJC-H, Yang M-JA. Ullas Batra,Byoung-Chul Cho,Gerardo Cornelio,Tony Lim,Tony Mok,Kumar Prabhash,Thanyanan Reungwetwattana,Sheng-Xiang Ren,Navneet Singh,Shinichi Toyooka,Yi-Long Wu,Pan-Chyr Yang,Yasushi Yatabe.Expert Consensus recommendations on Biomarker Testing in Metastatic and Nonmetastatic NSCLC in Asia[J] J Thorac Oncol. 2023;18(4):436&#x2013;46.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">36379356</ArticleId></ArticleIdList></Reference><Reference><Citation>Marina CG, Julien Mazieres, Martin Reck, Christos Chouaid, Helge Bischoff, Niels Reinmuth, Laura Cove-Smith, Talal Mansy,Diego Cortinovis, Maria RM. Angelo Delmonte, Jos&#xe9; Garcia S&#xe1;nchez, Luis Enrique Chara Velarde, Reyes Bernabe, Luis Paz-Ares, Ignacio Diaz Perez, Nataliya Trunova,Kayhan Foroutanpour, Corinne Faivre Finn. Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial[J]. J Thorac Oncol, 2022,17(12):1415&#x2013;1427.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">35961520</ArticleId></ArticleIdList></Reference><Reference><Citation>Hideyuki S. Tatsuya Ohno, Kazuhiko Ogawa. Current status and future prospects of particle therapy (proton beam and heavy ion therapy) in Japan-in the special issue of the J Radiation Research[J] J Radiat Res 2023,64(Suppl 1):i1.10.1093/jrr/rrad034.</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC10278875</ArticleId><ArticleId IdType=\"pubmed\">37210628</ArticleId></ArticleIdList></Reference><Reference><Citation>Zihan Z. Bingjie Guan, Huang Xia, Rong Zheng, Benhua Xu. Particle radiotherapy in the era of radioimmunotherapy[J]. Cancer Lett 2023 567:21626810.1016/j.canlet.2023.216268.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">37331583</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Huang WY-YLTWY-Y. Ping Xia.Computed tomography-guided lung biopsy with rapid on-site evaluation for diagnosis of lung lesions: a meta-analysis[J] J Cardiothorac Surg. 2023;18(1):122. doi: 10.1186/s13019-023-02212-6.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1186/s13019-023-02212-6</ArticleId><ArticleId IdType=\"pmc\">PMC10088145</ArticleId><ArticleId IdType=\"pubmed\">37038189</ArticleId></ArticleIdList></Reference><Reference><Citation>Lori M, Minasian,Ann O&#x2019;Mara,Sandra AM. Clinician and patient reporting of symptomatic adverse events in Cancer clinical trials: using CTCAE and PRO-CTCAE&#xae; to provide two distinct and complementary Perspectives[J] Patient Relat Outcome Meas. 2022;13:249&#x2013;58. doi: 10.2147/PROM.S256567.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.2147/PROM.S256567</ArticleId><ArticleId IdType=\"pmc\">PMC9744864</ArticleId><ArticleId IdType=\"pubmed\">36524232</ArticleId></ArticleIdList></Reference><Reference><Citation>Olga Rodak, Manuel David Peris-D&#xed;az, Mateusz Olbromski, Marzenna Podhorska-Oko&#x142;&#xf3;w,Piotr Dzi&#x119;giel.Current Landscape of Non-small Cell Lung Cancer: Epidemiology, histological classification, targeted therapies, and Immunotherapy[J]. Cancers (Basel),2021,13(18):4705.10.3390/cancers13184705.</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC8470525</ArticleId><ArticleId IdType=\"pubmed\">34572931</ArticleId></ArticleIdList></Reference><Reference><Citation>Alessandra B. Giulia Pasello, Giuseppe De Luca, Alberto Bortolami, Manuel Zorzi,Federico Rea, Carlo Pinato,Antonella Dal Cin, Anna De Polo,Marco Schiavon, Andrea Zuin,Marco Marchetti, Giovanna Scroccaro, Vincenzo Baldo,Massimo Rugge, Valentina Guarneri, PierFranco Conte. Non-Small-Cell Lung Cancer: real-world Cost Consequence Analysis[J]. JCO Oncol Pract,2021,17(8):e1085&#x2013;93.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">33826354</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiajia W. Zhenghong Lin. Non-Small Cell Lung Cancer targeted therapy: Drugs and mechanisms of Drug Resistance[J]. Int J Mol Sci 2022,23(23):15056.10.3390/ijms232315056.</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC9738331</ArticleId><ArticleId IdType=\"pubmed\">36499382</ArticleId></ArticleIdList></Reference><Reference><Citation>Tina C. Jared Fradette, Monika Pradhan, Don L Gibbons. Tumor Immunology and Immunotherapy of Non-small-cell Lung Cancer[J]. Cold Spring Harb Perspect Med,2022,12(5):a037895.10.1101/cshperspect.a037895.</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC8957639</ArticleId><ArticleId IdType=\"pubmed\">34580079</ArticleId></ArticleIdList></Reference><Reference><Citation>Soo-Ryum Yang,Anne M, Schultheis Helena Yu,Diana Mandelker,Marc Ladanyi,Reinhard B&#xfc;ttner.Precision medicine in non-small cell Lung cancer: current applications and future directions[J] Semin Cancer Biol. 2022;84:184&#x2013;98. doi: 10.1016/j.semcancer.2020.07.009.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.semcancer.2020.07.009</ArticleId><ArticleId IdType=\"pubmed\">32730814</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabine Semrau,Gunther Klautke, Rainer Fietkau.Baseline cardiopulmonary function as an Independent prognostic factor for survival of inoperable non-small-cell Lung cancer after concurrent chemoradiotherapy: a single-center analysis of 161 cases[J]. Int J Radiat Oncol Biol Phys, 2011,79(1):96&#x2013;104.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">20350789</ArticleId></ArticleIdList></Reference><Reference><Citation>John C. Astra Z.Rationale for concurrent chemoradiotherapy for patients with stage III non-small-cell Lung cancer[J] Br J Cancer. 2020;123(1):10&#x2013;7.</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC7735212</ArticleId><ArticleId IdType=\"pubmed\">33293671</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z. Pingfan Shi,Chenge Qin,Wen Zhang,Shumeng Lin,Tiansheng Zheng,Ming Li,Lihong Fan.Nomogram predicting overall survival of stage IIIB non-small-cell Lung cancer patients based on the SEER database[J] Clin Respir J. 2023 doi: 10.1111/crj.13660.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1111/crj.13660</ArticleId><ArticleId IdType=\"pubmed\">37466041</ArticleId></ArticleIdList></Reference><Reference><Citation>Cortiula F, Reymen B, Peters S, Van Mol P, Wauters E, Vansteenkiste J, De Ruysscher D. L E L.Hendriks Immunotherapy in unresectable stage III non-small-cell Lung cancer: state of the art and novel therapeutic approaches[J]. Ann Oncol 2022,33(9):893&#x2013;908.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">35777706</ArticleId></ArticleIdList></Reference><Reference><Citation>Yonglong JYCWXB, Li Jinpeng Xu,Dunmin Zhuang,Lina Dong,Xiguang Liu. The Co-mutation of CDKN2A and PDCD1LG2 may be a predictor of Duvalizumab -Induced Cytokine Storm in Non-small-cell Lung Cancer: a Case Report[J] Global J Pharm Pharm Sci. 2021;8(5):159&#x2013;65.</Citation></Reference><Reference><Citation>Nan BKXHGMCMLZJCX, Zhang. Xiao Ding, Bing Xia,Lujun Zhao, Lijie Han,Jiancheng Li, Chen Hu,Luhua Wang. Real-world treatment patterns and clinical outcomes in EGFR-mutant locally advanced lung adenocarcinoma: a multi-center cohort study[J]. J Natl Cancer Cent 2023, 3(1):65&#x2013;71.</Citation></Reference><Reference><Citation>Zhe Chen MM, Dominello. Michael,Joiner, Jay W Burmeister. Proton versus photon radiation therapy: a clinical review[J].Front Oncol, 2023,10.3389/fonc.2023.1133909.</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC10091462</ArticleId><ArticleId IdType=\"pubmed\">37064131</ArticleId></ArticleIdList></Reference><Reference><Citation>Sophia CK, Jay OL, Jason AE. Proton versus photon-based radiation therapy for Prostate cancer: emerging evidence and considerations in the era of value-based cancer care[J]. Prostate Cancer Prostatic Dis 2019,22(4):509&#x2013;21.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">30967625</ArticleId></ArticleIdList></Reference><Reference><Citation>Habash M. Bohorquez LC, Kyriakou E. Clinical and functional assays of radiosensitivity and radiation induced second cancer[J]. Cancer(Basel), 2017,9(11):E147.</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC5704165</ArticleId><ArticleId IdType=\"pubmed\">29077012</ArticleId></ArticleIdList></Reference><Reference><Citation>Gandhi S. Chandna S.Radiation induced in flammatory cascad and its reverberating crosstalks as potential cause of post radiotherapy second malignancies[J] Cancer Metastasis Rev. 2017;36(2):375&#x2013;93. doi: 10.1007/s10555-017-9669-x.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1007/s10555-017-9669-x</ArticleId><ArticleId IdType=\"pubmed\">28707199</ArticleId></ArticleIdList></Reference><Reference><Citation>Randall JB. Nima Sharifai, Benjamin Fischer-Valuck, Comron Hassanzadeh, Jeffrey Guzelian, John S A Chrisinger, Jeff M Michalski, Peter Oppelt,Brian C Baumann. Abscopal Effect Following Proton Beam Radiotherapy in a Patient With Inoperable Metastatic Retroperitoneal Sarcoma[J]. Front Oncol,2019,9:922.10.3389/fonc.2019.00922.</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC6775241</ArticleId><ArticleId IdType=\"pubmed\">31616634</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshitaka Matsumoto, Nobuyoshi Fukumitsu, Hitoshi Ishikawa, Kei Nakai,Hideyuki Sakurai. A Critical Review of Radiation Therapy: From Particle Beam Therapy (Proton, Carbon, and BNCT) to Beyond[J]. J Pers Med,2021,11(8):825. 10.3390/jpm11080825.</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC8399040</ArticleId><ArticleId IdType=\"pubmed\">34442469</ArticleId></ArticleIdList></Reference><Reference><Citation>Gjyshi O. Zhongxing Liao.Proton therapy for locally advanced non-small cell Lung cancer[J] Br J Radiol. 2020;93(1107):20190378. doi: 10.1259/bjr.20190378.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1259/bjr.20190378</ArticleId><ArticleId IdType=\"pmc\">PMC7066957</ArticleId><ArticleId IdType=\"pubmed\">31430188</ArticleId></ArticleIdList></Reference><Reference><Citation>Sejpal S, Komaki R, Tsao A, Chang JY, Liao Z, Wei X, Allen PK, Lu C, Gillin M, Cox JD. Early findings on toxicity of proton beam therapy with concurrent chemotherapy for nonsmall cell Lung cancer[J]. Volume 117. Cancer; 2011. pp. 3004&#x2013;13.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">21264827</ArticleId></ArticleIdList></Reference><Reference><Citation>Toshiki O. Yoshiko Oshiro,Masashi Mizumoto,Haruko Numajiri,Hitoshi Ishikawa,Toshiyuki Okumura,Toshiyuki Terunuma,Takeji Sakae,Hideyuki Sakurai.Comparison of dose-volume histograms between proton beam and X-ray conformal radiotherapy for locally advanced non-small-cell Lung cancer[J] J Radiat Res. 2015;56(1):128&#x2013;33. doi: 10.1093/jrr/rru082.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1093/jrr/rru082</ArticleId><ArticleId IdType=\"pmc\">PMC4572589</ArticleId><ArticleId IdType=\"pubmed\">25368341</ArticleId></ArticleIdList></Reference><Reference><Citation>Hwang E, Gaito,A France,A M Crellin S, Thwaites DI, Ahern V, Indelicato D, Timmermann B. E Smith.Outcomes of patients treated in the UK Proton Overseas Programme: non-central nervous system. Group[J] Clin Oncol. 2023;35(5):292&#x2013;300. doi: 10.1016/j.clon.2023.02.009.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.clon.2023.02.009</ArticleId><ArticleId IdType=\"pubmed\">36813694</ArticleId></ArticleIdList></Reference><Reference><Citation>Simona Gaito, Giulia Marvaso, Ramon Ortiz, Adrian Crellin, Marianne C, Aznar,Daniel JI. Shermaine Pan,Gillian Whitfield, Filippo Alongi, Barbara Alicja Jereczek Fossa,Neil Burnet, Michelle P Li, Bethany Rothwell, Ed Smith, Rovel J Colaco. Proton Beam Therapy in the Oligometastatic/Oligorecurrent setting: is there a Role? A Literature Review[J].Cancers (Basel), 2023,15(9): 2489.</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC10177340</ArticleId><ArticleId IdType=\"pubmed\">37173955</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaito S, Burnet NG, Aznar MC, Marvaso G, Fossa BAJ, Crellin A, Indelicato D, Pan S, Colaco R, Rieu R, Smith E. Whitfield.Proton Beam Therapy in the reirradiation setting of Brain and Base of Skull Tumour. Recurrences[J] Clin Oncol. 2023;35(10):673&#x2013;81. doi: 10.1016/j.clon.2023.07.010.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.clon.2023.07.010</ArticleId><ArticleId IdType=\"pubmed\">37574418</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaito S, Aznar MC, Burnet NG, Crellin A, France A, Indelicato D, Kirkby KJ, Pan S, Whitfield G. E. Smith.Assessing equity of Access to Proton Beam Therapy: A literature Review[J] Clin Oncol 2023,35(9):e528&#x2013;36.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">37296036</ArticleId></ArticleIdList></Reference><Reference><Citation>Neil G, Burnet,Thomas MS, Gaito, Norman F, Kirkby, Adam H, Aitkenhead, Carmel N, Anandadas, Marianne C, Aznar, Lisa H, Barraclough, Gerben Borst,Frances C, Charlwood, Matthew Clarke, Rovel J, Colaco, Adrian M, Crellin, Noemie N, Defourney,Christina JH, Henthorn,Kirsten T, Hopkins I, Hwang, Sam E, Ingram,Karen P, Kirkby,Lip J, Lee W, Catherine A, McBain,Michael J, Merchant,David J, Noble, Shermaine Pan, James M, Price. Ganesh Radhakrishna, David Reboredo-Gil, Ahmed Salem, Srijith Sashidharan, Peter Sitch, Ed Smith, Edward Ak Smith, Michael J Taylor, David J Thomson, Nicola J Thorp, Tracy Sa Underwood, John W Warmenhoven, James P Wylie, Gillian Whitfield. Estimating the percentage of patients who might benefit from proton beam therapy instead of X-ray radiotherapy[J]. Br J Radiol, 2022,95(1133):20211175.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">35220723</ArticleId></ArticleIdList></Reference><Reference><Citation>Hwang E, Burnet NG, Crellin AM, Ahern V, Thwaites DI, Gaito S, Chang YC, Smith E. Therapy[J] Clin Oncol. 2022;34(1):11&#x2013;8. .A Novel Model and Infrastructure for Clinical Outcomes Data Collection and Their Systematic Evaluation for UK Patients Receiving Proton Beam.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">34602320</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>\n",
            "XML saved to: path/to/save/xml/37974211.xml\n",
            "Details URL: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=37973983&retmode=xml&api_key=9edd38677707c08b2a96ed1a6e8c61c47408\n",
            "Details Response Content: <?xml version=\"1.0\" ?>\n",
            "<!DOCTYPE PubmedArticleSet PUBLIC \"-//NLM//DTD PubMedArticle, 1st January 2023//EN\" \"https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd\">\n",
            "<PubmedArticleSet>\n",
            "<PubmedArticle><MedlineCitation Status=\"MEDLINE\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">37973983</PMID><DateCompleted><Year>2023</Year><Month>11</Month><Day>20</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>24</Day></DateRevised><Article PubModel=\"Electronic\"><Journal><ISSN IssnType=\"Electronic\">2045-2322</ISSN><JournalIssue CitedMedium=\"Internet\"><Volume>13</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Nov</Month><Day>16</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Risk of secondary malignancy following radiation therapy for prostate cancer.</ArticleTitle><Pagination><StartPage>20083</StartPage><MedlinePgn>20083</MedlinePgn></Pagination><ELocationID EIdType=\"pii\" ValidYN=\"Y\">20083</ELocationID><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.1038/s41598-023-45856-z</ELocationID><Abstract><AbstractText>We investigated whether prostate cancer patients treated with external beam radiation therapy (EBRT) have a higher cumulative incidence of secondary cancer compared with patients treated with radical prostatectomy (RP). We used state-wide linked data from South Australia to follow men with prostate cancer diagnosed from 2002 to 2019. The cumulative incidence of overall and site-specific secondary cancers between 5 and 15&#xa0;years after treatment was estimated. Fine-Gray competing risk analyses were performed with additional sensitivity analyses to test different scenarios. A total of 7625 patients were included (54% underwent RP and 46% EBRT). Characteristics of the two groups differed significantly, with the EBRT group being older (71 vs. 64&#xa0;years), having higher comorbidity burden and being more likely to die during follow-up than the RP group. Fifteen-year cumulative incidence for all secondary cancers was 27.4% and 22.3% in EBRT and RP groups, respectively. In the adjusted models, patients in the EBRT group had a significantly higher risk of genitourinary (adjusted subhazard ratio (aSHR), 2.29; 95%CI 1.16-4.51) and lung (aSHR, 1.93; 95%CI 1.05-3.56) cancers compared with patients in the RP group. However, there was no statistically significant difference between the two groups for risk of any secondary cancer, gastro-intestinal, skin or haematologic cancers. No statistically significant differences in overall risk of secondary cancer were observed in any of the sensitivity analyses and patterns for risk at specific cancer sites were relatively consistent across different age restriction and latency/time-lag scenarios. In conclusion, the increased risk of genitourinary and lung cancers among men undergoing EBRT may relate partly to treatment effects and partly to unmeasured residual confounding.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Tiruye</LastName><ForeName>Tenaw</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Cancer Epidemiology and Population Health Research Group, Allied Health and Human Performance, University of South Australia, North Terrace, SAHMRI Building, Adelaide, 5001, Australia. Tenaw.Tiruye@unisa.edu.au.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Public Health Department, Debre Markos University, Debre Markos, Ethiopia. Tenaw.Tiruye@unisa.edu.au.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>David</LastName><ForeName>Rowan</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Urology Unit, Flinders Medical Centre, Bedford Park, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Flinders Health and Medical Research Institute, Flinders University, Adelaide, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>O'Callaghan</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Urology Unit, Flinders Medical Centre, Bedford Park, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Flinders Health and Medical Research Institute, Flinders University, Adelaide, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>South Australian Prostate Cancer Clinical Outcomes Collaborative, Adelaide, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>FitzGerald</LastName><ForeName>Liesel M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Higgs</LastName><ForeName>Braden</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Cancer Epidemiology and Population Health Research Group, Allied Health and Human Performance, University of South Australia, North Terrace, SAHMRI Building, Adelaide, 5001, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiation Oncology, Royal Adelaide Hospital, Adelaide, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Kahokehr</LastName><ForeName>Arman A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Flinders Health and Medical Research Institute, Flinders University, Adelaide, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Urology Unit, Lyell McEwin Hospital, Elizabeth Vale, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Roder</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Cancer Epidemiology and Population Health Research Group, Allied Health and Human Performance, University of South Australia, North Terrace, SAHMRI Building, Adelaide, 5001, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Beckmann</LastName><ForeName>Kerri</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Cancer Epidemiology and Population Health Research Group, Allied Health and Human Performance, University of South Australia, North Terrace, SAHMRI Building, Adelaide, 5001, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType><PublicationType UI=\"D013485\">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2023</Year><Month>11</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI=\"D008297\" MajorTopicYN=\"N\">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D006801\" MajorTopicYN=\"N\">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI=\"D001918\" MajorTopicYN=\"Y\">Brachytherapy</DescriptorName><QualifierName UI=\"Q000009\" MajorTopicYN=\"N\">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D011471\" MajorTopicYN=\"Y\">Prostatic Neoplasms</DescriptorName><QualifierName UI=\"Q000453\" MajorTopicYN=\"N\">epidemiology</QualifierName><QualifierName UI=\"Q000209\" MajorTopicYN=\"N\">etiology</QualifierName><QualifierName UI=\"Q000532\" MajorTopicYN=\"N\">radiotherapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D016609\" MajorTopicYN=\"Y\">Neoplasms, Second Primary</DescriptorName><QualifierName UI=\"Q000453\" MajorTopicYN=\"N\">epidemiology</QualifierName><QualifierName UI=\"Q000209\" MajorTopicYN=\"N\">etiology</QualifierName><QualifierName UI=\"Q000601\" MajorTopicYN=\"N\">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D011467\" MajorTopicYN=\"N\">Prostate</DescriptorName><QualifierName UI=\"Q000473\" MajorTopicYN=\"N\">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D011468\" MajorTopicYN=\"N\">Prostatectomy</DescriptorName><QualifierName UI=\"Q000009\" MajorTopicYN=\"N\">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI=\"D016896\" MajorTopicYN=\"N\">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"received\"><Year>2023</Year><Month>8</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus=\"accepted\"><Year>2023</Year><Month>10</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus=\"medline\"><Year>2023</Year><Month>11</Month><Day>20</Day><Hour>6</Hour><Minute>54</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2023</Year><Month>11</Month><Day>17</Day><Hour>15</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2023</Year><Month>11</Month><Day>17</Day><Hour>1</Hour><Minute>31</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">37973983</ArticleId><ArticleId IdType=\"pmc\">PMC10654670</ArticleId><ArticleId IdType=\"doi\">10.1038/s41598-023-45856-z</ArticleId><ArticleId IdType=\"pii\">10.1038/s41598-023-45856-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Donovan JL, Hamdy FC, Lane J, Mason M, Metcalfe C, Walsh E, et al. Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N. Engl. J. Med. 2016;375:1425&#x2013;1437. doi: 10.1056/NEJMoa1606221.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1056/NEJMoa1606221</ArticleId><ArticleId IdType=\"pmc\">PMC5134995</ArticleId><ArticleId IdType=\"pubmed\">27626365</ArticleId></ArticleIdList></Reference><Reference><Citation>Tiruye T, O&#x2019;Callaghan M, Moretti K, Jay A, Higgs B, Santoro K, et al. Patient-reported functional outcome measures and treatment choice for prostate cancer. BMC Urol. 2022;22(1):169. doi: 10.1186/s12894-022-01117-1.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1186/s12894-022-01117-1</ArticleId><ArticleId IdType=\"pmc\">PMC9637295</ArticleId><ArticleId IdType=\"pubmed\">36335325</ArticleId></ArticleIdList></Reference><Reference><Citation>Baxter NN, Tepper JE, Durham SB, Rothenberger DA, Virnig BA. Increased risk of rectal cancer after prostate radiation: A population-based study. Gastroenterology. 2005;128(4):819&#x2013;824. doi: 10.1053/j.gastro.2004.12.038.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1053/j.gastro.2004.12.038</ArticleId><ArticleId IdType=\"pubmed\">15825064</ArticleId></ArticleIdList></Reference><Reference><Citation>Moschini M, Zaffuto E, Karakiewicz PI, Andrea DD, Foerster B, Abufaraj M, et al. External Beam radiotherapy increases the risk of bladder cancer when compared with radical prostatectomy in patients affected by prostate cancer: A population-based analysis. Eur. Urol. 2019;75(2):319&#x2013;328. doi: 10.1016/j.eururo.2018.09.034.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.eururo.2018.09.034</ArticleId><ArticleId IdType=\"pubmed\">30293908</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallis CJD, Mahar AL, Choo R, Herschorn S, Kodama RT, Shah PS, et al. Second malignancies after radiotherapy for prostate cancer: Systematic review and meta-analysis. BMJ. 2016;352:i851. doi: 10.1136/bmj.i851.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1136/bmj.i851</ArticleId><ArticleId IdType=\"pmc\">PMC4775870</ArticleId><ArticleId IdType=\"pubmed\">26936410</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan C-Y, Huang W-Y, Lin C-S, Su Y-F, Lo C-H, Tsao C-C, et al. Risk of second primary malignancies among patients with prostate cancer: A population-based cohort study. PLOS One. 2017;12(4):e0175217. doi: 10.1371/journal.pone.0175217.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1371/journal.pone.0175217</ArticleId><ArticleId IdType=\"pmc\">PMC5383246</ArticleId><ArticleId IdType=\"pubmed\">28384363</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhojani N, Capitanio U, Suardi N, Jeldres C, Isbarn H, Shariat SF, et al. The rate of secondary malignancies after radical prostatectomy versus external beam radiation therapy for localized prostate cancer: A population-based study on 17,845 patients. Int. J. Radiat. Oncol. Biol. Phys. 2010;76(2):342&#x2013;8. doi: 10.1016/j.ijrobp.2009.02.011.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.ijrobp.2009.02.011</ArticleId><ArticleId IdType=\"pubmed\">20117287</ArticleId></ArticleIdList></Reference><Reference><Citation>Nam RK, Cheung P, Herschorn S, Saskin R, Su J, Klotz LH, et al. Incidence of complications other than urinary incontinence or erectile dysfunction after radical prostatectomy or radiotherapy for prostate cancer: A population-based cohort study. Lancet Oncol. 2014;15(2):223&#x2013;231. doi: 10.1016/S1470-2045(13)70606-5.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/S1470-2045(13)70606-5</ArticleId><ArticleId IdType=\"pubmed\">24440474</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdel-Wahab M, Reis IM, Hamilton K. Second primary cancer after radiotherapy for prostate cancer&#x2014;a seer analysis of brachytherapy versus external beam radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 2008;72(1):58&#x2013;68. doi: 10.1016/j.ijrobp.2007.12.043.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.ijrobp.2007.12.043</ArticleId><ArticleId IdType=\"pubmed\">18374503</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang J, Kestin LL, Ye H, Wallace M, Martinez AA, Vicini FA. Analysis of second malignancies after modern radiotherapy versus prostatectomy for localized prostate cancer. Radiotherapy Oncol. 2011;98(1):81&#x2013;86. doi: 10.1016/j.radonc.2010.09.012.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.radonc.2010.09.012</ArticleId><ArticleId IdType=\"pubmed\">20951450</ArticleId></ArticleIdList></Reference><Reference><Citation>Zelefsky MJ, Pei X, Teslova T, Kuk D, Magsanoc JM, Kollmeier M, et al. Secondary cancers after intensity-modulated radiotherapy, brachytherapy and radical prostatectomy for the treatment of prostate cancer: Incidence and cause-specific survival outcomes according to the initial treatment intervention. BJU Int. 2012;110(11):1696&#x2013;1701. doi: 10.1111/j.1464-410X.2012.11385.x.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1111/j.1464-410X.2012.11385.x</ArticleId><ArticleId IdType=\"pubmed\">22889401</ArticleId></ArticleIdList></Reference><Reference><Citation>Zelefsky MJ, Housman DM, Pei X, Alicikus Z, Magsanoc JM, Dauer LT, et al. Incidence of secondary cancer development after high-dose intensity-modulated radiotherapy and image-guided brachytherapy for the treatment of localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 2012;83(3):953&#x2013;9. doi: 10.1016/j.ijrobp.2011.08.034.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.ijrobp.2011.08.034</ArticleId><ArticleId IdType=\"pubmed\">22172904</ArticleId></ArticleIdList></Reference><Reference><Citation>Hegemann N-S, Schlesinger-Raab A, Ganswindt U, H&#xf6;rl C, Combs SE, H&#xf6;lzel D, et al. Risk of second cancer following radiotherapy for prostate cancer: A population-based analysis. Radiat. Oncol. 2017;12(1):2. doi: 10.1186/s13014-016-0738-z.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1186/s13014-016-0738-z</ArticleId><ArticleId IdType=\"pmc\">PMC5209816</ArticleId><ArticleId IdType=\"pubmed\">28049538</ArticleId></ArticleIdList></Reference><Reference><Citation>Kendal WS, Eapen L, MacRae R, Malone S, Nicholas G. Prostatic irradiation is not associated with any measurable increase in the risk of subsequent rectal cancer. Int. J. Radiat. Oncol. Biol. Phys. 2006;65(3):661&#x2013;8. doi: 10.1016/j.ijrobp.2005.11.013.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.ijrobp.2005.11.013</ArticleId><ArticleId IdType=\"pubmed\">16545920</ArticleId></ArticleIdList></Reference><Reference><Citation>Bostrom PJ, Soloway MS. Secondary cancer after radiotherapy for prostate cancer: Should we be more aware of the risk? Eur. Urol. 2007;52(4):973&#x2013;982. doi: 10.1016/j.eururo.2007.07.002.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.eururo.2007.07.002</ArticleId><ArticleId IdType=\"pubmed\">17644245</ArticleId></ArticleIdList></Reference><Reference><Citation>Pratt NL, Kerr M, Barratt JD, Kemp-Casey A, Ellett LMK, Ramsay E, et al. The validity of the Rx-Risk comorbidity index using medicines mapped to the anatomical therapeutic chemical (ATC) classification system. BMJ Open. 2018;8(4):e021122. doi: 10.1136/bmjopen-2017-021122.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1136/bmjopen-2017-021122</ArticleId><ArticleId IdType=\"pmc\">PMC5905736</ArticleId><ArticleId IdType=\"pubmed\">29654048</ArticleId></ArticleIdList></Reference><Reference><Citation>Australian Bureau of Statistics. Census of Population and Housing: Socio-Economic Indexes for Areas (SEIFA), Australia, 2016 Australia: ABS Website; 2018 [Available from: https://www.abs.gov.au/ausstats/abs@.nsf/mf/2033.0.55.001.</Citation></Reference><Reference><Citation>Australian Bureau of Statistics. Statistical Area Level 3: Australian Statistical Geography Standard (ASGS) ABS Website2021 [3:[Available from: https://www.abs.gov.au/statistics/standards/australian-statistical-geography-standard-asgs-edition-3/jul2021-jun2026/main-structure-and-greater-capital-city-statistical-areas/statistical-area-level-3.</Citation></Reference><Reference><Citation>National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Prostate Cancer Version 3.2022: National Comprehensive Cancer Network; 2022. Available from: https://www.nccn.org/guidelines/guidelines-detail?category=1&amp;id=1459.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">36898367</ArticleId></ArticleIdList></Reference><Reference><Citation>Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J. Am. Stat. Assoc. 1999;94(446):496&#x2013;509. doi: 10.1080/01621459.1999.10474144.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1080/01621459.1999.10474144</ArticleId></ArticleIdList></Reference><Reference><Citation>Berrington de Gonzalez A, Curtis RE, Kry SF, Gilbert E, Lamart S, Berg CD, et al. Proportion of second cancers attributable to radiotherapy treatment in adults: a cohort study in the US SEER cancer registries. Lancet Oncol. 2011;12(4):353&#x2013;60. doi: 10.1016/S1470-2045(11)70061-4.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/S1470-2045(11)70061-4</ArticleId><ArticleId IdType=\"pmc\">PMC3086738</ArticleId><ArticleId IdType=\"pubmed\">21454129</ArticleId></ArticleIdList></Reference><Reference><Citation>Cumberbatch MG, Rota M, Catto JWF, La Vecchia C. The role of tobacco smoke in bladder and kidney carcinogenesis: A comparison of exposures and meta-analysis of incidence and mortality risks. Eur. Urol. 2016;70(3):458&#x2013;466. doi: 10.1016/j.eururo.2015.06.042.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.eururo.2015.06.042</ArticleId><ArticleId IdType=\"pubmed\">26149669</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhojani N, Capitanio U, Suardi N, Jeldres C, Isbarn H, Shariat SF, et al. The rate of secondary malignancies after radical prostatectomy versus external beam radiation therapy for localized prostate cancer: A population-based study on 17,845 patients. Int. J. Radiat. Oncol. Biol. Phys. 2010;76(2):342&#x2013;348. doi: 10.1016/j.ijrobp.2009.02.011.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.ijrobp.2009.02.011</ArticleId><ArticleId IdType=\"pubmed\">20117287</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison RM. Second cancers following radiotherapy: A suggested common dosimetry framework for therapeutic and concomitant exposures. Br. J. Radiol. 2004;77(924):986&#x2013;990. doi: 10.1259/bjr/21023216.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1259/bjr/21023216</ArticleId><ArticleId IdType=\"pubmed\">15569639</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen J, Vo NTK, Chettle DR, McNeill FE, Seymour CB, Mothersill CE. Quantifying biophoton emissions from human cells directly exposed to low-dose gamma radiation. Dose-Response. 2020;18(2):1559325820926763. doi: 10.1177/1559325820926763.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1177/1559325820926763</ArticleId><ArticleId IdType=\"pmc\">PMC7238447</ArticleId><ArticleId IdType=\"pubmed\">32489340</ArticleId></ArticleIdList></Reference><Reference><Citation>Reyes-Ortiz CA, Goodwin JS, Freeman JL. The effect of socioeconomic factors on incidence, stage at diagnosis and survival of cutaneous melanoma. Med Sci Monit. 2005;11(5):163&#x2013;172.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">15874907</ArticleId></ArticleIdList></Reference><Reference><Citation>Moon K, Stukenborg GJ, Keim J, Theodorescu D. Cancer incidence after localized therapy for prostate cancer. Cancer Interdiscip. Int. J. Am. Cancer Soc. 2006;107(5):991&#x2013;8.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">16878323</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall EJ. Intensity-modulated radiation therapy, protons, and the risk of second cancers. Int. J. Radiat. Oncol. Biol. Phys. 2006;65(1):1&#x2013;7. doi: 10.1016/j.ijrobp.2006.01.027.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.ijrobp.2006.01.027</ArticleId><ArticleId IdType=\"pubmed\">16618572</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>\n",
            "XML saved to: path/to/save/xml/37973983.xml\n",
            "Details URL: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=37970369&retmode=xml&api_key=9edd38677707c08b2a96ed1a6e8c61c47408\n",
            "Details Response Content: <?xml version=\"1.0\" ?>\n",
            "<!DOCTYPE PubmedArticleSet PUBLIC \"-//NLM//DTD PubMedArticle, 1st January 2023//EN\" \"https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd\">\n",
            "<PubmedArticleSet>\n",
            "<PubmedArticle><MedlineCitation Status=\"PubMed-not-MEDLINE\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">37970369</PMID><DateRevised><Year>2023</Year><Month>11</Month><Day>17</Day></DateRevised><Article PubModel=\"Electronic-eCollection\"><Journal><ISSN IssnType=\"Print\">2156-6976</ISSN><JournalIssue CitedMedium=\"Print\"><Volume>13</Volume><Issue>10</Issue><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>American journal of cancer research</Title><ISOAbbreviation>Am J Cancer Res</ISOAbbreviation></Journal><ArticleTitle>H2H rehabilitation care promotes high quality recovery of patients with lung cancer comorbid with chronic obstructive pulmonary disease.</ArticleTitle><Pagination><StartPage>4613</StartPage><EndPage>4622</EndPage><MedlinePgn>4613-4622</MedlinePgn></Pagination><Abstract><AbstractText>H2H is a patient and family-centered approach that integrates hospital and home care, emphasizing continuity, individualized rehabilitation training, and the active participation of patients and their families. However, it is still unclear whether H2H improves the efficacy for patients with COPD and lung cancer. This study investigated the efficacy of Hospital-to-Home (H2H) rehabilitation nursing for lung cancer patients with Chronic Obstructive Pulmonary Disease (COPD). We conducted a retrospective analysis to the clinical data of 95 patients treated in the Pingdingshan University Medical College from January 2018 to January 2020. We compared the effects of conventional nursing (control group, n=45) and H2H nursing (observation group, n=50) on the clinical efficacy for the patients. In this study, after nursing intervention, the quality of life and adverse emotions in the observation group were significantly improved compared to the control group (P&lt;0.0001). Moreover, the lung function and blood oxygen saturation of patients in the H2H nursing model improved after the intervention (P&lt;0.0001). In addition, there was no difference in the 3-year survival rate between the control group and the observation group (P=0.260). Multivariate COX regression analysis showed that the nursing scheme had no effect on the patients' 3-year survival, but the SAS score, SDS score, and CEA were independent prognostic factors affecting the 3-year survival rate (P&lt;0.05). These results demonstrate that H2H rehabilitation care significantly improves the quality of life, emotional health, and lung function of patients with COPD and lung cancer, but does not affect the patients' 3-year survival rate.</AbstractText><CopyrightInformation>AJCR Copyright &#xa9; 2023.</CopyrightInformation></Abstract><AuthorList CompleteYN=\"Y\"><Author ValidYN=\"Y\"><LastName>Liu</LastName><ForeName>Xiao</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>School of Medicine of Pingdingshan University Middle Section of Chongwen Road, Xincheng District, Pingdingshan 467000, Henan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Philippine Women's University College of Nursing 1743 Taft Ave, Malate, Manila, Metro Manila 1004, Philippines.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Li</LastName><ForeName>Xin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>School of Medicine of Pingdingshan University Middle Section of Chongwen Road, Xincheng District, Pingdingshan 467000, Henan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Philippine Women's University College of Nursing 1743 Taft Ave, Malate, Manila, Metro Manila 1004, Philippines.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Liu</LastName><ForeName>Yali</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>School of Medicine of Pingdingshan University Middle Section of Chongwen Road, Xincheng District, Pingdingshan 467000, Henan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Philippine Women's University College of Nursing 1743 Taft Ave, Malate, Manila, Metro Manila 1004, Philippines.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Yuan</LastName><ForeName>Fengjuan</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>School of Medicine of Pingdingshan University Middle Section of Chongwen Road, Xincheng District, Pingdingshan 467000, Henan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Philippine Women's University College of Nursing 1743 Taft Ave, Malate, Manila, Metro Manila 1004, Philippines.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Li</LastName><ForeName>Kaige</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>School of Medicine of Pingdingshan University Middle Section of Chongwen Road, Xincheng District, Pingdingshan 467000, Henan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Wang</LastName><ForeName>Jihong</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>School of Medicine of Pingdingshan University Middle Section of Chongwen Road, Xincheng District, Pingdingshan 467000, Henan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Zhang</LastName><ForeName>Songqin</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>The Second Department of Orthopedic Surgery, The First Affiliated Hospital of Pingdingshan Medical College Pingdingshan 467000, Henan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN=\"Y\"><LastName>Zhang</LastName><ForeName>Shanshan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>School of Medicine of Pingdingshan University Middle Section of Chongwen Road, Xincheng District, Pingdingshan 467000, Henan, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI=\"D016428\">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType=\"Electronic\"><Year>2023</Year><Month>10</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Cancer Res</MedlineTA><NlmUniqueID>101549944</NlmUniqueID><ISSNLinking>2156-6976</ISSNLinking></MedlineJournalInfo><KeywordList Owner=\"NOTNLM\"><Keyword MajorTopicYN=\"N\">3-year survival</Keyword><Keyword MajorTopicYN=\"N\">H2H rehabilitation care</Keyword><Keyword MajorTopicYN=\"N\">chronic obstructive pulmonary disease</Keyword><Keyword MajorTopicYN=\"N\">emotion</Keyword><Keyword MajorTopicYN=\"N\">lung cancer</Keyword><Keyword MajorTopicYN=\"N\">lung function</Keyword><Keyword MajorTopicYN=\"N\">quality of life</Keyword></KeywordList><CoiStatement>None.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus=\"received\"><Year>2023</Year><Month>5</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus=\"accepted\"><Year>2023</Year><Month>8</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus=\"medline\"><Year>2023</Year><Month>11</Month><Day>16</Day><Hour>6</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"pubmed\"><Year>2023</Year><Month>11</Month><Day>16</Day><Hour>6</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus=\"entrez\"><Year>2023</Year><Month>11</Month><Day>16</Day><Hour>4</Hour><Minute>30</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType=\"pubmed\">37970369</ArticleId><ArticleId IdType=\"pmc\">PMC10636661</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rabe KF, Watz H. Chronic obstructive pulmonary disease. Lancet. 2017;389:1931&#x2013;1940.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">28513453</ArticleId></ArticleIdList></Reference><Reference><Citation>Labaki WW, Rosenberg SR. Chronic obstructive pulmonary disease. Ann Intern Med. 2020;173:ITC17&#x2013;ITC32.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">32745458</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritchie AI, Wedzicha JA. Definition, causes, pathogenesis, and consequences of chronic obstructive pulmonary disease exacerbations. Clin Chest Med. 2020;41:421&#x2013;438.</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC7423341</ArticleId><ArticleId IdType=\"pubmed\">32800196</ArticleId></ArticleIdList></Reference><Reference><Citation>Duffy SP, Criner GJ. Chronic obstructive pulmonary disease: evaluation and management. Med Clin North Am. 2019;103:453&#x2013;461.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">30955513</ArticleId></ArticleIdList></Reference><Reference><Citation>Torre LA, Siegel RL, Jemal A. Lung cancer statistics. Adv Exp Med Biol. 2016;893:1&#x2013;19.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">26667336</ArticleId></ArticleIdList></Reference><Reference><Citation>Bade BC, Dela Cruz CS. Lung cancer 2020: epidemiology, etiology, and prevention. Clin Chest Med. 2020;41:1&#x2013;24.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">32008623</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubin S, Griffin D. Lung cancer in non-smokers. Mo Med. 2020;117:375&#x2013;379.</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC7431055</ArticleId><ArticleId IdType=\"pubmed\">32848276</ArticleId></ArticleIdList></Reference><Reference><Citation>She Y, Jin Z, Wu J, Deng J, Zhang L, Su H, Jiang G, Liu H, Xie D, Cao N, Ren Y, Chen C. Development and validation of a deep learning model for non-small cell lung cancer survival. JAMA Netw Open. 2020;3:e205842.</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC7272121</ArticleId><ArticleId IdType=\"pubmed\">32492161</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai J, Yang P, Cox A, Jiang G. Lung cancer and chronic obstructive pulmonary disease: from a clinical perspective. Oncotarget. 2017;8:18513&#x2013;18524.</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC5392346</ArticleId><ArticleId IdType=\"pubmed\">28061470</ArticleId></ArticleIdList></Reference><Reference><Citation>Biswas A, Mehta HJ, Folch EE. Chronic obstructive pulmonary disease and lung cancer: inter-relationships. Curr Opin Pulm Med. 2018;24:152&#x2013;160.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">29210751</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhai T, Li S, Hu W, Li D, Leng S. Potential micronutrients and phytochemicals against the pathogenesis of chronic obstructive pulmonary disease and lung cancer. Nutrients. 2018;10:813.</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC6073117</ArticleId><ArticleId IdType=\"pubmed\">29941777</ArticleId></ArticleIdList></Reference><Reference><Citation>Siegfried JM. Sex and gender differences in lung cancer and chronic obstructive lung disease. Endocrinology. 2022;163:bqab254.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">34927202</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai Q, Cai SB, Chen JK, Bai XH, Jing CX, Zhang X, Li JQ. Tai Chi for anxiety and depression symptoms in cancer, stroke, heart failure, and chronic obstructive pulmonary disease: a systematic review and meta-analysis. Complement Ther Clin Pract. 2022;46:101510.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">34749040</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X, Huang X, Yin M. Implementation of hospital-to-home model for nutritional nursing management of patients with chronic kidney disease using artificial intelligence algorithm combined with CT internet. Contrast Media Mol Imaging. 2022;2022:1183988.</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC8977294</ArticleId><ArticleId IdType=\"pubmed\">35414801</ArticleId></ArticleIdList></Reference><Reference><Citation>Reich K, Kristensen LE, Smith SD, Rich P, Sapin C, Leage SL, McKenzie R, Schuster C, Riedl E, Gooderham M. Efficacy and safety of ixekizumab versus adalimumab in biologic-naive patients with active psoriatic arthritis and moderate-to-severe psoriasis: 52-week results from the randomized SPIRIT-H2H trial. Dermatol Pract Concept. 2022;12:e2022104.</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC9116563</ArticleId><ArticleId IdType=\"pubmed\">35646453</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang L, Wang J, Han L, Hu Y, Si L, Shao X, Lu F, Zhang L. Effect of H2H management mode on blood sugar control and living ability in patients with schizophrenia and type 2 diabetes mellitus. Am J Transl Res. 2023;15:223&#x2013;232.</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC9908448</ArticleId><ArticleId IdType=\"pubmed\">36777852</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Fabbri LM, Frith P, Halpin DM, Lopez Varela MV, Nishimura M, Roche N, Rodriguez-Roisin R, Sin DD, Singh D, Stockley R, Vestbo J, Wedzicha JA, Agusti A. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD executive summary. Am J Respir Crit Care Med. 2017;195:557&#x2013;582.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">28128970</ArticleId></ArticleIdList></Reference><Reference><Citation>Song G, Liu H. Effect of hospital to home nutrition management model on postoperative clinical outcomes of patients with laryngeal carcinoma. Oncol Lett. 2017;14:4059&#x2013;4064.</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC5604143</ArticleId><ArticleId IdType=\"pubmed\">28943912</ArticleId></ArticleIdList></Reference><Reference><Citation>Perrotta F, D&#x2019;Agnano V, Scialo F, Komici K, Allocca V, Nucera F, Salvi R, Stella GM, Bianco A. Evolving concepts in COPD and lung cancer: a narrative review. Minerva Med. 2022;113:436&#x2013;448.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">35156786</ArticleId></ArticleIdList></Reference><Reference><Citation>Taucher E, Mykoliuk I, Lindenmann J, Smolle-Juettner FM. Implications of the immune landscape in COPD and lung cancer: smoking versus other causes. Front Immunol. 2022;13:846605.</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC8978964</ArticleId><ArticleId IdType=\"pubmed\">35386685</ArticleId></ArticleIdList></Reference><Reference><Citation>Yue T, Li Q, Wang R, Liu Z, Guo M, Bai F, Zhang Z, Wang W, Cheng Y, Wang H. Comparison of hospital anxiety and depression scale (HADS) and Zung self-rating anxiety/depression scale (SAS/SDS) in evaluating anxiety and depression in patients with psoriatic arthritis. Dermatology. 2020;236:170&#x2013;178.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">31434087</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei J, Yang J, Dong L, Xu J, Chen J, Hou X, Bai Z. An exercise prescription for patients with lung cancer improves the quality of life, depression, and anxiety. Front Public Health. 2022;10:1050471.</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC9714027</ArticleId><ArticleId IdType=\"pubmed\">36466452</ArticleId></ArticleIdList></Reference><Reference><Citation>Dal Bello MG, Filiberti RA, Alama A, Orengo AM, Mussap M, Coco S, Vanni I, Boccardo S, Rijavec E, Genova C, Biello F, Barletta G, Rossi G, Tagliamento M, Maggioni C, Grossi F. The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients. J Transl Med. 2019;17:74.</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC6408784</ArticleId><ArticleId IdType=\"pubmed\">30849967</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan J, Sun Y, Wang K, Wang Z, Li D, Fan M, Bu X, Chen J, Wu Z, Geng H, Wu J, Xu Y, Chen M, Ren H. Development and validation of reassigned CEA, CYFRA21-1 and NSE-based models for lung cancer diagnosis and prognosis prediction. BMC Cancer. 2022;22:686.</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC9214980</ArticleId><ArticleId IdType=\"pubmed\">35729538</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>\n",
            "XML saved to: path/to/save/xml/37970369.xml\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "import os\n",
        "import xml.etree.ElementTree as ET\n",
        "\n",
        "def extract_abstract_from_file(file_path):\n",
        "    try:\n",
        "        tree = ET.parse(file_path)\n",
        "        root = tree.getroot()\n",
        "\n",
        "        # Mencari elemen abstract dalam XML\n",
        "        abstract_element = root.find(\".//AbstractText\")\n",
        "\n",
        "        if abstract_element is not None:\n",
        "            abstract_text = abstract_element.text\n",
        "            return abstract_text\n",
        "        else:\n",
        "            print(f\"Tidak dapat menemukan elemen AbstractText dalam file {file_path}\")\n",
        "            return None\n",
        "    except ET.ParseError as e:\n",
        "        print(f\"XML Parse Error: {e}\")\n",
        "        return None\n",
        "\n",
        "def main():\n",
        "    xml_directory = 'path/to/save/xml/'  # Sesuaikan dengan direktori tempat Anda menyimpan file-file XML\n",
        "\n",
        "    # Mendapatkan daftar file XML dalam direktori\n",
        "    xml_files = [f for f in os.listdir(xml_directory) if f.endswith(\".xml\")]\n",
        "\n",
        "    for xml_file in xml_files:\n",
        "        file_path = os.path.join(xml_directory, xml_file)\n",
        "        abstract_text = extract_abstract_from_file(file_path)\n",
        "\n",
        "        if abstract_text:\n",
        "            print(f\"Abstract from {xml_file}:\\n{abstract_text}\\n\")\n",
        "\n",
        "if __name__ == \"__main__\":\n",
        "    main()\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "HSnRect-Q5oW",
        "outputId": "cc9e861f-0294-4b0b-bc88-979abc93a8ca"
      },
      "execution_count": 44,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Abstract from 38063017.xml:\n",
            "Limited data exist on the temporal relationship between new-onset atrial fibrillation (AF) and ischemic stroke and its impact on patients' clinical characteristics and mortality.\n",
            "\n",
            "Abstract from 38003929.xml:\n",
            "The in-hospital mortality of cardiogenic shock (CS) remains high (28% to 45%). As a result, several studies developed prediction models to assess the mortality risk and provide guidance on treatment, including CardShock and IABP-SHOCK II scores, which performed modestly in external validation studies, reflecting the heterogeneity of the CS populations. Few articles established predictive scores of CS based on Asian people with a higher burden of comorbidities than Caucasians. We aimed to describe the clinical characteristics of a contemporary Asian population with CS, identify risk factors, and develop a predictive scoring model.\n",
            "\n",
            "Abstract from 38016200.xml:\n",
            "The association between asthma and COVID-19 mortality remains inconclusive. We examined the association between asthma and clinical outcomes of patients with COVID-19.\n",
            "\n",
            "Abstract from 38097480.xml:\n",
            "The treatment advantage of guideline-based therapy (GBT) in Mycobacterium avium complex lung disease (MAC-LD) is well-known. However, GBT is not always feasible. The aim of the study was to analyze the relationship of treatment regimens and duration with outcomes.\n",
            "\n",
            "Abstract from 38012569.xml:\n",
            "Cancer is the disease of the ageing. Most of the elderly cancer patients have pre-existing illnesses requiring complexity of medical care. Excessive medications would lead not only futility, but also result in adverse outcomes especially if such over-prescription is not appropriate. This study was intended to determine the prevalence of polypharmacy (PP) and potentially-inappropriate medications (PIMs) among elderly cancer patients eligible for active cancer care and their associations with hospitalization and mortality.\n",
            "\n",
            "Abstract from 38056855.xml:\n",
            "The number of elderly patients in thoracic surgery is increasing. The percentage of patients over the age of 80 in surgical cases of malignant diseases such as lung cancer and mediastinal tumors is increasing every year. It is also true that the indications for surgery have been expanding as surgery itself has become less invasive, such as thoracoscopic and robotic surgery. However, it is not uncommon for patients over 80 years of age to have some organ dysfunction and many comorbidities. Therefore, when performing surgery for lung cancer and other diseases, it is important to assess the patient's ability to tolerate surgery, including respiratory and cardiac functions, and to perform risk management. To prevent postoperative complications and improve the accuracy of perioperative management, respiratory rehabilitation should be conducted before and after surgery, and not only smoking cessation instruction but also inhalation training using incentive spirometry( IS), breathing exercises, and the use of inhalers such as long-acting 2 agonist (LABA)/long-acting muscaring antagonist (LAMA) for patients with chronic obstructive pulmonary disease( COPD) are useful.\n",
            "\n",
            "Abstract from 37983029.xml:\n",
            "Involvement of a cardiologist in the care of adults during a hospitalization for heart failure (HF) is associated with reduced rates of in-hospital mortality and hospital readmission. However, not all patients see a cardiologist when they are hospitalized for HF.\n",
            "\n",
            "Abstract from 37973983.xml:\n",
            "We investigated whether prostate cancer patients treated with external beam radiation therapy (EBRT) have a higher cumulative incidence of secondary cancer compared with patients treated with radical prostatectomy (RP). We used state-wide linked data from South Australia to follow men with prostate cancer diagnosed from 2002 to 2019. The cumulative incidence of overall and site-specific secondary cancers between 5 and 15years after treatment was estimated. Fine-Gray competing risk analyses were performed with additional sensitivity analyses to test different scenarios. A total of 7625 patients were included (54% underwent RP and 46% EBRT). Characteristics of the two groups differed significantly, with the EBRT group being older (71 vs. 64years), having higher comorbidity burden and being more likely to die during follow-up than the RP group. Fifteen-year cumulative incidence for all secondary cancers was 27.4% and 22.3% in EBRT and RP groups, respectively. In the adjusted models, patients in the EBRT group had a significantly higher risk of genitourinary (adjusted subhazard ratio (aSHR), 2.29; 95%CI 1.16-4.51) and lung (aSHR, 1.93; 95%CI 1.05-3.56) cancers compared with patients in the RP group. However, there was no statistically significant difference between the two groups for risk of any secondary cancer, gastro-intestinal, skin or haematologic cancers. No statistically significant differences in overall risk of secondary cancer were observed in any of the sensitivity analyses and patterns for risk at specific cancer sites were relatively consistent across different age restriction and latency/time-lag scenarios. In conclusion, the increased risk of genitourinary and lung cancers among men undergoing EBRT may relate partly to treatment effects and partly to unmeasured residual confounding.\n",
            "\n",
            "Abstract from 37996867.xml:\n",
            "Lower socioeconomic status has been identified as an emerging risk factor for health disparities, including lung cancer outcomes. Most research investigating these outcomes includes patients from formal lung cancer screening programs. There is a paucity of studies assessing the relationship between socioeconomic status and incidental lung nodules. This study aimed to investigate the association between socioeconomic status and the size of incidental lung nodules on initial presentation at an urban safety net hospital, which did not have a formal lung cancer screening program or incidental lung nodule program.\n",
            "\n",
            "Abstract from 38075997.xml:\n",
            "This study aims to evaluate surgical outcomes and prognosis in patients who underwent extended lung resection for locally advanced lung cancer.\n",
            "\n",
            "Abstract from 38090326.xml:\n",
            "Several studies have shown racial disparities in lung cancer care in the United States in the Black and Hispanic populations but not many have included American Indian/Alaska Native (AI/AN) patients. We retrospectively evaluated the factors associated with receipt of guideline-concordant care in AI/AN and non-Hispanic White (NHW) patients with stage I non-small cell lung cancer (NSCLC) and describe the relationship between guideline-concordant care and survival outcomes in these populations.\n",
            "\n",
            "Abstract from 38056852.xml:\n",
            "Postoperative bronchopleural fistula (BPF) is a rare but severe and sometimes life-threatening complication that needs immediate and proper treatment. Thoracic surgeons should strictly manage the comorbidities such as diabetes mellitus for BPF prevention. Also, coverage of the bronchial stump with pericardial fat tissue will prevent BPF, or at least prevent the turning severe of BPF. However, when BPF occurs, we must promptly determine whether to perform conservative treatment or invasive treatment such as fenestration.\n",
            "\n",
            "Abstract from 38103006.xml:\n",
            "There have been studies on antibiotic use concerning lung cancer and its potential impact on carcinogenesis and microbiome. However, subsequent research has failed to support these associations consistently. In terms of the potential carcinogenic of antibiotics on lung cancer, the available evidence has not been sufficient to draw any definitive conclusions. Maintaining immune homeostasis and preventing pathogen invasion is critically dependent on the microbiome. The subtle balance of the body microbiota, including the lungs, is susceptible to disruption by antibiotic use. There is an association between disruptions of the lung microbiome and respiratory diseases, including lung cancer, and decreased efficacy of treatments. Patients with lung cancer are often indicated for antibiotic treatment due to respiratory infections or other comorbidities. Pulmonary infections in the area of undetected lung tumors are not uncommon. They can be an early sign of malignancy, which may explain the association between antibiotic use and lung cancer diagnosis. Antibiotic use can also affect the effectiveness of immune checkpoint inhibitor therapy. Studies suggest that antibiotic use can impair the efficacy of immune checkpoint inhibitor therapy in lung cancer patients, particularly around the time when treatment is initiated. These findings require further study, understanding underlying mechanisms, and identifying microbiota signatures associated with treatment response.\n",
            "\n",
            "Abstract from 38011678.xml:\n",
            "The aim of this study was to compare the short- and long-term results of video-assisted thoracoscopic surgery (VATS) and thoracotomy for non-small-cell lung cancer in a medium-volume centre, where cardiothoracic surgeons perform both cardiac and general thoracic surgery. The primary outcome of interest was 5-year overall survival and disease-specific survival. Secondary outcomes were short-term postoperative complications, length of hospital stay and lymph node yield.\n",
            "\n",
            "Abstract from 38067372.xml:\n",
            "Surgical resection remains the gold standard of treatment for early-stage lung cancer. Several risk models exist to predict postoperative morbidity and mortality. Psoas muscle sarcopenia has already successfully been used for morbidity prediction in lung transplantation and is not yet included in the available risk scores for pulmonary resections. We hypothesized that the skeletal muscle index and mediastinal adipose tissue might also have an impact on postoperative outcomes after primary surgery for primary lung cancer. The institutional database was queried for patients with primary lung cancer who were treated with primary lobectomy or segmentectomy between February 2009 and November 2018. In total, 311 patients were included for analysis. Patients receiving neo-/adjuvant chemotherapy or with a positive nodal status were excluded to rule out any morbidity or mortality due to (neo-)adjuvant treatment. Sarcopenia was defined as a skeletal muscle index of <34.4 cm\n",
            "\n",
            "Abstract from 37979368.xml:\n",
            "In cancer care, symptom monitoring during treatment results in improved clinical outcomes such as improved quality of life, longer survival, and fewer hospital admissions. However, as the majority of patients with cancer are older and have multimorbidity, they may benefit from monitoring of additional symptoms. The aim of this study was to identify a core set of symptoms to monitor in older patients with multimorbidity treated for cancer, including symptoms caused by treatment side effects, destabilization of comorbidities, and functional decline.\n",
            "\n",
            "Abstract from 38112578.xml:\n",
            "Combat trauma can lead to widespread tissue damage and limb loss. This may result in chronic neuropathic and post amputation pain, including phantom limb pain (PLP) and residual limb pain (RLP). The military population is distinct with respect to demographic, injury, and social characteristics compared with other amputation and trauma cohorts. We undertook a systematic review of studies of military personnel, with a history of combat injury, that reported a prevalence of any type of postamputation pain or chronic neuropathic pain, identified from Embase and MEDLINE databases.Using the inverse variance method with a random-effects model, we undertook a meta-analysis to determine an overall prevalence and performed exploratory analyses to identify the effect of the type of pain, conflict, and time since injury on prevalence. Pain definitions and types of pain measurement tools used in studies were recorded. Thirty-one studies (14,738 participants) were included. The pooled prevalence of PLP, RLP, and chronic neuropathic pain were 57% (95% CI: 46-68), 61% (95% CI: 50-71), and 26% (95% CI: 10-54), respectively. Between-study heterogeneity was high (I2: 94%-98%). Characterisation of duration, frequency, and impact of pain was limited. Factors reported by included studies as being associated with PLP included the presence of RLP and psychological comorbidity. The prevalence of postamputation pain and chronic neuropathic pain after combat trauma is high. We highlight inconsistency of case definitions and terminology for pain and the need for consensus in future research of traumatic injury.\n",
            "\n",
            "Abstract from 38071660.xml:\n",
            "Embedded smoking cessation support within lung cancer screening is recommended in the UK; however, little is known about why individuals decline smoking cessation support in this setting. This study identified psychosocial factors that influence smoking cessation and quit motivation among those who declined support for quitting smoking alongside lung cancer screening.\n",
            "\n",
            "Abstract from 37999149.xml:\n",
            "ALK tyrosine kinase inhibitors (TKIs) have revolutionized the treatment and largely improved the survival outcomes of patients with NSCLC harboring \n",
            "\n",
            "Abstract from 37997884.xml:\n",
            "Small cell lung cancer (SCLC) is characterized by aggressive growth and poor prognosis. Although SCLC affects nearly exclusively heavy smokers and leads to frequent respiratory symptoms, the impact of pre-therapeutic lung function testing in SCLC is sparely investigated until now. Therefore, we sought to examine whether we could find prognostic markers in pre-therapeutic lung function testing of SCLC patients.\n",
            "\n",
            "Abstract from 37977487.xml:\n",
            "Although the importance of lung cancer screening for early diagnosis is established, because of poor enrollment, incidental findings still play a role in diagnosis of patients who qualify. Nevertheless, analysis of this incidental cohort is lacking. We present a retrospective analysis comparing patients with thoracic surgery with incidental versus screening detected stage I lung cancer.\n",
            "\n",
            "Abstract from 37970369.xml:\n",
            "H2H is a patient and family-centered approach that integrates hospital and home care, emphasizing continuity, individualized rehabilitation training, and the active participation of patients and their families. However, it is still unclear whether H2H improves the efficacy for patients with COPD and lung cancer. This study investigated the efficacy of Hospital-to-Home (H2H) rehabilitation nursing for lung cancer patients with Chronic Obstructive Pulmonary Disease (COPD). We conducted a retrospective analysis to the clinical data of 95 patients treated in the Pingdingshan University Medical College from January 2018 to January 2020. We compared the effects of conventional nursing (control group, n=45) and H2H nursing (observation group, n=50) on the clinical efficacy for the patients. In this study, after nursing intervention, the quality of life and adverse emotions in the observation group were significantly improved compared to the control group (P<0.0001). Moreover, the lung function and blood oxygen saturation of patients in the H2H nursing model improved after the intervention (P<0.0001). In addition, there was no difference in the 3-year survival rate between the control group and the observation group (P=0.260). Multivariate COX regression analysis showed that the nursing scheme had no effect on the patients' 3-year survival, but the SAS score, SDS score, and CEA were independent prognostic factors affecting the 3-year survival rate (P<0.05). These results demonstrate that H2H rehabilitation care significantly improves the quality of life, emotional health, and lung function of patients with COPD and lung cancer, but does not affect the patients' 3-year survival rate.\n",
            "\n",
            "Abstract from 38023743.xml:\n",
            "We describe herein two patients with epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer (NSCLC) who developed cancer-associated ischemic stroke (CAIS), infarction caused by thromboembolism in the central nervous system. Case 1 was a 63-year-old man with Exon 19 deletion type EGFR mutated lung adenocarcinoma presenting with CAIS. Case 2 was a 71-year-old woman with Exon 21 L858R type EGFR mutated lung adenocarcinoma who developed CAIS during chemotherapy after EGFR-tyrosine kinase inhibitor (TKI) resistance. Although there was no recurrence of CAIS in these patients, anticancer therapy could be hampered by the comorbidity of CAIS. This can develop anytime from before clinical manifestations of NSCLC to the next treatment after EGFR-TKI resistance. The development of CAIS should be noted in patients with EGFR mutated NSCLC, who have a promising long-term prognosis. Anticancer and anticoagulant therapies as well as rehabilitation are important for patients who develop CAIS. Establishment of measurement tests to detect CAIS before onset is desired.\n",
            "\n",
            "Abstract from 37990203.xml:\n",
            "There is a lack of real-world characterization of healthcare costs and associated cost drivers in patients with pulmonary hypertension secondary to chronic obstructive pulmonary disease (PH-COPD).\n",
            "\n",
            "Abstract from 38063366.xml:\n",
            "With the rapid evolution of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, the development of effective and safe vaccines was of utmost importance to protect vulnerable individuals, including cancer patients. Studies comparing the clinical outcomes of cancer patients with or without vaccination against coronavirus disease 2019 (COVID-19) have not demonstrated clear benefit. We aimed to determine the protective effects of COVID-19 vaccination by comparing vaccinated and unvaccinated cancer patients after the initial phase of vaccine roll-out and to identify risk factors associated with hospitalization, severe COVID-19, and 30-day COVID-19 attributable mortality.\n",
            "\n",
            "Abstract from 37999105.xml:\n",
            "Pneumonectomy is a major surgical resection that still remains a high-risk operation. The current study aims to investigate perioperative risk factors for postoperative morbidity and early mortality after pneumonectomy for thoracic malignancies.\n",
            "\n",
            "Abstract from 38029007.xml:\n",
            "Stereotactic body proton therapy (SBPT) is an emerging treatment strategy for lung tumors that aims to combine the excellent local control benefits of ultra-hypofractionation with the physical advantages of protons, which reduce the integral dose to organs at risk (OARs) compared to photons. To date, however, very little data delivering SBPT in 5 or fewer fractions to lung tumors have been reported. Given that photon stereotactic body radiation therapy can struggle to deliver ablative doses to high-risk tumors (i.e., central/ultra-central location, prior in-field radiation, tumor size >5 cm, or the presence of severe pulmonary comorbidities) while adhering to OAR dose constraints, we hypothesized that SBPT would be an effective alternative for patients with high-risk tumors.\n",
            "\n",
            "Abstract from 38029831.xml:\n",
            "To date, studies have not provided definitive answers regarding whether previous immune checkpoint inhibitor (ICI) treatment alters outcomes for cancer patients with COVID-19.\n",
            "\n",
            "Abstract from 38103121.xml:\n",
            "Small cell lung cancer (SCLC) is an extremely malignant subtype of lung cancer because of its high potential for metastases. Cardiac invasion of SCLC is a serious concern that may lead to systemic embolism or tract obstruction. It has aroused much concern that cardiovascular comorbidities may significantly affect the survival of SCLC patients and their treatment decisions.\n",
            "\n",
            "Abstract from 38090511.xml:\n",
            "Postoperative pneumonia (POP) is a hospital acquired pneumonia that occurs >48 hours after tracheal intubation. The diagnosis of POP should be based on clinical and radiological findings within 30 days after surgery. It is a common complication after thoracoscopic surgery for lung cancer patients. However, the specific impact of preoperative comorbidities on the incidence of POP remains unclear. This study aimed to analyze the preoperative data of patients with lung cancer to help surgeons predict the risk of incidence of POP after thoracoscopic lung resection.\n",
            "\n",
            "Abstract from 38090298.xml:\n",
            "The beneficial effect of preserved superior segment (S6) after common basal segmentectomy remains unknown. We aimed to evaluate the effect of preserved superior segment on lung volume and function.\n",
            "\n",
            "Abstract from 38023992.xml:\n",
            "Oncology patients are more susceptible to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection due to hospital contact and an immunological system that can be compromised by antineoplastic therapy and supportive treatments. Certain similarities have been described in the physiopathology of coronavirus disease 2019 (COVID-19) and lung cancer (LC) that may explain the higher probability of these patients of developing a more serious disease with more frequent hospitalizations and even death, especially with the addition of smoking, cardiovascular and respiratory comorbidities, old age and corticosteroids use. Pre-existing lesions and cancer therapies change the normal architecture of the lungs, so diagnostic scales such as COVID-19 Reporting and Data System (CO-RADS) are of vital importance for a correct diagnosis and patient homogenization, with a high inter-observer correlation. Moreover, anticancer treatments have required an adaptation to reduce the number of visits to the hospital [hypofractionated radiotherapy (RT), larger intervals between chemotherapy cycles, delay in follow-up tests, among others]. In a way, this has also caused a delay in the diagnosis of new cancers. On the other hand, vaccination has had a positive impact on the mortality of these patients, who maintain a similar seroprevalence to the rest of the population, with a similar impact in mortality.\n",
            "\n",
            "Abstract from 38037323.xml:\n",
            "We examined the associations of socioeconomic factors, health behaviors, and comorbidities with early-onset lung cancer.\n",
            "\n",
            "Abstract from 38066463.xml:\n",
            "The object was to compare changes in patients undergoing lung surgery before and after COVID-19 outbreak, and to explore the impact of COVID-19 on lung surgery and its coping strategies.\n",
            "\n",
            "Abstract from 38066848.xml:\n",
            "Telomere biology disorders (TBDs) are a spectrum of inherited bone marrow failure syndromes caused by impaired telomere function due to pathogenic germline variants in genes involved in telomere maintenance. TBDs can affect many organ systems and are often thought of as diseases of childhood. However, TBDs may present in mid- or even late adulthood with features similar to but not always the same as the childhood-onset TBDs. Adult-onset TBDs are often cryptic with isolated pulmonary, liver, or hematologic disease, or cancer, and may lack the classic disease-defining triad of abnormal skin pigmentation, nail dysplasia, and oral leukoplakia. Diagnostics include detection of very short leukocyte telomeres and germline genetic testing. Notably, adult-onset TBDs may show telomeres in the 1st to 10th percentile for age, and some cases may not have an identifiable genetic cause. TBD genetic etiology includes all modes of inheritance, with autosomal dominant the most frequent in adult-onset disease. Variable symptom onset due to incomplete penetrance, variable expressivity, and genetic anticipation add to the diagnostic challenges. Adult-onset TBDs are likely underrecognized, but their correct identification is of utmost importance, since affected patients are faced with numerous clinical complications, including but not limited to an increased risk of malignancies requiring close surveillance for early detection. Currently lung, liver, or hematopoietic cell transplants are the only curative therapeutic approaches but can be complicated by comorbidities, despite improved medical care. This review highlights the challenges of identifying adult-onset TBDs and addresses currently recommended clinical screening measures and therapy options.\n",
            "\n",
            "Abstract from 38092558.xml:\n",
            "Chronic obstructive pulmonary disease (COPD) is less prevalent in females than males, but it affects mortality in females. There may be sex differences in the clinical characteristics of COPD.\n",
            "\n",
            "Abstract from 38016003.xml:\n",
            "Previous studies investigating comorbidity impact on biologic effectiveness have been relatively small, of short duration, and have not compared biologic classes.\n",
            "\n",
            "Abstract from 37985822.xml:\n",
            "As recreational use of cannabis is being decriminalized in many places and medical use widely sanctioned, there are growing concerns about increases in cannabis use disorder (CanUD), which is associated with numerous medical comorbidities. Here we performed a genome-wide association study of CanUD in the Million Veteran Program (MVP), followed by meta-analysis in 1,054,365 individuals (n\n",
            "\n",
            "Abstract from 38085543.xml:\n",
            "Despite the recommendations of lung cancer screening guidelines and the evidence supporting the effectiveness of population-based lung screening, a common barrier to effective lung cancer screening is that the participation rates of low-dose computed tomography (LDCT) screening among individuals with the highest risk are not large. There are limited data from clinical practice regarding whether opportunistic LDCT screening is associated with reduced lung-cancer mortality.\n",
            "\n",
            "Abstract from 37995046.xml:\n",
            "To offer a narrative review of literature and an update on rheumatoid arthritis (RA) multimorbidity research over the past five years as well as future directions.\n",
            "\n",
            "Abstract from 37981476.xml:\n",
            "Optimal time to treatment for early-stage lung cancer is uncertain. We examined causes of delays in care for Veterans who presented with early-stage non-small cell lung cancer (NSCLC) and whether workup time was associated with increased upstaging or all-cause mortality.\n",
            "\n",
            "Abstract from 38100106.xml:\n",
            "Biomarker testing for driver mutations is essential for selecting appropriate non-small cell lung cancer (NSCLC) treatment but is insufficient.\n",
            "\n",
            "Abstract from 38075485.xml:\n",
            "Male breast cancer treatment involves multimodality therapy, including radiation therapy; nevertheless, few men have received proton therapy (PT) for it. Further, heart disease is an established leading cause of death in men, and radiation therapy heart dose correlates with cardiac toxicity, highlighting the need for cardiac-sparing radiation techniques. Thus, we provide a descriptive analysis of PT in a male breast cancer cohort.\n",
            "\n",
            "Abstract from 37974211.xml:\n",
            "To discuss the optimal treatment modality for inoperable locally advanced Non-Small Cell Lung Cancer patients with poor physical status, impaired cardio-pulmonary function, and negative driver genes, and provide clinical evidence.\n",
            "\n",
            "Abstract from 38007507.xml:\n",
            "The successful implementation of the Enhanced recovery after surgery (ERAS) concept in thoracic surgery has made it possible to complete the surgery in the day surgery unit. However, it is still unclear whether day surgery for lung cancer patients can achieve the same or even better results.\n",
            "\n",
            "Abstract from 38021960.xml:\n",
            "Background Ventilator-associated pneumonia (VAP) is a critical concern in the intensive care unit(ICU), with significant implications for patient outcomes. This retrospective cross-sectional study aimed to determine the prevalence of VAP in an ICU of a developing country, identify the predominant etiological factors, assess patient outcomes, and underscore the need for tailored interventions in high-risk patient groups. Methods This retrospective cross-sectional study included 589 ICU patients who underwent ventilator-assisted breathing for over 48 hours. Among them, 151 developed VAP. The diagnosis was made on clinical, laboratory, and radiological findings, and tracheal aspirate cultures. Exclusions included pediatric patients, less than 48 hours of ventilation, and pre-existing lung infections. Patient data encompassed gender, age, comorbidities, outcomes, admission reasons, isolated microorganisms, and clinical findings. Results 151 patients out of the 589 developed VAP. The age of the patients ranged between 31 to 69 years and the mean age was 45.43  8.92 years. Clinical diagnoses upon ICU admission varied, including sepsis, trauma, stroke, and metabolic disorders. Chest X-rays commonly revealed atelectasis (19.2%), consolidation (21.9%), pleural effusion (11.9%), and lobar pneumonia (45.7%). Tracheal aspirate cultures predominantly isolated multidrug-resistant gram-negative rods, with methicillin-resistant gram-positive cocci and fungal pneumonia prevalent in neutropenic sepsis cases. Notably, only 54 (35.8%) of patients survived, with significantly poorer outcomes observed in sepsis, neutropenic sepsis, and stroke cases compared to trauma and post-operative admissions. Conclusion Multidrug-resistant organisms and the spread of nosocomial infections are the predominant causes ofVAP in the ICU. This emphasizes the urgent need for multifaceted interventions to prevent and manage VAP effectively. Developing and implementing targeted strategies, considering the unique challenges faced in resource-constrained healthcare settings can aid in decreasing the mortality associated with it.\n",
            "\n",
            "Abstract from 38025819.xml:\n",
            "Evidence for the effects of immunotherapy in non-small cell lung cancer (NSCLC) patients with distant organ metastasis is insufficient, and the predictive efficacy of established markers in tissue and blood is elusive. Our study aimed to determine the prognostic factors and develop a survival prognosis model for these patients.\n",
            "\n",
            "Abstract from 38027239.xml:\n",
            "The study aimed to determine the post-operative prevalence and factors associated to poor sleep quality in non-small cell lung cancer (NSCLC) patients in China.\n",
            "\n",
            "Abstract from 38102837.xml:\n",
            "This review aims to critically analyze the pathways of interaction and the pathogenic mechanisms linking periodontitis and oral bacteria with the initiation/progression of cancer at different body compartments. A higher risk of head and neck cancer has been consistently associated with periodontitis. This relationship has been explained by the local promotion of dysbiosis, chronic inflammation, immune evasion, and direct (epi)genetic damage to epithelial cells by periodontal pathobionts and their toxins. Epidemiological reports have also studied a possible link between periodontitis and the incidence of other malignancies at distant sites, such as lung, breast, prostate, and digestive tract cancers. Mechanistically, different pathways have been involved, including the induction of a chronic systemic inflammatory state and the spreading of oral pathobionts with carcinogenic potential. Indeed, periodontitis may promote low-grade systemic inflammation and phenotypic changes in the mononuclear cells, leading to the release of free radicals and cytokines, as well as extracellular matrix degradation, which are all mechanisms involved in carcinogenic and metastatic processes. Moreover, the transient hematogenous spill out or micro-aspiration/swallowing of periodontal bacteria and their virulence factors (i.e., lipopolysaccharides, fimbriae), may lead to non-indigenous bacterial colonization of multiple microenvironments. These events may in turn replenish the tumor-associated microbiome and thus influence the molecular hallmarks of cancer. Particularly, specific strains of oral pathobionts (e.g., Porphyromonas gingivalis and Fusobacterium nucleatum) may translocate through the hematogenous and enteral routes, being implicated in esophageal, gastric, pancreatic, and colorectal tumorigenesis through the modulation of the gastrointestinal antitumor immune system (i.e., tumor-infiltrating T cells) and the increased expression of pro-inflammatory/oncogenic genes. Ultimately, the potential influence of common risk factors, relevant comorbidities, and upstream drivers, such as gerovulnerability to multiple diseases, in explaining the relationship cannot be disregarded. The evidence analyzed here emphasizes the possible relevance of periodontitis in cancer initiation/progression and stimulates future research endeavors.\n",
            "\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "import os\n",
        "import xml.etree.ElementTree as ET\n",
        "import requests\n",
        "\n",
        "def get_article_details(api_key, pmid, save_path):\n",
        "    base_url = \"https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi\"\n",
        "\n",
        "    params = {\n",
        "        'db': 'pubmed',\n",
        "        'id': pmid,\n",
        "        'retmode': 'xml',\n",
        "        'api_key': api_key\n",
        "    }\n",
        "\n",
        "    try:\n",
        "        response = requests.get(base_url, params=params)\n",
        "        response.raise_for_status()  # Check for errors in the response\n",
        "\n",
        "        if response.text.strip():  # Check if response content is non-empty\n",
        "            # Save XML to file\n",
        "            save_xml_to_file(response.text, os.path.join(save_path, f'{pmid}.xml'))\n",
        "\n",
        "            # Extract comorbidity names\n",
        "            comorbidities = extract_comorbidities(response.text)\n",
        "            print(f\"Comorbidities for PMID {pmid}: {', '.join(comorbidities)}\")\n",
        "        else:\n",
        "            print(\"Empty response content\")\n",
        "    except requests.exceptions.HTTPError as errh:\n",
        "        print(\"HTTP Error:\", errh)\n",
        "    except requests.exceptions.ConnectionError as errc:\n",
        "        print(\"Error Connecting:\", errc)\n",
        "    except requests.exceptions.Timeout as errt:\n",
        "        print(\"Timeout Error:\", errt)\n",
        "    except requests.exceptions.RequestException as err:\n",
        "        print(\"Error:\", err)\n",
        "\n",
        "    return None\n",
        "\n",
        "def save_xml_to_file(xml_content, file_path):\n",
        "    try:\n",
        "        os.makedirs(os.path.dirname(file_path), exist_ok=True)  # Create directory if not exists\n",
        "        with open(file_path, 'w', encoding='utf-8') as file:\n",
        "            file.write(xml_content)\n",
        "        print(f\"XML saved to: {file_path}\")\n",
        "    except Exception as e:\n",
        "        print(f\"Error saving XML: {e}\")\n",
        "\n",
        "def extract_comorbidities(xml_content):\n",
        "    comorbidities = []\n",
        "    try:\n",
        "        root = ET.fromstring(xml_content)\n",
        "        for element in root.findall('.//MeshHeadingList/MeshHeading/DescriptorName'):\n",
        "            comorbidity = element.text\n",
        "            comorbidities.append(comorbidity)\n",
        "    except ET.ParseError as e:\n",
        "        print(f\"Error parsing XML: {e}\")\n",
        "    return comorbidities\n",
        "\n",
        "def main():\n",
        "    api_key = '9edd38677707c08b2a96ed1a6e8c61c47408'  # Replace with your PubMed API key\n",
        "    query = 'lung cancer AND comorbidities'  # Adjust your search query\n",
        "    save_path = 'path/to/save/xml/'  # Adjust the path to save XML files\n",
        "\n",
        "    # Get list of IDs\n",
        "    id_list =['38112578', '38103121', '38103006', '38102837', '38100106', '38097480', '38092558', '38090511', '38090326', '38090298', '38085543', '38075997', '38075485', '38071660', '38067372', '38067306', '38066848', '38066463', '38063366', '38063017', '38056855', '38056852', '38037323', '38029831', '38029007', '38027239', '38025819', '38023992', '38023743', '38021960', '38016200', '38016003', '38012569', '38011678', '38007507', '38003929', '37999149', '37999105', '37997884', '37996867', '37995046', '37990203', '37985822', '37983029', '37981476', '37979368', '37977487', '37974211', '37973983', '37970369']\n",
        "\n",
        "    for pmid in id_list:\n",
        "        get_article_details(api_key, pmid, save_path)\n",
        "\n",
        "if __name__ == \"__main__\":\n",
        "    main()\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "rplsFPZOdoMa",
        "outputId": "ebcddfae-aabc-4e1e-b234-9e23906b4c60"
      },
      "execution_count": 45,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "XML saved to: path/to/save/xml/38112578.xml\n",
            "Comorbidities for PMID 38112578: \n",
            "XML saved to: path/to/save/xml/38103121.xml\n",
            "Comorbidities for PMID 38103121: \n",
            "XML saved to: path/to/save/xml/38103006.xml\n",
            "Comorbidities for PMID 38103006: Humans, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Anti-Bacterial Agents, Immune Checkpoint Inhibitors, Lung\n",
            "XML saved to: path/to/save/xml/38102837.xml\n",
            "Comorbidities for PMID 38102837: \n",
            "XML saved to: path/to/save/xml/38100106.xml\n",
            "Comorbidities for PMID 38100106: Male, Humans, Aged, Female, Carcinoma, Non-Small-Cell Lung, Cohort Studies, Prospective Studies, Protein-Tyrosine Kinases, Proto-Oncogene Proteins B-raf, Retrospective Studies, Lung Neoplasms, Proto-Oncogene Proteins, Adenocarcinoma, Biomarkers, ErbB Receptors, Receptor Protein-Tyrosine Kinases\n",
            "XML saved to: path/to/save/xml/38097480.xml\n",
            "Comorbidities for PMID 38097480: \n",
            "XML saved to: path/to/save/xml/38092558.xml\n",
            "Comorbidities for PMID 38092558: \n",
            "XML saved to: path/to/save/xml/38090511.xml\n",
            "Comorbidities for PMID 38090511: \n",
            "XML saved to: path/to/save/xml/38090326.xml\n",
            "Comorbidities for PMID 38090326: \n",
            "XML saved to: path/to/save/xml/38090298.xml\n",
            "Comorbidities for PMID 38090298: \n",
            "XML saved to: path/to/save/xml/38085543.xml\n",
            "Comorbidities for PMID 38085543: Adult, Humans, Female, Middle Aged, Male, Lung Neoplasms, Cohort Studies, Early Detection of Cancer, Tomography, X-Ray Computed, Lung\n",
            "XML saved to: path/to/save/xml/38075997.xml\n",
            "Comorbidities for PMID 38075997: \n",
            "XML saved to: path/to/save/xml/38075485.xml\n",
            "Comorbidities for PMID 38075485: \n",
            "XML saved to: path/to/save/xml/38071660.xml\n",
            "Comorbidities for PMID 38071660: \n",
            "XML saved to: path/to/save/xml/38067372.xml\n",
            "Comorbidities for PMID 38067372: \n",
            "XML saved to: path/to/save/xml/38067306.xml\n",
            "Comorbidities for PMID 38067306: \n",
            "XML saved to: path/to/save/xml/38066848.xml\n",
            "Comorbidities for PMID 38066848: Adult, Humans, Germ-Line Mutation, Hematologic Diseases, Neoplasms, Telomere, Biology\n",
            "XML saved to: path/to/save/xml/38066463.xml\n",
            "Comorbidities for PMID 38066463: Humans, Female, Lung Neoplasms, Early Detection of Cancer, Tomography, X-Ray Computed, Retrospective Studies, China, COVID-19\n",
            "XML saved to: path/to/save/xml/38063366.xml\n",
            "Comorbidities for PMID 38063366: \n",
            "XML saved to: path/to/save/xml/38063017.xml\n",
            "Comorbidities for PMID 38063017: \n",
            "XML saved to: path/to/save/xml/38056855.xml\n",
            "Comorbidities for PMID 38056855: Humans, Aged, 80 and over, Aged, Muscarinic Antagonists, Adrenergic beta-2 Receptor Agonists, Administration, Inhalation, Respiratory Therapy, Pulmonary Disease, Chronic Obstructive, Lung Neoplasms, Drug Therapy, Combination\n",
            "XML saved to: path/to/save/xml/38056852.xml\n",
            "Comorbidities for PMID 38056852: Humans, Pneumonectomy, Bronchial Fistula, Pleural Diseases, Risk Factors, Postoperative Complications, Lung, Lung Neoplasms\n",
            "XML saved to: path/to/save/xml/38037323.xml\n",
            "Comorbidities for PMID 38037323: \n",
            "XML saved to: path/to/save/xml/38029831.xml\n",
            "Comorbidities for PMID 38029831: \n",
            "XML saved to: path/to/save/xml/38029007.xml\n",
            "Comorbidities for PMID 38029007: \n",
            "XML saved to: path/to/save/xml/38027239.xml\n",
            "Comorbidities for PMID 38027239: \n",
            "XML saved to: path/to/save/xml/38025819.xml\n",
            "Comorbidities for PMID 38025819: \n",
            "XML saved to: path/to/save/xml/38023992.xml\n",
            "Comorbidities for PMID 38023992: \n",
            "XML saved to: path/to/save/xml/38023743.xml\n",
            "Comorbidities for PMID 38023743: \n",
            "XML saved to: path/to/save/xml/38021960.xml\n",
            "Comorbidities for PMID 38021960: \n",
            "XML saved to: path/to/save/xml/38016200.xml\n",
            "Comorbidities for PMID 38016200: \n",
            "XML saved to: path/to/save/xml/38016003.xml\n",
            "Comorbidities for PMID 38016003: \n",
            "XML saved to: path/to/save/xml/38012569.xml\n",
            "Comorbidities for PMID 38012569: Humans, Male, Female, Aged, Inappropriate Prescribing, Prospective Studies, Polypharmacy, Potentially Inappropriate Medication List, Lung Neoplasms\n",
            "XML saved to: path/to/save/xml/38011678.xml\n",
            "Comorbidities for PMID 38011678: \n",
            "XML saved to: path/to/save/xml/38007507.xml\n",
            "Comorbidities for PMID 38007507: Humans, Lung Neoplasms, Retrospective Studies, Inpatients, Thoracic Surgery, Ambulatory Surgical Procedures, Pneumonectomy, Thoracic Surgery, Video-Assisted\n",
            "XML saved to: path/to/save/xml/38003929.xml\n",
            "Comorbidities for PMID 38003929: \n",
            "XML saved to: path/to/save/xml/37999149.xml\n",
            "Comorbidities for PMID 37999149: Humans, Lung Neoplasms, Anaplastic Lymphoma Kinase, Protein-Tyrosine Kinases, Tyrosine Kinase Inhibitors, Carcinoma, Non-Small-Cell Lung, Protein Kinase Inhibitors, Lactams, Macrocyclic\n",
            "XML saved to: path/to/save/xml/37999105.xml\n",
            "Comorbidities for PMID 37999105: Humans, Pneumonectomy, Prognosis, Retrospective Studies, Lung Neoplasms, Lung, Morbidity, Postoperative Complications\n",
            "XML saved to: path/to/save/xml/37997884.xml\n",
            "Comorbidities for PMID 37997884: Humans, Lung, Small Cell Lung Carcinoma, Retrospective Studies, Pulmonary Disease, Chronic Obstructive, Prognosis, Lung Neoplasms\n",
            "XML saved to: path/to/save/xml/37996867.xml\n",
            "Comorbidities for PMID 37996867: Humans, Lung Neoplasms, Retrospective Studies, Early Detection of Cancer, Safety-net Providers, Incidental Findings, Lung, Social Class, Solitary Pulmonary Nodule\n",
            "XML saved to: path/to/save/xml/37995046.xml\n",
            "Comorbidities for PMID 37995046: \n",
            "XML saved to: path/to/save/xml/37990203.xml\n",
            "Comorbidities for PMID 37990203: Humans, Hypertension, Pulmonary, Retrospective Studies, Pulmonary Disease, Chronic Obstructive, Delivery of Health Care, Data Analysis\n",
            "XML saved to: path/to/save/xml/37985822.xml\n",
            "Comorbidities for PMID 37985822: Humans, Genome-Wide Association Study, Public Health, Black People, Polymorphism, Single Nucleotide, Marijuana Abuse, Biology, Genetic Predisposition to Disease\n",
            "XML saved to: path/to/save/xml/37983029.xml\n",
            "Comorbidities for PMID 37983029: Humans, Adult, Female, Aged, Cohort Studies, Retrospective Studies, Social Determinants of Health, Cardiologists, Heart Failure\n",
            "XML saved to: path/to/save/xml/37981476.xml\n",
            "Comorbidities for PMID 37981476: \n",
            "XML saved to: path/to/save/xml/37979368.xml\n",
            "Comorbidities for PMID 37979368: \n",
            "XML saved to: path/to/save/xml/37977487.xml\n",
            "Comorbidities for PMID 37977487: \n",
            "XML saved to: path/to/save/xml/37974211.xml\n",
            "Comorbidities for PMID 37974211: Humans, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Proton Therapy, Protons, Retrospective Studies, Chemoradiotherapy, Antineoplastic Combined Chemotherapy Protocols, Esophagitis, Pneumonia, Combined Modality Therapy\n",
            "XML saved to: path/to/save/xml/37973983.xml\n",
            "Comorbidities for PMID 37973983: Male, Humans, Brachytherapy, Prostatic Neoplasms, Neoplasms, Second Primary, Prostate, Prostatectomy, Treatment Outcome\n",
            "XML saved to: path/to/save/xml/37970369.xml\n",
            "Comorbidities for PMID 37970369: \n"
          ]
        }
      ]
    }
  ]
}